PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Tolosa, E				Tolosa, Eduardo			Movement disorders: advances on many fronts	LANCET NEUROLOGY			English	News Item							PARKINSONS-DISEASE; ESSENTIAL TREMOR; LRRK2 G2019S		Univ Barcelona, Hosp Clin, Movement Disorder Unit, Neurol Serv, E-08007 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona	Tolosa, E (corresponding author), Univ Barcelona, Hosp Clin, Movement Disorder Unit, Neurol Serv, E-08007 Barcelona, Spain.	etolosa@clinic.ub.es						Bachoud-Levi AC, 2006, LANCET NEUROL, V5, P303, DOI 10.1016/S1474-4422(06)70381-7; Lesage S, 2006, NEW ENGL J MED, V354, P422, DOI 10.1056/NEJMc055540; Louis ED, 2006, NEUROLOGY, V66, P1756, DOI 10.1212/01.wnl.0000218162.80315.b9; Louis ED, 2006, ARCH NEUROL-CHICAGO, V63, P1189, DOI 10.1001/archneur.63.8.1189; Ozelius LJ, 2006, NEW ENGL J MED, V354, P424, DOI 10.1056/NEJMc055509; Scherfler C, 2006, BRAIN, V129, P538, DOI 10.1093/brain/awh674	6	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					7	8		10.1016/S1474-4422(06)70661-5	http://dx.doi.org/10.1016/S1474-4422(06)70661-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119UI	17166790				2022-12-18	WOS:000243039000005
J	O'Brien, JT				O'Brien, John T.			NICE and anti-dementia drugs: a triumph of health economics over clinical wisdom?	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS-DISEASE; DEMENTIA		Newcastle Gen Hosp, Wolfson Res Ctr, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital; Newcastle University - UK	O'Brien, JT (corresponding author), Newcastle Gen Hosp, Wolfson Res Ctr, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	j.t.o'brien@ncl.ac.uk		O'Brien, John/0000-0002-0837-5080				Coucill W, 2001, MED CARE, V39, P760, DOI 10.1097/00005650-200108000-00003; Fossey J, 2002, INT J GERIATR PSYCH, V17, P1064, DOI 10.1002/gps.708; Getsios D, 2001, NEUROLOGY, V57, P972, DOI 10.1212/WNL.57.6.972; Neumann PJ, 1999, MED CARE, V37, P27, DOI 10.1097/00005650-199901000-00005; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Smith SC, 2005, HEALTH TECHNOL ASSES, V9, P1	6	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2006	5	12					994	996		10.1016/S1474-4422(06)70607-X	http://dx.doi.org/10.1016/S1474-4422(06)70607-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	108VA	17110274				2022-12-18	WOS:000242266100005
J	Paulson, H; Gonzalez-Alegre, P				Paulson, Henry; Gonzalez-Alegre, Pedro			RNAi gets its prize	LANCET NEUROLOGY			English	Editorial Material							DOUBLE-STRANDED-RNA; MESSENGER-RNA; MICRORNAS; INTERFERENCE		Univ Iowa, Coll Med, Iowa City, IA 52242 USA	University of Iowa	Paulson, H (corresponding author), Univ Iowa, Coll Med, Iowa City, IA 52242 USA.	henry-paulson@uiowa.edu						Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Jin P, 2004, NAT CELL BIOL, V6, P1048, DOI 10.1038/ncb1104-1048; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Rodriguez-Lebron Edgardo, 2006, Expert Rev Neurother, V6, P223, DOI 10.1586/14737175.6.2.223; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	10	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2006	5	12					997	999		10.1016/S1474-4422(06)70609-3	http://dx.doi.org/10.1016/S1474-4422(06)70609-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	108VA	17110276				2022-12-18	WOS:000242266100007
J	Coles, A				Coles, Alasdair			The curious incident of disability in multiple sclerosis trials	LANCET NEUROLOGY			English	Editorial Material									Univ Cambridge, Dept Clin Neurosci, Cambridge, England	University of Cambridge	Coles, A (corresponding author), Univ Cambridge, Dept Clin Neurosci, Cambridge, England.	ajcl020@medschl.cam.ac.uk		Coles, Alasdair/0000-0003-4738-0760				Brex PA, 2002, NEW ENGL J MED, V346, P158, DOI 10.1056/NEJMoa011341; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Ebers GC, 2001, LANCET, V357, P1547, DOI 10.1016/S0140-6736(00)04778-4; Filippi M, 2004, LANCET, V364, P1489, DOI 10.1016/S0140-6736(04)17271-1; Filippini G, 2003, LANCET, V361, P545, DOI 10.1016/S0140-6736(03)12512-3; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; KAPPOS CH, 2006, NEUROLOGY, DOI DOI 10.1212/01.WNL.0000237641.33768.8D; Kinkel RP, 2006, NEUROLOGY, V66, P678	8	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2006	5	11					899	900		10.1016/S1474-4422(06)70585-3	http://dx.doi.org/10.1016/S1474-4422(06)70585-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	099JY	17052654				2022-12-18	WOS:000241591600004
J	Burton, A				Burton, A			mtDNA deletions associated with ageing and PD	LANCET NEUROLOGY			English	News Item																			0	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					477	477		10.1016/S1474-4422(06)70464-1	http://dx.doi.org/10.1016/S1474-4422(06)70464-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16739300				2022-12-18	WOS:000237906000014
J	Nelson, R				Nelson, R			Potassium channels have a key role in neurodegeneration	LANCET NEUROLOGY			English	News Item																			0	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2006	5	4					298	299		10.1016/S1474-4422(06)70399-4	http://dx.doi.org/10.1016/S1474-4422(06)70399-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	029CI	16578919				2022-12-18	WOS:000236535200015
J	Rosser, AE; Dunnett, SB				Rosser, AE; Dunnett, SB			Cell transplantation for Huntington's disease	LANCET NEUROLOGY			English	Editorial Material									Univ Cardiff Wales, Sch Med, Dept Neurol, Cardiff CF14 4XN, S Glam, Wales; Univ Cardiff Wales, Sch Biosci, Cardiff CH10 3US, S Glam, Wales	Cardiff University; Cardiff University	Rosser, AE (corresponding author), Univ Cardiff Wales, Sch Med, Dept Neurol, Cardiff CF14 4XN, S Glam, Wales.		Rosser, Anne/A-6239-2010; Dunnett, Stephen B/A-5869-2010	Dunnett, Stephen B/0000-0003-1826-1578; Rosser, Anne/0000-0002-4716-4753	MRC [G0200489] Funding Source: UKRI; Medical Research Council [G0200489] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bachoud-Levi A, 2000, LANCET, V356, P1975, DOI 10.1016/S0140-6736(00)03310-9; BAHOUDLEVI AC, 2006, LANCET NEUROL, V5, P303; Brasted PJ, 1999, P NATL ACAD SCI USA, V96, P10524, DOI 10.1073/pnas.96.18.10524; Freeman TB, 2000, P NATL ACAD SCI USA, V97, P13877, DOI 10.1073/pnas.97.25.13877; Handley OJ, 2006, CLIN SCI, V110, P73, DOI 10.1042/CS20050148; Nance MA, 1998, J GERIATR PSYCH NEUR, V11, P61, DOI 10.1177/089198879801100204	6	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2006	5	4					284	285		10.1016/S1474-4422(06)70385-4	http://dx.doi.org/10.1016/S1474-4422(06)70385-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	029CI	16545739				2022-12-18	WOS:000236535200002
J	Servera, E; Sancho, J				Servera, E; Sancho, J			Non-invasive ventilation in amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Editorial Material							QUALITY-OF-LIFE; MANAGEMENT; ALS		Univ Valencia, Hosp Clin Univ, Dept Resp Med, Resp Care Unit, Valencia, Spain	Hospital Clinic Universitari de Valencia; University of Valencia	Servera, E (corresponding author), Univ Valencia, Hosp Clin Univ, Dept Resp Med, Resp Care Unit, Valencia, Spain.	Emilio.Servera@uv.es		Williams, Timothy/0000-0002-1221-7843; Shaw, Pamela/0000-0002-8925-2567				Andersen PM, 2005, EUR J NEUROL, V12, P921, DOI 10.1111/j.1468-1331.2005.01351.x; Bourke SC, 2006, LANCET NEUROL, V5, P140, DOI 10.1016/S1474-4422(05)70326-4; Bourke SC, 2003, NEUROLOGY, V61, P171, DOI 10.1212/01.WNL.0000076182.13137.38; Oppenheimer EA, 2003, J NEUROL SCI, V209, P1, DOI 10.1016/S0022-510X(03)00035-2; Servera E, 2005, CHEST, V127, P1879, DOI 10.1378/chest.127.6.1879	5	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2006	5	4					291	292		10.1016/S1474-4422(06)70390-8	http://dx.doi.org/10.1016/S1474-4422(06)70390-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	029CI	16545744				2022-12-18	WOS:000236535200007
J	Piepers, S; van den Berg, LH				Piepers, S; van den Berg, LH			Evidence-based care in amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Editorial Material									Univ Med Ctr Utrecht, Dept Neurol, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Piepers, S (corresponding author), Univ Med Ctr Utrecht, Dept Neurol, Rudolf Magnus Inst Neurosci, Heidelberglaan 100, Utrecht, Netherlands.	l.h.vandenberg@umcutrecht.nl						BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Borasio GD, 1998, J NEUROL, V245, P717, DOI 10.1007/s004150050273; Bourke SC, 2006, LANCET NEUROL, V5, P140, DOI 10.1016/S1474-4422(05)70326-4; del Aguila MA, 2003, NEUROLOGY, V60, P813, DOI 10.1212/01.WNL.0000049472.47709.3B; Lyall RA, 2001, NEUROLOGY, V57, P153, DOI 10.1212/WNL.57.1.153; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Miller RG, 2001, AMYOTROPH LATERAL SC, V2, P3, DOI 10.1080/146608201300079355; PIEPERS S, IN PRESS AMYOTROPH L	8	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2006	5	2					105	106		10.1016/S1474-4422(06)70330-1	http://dx.doi.org/10.1016/S1474-4422(06)70330-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	006RO	16426982				2022-12-18	WOS:000234914800003
J	Kieseier, BC; Wiendl, H				Kieseier, BC; Wiendl, H			Multiple sclerosis: advances, excitements, disenchantments	LANCET NEUROLOGY			English	Editorial Material									Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany; Univ Wurzburg, Dept Neurol, D-95087 Wurzburg, Germany	Heinrich Heine University Dusseldorf; University of Wurzburg	Kieseier, BC (corresponding author), Univ Dusseldorf, Dept Neurol, Moorenstr 5, D-40225 Dusseldorf, Germany.	Bernd.Kieseier@uni-duesseldorf.de	Wiendl, Heinz/AAX-6041-2021	Wiendl, Heinz/0000-0003-4310-3432				Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Kutzelnigg A, 2005, BRAIN, V128, P2705, DOI 10.1093/brain/awh641; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Magnus T, 2005, J NEUROSCI, V25, P2537, DOI 10.1523/JNEUROSCI.4794-04.2005; Muraro PA, 2005, J EXP MED, V201, P805, DOI 10.1084/jem.20041679	5	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2006	5	1					2	3		10.1016/S1474-4422(05)70256-8	http://dx.doi.org/10.1016/S1474-4422(05)70256-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	998OI	16361006				2022-12-18	WOS:000234328100002
J	Ponsonby, AL; van der Mei, I; Dwyer, T; Blizzard, L; Taylor, B; Kemp, A				Ponsonby, AL; van der Mei, I; Dwyer, T; Blizzard, L; Taylor, B; Kemp, A			Birth order, infection in early life, and multiple sclerosis	LANCET NEUROLOGY			English	Letter							EPSTEIN-BARR-VIRUS		Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Tasmania, Menzies Res Inst, Hobart, Tas, Australia; Univ Otago, Christchurch Sch Med & Hlth Sci, Dunedin, New Zealand; Univ Sydney, Discipline Paediat & Child Hlth, Childrens Hosp Westmead, Sydney, NSW 2006, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Tasmania; Menzies Institute for Medical Research; University of Otago; University of Sydney	Ponsonby, AL (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.	anne-louise.ponsonby@mcri.edu.au	Ponsonby, Anne-Louise/AAE-4351-2019; van der Mei, Ingrid/J-7457-2014; van der Mei, Ingrid/AAI-2566-2020	van der Mei, Ingrid/0000-0001-9009-7472; van der Mei, Ingrid/0000-0001-9009-7472; Ebers, George/0000-0003-4771-4177; Ponsonby, Anne-Louise/0000-0002-6581-3657				Alotaibi S, 2004, JAMA-J AM MED ASSOC, V291, P1875, DOI 10.1001/jama.291.15.1875; Levin LI, 2005, JAMA-J AM MED ASSOC, V293, P2496, DOI 10.1001/jama.293.20.2496; Ponsonby AL, 2005, JAMA-J AM MED ASSOC, V293, P463, DOI 10.1001/jama.293.4.463; ROTHMAN K, 1998, MODERN EPIDEMIOLOGY, P157; Sadovnick AD, 2005, LANCET NEUROL, V4, P611, DOI 10.1016/S1474-4422(05)70170-8	5	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2005	4	12					793	794		10.1016/S1474-4422(05)70233-7	http://dx.doi.org/10.1016/S1474-4422(05)70233-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	989SG	16297836				2022-12-18	WOS:000233693500006
J	Siva, N				Siva, N			Astrocytes have a key role in epilepsy	LANCET NEUROLOGY			English	News Item																			0	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2005	4	10					601	601		10.1016/S1474-4422(05)70186-1	http://dx.doi.org/10.1016/S1474-4422(05)70186-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969PG	16208873				2022-12-18	WOS:000232245900013
J	Chaudhuri, A				Chaudhuri, A			Interferon beta, progressive MS, and brain atrophy	LANCET NEUROLOGY			English	Editorial Material							MULTIPLE-SCLEROSIS PATIENTS; CEREBRAL ATROPHY; CONTROLLED TRIAL; IA		Inst Neurol Sci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow	Chaudhuri, A (corresponding author), Inst Neurol Sci, Dept Neurol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.	ac54p@udcf.gla.ac.uk						Cohen JA, 2004, NEUROLOGY, V63, P1768, DOI 10.1212/01.WNL.0000147171.32178.48; Filippi M, 2004, LANCET, V364, P1489, DOI 10.1016/S0140-6736(04)17271-1; Gasperini C, 2002, MULT SCLER J, V8, P119, DOI 10.1191/1352458502ms788oa; Jones CK, 2001, NEUROLOGY, V56, pA379; Kalkers NF, 2002, ARCH NEUROL-CHICAGO, V59, P1572, DOI 10.1001/archneur.59.10.1572; Leary SM, 2003, NEUROLOGY, V60, P44, DOI 10.1212/WNL.60.1.44; Molyneux PD, 2000, BRAIN, V123, P2256, DOI 10.1093/brain/123.11.2256; Panitch H, 2004, NEUROLOGY, V63, P1788; Rudick RA, 2004, ANN NEUROL, V56, P548, DOI 10.1002/ana.20224; Rudick RA, 2000, MULT SCLER, V6, P365, DOI 10.1191/135245800701566322	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2005	4	4					208	209		10.1016/S1474-4422(05)70028-4	http://dx.doi.org/10.1016/S1474-4422(05)70028-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	910ID	15778099				2022-12-18	WOS:000227923600005
J	Jaaskelainen, S				Jaaskelainen, S			Pregabalin for painful neuropathy	LANCET NEUROLOGY			English	Editorial Material									Turku Univ Hosp, Dept Clin Neurophysiol, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Anaesthesiol & Intens Care, Pain Clin, FIN-20520 Turku, Finland	University of Turku; University of Turku	Jaaskelainen, S (corresponding author), Turku Univ Hosp, Dept Clin Neurophysiol, FIN-20520 Turku, Finland.	satu.jaaskelainen@tyks.fi	Jääskeläinen, Satu/X-8755-2019					Dubinsky RM, 2004, NEUROLOGY, V63, P959, DOI 10.1212/01.WNL.0000140708.62856.72; Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524; England JD, 2005, NEUROLOGY, V64, P199, DOI 10.1212/01.WNL.0000149522.32823.EA; Lesser H, 2004, NEUROLOGY, V63, P2104, DOI 10.1212/01.WNL.0000145767.36287.A1; Sindrup SH, 2000, NEUROLOGY, V55, P915, DOI 10.1212/WNL.55.7.915	5	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2005	4	4					207	208		10.1016/S1474-4422(05)70027-2	http://dx.doi.org/10.1016/S1474-4422(05)70027-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	910ID	15778098				2022-12-18	WOS:000227923600004
J	Lee, VH; Brown, RB				Lee, VH; Brown, RB			Prevention of in-hospital mortality after stroke	LANCET NEUROLOGY			English	Editorial Material							1ST CEREBRAL INFARCTION; RECURRENCE; PREDICTORS; SURVIVAL		Mayo Clin, Coll Med, Div Cerebrovasc Dis, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Lee, VH (corresponding author), Mayo Clin, Coll Med, Div Cerebrovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	brown@mayo.edu						Baptista MV, 1999, J NEUROL SCI, V166, P107; Heuschmann PU, 2004, ARCH INTERN MED, V164, P1761, DOI 10.1001/archinte.164.16.1761; Heuschmann PU, 2004, JAMA-J AM MED ASSOC, V292, P1831, DOI 10.1001/jama.292.15.1831; Petty GW, 1998, NEUROLOGY, V50, P208, DOI 10.1212/WNL.50.1.208; Petty GW, 2000, STROKE, V31, P1062, DOI 10.1161/01.STR.31.5.1062; Vernino S, 2003, STROKE, V34, P1828, DOI 10.1161/01.STR.0000080534.98416.A0	6	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					73	74		10.1016/S1474-4422(05)00973-7	http://dx.doi.org/10.1016/S1474-4422(05)00973-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15664537				2022-12-18	WOS:000226712300005
J	Hayward, P				Hayward, P			Presenilin dysfunction leads to memory and plasticity defects	LANCET NEUROLOGY			English	News Item																			0	5	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					327	327		10.1016/S1474-4422(04)00784-7	http://dx.doi.org/10.1016/S1474-4422(04)00784-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15176406				2022-12-18	WOS:000221663000007
J	De Jager, PL; Hafler, DA				De Jager, PL; Hafler, DA			Gene expression profiling in MS: what is the clinical relevance?	LANCET NEUROLOGY			English	Editorial Material							MULTIPLE-SCLEROSIS		Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; MIT, Broad Inst, Cambridge, MA 02139 USA; Harvard Univ, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	De Jager, PL (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	pdejager@rics.bwh.harvard.edu						Achiron A, 2004, ANN NEUROL, V55, P410, DOI 10.1002/ana.20008; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Lock CB, 2003, TRENDS MOL MED, V9, P535, DOI 10.1016/j.molmed.2003.10.008; Steinman L, 2003, NAT REV IMMUNOL, V3, P483, DOI 10.1038/nri1108	4	5	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2004	3	5					269	269		10.1016/S1474-4422(04)00731-8	http://dx.doi.org/10.1016/S1474-4422(04)00731-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817EL	15099539				2022-12-18	WOS:000221160700017
J	Hayward, P				Hayward, P			Lithium reverses tau pathology in Drosophila	LANCET NEUROLOGY			English	News Item																			0	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2004	3	5					265	265		10.1016/S1474-4422(04)00759-8	http://dx.doi.org/10.1016/S1474-4422(04)00759-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817EL					2022-12-18	WOS:000221160700012
J	Limousin-Dowsey, P				Limousin-Dowsey, P			Thalamic stimulation in essential tremor	LANCET NEUROLOGY			English	Editorial Material							SUPPRESSION		Inst Neurol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Limousin-Dowsey, P (corresponding author), Inst Neurol, Queen Sq, London WC1N 3BG, England.	P.limousin@ion.ucl.ac.uk						BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; Hariz GM, 2002, J NEUROL NEUROSUR PS, V72, P47, DOI 10.1136/jnnp.72.1.47; Limousin P, 1999, J NEUROL NEUROSUR PS, V66, P289, DOI 10.1136/jnnp.66.3.289; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Sydow O, 2003, J NEUROL NEUROSUR PS, V74, P1387, DOI 10.1136/jnnp.74.10.1387	5	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2004	3	2					80	80		10.1016/S1474-4422(03)00656-2	http://dx.doi.org/10.1016/S1474-4422(03)00656-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	772AQ	14746995				2022-12-18	WOS:000188818500013
J	Rockwood, K				Rockwood, K			Lending a helping eye: artists in residence at a memory clinic	LANCET NEUROLOGY			English	Editorial Material								An artist-in-residence programme at the Capital Health Memory Clinic in Halifax, Canada, was established 6 years ago. The artists contribute to the clinic's academic mission by helping to describe how Alzheimer's disease treated by cholinesterase inhibitors is providing a better understanding of human cholinergic neurotransmission. The artists also contribute to the clinical programme by helping to establish a therapeutic ambience, and by allowing clinicians to see themselves through their patients' eyes. The artist programme has inspired a design initiative for the improvement of the physical environment for older patients, and has created a unique art collection that is becoming a resource for scholarship.	Dalhousie Univ, Halifax, NS, Canada	Dalhousie University	Rockwood, K (corresponding author), Ctr Hlth Care Elderly, 5955 Vet Mem Lane,Suite 1421, Halifax, NS B3H 2E1, Canada.	kenneth.rockwood@dal.ca	Rockwood, Kenneth/AAD-8951-2019					Rockwood K, 2003, LANCET NEUROL, V2, P630, DOI 10.1016/S1474-4422(03)00533-7; Rockwood K, 2002, INT J GERIATR PSYCH, V17, P1006, DOI 10.1002/gps.733	2	5	5	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2004	3	2					119	123		10.1016/S1474-4422(03)00665-3	http://dx.doi.org/10.1016/S1474-4422(03)00665-3			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	772AQ	14747004				2022-12-18	WOS:000188818500022
J	Fox, RJ; Rudick, RA				Fox, RJ; Rudick, RA			Multiple sclerosis: disease markers accelerate progress	LANCET NEUROLOGY			English	Editorial Material									Cleveland Clin Fdn, Dept Neurol, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Fox, RJ (corresponding author), Cleveland Clin Fdn, Dept Neurol, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44195 USA.	rudickr@ccf.org						Barkhof F, 2003, ARCH NEUROL-CHICAGO, V60, P1073, DOI 10.1001/archneur.60.8.1073; Berger T, 2003, NEW ENGL J MED, V349, P139, DOI 10.1056/NEJMoa022328; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Rocca MA, 2003, NEUROLOGY, V61, P1078, DOI 10.1212/01.WNL.0000086821.49353.40; Wandinger KP, 2003, LANCET, V361, P2036, DOI 10.1016/S0140-6736(03)13641-0	5	5	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					10	10		10.1016/S1474-4422(03)00610-0	http://dx.doi.org/10.1016/S1474-4422(03)00610-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14693099				2022-12-18	WOS:000187447100013
J	Tilstone, C				Tilstone, C			Neurofeedback provides a better theta-rical performance	LANCET NEUROLOGY			English	News Item																			0	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2003	2	11					655	655		10.1016/S1474-4422(03)00578-7	http://dx.doi.org/10.1016/S1474-4422(03)00578-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	734ZN					2022-12-18	WOS:000186088000010
J	Chalmers, J				Chalmers, J			The management of blood pressure in acute stroke	LANCET NEUROLOGY			English	Editorial Material							OF-HYPERTENSION ISH; STATEMENT		Univ Sydney, Inst Int Hlth, Sydney, NSW 2042, Australia	University of Sydney	Chalmers, J (corresponding author), Univ Sydney, Inst Int Hlth, C37,144-46 Burren St, Sydney, NSW 2042, Australia.	chalmers@iih.usyd.edu.au		Chalmers, John/0000-0002-9931-0580				Bath P, 2003, J HYPERTENS, V21, P665, DOI 10.1097/01.hjh.0000052489.18130.43; Chalmers J, 2003, J HYPERTENS, V21, P651, DOI 10.1097/01.hjh.0000052490.18130.95; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Schrader J, 2003, STROKE, V34, P1699, DOI 10.1161/01.STR.0000075777.18006.89	5	5	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2003	2	10					593	593		10.1016/S1474-4422(03)00525-8	http://dx.doi.org/10.1016/S1474-4422(03)00525-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	723KR	14505579				2022-12-18	WOS:000185432000011
J	Morris, K				Morris, K			Neuropathic pain research pinpoints new role for microglia	LANCET NEUROLOGY			English	News Item																			0	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2003	2	10					587	587		10.1016/S1474-4422(03)00545-3	http://dx.doi.org/10.1016/S1474-4422(03)00545-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	723KR					2022-12-18	WOS:000185432000003
J	Grasso, G				Grasso, G			Erythropoiesis and neuroprotection: two sides of the same coin?	LANCET NEUROLOGY			English	Editorial Material									Univ Messina, Dept Neurosurg, Messina, Italy	University of Messina	Grasso, G (corresponding author), Univ Messina, Dept Neurosurg, Messina, Italy.		grasso, giovanni/K-3774-2018	grasso, giovanni/0000-0001-5362-0092				AMGEN I, 2000, PHYSICIANS DESK REFE; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474	5	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2003	2	6					332	332		10.1016/S1474-4422(03)00403-4	http://dx.doi.org/10.1016/S1474-4422(03)00403-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	682WH	12849145				2022-12-18	WOS:000183115000012
J	Senior, K				Senior, K			Soluble amyloid oligomers: a common cause of neurodegeneration?	LANCET NEUROLOGY			English	News Item																		Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469	1	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2003	2	6					330	330		10.1016/S1474-4422(03)00431-9	http://dx.doi.org/10.1016/S1474-4422(03)00431-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	682WH					2022-12-18	WOS:000183115000010
J	Gass, A; Hennerici, MG				Gass, A; Hennerici, MG			MRI of basilar-artery-aneurysm growth	LANCET NEUROLOGY			English	Article									Univ Heidelberg, Klinikum Mannheim, Dept Neurol, D-68137 Mannheim, Germany	Ruprecht Karls University Heidelberg	Gass, A (corresponding author), Univ Heidelberg, Klinikum Mannheim, Dept Neurol, Theodor Kutzer Ufer 1-3, D-68137 Mannheim, Germany.								0	5	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2003	2	2					128	128		10.1016/S1474-4422(03)00309-0	http://dx.doi.org/10.1016/S1474-4422(03)00309-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	638BY	12849269				2022-12-18	WOS:000180550600020
J	Paulson, H				Paulson, H			Yet another spinocerebellar ataxia - will it ever end?	LANCET NEUROLOGY			English	Editorial Material									Univ Iowa, Dept Neurol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa	Paulson, H (corresponding author), Univ Iowa, Dept Neurol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA.							Devos D, 2001, NEUROLOGY, V56, P234, DOI 10.1212/WNL.56.2.234; Paulson H, 2001, NEUROL CLIN, V19, P759, DOI 10.1016/S0733-8619(05)70044-X; Vuillaume I, 2002, ANN NEUROL, V52, P666, DOI 10.1002/ana.10344	3	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2002	1	8					471	471		10.1016/S1474-4422(02)00234-X	http://dx.doi.org/10.1016/S1474-4422(02)00234-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	618PP	12849326				2022-12-18	WOS:000179426700017
J	Senior, K				Senior, K			Homing in on COX-3-the elusive target of paracetamol	LANCET NEUROLOGY			English	News Item																			0	5	6	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2002	1	7					399	399		10.1016/S1474-4422(02)00207-7	http://dx.doi.org/10.1016/S1474-4422(02)00207-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	606KC					2022-12-18	WOS:000178732300005
J	Ihara, M; Yamamoto, Y; Hattori, Y; Liu, WY; Kobayashi, H; Ishiyama, H; Yoshimoto, T; Miyawaki, S; Clausen, T; Bang, OY; Steinberg, GK; Tournier-Lasserve, E; Koizumi, A				Ihara, Masafumi; Yamamoto, Yumi; Hattori, Yorito; Liu, Wanyang; Kobayashi, Hatasu; Ishiyama, Hiroyuki; Yoshimoto, Takeshi; Miyawaki, Satoru; Clausen, Tim; Bang, Oh Young; Steinberg, Gary K.; Tournier-Lasserve, Elisabeth; Koizumi, Akio			Moyamoya disease: diagnosis and interventions	LANCET NEUROLOGY			English	Review							EXTRACRANIAL-INTRACRANIAL BYPASS; RISK-FACTORS; RNF213; VARIANT; ONSET; REVASCULARIZATION; ASSOCIATION; CIRCULATION; P.R4810K; JAPAN	Moyamoya disease is a rare cause of stroke, radiologically characterised by progressive stenosis of the terminal portion of the internal carotid arteries and compensatory capillary collaterals. The discovery that RNF213, which encodes an unconventional E3 ubiquitin ligase, is the major susceptibility gene for moyamoya disease in people from east Asia has opened new avenues for investigation into the mechanisms of disease and potential treatment targets. The Arg4810Lys variant of the gene is most strongly associated with moyamoya disease, but the penetrance is lower than 1%, suggesting a synergistic relationship with additional environmental and genetic risk factors. White people carry less common non-Arg4810Lys variants of RNF213, which partly explains the lower prevalence of moyamoya disease in European countries and in the USA than in east Asian countries. Several monogenic moyamoya syndromes possess the radiological characteristics of moyamoya disease and have been associated with multiple genes and pathways involved in moyamoya angiopathy pathogenesis. Further clarification of the genetic and environmental factors that contribute to the emergence of moyamoya angiopathy could enable development of new treatment strategies for moyamoya disease.	[Ihara, Masafumi; Hattori, Yorito; Ishiyama, Hiroyuki; Yoshimoto, Takeshi] Natl Cerebral & Cardiovasc Ctr, Dept Neurol, Osaka 5648565, Japan; [Yamamoto, Yumi] Natl Cerebral & Cardiovasc Ctr, Dept Mol Innovat Lipidemiol, Osaka, Japan; [Liu, Wanyang] China Med Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Shenyang, Peoples R China; [Kobayashi, Hatasu] Mie Univ, Dept Environm & Mol Med, Tsu, Mie, Japan; [Miyawaki, Satoru] Univ Tokyo, Fac Med, Dept Neurosurg, Tokyo, Japan; [Clausen, Tim] Med Univ Vienna, Res Inst Mol Pathol, Vienna, Austria; [Bang, Oh Young] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurol, Sch Med, Seoul, South Korea; [Steinberg, Gary K.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Tournier-Lasserve, Elisabeth] Univ Paris, St Louis Hosp, AP HP, INSERM U1141, Paris, France; [Koizumi, Akio] Kyoto Hokenkai Fdn, Inst Publ Hlth, Kyoto, Japan	National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan; China Medical University; Mie University; University of Tokyo; Medical University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Sungkyunkwan University (SKKU); Samsung Medical Center; Stanford University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Ihara, M (corresponding author), Natl Cerebral & Cardiovasc Ctr, Dept Neurol, Osaka 5648565, Japan.	ihara@ncvc.go.jp	Yoshimoto, Takeshi/GQY-8670-2022; Yoshimoto, Takeshi/AAR-1805-2020	Yoshimoto, Takeshi/0000-0003-3178-8171; Yoshimoto, Takeshi/0000-0003-3178-8171; Steinberg, Gary/0000-0001-6374-1058	Japan Agency for Medical Research and Development [JP21ek0210120, JP21ek0210126]; Bristol Myers Squibb; Shingakujyutsu [17H06397]	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Bristol Myers Squibb(Bristol-Myers Squibb); Shingakujyutsu	MI has received support for his work from the Japan Agency for Medical Research and Development (grant numbers: JP21ek0210120 and JP21ek0210126). MI has also received research funding from Bristol Myers Squibb. HK and AK have received funding from Shingakujyutsu (17H06397). All funders had no role in the preparation of any aspect of the manuscript or decision to submit the manuscript for publication. The other authors declare no conflicts of interest.	Abdelilah-Seyfried S, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI160227; Acker G, 2015, EUR J NEUROL, V22, P1012, DOI 10.1111/ene.12702; Ahel J., 2021, BIORXIV, DOI [10.1101/2021.05.10.443411, DOI 10.1101/2021.05.10.443411]; Ahel J, 2020, ELIFE, V9, DOI 10.7554/eLife.56185; Ando S, 2019, NEUROL RES, V41, P480, DOI 10.1080/01616412.2019.1580455; Antonucci MU, 2016, AM J NEURORADIOL, V37, P228, DOI 10.3174/ajnr.A4535; Baik JS, 2010, MOVEMENT DISORD, V25, P1482, DOI 10.1002/mds.23130; Bang OY, 2020, TRANSL STROKE RES, V11, P580, DOI 10.1007/s12975-019-00743-6; Bang OY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156607; Bedini G, 2016, CURR MED CHEM, V23, P315, DOI 10.2174/092986732304160204181543; Bersano A, 2016, CEREBROVASC DIS, V41, P105, DOI 10.1159/000442298; Bhardwaj A, 2022, LIFE SCI ALLIANCE, V5, DOI 10.26508/lsa.202000807; Choi EH, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.011996; Chung JW, 2016, EUR NEUROL, V75, P178, DOI 10.1159/000445348; European Stroke Organization, 2021, ESO GUID DIR; Fujimura M, 2022, NEUROL MED-CHIR, V62, P165, DOI 10.2176/jns-nmc.2021-0382; Funaki T, 2019, J NEUROSURG, V130, P525, DOI 10.3171/2017.9.JNS17576; Funaki T, 2016, J NEUROSURG, V124, P1766, DOI 10.3171/2015.6.JNS15845; Ganguly D, 2013, NAT REV IMMUNOL, V13, P566, DOI 10.1038/nri3477; Guey S, 2017, EUR J HUM GENET, V25, P995, DOI 10.1038/ejhg.2017.92; Guey S, 2015, APPL CLIN GENET, V8, P49, DOI 10.2147/TACG.S42772; Hauser TK, 2019, NEUROIMAGE-CLIN, V22, DOI 10.1016/j.nicl.2019.101713; He SH, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01898-8; Hirano Y, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132815; Hirano Y, 2020, STROKE, V51, P3124, DOI 10.1161/STROKEAHA.120.030653; Hongo H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68888-1; Jee TK, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016670; Kaku Y, 2012, ACTA NEUROCHIR, V154, P2151, DOI 10.1007/s00701-012-1472-4; Kamada F, 2011, J HUM GENET, V56, P34, DOI 10.1038/jhg.2010.132; Kanamori F, 2021, NEUROSURG FOCUS, V51, DOI 10.3171/2021.6.FOCUS20870; KARASAWA J, 1993, J NEUROSURG, V79, P192, DOI 10.3171/jns.1993.79.2.0192; Kim JS, 2016, J STROKE, V18, P2, DOI 10.5853/jos.2015.01627; Kim SJ, 2010, STROKE, V41, P173, DOI 10.1161/STROKEAHA.109.562264; Kitakami K, 2022, CEREBROVASC DIS, V51, P158, DOI 10.1159/000518725; Kobayashi H, 2018, PULM CIRC, V8, DOI 10.1177/2045894018778155; Kobayashi H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164759; Kobayashi H, 2013, BIOCHEM BIOPH RES CO, V432, P519, DOI 10.1016/j.bbrc.2013.02.015; Koizumi A, 2016, ENVIRON HEALTH PREV, V21, P55, DOI 10.1007/s12199-015-0498-7; Koizumi A, 2013, ENVIRON HEALTH PREV, V18, P121, DOI 10.1007/s12199-012-0299-1; Kundishora AJ, 2021, JAMA NEUROL, V78, P993, DOI 10.1001/jamaneurol.2021.1681; Kuroda S, 2022, SURG CEREB STROKE JP, V50, P1; Kuroda S, 2021, MOYAMOYA DIS CURRENT, V1st, P143; Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0; Kuroda S, 2015, NEUROL MED-CHIR, V55, P194, DOI 10.2176/nmc.ra.2014-0305; Lai PMR, 2022, WORLD NEUROSURG, V161, pE146, DOI 10.1016/j.wneu.2022.01.076; Lai PMR, 2021, NEUROSURGERY, V89, P315, DOI 10.1093/neuros/nyab156; Letchuman V, 2021, NEUROSURG FOCUS, V51, DOI 10.3171/2021.5.FOCUS21282; Li H, 2011, STROKE, V42, P1138, DOI 10.1161/STROKEAHA.110.608471; Liao X, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0788-9; Liao X, 2017, ENVIRON HEALTH PREV, V22, DOI 10.1186/s12199-017-0680-1; Lin K, 2021, BRAIN BEHAV, V11, DOI 10.1002/brb3.2356; Liu WY, 2012, NEUROL MED-CHIR, V52, P299, DOI 10.2176/nmc.52.299; Liu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022542; Mikami T, 2015, NEUROL RES, V37, P880, DOI 10.1179/1743132815Y.0000000069; MIYAMOTO S, 1986, J NEUROSURG, V65, P454, DOI 10.3171/jns.1986.65.4.0454; Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386; Miyatake S, 2012, NEUROLOGY, V78, P803, DOI 10.1212/WNL.0b013e318249f71f; Miyawaki S, 2012, STROKE, V43, P3371, DOI 10.1161/STROKEAHA.112.663864; Mori N, 2008, INVEST RADIOL, V43, P574, DOI 10.1097/RLI.0b013e31817fb432; Morimoto T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22064-8; Morimoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175649; Noguchi T, 2015, EUR J RADIOL, V84, P1137, DOI 10.1016/j.ejrad.2015.03.011; Okazaki S, 2019, CIRCULATION, V139, P295, DOI 10.1161/CIRCULATIONAHA.118.038439; Otten EG, 2021, NATURE, V594, P111, DOI 10.1038/s41586-021-03566-4; Rallo MS, 2021, NEUROSURG FOCUS, V51, DOI 10.3171/2021.6.FOCUS21284; Richards M, 2019, AM J PSYCHIAT, V176, P269, DOI 10.1176/appi.ajp.2018.18040404; Roder C, 2020, J NEUROSURG, V132, P1845, DOI 10.3171/2019.2.JNS19106; Ryoo S, 2014, STROKE, V45, P2457, DOI 10.1161/STROKEAHA.114.004761; Sato Y, 2019, STROKE, V50, P1973, DOI 10.1161/STROKEAHA.119.024689; Scholz B, 2016, DEV CELL, V36, P79, DOI 10.1016/j.devcel.2015.12.015; Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622; Seo WK, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.017701; Seol HJ, 2005, J NEUROSURG, V103, P439, DOI 10.3171/ped.2005.103.5.0439; Sigdel TK, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-45; Sonobe S, 2014, BRAIN RES, V1552, P64, DOI 10.1016/j.brainres.2014.01.011; Strong A, 2021, AM J MED GENET A, V185, P2168, DOI 10.1002/ajmg.a.62215; Tabara Y, 2021, J HYPERTENS, V39, P2521, DOI 10.1097/HJH.0000000000002964; Takagi Y, 2015, NEUROL MED-CHIR, V55, P199, DOI 10.2176/nmc.ra.2014-0326; Takahashi JC, 2016, STROKE, V47, P37, DOI 10.1161/STROKEAHA.115.010819; Tanigawara T, 1997, CLIN NEUROL NEUROSUR, V99, pS225; Tashiro R, 2021, J CELL PHYSIOL, V236, P7554, DOI 10.1002/jcp.30396; Teo M, 2020, NEUROSURGERY, V86, P203, DOI 10.1093/neuros/nyz025; Thery F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26061-w; Tinelli F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165763; Togao O, 2018, EUR RADIOL, V28, P4871, DOI 10.1007/s00330-018-5462-7; Uchino H, 2017, J NEUROSURG-PEDIATR, V20, P485, DOI 10.3171/2017.5.PEDS17198; Uchino K, 2005, NEUROLOGY, V65, P956, DOI 10.1212/01.wnl.0000176066.33797.82; Wallace S, 2016, CLIN GENET, V90, P351, DOI 10.1111/cge.12739; Wang QN, 2021, NEUROSURG FOCUS, V51, DOI 10.3171/2021.6.FOCUS21112; Wang Y, 2018, J STROKE CEREBROVASC, V27, P2259, DOI 10.1016/j.jstrokecerebrovasdis.2018.04.013; Wen J, 2016, BRAIN RES, V1644, P70, DOI 10.1016/j.brainres.2016.04.051; Wu ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048179; Xu RS, 2022, NEUROSURGERY, V90, P434, DOI 10.1227/NEU.0000000000001850; Yamaguchi E, 2022, STROKE VASC INTERV N, V2; Yamamoto S, 2019, J NEUROSURG, V130, P884, DOI 10.3171/2017.9.JNS172231; Zhang H, 2019, EXP THER MED, V17, P1977, DOI 10.3892/etm.2019.7198; Zhang Q, 2017, J NEUROSURG, V126, P1106, DOI 10.3171/2016.2.JNS152173; Zhang XT, 2019, ATHEROSCLEROSIS, V280, P140, DOI 10.1016/j.atherosclerosis.2018.11.032; Zhu GM, 2011, CELL BIOCHEM BIOPHYS, V61, P47, DOI 10.1007/s12013-011-9159-7	99	4	4	19	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2022	21	8					747	758		10.1016/S1474-4422(22)00165-X	http://dx.doi.org/10.1016/S1474-4422(22)00165-X			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	4P3VT	35605621				2022-12-18	WOS:000855325100021
J	Tabrizi, SJ; Schobel, S; Gantman, EC; Mansbach, A; Borowsky, B; Konstantinova, P; Mestre, TA; Panagoulias, J; Ross, CA; Zauderer, M; Mullin, AP; Romero, K; Sivakumaran, S; Turner, EC; Long, JD; Sampaio, C				Tabrizi, Sarah J.; Schobel, Scott; Gantman, Emily C.; Mansbach, Alexandra; Borowsky, Beth; Konstantinova, Pavlina; Mestre, Tiago A.; Panagoulias, Jennifer; Ross, Christopher A.; Zauderer, Maurice; Mullin, Ariana P.; Romero, Klaus; Sivakumaran, Sudhir; Turner, Emily C.; Long, Jeffrey D.; Sampaio, Cristina		Huntingtons Dis Regulatory Sci Con	A biological classification of Huntington's disease: the Integrated Staging System	LANCET NEUROLOGY			English	Article							AGE-OF-ONSET; REDUCED PENETRANCE; TRINUCLEOTIDE REPEAT; DIAGNOSTIC-CRITERIA; CLINICAL-TRIALS; MOTOR; GENE; HD; PROGRESSION; MODEL	The current research paradigm for Huntington's disease is based on participants with overt clinical phenotypes and does not address its pathophysiology nor the biomarker changes that can precede by decades the functional decline. We have generated a new research framework to standardise clinical research and enable interventional studies earlier in the disease course. The Huntington's Disease Integrated Staging System (HD-ISS) comprises a biological research definition and evidence-based staging centred on biological, clinical, and functional assessments. We used a formal consensus method that involved representatives from academia, industry, and non-profit organisations. The HD-ISS characterises individuals for research purposes from birth, starting at Stage 0 (ie, individuals with the Huntington's disease genetic mutation without any detectable pathological change) by using a genetic definition of Huntington's disease. Huntington's disease progression is then marked by measurable indicators of underlying pathophysiology (Stage 1), a detectable clinical phenotype (Stage 2), and then decline in function (Stage 3). Individuals can be precisely classified into stages based on thresholds of stage-specific landmark assessments. We also demonstrated the internal validity of this system. The adoption of the HD-ISS could facilitate the design of clinical trials targeting populations before clinical motor diagnosis and enable data standardisation across ongoing and future studies.	[Tabrizi, Sarah J.] UCL, UK Dementia Res Inst, UCL Queen Sq Inst Neurol, Dept Neurodegenerat Dis,UCL Huntingtons Dis Ctr, London WC1N 3BG, England; [Schobel, Scott] F Hoffmann La Roche, Prod Dev Neurosci, Basel, Switzerland; [Gantman, Emily C.; Sampaio, Cristina] CHDI Management CHDI Fdn, Princeton, NJ 08540 USA; [Sampaio, Cristina] Univ Lisbon, Fac Med Lisboa, Clin Pharmacol Lab, Lisbon, Portugal; [Mansbach, Alexandra] APS Consulting Serv, Washington, DC USA; [Borowsky, Beth] Novartis Pharmaceut, E Hanover, NJ USA; [Konstantinova, Pavlina] VectorY BV, Amsterdam, Netherlands; [Mestre, Tiago A.] Univ Ottawa, Brain & Mind Res Inst, Ottawa Hosp Res Inst, Div Neurol,Dept Med,Parkinsons Dis & Movement Dis, Ottawa, ON, Canada; [Panagoulias, Jennifer; Mullin, Ariana P.] Wave Life Sci, Cambridge, MA USA; [Ross, Christopher A.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Ross, Christopher A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Ross, Christopher A.] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; [Zauderer, Maurice] Vaccinex, Rochester, NY USA; [Romero, Klaus; Sivakumaran, Sudhir; Turner, Emily C.] Crit Path Inst, Tucson, AZ 85718 USA; [Long, Jeffrey D.] Univ Iowa, Dept Psychiat, Dept Biostat, Iowa City, IA 52242 USA	University of London; University College London; Roche Holding; Universidade de Lisboa; Novartis; University of Ottawa; Ottawa Hospital Research Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Iowa	Tabrizi, SJ (corresponding author), UCL, UK Dementia Res Inst, UCL Queen Sq Inst Neurol, Dept Neurodegenerat Dis,UCL Huntingtons Dis Ctr, London WC1N 3BG, England.; Sampaio, C (corresponding author), CHDI Management CHDI Fdn, Princeton, NJ 08540 USA.	s.tabrizi@ucl.ac.uk; cristina.sampaio@chdifoundation.org		Tabrizi, Sarah/0000-0003-2716-2045; Gantman, Emily/0000-0002-6527-7559	CHDI Foundation; HD-RSC Coordinating Committee	CHDI Foundation; HD-RSC Coordinating Committee	CHDI Foundation provided financial support to the Critical Path Institute for the Huntington's Disease Regulatory Science Consortium (HD-RSC), including all working group efforts. The scope and activities of the working groups within the HD-RSC were agreed on by the members of the HD-RSC Executive Committee. We thank HD-COPE for their helpful input. Data used in this work were generously provided by the participants in the Enroll-HD study and made available by CHDI Foundation. Enroll-HD is a clinical research platform and longitudinal observational study for Huntington's disease families intended to accelerate progress towards therapeutics; it is sponsored by CHDI Foundation, a non-profit biomedical research organisation exclusively dedicated to collaboratively developing therapeutics for Huntington's disease. Enroll-HD would not be possible without the vital contribution of the research participants and their families. Core datasets are collected annually from all research participants as part of this multicentre longitudinal observational study. Data are monitored for quality and accuracy using a risk-based monitoring approach. All sites are required to obtain and maintain local ethical approval. IMAGE-HD data was provided by Monash University (Clayton, VIC, Australia); PREDICT-HD data was provided by the investigators and coordinators of the Huntington Study Group, made available by Jane Paulsen (University of Iowa, Iowa City, IL, USA); and TRACK-HD data was made available by Sarah Tabrizi (University College London, London, UK). We thank Robi Blumenstein (CHDI Management/CHDI Foundation, Princeton, NJ, USA), Martha Brumfield (C-Path, Tucson, AZ, USA), Darren Freeman (CHDI Management/CHDI Foundation, Princeton, NJ, USA), Simon Noble (CHDI Management/CHDI Foundation, Princeton, NJ, USA), Chris Rackow (CHDI Management/CHDI Foundation, Princeton, NJ, USA), and Swati Sathe (CHDI Management/CHDI Foundation, Princeton, NJ, USA) for their input and support during this project and in the drafting of the Position paper. We thank Teresa Moogan (Brooklyn, NY, USA) for her copyediting. We appreciate the support of the HD-RSC Coordinating Committee and their useful feedback, and thank Danielle Gartner (C-Path, Tucson, AZ, USA), Jacqueline Major (C-Path, Tucson, AZ, USA), and Sandra Gonzalez (CHDI Management/CHDI Foundation, Princeton, NJ, USA) for administrative support of consortium activities. The authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Aylward EH, 2004, NEUROLOGY, V63, P66, DOI 10.1212/01.WNL.0000132965.14653.D1; Aziz NA, 2018, NEUROLOGY, V90, pE2099, DOI 10.1212/WNL.0000000000005690; Bates GP, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.5; Black HF, 2020, GENET MED, V22, P2108, DOI 10.1038/s41436-020-0917-z; Braisch U, 2019, AM J MED GENET B, V180, P232, DOI 10.1002/ajmg.b.32719; Brinkman RR, 1997, AM J HUM GENET, V60, P1202; Clark LR, 2016, ARCH CLIN NEUROPSYCH, V31, P675, DOI 10.1093/arclin/acw024; Cooper DN, 2013, HUM GENET, V132, P1077, DOI 10.1007/s00439-013-1331-2; Cronin T, 2019, J HUNTINGTONS DIS, V8, P171, DOI 10.3233/JHD-180339; Dorsey ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029522; Dos Santos DM, 2000, STAT MED, V19, P3377, DOI 10.1002/1097-0258(20001230)19:24<3377::AID-SIM526>3.0.CO;2-E; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Georgiou-Karistianis N, 2013, BRAIN COGNITION, V83, P80, DOI 10.1016/j.bandc.2013.07.004; Georgiou-Karistianis N, 2013, NEUROSCI BIOBEHAV R, V37, P480, DOI 10.1016/j.neubiorev.2013.01.022; Ghosh Soumya, 2017, AMIA Jt Summits Transl Sci Proc, V2017, P92; GONNELLA JS, 1970, J AMER MED ASSOC, V214, P2040, DOI 10.1001/jama.214.11.2040; Griffiths W.M., 2000, TRANSCRIPTION OVERVI; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; Hogarth P, 2005, MOVEMENT DISORD, V20, P293, DOI 10.1002/mds.20332; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Kay C, 2016, NEUROLOGY, V87, P282, DOI 10.1212/WNL.0000000000002858; KENDALL M. G., 1948, Rank correlation methods.; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; Kim SD, 2014, CURR OPIN NEUROL, V27, P477, DOI 10.1097/WCO.0000000000000116; Kinnunen KM, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.712565; Kinnunen KM, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.712555; Kloppel S, 2015, EBIOMEDICINE, V2, P1420, DOI 10.1016/j.ebiom.2015.08.002; Koscik RL, 2019, J INT NEUROPSYCH SOC, V25, P1, DOI 10.1017/S1355617718000929; LAIRD CD, 1990, TRENDS GENET, V6, P242, DOI 10.1016/0168-9525(90)90206-L; Landwehrmeyer GB, 2017, MOV DISORD CLIN PRAC, V4, P212, DOI 10.1002/mdc3.12388; Langbehn DR, 2020, MOVEMENT DISORD, V35, P2193, DOI 10.1002/mds.28222; Langbehn DR, 2019, JAMA NEUROL, V76, P1375, DOI 10.1001/jamaneurol.2019.2368; Langbehn DR, 2004, CLIN GENET, V65, P267, DOI 10.1111/j.1399-0004.2004.00241.x; Lee JM, 2012, NEUROLOGY, V78, P690, DOI 10.1212/WNL.0b013e318249f683; Lee JM, 2019, CELL, V178, P887, DOI 10.1016/j.cell.2019.06.036; Litvan I, 2012, MOVEMENT DISORD, V27, P349, DOI 10.1002/mds.24893; Liu DW, 2015, J NEUROL, V262, P2691, DOI 10.1007/s00415-015-7900-7; Long JD, 2015, MOVEMENT DISORD, V30, P1664, DOI 10.1002/mds.26364; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Martinez-Horta S, 2018, MOVEMENT DISORD, V33, P1151, DOI 10.1002/mds.27395; McCusker EA, 2017, TREMOR OTHER HYPERK, V7, DOI 10.7916/D8PK0TDD; McNeil SM, 1997, HUM MOL GENET, V6, P775, DOI 10.1093/hmg/6.5.775; Mills JA, 2020, ARCH CLIN NEUROPSYCH, V35, P671, DOI 10.1093/arclin/acaa026; Morkl S, 2016, EUR ARCH PSY CLIN N, V266, P663, DOI 10.1007/s00406-016-0707-4; Morrison A, 2012, INT J TECHNOL ASSESS, V28, P138, DOI 10.1017/S0266462312000086; Mueller M, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0495-9; Nair R, 2011, SEMIN ARTHRITIS RHEU, V41, P95, DOI 10.1016/j.semarthrit.2010.12.001; Oosterloo M, 2021, MOV DISORD CLIN PRAC, V8, P352, DOI 10.1002/mdc3.13148; Orth Michael, 2010, PLoS Curr, V2, DOI 10.1371/currents.RRN1184; Ounpraseuth ST, 2017, J OBSTET GYNAECOL RE, V43, P1122, DOI 10.1111/jog.13332; Paulsen JS, 2008, J NEUROL NEUROSUR PS, V79, P874, DOI 10.1136/jnnp.2007.128728; Paulsen JS, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00078; Paulsen JS, 2006, ARCH NEUROL-CHICAGO, V63, P883, DOI 10.1001/archneur.63.6.883; PERICAKVANCE MA, 1978, CYTOGENET CELL GENET, V22, P640, DOI 10.1159/000131042; Podvin S, 2019, J NEUROL, V266, P551, DOI 10.1007/s00415-018-8940-6; Quarrell OWJ, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.045120; Reilmann R, 2014, MOVEMENT DISORD, V29, P1335, DOI 10.1002/mds.26011; Ross CA, 2019, MOV DISORD CLIN PRAC, V6, P541, DOI 10.1002/mdc3.12808; Ross CA, 2014, NAT REV NEUROL, V10, P204, DOI 10.1038/nrneurol.2014.24; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Scahill RI, 2020, LANCET NEUROL, V19, P502, DOI 10.1016/S1474-4422(20)30143-5; Schobel SA, 2017, NEUROLOGY, V89, P2495, DOI 10.1212/WNL.0000000000004743; Schomaker M, 2018, STAT MED, V37, P2252, DOI 10.1002/sim.7654; Semaka A, 2006, CLIN GENET, V70, P283, DOI 10.1111/j.1399-0004.2006.00668.x; SHOULSON I, 1979, NEUROLOGY, V29, P1, DOI 10.1212/WNL.29.1.1; Shoulson I, 2006, ARCH NEUROL-CHICAGO, V63, P991; Simpson J, 2019, CORTEX, V120, P353, DOI 10.1016/j.cortex.2019.06.012; Stevens, 1976, HUNTINGTON CHOREA DE; Stout JC, 2014, MOVEMENT DISORD, V29, P1281, DOI 10.1002/mds.25964; Sun ZA, 2019, JAMIA OPEN, V2, P123, DOI 10.1093/jamiaopen/ooy060; Tabrizi SJ, 2013, LANCET NEUROL, V12, P637, DOI 10.1016/S1474-4422(13)70088-7; Tabrizi SJ, 2011, LANCET NEUROL, V10, P31, DOI 10.1016/S1474-4422(10)70276-3; Tabrizi SJ, 2009, LANCET NEUROL, V8, P791, DOI 10.1016/S1474-4422(09)70170-X; Tang C, 2012, NEURODEGENER DIS MAN, V2, P421, DOI 10.2217/NMT.12.34; Tang HN, 2021, PARKINSONISM RELAT D, V93, P89, DOI 10.1016/j.parkreldis.2021.10.013; Turner EC, 2022, J HUNTINGTONS DIS, V11, P97, DOI 10.3233/JHD-220533; United Nations, WORLD POPULATION PRO; US Food and Drug Administration, 2018, ALZH DIS DEV DRUGS T; Wei Y, 2006, STAT MED, V25, P1369, DOI 10.1002/sim.2271; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101; WHO, 2020, METH DAT SOURC LIF T; Wijeratne PA, 2018, ANN CLIN TRANSL NEUR, V5, P570, DOI 10.1002/acn3.558; Wild EJ, 2010, MOVEMENT DISORD, V25, P888, DOI 10.1002/mds.22969; Wright GEB, 2020, LANCET NEUROL, V19, P930, DOI 10.1016/S1474-4422(20)30343-4; Wright GEB, 2019, AM J HUM GENET, V104, P1116, DOI 10.1016/j.ajhg.2019.04.007	85	4	4	4	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2022	21	7					632	644		10.1016/S1474-4422(22)00120-X	http://dx.doi.org/10.1016/S1474-4422(22)00120-X			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3J4YF	35716693				2022-12-18	WOS:000833401200016
J	Baak, LM; Wagenaar, N; van der Aa, NE; Groenendaal, F; Dudink, J; Tataranno, ML; Mahamuud, U; Verhage, CH; Eijsermans, RMJC; Smit, LS; Jellema, RK; de Haan, TR; Ter Horst, HJ; de Boode, WP; Steggerda, SJ; Prins, HJ; de Haar, CG; de Vries, LS; van Bel, F; Heijnen, CJ; Nijboer, CH; Benders, MJNL				Baak, Lisanne M.; Wagenaar, Nienke; van der Aa, Niek E.; Groenendaal, Floris; Dudink, Jeroen; Tataranno, Maria Luisa; Mahamuud, Ubah; Verhage, Cornelia H.; Eijsermans, Rian M. J. C.; Smit, Liesbeth S.; Jellema, Reint K.; de Haan, Timo R.; Ter Horst, Hendrik J.; de Boode, Willem P.; Steggerda, Sylke J.; Prins, Henk-Jan; de Haar, Colin G.; de Vries, Linda S.; van Bel, Frank; Heijnen, Cobi J.; Nijboer, Cora H.; Benders, Manon J. N. L.			Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study	LANCET NEUROLOGY			English	Article							STEM-CELLS; INFANTS	Background Perinatal arterial ischaemic stroke (PAIS) is an important cause of neurodevelopmental disabilities. In this first-in-human study, we aimed to assess the feasibility and safety of intranasally delivered bone marrow-derived allogeneic mesenchymal stromal cells (MSCs) to treat PAIS in neonates. Methods In this open-label intervention study in collaboration with all neonatal intensive care units in the Netherlands, we included neonates born at full term (>= 36 weeks of gestation) with MRI-confirmed PAIS in the middle cerebral artery region. All eligible patients were transferred to the neonatal intensive care unit of the Wilhelmina Children's Hospital. Neonates received one dose of 45-50 x 10(6) bone-marrow derived MSCs intranasally within 7 days of presenting signs of PAIS. The primary endpoints were acute and subacute safety outcomes, including vital signs, blood markers, and the occurrence of toxicity, adverse events, and serious adverse events. The occurrence of unexpected cerebral abnormalities by a repeat MRI at 3 months of age was a secondary endpoint. As part of standard clinical follow-up at Wilhelmina Children's Hospital, we assessed corticospinal tract development on MRI and performed motor assessments at 4 months of age. This study is registered with ClinicalTrials.gov, NCT03356821. Findings Between Feb 11, 2020, and April 29, 2021, ten neonates were enrolled in the study. Intranasal administration of MSCs was well tolerated in all ten neonates. No serious adverse events were observed. One adverse event was seen: a mild transient fever of 38 degrees C without the need for clinical intervention. Blood inflammation markers (C-reactive protein, procalcitonin, and leukocyte count) were not significantly different pre-administration versus postadministration and, although thrombocyte levels increased (p=0.011), all were within the physiological range. Followup MRI scans did not show unexpected structural cerebral abnormalities. All ten patients had initial pre-Wallerian changes in the corticospinal tracts, but only four (40%) patients showed asymmetrical corticospinal tracts at follow-up MRI. Abnormal early motor assessment was found in three (30%) infants. Interpretation This first-in-human study demonstrates that intranasal bone marrow-derived MSC administration in neonates after PAIS is feasible and no serious adverse events were observed in patients followed up until 3 months of age. Future large-scale placebo-controlled studies are needed to determine the therapeutic effect of intranasal MSCs for PAIS. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[Baak, Lisanne M.; Wagenaar, Nienke; van der Aa, Niek E.; Groenendaal, Floris; Dudink, Jeroen; Tataranno, Maria Luisa; Mahamuud, Ubah; de Vries, Linda S.; van Bel, Frank; Benders, Manon J. N. L.] Univ Utrecht, Utrecht Brain Ctr, Univ Med Ctr, Dept Neonatol, Utrecht, Netherlands; [Verhage, Cornelia H.; Eijsermans, Rian M. J. C.] Univ Utrecht, Utrecht Brain Ctr, Univ Med Ctr, Child Dev & Exercise Ctr, Utrecht, Netherlands; [Nijboer, Cora H.] Univ Utrecht, Utrecht Brain Ctr, Univ Med Ctr, Dept Dev Origins Dis, Utrecht, Netherlands; [Nijboer, Cora H.] Univ Utrecht, Wilhelmina Childrens Hosp, Utrecht, Netherlands; [Smit, Liesbeth S.] Erasmus MC, Sophia Childrens Hosp, Neurol, Rotterdam, Netherlands; [Jellema, Reint K.] Maastricht Univ, Med Ctr, Dept Neonatol, Maastricht, Netherlands; [de Haan, Timo R.] Amsterdam Univ Med Ctr, Acad Med Ctr, Emma Childrens Hosp, Dept Neonatol, Amsterdam, Netherlands; [Ter Horst, Hendrik J.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Neonatol, Groningen, Netherlands; [de Boode, Willem P.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Amalia Childrens Hosp,Dept Neonatol, Nijmegen, Netherlands; [Steggerda, Sylke J.] Leiden Univ, Med Ctr, Willem Alexander Childrens Hosp, Dept Neonatol, Leiden, Netherlands; [Prins, Henk-Jan; de Haar, Colin G.] Univ Med Ctr Utrecht, Pharm Dept, Cell Therapy Facil, Utrecht, Netherlands; [Heijnen, Cobi J.] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Div Internal Med, Houston, TX 77030 USA	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Wilhelmina Kinderziekenhuis; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Maastricht University; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center; University of Texas System; UTMD Anderson Cancer Center	Benders, MJNL (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, NL-3508 AB Utrecht, Netherlands.	m.benders@umcutrecht.nl		de Haar, Colin/0000-0003-4358-2410	Netherlands Organization for Health Research and Development (ZonMw)	Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	Netherlands Organization for Health Research and Development (ZonMw).	Ahn SY, 2021, STEM CELL TRANSL MED, V10, P1129, DOI 10.1002/sctm.20-0330; Ahn SY, 2018, STEM CELL TRANSL MED, V7, P847, DOI 10.1002/sctm.17-0219; Ahn SY, 2017, J PEDIATR-US, V185, P49, DOI 10.1016/j.jpeds.2017.02.061; Benders MJ, 2014, J PEDIATR-US, V164, P481, DOI 10.1016/j.jpeds.2013.10.084; Cotten CM, 2014, J PEDIATR-US, V164, P973, DOI 10.1016/j.jpeds.2013.11.036; Danielyan L, 2009, EUR J CELL BIOL, V88, P315, DOI 10.1016/j.ejcb.2009.02.001; De Vries LS, 2005, NEUROPEDIATRICS, V36, P12, DOI 10.1055/s-2005-837544; Domi T, 2009, STROKE, V40, P780, DOI 10.1161/STROKEAHA.108.529958; Donega V, 2015, PEDIATR RES, V78, P520, DOI 10.1038/pr.2015.145; Donega V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112339; Donega V, 2014, EXP NEUROL, V261, P53, DOI 10.1016/j.expneurol.2014.06.009; Donega V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051253; Einspieler C, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101616; Einspieler C, 2016, J PEDIAT-BRAZIL, V92, pS64, DOI 10.1016/j.jped.2015.12.003; Ek L, 2019, DEV MED CHILD NEUROL, V61, P1087, DOI 10.1111/dmcn.14163; Gale C, 2018, ARCH DIS CHILD-FETAL, V103, pF301, DOI 10.1136/archdischild-2017-313707; Govaert P, 2009, SEMIN FETAL NEONAT M, V14, P284, DOI 10.1016/j.siny.2009.07.006; Haataja L, 1999, J PEDIATR-US, V135, P153, DOI 10.1016/S0022-3476(99)70016-8; Hay K, 2018, PEDIATR NEUROL, V87, P70, DOI 10.1016/j.pediatrneurol.2018.07.002; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Kersbergen KJ, 2014, NEUROIMAGE, V103, P214, DOI 10.1016/j.neuroimage.2014.09.039; Kirton A, 2007, STROKE, V38, P974, DOI 10.1161/01.STR.0000258101.67119.72; Krumlinde-Sundholm L, 2017, DEV MED CHILD NEUROL, V59, P1276, DOI 10.1111/dmcn.13585; Lalu MM, 2020, TRANSL STROKE RES, V11, P345, DOI 10.1007/s12975-019-00736-5; Li YH, 2015, EXP MOL PATHOL, V98, P145, DOI 10.1016/j.yexmp.2015.01.016; Rijken M, 2015, GUIDELINES NATL NEON; Ryll UC, 2021, DEV MED CHILD NEUROL, V63, P436, DOI 10.1111/dmcn.14739; Sorg AL, 2021, NEONATOLOGY, DOI 10.1159/000514922; Tsuji M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61311-9; Vaes JEG, 2021, GLIA, V69, P655, DOI 10.1002/glia.23919; van Velthoven CTJ, 2010, PEDIATR RES, V68, P419, DOI 10.1203/PDR.0b013e3181f1c289; Wagenaar N, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2017-4164; Wagenaar N, 2017, DEV MED CHILD NEUROL, V59, P997, DOI 10.1111/dmcn.13528; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213; Wiedmeier SE, 2009, J PERINATOL, V29, P130, DOI 10.1038/jp.2008.141	35	4	4	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2022	21	6					528	536		10.1016/S1474-4422(22)00117-X	http://dx.doi.org/10.1016/S1474-4422(22)00117-X			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3Z0EK	35568047				2022-12-18	WOS:000844093900005
J	Lagreze, WA; Kuchlin, S; Ihorst, G; Grotejohann, B; Beisse, F; Volkmann, M; Heinrich, SP; Albrecht, P; Ungewiss, J; Worner, M; Hug, MJ; Wolf, S; Diem, R				Lagreze, Wolf A.; Kuechlin, Sebastian; Ihorst, Gabriele; Grotejohann, Birgit; Beisse, Flemming; Volkmann, Martin; Heinrich, Sven P.; Albrecht, Philipp; Ungewiss, Judith; Woerner, Michael; Hug, Martin J.; Wolf, Sebastian; Diem, Ricarda		Tone Study Grp	Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	LANCET NEUROLOGY			English	Article							MULTIPLE-SCLEROSIS; PHASE-2; METHYLPREDNISOLONE; NEUROPROTECTION; TRIAL; NEURONS; PROTECT; BRAIN	Background The human cytokine erythropoietin conveys neuroprotection in animal models but has shown ambiguous results in phase 2 clinical trials in patients with optic neuritis. We assessed the safety and efficacy of erythropoietin in patients with optic neuritis as a clinically isolated syndrome in a multicentre, prospective, randomised clinical trial. Methods This randomised, placebo -controlled, double-blind phase 3 trial, conducted at 12 tertiary referral centres in Gertnany, included participants aged 18-50 years, within 10 days of onset of unilateral optic neuritis, with visual acuity of 0.5 or less, and without a previous diagnosis of multiple sclerosis. Participants were randomly assigned (1:1) to receive either 33 000 IU erythropoietin or placebo intravenously for 3 days as an adjunct to high -dose intravenous methylprednisolone (1000 mg per day). Block randomisation was perfoirned by the trial statistician using an SAS code that generated randomly varying block sizes, stratified by study site and distributed using sealed envelopes. All trial participants and all study staff were masked to treatment assignment, except the trial pharmacist. The first primary outcome was atrophy of the peripapillary retinal nerve fibre layer (pRNFL), measured by optic coherence tomography (OCT) as the difference in pRNFL thickness between the affected eye at week 26 and the unaffected eye at baseline. The second primary outcome was low contrast letter acuity at week 26, measured as the 2.5% Sloan chart score of the affected eye. Analysis was performed in the full analysis set of all randomised participants for whom treatment was started and at least one follow-up OCT measurement was available. Safety was analysed in all patients who received at least one dose of the trial tnedication. This trial is registered at ClinicalTrials.gov, NCT01962571. Findings 108 participants were enrolled between Nov 25,2014, and Oct 9,2017, of whom 55 were assigned to erythropoietin and 53 to placebo. Five patients were excluded from the primary analysis due to not receiving the allocated medication, withdrawn consent, revised diagnosis, or loss to follow-up, yielding a full analysis set of 52 patients in the erythropoietin group and 51 in the placebo group. Mean pRNFL atrophy was 15.93 pm (SD 14.91) in the erythropoietin group and 14.65 pm (15.60) in the placebo group (adjusted mean treatment difference 1.02 pm; 95% CI 5.51 to 7.55; p=0.76). Mean low contrast letter acuity scores were 49.60 (21.31) in the erythropoietin group and 49.06 (21.93) in the placebo group (adjusted mean treatment difference 4.03; 13.06 to 5.01). Adverse events occurred in 43 (81%) participants in the erythropoietin group and in 42 (81%) in the placebo group. The most common adverse event was headache, occuring in 15 (28%) patients in the erythropoietin group and 13 (25%) patients in the placebo group. Serious adverse events occurred in eight (15%) participants in the erythropoietin and in four (8%) in the placebo group. One patient (2%) in the erythropoietin group developed a venous sinus thrombosis, which was treated with anticoagulants and resolved without sequelae. Interpretation Erythropoietin as an adjunct to corticosteroids conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis. Future research could focus on modified erythropoietin administration, assess its efficacy independent of corticosteroids, and investigate whether it affects the conversion of optic neuritis to multiple sclerosis.	[Lagreze, Wolf A.; Kuechlin, Sebastian; Heinrich, Sven P.] Univ Freiburg, Fac Med, Med Ctr, Ctr Eye, D-79106 Freiburg, Germany; [Ihorst, Gabriele; Grotejohann, Birgit] Univ Freiburg, Fac Med, Med Ctr, Clin Trials Unit, Freiburg, Germany; [Hug, Martin J.] Univ Freiburg, Fac Med, Med Ctr, Pharm, Freiburg, Germany; [Beisse, Flemming] Heidelberg Univ, Univ Hosp, Dept Ophthalmol, Heidelberg, Germany; [Diem, Ricarda] Heidelberg Univ, Univ Hosp, Dept Neurol, Heidelberg, Germany; [Volkmann, Martin] Med Serv Ctr PD Dr Volkmann & Colleagues, Karlsruhe, Germany; [Albrecht, Philipp] Heinrich Heine Univ Dusseldorf, Fac Med, Dept Neurol, Dusseldorf, Germany; [Ungewiss, Judith; Woerner, Michael] Aalen Univ Appl Sci, Competence Ctr Vis Res, Aalen, Germany; [Woerner, Michael] Blickshift, Stuttgart, Germany; [Wolf, Sebastian] Univ Bern, Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland; [Diem, Ricarda] German Canc Res Ctr DFKZ, Clin Cooperat Unit Neurooncol, German Canc Consortium DKTK, Heidelberg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Heinrich Heine University Dusseldorf; Hochschule Aalen; University of Bern; University Hospital of Bern; Helmholtz Association; German Cancer Research Center (DKFZ)	Lagreze, WA (corresponding author), Univ Freiburg, Fac Med, Med Ctr, Ctr Eye, D-79106 Freiburg, Germany.	wolf.lagreze@uniklinik-freiburg.de		Mulazzani, Elisabeth/0000-0003-0721-8072; Kuechlin, Sebastian/0000-0003-0758-5120	German Federal Ministry of Education and Research (BMBF)	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	German Federal Ministry of Education and Research (BMBF).	Bond WS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00523; Borhani-Haghighi A, 2012, NEUROSCIENCES, V17, P151; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brodsky M, 2008, ARCH NEUROL-CHICAGO, V65, P727, DOI 10.1001/archneur.65.6.727; Cadavid Diego, 2017, Lancet Neurol, V16, P189, DOI 10.1016/S1474-4422(16)30377-5; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Cruz-Herranz A, 2016, NEUROLOGY, V86, P2303, DOI 10.1212/WNL.0000000000002774; Davies AL, 2013, ANN NEUROL, V74, P815, DOI 10.1002/ana.24006; Diem R, 2005, BRAIN, V128, P375, DOI 10.1093/brain/awh365; Diem R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010956; Dreixler JC, 2009, ANESTHESIOLOGY, V110, P774, DOI 10.1097/ALN.0b013e31819c4601; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Gal RL, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001430.pub4; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Henderson APD, 2010, BRAIN, V133, P2592, DOI 10.1093/brain/awq146; King CE, 2007, EXP NEUROL, V205, P48, DOI 10.1016/j.expneurol.2007.01.017; Kretz A, 2005, MOL CELL NEUROSCI, V29, P569, DOI 10.1016/j.mcn.2005.04.009; Kupersmith MJ, 2007, NEUROLOGY, V69, P508, DOI 10.1212/01.wnl.0000267272.60714.42; Lassmann H, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a028936; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; Odom JV, 2016, DOC OPHTHALMOL, V133, P1, DOI 10.1007/s10633-016-9553-y; Petzold A, 2020, J NEUROL NEUROSUR PS, V91, P9, DOI 10.1136/jnnp-2019-321653; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Polman Chris H, 2011, Ann Neurol, V69, P292, DOI 10.1002/ana.22366; Raftopoulos R, 2016, LANCET NEUROL, V15, P259, DOI 10.1016/S1474-4422(16)00004-1; Sanjari MS, 2019, J OPHTHAL VIS RES, V14, P299, DOI 10.18502/jovr.v14i3.4786; Schreiber K, 2017, MULT SCLER J, V23, P675, DOI 10.1177/1352458516661048; Shayegannejad V, 2015, GRAEF ARCH CLIN EXP, V253, P797, DOI 10.1007/s00417-014-2925-7; Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544; Suhs KW, 2012, ANN NEUROL, V72, P199, DOI 10.1002/ana.23573; Tamura T, 2017, BRAIN RES, V1662, P65, DOI 10.1016/j.brainres.2017.02.023; Tewarie P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034823; Tsakiri A, 2012, MULT SCLER J, V18, P72, DOI 10.1177/1352458511415452; Zhang F, 2006, J NEUROSCI RES, V83, P1241, DOI 10.1002/jnr.20816	34	4	4	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2021	20	12					991	1000		10.1016/S1474-4422(21)00322-7	http://dx.doi.org/10.1016/S1474-4422(21)00322-7			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YZ6RX	34800417				2022-12-18	WOS:000755602800024
J	Bachynski, KE; Smoliga, JM				Bachynski, Kathleen E.; Smoliga, James M.			Pseudomedicine for sports concussions in the USA	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2021	20	10					791	792		10.1016/S1474-4422(19)30250-9	http://dx.doi.org/10.1016/S1474-4422(19)30250-9		SEP 2021	2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UY8AW	31279745				2022-12-18	WOS:000701741000013
J	Rothwell, PM; Buchan, A				Rothwell, Peter M.; Buchan, Alastair			A new thrombolytic drug for acute ischaemic stroke	LANCET NEUROLOGY			English	Editorial Material							RECOMBINANT STAPHYLOKINASE		[Rothwell, Peter M.] Univ Oxford, Nuffield Dept Clin Neurosci, Wolfson Ctr Prevent Stroke & Dementia, Oxford OX3 9DU, England; [Buchan, Alastair] Univ Oxford, Radcliffe Dept Med, Acute Stroke Programme, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Rothwell, PM (corresponding author), Univ Oxford, Nuffield Dept Clin Neurosci, Wolfson Ctr Prevent Stroke & Dementia, Oxford OX3 9DU, England.	peter.rothwell@ndcn.ox.ac.uk						Collen D, 1997, CIRCULATION, V95, P463; Collen D, 1998, NAT MED, V4, P279, DOI 10.1038/nm0398-279; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Gusev EI, 2021, LANCET NEUROL, V20, P721, DOI 10.1016/S1474-4422(21)00210-6; Lin CJ, 2019, STROKE, V50, P3519, DOI 10.1161/STROKEAHA.119.026717; Rother J, 2013, CEREBROVASC DIS, V35, P313, DOI 10.1159/000348705; Stefanos R, 2020, INTERN EMERG MED, V15, P1085, DOI 10.1007/s11739-020-02450-9; The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581, DOI [DOI 10.1056/NEJM199512143332401, 10.1056/NEJM199512143332401 PMID: 7477192, DOI 10.1056/NEJM199512143332401PMID:7477192]; Yaghi S, 2014, JAMA NEUROL, V71, P1181, DOI 10.1001/jamaneurol.2014.1210	9	4	4	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2021	20	9					687	689		10.1016/S1474-4422(21)00256-8	http://dx.doi.org/10.1016/S1474-4422(21)00256-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UK3MC	34418384				2022-12-18	WOS:000691876000002
J	Gillespie, CS; Bandyopadhyay, S; Jenkins, AJ; Hutchinson, P				Gillespie, Conor S.; Bandyopadhyay, Soham; Jenkins, Alistair J.; Hutchinson, Peter		Neurology Neurosurg Interest Grp	Inspiring the next generation	LANCET NEUROLOGY			English	Letter									[Gillespie, Conor S.] Univ Liverpool, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England; [Bandyopadhyay, Soham] Univ Oxford, Nuffield Dept Surg Sci, Div Med Sci, Oxford Univ Global Surg Grp, Oxford OX3 9DU, England; [Jenkins, Alistair J.] Royal Victoria Infirm, Dept Neurosurg, Newcastle Upon Tyne, Tyne & Wear, England; [Hutchinson, Peter] Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge, England; [Hutchinson, Peter] Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England	University of Liverpool; University of Oxford; Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Gillespie, CS (corresponding author), Univ Liverpool, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England.	nasnsiggroup@gmail.com		Bandyopadhyay, Soham/0000-0001-6553-3842	National Institute for Health Research (NIHR); NIHR Cambridge Biomedical Research Centre; European Union Seventh Framework Program (CENTER-TBI) [602150]; NIHR Senior Investigator Award; Royal College of Surgeons of England	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); European Union Seventh Framework Program (CENTER-TBI); NIHR Senior Investigator Award; Royal College of Surgeons of England	PH is supported by a Research Professorship from the National Institute for Health Research (NIHR), the NIHR Cambridge Biomedical Research Centre, a European Union Seventh Framework Program grant (CENTER-TBI; grant number 602150), a NIHR Senior Investigator Award, and the Royal College of Surgeons of England. All other authors declare no competing interests. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Bandyopadhyay S, 2022, BRIT J NEUROSURG, V36, P19, DOI 10.1080/02688697.2020.1849555; Lim GHT, 2021, PERSPECT MED EDUC, V10, P130, DOI 10.1007/s40037-020-00645-6; Norton EJ, 2020, LANCET NEUROL, V19, P382, DOI 10.1016/S1474-4422(20)30080-6	3	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					256	+		10.1016/S1474-4422(21)00068-5	http://dx.doi.org/10.1016/S1474-4422(21)00068-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33743231	Bronze			2022-12-18	WOS:000630325700009
J	Goemans, N				Goemans, Nathalie			Gene therapy for spinal muscular atrophy: hope and caution	LANCET NEUROLOGY			English	Editorial Material							REPLACEMENT THERAPY; DELIVERY		[Goemans, Nathalie] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium	KU Leuven; University Hospital Leuven	Goemans, N (corresponding author), Univ Hosp Leuven, Dept Pediat, Leuven, Belgium.	nathalie.goemans@uzleuven.be						Bevan AK, 2011, MOL THER, V19, P1971, DOI 10.1038/mt.2011.157; Dangouloff T, 2020, NEUROMUSCULAR DISORD, V30, P93, DOI 10.1016/j.nmd.2019.11.002; Day JW, 2021, LANCET NEUROL, V20, P284, DOI 10.1016/S1474-4422(21)00001-6; Finkel RS, 2014, NEUROLOGY, V83, P810, DOI 10.1212/WNL.0000000000000741; Govoni A, 2018, MOL NEUROBIOL, V55, P6307, DOI 10.1007/s12035-017-0831-9; Kirschner J, 2020, EUR J PAEDIATR NEURO, V28, P38, DOI 10.1016/j.ejpn.2020.07.001; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Saraiva J, 2016, J CONTROL RELEASE, V241, P94, DOI 10.1016/j.jconrel.2016.09.011; Soler-Botija C, 2002, BRAIN, V125, P1624, DOI 10.1093/brain/awf155	9	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					251	+		10.1016/S1474-4422(21)00071-5	http://dx.doi.org/10.1016/S1474-4422(21)00071-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33743228				2022-12-18	WOS:000630325700006
J	Cross, JH				Cross, J. Helen			Epilepsy in 2020-a new dawn	LANCET NEUROLOGY			English	Editorial Material									[Cross, J. Helen] UCL Natl Inst Hlth Res BRC Great Ormond St Inst C, London WC1N 1EH, England		Cross, JH (corresponding author), UCL Natl Inst Hlth Res BRC Great Ormond St Inst C, London WC1N 1EH, England.	h.cross@ucl.ac.uk	Cross, J. Helen/ACK-3032-2022	Cross, J. Helen/0000-0001-7345-4829				Colasante G, 2020, MOL THER, V28, P235, DOI 10.1016/j.ymthe.2019.08.018; Han Z, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz6100; Hatton Sean N, 2020, Brain, V143, P2454, DOI 10.1093/brain/awaa200; Lagae L, 2019, LANCET, V394, P2243, DOI 10.1016/S0140-6736(19)32500-0; Lamberink HJ, 2020, LANCET NEUROL, V19, P748, DOI 10.1016/S1474-4422(20)30220-9; Lu L, 2020, EPILEPSIA, V61, pE49, DOI 10.1111/epi.16524; Miller WR, 2020, EPILEPSY BEHAV, V111, DOI 10.1016/j.yebeh.2020.107238; Nabbout R, 2020, JAMA NEUROL, V77, P300, DOI 10.1001/jamaneurol.2019.4113; Niestroj LM, 2020, BRAIN, V143, P2106, DOI 10.1093/brain/awaa171; Sourbron J, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00191	10	4	4	2	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					8	+		10.1016/S1474-4422(20)30438-5	http://dx.doi.org/10.1016/S1474-4422(20)30438-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33340487				2022-12-18	WOS:000600831400007
J	Ortega, MD; Borrel, JM; Bermejo, TD; Gonzalez-Lamuno, D; Manso, C; de la Torre, R; Mayer, MA; de Asua, DR; Dierssen, M				del Carmen Ortega, Maria; Borrel, Jose M.; de Jesus Bermejo, Teresa; Gonzalez-Lamuno, Domingo; Manso, Coral; de la Torre, Rafael; Mayer, Miguel-Angel; Real de Asua, Diego; Dierssen, Mara		Spanish Trisomy 2	Lessons from individuals with Down syndrome during COVID-19	LANCET NEUROLOGY			English	Letter									[del Carmen Ortega, Maria] Hosp Univ 12 Octubre, Res Inst i 12, Dept Psychiat, Madrid, Spain; [Borrel, Jose M.; Manso, Coral] Down Espana Huesca, Huesca, Spain; [de Jesus Bermejo, Teresa] Inst Hispalense Pediat, Unidad Neuropediat, Seville, Spain; [Gonzalez-Lamuno, Domingo] Univ Cantabria, Univ Hosp Marques Valdecilla, Dept Pediat, Santander, Spain; [de la Torre, Rafael] Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid, Spain; [Mayer, Miguel-Angel] Univ Pompeu Fabra, Hosp del Mar Med Res Inst, Res Programme Biomed Informat, Neurosci Res Programme RdlT, Barcelona, Spain; [Dierssen, Mara] Univ Pompeu Fabra, Ctr Genom Regulat, Barcelona Inst Sci & Technol, Ctr Invest Biomed Red Enfermedades Raras, Barcelona, Spain; [Real de Asua, Diego] Hosp Univ La Princesa, Dept Internal Med, Adult Down Syndrome Outpatient Unit, Madrid, Spain; [Real de Asua, Diego] Hosp Univ La Princesa, Inst Invest Sanitaria La Princesa, Hosp Univ La Princesa, Madrid, Spain	Hospital Universitario 12 de Octubre; Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital de La Princesa; Hospital de La Princesa	Dierssen, M (corresponding author), Univ Pompeu Fabra, Ctr Genom Regulat, Barcelona Inst Sci & Technol, Ctr Invest Biomed Red Enfermedades Raras, Barcelona, Spain.	mara.dierssen@crg.eu	Mayer, Miguel Angel/AAL-2810-2021; Ortega Bernardo, Maria del Carmen/AHD-8046-2022; Dierssen, Mara/G-3552-2015	Mayer, Miguel Angel/0000-0003-0362-6298; Ortega Bernardo, Maria del Carmen/0000-0002-3964-0123; Dierssen, Mara/0000-0003-0853-6865				Courtenay K, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1609; Dierssen M, 2012, NAT REV NEUROSCI, V13, P844, DOI 10.1038/nrn3314; Espinosa JM, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100019; Grieco J, 2015, AM J MED GENET C, V169, P135, DOI 10.1002/ajmg.c.31439; Wishart JG, 2007, J INTELL DISABIL RES, V51, P996, DOI 10.1111/j.1365-2788.2007.01007.x	5	4	4	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2020	19	12					974	+		10.1016/S1474-4422(20)30401-4	http://dx.doi.org/10.1016/S1474-4422(20)30401-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PG3EL	33212059	Green Published, Bronze			2022-12-18	WOS:000599622000010
J	Gorelick, PB; Sorond, F				Gorelick, Philip B.; Sorond, Farzaneh			Cognitive function in SPRINT: where do we go next?	LANCET NEUROLOGY			English	Editorial Material							BLOOD-PRESSURE; PREVENTION; DEMENTIA; TRIAL		[Gorelick, Philip B.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA; Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Feinberg School of Medicine	Gorelick, PB (corresponding author), Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA.	pgorelick@thorek.org						Gorelick PB, 2018, J NEUROCHEM, V144, P609, DOI 10.1111/jnc.14113; Gorelick PB, 2014, JAMA NEUROL, V71, P1211, DOI 10.1001/jamaneurol.2014.2014; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Nasrallah IM, 2019, JAMA-J AM MED ASSOC, V322, P524, DOI 10.1001/jama.2019.10551; Peters R, 2019, NEUROLOGY, V92, P1017, DOI 10.1212/WNL.0000000000007543; Rapp SR, 2020, LANCET NEUROL, V19, P899, DOI 10.1016/S1474-4422(20)30319-7; SPRINT Research Group, 2015, N Engl J Med, V373, P2103, DOI 10.1056/NEJMoa1511939; The SPRINT MIND Investigators for the SPRINT Research Group, 2019, JAMA-J AM MED ASSOC, V321, P553, DOI DOI 10.1001/jama.2018.21442; Whelton Paul K, 2018, J Am Soc Hypertens, V12, DOI [10.1161/HYP.0000000000000065, 10.1016/j.jash.2018.06.010]	9	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2020	19	11					880	881		10.1016/S1474-4422(20)30356-2	http://dx.doi.org/10.1016/S1474-4422(20)30356-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3OI	33098785				2022-12-18	WOS:000581121200004
J	Isaacs, JD; Boenink, M				Isaacs, Jeremy D.; Boenink, Marianne			Biomarkers for dementia: too soon for routine clinical use	LANCET NEUROLOGY			English	Editorial Material							AMYLOID-PET		[Isaacs, Jeremy D.] St George Hosp, Dept Neurol, London SW17 0QT, England; [Isaacs, Jeremy D.] St Georges Univ London, Neurosci Res Ctr, London, England; [Boenink, Marianne] Radboud Univ Nijmegen, Med Ctr, IQ Healthcare, Nijmegen, Netherlands	St Georges University London; St Georges University London; University of London; King's College London; Radboud University Nijmegen	Isaacs, JD (corresponding author), St George Hosp, Dept Neurol, London SW17 0QT, England.; Isaacs, JD (corresponding author), St Georges Univ London, Neurosci Res Ctr, London, England.	jeremy.isaacs@nhs.net	Boenink, Marianne/GOE-4340-2022		Roche; Innovative Medicines Initiative; ZonMW	Roche(Roche Holding); Innovative Medicines Initiative; ZonMW(Netherlands Organization for Health Research and Development)	JDI has received an honorarium from Biogen for participation in an advisory board and conference fees and travel and accommodation expenses from Roche. He is a principal investigator on clinical trials of anti-amyloid therapies for Alzheimer's disease sponsored by Roche. He is a co-applicant with one of the authors of the linked Personal View (HZ) on a research grant under review investigating biomarkers of vascular contributions to cognitive impairment and dementia. MB is a non-paid member of the Ethics Advisory Board of the European Prevention of Alzheimer's Disease and the Amyloid Imaging to Prevent Alzheimer's Disease project, both funded by the Innovative Medicines Initiative. She has been a co-applicant on two ZonMW-funded projects investigating the diagnostic and prognostic value of tau-PET biomarkers, led by one of the authors of the linked Personal View (RO).	Boenink M, 2016, HEALTH TECHNOL SOC, P1, DOI 10.1057/978-1-137-54097-3; Chetelat G, 2020, LANCET NEUROL, V19, P951, DOI 10.1016/S1474-4422(20)30314-8; Jack CR, 2014, LANCET NEUROL, V13, P997, DOI 10.1016/S1474-4422(14)70194-2; Johnson KA, 2013, J NUCL MED, V54, P476, DOI 10.2967/jnumed.113.120618; Livingston G, 2020, BRIT J PSYCHIAT, V216, P35, DOI 10.1192/bjp.2019.160; Rabinovici GD, 2019, JAMA-J AM MED ASSOC, V321, P1286, DOI 10.1001/jama.2019.2000; Roberts RO, 2018, JAMA NEUROL, V75, P970, DOI 10.1001/jamaneurol.2018.0629; Schermer MHN, 2019, BIOETHICS, V33, P138, DOI 10.1111/bioe.12516; Swallow J, 2017, SOC SCI MED, V184, P57, DOI 10.1016/j.socscimed.2017.05.017; van der Burg S, 2019, MED HEALTH CARE PHIL, V22, P439, DOI 10.1007/s11019-018-09883-2	10	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2020	19	11					884	+		10.1016/S1474-4422(20)30365-3	http://dx.doi.org/10.1016/S1474-4422(20)30365-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	OF3OI	33098787				2022-12-18	WOS:000581121200007
J	McAlpine, LS; Zubair, AS; Moeller, J; Baehring, J; Spudich, S				McAlpine, Lindsay S.; Zubair, Adeel S.; Moeller, Jeremy; Baehring, Joachim; Spudich, Serena			Lessons from a neurology consult service for patients with COVID-19	LANCET NEUROLOGY			English	Letter									[McAlpine, Lindsay S.; Zubair, Adeel S.; Moeller, Jeremy; Baehring, Joachim; Spudich, Serena] Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06520 USA	Yale University	Spudich, S (corresponding author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St, New Haven, CT 06520 USA.	serena.spudich@yale.edu						Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; Kirby T, 2020, LANCET RESP MED, V8, P547, DOI 10.1016/S2213-2600(20)30228-9; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; United States Census Bureau, QUICKFACTS CONN; Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					806	+		10.1016/S1474-4422(20)30316-1	http://dx.doi.org/10.1016/S1474-4422(20)30316-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3NN	32949536	Bronze, Green Published			2022-12-18	WOS:000581119100010
J	[Anonymous]				[Anonymous]			Latin America takes centre stage in dementia prevention	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2020	19	9					711	711		10.1016/S1474-4422(20)30260-X	http://dx.doi.org/10.1016/S1474-4422(20)30260-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NE4GY	32822620	Bronze			2022-12-18	WOS:000562556500003
J	Maegele, M				Maegele, Marc			Global traumatic brain injury research enters a new era	LANCET NEUROLOGY			English	Editorial Material							CENTER-TBI; MULTICENTER; OUTCOMES; CHINA; CARE		[Maegele, Marc] Univ Witten Herdecke, Inst Res Operat Med, Dept Traumatol & Orthopaed Surg, Cologne Merheim Med Ctr, D-51109 Cologne, Germany; [Maegele, Marc] Southern Med Univ, Treatment Ctr Traumat Injuries, Flexible Recruitment Program Foreign Talents, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China	Witten Herdecke University; Southern Medical University - China	Maegele, M (corresponding author), Univ Witten Herdecke, Inst Res Operat Med, Dept Traumatol & Orthopaed Surg, Cologne Merheim Med Ctr, D-51109 Cologne, Germany.; Maegele, M (corresponding author), Southern Med Univ, Treatment Ctr Traumat Injuries, Flexible Recruitment Program Foreign Talents, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.	marc.maegele@t-online.de			European Union 7th Framework Programme (EC) [602150]	European Union 7th Framework Programme (EC)	I am a collaborator and work package lead to the European CENTER-TBI project supported by the European Union 7th Framework Programme (EC grant 602150).	Feng JF, 2020, J NEUROTRAUM, V37, P1806, DOI 10.1089/neu.2019.6900; Gao GY, 2020, LANCET NEUROL, V19, P670, DOI 10.1016/S1474-4422(20)30182-4; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Sahuquillo J, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub3; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803	7	4	4	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2020	19	8					637	639		10.1016/S1474-4422(20)30208-8	http://dx.doi.org/10.1016/S1474-4422(20)30208-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT8ZY	32702323				2022-12-18	WOS:000573228000016
J	Hellmuth, J				Hellmuth, Joanna			Can we trust The End of Alzheimer's?	LANCET NEUROLOGY			English	Book Review									[Hellmuth, Joanna] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Hellmuth, J (corresponding author), Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA.							BREDESEN D, 2017, END ALZHEIMERS	1	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					389	390		10.1016/S1474-4422(20)30113-7	http://dx.doi.org/10.1016/S1474-4422(20)30113-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32333896	Green Accepted			2022-12-18	WOS:000573045100013
J	Filippi, M; Rocca, MA				Filippi, Massimo; Rocca, Maria A.			Rethinking multiple sclerosis treatment strategies	LANCET NEUROLOGY			English	Editorial Material							GUIDELINE; GRAY		[Filippi, Massimo; Rocca, Maria A.] IRCCS San Raffaele Sci Inst, Neuroimaging Res Unit, Inst Expt Neurol, Div Neurosci, I-20132 Milan, Italy; [Filippi, Massimo; Rocca, Maria A.] IRCCS San Raffaele Sci Inst, Neurol Unit, I-20132 Milan, Italy; [Filippi, Massimo] IRCCS San Raffaele Sci Inst, Neurophysiol Unit, I-20132 Milan, Italy; [Filippi, Massimo] Univ Vita Salute San Raffaele, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Filippi, M (corresponding author), IRCCS San Raffaele Sci Inst, Neuroimaging Res Unit, Inst Expt Neurol, Div Neurosci, I-20132 Milan, Italy.; Filippi, M (corresponding author), IRCCS San Raffaele Sci Inst, Neurol Unit, I-20132 Milan, Italy.; Filippi, M (corresponding author), IRCCS San Raffaele Sci Inst, Neurophysiol Unit, I-20132 Milan, Italy.; Filippi, M (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.	filippi.massimo@hsr.it	Filippi, Massimo/K-1755-2018	Filippi, Massimo/0000-0002-5485-0479				Filippi M, 2013, NEUROLOGY, V81, P1759, DOI 10.1212/01.wnl.0000435551.90824.d0; Harding K, 2019, JAMA NEUROL, V76, P536, DOI 10.1001/jamaneurol.2018.4905; He A, 2020, LANCET NEUROL, V19, P307, DOI 10.1016/S1474-4422(20)30067-3; Montalban X, 2018, EUR J NEUROL, V25, P215, DOI 10.1111/ene.13536; Rae-Grant A, 2018, NEUROLOGY, V90, P777, DOI 10.1212/WNL.0000000000005347; Rocca MA, 2017, BRAIN, V140, P2814, DOI 10.1093/brain/awx250; Rocca MA, 2016, RADIOLOGY, V278, P841, DOI 10.1148/radiol.2015150532; Rush CA, 2015, NAT REV NEUROL, V11, P379, DOI 10.1038/nrneurol.2015.85; Tramacere I, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011381.pub2; Weideman AM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00577	10	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2020	19	4					281	+		10.1016/S1474-4422(20)30063-6	http://dx.doi.org/10.1016/S1474-4422(20)30063-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KW1GS	32199086				2022-12-18	WOS:000520920500005
J	Goyal, M; Ospel, J				Goyal, Mayank; Ospel, Johanna			Challenges to stroke care 5 years after endovascular therapy became the standard	LANCET NEUROLOGY			English	Editorial Material													Ospel, Johanna/AAK-9939-2020	Ospel, Johanna/0000-0003-0029-6764					0	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					210	211		10.1016/S1474-4422(20)30005-3	http://dx.doi.org/10.1016/S1474-4422(20)30005-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	32085835				2022-12-18	WOS:000514832700016
J	Laurson-Doube, J; Rijke, N; Costello, K; McDonell, J; Giovannoni, G; Banwell, B; Baneke, P				Laurson-Doube, Joanna; Rijke, Nick; Costello, Kathleen; McDonell, Jennifer; Giovannoni, Gavin; Banwell, Brenda; Baneke, Peer			Health-care disparities for people with multiple sclerosis	LANCET NEUROLOGY			English	Letter									[Laurson-Doube, Joanna; Rijke, Nick; Baneke, Peer] Multiple Sclerosis Int Federat, London SE1 0LX, England; [Costello, Kathleen] Natl Multiple Sclerosis Soc, New York, NY USA; [McDonell, Jennifer] Multiple Sclerosis Soc Canada, Toronto, ON, Canada; [Giovannoni, Gavin] Queen Mary Univ London, Barts & London Sch Med, Blizard Inst, London, England; [Banwell, Brenda] Childrens Hosp Philadelphia, Dept Pediat Neurol, Philadelphia, PA 19104 USA	University of London; Queen Mary University London; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Laurson-Doube, J (corresponding author), Multiple Sclerosis Int Federat, London SE1 0LX, England.	joanna@msif.org		Laurson-Doube, Joanna/0000-0001-9619-9170; Rijke, Nick/0000-0002-0328-1309				[Anonymous], 2019, LANCET NEUROL, V18, P1067, DOI 10.1016/S1474-4422(19)30390-4; Chowdhury S, 2019, NEW ENGL J MED, V381, P1501, DOI 10.1056/NEJMp1907988; WHO, 2015, SEL US ESS MED; WHO, 2019, SEL US ESS MED	4	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					207	+		10.1016/S1474-4422(19)30486-7	http://dx.doi.org/10.1016/S1474-4422(19)30486-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	32085833	Bronze			2022-12-18	WOS:000514832700013
J	Rowland, MJ; Veenith, T; Hutchinson, PJ; Perkins, GD				Rowland, Matthew J.; Veenith, Tonny; Hutchinson, Peter J.; Perkins, Gavin D.		SOS Trial Investigators	Osmotherapy in traumatic brain injury	LANCET NEUROLOGY			English	Letter									[Rowland, Matthew J.] Univ Oxford, Nuffield Dept Clin Neurosci, Kadoorie Ctr Crit Care Res, Oxford OX3 9DU, England; [Veenith, Tonny] Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England; [Hutchinson, Peter J.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge, England; [Perkins, Gavin D.] Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Warwick, England	University of Oxford; University of Birmingham; University of Cambridge; University of Warwick	Rowland, MJ (corresponding author), Univ Oxford, Nuffield Dept Clin Neurosci, Kadoorie Ctr Crit Care Res, Oxford OX3 9DU, England.	matthew.rowland@ndcn.ox.ac.uk	Veenith, Tonny/AAI-3067-2020; Veenith, Tonny/A-9948-2010; Perkins, Gavin/E-7613-2010	Veenith, Tonny/0000-0002-4125-8804; Veenith, Tonny/0000-0002-4125-8804; Perkins, Gavin/0000-0003-3027-7548				Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Roquilly A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018035; Rowland MJ., 2020, J INTENSIVE CARE SOC, DOI [10.1177/1751143720901690, DOI 10.1177/1751143720901690]; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1	4	4	4	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					208	208		10.1016/S1474-4422(20)30003-X	http://dx.doi.org/10.1016/S1474-4422(20)30003-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	32085834	Bronze			2022-12-18	WOS:000514832700014
J	Schneider, J				Schneider, Julie			Research momentum brings hope for dementia in 2019	LANCET NEUROLOGY			English	Editorial Material									[Schneider, Julie] Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA	Rush University	Schneider, J (corresponding author), Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA.	julie_a_schneider@rush.edu						Arboleda-Velasquez JF, 2019, NAT MED, V25, P1680, DOI 10.1038/s41591-019-0611-3; Deming Y, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau2291; Faraco G, 2019, NATURE, V574, P686, DOI 10.1038/s41586-019-1688-z; Lourida I, 2019, JAMA-J AM MED ASSOC, V322, P430, DOI 10.1001/jama.2019.9879; Shi Y, 2019, J EXP MED, V216, P2546, DOI 10.1084/jem.20190980; Shi Y, 2017, NATURE, V549, P523, DOI 10.1038/nature24016; Williamson JD, 2019, JAMA-J AM MED ASSOC, V321, P553, DOI 10.1001/jama.2018.21442	7	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					3	+		10.1016/S1474-4422(19)30453-3	http://dx.doi.org/10.1016/S1474-4422(19)30453-3			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM	31839245				2022-12-18	WOS:000502286000005
J	Becker, WJ				Becker, Werner J.			New treatment options needed for chronic cluster headache	LANCET NEUROLOGY			English	Editorial Material							STIMULATION		[Becker, Werner J.] Univ Calgary, Calgary, AB, Canada; [Becker, Werner J.] Richmond Rd Diagnost & Treatment Ctr, Chron Pain Ctr, Calgary, AB T2T 5C7, Canada	University of Calgary	Becker, WJ (corresponding author), Univ Calgary, Calgary, AB, Canada.; Becker, WJ (corresponding author), Richmond Rd Diagnost & Treatment Ctr, Chron Pain Ctr, Calgary, AB T2T 5C7, Canada.	wbecker@ucalgary.ca						Goadsby PJ, 2019, LANCET NEUROL, V18, P1081, DOI 10.1016/S1474-4422(19)30322-9; Guo S, 2018, CEPHALALGIA, V38, P1418, DOI 10.1177/0333102417738250; James KE, 1996, STAT MED, V15, P1421; Leone M, 2016, NEUROLOGY, V86, P194, DOI 10.1212/WNL.0000000000002117; Schoenen J, 2013, CEPHALALGIA, V33, P816, DOI 10.1177/0333102412473667	5	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1068	1069		10.1016/S1474-4422(19)30364-3	http://dx.doi.org/10.1016/S1474-4422(19)30364-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	31701886				2022-12-18	WOS:000495892200003
J	Finkel, AM; Brand, KP; Caplan, AL; Evans, JS; Wolpe, PR				Finkel, Adam M.; Brand, Kevin P.; Caplan, Arthur L.; Evans, John S.; Wolpe, Paul R.			First report the findings: genuine balance when reporting CTE	LANCET NEUROLOGY			English	Letter									[Finkel, Adam M.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA; [Brand, Kevin P.] Univ Ottawa, Telfer Sch Management, Ottawa, ON, Canada; [Caplan, Arthur L.] NYU, Sch Med, Div Med Eth, New York, NY USA; [Evans, John S.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Wolpe, Paul R.] Emory Univ, Ctr Eth, Atlanta, GA 30322 USA	University of Michigan System; University of Michigan; University of Ottawa; New York University; Harvard University; Harvard T.H. Chan School of Public Health; Emory University	Finkel, AM (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.	adfinkel@umich.edu		Caplan, Art/0000-0002-4061-8011; Finkel, Adam M./0000-0001-6259-9387; Evans, John/0000-0001-9837-1026				Binney ZO, 2019, NEUROLOGY, V92, P43, DOI 10.1212/WNL.0000000000006699; Brand KP, 2019, SEMIN NEUROL; Finkel AM, 2019, HUM ECOL RISK ASSESS, V25, P564, DOI 10.1080/10807039.2018.1456899; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Moore A, 2006, EMBO REP, V7, P1193, DOI 10.1038/sj.embor.7400862; SOKOL DK, 2013, BMJ-BRIT MED J, V347, DOI DOI 10.1136/BMJ.F6426; Stewart W, 2019, LANCET NEUROL, V18, P231, DOI 10.1016/S1474-4422(19)30020-1	7	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2019	18	6					521	522		10.1016/S1474-4422(19)30159-0	http://dx.doi.org/10.1016/S1474-4422(19)30159-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HY7RQ	31122490	Bronze			2022-12-18	WOS:000468334100008
J	Sorensen, HT				Sorensen, Henrik Toft			Global burden of neurological disorders: challenges and opportunities with the available data	LANCET NEUROLOGY			English	Editorial Material									[Sorensen, Henrik Toft] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8200 Aarhus N, Denmark	Aarhus University	Sorensen, HT (corresponding author), Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8200 Aarhus N, Denmark.	hts@clin.au.dk	Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040				Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI [10.1016/S1474-4422(18)30499-X, 10.1136/bmj.l94, 10.1016/S1474-4422(19)30034-1]; Johnson CO, 2019, LANCET NEUROL, V18, P439, DOI 10.1016/S1474-4422(19)30034-1; Logroscino G, 2018, LANCET NEUROL, V17, P1083, DOI 10.1016/S1474-4422(18)30404-6; Nichols E, 2019, LANCET NEUROL, V18, P88, DOI 10.1016/S1474-4422(18)30403-4; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Sorensen HT, 1996, INT J EPIDEMIOL, V25, P435, DOI 10.1093/ije/25.2.435; Wallin MT, 2019, LANCET NEUROL, V18, P269, DOI 10.1016/S1474-4422(18)30443-5; Weis NS, 2014, EPIDEMIOLOGIC METHOD, P27; Zunt JR, 2018, LANCET NEUROL, V17, P1061, DOI 10.1016/S1474-4422(18)30387-9	9	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2019	18	5					420	421		10.1016/S1474-4422(19)30027-4	http://dx.doi.org/10.1016/S1474-4422(19)30027-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HS8SW	30885508				2022-12-18	WOS:000464140400007
J	Hauser, WA				Hauser, W. Allen			An unparalleled assessment of the global burden of epilepsy	LANCET NEUROLOGY			English	Editorial Material									[Hauser, W. Allen] Columbia Univ, Sergievsky Ctr, New York, NY 10032 USA	Columbia University	Hauser, WA (corresponding author), Columbia Univ, Sergievsky Ctr, New York, NY 10032 USA.	wahauser@optonline.net	Hauser, W Allen/AAB-5277-2020					[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Beghi E, 2019, LANCET NEUROL, V18, P357, DOI 10.1016/S1474-4422(18)30454-X; Cardenas VM, 2014, EPILEPSIA, V55, P1347, DOI 10.1111/epi.12719; Ding D, 2006, EPILEPSIA, V47, P2032, DOI 10.1111/j.1528-1167.2006.00802.x; Kwan P, 2013, EPILEPSIA, V54, P537, DOI 10.1111/epi.12022; Nord E, 2015, LANCET GLOB HEALTH, V3, pE661, DOI 10.1016/S2214-109X(15)00189-8; Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709; Wang WZ, 2008, B WORLD HEALTH ORGAN, V86, P964, DOI 10.2471/BLT.07.047050	8	4	4	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2019	18	4					322	324		10.1016/S1474-4422(19)30042-0	http://dx.doi.org/10.1016/S1474-4422(19)30042-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HO7ZR	30773429	hybrid			2022-12-18	WOS:000461169400005
J	Spence, JD				Spence, J. David			Periprocedural events dominate outcomes of carotid stenting and endarterectomy	LANCET NEUROLOGY			English	Editorial Material							TRANSCRANIAL DOPPLER; MEDICAL THERAPY; FLOW REVERSAL; RISK		[Spence, J. David] Western Univ, Stroke Prevent & Atherosclerosis Res Ctr, Robarts Res Inst, London, ON N6G 2V4, Canada	Western University (University of Western Ontario)	Spence, JD (corresponding author), Western Univ, Stroke Prevent & Atherosclerosis Res Ctr, Robarts Res Inst, London, ON N6G 2V4, Canada.	dspence@robarts.ca	Spence, J. David/K-6396-2013	Spence, J. David/0000-0001-7478-1098				Almekhlafi MA, 2013, STROKE, V44, P1317, DOI 10.1161/STROKEAHA.111.000659; Alvarez B, 2012, J VASC SURG, V55, P978, DOI 10.1016/j.jvs.2011.10.084; Bogiatzi C, 2016, ISCHEMIC STROKE THER, P147; Brott TG, 2019, LANCET NEUROL, V18, P348, DOI 10.1016/S1474-4422(19)30028-6; Brott TG, 2016, NEW ENGL J MED, V374, P1021, DOI 10.1056/NEJMoa1505215; Chaturvedi S, 2013, STROKE, V44, P2957, DOI 10.1161/STROKEAHA.113.000918; Hicks CW, 2018, J VASC SURG, V67, P1736, DOI 10.1016/j.jvs.2017.09.056; Pelz DM, 2015, J NEUROSURG, V123, P856, DOI 10.3171/2014.9.JNS14811; Ribo M, 2006, STROKE, V37, P2846, DOI 10.1161/01.STR.0000244781.68371.59; Rosenfield K, 2016, NEW ENGL J MED, V374, P1011, DOI 10.1056/NEJMoa1515706; Spence JD, 2010, ARCH NEUROL-CHICAGO, V67, P180, DOI 10.1001/archneurol.2009.289	11	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2019	18	4					321	322		10.1016/S1474-4422(19)30040-7	http://dx.doi.org/10.1016/S1474-4422(19)30040-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HO7ZR	30738707				2022-12-18	WOS:000461169400004
J	Barker, R; Mason, SL				Barker, Roger; Mason, Sarah L.			The hunt for better treatments for Huntington's disease	LANCET NEUROLOGY			English	Editorial Material									[Barker, Roger; Mason, Sarah L.] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 0PY, England	University of Cambridge	Barker, R (corresponding author), Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 0PY, England.	rab46@cam.ac.uk		Barker, Roger Alistair/0000-0001-8843-7730				de Yebenes JG, 2011, LANCET NEUROL, V10, P1049, DOI 10.1016/S1474-4422(11)70233-2; Ionis Pharmaceuticals, 2017, ION PHARM LIC IONIS; Ionis Pharmaceuticals, 2018, NEW DAT IONIS HTT RX; Kara E, 2010, BRIT J PHARMACOL, V161, P1343, DOI 10.1111/j.1476-5381.2010.01010.x; Kieburtz K, 2013, MOVEMENT DISORD, V28, P1407, DOI 10.1002/mds.25362; Mason SL, 2016, EXPERT OPIN PHARMACO, V17, P41, DOI 10.1517/14656566.2016.1109630; McGarry A, 2017, J HUNTINGTONS DIS, V6, P189, DOI 10.3233/JHD-170241; Reilmann R, 2019, LANCET NEUROL, V18, P165, DOI 10.1016/S1474-4422(18)30391-0; Sahlholm K, 2015, PSYCHOPHARMACOLOGY, V232, P3443, DOI 10.1007/s00213-015-3997-8; Snowden J., 2014, HUNTINGTONS DIS, P36	10	4	4	3	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2019	18	2					131	133		10.1016/S1474-4422(18)30448-4	http://dx.doi.org/10.1016/S1474-4422(18)30448-4			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HI0TY	30563777	Green Submitted			2022-12-18	WOS:000456158200004
J	Gunn, AJ; Battin, M				Gunn, Alistair J.; Battin, Malcolm			Towards faster studies of neonatal encephalopathy	LANCET NEUROLOGY			English	Editorial Material									[Gunn, Alistair J.] Univ Auckland, Dept Physiol, Auckland 1023, New Zealand; [Battin, Malcolm] Auckland City Hosp, Newborn Serv, Auckland, New Zealand	University of Auckland; Auckland City Hospital	Gunn, AJ (corresponding author), Univ Auckland, Dept Physiol, Auckland 1023, New Zealand.	ajgunn@auckland.ac.nz			Health Research Council of New Zealand; Neurological foundation of New Zealand	Health Research Council of New Zealand(Health Research Council of New Zealand); Neurological foundation of New Zealand	We are supported by the Health Research Council of New Zealand and the Neurological foundation of New Zealand. We declare no competing interests.	Celcus AC, 1935, ON MEDICINE, V1, P1; Chalak LF, 2018, PEDIATR RES, V84, P861, DOI 10.1038/s41390-018-0174-x; Davidson JO, 2018, FRONT BIOSCI-LANDMRK, V23, P2204, DOI 10.2741/4700; Gunn AJ, 2009, CLIN PERINATOL, V36, P579, DOI 10.1016/j.clp.2009.06.007; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Lally PJ, 2019, LANCET NEUROL, V18, P35, DOI 10.1016/S1474-4422(18)30325-9; Lodygensky GA, 2018, JAMA PEDIATR, V172, P3, DOI 10.1001/jamapediatrics.2017.3044; Rutherford M, 2010, LANCET NEUROL, V9, P39, DOI 10.1016/S1474-4422(09)70295-9; Shankaran S, 2017, JAMA-J AM MED ASSOC, V318, P57, DOI 10.1001/jama.2017.7218	9	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2019	18	1					21	22		10.1016/S1474-4422(18)30370-3	http://dx.doi.org/10.1016/S1474-4422(18)30370-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HE1CJ	30447972	hybrid			2022-12-18	WOS:000453007700015
J	Stout, JC				Stout, Julie C.			Juvenile Huntington's disease: left behind?	LANCET NEUROLOGY			English	Editorial Material									[Stout, Julie C.] Monash Univ, Inst Cognit & Clin Neurosci, Sch Psychol Sci, Clayton, Vic 3800, Australia	Monash University	Stout, JC (corresponding author), Monash Univ, Inst Cognit & Clin Neurosci, Sch Psychol Sci, Clayton, Vic 3800, Australia.	julie.stout@monash.edu		Stout, Julie/0000-0001-9637-8590	CHDI Foundation, Inc.; Ionis Pharmaceuticals; Teva Pharmaceuticals; Vaccinex	CHDI Foundation, Inc.; Ionis Pharmaceuticals; Teva Pharmaceuticals(Teva Pharmaceutical Industries); Vaccinex	I have received other support from Ionis Pharmaceuticals, Teva Pharmaceuticals, and Vaccinex, personal fees from Roche, Prana Biotechnology, Mitoconix, UniQure, and Huntington's Study Group, and grants and personal fees from the CHDI Foundation, Inc.	Fusilli C, 2018, LANCET NEUROL, V17, P986, DOI 10.1016/S1474-4422(18)30294-1; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; Landwehrmeyer GB, 2017, MOV DISORD CLIN PRAC, V4, P212, DOI 10.1002/mdc3.12388; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Myers Richard H, 2004, NeuroRx, V1, P255, DOI 10.1602/neurorx.1.2.255; Paulsen JS, 2008, J NEUROL NEUROSUR PS, V79, P874, DOI 10.1136/jnnp.2007.128728	6	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2018	17	11					932	933		10.1016/S1474-4422(18)30334-X	http://dx.doi.org/10.1016/S1474-4422(18)30334-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GX3PG	30243863				2022-12-18	WOS:000447637500005
J	Westeneng, HJ; Al-Chalabi, A; Hardiman, O; Debray, TPA; van den Berg, LH				Westeneng, Henk-Jan; Al-Chalabi, Ammar; Hardiman, Orla; Debray, Thomas P. A.; van den Berg, Leonard H.			The life expectancy of Stephen Hawking, according to the ENCALS model	LANCET NEUROLOGY			English	Letter									[Westeneng, Henk-Jan; van den Berg, Leonard H.] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, NL-3584 CX Utrecht, Netherlands; [Al-Chalabi, Ammar] Kings Coll London, Inst Psychiat Psychol & Neurosci, Maurice Wohl Clin Neurosci Inst, London, England; [Al-Chalabi, Ammar] Kings Coll London, Inst Psychiat Psychol & Neurosci, United Kingdom Dementia Res Inst, London, England; [Hardiman, Orla] Trinity Coll Dublin, Trinity Biomed Sci Inst, Acad Unit Neurol, Dublin, Ireland; [Hardiman, Orla] Beaumont Hosp, Dept Neurol, Beaumont, Ireland; [Debray, Thomas P. A.] Univ Med Ctr Utrecht, Dept Epidemiol, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Debray, Thomas P. A.] Univ Med Ctr Utrecht, Cochrane Netherlands, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; University of London; King's College London; University of London; King's College London; Trinity College Dublin; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	van den Berg, LH (corresponding author), Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, NL-3584 CX Utrecht, Netherlands.	lberg@umcutrecht.nl	Hardiman, Orla/Y-3441-2019; Debray, Thomas/J-7413-2012; Al-Chalabi, Ammar/E-5361-2010	Hardiman, Orla/0000-0003-2610-1291; Debray, Thomas/0000-0002-1790-2719; Al-Chalabi, Ammar/0000-0002-4924-7712	MRC [MR/R024804/1] Funding Source: UKRI; Medical Research Council [MR/R024804/1, MR/L501529/1] Funding Source: Medline; Motor Neurone Disease Association [ALCHALABI-TALBOT/APR14/926-794] Funding Source: Medline; Motor Neurone Disease Association [AlChalabi-Talbot/Apr14/926-794] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Motor Neurone Disease Association; Motor Neurone Disease Association		Hawking S, 2002, BRIT MED J, V324, P1478, DOI 10.1136/bmj.324.7352.1478; McCoy T., 2015, WASHINGTON POST; van Es MA, 2017, LANCET, V390, P2084, DOI 10.1016/S0140-6736(17)31287-4; Westeneng HJ, 2018, LANCET NEUROL, V17, P423, DOI 10.1016/S1474-4422(18)30089-9	4	4	4	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2018	17	8					662	U4		10.1016/S1474-4422(18)30241-2	http://dx.doi.org/10.1016/S1474-4422(18)30241-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN5BH	30033055	Bronze, Green Submitted			2022-12-18	WOS:000439057500008
J	Thaler, D				Thaler, David			Patent foramen ovale in older patients with cryptogenic stroke or transient ischaemic attack	LANCET NEUROLOGY			English	Editorial Material							CLOSURE; EMBOLISM; THERAPY		[Thaler, David] Tufts Univ, Sch Med, Dept Neurol, Boston, MA 02111 USA	Tufts University	Thaler, D (corresponding author), Tufts Univ, Sch Med, Dept Neurol, Boston, MA 02111 USA.	dthaler@tuftsmedicalcenter.org			Abbott Laboratories	Abbott Laboratories(Abbott Laboratories)	DT reports personal fees from Abbott Laboratories for serving on a steering committee.	Kent DM, 2013, NEUROLOGY, V81, P619, DOI 10.1212/WNL.0b013e3182a08d59; Larsson SC, 2014, NEUROLOGY, V83, P1699, DOI 10.1212/WNL.0000000000000954; Mazzucco S, 2018, LANCET NEUROL, DOI [10.1016/S1474-4422(18)30198-4, DOI 10.1016/S1474-4422(18)30198-4]; Meier B, 2013, NEW ENGL J MED, V368, P1083, DOI 10.1056/NEJMoa1211716; Saver JL, 2017, NEW ENGL J MED, V377, P1022, DOI 10.1056/NEJMoa1610057; Sondergaard L, 2017, NEW ENGL J MED, V377, P1033, DOI 10.1056/NEJMoa1707404; Wessler BS, 2014, CIRC-CARDIOVASC IMAG, V7, P125, DOI 10.1161/CIRCIMAGING.113.000807	7	4	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2018	17	7					573	574		10.1016/S1474-4422(18)30198-4	http://dx.doi.org/10.1016/S1474-4422(18)30198-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GK8RP	29887163	hybrid			2022-12-18	WOS:000436495200004
J	Chataway, J				Chataway, Jeremy			Tackling progression in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							PLACEBO; TRIAL; MS		[Chataway, Jeremy] UCL, Inst Neurol, Dept Neuroinflammat, Queen Sq Multiple Sclerosis Ctr, London WC1N 3BG, England	University of London; University College London	Chataway, J (corresponding author), UCL, Inst Neurol, Dept Neuroinflammat, Queen Sq Multiple Sclerosis Ctr, London WC1N 3BG, England.	j.chataway@ucl.ac.uk			Efficacy and Mechanism Evaluation Programme; Health Technology Assessment Programme (National Institute for Health Research); UK Multiple Sclerosis Society; National Multiple Sclerosis Society; Receptos; Novartis; Roche; Biogen Idec	Efficacy and Mechanism Evaluation Programme; Health Technology Assessment Programme (National Institute for Health Research); UK Multiple Sclerosis Society; National Multiple Sclerosis Society(National Multiple Sclerosis Society); Receptos; Novartis(Novartis); Roche(Roche Holding); Biogen Idec(Biogen)	JC has received support from the Efficacy and Mechanism Evaluation Programme and Health Technology Assessment Programme (National Institute for Health Research), UK Multiple Sclerosis Society, and the National Multiple Sclerosis Society. In the past 3 years, he has been a local principal investigator for trials in multiple sclerosis funded by Receptos, Novartis, Roche, and Biogen Idec, and has received an investigator grant from Novartis. He has taken part in advisory boards and consultancy for Roche, Merck KGaA Germany, MedDay, Biogen, and Apitope.	Chataway J, 2014, LANCET, V383, P2213, DOI 10.1016/S0140-6736(13)62242-4; Comi G, 2017, LANCET, V389, P1347, DOI 10.1016/S0140-6736(16)32388-1; Fox RJ, 2017, SPRINT MS NN 102 PHA, P278; Kapoor R, 2018, LANCET NEUROL, V17, P405, DOI 10.1016/S1474-4422(18)30069-3; Kappos L, 2018, LANCET, V391, P1263, DOI 10.1016/S0140-6736(18)30475-6; Lassmann H, 2017, MULT SCLER J, V23, P1593, DOI 10.1177/1352458517729455; Lublin F, 2016, LANCET, V387, P1075, DOI 10.1016/S0140-6736(15)01314-8; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468; Ontaneda D, 2015, LANCET NEUROL, V14, P208, DOI 10.1016/S1474-4422(14)70264-9; Tourbah A, 2016, MULT SCLER J, V22, P1719, DOI 10.1177/1352458516667568	11	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2018	17	6					489	491		10.1016/S1474-4422(18)30158-3	http://dx.doi.org/10.1016/S1474-4422(18)30158-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GG1RD	29778353	Green Submitted			2022-12-18	WOS:000432463400007
J	Cordonnier, C				Cordonnier, Charlotte			Balancing risks versus benefits of anticoagulants in stroke prevention	LANCET NEUROLOGY			English	Editorial Material							ATRIAL-FIBRILLATION; BRAIN MICROBLEEDS; METAANALYSIS		[Cordonnier, Charlotte] Univ Lille, CHU Lille, Inserm U1171, Dept Neurol,Degenerat & Vasc Cognit Disorders, F-59000 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille	Cordonnier, C (corresponding author), Univ Lille, CHU Lille, Inserm U1171, Dept Neurol,Degenerat & Vasc Cognit Disorders, F-59000 Lille, France.	charlotte.cordonnier@univ-lille2.fr			French Ministry of Health (PHRC); AstraZeneca; Boehringer-Ingelheim; Daichii-Sankyo; Servier	French Ministry of Health (PHRC); AstraZeneca(AstraZeneca); Boehringer-Ingelheim(Boehringer Ingelheim); Daichii-Sankyo(Daiichi Sankyo Company Limited); Servier(Servier)	I have received grants from the French Ministry of Health (PHRC) as the principal investigator of A<INF>3</INF>ICH trial. I have been an investigator for clinical trials funded by AstraZeneca, Boehringer-Ingelheim, Daichii-Sankyo, and Servier, and have participated on an advisory board for Bristol-Myers Squibb-Pfizer.	Charidimou A, 2017, NEUROLOGY, V89, P2317, DOI 10.1212/WNL.0000000000004704; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/awl387; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Shoamanesh A, 2017, ANN NEUROL, V82, P196, DOI 10.1002/ana.24988; Wilson D, 2018, LANCET NEUROL, V17, P539, DOI 10.1016/S1474-4422(18)30145-5	8	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2018	17	6					487	488		10.1016/S1474-4422(18)30164-9	http://dx.doi.org/10.1016/S1474-4422(18)30164-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GG1RD	29778352	hybrid			2022-12-18	WOS:000432463400005
J	Smoliga, JM				Smoliga, James M.			Reconsidering the woodpecker model of traumatic brain injury	LANCET NEUROLOGY			English	Letter									[Smoliga, James M.] High Point Univ, Dept Phys Therapy, High Point, NC 27262 USA		Smoliga, JM (corresponding author), High Point Univ, Dept Phys Therapy, High Point, NC 27262 USA.	jsmoliga@highpoint.edu						Bock WJ, 1999, OSTRICH, V70, P23, DOI 10.1080/00306525.1999.9639746; Farah G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191526; Gibson LJ, 2006, J ZOOL, V270, P462, DOI 10.1111/j.1469-7998.2006.00166.x; Lemire J., 2017, BRAIN PROTECTING Q C; MAY PRA, 1976, LANCET, V1, P1347; Ni YK, 2017, COMPUT METHOD BIOMEC, V20, P1483, DOI 10.1080/10255842.2017.1378648; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	7	4	4	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2018	17	6					500	501		10.1016/S1474-4422(18)30157-1	http://dx.doi.org/10.1016/S1474-4422(18)30157-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GG1RD	29778361	Bronze			2022-12-18	WOS:000432463400020
J	Galovic, M; Dohler, N; Keezer, MR; Duncan, J; Sander, JW; Koepp, MJ; Tettenborn, B; Collaborators, SS				Galovic, Marian; Dohler, Nico; Keezer, Mark R.; Duncan, John; Sander, Josemir W.; Koepp, Matthias J.; Tettenborn, Barbara; Collaborators, SeLECT Score			The SeLECT score is useful to predict post-stroke epilepsy	LANCET NEUROLOGY			English	Letter							SEIZURES		[Galovic, Marian; Dohler, Nico; Tettenborn, Barbara] Kantonsspital St Gallen, Dept Neurol, CH-9007 St Gallen, Switzerland; [Galovic, Marian; Keezer, Mark R.; Duncan, John; Sander, Josemir W.; Koepp, Matthias J.] UCL, Dept Clin & Expt Epilepsy, Natl Inst Hlth Res, Univ Coll London Hosp Biomed Res Ctr, London, England; [Galovic, Marian; Keezer, Mark R.; Duncan, John; Sander, Josemir W.; Koepp, Matthias J.] Chalfont Ctr Epilepsy, Gerrards Cross, England; [Keezer, Mark R.] Hop Notre Dame De Bon Secours, CHUM, Montreal, PQ, Canada; [Keezer, Mark R.; Sander, Josemir W.] SEIN, Heemstede, Netherlands	Kantonsspital St. Gallen; University College London Hospitals NHS Foundation Trust; University of London; University College London; Universite de Montreal	Galovic, M (corresponding author), Kantonsspital St Gallen, Dept Neurol, CH-9007 St Gallen, Switzerland.; Galovic, M (corresponding author), UCL, Dept Clin & Expt Epilepsy, Natl Inst Hlth Res, Univ Coll London Hosp Biomed Res Ctr, London, England.; Galovic, M (corresponding author), Chalfont Ctr Epilepsy, Gerrards Cross, England.	m.galovic@ucl.ac.uk	Sander, Josemir/C-1576-2008	Sander, Josemir/0000-0001-6041-9661; Dohler, Nico/0000-0001-9795-9127; Galovic, Marian/0000-0002-2307-071X; Duncan, John S/0000-0002-1373-0681	UK National Institute for Health Research University College London Hospitals and University College London Biomedical Research Centre; Marvin Weil Epilepsy Research Fund; MRC [MR/L013215/1] Funding Source: UKRI	UK National Institute for Health Research University College London Hospitals and University College London Biomedical Research Centre; Marvin Weil Epilepsy Research Fund; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	MRK reports grants and personal fees from UCB, and personal fees from Sage Therapeutics and Novartis, outside of the submitted work. JSD is supported by the UK National Institute for Health Research University College London Hospitals and University College London Biomedical Research Centre as a senior investigator. JWS reports grants and personal fees from Eisai and UCB; grants from GlaxoSmithKline, WHO, and Netherland Epilepsy Funds; and personal fees from Lundbeck and Teva, outside of the submitted work. JWS's current position is endowed by the Epilepsy Society; he is a member of the editorial board of The Lancet Neurology and receives research support from the Marvin Weil Epilepsy Research Fund. All other authors declare no competing interests.	Crompton DE, 2009, LANCET NEUROL, V8, P370, DOI 10.1016/S1474-4422(09)70059-6; Finsterer J, 2018, LANCET NEUROL, V17, P106, DOI 10.1016/S1474-4422(17)30460-X; Foote C, 2017, AM J KIDNEY DIS, V69, P555, DOI 10.1053/j.ajkd.2017.02.005; Galovic M, 2018, LANCET NEUROL, V17, P143, DOI 10.1016/S1474-4422(17)30404-0; Moons KGM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b375	5	4	4	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2018	17	5					395	396		10.1016/S1474-4422(18)30075-9	http://dx.doi.org/10.1016/S1474-4422(18)30075-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GC7JA	29456162	Bronze, Green Submitted			2022-12-18	WOS:000429968100013
J	Grisold, W; Wasay, M				Grisold, W.; Wasay, M.			The advocacy role of the World Federation of Neurology (vol 17, pg 204, 2018)	LANCET NEUROLOGY			English	Correction																		Grisold W, 2018, LANCET NEUROL, V17, P204, DOI 10.1016/S1474-4422(18)30051-6	1	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2018	17	5					392	392		10.1016/S1474-4422(18)30051-6	http://dx.doi.org/10.1016/S1474-4422(18)30051-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GC7JA	29452678	Green Submitted, Bronze			2022-12-18	WOS:000429968100008
J	Antonini, A; Obeso, JA				Antonini, Angelo; Obeso, Jose A.			DBS for Parkinson's disease with behavioural disturbances	LANCET NEUROLOGY			English	Editorial Material							IMPULSE CONTROL DISORDERS; SUBTHALAMIC NUCLEUS; STIMULATION		[Antonini, Angelo] Univ Padua, Dept Neurosci, I-35128 Padua, Italy; [Obeso, Jose A.] CEU San Pablo Univ, CINAC, HM Puerta del Sur, Hosp Madrid,Mostoles Med Sch, Madrid, Spain	University of Padua; San Pablo CEU University	Antonini, A (corresponding author), Univ Padua, Dept Neurosci, I-35128 Padua, Italy.	angelo3000@yahoo.com	Antonini, Angelo/H-9726-2019	Antonini, Angelo/0000-0003-1040-2807	Spanish Science and Education Ministry; European Union (REPLACES)	Spanish Science and Education Ministry(Spanish Government); European Union (REPLACES)	AA received honoraria from and served on advisory boards for AbbVie, Lundbeck, GE, UCB, Zambon, Neuroderm, Boehringer Ingelheim, and Acadia. JAO received research support from the Spanish Science and Education Ministry and the European Union (REPLACES), honoraria for lecturing at meetings by GSK, Lundbeck, UCB, TEVA-Neuroscience, and Boehringer Ingelheim, and serves on two advisory boards (2014, 2017) on behalf of Insightec.	Antonini A, MOV DISORD IN PRESS; Bejjani BP, 1999, NEW ENGL J MED, V340, P1476, DOI 10.1056/NEJM199905133401905; Biundo R, 2017, MOVEMENT DISORD, V32, P1557, DOI 10.1002/mds.27181; Lhommee E, 2018, LANCET NEUROL, V17, P223, DOI 10.1016/S1474-4422(18)30035-8; Martinez-Fernandez R, 2018, LANCET NEUROL, V17, P54, DOI 10.1016/S1474-4422(17)30403-9; Rodriguez-Oroz MC, 2011, BRAIN, V134, P36, DOI 10.1093/brain/awq301; Samuel M, 2015, MOVEMENT DISORD, V30, P150, DOI 10.1002/mds.26099; Schuepbach WMM, 2013, NEW ENGL J MED, V368, P610, DOI 10.1056/NEJMoa1205158; Soulas T, 2008, J NEUROL NEUROSUR PS, V79, P952, DOI 10.1136/jnnp.2007.130583; Stocchi F, 2014, PARKINSONISM RELAT D, V20, P204, DOI 10.1016/j.parkreldis.2013.10.027	10	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2018	17	3					195	197		10.1016/S1474-4422(18)30044-9	http://dx.doi.org/10.1016/S1474-4422(18)30044-9			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FW1WE	29452675				2022-12-18	WOS:000425090000003
J	French, J; Friedman, D				French, Jacqueline; Friedman, Daniel			The evolving landscape of epilepsy neuropathology	LANCET NEUROLOGY			English	Editorial Material							UNITED-STATES; SURGERY; GERMANY; CENTERS; TRENDS; ADULT		[French, Jacqueline; Friedman, Daniel] NYU, Sch Med, NYU Langone Comprehens Epilepsy Ctr, New York, NY 10016 USA	New York University	French, J (corresponding author), NYU, Sch Med, NYU Langone Comprehens Epilepsy Ctr, New York, NY 10016 USA.	Jacqueline.French@nyumc.org	French, Jacqueline A/G-6795-2013	French, Jacqueline A/0000-0003-2242-8027	Accorda; Alexza; Biopharm solutions; Eisai Medical Research; Epilepsy Therapy Project; Epilepsy Research Foundation; Epilepsy Study Consortium; Adamas Pharmaceuticals; Lundbeck; LCGH; Pfizer; UCB Pharma; Sunovion; SK life sciences; Neurelis; Glaxo Smith-Kline; Johnson and Johnson; Marinus; Novartis; Supernus Pharmaceuticals; Upsher-Smith; Anavex; Biogen; Engage; GW Pharma; Nestle Health-Science; Ovid; Sage Therapeutics; Takeda; Zogenix; Zynerba; Empatica; Supernus; GW Pharmaceuticals; Neuropace Inc; Liva Nova; NYU	Accorda; Alexza; Biopharm solutions; Eisai Medical Research(Eisai Co Ltd); Epilepsy Therapy Project; Epilepsy Research Foundation; Epilepsy Study Consortium; Adamas Pharmaceuticals; Lundbeck(Lundbeck Corporation); LCGH; Pfizer(Pfizer); UCB Pharma(UCB Pharma SA); Sunovion; SK life sciences; Neurelis; Glaxo Smith-Kline(GlaxoSmithKline); Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Marinus; Novartis(Novartis); Supernus Pharmaceuticals; Upsher-Smith; Anavex; Biogen(Biogen); Engage; GW Pharma; Nestle Health-Science; Ovid; Sage Therapeutics; Takeda(Takeda Pharmaceutical Company Ltd); Zogenix; Zynerba; Empatica; Supernus; GW Pharmaceuticals; Neuropace Inc; Liva Nova; NYU	JF received grants from Accorda, Alexza, Biopharm solutions, Eisai Medical Research, Epilepsy Therapy Project, Epilepsy Research Foundation, Epilepsy Study Consortium, Adamas Pharmaceuticals, Lundbeck, LCGH, Pfizer, UCB Pharma, Sunovion, SK life sciences, and Neurelis; consulting fees from Accorda, Glaxo Smith-Kline, Adamas Pharmaceuticals, Johnson and Johnson, Marinus, Novartis, Pfizer, Sunovion, SK life sciences, Supernus Pharmaceuticals, UCB Pharma, Upsher-Smith, Alexza, Anavex, Biogen, Biopharm solutions, Engage, GW Pharma, Nestle Health-Science, Neurelis, Ovid, Sage Therapeutics, Takeda, Zogenix, and Zynerba; travel fees from Pfizer, Sunovion, UCB Pharma, Biogen, GW Pharma, Nestle Health-Science, Neurelis, Sage Therapeutics, Takeda, Zogenix, and Zynerba; is principal investigator of a clinical trial funded by Eisai Medical Research, Novartis, Supernus Pharmaceuticals, Upsher-Smith, and Alexza; serves on the advisory board for Eisai Medical Research, Glaxo SmithKline, SK life sciences, UCB Pharma, Upsher-Smith, and the scientific advisory board for Ovid and Sage Therapeutics; is Chief Scientific Officer of the Epilepsy Foundation, with salary support paid to the NYU; is president of the Epilepsy Study Consortium, and all consulting is done on behalf of the consortium, with fees paid to the consortium and the NYU receives salary support from the consortium; and was chief scientific officer of the Epilepsy Therapy project and received salary support for this role. DF received grants from UCB Pharma and Empatica, personal fees from UCB Pharma, Supernus, GW Pharmaceuticals, Neuropace Inc, and Liva Nova, and salary support from the Epilepsy Study Consortium.	Blumcke I, 2017, NEW ENGL J MED, V377, P1648, DOI 10.1056/NEJMoa1703784; Cendes F, 2014, ACTA NEUROPATHOL, V128, P21, DOI 10.1007/s00401-014-1292-0; Dugan P, 2017, EPILEPSIA, V58, P792, DOI 10.1111/epi.13730; Englot DJ, 2012, NEUROLOGY, V78, P1200, DOI 10.1212/WNL.0b013e318250d7ea; Helmstaedter C, 2014, EUR J NEUROL, V21, P827, DOI 10.1111/ene.12322; Jehi L, 2015, EPILEPSIA, V56, P1526, DOI 10.1111/epi.13116; Kaiboriboon K, 2015, EPILEPSY RES, V116, P105, DOI 10.1016/j.eplepsyres.2015.07.007; Neligan A, 2013, EPILEPSIA, V54, pe62, DOI 10.1111/epi.12148; Ryvlin P, 2016, CURR OPIN NEUROL, V29, P182, DOI 10.1097/WCO.0000000000000306; Van Gompel JJ, 2012, ARCH NEUROL-CHICAGO, V69, P1476, DOI 10.1001/archneurol.2012.1200	10	4	4	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2018	17	3					202	203		10.1016/S1474-4422(17)30429-5	http://dx.doi.org/10.1016/S1474-4422(17)30429-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FW1WE	29198966				2022-12-18	WOS:000425090000007
J	Grisold, W; Mohammad, W				Grisold, Wolfgang; Mohammad, Wasay			The advocacy role of the World Federation of Neurology	LANCET NEUROLOGY			English	Letter									[Grisold, Wolfgang; Mohammad, Wasay] World Federat Neurol, London, England; [Grisold, Wolfgang] Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; [Mohammad, Wasay] Aga Khan Univ, Dept Neurol, Karachi, Pakistan	Ludwig Boltzmann Institute; Aga Khan University	Grisold, W (corresponding author), World Federat Neurol, London, England.; Grisold, W (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria.	wolfgang.grisold@wfneurology.org						European Academy of Neurology, 2016, GUID REG TEACH COURS; Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5; Grisold W, 2017, J NEUROL SCI, V379, P25, DOI 10.1016/j.jns.2017.05.003; Wasay M, 2016, LANCET NEUROL, V15, P1008, DOI 10.1016/S1474-4422(16)30171-5; World Health Organization, 2017, ATL COUNTR RES NEUR	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2018	17	3					204	204		10.1016/S1474-4422(18)30051-6	http://dx.doi.org/10.1016/S1474-4422(18)30051-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FW1WE	29452678	Green Submitted, Bronze			2022-12-18	WOS:000425090000009
J	Tijms, BM; Visser, PJ				Tijms, Betty M.; Visser, Pieter Jelle			Capturing the Alzheimer's disease pathological cascade	LANCET NEUROLOGY			English	Editorial Material							AMYLOID-BETA DEPOSITION; DEMENTIA		[Tijms, Betty M.; Visser, Pieter Jelle] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, NL-1007 MB Amsterdam, Netherlands; [Tijms, Betty M.; Visser, Pieter Jelle] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands; [Visser, Pieter Jelle] Maastricht Univ, Dept Psychiat & Neuropsychol, Sch Mental Hlth & Neurosci, Maastricht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Maastricht University	Tijms, BM (corresponding author), Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, NL-1007 MB Amsterdam, Netherlands.; Tijms, BM (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands.	b.tijms@vumc.nl	Visser, Pieter Jelle/S-5242-2019; Tijms, Betty M./I-2218-2019; Visser, Pieter J/C-8541-2015	Visser, Pieter Jelle/0000-0001-8008-9727; Tijms, Betty M./0000-0002-2612-1797; Visser, Pieter J/0000-0001-8008-9727	ZonMw; Biogen; Innovative Medicine Initiative; Eli-Lilly; Janssen Pharmaceutica; European Union; European Federation of Pharmaceutical Industries; Associations Innovative Medicines Initiative Joint Undertaking [115372]; European Prevention of Alzheimer's Dementia Consortium grant [115736]; ROADMAP [116020]; ZonMW Memorabel programme [733050506, 733050824]	ZonMw(Netherlands Organization for Health Research and Development); Biogen(Biogen); Innovative Medicine Initiative; Eli-Lilly(Eli Lilly); Janssen Pharmaceutica(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); European Union(European Commission); European Federation of Pharmaceutical Industries; Associations Innovative Medicines Initiative Joint Undertaking; European Prevention of Alzheimer's Dementia Consortium grant; ROADMAP; ZonMW Memorabel programme	BMT reports grants from ZonMw and Biogen. PJV reports grants from the Innovative Medicine Initiative, ZonMw, and Biogen, non-financial support (in-kind supply of an amyloid tracer) from GE Healthcare, and fees for consultancy from Eli-Lilly and Janssen Pharmaceutica. Our work is supported by the European Union and European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking (European Medical Information Framework grant 115372; European Prevention of Alzheimer's Dementia Consortium grant 115736; ROADMAP grant 116020 [PJV]) and the ZonMW Memorabel programme (grants 733050506 [BMT] and 733050824 [BMT, PJV]).	Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bekris LM, 2010, J GERIATR PSYCH NEUR, V23, P213, DOI 10.1177/0891988710383571; Bero AW, 2011, NAT NEUROSCI, V14, P750, DOI 10.1038/nn.2801; Bertens D, 2015, ALZHEIMERS DEMENT, V11, P511, DOI 10.1016/j.jalz.2014.05.1754; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Gordon BA, 2018, LANCET NEUROL; Hardy J, 2014, J INTERN MED, V275, P296, DOI 10.1111/joim.12192; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Palmqvist S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01150-x; ten Kate M, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0299-x; Villain N, 2012, BRAIN, V135, P2126, DOI 10.1093/brain/aws125; Vlassenko AG, 2010, P NATL ACAD SCI USA, V107, P17763, DOI 10.1073/pnas.1010461107	12	4	4	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2018	17	3					199	200		10.1016/S1474-4422(18)30043-7	http://dx.doi.org/10.1016/S1474-4422(18)30043-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FW1WE	29397304				2022-12-18	WOS:000425090000005
J	Cross, AH; Naismith, RT				Cross, Anne H.; Naismith, Robert T.			Refining the use of MRI to predict multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							CRITERIA; MULTICENTER; GUIDELINES; DIAGNOSIS		[Cross, Anne H.; Naismith, Robert T.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Cross, AH (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	crossa@wustl.edu		Cross, Anne/0000-0003-0829-7569; frederiksen, jette/0000-0003-1661-7438	AbbVie; Bayer; Biogen; EMD Serono; Genentech Roche; Genzyme Sanofi; Mallinckodt; Novartis; Teva	AbbVie(AbbVie); Bayer(Bayer AG); Biogen(Biogen); EMD Serono; Genentech Roche(Roche HoldingGenentech); Genzyme Sanofi(Sanofi-AventisGenzyme Corporation); Mallinckodt; Novartis(Novartis); Teva(Teva Pharmaceutical Industries)	AHC has received consulting fees from AbbVie, Bayer, Biogen, EMD Serono, Genentech Roche, Genzyme Sanofi, Mallinckodt, Novartis, and Teva. RTN has consulted for Acorda, Alkermes, Bayer, Biogen, EMD Serono, Genentech, Genzyme, Novartis, and Teva.	Barkhof F, 1997, BRAIN, V120, P2059, DOI 10.1093/brain/120.11.2059; Filippi M, 2016, LANCET NEUROL, V15, P292, DOI 10.1016/S1474-4422(15)00393-2; Jokubaitis VG, 2015, ANN CLIN TRANSL NEUR, V2, P479, DOI 10.1002/acn3.187; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Solomon AJ, 2016, NEUROLOGY, V87, P1393, DOI 10.1212/WNL.0000000000003152; Swanton JK, 2007, LANCET NEUROL, V6, P677, DOI 10.1016/S1474-4422(07)70176-X; Trojano M, 2009, ANN NEUROL, V66, P513, DOI 10.1002/ana.21757	8	4	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2018	17	2					105	106		10.1016/S1474-4422(17)30459-3	http://dx.doi.org/10.1016/S1474-4422(17)30459-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT0PA	29275978				2022-12-18	WOS:000422828500003
J	Figaji, A; Taylor, A; Mahmud, MR; Bello, S; Wegoye, E; Ssenyonga, P; Mogere, E; Mankahla, N; Fieggen, G; Qureshi, M				Figaji, Anthony; Taylor, Allan; Mahmud, Muhammad Raji; Bello, Shehu; Wegoye, Emmanuel; Ssenyonga, Peter; Mogere, Edwin; Mankahla, Ncedile; Fieggen, Graham; Qureshi, Mahmood			On progress in Africa, by African experts	LANCET NEUROLOGY			English	Letter									[Figaji, Anthony; Taylor, Allan; Mankahla, Ncedile; Fieggen, Graham] Univ Cape Town, ZA-7700 Cape Town, South Africa; [Mahmud, Muhammad Raji] Natl Hosp Abuja, Abuja, Nigeria; [Bello, Shehu] Fed Univ Birnin Kebbi, Kalgo, Nigeria; [Wegoye, Emmanuel] Kijabe Hosp, Kijabe, Kenya; [Ssenyonga, Peter] CURE Childrens Hosp Uganda, Mbale, Uganda; [Mogere, Edwin; Qureshi, Mahmood] Aga Khan Univ Hosp, Nairobi, Kenya	University of Cape Town	Figaji, A (corresponding author), Univ Cape Town, ZA-7700 Cape Town, South Africa.	anthony.figaji@uct.ac.za	Figaji, Anthony/ADH-9410-2022	Figaji, Anthony/0000-0002-3357-6490				Burton A, 2017, LANCET NEUROL, V16, P499, DOI [10.1016/S1474-4422(17)30164-3, 10.1016/S1474-4422(17)30087-X, 10.1016/S1474-4422(17)30246-6]	1	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2018	17	2					114	114		10.1016/S1474-4422(17)30457-X	http://dx.doi.org/10.1016/S1474-4422(17)30457-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT0PA	29413307	Bronze			2022-12-18	WOS:000422828500009
J	Gulani, V; Calamante, F; Shellock, FG; Kanal, E; Reeder, SB				Gulani, Vikas; Calamante, Fernando; Shellock, Frank G.; Kanal, Emanuel; Reeder, Scott B.		Int Soc Magnet Resonance Med	Chelated or dechelated gadolinium deposition reply	LANCET NEUROLOGY			English	Letter							MAGNETIC-RESONANCE; RESIDUAL-GADOLINIUM; CONTRAST AGENTS; BRAIN		[Gulani, Vikas] Case Western Reserve Univ, Dept Radiol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Gulani, Vikas] Case Western Reserve Univ, Dept Urol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Gulani, Vikas] Case Western Reserve Univ, Dept Biomed Engn, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Gulani, Vikas] Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Calamante, Fernando] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Calamante, Fernando] Univ Melbourne, Florey Dept Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Shellock, Frank G.] Univ Southern Calif, Dept Radiol, Los Angeles, CA USA; [Shellock, Frank G.] Univ Southern Calif, Dept Med, Los Angeles, CA USA; [Shellock, Frank G.] Univ Southern Calif, Natl Sci Fdn, Engn Res Ctr, Los Angeles, CA USA; [Kanal, Emanuel] Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA USA; [Reeder, Scott B.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Reeder, Scott B.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, 1530 Med Sci Ctr, Madison, WI 53706 USA; [Reeder, Scott B.] Univ Wisconsin, Dept Biomed Engn, Sch Med & Publ Hlth, Madison, WI USA; [Reeder, Scott B.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Reeder, Scott B.] Univ Wisconsin, Dept Emergency Med, Sch Med & Publ Hlth, Madison, WI USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Southern California; University of Southern California; National Science Foundation (NSF); University of Southern California; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gulani, V (corresponding author), Case Western Reserve Univ, Dept Radiol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.; Gulani, V (corresponding author), Case Western Reserve Univ, Dept Urol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.; Gulani, V (corresponding author), Case Western Reserve Univ, Dept Biomed Engn, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.; Gulani, V (corresponding author), Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.	vikas@case.edu	Reeder, Scott/F-8665-2014		Bayer; Siemens Healthcare; US National Institutes of Health; Bracco Diagnostics; Guerbet; Bayer Healthcare; GE Healthcare	Bayer(Bayer AG); Siemens Healthcare(Siemens AG); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bracco Diagnostics; Guerbet; Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); GE Healthcare(General ElectricGE Healthcare)	VG reports grants from Siemens Healthcare and the US National Institutes of Health; VG has a patent for Magnetic Resonance Fingerprinting licensed to Siemens Healthcare. FC reports grants from Siemens Healthcare. FGS reports grants from Bracco Diagnostics. EK reports grants, fees for consulting services, and income from sale of software from Bracco Diagnostics, fees for consulting services and software licensing from Guerbet, and fees for consulting services from Bayer Healthcare. SBR reports that GE Healthcare and Bracco Diagnostics provide research support to the University of Wisconsin, and that he is a Founder of Calimetrix. LLC and holds ownership interests in Elucent Medical and Cellectar Biosciences.	Bjornerud A, 2017, RADIOLOGY, V285, P434, DOI 10.1148/radiol.2017170391; Bussi S, 2018, J MAGN RESON IMAGING, V47, P746, DOI 10.1002/jmri.25822; Espagnet MCR, 2017, PEDIATR RADIOL, V47, P1345, DOI 10.1007/s00247-017-3874-1; Frenzel T, 2017, INVEST RADIOL, V52, P396, DOI 10.1097/RLI.0000000000000352; Gulani V, 2017, LANCET NEUROL, V16, P564, DOI 10.1016/S1474-4422(17)30158-8; Lohrke J, 2017, INVEST RADIOL, V52, P324, DOI 10.1097/RLI.0000000000000344; McDonald RJ, 2017, RADIOLOGY, V285, P546, DOI 10.1148/radiol.2017161595; Naganawa S, 2017, MAGN RESON MED SCI, V16, P61, DOI 10.2463/mrms.mp.2016-0039; Oner AY, 2017, INVEST RADIOL, V52, P195, DOI 10.1097/RLI.0000000000000327; Vogler H, 1995, EUR J RADIOL, V21, P1, DOI 10.1016/0720-048X(95)00679-K	10	4	4	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2017	16	12					955	956		10.1016/S1474-4422(17)30365-4	http://dx.doi.org/10.1016/S1474-4422(17)30365-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FM8DJ	29165254	Bronze			2022-12-18	WOS:000415315400012
J	Stoessl, AJ				Stoessl, A. Jon			Challenges and unfulfilled promises in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							ACTIVATION; RECEPTOR; GLP-1		[Stoessl, A. Jon] Univ British Columbia, Div Neurol, Pacific Parkinsons Res Ctr, Vancouver, BC V6T 1Z3, Canada; [Stoessl, A. Jon] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 1Z3, Canada; [Stoessl, A. Jon] Vancouver Coastal Hlth, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Stoessl, AJ (corresponding author), Univ British Columbia, Div Neurol, Pacific Parkinsons Res Ctr, Vancouver, BC V6T 1Z3, Canada.; Stoessl, AJ (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 1Z3, Canada.; Stoessl, AJ (corresponding author), Vancouver Coastal Hlth, Vancouver, BC V6T 1Z3, Canada.	jstoessl@mail.ubc.ca	Stoessl, A Jon/J-9661-2015	Stoessl, A Jon/0000-0002-9778-7246	Cundill Foundation; NTCell; Pacific Parkinson's Research Institute; Weston Brain Institute; Canada Research Chairs; AbbVie; Genentech; Kyowa; Pfizer	Cundill Foundation; NTCell; Pacific Parkinson's Research Institute; Weston Brain Institute; Canada Research Chairs(Canada Research ChairsCGIAR); AbbVie(AbbVie); Genentech(Roche HoldingGenentech); Kyowa; Pfizer(Pfizer)	AJS reports grants from the Cundill Foundation, NTCell, Pacific Parkinson's Research Institute, and Weston Brain Institute; and funding paid to his institution from Canada Research Chairs; and personal fees from AbbVie, Genentech, Kyowa, and Pfizer.	Athauda D., 2017, LANCET; Athauda D, 2016, DRUG DISCOV TODAY, V21, P802, DOI 10.1016/j.drudis.2016.01.013; Aviles-Olmos I, 2014, J PARKINSON DIS, V4, P337, DOI 10.3233/JPD-140364; Fortin SM, 2017, PHYSIOL BEHAV, V176, P17, DOI 10.1016/j.physbeh.2017.03.019; Holscher C, 2012, CNS DRUGS, V26, P871, DOI 10.2165/11635890-000000000-00000; Kordower JH, 2013, BRAIN, V136, P2419, DOI 10.1093/brain/awt192; Mittal S, 2017, SCIENCE, V357, P891, DOI 10.1126/science.aaf3934; Robledo I, 2017, MOVEMENT DISORD, V32, P1319, DOI 10.1002/mds.26993; Spathis AD, 2017, P NATL ACAD SCI USA, V114, P3999, DOI 10.1073/pnas.1616874114; Thibault L, 2017, MOVEMENT DISORD, V32, P1365, DOI 10.1002/mds.27055	10	4	4	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2017	16	11					866	867		10.1016/S1474-4422(17)30334-4	http://dx.doi.org/10.1016/S1474-4422(17)30334-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FJ3WM	29029841				2022-12-18	WOS:000412663200007
J	Escott-Price, V; Jones, L				Escott-Price, Valentina; Jones, Lesley			Genomic profiling and diagnostic biomarkers in Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material									[Escott-Price, Valentina; Jones, Lesley] Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Cardiff CF24 4HQ, S Glam, Wales	Cardiff University	Jones, L (corresponding author), Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Cardiff CF24 4HQ, S Glam, Wales.	jonesl1@cf.ac.uk		Escott-Price, Valentina/0000-0003-1784-5483	MRC [UKDRI-3003, G0801418, MR/L023784/2, MR/P005748/1, MR/L023784/1] Funding Source: UKRI; Medical Research Council [UKDRI-3003, G0801418B] Funding Source: researchfish; Medical Research Council [MR/L023784/1, MR/L023784/2, MR/L010305/1, G0801418, MR/P005748/1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ayme A, 2014, BREAST CANCER RES TR, V144, P379, DOI 10.1007/s10549-014-2864-3; Boccardi M, 2017, NEUROBIOL AGING, V52, P141, DOI 10.1016/j.neurobiolaging.2017.01.021; Desikan RS, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002258; Escott-Price V, 2017, NEUROBIOL AGING, V49, DOI 10.1016/j.neurobiolaging.2016.07.018; Escott-Price V, 2015, BRAIN, V138, P3673, DOI 10.1093/brain/awv268; Hampel H, 2016, J Prev Alzheimers Dis, V3, P243, DOI 10.14283/jpad.2016.112; Milne R, 2017, LANCET PSYCHIAT, V4, pE6, DOI 10.1016/S2215-0366(17)30089-5; Nance MA, 2017, AM J MED GENET B, V174, P75, DOI 10.1002/ajmg.b.32453; Sharaf RN, 2013, CLIN GASTROENTEROL H, V11, P1093, DOI 10.1016/j.cgh.2013.04.044; Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864	10	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2017	16	8					582	583		10.1016/S1474-4422(17)30202-8	http://dx.doi.org/10.1016/S1474-4422(17)30202-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FA1LP	28721917	Green Accepted			2022-12-18	WOS:000405201300008
J	Benedicenti, F; Superti-Furga, A				Benedicenti, Francesco; Superti-Furga, Andrea			The multiple faces of artwork diagnoses	LANCET NEUROLOGY			English	Letter									[Benedicenti, Francesco] Reg Hosp Bolzano, Dept Pediat, Coordinat Ctr Rare Dis, Clin Genet Serv & South Tyrol, I-39100 Bolzano, Italy; [Superti-Furga, Andrea] Univ Lausanne, Ctr Hosp Univ Vaudois, Div Med Genet, Lausanne, Switzerland	Krankenhaus Bozen; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Benedicenti, F (corresponding author), Reg Hosp Bolzano, Dept Pediat, Coordinat Ctr Rare Dis, Clin Genet Serv & South Tyrol, I-39100 Bolzano, Italy.	francesco.benedicenti@sabes.it	superti-furga, andrea/E-9162-2015	superti-furga, andrea/0000-0002-3543-7531; Benedicenti, Francesco/0000-0002-9458-0688				Bianucci Raffaella, 2016, Lancet Neurol, V15, P1123, DOI 10.1016/S1474-4422(16)30210-1; EMERY AEH, 1994, J MED GENET, V31, P420, DOI 10.1136/jmg.31.5.420; Kunze J, 1986, GENETICS MALFORMATIO	3	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2017	16	6					417	417		10.1016/S1474-4422(17)30128-X	http://dx.doi.org/10.1016/S1474-4422(17)30128-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EU1WD	28504105	Bronze			2022-12-18	WOS:000400815800006
J	[Anonymous]				[Anonymous]			Investing in autism: better evidence for better care	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2017	16	4					251	251		10.1016/S1474-4422(17)30049-2	http://dx.doi.org/10.1016/S1474-4422(17)30049-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	EN9RF	28327327	Bronze			2022-12-18	WOS:000396336600001
J	Baumann, CR				Baumann, Christian R.			Wide implications of a trial on pitolisant for cataplexy	LANCET NEUROLOGY			English	Editorial Material							SLEEP LATENCY; NARCOLEPSY		[Baumann, Christian R.] Univ Zurich, Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Baumann, CR (corresponding author), Univ Zurich, Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland.	christian.baumann@usz.ch		Baumann, Christian/0000-0003-3417-1978	Teva Pharma; UCB Pharma	Teva Pharma(Teva Pharmaceutical Industries); UCB Pharma(UCB Pharma SA)	CRB reports personal fees from Teva Pharma and grants from UCB Pharma.	*AASM, 2005, INT CLASS SLEEP DIS; American Academy of Sleep Medicine (AASM), 2014, INT CLASS SLEEP DIS, Vthird; Andlauer O, 2013, JAMA NEUROL, V70, P891, DOI 10.1001/jamaneurol.2013.1589; Baumann CR, 2008, REGUL PEPTIDES, V147, P1, DOI 10.1016/j.regpep.2007.11.006; Dauvilliers Y, 2013, LANCET NEUROL, V12, P1068, DOI 10.1016/S1474-4422(13)70225-4; Drakatos P, 2013, J NEUROL NEUROSUR PS, V84, P223, DOI 10.1136/jnnp-2012-303578; Goldbart A, 2014, SLEEP, V37, P1043, DOI 10.5665/sleep.3758; Marti I, 2009, SLEEP MED, V10, P1146, DOI 10.1016/j.sleep.2009.03.008; Szakacs Z, 2017, LANCET NEUROL; Trotti LM, 2013, J CLIN SLEEP MED, V9, P789, DOI 10.5664/jcsm.2922; Valko PO, 2013, ANN NEUROL, V74, P794, DOI 10.1002/ana.24019	11	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2017	16	3					173	174		10.1016/S1474-4422(16)30398-2	http://dx.doi.org/10.1016/S1474-4422(16)30398-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EK4ZC	28129984	Green Accepted			2022-12-18	WOS:000393935700003
J	Koeleman, BPC				Koeleman, Bobby P. C.			Genetics of common forms of epilepsy	LANCET NEUROLOGY			English	Editorial Material									[Koeleman, Bobby P. C.] Univ Med Ctr Utrecht, Dept Genet, Univ Weg 100, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Koeleman, BPC (corresponding author), Univ Med Ctr Utrecht, Dept Genet, Univ Weg 100, NL-3584 CX Utrecht, Netherlands.	b.p.c.koeleman@umcutrecht.nl			Dutch Epilepsy Foundation; Ming funds	Dutch Epilepsy Foundation; Ming funds	BK is supported by the Dutch Epilepsy Foundation and the Ming funds.	Allen AS, 2017, LANCET NEUROL, V16, P135, DOI 10.1016/S1474-4422(16)30359-3; Berkovic F, 2015, LANCET NEUROL, V14, P1219, DOI 10.1016/S1474-4422(15)00199-4; International League Against Epilepsy Consortium on Complex Epilepsies, 2014, LANCET NEUROL, V13, P89; Minikel EV, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5169; Striano P, 2016, PHARMACOL RES, V107, P426, DOI 10.1016/j.phrs.2016.04.006	5	4	4	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2017	16	2					101	102		10.1016/S1474-4422(16)30400-8	http://dx.doi.org/10.1016/S1474-4422(16)30400-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EH6VA	28102142				2022-12-18	WOS:000391910800004
J	Calabresi, P; Tambasco, N				Calabresi, Paolo; Tambasco, Nicola			Movement disorders in 2016: from genes to phenotypes	LANCET NEUROLOGY			English	Editorial Material							PARKINSONS-DISEASE; MUTATION; MOTOR		[Calabresi, Paolo; Tambasco, Nicola] Osped S Maria Misericordia, Dept Med, Neurol Clin, I-06132 Perugia, Italy	Hospital Santa Maria della Misericordia	Calabresi, P (corresponding author), Osped S Maria Misericordia, Dept Med, Neurol Clin, I-06132 Perugia, Italy.	paolo.calabresi@unipg.it	Calabresi, Paolo/G-8496-2011; Tambasco, Nicola/K-4788-2018	Calabresi, Paolo/0000-0003-0326-5509; Tambasco, Nicola/0000-0003-1497-4482				Calabresi P, 2016, MOVEMENT DISORD, V31, P769, DOI 10.1002/mds.26683; Cilia R, 2016, ANN NEUROL, V80, P662, DOI 10.1002/ana.24777; Davis MY, 2016, JAMA NEUROL, V73, P1217, DOI 10.1001/jamaneurol.2016.2245; Majbour NK, 2016, MOVEMENT DISORD, V31, P1535, DOI 10.1002/mds.26754; Mao X, 2016, SCIENCE, DOI [10.1126/science.aah3374, DOI 10.1126/SCIENCE.AAH3374.]; Marras C, 2016, MOVEMENT DISORD, V31, P1192, DOI 10.1002/mds.26614; Mata IF, 2016, MOVEMENT DISORD, V31, P95, DOI 10.1002/mds.26359; Papadimitriou D, 2016, MOVEMENT DISORD, V31, P1226, DOI 10.1002/mds.26615; PARKINSONS J, 2016, ESSAY SHAKING PALSY; Soldner F, 2016, NATURE, V533, P95, DOI 10.1038/nature17939; Trinh J, 2016, LANCET NEUROL, V15, P1246, DOI 10.1016/S1474-4422(16)30203-4	11	4	4	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					9	10		10.1016/S1474-4422(16)30345-3	http://dx.doi.org/10.1016/S1474-4422(16)30345-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27979359				2022-12-18	WOS:000389869200006
J	Mestre, TA; Lang, AE				Mestre, Tiago A.; Lang, Anthony E.			Placebos in clinical trials: unravelling a complex phenomenon	LANCET NEUROLOGY			English	Letter							PARKINSON DISEASE; METAANALYSES		[Mestre, Tiago A.; Lang, Anthony E.] Ottawa Hosp, Civ Campus, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute	Mestre, TA (corresponding author), Ottawa Hosp, Civ Campus, Ottawa, ON K1Y 4E9, Canada.	tmestre@toh.on.ca	Lang, Anthony/ABF-8114-2021	Lang, Anthony/0000-0003-1229-3667				Benedetti F, 2016, LANCET NEUROL, V15, P736, DOI [10.1016/S1474-4422(16)00066-1, 10.1016/s1474-4422(16)00066-1]; Espay AJ, 2015, NEUROLOGY, V84, P794, DOI 10.1212/WNL.0000000000001282; Hall KT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048135; Ko JH, 2014, J CLIN INVEST, V124, P3656, DOI 10.1172/JCI75073; Mestre TA, 2014, NEUROLOGY, V82, P1402, DOI 10.1212/WNL.0000000000000340; Sinyor M, 2010, J CLIN PSYCHIAT, V71, P270, DOI 10.4088/JCP.08r04516blu; Sneed JR, 2008, AM J GERIAT PSYCHIAT, V16, P65, DOI 10.1097/JGP.0b013e3181256b1d	7	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					28	29		10.1016/S1474-4422(16)30349-0	http://dx.doi.org/10.1016/S1474-4422(16)30349-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27979350	Bronze			2022-12-18	WOS:000389869200023
J	Gan-Or, Z; Rouleau, GA				Gan-Or, Ziv; Rouleau, Guy A.			Calpain 1 in neurodegeneration: a therapeutic target?	LANCET NEUROLOGY			English	Letter							ALZHEIMERS-DISEASE		[Gan-Or, Ziv; Rouleau, Guy A.] McGill Univ, Dept Human Genet, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	Gan-Or, Z (corresponding author), McGill Univ, Dept Human Genet, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada.	ziv.gan-or@mail.mcgill.ca		Gan-Or, Ziv/0000-0003-0332-234X				Baudry M, 2016, TRENDS NEUROSCI, V39, P235, DOI 10.1016/j.tins.2016.01.007; Fa M, 2016, J ALZHEIMERS DIS, V49, P707, DOI 10.3233/JAD-150618; Gan-Or Z, 2016, AM J HUM GENET, V98, P1038, DOI 10.1016/j.ajhg.2016.04.002; Kurbatskaya K, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0299-2; Wang YB, 2016, CELL REP, V16, P79, DOI 10.1016/j.celrep.2016.05.044	5	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2016	15	11					1118	1118		10.1016/S1474-4422(16)30175-2	http://dx.doi.org/10.1016/S1474-4422(16)30175-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DX3MJ	27647640	Bronze			2022-12-18	WOS:000384276900013
J	Hohlfeld, R; Kerschensteiner, M				Hohlfeld, Reinhard; Kerschensteiner, Martin			Antiglutamatergic therapy for multiple sclerosis?	LANCET NEUROLOGY			English	Editorial Material							MECHANISMS		[Hohlfeld, Reinhard; Kerschensteiner, Martin] Univ Munich, Biomed Ctr, Inst Clin Neuroimmunol, D-81377 Munich, Germany; [Hohlfeld, Reinhard; Kerschensteiner, Martin] Univ Munich, Univ Hosp, D-81377 Munich, Germany; [Hohlfeld, Reinhard; Kerschensteiner, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany	University of Munich; University of Munich; University of Munich	Hohlfeld, R (corresponding author), Univ Munich, Biomed Ctr, Inst Clin Neuroimmunol, D-81377 Munich, Germany.; Hohlfeld, R (corresponding author), Univ Munich, Univ Hosp, D-81377 Munich, Germany.; Hohlfeld, R (corresponding author), Munich Cluster Syst Neurol SyNergy, Munich, Germany.	reinhard.hohlfeld@med.uni-muenchen.de						Chamorro A, 2016, LANCET NEUROL, V15, P869, DOI 10.1016/S1474-4422(16)00114-9; Chataway J, 2014, LANCET, V383, P2213, DOI 10.1016/S0140-6736(13)62242-4; Dutta R, 2011, ANN NEUROL, V69, P445, DOI 10.1002/ana.22337; Fernandez O, 2016, REV NEUROLOGIA, V62, P559, DOI 10.33588/rn.6212.2016196; Friese MA, 2014, NAT REV NEUROL, V10, P225, DOI 10.1038/nrneurol.2014.37; Jurgens T, 2016, BRAIN, V139, P39, DOI 10.1093/brain/awv353; Kremer D, 2016, TRENDS NEUROSCI, V39, P246, DOI 10.1016/j.tins.2016.02.004; Macrez R, 2016, LANCET NEUROL, V15, P1089, DOI 10.1016/S1474-4422(16)30165-X; Raftopoulos R, 2016, LANCET NEUROL, V15, P259, DOI 10.1016/S1474-4422(16)00004-1; Saab AS, 2016, NEURON, V91, P119, DOI 10.1016/j.neuron.2016.05.016; Sedel F, 2015, NEUROPHARMACOLOGY, DOI [10.1016/j.neuropharm.2015.08.028, DOI 10.1016/J.NEUROPHARM.2015.08.028.]	11	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2016	15	10					1003	+		10.1016/S1474-4422(16)30163-6	http://dx.doi.org/10.1016/S1474-4422(16)30163-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1ZJ	27571145				2022-12-18	WOS:000381280300007
J	Husain, AM				Husain, Aatif M.			Clarity in EEG diagnosis of non-convulsive status epilepticus	LANCET NEUROLOGY			English	Editorial Material							CRITERIA; TERMINOLOGY		[Husain, Aatif M.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC 27710 USA; [Husain, Aatif M.] Vet Affairs Med Ctr, Neurodiagnost Ctr, Durham, NC 27710 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Husain, AM (corresponding author), Duke Univ, Med Ctr, Dept Neurol, Durham, NC 27710 USA.; Husain, AM (corresponding author), Vet Affairs Med Ctr, Neurodiagnost Ctr, Durham, NC 27710 USA.	aatif.husain@duke.edu	Husain, Aatif/AAN-7058-2021					Beniczky S, 2013, EPILEPSIA, V54, P28, DOI 10.1111/epi.12270; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; French JA, 2015, EPILEPSIA, V56, P13; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI [10.1097/WNP.0b013e3182784729, 10.1097/WNP.0000000000000806]; Husain AM, 2015, EPILEPSY BEHAV, V49, P337, DOI 10.1016/j.yebeh.2015.06.018; Kaplan PW, 2007, EPILEPSIA, V48, P39, DOI 10.1111/j.1528-1167.2007.01345.x; Leitinger M, 2016, LANCET NEUROL, V15, P1054, DOI 10.1016/S1474-4422(16)30137-5; Swisher CB, 2015, J CLIN NEUROPHYSIOL, V32, P147, DOI 10.1097/WNP.0000000000000157; TREIMAN DM, 1990, EPILEPSY RES, V5, P49, DOI 10.1016/0920-1211(90)90065-4; Young GB, 1996, NEUROLOGY, V47, P83	10	4	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2016	15	10					1001	+		10.1016/S1474-4422(16)30172-7	http://dx.doi.org/10.1016/S1474-4422(16)30172-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1ZJ	27571144				2022-12-18	WOS:000381280300006
J							Lancet Neurology	The shared burden of stroke and dementia	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2016	15	9					891	891		10.1016/S1474-4422(16)30132-6	http://dx.doi.org/10.1016/S1474-4422(16)30132-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1YY	27478943				2022-12-18	WOS:000381279200001
J	Coralli, A; Perciaccante, A				Coralli, A.; Perciaccante, A.			Leonardo's recurrent stroke? (vol 15, pg 667, 2016)	LANCET NEUROLOGY			English	Correction																		Coralli Alessia, 2016, Lancet Neurol, V15, P667, DOI 10.1016/S1474-4422(16)30051-5	1	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2016	15	8					787	787		10.1016/S1474-4422(16)30051-5	http://dx.doi.org/10.1016/S1474-4422(16)30051-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO1NR	27571153				2022-12-18	WOS:000377545800009
J	Koepp, MJ				Koepp, Matthias J.			The help of biomarkers in the prevention of epilepsy	LANCET NEUROLOGY			English	Editorial Material							PREDICTION; SEIZURES		[Koepp, Matthias J.] UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England	University of London; University College London	Koepp, MJ (corresponding author), UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England.	m.koepp@ucl.ac.uk						Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; Brandt C, 2015, NEUROBIOL DIS, V75, P78, DOI 10.1016/j.nbd.2014.12.015; Cook MJ, 2013, LANCET NEUROL, V12, P563, DOI 10.1016/S1474-4422(13)70075-9; Feldmann M, 2013, LANCET NEUROL, V12, P777, DOI 10.1016/S1474-4422(13)70109-1; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Kasperaviciute D, 2013, BRAIN, V136, P3140, DOI 10.1093/brain/awt233; Mueller Susanne G, 2005, Alzheimers Dement, V1, P55, DOI 10.1016/j.jalz.2005.06.003; Pitkanen A, 2016, LANCET NEUROL, V15, P843, DOI 10.1016/S1474-4422(16)00112-5	9	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2016	15	8					782	784		10.1016/S1474-4422(16)30081-3	http://dx.doi.org/10.1016/S1474-4422(16)30081-3			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO1NR	27302346				2022-12-18	WOS:000377545800006
J	Smith, DH; Stewart, W				Smith, Douglas H.; Stewart, William			Tackling concussion, beyond Hollywood	LANCET NEUROLOGY			English	Letter							INJURY		[Smith, Douglas H.; Stewart, William] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Smith, Douglas H.; Stewart, William] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland	University of Pennsylvania; University of Pennsylvania; Queen Elizabeth University Hospital (QEUH); University of Glasgow	Stewart, W (corresponding author), Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.; Stewart, W (corresponding author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.; Stewart, W (corresponding author), Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland.; Stewart, W (corresponding author), Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland.	william.Stewart@glasgow.ac.uk		Stewart, William/0000-0003-2199-2582	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS094003, R01NS038104, R01NS092398, P01NS056202] Funding Source: NIH RePORTER; NIBIB NIH HHS [R01 EB021293] Funding Source: Medline; NINDS NIH HHS [R01 NS038104, P01 NS056202, R01 NS092398, R01 NS094003] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29	5	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2016	15	7					662	663		10.1016/S1474-4422(16)30037-0	http://dx.doi.org/10.1016/S1474-4422(16)30037-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DM7OG	27302233	Bronze, Green Accepted			2022-12-18	WOS:000376549300016
J	Stoessl, AJ				Stoessl, A. Jon			Salivary gland biopsy for diagnosis of Parkinson's disease?	LANCET NEUROLOGY			English	Editorial Material							SLEEP BEHAVIOR DISORDER; ALPHA-SYNUCLEIN; NERVES; RISK		[Stoessl, A. Jon] Univ British Columbia, Pacific Parkinsons Res Ctr, Div Neurol, Vancouver, BC V6T 1Z3, Canada; [Stoessl, A. Jon] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 1Z3, Canada; [Stoessl, A. Jon] Vancouver Coastal Hlth, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Stoessl, AJ (corresponding author), Univ British Columbia, Pacific Parkinsons Res Ctr, Div Neurol, Vancouver, BC V6T 1Z3, Canada.; Stoessl, AJ (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 1Z3, Canada.; Stoessl, AJ (corresponding author), Vancouver Coastal Hlth, Vancouver, BC V6T 1Z3, Canada.	jstoessl@mail.ubc.ca	Stoessl, A Jon/J-9661-2015	Stoessl, A Jon/0000-0002-9778-7246				Adler CH, 2014, NEUROLOGY, V82, P858, DOI 10.1212/WNL.0000000000000204; Doppler K, 2015, MOVEMENT DISORD, V30, P1688, DOI 10.1002/mds.26293; Healy DG, 2008, LANCET NEUROL, V7, P583, DOI 10.1016/S1474-4422(08)70117-0; Hughes AJ, 2001, NEUROLOGY, V57, P1497, DOI 10.1212/WNL.57.8.1497; Iranzo A, 2013, LANCET NEUROL, V12, P443, DOI 10.1016/S1474-4422(13)70056-5; Jennings D, 2014, NEUROLOGY, V83, P1739, DOI 10.1212/WNL.0000000000000960; Kashihara K, 2010, PARKINSONISM RELAT D, V16, P252, DOI 10.1016/j.parkreldis.2009.12.010; Kotagal V, 2012, ANN NEUROL, V71, P560, DOI 10.1002/ana.22691; Postuma RB, 2012, MOVEMENT DISORD, V27, P720, DOI 10.1002/mds.24939; Vilas D, 2016, LANCET NEUROL; Wang NS, 2013, NEUROLOGY, V81, P1604, DOI 10.1212/WNL.0b013e3182a9f449	11	4	4	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2016	15	7					654	656		10.1016/S1474-4422(16)30031-X	http://dx.doi.org/10.1016/S1474-4422(16)30031-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DM7OG	27102890				2022-12-18	WOS:000376549300005
J	Devinsky, O; Marsh, E; Friedman, D				Devinsky, O.; Marsh, E.; Friedman, D.			Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial (vol 15, pg 270, 2016)	LANCET NEUROLOGY			English	Correction																		Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8	1	4	4	2	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					352	352		10.1016/S1474-4422(16)00061-2	http://dx.doi.org/10.1016/S1474-4422(16)00061-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP		Bronze			2022-12-18	WOS:000371974000009
J	Perucca, E				Perucca, Emilio			The safety of generic substitution in epilepsy	LANCET NEUROLOGY			English	Editorial Material							ANTIEPILEPTIC DRUGS; BIOEQUIVALENCE		[Perucca, Emilio] Univ Pavia, Dept Internal Med & Therapeut, Via Ferrata 9, I-27100 Pavia, Italy; [Perucca, Emilio] C Mondino Natl Neurol Inst, Via Ferrata 9, I-27100 Pavia, Italy	University of Pavia; IRCCS Fondazione Casimiro Mondino	Perucca, E (corresponding author), Univ Pavia, Dept Internal Med & Therapeut, Via Ferrata 9, I-27100 Pavia, Italy.; Perucca, E (corresponding author), C Mondino Natl Neurol Inst, Via Ferrata 9, I-27100 Pavia, Italy.	perucca@unipv.it	Perucca, Emilio/Q-7308-2019	Perucca, Emilio/0000-0001-8703-223X				Cameron A, 2012, VALUE HEALTH, V15, P664, DOI 10.1016/j.jval.2012.04.004; Davit BM, 2009, ANN PHARMACOTHER, V43, P1583, DOI 10.1345/aph.1M141; Karalis V, 2014, CNS DRUGS, V28, P69, DOI 10.1007/s40263-013-0112-8; Kesselheim AS, 2010, DRUGS, V70, P605, DOI 10.2165/10898530-000000000-00000; Laroche ML, 2005, EPILEPSIA, V46, P1293, DOI 10.1111/j.1528-1167.2005.01805.x; MHRA, ANT CHANG PROD; National Institute for Health and Care Excellence (NICE), 2012, EP DIAGN TREATM CLIN; Privitera M, 2016, LANCET NEUROL; Scottish Intercollegiate Guidelines Network (SIGN), 2015, DIAGN MAN EP AD; US FDA, UND GEN DRUGS	10	4	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					344	345		10.1016/S1474-4422(16)00042-9	http://dx.doi.org/10.1016/S1474-4422(16)00042-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP	26875742				2022-12-18	WOS:000371974000002
J							NINDS Stroke Genetics Network SIGN; ISGC	International Stroke Genetics Consortium (ISGC). Loci associated with ischaemic stroke and its subtypes (SIGN): a genome-wide association study (vol 15, pg 174, 2016)	LANCET NEUROLOGY			English	Correction																		Rosand J, 2016, LANCET NEUROL, V15, P174, DOI 10.1016/S1474-4422(15)00338-5	1	4	4	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2016	15	3					241	241		10.1016/S1474-4422(15)00338-5	http://dx.doi.org/10.1016/S1474-4422(15)00338-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DE1ON		Green Submitted, Green Accepted			2022-12-18	WOS:000370396400011
J	Claassen, J				Claassen, Jan			Dr No: double drug fails to eliminate status epilepticus	LANCET NEUROLOGY			English	Editorial Material							ADULTS		[Claassen, Jan] Columbia Univ, Neurol Inst, Dept Neurol, New York, NY 10032 USA	Columbia University	Claassen, J (corresponding author), Columbia Univ, Neurol Inst, Dept Neurol, New York, NY 10032 USA.	jc1439@columbia.edu	Claassen, Jan/AAA-5451-2020					Alldredge BK, 2001, NEW ENGL J MED, V345, P631, DOI 10.1056/NEJMoa002141; Betjemann JP, 2015, LANCET NEUROL, V14, P615, DOI 10.1016/S1474-4422(15)00042-3; Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X; Cock HR, 2011, EPILEPSIA, V52, P50, DOI 10.1111/j.1528-1167.2011.03237.x; Klitgaard H, 2003, SEIZURE-EUR J EPILEP, V12, P92, DOI 10.1016/S1059131102001930; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; Misra UK, 2012, J NEUROL, V259, P645, DOI 10.1007/s00415-011-6227-2; Navarro V, 2015, LANCET NEUROLOGY; Silbergleit R, 2012, NEW ENGL J MED, V366, P591, DOI 10.1056/NEJMoa1107494; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202	10	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					23	24		10.1016/S1474-4422(15)00333-6	http://dx.doi.org/10.1016/S1474-4422(15)00333-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26627364				2022-12-18	WOS:000366313900013
J	[Anonymous]				[Anonymous]			Building on 50 years of levodopa therapy	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					1	1		10.1016/S1474-4422(15)00349-X	http://dx.doi.org/10.1016/S1474-4422(15)00349-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700892	Bronze			2022-12-18	WOS:000366313900001
J	Schmidt, D				Schmidt, Dieter			The end of regulatory monotherapy trials?	LANCET NEUROLOGY			English	Editorial Material							REFRACTORY EPILEPSY		[Schmidt, Dieter] Epilepsy Res Grp, Berlin, Germany	Epilepsy Research Group	Schmidt, D (corresponding author), Epilepsy Res Grp, Berlin, Germany.	dbschmidt@t-online.de						Beyenburg S, 2010, EPILEPSIA, V51, P7, DOI 10.1111/j.1528-1167.2009.02299.x; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Mintzer S, 2015, LANCET NEUROL, V14, P1229, DOI 10.1016/S1474-4422(15)00229-X	3	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2015	14	12					1150	1151		10.1016/S1474-4422(15)00304-X	http://dx.doi.org/10.1016/S1474-4422(15)00304-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW2WZ	26581962				2022-12-18	WOS:000364855100006
J	Grioni, D; Rovelli, A; Pavan, F; Prunotto, G				Grioni, Daniele; Rovelli, Attilio; Pavan, Fabio; Prunotto, Giulia			The diagnosis of posterior reversible encephalopathy syndrome	LANCET NEUROLOGY			English	Letter									[Grioni, Daniele] Milano Bicocca Univ, San Gerardo Hosp, Child Neuropsychiat Dept, I-20900 Monza, Italy; [Rovelli, Attilio; Pavan, Fabio; Prunotto, Giulia] Milano Bicocca Univ, BMT Unit, Dept Pediat, MBBM Fdn, I-20900 Monza, Italy	San Gerardo Hospital; University of Milano-Bicocca; University of Milano-Bicocca	Grioni, D (corresponding author), Milano Bicocca Univ, San Gerardo Hosp, Child Neuropsychiat Dept, I-20900 Monza, Italy.	neuroped@hsgerardo.org						Fugate JE, 2015, LANCET NEUROL, V14, P914, DOI 10.1016/S1474-4422(15)00111-8; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Lucchini G, 2008, PEDIATR BLOOD CANCER, V51, P629, DOI 10.1002/pbc.21688	3	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2015	14	11					1073	1074		10.1016/S1474-4422(15)00254-9	http://dx.doi.org/10.1016/S1474-4422(15)00254-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT7DY	26466775	Bronze			2022-12-18	WOS:000362975200008
J	Compter, A; van der Worp, HB; Algra, A; Kappelle, LJ				Compter, Annette; van der Worp, H. Bart; Algra, Ale; Kappelle, L. Jaap		VAST Investigators	Risks of stenting in patients with extracranial and intracranial vertebral artery stenosis	LANCET NEUROLOGY			English	Letter							MEDICAL-TREATMENT; TRIAL		[Compter, Annette; van der Worp, H. Bart; Algra, Ale; Kappelle, L. Jaap] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Algra, Ale] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Compter, A (corresponding author), Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands.	a.compter@umcutrecht.nl						Compter A, 2015, LANCET NEUROL, V14, P606, DOI 10.1016/S1474-4422(15)00017-4; Derdeyn CP, 2014, LANCET, V383, P333, DOI 10.1016/S0140-6736(13)62038-3; Eberhardt O, 2006, J VASC SURG, V43, P1145, DOI 10.1016/j.jvs.2006.02.027; Gulli G, 2013, STROKE, V44, P598, DOI 10.1161/STROKEAHA.112.669929; Turan TN, 2015, LANCET NEUROL, V14, P565, DOI 10.1016/S1474-4422(15)00049-6; Zaidat OO, 2015, JAMA-J AM MED ASSOC, V313, P1240, DOI 10.1001/jama.2015.1693	6	4	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2015	14	9					875	875		10.1016/S1474-4422(15)00142-8	http://dx.doi.org/10.1016/S1474-4422(15)00142-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CP4YZ	26293559				2022-12-18	WOS:000359889800007
J	Malm, J				Malm, Jan			Improving research and care for patients with idiopathic NPH	LANCET NEUROLOGY			English	Editorial Material							NORMAL-PRESSURE HYDROCEPHALUS		Umea Univ, Dept Clin Neurosci, S-90185 Umea, Sweden	Umea University	Malm, J (corresponding author), Umea Univ, Dept Clin Neurosci, S-90185 Umea, Sweden.	jan.malm@umu.se	Malm, Jan/AAY-6275-2020	Malm, Jan/0000-0001-6451-1940				Andren K, 2014, J NEUROL NEUROSUR PS, V85, P806, DOI 10.1136/jnnp-2013-306117; Eklund A, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-12; Farahmand D, 2009, J NEUROL NEUROSUR PS, V80, P1248, DOI 10.1136/jnnp.2007.141416; Kazui H, 2015, LANCET NEUROL; Klinge P, 2012, ACTA NEUROL SCAND, V126, P145, DOI 10.1111/j.1600-0404.2012.01676.x; Malm J., 2006, PRACT NEUROL, V6, P14, DOI DOI 10.1136/JNNP.2006.088351; Malm J, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-22; Marmarou A, 2005, NEUROSURGERY, V57, P17, DOI 10.1227/01.NEU.0000168184.01002.60; Marmarou Anthony, 2005, Neurosurgery, V57, pS1; Tisell M, 2011, J NEUROSURG, V114, P1432, DOI 10.3171/2010.11.JNS10967; Toma AK, 2013, ACTA NEUROCHIR, V155, P1977, DOI 10.1007/s00701-013-1835-5	11	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2015	14	6					561	563		10.1016/S1474-4422(15)00055-1	http://dx.doi.org/10.1016/S1474-4422(15)00055-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CI5WG	25934243				2022-12-18	WOS:000354829900003
J	de Carvalho, M				de Carvalho, Mamede			Tackling diagnostic delays in ALS	LANCET NEUROLOGY			English	Editorial Material									[de Carvalho, Mamede] Univ Lisbon, Inst Physiol, Inst Mol Med, Fac Med, P-1699 Lisbon, Portugal; [de Carvalho, Mamede] Hosp Santa Maria, Ctr Hosp Lisboa Norte, Dept Neurosci, Lisbon, Portugal	Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria	de Carvalho, M (corresponding author), Univ Lisbon, Inst Physiol, Inst Mol Med, Fac Med, P-1699 Lisbon, Portugal.	mamedemg@mail.telepac.pt	de Carvalho, Mamede/I-6295-2019	de Carvalho, Mamede/0000-0001-7556-0158				Bruneteau G, 2015, ANN CLIN TRANSL NEUR, V2, P362, DOI 10.1002/acn3.179; de Carvalho M, 2013, J NEUROL NEUROSUR PS, V84, P963, DOI 10.1136/jnnp-2012-304545; de Carvalho M, 2011, CLIN NEUROPHYSIOL, V122, P629, DOI 10.1016/j.clinph.2010.07.019; deCarvalho M, 1997, J NEUROL, V244, P304, DOI 10.1007/s004150050091; EISEN A, 1992, MUSCLE NERVE, V15, P219, DOI 10.1002/mus.880150215; Foerster BR, 2012, NEUROLOGY, V78, P1596, DOI 10.1212/WNL.0b013e3182563b57; Menon P, 2015, LANCET NEUROL; Menon P, 2015, CLIN NEUROPHYSIOL, V126, P803, DOI 10.1016/j.clinph.2014.04.023; RIDDING MC, 1995, ANN NEUROL, V37, P181, DOI 10.1002/ana.410370208; Rocha MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073846	10	4	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2015	14	5					457	458		10.1016/S1474-4422(15)00020-4	http://dx.doi.org/10.1016/S1474-4422(15)00020-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG6SY	25843899				2022-12-18	WOS:000353433900003
J	Glass, HC				Glass, Hannah C.			Bumetanide for treatment of seizures in neonates	LANCET NEUROLOGY			English	Editorial Material							DEVELOPING RAT-BRAIN; ANTIEPILEPTIC DRUGS; WORKSHOP		[Glass, Hannah C.] Univ Calif San Francisco, Dept Neurol, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Glass, Hannah C.] Univ Calif San Francisco, Dept Pediat, Benioff Childrens Hosp, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Glass, HC (corresponding author), Univ Calif San Francisco, Dept Neurol, Benioff Childrens Hosp, San Francisco 414C, San Francisco, CA 94143 USA.	hannah.glass@ucsf.edu			NINDS NIH HHS [K23NS066137] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS066137] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bittigau P, 2002, P NATL ACAD SCI USA, V99, P15089, DOI 10.1073/pnas.222550499; Clancy RR, 2006, CLIN THER, V28, P1342, DOI 10.1016/j.clinthera.2006.09.004; Glier C, 2004, EXP NEUROL, V187, P403, DOI 10.1016/j.expneurol.2004.01.025; Jacobs S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub2; Manthey D, 2005, EXP NEUROL, V193, P497, DOI 10.1016/j.expneurol.2005.01.006; Pressler RM, 2015, LANCET NEUROL; Silverstein FS, 2008, PEDIATR NEUROL, V39, P77, DOI 10.1016/j.pediatrneurol.2008.04.008; Silverstein FS, 2008, J PEDIATR-US, V153, P12, DOI 10.1016/j.jpeds.2008.01.041	8	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2015	14	5					456	457		10.1016/S1474-4422(15)70024-4	http://dx.doi.org/10.1016/S1474-4422(15)70024-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG6SY	25765332	Green Submitted			2022-12-18	WOS:000353433900002
J	Stuve, O; Cutter, GR				Stueve, Olaf; Cutter, Gary R.			Multiple sclerosis drugs: how much bang for the buck?	LANCET NEUROLOGY			English	Editorial Material							INTERFERON-BETA; PROGRESSION; ASSOCIATION		[Stueve, Olaf] VA North Texas Hlth Care Syst, Neurol Sect, Med Serv Dallas, VA Med Ctr, Dallas, TX 75216 USA; [Stueve, Olaf] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Stueve, Olaf] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-80290 Munich, Germany; [Cutter, Gary R.] Univ Alabama, Dept Biostat, Sect Res Methods & Clin Trials, Tuscaloosa, AL 35487 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System; University of Texas System; University of Texas Southwestern Medical Center Dallas; Technical University of Munich; University of Alabama System; University of Alabama Tuscaloosa	Stuve, O (corresponding author), VA North Texas Hlth Care Syst, Neurol Sect, Med Serv Dallas, VA Med Ctr, Dallas, TX 75216 USA.	olaf.stuve@utsouthwestern.edu	Cutter, Gary/AAY-5392-2021	Cutter, Gary/0000-0002-8455-980X				Chilcott J, 2003, BRIT MED J, V326, P522, DOI 10.1136/bmj.326.7388.522; Himmelstein DU, 2009, AM J MED, V122, P741, DOI 10.1016/j.amjmed.2009.04.012; Karim ME, 2014, AM J EPIDEMIOL, V180, P160, DOI 10.1093/aje/kwu125; Palace J, 2015, LANCET NEUROL; Shirani A, 2012, JAMA-J AM MED ASSOC, V308, P247, DOI 10.1001/jama.2012.7625; Stachowiak J., MULTIPLE SCLEROSIS D; Uitdehaag BMJ, 2011, CURR MED RES OPIN, V27, P1529, DOI 10.1185/03007995.2011.591370	7	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2015	14	5					460	461		10.1016/S1474-4422(15)00016-2	http://dx.doi.org/10.1016/S1474-4422(15)00016-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG6SY	25841666				2022-12-18	WOS:000353433900005
J	Abdul-Rahim, AH; Lees, KR				Abdul-Rahim, Azmil H.; Lees, Kennedy R.			Screening for atrial fibrillation after stroke or TIA	LANCET NEUROLOGY			English	Editorial Material							TRANSIENT ISCHEMIC ATTACK		[Abdul-Rahim, Azmil H.; Lees, Kennedy R.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Abdul-Rahim, AH (corresponding author), Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland.	azmil.abdul-rahim@glasgow.ac.uk	Abdul-Rahim, Azmil/G-6821-2012	Abdul-Rahim, Azmil/0000-0002-1318-4027	Chief Scientist Office [CZG/2/475] Funding Source: Medline	Chief Scientist Office		Andrew NE, 2013, NEUROEPIDEMIOLOGY, V40, P227, DOI 10.1159/000343667; [Anonymous], NAVIGATE ESUS TRIAL; Diener HC, 2014, CEREBROVASC DIS, V37, P261; Guyler P., 2014, BR J CARDIOL, V21, P102; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Ntaios G, 2012, STROKE, V43, P3298, DOI 10.1161/STROKEAHA.112.673558; Rankin AJ, 2014, QJM, V107, P835; Sposato LA, 2015, LANCET NEUROL; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	9	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2015	14	4					345	347		10.1016/S1474-4422(15)70039-6	http://dx.doi.org/10.1016/S1474-4422(15)70039-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CE5RD	25748101				2022-12-18	WOS:000351892400004
J	Kiernan, MC				Kiernan, Matthew C.			Palliative care in amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Editorial Material							MANAGEMENT; ALS		Univ Sydney, Brain & Mind Res Inst, Sydney, NSW 2050, Australia	University of Sydney	Kiernan, MC (corresponding author), Univ Sydney, Brain & Mind Res Inst, Sydney, NSW 2050, Australia.	matthew.kiernan@sydney.edu.au	Kiernan, Matthew C/E-4460-2011	Kiernan, Matthew/0000-0001-9054-026X				Andersen PM, 2007, AMYOTROPH LATERAL SC, V8, P195, DOI 10.1080/17482960701262376; Bede P, 2011, J NEUROL NEUROSUR PS, V82, P413, DOI 10.1136/jnnp.2010.232637; Bradley WG, 2001, NEUROLOGY, V57, P500, DOI 10.1212/WNL.57.3.500; Caga J, 2015, PALLIAT SUPPORT CARE, V13, P1019, DOI 10.1017/S1478951514000881; Connolly S, 2015, LANCET NEUROL; Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7; Matthews W. B, 1963, PRACTICAL NEUROLOGY; Traynor BJ, 2003, J NEUROL NEUROSUR PS, V74, P1258, DOI 10.1136/jnnp.74.9.1258; Turner MR, 2013, LANCET NEUROL, V12, P310, DOI 10.1016/S1474-4422(13)70036-X; Winhammar JMC, 2005, LANCET NEUROL, V4, P229, DOI 10.1016/S1474-4422(05)70042-9	10	4	4	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2015	14	4					347	348		10.1016/S1474-4422(14)70289-3	http://dx.doi.org/10.1016/S1474-4422(14)70289-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CE5RD	25728959				2022-12-18	WOS:000351892400005
J	Lassmann, H				Lassmann, Hans			Spinal cord pathology in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material									Med Univ Vienna, Ctr Brain Res, A-1090 Vienna, Austria	Medical University of Vienna	Lassmann, H (corresponding author), Med Univ Vienna, Ctr Brain Res, Spitalgasse 4, A-1090 Vienna, Austria.	hans.lassmann@meduniwien.ac.at	Lassmann, Hans/Z-2269-2019	Lassmann, Hans/0000-0001-8617-5052				Androdias G, 2010, ANN NEUROL, V68, P465, DOI 10.1002/ana.22054; Evangelou N, 2005, BRAIN, V128, P29, DOI 10.1093/brain/awh323; FOG T, 1950, ARCH NEURO PSYCHIATR, V63, P382, DOI 10.1001/archneurpsyc.1950.02310210028003; Gass A., 2015, LANCET NEUROL; Gilmore CP, 2006, BRAIN PATHOL, V16, P202, DOI 10.1111/j.1750-3639.2006.00018.x; Gilmore CP, 2009, BRAIN PATHOL, V19, P642, DOI 10.1111/j.1750-3639.2008.00228.x; Gnanapavan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070019; HASSON J, 1958, NEUROLOGY, V8, P503, DOI 10.1212/WNL.8.7.503; JELLINGER K, 1969, WIEN Z NERVENHEIL S2, P12; Nijeholt GJLA, 2001, BRAIN, V124, P154, DOI 10.1093/brain/124.1.154	10	4	4	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2015	14	4					348	349		10.1016/S1474-4422(15)70037-2	http://dx.doi.org/10.1016/S1474-4422(15)70037-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CE5RD	25748100				2022-12-18	WOS:000351892400006
J	[Anonymous]				[Anonymous]			The stroke care revolution	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2015	14	4					341	341		10.1016/S1474-4422(15)70023-2	http://dx.doi.org/10.1016/S1474-4422(15)70023-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CE5RD	25752414				2022-12-18	WOS:000351892400001
J	Engel, J				Engel, Jerome, Jr.			Who will use epilepsy surgery nomograms, and why?	LANCET NEUROLOGY			English	Editorial Material							TEMPORAL-LOBE EPILEPSY; RESECTIONS; TRIAL; LONG		Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Engel, J (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	engel@ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS015654, P20NS080181, P01NS002808, R01NS033310, R37NS033310] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33310, NS15654, NS02808, NS80181] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], EPILEPSY CURR; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; de Tisi J, 2011, LANCET, V378, P1388, DOI 10.1016/S0140-6736(11)60890-8; Engel J, 2003, NEUROLOGY, V60, P538, DOI 10.1212/01.WNL.0000055086.35806.2D; Engel J, 2012, JAMA-J AM MED ASSOC, V307, P922, DOI 10.1001/jama.2012.220; Englot DJ, 2012, NEUROLOGY, V78, P1200, DOI 10.1212/WNL.0b013e318250d7ea; Hader WJ, 2013, EPILEPSIA, V54, P840, DOI 10.1111/epi.12161; Haneef Z, 2010, NEUROLOGY, V75, P699, DOI 10.1212/WNL.0b013e3181eee457; Jehi L, 2015, LANCET NEUROL; Spencer S, 2008, LANCET NEUROL, V7, P525, DOI 10.1016/S1474-4422(08)70109-1; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501	11	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2015	14	3					240	241		10.1016/S1474-4422(15)70011-6	http://dx.doi.org/10.1016/S1474-4422(15)70011-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4JM	25638641	Green Submitted			2022-12-18	WOS:000349594000005
J	Quaglio, G; McGuinness, M; Rubig, P; Nutt, D; Karapiperis, T; Pandolfo, M; Sudhof, TC				Quaglio, Gianluca; McGuinness, Mairead; Ruebig, Paul; Nutt, David; Karapiperis, Theodoros; Pandolfo, Massimo; Suedhof, Thomas Christian			Building bridges between neuroscientific evidence and policy	LANCET NEUROLOGY			English	Editorial Material									[Quaglio, Gianluca; Karapiperis, Theodoros] European Parliamentary Res Serv, Sci Foresight Sci & Technol Opt Assessment STOA, Brussels, Belgium; [McGuinness, Mairead; Ruebig, Paul] European Parliament, Brussels, Belgium; [Nutt, David] Univ London Imperial Coll Sci Technol & Med, London, England; [Nutt, David] European Brain Council, Brussels, Belgium; [Pandolfo, Massimo] ULB, Hop Erasme, Dept Neurol, Brussels, Belgium; [Suedhof, Thomas Christian] Stanford Univ, Sch Med, Stanford, CA 94305 USA	Imperial College London; Universite Libre de Bruxelles; Stanford University	Quaglio, G (corresponding author), European Parliamentary Res Serv, Sci Foresight Sci & Technol Opt Assessment STOA, Brussels, Belgium.	gianluca.quaglio@europarl.europa.eu							0	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2015	14	3					243	245		10.1016/S1474-4422(15)70014-1	http://dx.doi.org/10.1016/S1474-4422(15)70014-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4JM	25728434				2022-12-18	WOS:000349594000007
J	Angelini, C				Angelini, Corrado			Prevention of cardiomyopathy in Duchenne muscular dystrophy	LANCET NEUROLOGY			English	Editorial Material									IRCCS Fdn San Camillo Hosp, Venice, Italy	IRCCS Ospedale San Camillo	Angelini, C (corresponding author), IRCCS Fdn San Camillo Hosp, Venice, Italy.	corrado.angelini@ospedalesancamillo.net	Angelini, Corrado I/J-3655-2019	Angelini, Corrado I/0000-0002-9554-8794				Angelini C, 2007, MUSCLE NERVE, V36, P424, DOI 10.1002/mus.20812; Biggar WD, 2006, NEUROMUSCULAR DISORD, V16, P249, DOI 10.1016/j.nmd.2006.01.010; Bushby K, 2004, Neuromuscul Disord, V14, P526, DOI 10.1016/j.nmd.2004.05.006; Duboc D, 2005, J AM COLL CARDIOL, V45, P855, DOI 10.1016/j.jacc.2004.09.078; Finkel RS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081302; Markham LW, 2005, PEDIATR CARDIOL, V26, P768, DOI 10.1007/s00246-005-0909-4; Melacini P, 1996, NEUROMUSCULAR DISORD, V6, P367, DOI 10.1016/0960-8966(96)00357-4; Melacini P., 2013, MUSCULAR DYSTROPHY C, P367; Ogata H, 2009, J CARDIOL, V53, P72, DOI 10.1016/j.jjcc.2008.08.013; Raman SV, 2014, LANCET NEUROL	10	4	4	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2015	14	2					127	128		10.1016/S1474-4422(14)70326-6	http://dx.doi.org/10.1016/S1474-4422(14)70326-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AY9KS	25554403				2022-12-18	WOS:000347869400003
J	Kallio, ME				Kallio, Merja E.			Neuropsychiatric outcomes after stroke	LANCET NEUROLOGY			English	Letter							DEPRESSION		Univ Helsinki, Cent Hosp, Dept Neurol, FI-00029 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Kallio, ME (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurol, FI-00029 Helsinki, Finland.	merja.kallio@helsinki.fi						Berg A, 2009, STROKE, V40, P523, DOI 10.1161/STROKEAHA.108.527705; Carson AJ, 2000, LANCET, V356, P122, DOI 10.1016/S0140-6736(00)02448-X; Gainotti G, 1997, J CLIN EXP NEUROPSYC, V19, P340, DOI 10.1080/01688639708403863; Hackett ML, 2014, LANCET NEUROL, V13, P525, DOI [10.1016/s1474-4422(14)70016-X, 10.1016/S1474-4422(14)70016-X]	4	4	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2014	13	12					1168	1169		10.1016/S1474-4422(14)70223-6	http://dx.doi.org/10.1016/S1474-4422(14)70223-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU5XG	25453452				2022-12-18	WOS:000345676300006
J	Saft, C				Saft, Carsten			What is the course of Huntington's disease?	LANCET NEUROLOGY			English	Editorial Material									Ruhr Univ Bochum, St Josef Hosp, Huntington Ctr NRW, Dept Neurol, D-44791 Bochum, Germany	Ruhr University Bochum	Saft, C (corresponding author), Ruhr Univ Bochum, St Josef Hosp, Huntington Ctr NRW, Dept Neurol, D-44791 Bochum, Germany.	carsten.saft@ruhr-uni-bochum.de		Saft, Carsten/0000-0002-3983-7292				FOLSTEIN SE, 1983, PSYCHOL MED, V13, P537, DOI 10.1017/S0033291700047966; Lo Sardo V, 2012, NAT NEUROSCI, V15, P713, DOI 10.1038/nn.3080; Muhlau M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029809; Paulsen JS, 2014, LANCET NEUROL; Reilmann R, 2014, MOVEMENT DISORD, V29, P1335, DOI 10.1002/mds.26011; Ross CA, 2014, NAT REV NEUROL, V10, P204, DOI 10.1038/nrneurol.2014.24; Saft C, 2009, AKTUEL NEUROL, V36, P506, DOI 10.1055/s-0029-1223409; Tabrizi S, 2012, J NEUROL NEUROSUR PS, V83, pe1; Tabrizi SJ, 2013, LANCET NEUROL, V12, P637, DOI 10.1016/S1474-4422(13)70088-7; Vinther-Jensen T, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0114-8; Wild EJ, 2014, MOVEMENT DISORD, V29, P1434, DOI 10.1002/mds.26007	11	4	4	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2014	13	12					1165	1166		10.1016/S1474-4422(14)70260-1	http://dx.doi.org/10.1016/S1474-4422(14)70260-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU5XG	25453450				2022-12-18	WOS:000345676300004
J	George, AL				George, Alfred L., Jr.			Lessons learned from genetic testing for channelopathies Comment	LANCET NEUROLOGY			English	Editorial Material							DISEASE		[George, Alfred L., Jr.] Northwestern Univ, Feinberg Sch Med, Dept Pharmacol, Chicago, IL 60611 USA; [George, Alfred L., Jr.] Northwestern Univ, Feinberg Sch Med, Ctr Pharmacogenom, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	George, AL (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pharmacol, Chicago, IL 60611 USA.	al.george@northwestern.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS032387, R01NS032387] Funding Source: NIH RePORTER; NINDS NIH HHS [NS032387] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Galehdari H, 2013, INT J MOL EPIDEMIOL, V4, P77; MacArthur DG, 2014, NATURE, V508, P469, DOI 10.1038/nature13127; Richards CS, 2008, GENET MED, V10, P294, DOI 10.1097/GIM.0b013e31816b5cae; Schwartz MK, 1999, CLIN CHEM, V45, P739; Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486; Thusberg J, 2011, HUM MUTAT, V32, P358, DOI 10.1002/humu.21445; Waxman SG, 2014, LANCET NEUROL, V13, P1152, DOI 10.1016/S1474-4422(14)70150-4	8	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2014	13	11					1068	1070		10.1016/S1474-4422(14)70123-1	http://dx.doi.org/10.1016/S1474-4422(14)70123-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR7TZ	25316008				2022-12-18	WOS:000343783900006
J	Ciccone, A				Ciccone, Alfonso		SYNTH Expansion Investigators	Complexity of the endovascular intervention and clinical outcomes in acute ischaemic stroke	LANCET NEUROLOGY			English	Letter									[Ciccone, Alfonso; SYNTH Expansion Investigators] Carlo Poma Hosp, Dept Neurosci, I-46100 Mantua, Italy	Hospital Carlo Poma	Ciccone, A (corresponding author), Carlo Poma Hosp, Dept Neurosci, Str Lago Paiolo 10, I-46100 Mantua, Italy.	alfonso.ciccone@aopoma.it	Zini, Andrea/K-1136-2014; Ciccone, Alfonso/AAB-6942-2022	Zini, Andrea/0000-0003-1486-4507; Ciccone, Alfonso/0000-0002-4590-3575				Ciccone A, 2014, 23 EUR STROK C NIC F; Ciccone A, 2013, NEW ENGL J MED, V368, P904, DOI 10.1056/NEJMoa1213701; del Zoppo GJ, 2014, RATIONAL BASIS CLIN, P213; Khatri P, 2014, LANCET NEUROL, V13, P567, DOI 10.1016/S1474-4422(14)70066-3	4	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2014	13	9					865	865		10.1016/S1474-4422(14)70174-7	http://dx.doi.org/10.1016/S1474-4422(14)70174-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO5SK	25142453				2022-12-18	WOS:000341405400010
J	Gaig, C; Iranzo, A; Santamaria, J; Dalmau, J; Graus, F				Gaig, Carles; Iranzo, Alex; Santamaria, Joan; Dalmau, Josep; Graus, Francesc			Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia? Reply	LANCET NEUROLOGY			English	Letter									[Gaig, Carles; Iranzo, Alex; Santamaria, Joan; Dalmau, Josep; Graus, Francesc] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain; [Gaig, Carles; Iranzo, Alex; Santamaria, Joan; Graus, Francesc] Hosp Clin Barcelona, Dept Neurol, Barcelona, Spain; [Gaig, Carles; Iranzo, Alex; Santamaria, Joan] Hosp Clin Barcelona, Multidisciplinary Sleep Disorders Unit, Barcelona, Spain; [Dalmau, Josep] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Dalmau, Josep] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Pennsylvania; ICREA	Gaig, C (corresponding author), Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain.	fgraus@clinic.ub.es		Dalmau, Josep/0000-0001-5856-2813; Graus, Francesc/0000-0002-8924-8322	ICREA Funding Source: Custom	ICREA(ICREA)		Sabater L, 2014, LANCET NEUROL, V13, P575, DOI 10.1016/S1474-4422(14)70051-1	1	4	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2014	13	9					864	865		10.1016/S1474-4422(14)70157-7	http://dx.doi.org/10.1016/S1474-4422(14)70157-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO5SK	25142451				2022-12-18	WOS:000341405400009
J	Pal, DK; Strug, LJ				Pal, Deb K.; Strug, Lisa J.			The genetics of common epilepsies: common or distinct?	LANCET NEUROLOGY			English	Editorial Material							JUVENILE MYOCLONIC EPILEPSY; GENOME-WIDE ASSOCIATION; FOCAL EPILEPSIES; SUSCEPTIBILITY; MUTATIONS		[Pal, Deb K.] Kings Coll London, Inst Psychiat Psychol & Neurosci, London SE5 8AF, England; [Strug, Lisa J.] Univ Toronto, Program Genet & Genome Biol, Hosp Sick Children, Toronto, ON M5G 0A4, Canada; [Strug, Lisa J.] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Biostat, Toronto, ON M5G 0A4, Canada	University of London; King's College London; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Pal, DK (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, London SE5 8AF, England.	deb.pal@kcl.ac.uk		Strug, Lisa/0000-0003-0503-9740				Berkovic SF, 1998, ANN NEUROL, V43, P435, DOI 10.1002/ana.410430405; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Durner M, 2001, ANN NEUROL, V49, P328, DOI 10.1002/ana.69.abs; Han B, 2011, AM J HUM GENET, V88, P586, DOI 10.1016/j.ajhg.2011.04.014; International League Against Epilepsy Consortium on Complex Epilepsies, 2014, LANCET NEUROL; Ishida S, 2013, NAT GENET, V45, P552, DOI 10.1038/ng.2601; Lesca G, 2013, NAT GENET, V45, P1061, DOI 10.1038/ng.2726; O'Muircheartaigh J, 2012, BRAIN, V135, P3635, DOI 10.1093/brain/aws296; Steffens M, 2012, HUM MOL GENET, V21, P5359, DOI 10.1093/hmg/dds373; Sun L, 2012, NAT GENET, V44, P562, DOI 10.1038/ng.2221; Vounou M, 2010, NEUROIMAGE, V53, P1147, DOI 10.1016/j.neuroimage.2010.07.002	11	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2014	13	9					859	860		10.1016/S1474-4422(14)70124-3	http://dx.doi.org/10.1016/S1474-4422(14)70124-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO5SK	25087077	hybrid			2022-12-18	WOS:000341405400004
J	[Anonymous]				[Anonymous]			The Human Brain Project: mutiny on the flagship	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2014	13	9					855	855		10.1016/S1474-4422(14)70181-4	http://dx.doi.org/10.1016/S1474-4422(14)70181-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO5SK	25142450	Bronze			2022-12-18	WOS:000341405400001
J	Gelinas, J; Allukian, M				Gelinas, Julianna; Allukian, Myron, Jr.			Neurodevelopmental toxicity: still more questions than answers	LANCET NEUROLOGY			English	Letter									[Gelinas, Julianna; Allukian, Myron, Jr.] Amer Assoc Community Dent Programs, Philadelphia, PA 19134 USA		Gelinas, J (corresponding author), Amer Assoc Community Dent Programs, Nelson Pavil, Philadelphia, PA 19134 USA.	julianna.gelinas@tenethealth.com						Bazian Ltd, IND CRIT APPR SEL ST; Choi AL, 2012, ENVIRON HEALTH PERSP, V120, P1362, DOI 10.1289/ehp.1104912; Grandjean P, 2014, LANCET NEUROL, V13, P330, DOI 10.1016/S1474-4422(13)70278-3; SCHER, 2011, OP CRIT REV AN NEW E; SHANNON FT, 1986, NEW ZEAL MED J, V99, P416; Whitford GM, 2009, NEUROTOXICOL TERATOL, V31, P210, DOI 10.1016/j.ntt.2009.02.003	6	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2014	13	7					647	648		10.1016/S1474-4422(14)70119-X	http://dx.doi.org/10.1016/S1474-4422(14)70119-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK5RI	24943338				2022-12-18	WOS:000338483600009
J	Hartung, HP				Hartung, Hans-Peter			Interferon beta-1a for multiple sclerosis: old drug, new clothes	LANCET NEUROLOGY			English	Editorial Material							THERAPIES		Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Hartung, HP (corresponding author), Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany.	hans-peter.hartung@uni-duesseldorf.de						Bevan CJ, 2014, JAMA NEUROL, V71, P269, DOI 10.1001/jamaneurol.2013.5486; Calabresi P, 2014, LANCET NEURAL; Clanet MC, 2014, MULT SCLER J, V20, P1306, DOI 10.1177/1352458513513207; Hartung HP, 2014, CURR OPIN NEUROL, V27, P243, DOI 10.1097/WCO.0000000000000101; Hemmer B, 2005, LANCET NEUROL, V4, P403, DOI 10.1016/S1474-4422(05)70117-4; Hu X, 2012, J CLIN PHARMACOL, V52, P798, DOI 10.1177/0091270011407068; Kang JS, 2009, EXPERT OPIN EMERG DR, V14, P363, DOI 10.1517/14728210902907847; Lu E, 2012, NEUROLOGY, V79, P1130, DOI 10.1212/WNL.0b013e3182698c64; Neuhaus O, 2007, J NEUROL SCI, V259, P27, DOI 10.1016/j.jns.2006.05.071; Nikfar S, 2010, CLIN THER, V32, P1871, DOI 10.1016/j.clinthera.2010.10.006; Oh J, 2013, LANCET NEUROL, V12, P1115, DOI 10.1016/S1474-4422(13)70192-3; Pasut G, 2012, J CONTROL RELEASE, V161, P461, DOI 10.1016/j.jconrel.2011.10.037; Sorensen PS, 2014, CURR OPIN NEUROL, V27, P246, DOI 10.1097/WCO.0000000000000096; Wingerchuk DM, 2014, MAYO CLIN PROC, V89, P225, DOI 10.1016/j.mayocp.2013.11.002	14	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2014	13	7					638	639		10.1016/S1474-4422(14)70100-0	http://dx.doi.org/10.1016/S1474-4422(14)70100-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK5RI	24878062				2022-12-18	WOS:000338483600002
J	St-Hilaire, M				St-Hilaire, Marie			Occupational therapy for Parkinson's disease: increasing awareness	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; SELF-MANAGEMENT; PEOPLE		Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA	Boston University	St-Hilaire, M (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.	neuromsh@bu.edu						Foster ER, 2014, AM J OCCUP THER, V68, P39, DOI 10.5014/ajot.2014.008706; Hariz GM, 2011, ACTA NEUROL SCAND, V123, P20, DOI 10.1111/j.1600-0404.2010.01344.x; Law M., 2005, CANADIAN OCCUPATIONA; Morris ME, 2009, MOVEMENT DISORD, V24, P64, DOI 10.1002/mds.22295; Nieuwboer A, 2007, J NEUROL NEUROSUR PS, V78, P134, DOI 10.1136/jnnp.200X.097923; Saint-Hilaire M, 2013, ADV PARK DIS, V2, P118, DOI DOI 10.4236/APD.2013.24023; Sturkenboom IHWM, 2014, LANCET NEUROL; Tickle-Degnen L, 2012, MOVEMENT DISORD, V27, pS313; Tickle-Degnen L, 2010, MOVEMENT DISORD, V25, P194, DOI 10.1002/mds.22940	9	4	5	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2014	13	6					527	529		10.1016/S1474-4422(14)70074-2	http://dx.doi.org/10.1016/S1474-4422(14)70074-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI8YK	24726067				2022-12-18	WOS:000337212700003
J	Wenning, GK; Krismer, F; Poewe, W				Wenning, Gregor K.; Krismer, Florian; Poewe, Werner			Rifampicin for multiple system atrophy	LANCET NEUROLOGY			English	Editorial Material							MODERATE ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; NATURAL-HISTORY; DEGENERATION; PROGRESSION; INCLUSIONS; TRIALS		[Wenning, Gregor K.; Krismer, Florian; Poewe, Werner] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Wenning, GK (corresponding author), Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	gregor.wenning@i-med.ac.at	Krismer, Florian/T-1011-2017	Krismer, Florian/0000-0002-4493-5073; Wenning, Gregor/0000-0001-9077-1666	Austrian Science Fund FWF [F 4404] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Berg D, 2013, LANCET NEUROL, V12, P514, DOI 10.1016/S1474-4422(13)70047-4; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; Eberling JL, 2013, J PARKINSON DIS, V3, P565, DOI 10.3233/JPD-130247; Fellner L., 2013, CURR TOP BEHAV NEURO; Geser F, 2006, MOVEMENT DISORD, V21, P179, DOI 10.1002/mds.20678; GRAHAM JG, 1969, J NEUROL NEUROSUR PS, V32, P28, DOI 10.1136/jnnp.32.1.28; Kieburtz K, 2013, JAMA NEUROL, V70, P25, DOI 10.1001/2013.jamaneurol.382; Low PA, 2014, LANCET NEUROL, V13, P268, DOI 10.1016/S1474-4422(13)70301-6; Mitsui J, 2013, NEW ENGL J MED, V369, P233, DOI 10.1056/NEJMoa1212115; PAPP MI, 1989, J NEUROL SCI, V94, P79, DOI 10.1016/0022-510X(89)90219-0; QUINN N, 1989, J NEUROL NEUROSUR PS, P78; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Seppi K, 2006, NEUROIMAGE, V31, P240, DOI 10.1016/j.neuroimage.2005.12.006; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Ubhi K, 2008, NEUROREPORT, V19, P1271, DOI 10.1097/WNR.0b013e32830b3661; Wenning GK, 2013, LANCET NEUROL, V12, P264, DOI 10.1016/S1474-4422(12)70327-7	16	4	4	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2014	13	3					237	239		10.1016/S1474-4422(14)70022-5	http://dx.doi.org/10.1016/S1474-4422(14)70022-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AC1NW	24507092	Green Accepted			2022-12-18	WOS:000332264300004
J	Dan, B; Baxter, P				Dan, Bernard; Baxter, Peter			Paediatric neurology: a year of DNA technology	LANCET NEUROLOGY			English	Editorial Material							EXOME SEQUENCING REVEALS; CLINICAL SPECTRUM; MUTATIONS; SLC19A3		[Dan, Bernard] Univ Libre Bruxelles, Hop Univ Enfants Reine Fabiola, Dept Neurol, Brussels, Belgium; [Baxter, Peter] Sheffield Childrens NHS Fdn Trust, Ryegate Ctr, Sheffield, S Yorkshire, England	Universite Libre de Bruxelles; Sheffield Children's NHS Foundation Trust	Dan, B (corresponding author), Univ Libre Bruxelles, Hop Univ Enfants Reine Fabiola, Dept Neurol, Brussels, Belgium.	bernard.dan@ulb.ac.be		Dan, Bernard/0000-0002-2051-9876				Allen AS, 2013, NATURE, V501, P217, DOI 10.1038/nature12439; Depienne C, 2013, LANCET NEUROL, V12, P659, DOI 10.1016/S1474-4422(13)70053-X; Foley AR, 2014, BRAIN, V137, P44, DOI 10.1093/brain/awt315; Gerards M, 2013, BRAIN, V136, P882, DOI 10.1093/brain/awt013; Kato M, 2013, EPILEPSIA, V54, P1282, DOI 10.1111/epi.12200; Kevelam SH, 2013, BRAIN, V136, P1534, DOI 10.1093/brain/awt054; Krueger DA, 2013, ANN NEUROL, V74, P679, DOI 10.1002/ana.23960; Nakamura K, 2013, NEUROLOGY, V81, P992, DOI 10.1212/WNL.0b013e3182a43e57; Walsh AM, 2013, P NATL ACAD SCI USA, V110, P1012, DOI 10.1073/pnas.1205856110; Willer T, 2012, NAT GENET, V44, P575, DOI 10.1038/ng.2252; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555	11	4	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2014	13	1					16	18		10.1016/S1474-4422(13)70283-7	http://dx.doi.org/10.1016/S1474-4422(13)70283-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	280AL	24331788				2022-12-18	WOS:000329000900010
J	Sarraj, A; Grotto, JC				Sarraj, Amrou; Grotto, James C.			Stroke: new horizons in treatment	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; RANDOMIZED CONTROLLED-TRIAL; ENDOVASCULAR TREATMENT; CLOPIDOGREL; ASPIRIN; THERAPY		[Sarraj, Amrou; Grotto, James C.] Univ Texas Houston, Dept Neurol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Sarraj, A (corresponding author), Univ Texas Houston, Dept Neurol, 6410 Fannin St, Houston, TX 77030 USA.	james.c.grotta@uth.tmc.edu	Grotta, James/AAH-7423-2021	grotta, james/0000-0002-3667-4248				Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609; Benavente OR, 2012, NEW ENGL J MED, V367, P817, DOI 10.1056/NEJMoa1204133; Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300; Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335; Ciccone A, 2013, NEW ENGL J MED, V368, P904, DOI 10.1056/NEJMoa1213701; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Kidwell CS, 2013, NEW ENGL J MED, V368, P914, DOI 10.1056/NEJMoa1212793; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9; Pancioli AM, 2013, STROKE, V44, P2381, DOI 10.1161/STROKEAHA.113.001059; Sarraj A, 2013, STROKE, V44, P3324, DOI 10.1161/STROKEAHA.113.001050; Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1; Walter S, 2012, LANCET NEUROL, V11, P397, DOI 10.1016/S1474-4422(12)70057-1; Wang YJ, 2013, NEW ENGL J MED, V369, P11, DOI 10.1056/NEJMoa1215340; Weber JE, 2013, NEUROLOGY, V80, P163, DOI 10.1212/WNL.0b013e31827b90e5	15	4	4	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2014	13	1					2	3		10.1016/S1474-4422(13)70281-3	http://dx.doi.org/10.1016/S1474-4422(13)70281-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	280AL	24331780				2022-12-18	WOS:000329000900002
J	[Anonymous]				[Anonymous]			Strengthening connections between Down syndrome and AD	LANCET NEUROLOGY			English	Editorial Material																			0	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2013	12	10					931	931		10.1016/S1474-4422(13)70228-X	http://dx.doi.org/10.1016/S1474-4422(13)70228-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	237XV	24050729				2022-12-18	WOS:000325905800001
J	MaassenVanDenBrink, A; Ibrahimi, K; Edvinsson, L				MaassenVanDenBrink, Antoinette; Ibrahimi, Khatera; Edvinsson, Lars			Intracranial and extracranial arteries in migraine	LANCET NEUROLOGY			English	Letter							MAGNETIC-RESONANCE ANGIOGRAPHY		[MaassenVanDenBrink, Antoinette; Ibrahimi, Khatera; Edvinsson, Lars] Erasmus MC, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	MaassenVanDenBrink, A (corresponding author), Erasmus MC, Rotterdam, Netherlands.	a.vanharen-maassenvandenbrink@erasmusmc.nl		Edvinsson, Lars/0000-0002-1805-1346; Maassen van den Brink, Antoinette/0000-0001-7176-126X				Amin FM, 2013, LANCET NEUROL, V12, P454, DOI 10.1016/S1474-4422(13)70067-X; Asghar MS, 2011, ANN NEUROL, V69, P635, DOI 10.1002/ana.22292; HASSLER O, 1961, Acta Psychiatr Scand Suppl, V154, P1; VanDenBrink AM, 2009, BRAIN, V132, DOI 10.1093/brain/awn259	4	4	4	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2013	12	9					847	848		10.1016/S1474-4422(13)70198-4	http://dx.doi.org/10.1016/S1474-4422(13)70198-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	210WU	23948170				2022-12-18	WOS:000323866600010
J	Storey, E				Storey, Elsdon			Presymptomatic features of spinocerebellar ataxias	LANCET NEUROLOGY			English	Editorial Material							PRECLINICAL HUNTINGTONS-DISEASE; DOMINANT CEREBELLAR ATAXIAS; MEMORY		Monash Univ, Melbourne, Vic 3004, Australia	Monash University	Storey, E (corresponding author), Monash Univ, Melbourne, Vic 3004, Australia.	elsdon.storey@monash.edu						Globas C, 2008, MOVEMENT DISORD, V23, P2232, DOI 10.1002/mds.22288; Jacobi H, 2013, LANCET NEUROL; Jacobi H, 2012, CEREBELLUM, V11, P155, DOI 10.1007/s12311-011-0292-z; Kawai Y, 2009, EUR NEUROL, V61, P257, DOI 10.1159/000206850; Kipps CM, 2005, J NEUROL NEUROSUR PS, V76, P650, DOI 10.1136/jnnp.2004.047993; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Matilla-Duenas A, 2012, CEREBELLUM, V11, P821, DOI 10.1007/s12311-012-0376-4; Nehl C, 2001, J NEUROPSYCH CLIN N, V13, P342, DOI 10.1176/appi.neuropsych.13.3.342; Schmitz-Hubsch T, 2006, NEUROLOGY, V66, P1717, DOI 10.1212/01.wnl.0000219042.60538.92; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Snowden JS, 2002, J CLIN EXP NEUROPSYC, V24, P133, DOI 10.1076/jcen.24.2.133.998; Stevanin G, 2000, EUR J HUM GENET, V8, P4, DOI 10.1038/sj.ejhg.5200403	12	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2013	12	7					625	626		10.1016/S1474-4422(13)70116-9	http://dx.doi.org/10.1016/S1474-4422(13)70116-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	172CH	23707146				2022-12-18	WOS:000320977100003
J	Wardlaw, JM; Smith, C; Dichgans, M				Wardlaw, J. M.; Smith, C.; Dichgans, M.			Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging (vol 12, pg 483, 2013)	LANCET NEUROLOGY			English	Correction													Wardlaw, Joanna M/Y-3456-2019; Hernandez, María/GYU-3543-2022; Dichgans, Martin/HCH-3247-2022	Wardlaw, Joanna M/0000-0002-9812-6642; Dichgans, Martin/0000-0002-0654-387X				Wardlaw JM, 2013, LANCET NEUROL, V12, P483, DOI 10.1016/S1474-4422(13)70060-7	1	4	5	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2013	12	6					532	532		10.1016/S1474-4422(13)70060-7	http://dx.doi.org/10.1016/S1474-4422(13)70060-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161SL		Green Submitted, Green Accepted			2022-12-18	WOS:000320213500006
J	Deutch, AY				Deutch, Ariel Y.			Parkinson's disease redefined	LANCET NEUROLOGY			English	Editorial Material									Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University	Deutch, AY (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA.	ariel.deutch@vanderbilt.edu						Askanas V, 2000, J NEUROPATH EXP NEUR, V59, P592, DOI 10.1093/jnen/59.7.592; Berg D, 2013, LANCET NEUROL, V12, P514, DOI 10.1016/S1474-4422(13)70047-4; Bhidayasiri R, 2013, J NEURAL TRANSM, V120, P619, DOI 10.1007/s00702-013-1007-z; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157; Roden DM, 2008, CLIN PHARMACOL THER, V84, P362, DOI 10.1038/clpt.2008.89; Stern MB, 2012, MOVEMENT DISORD, V27, P54, DOI 10.1002/mds.24051	7	4	5	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2013	12	5					422	423		10.1016/S1474-4422(13)70052-8	http://dx.doi.org/10.1016/S1474-4422(13)70052-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142ZS	23582176				2022-12-18	WOS:000318836700006
J	Verchere, J; Blanot, S; Vergnaud, E; Vecchione, A; Zerah, M; Meyer, PG				Verchere, Juliette; Blanot, Stephane; Vergnaud, Estelle; Vecchione, Antonio; Zerah, Michel; Meyer, Philippe G.			Mortality in severe traumatic brain injury	LANCET NEUROLOGY			English	Letter							CHILDREN		[Verchere, Juliette; Blanot, Stephane; Vergnaud, Estelle; Vecchione, Antonio; Meyer, Philippe G.] Hop Univ Necker Enfants Malad, Dept Paediat Neurocrit Care & Anaesthesia, F-75015 Paris, France; [Zerah, Michel] Hop Univ Necker Enfants Malad, Dept Paediat Neurosurg, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Verchere, J (corresponding author), Hop Univ Necker Enfants Malad, Dept Paediat Neurocrit Care & Anaesthesia, F-75015 Paris, France.	philippe.meyer@nck.aphp.fr	ZERAH, Michel/E-6473-2012; Meyer, Philippe/ABE-4242-2020	Meyer, Philippe/0000-0002-3829-6631				Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Ducocq S, 2006, PEDIATR CRIT CARE ME, V7, P461; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Pineda JA, 2013, LANCET NEUROL, V12, P45, DOI 10.1016/S1474-4422(12)70269-7; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049	5	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2013	12	5					426	427		10.1016/S1474-4422(13)70073-5	http://dx.doi.org/10.1016/S1474-4422(13)70073-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142ZS	23602158				2022-12-18	WOS:000318836700012
J	[Anonymous]				[Anonymous]			Joining forces to fight neurodegenerative diseases	LANCET NEUROLOGY			English	Editorial Material																			0	4	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2013	12	2					119	119		10.1016/S1474-4422(13)70004-8	http://dx.doi.org/10.1016/S1474-4422(13)70004-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	081NZ	23332357	Bronze			2022-12-18	WOS:000314330200001
J	Gandy, S; DeKosky, ST				Gandy, Sam; DeKosky, Steven T.			2012: the year in dementia	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS-DISEASE		[Gandy, Sam] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Gandy, Sam] James J Peters VA Med Ctr, New York, NY 10029 USA; [DeKosky, Steven T.] Univ Virginia, Charlottesville, VA 22908 USA	Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; University of Virginia	Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.	samuel.gandy@mssm.edu; dekosky@virginia.edu		DeKosky, Steven/0000-0003-3743-2758	NIA NIH HHS [P50 AG005138] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005138] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Blennow K, 2012, ARCH NEUROL-CHICAGO, V69, P1002, DOI 10.1001/archneurol.2012.90; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Farlow M, 2012, ALZHEIMERS DEMENT, V8, P261, DOI 10.1016/j.jalz.2011.09.224; Gandy S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004274; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Jonsson T, 2012, NATURE, V488, P96, DOI 10.1038/nature11283; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Luk KC, 2012, J EXP MED, V209, P975, DOI 10.1084/jem.20112457; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Reiman EM, 2012, LANCET NEUROL, V11, P1048, DOI 10.1016/S1474-4422(12)70228-4; vom Berg J, 2012, NAT MED, V18, P1812, DOI 10.1038/nm.2965	12	4	4	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					4	6		10.1016/S1474-4422(12)70284-3	http://dx.doi.org/10.1016/S1474-4422(12)70284-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23237888	Green Accepted			2022-12-18	WOS:000312429400003
J	Maas, AIR; Menon, DK				Maas, Andrew I. R.; Menon, David K.			Integrated approaches to paediatric neurocritical care in traumatic brain injury	LANCET NEUROLOGY			English	Editorial Material							HEAD-INJURY; CLINICAL-TRIALS; MANAGEMENT; OUTCOMES		[Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Menon, David K.] Addenbrookes Hosp, Cambridge, England	University of Antwerp; University of Antwerp; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Maas, AIR (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium.	andrew.maas@uza.be	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264	National Institute for Health Research [NF-SI-0512-10090] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Pineda JA, 2012, LANCET NEUROL; Rayan N, 2012, J TRAUMA ACUTE CARE, V72, P585, DOI 10.1097/TA.0b013e318243da4d; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713	12	4	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					26	28		10.1016/S1474-4422(12)70272-7	http://dx.doi.org/10.1016/S1474-4422(12)70272-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23200263				2022-12-18	WOS:000312429400015
J	Miller, SP; Ferriero, DM				Miller, Steven P.; Ferriero, Donna M.			Paediatric neurology: improved care of the developing brain	LANCET NEUROLOGY			English	Editorial Material									[Miller, Steven P.] Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada; [Miller, Steven P.] Univ Toronto, Toronto, ON, Canada; [Ferriero, Donna M.] Benioff Childrens Hosp, Dept Pediat, San Francisco, CA 94143 USA; [Ferriero, Donna M.] Univ Calif San Francisco, San Francisco, CA 94143 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of California System; University of California San Francisco	Miller, SP (corresponding author), Hosp Sick Children, Dept Paediat, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	ferrierod@neuropeds.ucsf.edu		Miller, Steven/0000-0001-9102-9105				Berry-Kravis EM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004214; de Ligt J, 2012, NEW ENGL J MED, V367, P1921, DOI 10.1056/NEJMoa1206524; Gupta N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004373; Rodan L, 2012, ANN NEUROL, V72, P103, DOI 10.1002/ana.23574; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066	5	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					16	18		10.1016/S1474-4422(12)70292-2	http://dx.doi.org/10.1016/S1474-4422(12)70292-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23237895				2022-12-18	WOS:000312429400010
J	Schneider, SA; Obeso, JA				Schneider, Susanne A.; Obeso, Jose A.			Movement disorders: improved understanding of early disease	LANCET NEUROLOGY			English	Editorial Material							PREMOTOR PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; LEWY PATHOLOGY; NEURODEGENERATION		[Schneider, Susanne A.] Univ Kiel, Dept Neurol, D-2300 Kiel, Germany; Univ Navarra Clin, Pamplona 31180, Spain; CIMA, Sch Med, Pamplona 31180, Spain; CIBERNED, Pamplona 31180, Spain	University of Kiel; University of Navarra; CIBERNED	Schneider, SA (corresponding author), Univ Kiel, Dept Neurol, D-2300 Kiel, Germany.	jobeso@unav.es						Del Tredici K, 2012, MOVEMENT DISORD, V27, P597, DOI 10.1002/mds.24921; Duncan RP, 2012, NEUROREHAB NEURAL RE, V26, P132, DOI 10.1177/1545968311421614; Kwon DH, 2012, ANN NEUROL, V71, P267, DOI 10.1002/ana.22592; Li FZ, 2012, NEW ENGL J MED, V366, P511, DOI 10.1056/NEJMoa1107911; Litvan I, 2012, MOVEMENT DISORD, V27, P349, DOI 10.1002/mds.24893; Luk KC, 2012, SCIENCE, V338, P949, DOI 10.1126/science.1227157; Olanow CW, 2009, P NATL ACAD SCI USA, V106, P12571, DOI 10.1073/pnas.0906759106; Pouclet H, 2012, NEUROBIOL DIS, V45, P305, DOI 10.1016/j.nbd.2011.08.014; Shannon KM, 2012, MOVEMENT DISORD, V27, P716, DOI 10.1002/mds.25020; Siderowf A, 2012, MOVEMENT DISORD, V27, P608, DOI 10.1002/mds.24954; Tabrizi SJ, 2012, LANCET NEUROL, V11, P42, DOI 10.1016/S1474-4422(11)70263-0	11	4	4	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					10	12		10.1016/S1474-4422(12)70302-2	http://dx.doi.org/10.1016/S1474-4422(12)70302-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23237891				2022-12-18	WOS:000312429400006
J	Carpay, JA; Ferrari, MD				Carpay, Johannes A.; Ferrari, Michel D.			The adverse effects of antiepileptic drugs differ in patients with migraine	LANCET NEUROLOGY			English	Letter									[Carpay, Johannes A.] Tergooiziekenhuizen, Dept Neurol, NL-1201 DA Hilversum, Netherlands; [Carpay, Johannes A.; Ferrari, Michel D.] Leiden Univ, Dept Neurol, Med Ctr, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Carpay, JA (corresponding author), Tergooiziekenhuizen, Dept Neurol, POB 10016, NL-1201 DA Hilversum, Netherlands.	jcarpay@tergooiziekenhuizen.nl	Ferrari, Michel D./ABE-3758-2021	Ferrari, Michel D./0000-0001-9691-9449				Gilliam FG, 2004, NEUROLOGY, V62, P23, DOI 10.1212/WNL.62.1.23; Luykx J, 2009, CLIN PHARMACOL THER, V85, P283, DOI 10.1038/clpt.2008.203; Mulleners WM, 2008, CEPHALALGIA, V28, P585, DOI 10.1111/j.1468-2982.2008.01571.x; Perucca P, 2012, LANCET NEUROL, V11, P792, DOI 10.1016/S1474-4422(12)70153-9; Uijl SG, 2009, EUR J NEUROL, V16, P1173, DOI 10.1111/j.1468-1331.2009.02713.x	5	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2012	11	11					935	935		10.1016/S1474-4422(12)70247-8	http://dx.doi.org/10.1016/S1474-4422(12)70247-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	028KW	23079550				2022-12-18	WOS:000310422200008
J	Herholz, K				Herholz, Karl			Imaging cerebral amyloid plaques: clinical perspective	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS ASSOCIATION WORKGROUPS; FRONTOTEMPORAL DEMENTIA; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; FDG-PET; A-BETA; DISEASE; RECOMMENDATIONS; ACCURACY; CRITERIA		Univ Manchester, Wolfson Mol Imaging Ctr, Manchester M20 3LJ, Lancs, England	University of Manchester	Herholz, K (corresponding author), Univ Manchester, Wolfson Mol Imaging Ctr, 27 Palatine Rd, Manchester M20 3LJ, Lancs, England.	karl.herholz@manchester.ac.uk						Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Choi SR, 2012, ALZ DIS ASSOC DIS, V26, P8, DOI 10.1097/WAD.0b013e31821300bc; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; Clark CM, 2012, LANCET NEUROL; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Foster NL, 2007, BRAIN, V130, P2616, DOI 10.1093/brain/awm177; Leyton CE, 2011, BRAIN, V134, P3030, DOI 10.1093/brain/awr216; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; McNeill R, 2007, J NEUROL NEUROSUR PS, V78, P350, DOI 10.1136/jnnp.2006.106054; Okello A, 2009, NEUROLOGY, V73, P754, DOI 10.1212/WNL.0b013e3181b23564; Rabinovici GD, 2011, NEUROLOGY, V77, P2034, DOI 10.1212/WNL.0b013e31823b9c5e; Rowe CC, 2011, J NUCL MED, V52, P1733, DOI 10.2967/jnumed.110.076315; Scholl M, 2012, NEUROLOGY; Villemagne VL, 2011, J NUCL MED, V52, P1210, DOI 10.2967/jnumed.111.089730; Villemagne VL, 2011, ANN NEUROL, V69, P181, DOI 10.1002/ana.22248	15	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2012	11	8					652	653		10.1016/S1474-4422(12)70158-8	http://dx.doi.org/10.1016/S1474-4422(12)70158-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	983AX	22749064				2022-12-18	WOS:000307089700002
J	Rodriguez-Oroz, MC				Rodriguez-Oroz, Maria C.			Methylphenidate for freezing of gait in Parkinon's disease	LANCET NEUROLOGY			English	Editorial Material							PARKINSONS-DISEASE; PEDUNCULOPONTINE NUCLEUS		[Rodriguez-Oroz, Maria C.] Hosp Donostia, Dept Neurol, San Sebastian 20014, Spain; [Rodriguez-Oroz, Maria C.] Hosp Donostia, Neurosci Unit, San Sebastian 20014, Spain; [Rodriguez-Oroz, Maria C.] BioDonostia Res Inst, San Sebastian 20014, Spain; [Rodriguez-Oroz, Maria C.] Basque Fdn Sci, Ikerbasque, Bilbao, Spain	University Hospital Donostia; University Hospital Donostia; Basque Foundation for Science	Rodriguez-Oroz, MC (corresponding author), Hosp Donostia, Dept Neurol, San Sebastian 20014, Spain.	maria.rodriguezoroz@biodonostia.org	Rodriguez-Oroz, Maria Cruz/D-1490-2018	Rodriguez-Oroz, Maria Cruz/0000-0001-5962-772X				Espay AJ, 2011, NEUROLOGY, V76, P1256, DOI 10.1212/WNL.0b013e3182143537; Ferraye MU, 2010, BRAIN, V133, P205, DOI 10.1093/brain/awp229; Jankovic J, 2009, J NEUROL SCI, V284, P177, DOI 10.1016/j.jns.2009.03.022; JELLINGER K, 1988, J NEUROL NEUROSUR PS, V51, P540, DOI 10.1136/jnnp.51.4.540; Merola A, 2011, BRAIN, V134, P2074, DOI 10.1093/brain/awr121; Moreau C, 2012, LANCET NEUROL, V11, P589, DOI 10.1016/S1474-4422(12)70106-0; MORRIS ME, 1994, BRAIN, V117, P1169, DOI 10.1093/brain/117.5.1169; Nutt JG, 2011, LANCET NEUROL, V10, P734, DOI 10.1016/S1474-4422(11)70143-0; TOHGI H, 1993, J NEURAL TRANSM-PARK, V5, P17, DOI 10.1007/BF02260911; Williams-Gray CH, 2008, BRAIN, V131, P397, DOI 10.1093/brain/awm313	10	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2012	11	7					569	570		10.1016/S1474-4422(12)70145-X	http://dx.doi.org/10.1016/S1474-4422(12)70145-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969YN	22710750				2022-12-18	WOS:000306095400003
J	Frisoni, GB				Frisoni, Giovanni B.			ARIA from off-key operas?	LANCET NEUROLOGY			English	Editorial Material							TRIALS		IRCCS Fatebenefratelli, I-25125 Brescia, Italy	IRCCS Fatebenefratelli	Frisoni, GB (corresponding author), IRCCS Fatebenefratelli, I-25125 Brescia, Italy.	gfrisoni@fatebenefratelli.it	Frisoni, Giovanni B./K-1360-2016; Frisoni, Giovanni/K-1360-2016	Frisoni, Giovanni B./0000-0002-6419-1753; Frisoni, Giovanni/0000-0001-7075-7082				DiFrancesco JC, 2011, NEUROLOGY, V76, P842, DOI 10.1212/WNL.0b013e31820e773c; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; Sperling R, 2012, LANCET NEUROL, V11, P241, DOI 10.1016/S1474-4422(12)70015-7; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P367, DOI 10.1016/j.jalz.2011.05.2351	6	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2012	11	3					207	208		10.1016/S1474-4422(12)70021-2	http://dx.doi.org/10.1016/S1474-4422(12)70021-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	902BZ	22341028				2022-12-18	WOS:000301014900005
J	Turnbull, D				Turnbull, Doug			A new biomarker for mitochondrial disease	LANCET NEUROLOGY			English	Editorial Material									Newcastle Univ, Dept Neurol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK	Turnbull, D (corresponding author), Newcastle Univ, Dept Neurol, Framlington Pl, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	doug.turnbull@newcastle.ac.uk		Turnbull, Doug/0000-0002-8878-9901				Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776; McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2; SUOMALAINEN A, 2011, LANCET, DOI DOI 10.1016/S1474-4422(11)70155-7; Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310	4	4	4	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2011	10	9					777	778		10.1016/S1474-4422(11)70172-7	http://dx.doi.org/10.1016/S1474-4422(11)70172-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	815NM	21820357				2022-12-18	WOS:000294532300004
J	Goldstein, LB				Goldstein, Larry B.			Novel platelet antiaggregants and the changing landscape of stroke prevention	LANCET NEUROLOGY			English	Editorial Material							SECONDARY PREVENTION; ASPIRIN; TRIALS		[Goldstein, Larry B.] Duke Univ, Med Ctr, Durham, NC 27710 USA; [Goldstein, Larry B.] Durham VA Med Ctr, Durham, NC USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Goldstein, LB (corresponding author), Duke Univ, Med Ctr, Box 3651, Durham, NC 27710 USA.	golds004@mc.duke.edu		Goldstein, Larry/0000-0001-7747-128X				[Anonymous], 2011, CLIN AL ANG COMB STE; Bousser MG, 2011, LANCET, V377, P2013, DOI 10.1016/S0140-6736(11)60600-4; Chiuve SE, 2008, CIRCULATION, V118, P947, DOI 10.1161/CIRCULATIONAHA.108.781062; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; Hong KS, 2011, CIRCULATION, V123, P2111, DOI 10.1161/CIRCULATIONAHA.109.934786; Naylor AR, 2011, STROKE, V42, P2080, DOI 10.1161/STROKEAHA.110.597708; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; CAROTID OCCLUSION SU	10	4	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2011	10	8					678	680		10.1016/S1474-4422(11)70151-X	http://dx.doi.org/10.1016/S1474-4422(11)70151-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	803WJ	21777820				2022-12-18	WOS:000293612600006
J	Filippi, M; Rocca, MA				Filippi, Massimo; Rocca, Maria A.			The multiple sclerosis mystery: is there a vascular component?	LANCET NEUROLOGY			English	Editorial Material							CEREBROSPINAL VENOUS INSUFFICIENCY; HYPOPERFUSION; NO		[Filippi, Massimo] Inst Sci, Div Neurosci, Neuroimaging Res Unit, Milan, Italy; Univ Vita Salute San Raffaele, Hosp San Raffaele, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Filippi, M (corresponding author), Inst Sci, Div Neurosci, Neuroimaging Res Unit, Milan, Italy.	filippi.massimo@hsr.it	Filippi, Massimo/K-1755-2018; Rocca, Maria Assunta/K-1619-2018	Filippi, Massimo/0000-0002-5485-0479; Rocca, Maria Assunta/0000-0003-2358-4320				Baracchini C, 2011, ANN NEUROL, V69, P90, DOI 10.1002/ana.22228; Charil A, 2006, LANCET NEUROL, V5, P841, DOI 10.1016/S1474-4422(06)70572-5; D'haeseleer M, 2011, LANCET NEUROL, V10, P657, DOI 10.1016/S1474-4422(11)70105-3; De Keyser J, 2008, J CEREBR BLOOD F MET, V28, P1645, DOI 10.1038/jcbfm.2008.72; Filippi M, 2011, AM J NEURORADIOL, V32, P424, DOI 10.3174/ajnr.A2348; Hu WT, 2010, NEUROLOGY, V75, P881, DOI 10.1212/WNL.0b013e3181f11e35; Kalman B, 2003, NEUROMOL MED, V3, P147, DOI 10.1385/NMM:3:3:147; Khan O, 2010, ANN NEUROL, V67, P286, DOI 10.1002/ana.22001; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Przeklasa-Auth M, 2010, J CHILD NEUROL, V25, P732, DOI 10.1177/0883073809342490; Reekers JA, 2011, CARDIOVASC INTER RAD, V34, P1, DOI 10.1007/s00270-010-0050-5; Saindane AM, 2007, AM J NEURORADIOL, V28, P767; Zamboni P, 2009, J NEUROL NEUROSUR PS, V80, P392, DOI 10.1136/jnnp.2008.157164; Zivadinov R, 2011, NEUROLOGY	14	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2011	10	7					597	598		10.1016/S1474-4422(11)70124-7	http://dx.doi.org/10.1016/S1474-4422(11)70124-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	789BD	21683924				2022-12-18	WOS:000292487400005
J	Frisoni, GB				Frisoni, Giovanni B.			PET and F-18 ligands in the diagnosis of Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							BETA		IRCCS Fatebenefratelli, Brescia, Italy	IRCCS Fatebenefratelli	Frisoni, GB (corresponding author), IRCCS Fatebenefratelli, Brescia, Italy.	gfrisoni@fatebenefratelli.it	Frisoni, Giovanni B./K-1360-2016; Frisoni, Giovanni/K-1360-2016	Frisoni, Giovanni B./0000-0002-6419-1753; Frisoni, Giovanni/0000-0001-7075-7082				Barthel H, 2011, LANCET NEUROL, V10, P424, DOI 10.1016/S1474-4422(11)70077-1; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; JELLINGER K, 1990, J NEUROL SCI, V95, P239, DOI 10.1016/0022-510X(90)90072-U; KUKULL WA, 1990, NEUROLOGY, V40, P1364, DOI 10.1212/WNL.40.9.1364; Mathis CA, 2007, NUCL MED BIOL, V34, P809, DOI 10.1016/j.nucmedbio.2007.06.015; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Rowe CC, 2008, LANCET NEUROL, V7, P129, DOI 10.1016/S1474-4422(08)70001-2; Vandenberghe R, 2010, ANN NEUROL, V68, P319, DOI 10.1002/ana.22068	8	4	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2011	10	5					397	399		10.1016/S1474-4422(11)70075-8	http://dx.doi.org/10.1016/S1474-4422(11)70075-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	761TV	21481641				2022-12-18	WOS:000290424800003
J	Sohrabi, HR; Weinborn, M; Badcock, J; Bates, KA; Clarnette, R; Trivedi, D; Verdile, G; Sutton, T; Lenzo, NP; Gandy, SE; Martins, RN				Sohrabi, Hamid R.; Weinborn, Michael; Badcock, Johanna; Bates, Kristyn A.; Clarnette, Roger; Trivedi, Darshan; Verdile, Giuseppe; Sutton, Tom; Lenzo, Nat P.; Gandy, Samuel E.; Martins, Ralph N.			New lexicon and criteria for the diagnosis of Alzheimer's disease	LANCET NEUROLOGY			English	Letter									[Sohrabi, Hamid R.; Clarnette, Roger; Trivedi, Darshan; Verdile, Giuseppe; Lenzo, Nat P.; Martins, Ralph N.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Churchlands, WA 6018, Australia; [Sohrabi, Hamid R.; Clarnette, Roger; Verdile, Giuseppe; Sutton, Tom; Martins, Ralph N.] Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Perth, WA, Australia; [Lenzo, Nat P.] Fremantle Hosp, Dept Nucl Med, Perth, WA, Australia; [Weinborn, Michael] Univ Western Australia, Sch Psychol, Nedlands, WA 6009, Australia; [Bates, Kristyn A.] Univ Western Australia, Sch Anim Biol, Nedlands, WA 6009, Australia; [Sutton, Tom; Martins, Ralph N.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Nedlands, WA 6009, Australia; [Badcock, Johanna] Univ Western Australia, Graylands Hosp, Ctr Clin Res Neuropsychiat, Nedlands, WA 6009, Australia; [Gandy, Samuel E.] Dept Neurol, New York, NY USA	Edith Cowan University; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia	Sohrabi, HR (corresponding author), Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Churchlands, WA 6018, Australia.	r.martins@ecu.edu.au	Weinborn, Michael/H-6068-2014; Sohrabi, Hamid Reza/ABY-5173-2022; Badcock, Johanna C./C-3682-2013; Sohrabi, Hamid R Sohrabi R/L-2461-2016; Sohrabi, Hamid/D-2744-2013; Clarnette, Roger/ABC-7466-2020	Weinborn, Michael/0000-0001-7094-9930; Badcock, Johanna C./0000-0003-4629-2929; Sohrabi, Hamid R Sohrabi R/0000-0001-8017-8682; Sohrabi, Hamid/0000-0001-8017-8682; Verdile, Giuseppe/0000-0003-2475-0124; Martins, Ralph/0000-0002-4828-9363				Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4; Emery V., 2003, DEMENTIA PRESENTATIO; Foster J, 2008, INT PSYCHOGERIATR, V20, P853, DOI 10.1017/S1041610208006807; IVERSEN LL, 1987, NEUROBIOL AGING, V8, P554, DOI 10.1016/0197-4580(87)90132-1; Larner AJ, 2006, CLIN NEUROL NEUROSUR, V108, P705, DOI 10.1016/j.clineuro.2005.07.001	6	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2011	10	4					299	300		10.1016/S1474-4422(11)70056-4	http://dx.doi.org/10.1016/S1474-4422(11)70056-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745SB	21435594	Green Submitted			2022-12-18	WOS:000289185000012
J	Banno, H; Katsuno, M; Suzuki, K; Sobue, G				Banno, Haruhiko; Katsuno, Masahisa; Suzuki, Keisuke; Sobue, Gen			Dutasteride for spinal and bulbar muscular atrophy	LANCET NEUROLOGY			English	Editorial Material							TRANSGENIC MOUSE MODEL; LEUPRORELIN; EXPRESSION		[Banno, Haruhiko; Katsuno, Masahisa; Suzuki, Keisuke; Sobue, Gen] Nagoya Univ, Dept Neurol, Grad Sch Med, Nagoya, Aichi 4648601, Japan; [Banno, Haruhiko; Katsuno, Masahisa] Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Banno, H (corresponding author), Nagoya Univ, Dept Neurol, Grad Sch Med, Nagoya, Aichi 4648601, Japan.	sobueg@med.nagoya-u.ac.jp	Banno, Haruhiko/AAN-4305-2021; KATSUNO, MASAHISA/I-7502-2014; Banno, Haruhiko/Q-1029-2015	Banno, Haruhiko/0000-0002-0404-3839; KATSUNO, MASAHISA/0000-0001-9453-9311; Banno, Haruhiko/0000-0002-0404-3839				Banno H, 2009, ANN NEUROL, V65, P140, DOI 10.1002/ana.21540; Fernandez-Rhodes LE, 2011, LANCET NEUROL, V10, P140, DOI 10.1016/S1474-4422(10)70321-5; Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Katsuno M, 2010, LANCET NEUROL, V9, P875, DOI 10.1016/S1474-4422(10)70182-4; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Orr HT, 2007, ANNU REV NEUROSCI, V30, P575, DOI 10.1146/annurev.neuro.29.051605.113042; Schmidt BJ, 2002, NEUROLOGY, V59, P770, DOI 10.1212/WNL.59.5.770; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209	10	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2011	10	2					113	115		10.1016/S1474-4422(10)70324-0	http://dx.doi.org/10.1016/S1474-4422(10)70324-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	721IT	21216198				2022-12-18	WOS:000287347500004
J	Nagane, M				Nagane, Motoo			Neuro-oncology: continuing multidisciplinary progress	LANCET NEUROLOGY			English	Editorial Material							MALIGNANT GLIOMA; PHASE-II; GLIOBLASTOMA; RADIOTHERAPY; TEMOZOLOMIDE; CRITERIA; TRIAL		Kyorin Univ, Fac Med, Dept Neurosurg, Tokyo 1818611, Japan	Kyorin University	Nagane, M (corresponding author), Kyorin Univ, Fac Med, Dept Neurosurg, Tokyo 1818611, Japan.	nagane-nsu@umin.ac.jp						Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277, DOI 10.1200/JCO.1990.8.7.1277; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Perry JR, 2010, J CLIN ONCOL, V28, P2051, DOI 10.1200/JCO.2009.26.5520; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2010, J CLIN ONCOL, V28, P2712, DOI 10.1200/JCO.2009.26.6650; Thiel E, 2010, LANCET ONCOL, V11, P1036, DOI 10.1016/S1470-2045(10)70229-1; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541	10	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2011	10	1					18	20		10.1016/S1474-4422(10)70302-1	http://dx.doi.org/10.1016/S1474-4422(10)70302-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	701HX	21163442				2022-12-18	WOS:000285810100011
J	Benabid, AL				Benabid, Alim Louis			Gene therapy for Parkinson's disease: do we have the cure?	LANCET NEUROLOGY			English	Editorial Material							GAD GENE		CEA Minatec LETI, F-38054 Grenoble, France	CEA	Benabid, AL (corresponding author), CEA Minatec LETI, F-38054 Grenoble, France.		Benabid, Alim L/Q-3506-2017					Bjorklund A, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000350; Jarraya B, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000130; Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9; Kordower JH, 2006, ANN NEUROL, V60, P706, DOI 10.1002/ana.21032; Luo J, 2002, SCIENCE, V298, P425, DOI 10.1126/science.1074549; Marks WJ, 2010, LANCET NEUROL, V9, P1164, DOI 10.1016/S1474-4422(10)70254-4; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720	7	4	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2010	9	12					1142	1143		10.1016/S1474-4422(10)70256-8	http://dx.doi.org/10.1016/S1474-4422(10)70256-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	691KG	21087733				2022-12-18	WOS:000285078100003
J	Dulac, O				Dulac, Olivier			Cerebral malaria and epilepsy	LANCET NEUROLOGY			English	Editorial Material							NEUROLOGICAL SEQUELAE; CHILDREN; MENINGITIS; ENCEPHALITIS; SEIZURES; MALI		[Dulac, Olivier] Univ Paris 05, Necker Hosp, AP HP, Dept Neuropaediat, F-75015 Paris, France; [Dulac, Olivier] INSERM, U663, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Dulac, O (corresponding author), Univ Paris 05, Necker Hosp, AP HP, Dept Neuropaediat, F-75015 Paris, France.							ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407; Beare NAV, 2006, AM J TROP MED HYG, V75, P790, DOI 10.4269/ajtmh.2006.75.790; BIRBECK GL, 2010, LANCET NEUROL, DOI DOI 10.1016/S14744422(10)702702; Elbers JM, 2007, PEDIATRICS, V119, pE399, DOI 10.1542/peds.2006-1494; Goetghebuer T, 2000, TROP MED INT HEALTH, V5, P207, DOI 10.1046/j.1365-3156.2000.00535.x; Idro R, 2007, JAMA-J AM MED ASSOC, V297, P2232, DOI 10.1001/jama.297.20.2232; Ngoungou EB, 2007, REV NEUROL-FRANCE, V163, P583, DOI 10.1016/S0035-3787(07)90464-6; Ngoungou EB, 2006, EPILEPSIA, V47, P873, DOI 10.1111/j.1528-1167.2006.00524.x; Opoka RO, 2009, AFR HEALTH SCI, V9, P75; POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402; Potchen MJ, 2010, EUR J RADIOL, V74, P262, DOI 10.1016/j.ejrad.2009.02.010; Schijns OEMG, 2008, SEIZURE-EUR J EPILEP, V17, P731, DOI 10.1016/j.seizure.2008.04.006; Scott RC, 2003, BRAIN, V126, P2551, DOI 10.1093/brain/awg262	13	4	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2010	9	12					1144	1145		10.1016/S1474-4422(10)70278-7	http://dx.doi.org/10.1016/S1474-4422(10)70278-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	691KG	21056006				2022-12-18	WOS:000285078100004
J	Daoud, H; Belzil, V; Dion, PA; Rouleau, GA				Daoud, Hussein; Belzil, Veronique; Dion, Patrick A.; Rouleau, Guy A.			Chromosome 9p21 in amyotrophic lateral sclerosis: the plot thickens	LANCET NEUROLOGY			English	Editorial Material							FRONTOTEMPORAL DEMENTIA; SUSCEPTIBILITY; UNC13A; LOCUS; GENE		[Daoud, Hussein; Belzil, Veronique; Dion, Patrick A.; Rouleau, Guy A.] Univ Montreal, Ctr Excellence Neur, CHUM Res Ctr, Montreal, PQ, Canada	Universite de Montreal	Daoud, H (corresponding author), Univ Montreal, Ctr Excellence Neur, CHUM Res Ctr, Montreal, PQ, Canada.	guy.rouleau@umontreal.ca	Belzil, Veronique/J-9361-2012					Boxer AL, 2011, J NEUROL NEUROSUR PS, V82, P196, DOI 10.1136/jnnp.2009.204081; Daoud H, 2010, ARCH NEUROL-CHICAGO, V67, P516, DOI 10.1001/archneurol.2010.46; Dion PA, 2009, NAT REV GENET, V10, P769, DOI 10.1038/nrg2680; Dunckley T, 2007, NEW ENGL J MED, V357, P775, DOI 10.1056/NEJMoa070174; LAAKSOVIRTA H, 2010, LANCET NEUROL, DOI DOI 10.1016/S1474-4422(10)7984-8; Morita M, 2006, NEUROLOGY, V66, P839, DOI 10.1212/01.wnl.0000200048.53766.b4; SHATUNOV A, 2010, LANCET NEUROL; Valdmanis PN, 2007, ARCH NEUROL-CHICAGO, V64, P240, DOI 10.1001/archneur.64.2.240; Van Deerlin VM, 2010, NAT GENET, V42, P234, DOI 10.1038/ng.536; van Es MA, 2008, NAT GENET, V40, P29, DOI 10.1038/ng.2007.52; van Es MA, 2007, LANCET NEUROL, V6, P869, DOI 10.1016/S1474-4422(07)70222-3; van Es MA, 2009, NAT GENET, V41, P1083, DOI 10.1038/ng.442; Vance C, 2006, BRAIN, V129, P868, DOI 10.1093/brain/awl030	13	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2010	9	10					945	947		10.1016/S1474-4422(10)70211-8	http://dx.doi.org/10.1016/S1474-4422(10)70211-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	672WC	20801719				2022-12-18	WOS:000283616700004
J	Brown, MM; Mas, JL; Ringleb, PA; Hacke, W				Brown, Martin M.; Mas, Jean-Louis; Ringleb, Peter A.; Hacke, Werner			Carotid artery stenting versus surgery: adequate comparisons? Triallists' reply	LANCET NEUROLOGY			English	Letter							ENDARTERECTOMY; ANGIOPLASTY; STENOSIS; STROKE; DEATH		[Brown, Martin M.] UCL, Dept Brain Repair & Rehabil, Inst Neurol, London WC1E 6BT, England; [Mas, Jean-Louis] Paris Descartes Univ, Dept Neurol, INSERM, U894, Paris, France; [Ringleb, Peter A.; Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany	University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ruprecht Karls University Heidelberg	Brown, MM (corresponding author), UCL, Dept Brain Repair & Rehabil, Inst Neurol, London WC1E 6BT, England.	m.brown@ion.ucl.ac.uk	Hacke, Werner/ABE-8661-2020	Brown, Martin M/0000-0002-3273-1356				Ederle J, 2009, LANCET NEUROL, V8, P898, DOI 10.1016/S1474-4422(09)70228-5; Hobson RW, 2004, J VASC SURG, V40, P1106, DOI 10.1016/j.jvs.2004.10.022; *INT CAR STENT STU, 2010, LANCET, DOI DOI 10.1016/S0140-6736(10)60230-5; Laaksovirta Hannu, LANCET NEUROL, V9, P978, DOI [DOI 10.1016/S1474-4422(10)70057-0, 10.1016/S1474-4422(10)70184-8, DOI 10.1016/S1474-4422(21)00252-0]; Mas JL, 2008, LANCET NEUROL, V7, P885, DOI 10.1016/S1474-4422(08)70195-9; Mas JL, 2007, NEW ENGL J MED, V356, P306; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8; Stingele R, 2008, LANCET NEUROL, V7, P216, DOI 10.1016/S1474-4422(08)70024-3; Wholey MH, 2003, CATHETER CARDIO INTE, V60, P259, DOI 10.1002/ccd.10645	10	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2010	9	4					341	342		10.1016/S1474-4422(10)70029-6	http://dx.doi.org/10.1016/S1474-4422(10)70029-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	576KA		Bronze			2022-12-18	WOS:000276142000007
J	Groschel, K				Groeschel, Klaus			Has surgery won the race against endovascular treatment for carotid stenosis?	LANCET NEUROLOGY			English	Editorial Material							CEREBRAL PROTECTION; ENDARTERECTOMY; ANGIOPLASTY; LESIONS		Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany	University of Gottingen	Groschel, K (corresponding author), Univ Gottingen, Dept Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany.	klaus.groeschel@medizin.uni-goettingen.de	Gröschel, Klaus/ABC-4777-2021	Gröschel, Klaus/0000-0002-0244-6116				Barbato JE, 2008, J VASC SURG, V47, P760, DOI 10.1016/j.jvs.2007.11.058; Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5; Groschel K, 2008, J NEUROL SCI, V273, P112, DOI 10.1016/j.jns.2008.07.004; Jansen O, 2009, STROKE, V40, P841, DOI 10.1161/STROKEAHA.108.534289; Kastrup A, 2007, ACTA CHIR BELG, V107, P119, DOI 10.1080/00015458.2007.11680028; Kastrup A, 2003, STROKE, V34, P813, DOI 10.1161/01.STR.0000058160.53040.5F; Laaksovirta Hannu, LANCET NEUROL, V9, P978, DOI [DOI 10.1016/S1474-4422(10)70057-0, 10.1016/S1474-4422(10)70184-8, DOI 10.1016/S1474-4422(21)00252-0]; Macdonald S, 2010, CEREBROVASC DIS, V29, P282, DOI 10.1159/000275505; Mas JL, 2004, STROKE, V35, pE18, DOI 10.1161/01.STR.0000106913.33940.DD; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Schnaudigel S, 2008, STROKE, V39, P1911, DOI 10.1161/STROKEAHA.107.500603	11	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2010	9	4					332	333		10.1016/S1474-4422(10)70058-2	http://dx.doi.org/10.1016/S1474-4422(10)70058-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	576KA	20189460				2022-12-18	WOS:000276142000002
J	Stuve, O; Greenberg, BM				Stuve, Olaf; Greenberg, Benjamin M.			Anticipated benefits and surprising effects of daclizumab in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							NATURAL-KILLER-CELLS; ACTIVATION		[Stuve, Olaf; Greenberg, Benjamin M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Stuve, Olaf] Med Serv, Neurol Sect, VA N Texas Hlth Care Syst, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Stuve, O (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA.	olaf.stuve@utsouthwestern.edu	Greenberg, Benjamin/AAT-1027-2020	Greenberg, Benjamin/0000-0002-2091-8201				Bielekova B, 2006, P NATL ACAD SCI USA, V103, P5941, DOI 10.1073/pnas.0601335103; Bryceson YT, 2006, IMMUNOL REV, V214, P73, DOI 10.1111/j.1600-065X.2006.00457.x; Di Santo JP, 2008, NAT IMMUNOL, V9, P473, DOI 10.1038/ni.f.201; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Long EO, 2008, IMMUNOL REV, V224, P70, DOI 10.1111/j.1600-065X.2008.00660.x; Pillet AH, 2009, J IMMUNOL, V182, P6267, DOI 10.4049/jimmunol.0801933; Takahashi K, 2004, BRAIN, V127, P1917, DOI 10.1093/brain/awh219; Takahashi K, 2001, J CLIN INVEST, V107, pR23, DOI 10.1172/JCI11819; TIMONEN T, 1979, CELL IMMUNOL, V48, P133, DOI 10.1016/0008-8749(79)90106-0; van der Valk P, 2000, NEUROPATH APPL NEURO, V26, P2, DOI 10.1046/j.1365-2990.2000.00217.x; WYNN D, 2010, LANCET NEUROL	11	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2010	9	4					337	338		10.1016/S1474-4422(10)70032-6	http://dx.doi.org/10.1016/S1474-4422(10)70032-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	576KA	20163991				2022-12-18	WOS:000276142000005
J	Hughes, JC				Hughes, Julian C.			Promoting palliative care in dementia	LANCET NEUROLOGY			English	Editorial Material									Univ Newcastle, Wolfson Res Ctr, Inst Ageing & Hlth, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK	Hughes, JC (corresponding author), Univ Newcastle, Wolfson Res Ctr, Inst Ageing & Hlth, Campus Ageing & Vital, Newcastle Upon Tyne, Tyne & Wear, England.	j.c.hughes@ncl.ac.uk						[Anonymous], 2009, DEM ETH ISS; Hertogh C., 2010, SUPPORTIVE CARE PERS, P271; McCarthy M, 1997, INT J GERIATR PSYCH, V12, P404; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Sampson EL, 2009, BRIT J PSYCHIAT, V195, P61, DOI 10.1192/bjp.bp.108.055335; Shega Joseph W, 2003, J Palliat Med, V6, P315, DOI 10.1089/109662103764978641; van der Steen JT, 2002, ARCH INTERN MED, V162, P1753, DOI 10.1001/archinte.162.15.1753	7	4	4	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					25	27		10.1016/S1474-4422(09)70328-X	http://dx.doi.org/10.1016/S1474-4422(09)70328-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	20083030				2022-12-18	WOS:000273199700015
J	Kieburtz, K				Kieburtz, Karl			ADAGIO misses a beat?	LANCET NEUROLOGY			English	Editorial Material							MOTOR FLUCTUATIONS; PARKINSONS-DISEASE; CONTROLLED TRIAL; DELAYED-START; DOUBLE-BLIND; RASAGILINE; LEVODOPA		[Kieburtz, Karl] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA; [Kieburtz, Karl] Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Kieburtz, K (corresponding author), Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA.	karl.kieburtz@ctcc.rochester.edu						D'Agostino RB, 2009, NEW ENGL J MED, V361, P1304, DOI 10.1056/NEJMsm0904209; Leber P, 1996, ALZ DIS ASSOC DIS, V10, P31, DOI 10.1097/00002093-199601031-00009; Olanow CW, 2009, NEW ENGL J MED, V361, P1268, DOI 10.1056/NEJMoa0809335; Rascol O, 2005, LANCET, V365, P947, DOI 10.1016/S0140-6736(05)71083-7; Schwid SR, 2005, ARCH NEUROL-CHICAGO, V62, P241; Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937	6	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2009	8	12					1081	1082		10.1016/S1474-4422(09)70297-2	http://dx.doi.org/10.1016/S1474-4422(09)70297-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	523WS	19909902				2022-12-18	WOS:000272106100006
J	Brown, PD; Cerhan, JH				Brown, Paul D.; Cerhan, Jane H.			Same, better, or worse? Neurocognitive effects of radiotherapy for low-grade gliomas remain unknown	LANCET NEUROLOGY			English	Editorial Material							COGNITIVE FUNCTION		[Brown, Paul D.] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA; [Cerhan, Jane H.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Brown, PD (corresponding author), Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA.	brown.paul@mayo.edu						Brown Paul D, 2006, Curr Oncol Rep, V8, P71, DOI 10.1007/s11912-006-0012-x; Brown PD, 2006, J CLIN ONCOL, V24, P5427, DOI 10.1200/JCO.2006.08.5605; Brown PD, 2003, J CLIN ONCOL, V21, P2519, DOI 10.1200/JCO.2003.04.172; Brown PD, 2003, NEURO-ONCOLOGY, V5, P161, DOI 10.1215/S1152851702000431; Douw L, 2009, LANCET NEUROL, V8, P810, DOI 10.1016/S1474-4422(09)70204-2; Laack NN, 2005, INT J RADIAT ONCOL, V63, P1175, DOI 10.1016/j.ijrobp.2005.04.016; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; van den Bent MJ, 2005, LANCET, V366, P985, DOI 10.1016/S0140-6736(05)67070-5	8	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2009	8	9					779	781		10.1016/S1474-4422(09)70205-4	http://dx.doi.org/10.1016/S1474-4422(09)70205-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	487AD	19665932				2022-12-18	WOS:000269241700004
J	Paulsen, JS				Paulsen, Jane S.			Biomarkers to predict and track diseases	LANCET NEUROLOGY			English	Editorial Material							PRECLINICAL HUNTINGTONS-DISEASE; DIAGNOSIS; HD		[Paulsen, Jane S.] Univ Iowa, Dept Psychiat, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Paulsen, Jane S.] Univ Iowa, Dept Neurol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Paulsen, Jane S.] Univ Iowa, Dept Neurosci, Roy J & Lucille A Carver Coll Med, Iowa City, IA USA; [Paulsen, Jane S.] Univ Iowa, Dept Psychol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Paulsen, JS (corresponding author), Univ Iowa, Dept Psychiat, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA.		Paulsen, Jane/AAQ-2932-2020	Paulsen, Jane/0000-0002-0983-228X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040068] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000059] Funding Source: Medline; NINDS NIH HHS [R01 NS040068] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aylward EH, 2007, BRAIN RES BULL, V72, P152, DOI 10.1016/j.brainresbull.2006.10.028; Duff K, 2007, BIOL PSYCHIAT, V62, P1341, DOI 10.1016/j.biopsych.2006.11.034; Gomez-Tortosa E, 2001, ANN NEUROL, V49, P29, DOI 10.1002/1531-8249(200101)49:1<29::AID-ANA7>3.0.CO;2-B; Gusella JF, 1996, COLD SPRING HARB SYM, V61, P615; Johnson SA, 2007, BRAIN, V130, P1732, DOI 10.1093/brain/awm107; Nopoulos P, 2007, AM J PSYCHIAT, V164, P1428, DOI 10.1176/appi.ajp.2007.06081266; Paulsen JS, 2008, J NEUROL NEUROSUR PS, V79, P874, DOI 10.1136/jnnp.2007.128728; Paulsen JS, 2009, EXP NEUROL, V216, P272, DOI 10.1016/j.expneurol.2008.12.015; Paulsen JS, 2006, ARCH NEUROL-CHICAGO, V63, P883, DOI 10.1001/archneur.63.6.883; Paulsen JS, 2006, BIOL PSYCHIAT, V59, P57, DOI 10.1016/j.biopsych.2005.06.003; Tabrizi SJ, 2009, LANCET NEUROL, V8, P791, DOI 10.1016/S1474-4422(09)70170-X; WEAVER K, 2008, HUNTINGTONS DEMENTIA, P32; Zimbelman JL, 2007, J INT NEUROPSYCH SOC, V13, P758, DOI 10.1017/S1355617707071214	13	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2009	8	9					776	777		10.1016/S1474-4422(09)70203-0	http://dx.doi.org/10.1016/S1474-4422(09)70203-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	487AD	19646925	Green Accepted			2022-12-18	WOS:000269241700002
J	Puopolo, M; Pocchiari, M; Petrini, C				Puopolo, Maria; Pocchiari, Maurizio; Petrini, Carlo			Clinical trials and methodological problems in prion diseases	LANCET NEUROLOGY			English	Letter									[Puopolo, Maria; Pocchiari, Maurizio] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; [Petrini, Carlo] Ist Super Sanita, Bioeth Unit, Off President, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Puopolo, M (corresponding author), Ist Super Sanita, Dept Cell Biol & Neurosci, Viale Regina Elena 299, I-00161 Rome, Italy.	maria.puopolo@iss.it	Pocchiari, Maurizio/J-8443-2018; puopolo, maria/K-9907-2018	Pocchiari, Maurizio/0000-0002-7269-2486; puopolo, maria/0000-0001-5410-2334; Petrini, Carlo/0000-0002-7895-4440				Ashcroft R, 1999, BIOETHICS, V13, P314, DOI 10.1111/1467-8519.00160; Chow SC, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-11; Collinge J, 2009, LANCET NEUROL, V8, P334, DOI 10.1016/S1474-4422(09)70049-3; Grisso T, 1998, ASSESSING COMPETENCE; Pocchiari M, 2004, BRAIN, V127, P2348, DOI 10.1093/brain/awh249	5	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2009	8	9					782	782		10.1016/S1474-4422(09)70214-5	http://dx.doi.org/10.1016/S1474-4422(09)70214-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	487AD	19679270				2022-12-18	WOS:000269241700005
J	den Hertog, HM; van der Worp, HB; van Gernert, HMA; Algra, A; Kappelle, LJ; van Gijn, J; Koudstaal, PJ; Dippel, DWJ				den Hertog, Heleen M.; van der Worp, H. Bart; van Gernert, H. Maarten A.; Algra, Ale; Kappelle, L. Jaap; van Gijn, Jan; Koudstaal, Peter J.; Dippel, Diederik W. J.		PAIS Investigators	High-dose paracetamol in stroke: new trials are necessary and feasible	LANCET NEUROLOGY			English	Letter									[den Hertog, Heleen M.; van der Worp, H. Bart; van Gernert, H. Maarten A.; Algra, Ale; Kappelle, L. Jaap; van Gijn, Jan; Koudstaal, Peter J.; Dippel, Diederik W. J.; PAIS Investigators] Erasmus MC Univ, Med Ctr Rotterdam, Dept Neurol, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	den Hertog, HM (corresponding author), Erasmus MC Univ, Med Ctr Rotterdam, Dept Neurol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	m.denhertog@erasmusmc.nl	Dippel, Diederik/AAJ-2192-2020	Dippel, Diederik/0000-0002-9234-3515				den Hertog HM, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-29; den Hertog HM, 2009, LANCET NEUROL, V8, P434, DOI 10.1016/S1474-4422(09)70051-1; Kasner SE, 2009, LANCET NEUROL, V8, P415, DOI 10.1016/S1474-4422(09)70069-9	3	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2009	8	8					700	701		10.1016/S1474-4422(09)70191-7	http://dx.doi.org/10.1016/S1474-4422(09)70191-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	477YV	19608095				2022-12-18	WOS:000268555800010
J	Arboix, A				Arboix, Adria			Retinal microvasculature in acute lacunar stroke	LANCET NEUROLOGY			English	Editorial Material							PROGNOSIS; DISEASE		Univ Barcelona, Dept Neurol, Cerebrovasc Div, Hosp Univ Sagrat Cor, E-08029 Barcelona, Spain	University of Barcelona	Arboix, A (corresponding author), Univ Barcelona, Dept Neurol, Cerebrovasc Div, Hosp Univ Sagrat Cor, Viladomat 288, E-08029 Barcelona, Spain.	aarboix@hscor.com	Arboix, Adrià/E-2067-2018	Arboix, Adrià/0000-0002-8512-7881				Arboix A, 2009, EXPERT REV NEUROTHER, V9, P179, DOI 10.1586/14737175.9.2.179; Liew G, 2008, CIRC-CARDIOVASC IMAG, V1, P156, DOI 10.1161/CIRCIMAGING.108.784876; LINDLEY RI, 2009, LANCET NEUROL; Micheli S, 2008, J NEUROL, V255, P637, DOI 10.1007/s00415-008-0762-5; Norrving B, 2003, LANCET NEUROL, V2, P238, DOI 10.1016/S1474-4422(03)00352-1; Sacco S, 2006, NEUROLOGY, V66, P1335, DOI 10.1212/01.wnl.0000210457.89798.0e; van Dijk EJ, 2008, STROKE, V39, P2712, DOI 10.1161/STROKEAHA.107.513176; Wardlaw JM, 2003, STROKE, V34, P806, DOI 10.1161/01.STR.0000058480.77236.B3; Wardlaw JM, 2009, ANN NEUROL, V65, P194, DOI 10.1002/ana.21549; Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6	10	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2009	8	7					596	598		10.1016/S1474-4422(09)70137-1	http://dx.doi.org/10.1016/S1474-4422(09)70137-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466EN	19481978				2022-12-18	WOS:000267643700004
J	Chenoweth, L; King, MT; Jeon, YH				Chenoweth, L.; King, M. T.; Jeon, Y-H			Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial (vol 8, pg 317, 2009)	LANCET NEUROLOGY			English	Correction																		Chenoweth L, 2009, LANCET NEUROL, V8, P317, DOI 10.1016/S1474-4422(09)70045-6	1	4	4	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2009	8	5					419	419		10.1016/S1474-4422(09)70045-6	http://dx.doi.org/10.1016/S1474-4422(09)70045-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	435UE		Green Submitted			2022-12-18	WOS:000265368000006
J	Finsterer, J; Stollberger, C				Finsterer, Josef; Stoellberger, Claudia			Cardiopulmonary surveillance to prevent SUDEP	LANCET NEUROLOGY			English	Editorial Material							TAKOTSUBO CARDIOMYOPATHY; EPILEPSY; DEATH		[Finsterer, Josef; Stoellberger, Claudia] Krankenanstalt Rudolfstiftung Wien, Dept Med, A-1180 Vienna, Austria	Rudolfstiftung Hospital	Finsterer, J (corresponding author), Krankenanstalt Rudolfstiftung Wien, Dept Med, Postfach 20, A-1180 Vienna, Austria.	fifigs1@yahoo.de						Rugg-Gunn FJ, 2004, LANCET, V364, P2212, DOI 10.1016/S0140-6736(04)17594-6; Sealove BA, 2008, J GEN INTERN MED, V23, P1904, DOI 10.1007/s11606-008-0744-4; Seow SC, 2008, EUR J NEUROL, V15, pE46, DOI 10.1111/j.1468-1331.2008.02125.x; Stollberger C, 2004, EPILEPSY RES, V59, P51, DOI 10.1016/j.eplepsyres.2004.03.008; Tomson T, 2008, LANCET NEUROL, V7, P1021, DOI 10.1016/S1474-4422(08)70202-3	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2009	8	2					131	132		10.1016/S1474-4422(09)70003-1	http://dx.doi.org/10.1016/S1474-4422(09)70003-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	398SO	19161901				2022-12-18	WOS:000262752000005
J	[Anonymous]				[Anonymous]			Antipsychotic drugs for dementia: a balancing act	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2009	8	2					125	125		10.1016/S1474-4422(09)70001-8	http://dx.doi.org/10.1016/S1474-4422(09)70001-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	398SO	19161899	Bronze			2022-12-18	WOS:000262752000001
J	Lees, KR				Lees, Kennedy R.			Stroke: success for extending acute treatment	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; ACUTE INTRACEREBRAL HEMORRHAGE; ACTIVATED FACTOR-VII; ALTEPLASE; THROMBOLYSIS; TRIAL		[Lees, Kennedy R.] Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland; [Lees, Kennedy R.] Univ Glasgow, Western Infirm, Cerebrovasc Clin, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow; University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland.	k.r.lees@clinmed.gla.ac.uk			Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson CS, 2008, LANCET NEUROL, V7, P391, DOI 10.1016/S1474-4422(08)70069-3; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Hacke W, 2004, LANCET, V363, P768; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Wahlgren N, 2008, LANCET, V372, P1303, DOI 10.1016/S0140-6736(08)61339-2; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4	9	4	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2009	8	1					2	4		10.1016/S1474-4422(08)70270-9	http://dx.doi.org/10.1016/S1474-4422(08)70270-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	386CU	19081499				2022-12-18	WOS:000261860700002
J	Newton, CR; Neville, BG				Newton, Charles R.; Neville, Brian G.			Paediatric neurology: advances on many fronts	LANCET NEUROLOGY			English	Editorial Material							CHILDHOOD		[Newton, Charles R.; Neville, Brian G.] UCL, Inst Child Hlth, Neurosci Unit, London WC1N 2AP, England	University of London; University College London	Newton, CR (corresponding author), UCL, Inst Child Hlth, Neurosci Unit, London WC1N 2AP, England.	cnewton@ich.ucl.ac.uk	Newton, Charles RJC/B-7578-2014; Newton, Charles/V-7872-2019; Newton, Charles/C-6222-2009	Newton, Charles RJC/0000-0002-6999-5507; Newton, Charles/0000-0002-6999-5507; 	Wellcome Trust [083744] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Chin RFM, 2006, LANCET, V368, P222, DOI 10.1016/S0140-6736(06)69043-0; Kaler SG, 2008, NEW ENGL J MED, V358, P605, DOI 10.1056/NEJMoa070613; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Schmid RS, 2008, NEUROREPORT, V19, P393, DOI 10.1097/WNR.0b013e3282f5661c; Sodarangani M, 2008, LANCET NEUROL, V7, P145, DOI [10.1016/SI474-4422(07)70331-9, 10.1016/S1474-4422(07)70331-9]; Vestergaard M, 2008, LANCET, V372, P457, DOI 10.1016/S0140-6736(08)61198-8	6	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2009	8	1					14	15		10.1016/S1474-4422(08)70276-X	http://dx.doi.org/10.1016/S1474-4422(08)70276-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	386CU	19081505	Green Accepted			2022-12-18	WOS:000261860700008
J	Sorensen, PS				Sorensen, Per Soelberg			REGARD: what can we learn from randomised, open-label, head-to-head studies?	LANCET NEUROLOGY			English	Editorial Material							REMITTING MULTIPLE-SCLEROSIS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; INTERFERON BETA-1A; GLATIRAMER ACETATE; MULTICENTER; MS		Rigshosp, Dept Neurol 2082, Danish Multiple Sclerosis Res Ctr, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Sorensen, PS (corresponding author), Rigshosp, Dept Neurol 2082, Danish Multiple Sclerosis Res Ctr, DK-2100 Copenhagen, Denmark.	pss@rh.dk		Sorensen, Per Soelberg/0000-0002-2818-3780				Comi G, 2001, ANN NEUROL, V49, P290, DOI 10.1002/ana.64.abs; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Durelli L, 2002, LANCET, V359, P1453, DOI 10.1016/S0140-6736(02)08430-1; Ebers G, 1999, NEUROLOGY, V53, P679; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Koch-Henriksen N, 2006, NEUROLOGY, V66, P1056, DOI 10.1212/01.wnl.0000204018.52311.ec; Mikol DD, 2008, LANCET NEUROL, V7, P903, DOI 10.1016/S1474-4422(08)70200-X; *NAT MULT SCL SOC, CLIN TRIALS MULT SCL; O'Connor P, 2008, NEUROLOGY, V71, P153; Panitch H, 2002, NEUROLOGY, V59, P1496, DOI 10.1212/01.WNL.0000034080.43681.DA	12	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2008	7	10					864	866		10.1016/S1474-4422(08)70201-1	http://dx.doi.org/10.1016/S1474-4422(08)70201-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	355RJ	18789767				2022-12-18	WOS:000259725700004
J	Souayah, N; Chodos, A; Krivitskaya, N; Efthimiou, P; Lambert, WC; Sharer, LR				Souayah, Nizar; Chodos, Ari; Krivitskaya, Natalia; Efthimiou, Petros; Lambert, W. Clark; Sharer, Leroy R.			Isolated severe vasculitic neuropathy revealing sarcoidosis	LANCET NEUROLOGY			English	Article							PERIPHERAL NERVOUS-SYSTEM; CONDUCTION BLOCK; NEUROSARCOIDOSIS		[Souayah, Nizar; Krivitskaya, Natalia] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, Newark, NJ 07103 USA; [Chodos, Ari; Efthimiou, Petros] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA; [Lambert, W. Clark; Sharer, Leroy R.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Souayah, N (corresponding author), 90 Bergen St,DOC 8100, Newark, NJ 07103 USA.	souayani@umdnj.edu	Souayah, Nizar/B-5556-2017	Souayah, Nizar/0000-0003-3873-3448				Burns TM, 2006, J NEUROL SCI, V244, P77, DOI 10.1016/j.jns.2006.01.014; CHAPELON C, 1990, MEDICINE, V69, P261, DOI 10.1097/00005792-199009000-00001; Collins MP, 2004, CURR OPIN NEUROL, V17, P587, DOI 10.1097/00019052-200410000-00009; Collins MP, 2003, NEUROLOGY, V61, P623, DOI 10.1212/01.WNL.0000082715.48844.3E; Davies L, 1996, BRAIN, V119, P1441, DOI 10.1093/brain/119.5.1441; Dreyer M, 2004, J NEUROL NEUROSUR PS, V75, P1645, DOI 10.1136/jnnp.2003.028134; DYCK PJ, 1987, BRAIN, V110, P843, DOI 10.1093/brain/110.4.843; Garg S, 2005, CLIN NEUROL NEUROSUR, V107, P140, DOI 10.1016/j.clineuro.2004.06.009; Kernohan JW, 1938, ARCH NEURO PSYCHIATR, V39, P655, DOI 10.1001/archneurpsyc.1938.02270040011001; KISSEL JT, 1985, ANN NEUROL, V18, P251, DOI 10.1002/ana.410180213; Koffman B, 1999, MUSCLE NERVE, V22, P608, DOI 10.1002/(SICI)1097-4598(199905)22:5<608::AID-MUS9>3.3.CO;2-C; MAGISTRIS MR, 1994, EUR NEUROL, V34, P283, DOI 10.1159/000117057; OH SJ, 1980, ANN NEUROL, V7, P178, DOI 10.1002/ana.410070213; Puechal X, 1999, ARTHRITIS RHEUM, V42, P824, DOI 10.1002/1529-0131(199904)42:4<824::AID-ANR32>3.0.CO;2-0; Said G, 2002, BRAIN, V125, P264, DOI 10.1093/brain/awf027; SAID G, 1988, ANN NEUROL, V23, P461, DOI 10.1002/ana.410230506; Schaublin GA, 2005, LANCET NEUROL, V4, P853, DOI 10.1016/S1474-4422(05)70249-0; SCOTT TF, 1993, NEUROLOGY, V43, P8, DOI 10.1212/WNL.43.1_Part_1.8; Sharma OP, 1997, CHEST, V112, P220, DOI 10.1378/chest.112.1.220; Stern BJ, 2004, CURR OPIN NEUROL, V17, P311, DOI 10.1097/00019052-200406000-00013; STERN BJ, 1985, ARCH NEUROL-CHICAGO, V42, P909, DOI 10.1001/archneur.1985.04060080095022; Suzuki C, 2006, J PERIPHER NERV SYST, V11, P93, DOI 10.1111/j.1085-9489.2006.00071.x; VITAL C, 1982, ACTA NEUROPATHOL, V58, P111, DOI 10.1007/BF00691650; Vrancken AFJE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006050; ZUNIGA G, 1991, NEUROLOGY, V41, P1558, DOI 10.1212/WNL.41.10.1558	25	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2008	7	8					756	760		10.1016/S1474-4422(08)70166-2	http://dx.doi.org/10.1016/S1474-4422(08)70166-2			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	330VA	18635023				2022-12-18	WOS:000257969700022
J	Morris, K				Morris, Kelly			Experts urge smart thinking on cognitive enhancers	LANCET NEUROLOGY			English	Editorial Material												vital@dircon.co.uk						Dunbar GC, 2007, J PSYCHOPHARMACOL, V21, P171, DOI 10.1177/0269881107066855; Maher B, 2008, NATURE, V452, P674, DOI 10.1038/452674a; NATL CORE NEUROETHIC	3	4	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2008	7	6					476	477		10.1016/S1474-4422(08)70101-7	http://dx.doi.org/10.1016/S1474-4422(08)70101-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	305WF	18485312				2022-12-18	WOS:000256207800008
J	Vermeulen, M				Vermeulen, Marinus			Intravenous immunoglobulin: a first-line treatment in CIDP?	LANCET NEUROLOGY			English	Editorial Material							INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; POLYNEUROPATHY; PREDNISONE		[Vermeulen, Marinus] Acad Med Ctr Amsterdam, Dept Neurol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Vermeulen, M (corresponding author), Acad Med Ctr Amsterdam, Dept Neurol, PO Box 22700, NL-1100 DE Amsterdam, Netherlands.	m.vermeulen@amc.uva.nl						AUSTIN JH, 1958, BRAIN, V81, P157, DOI 10.1093/brain/81.2.157; DICK PJ, 1986, NEW ENGL J MED, V314, P461; DYCK PJ, 1982, ANN NEUROL, V11, P136, DOI 10.1002/ana.410110205; Hughes R, 2001, ANN NEUROL, V50, P195, DOI 10.1002/ana.1088; HUGHES RAC, 2008, LANCET NEUROL; Molenaar DSM, 1997, J NEUROL NEUROSUR PS, V62, P388, DOI 10.1136/jnnp.62.4.388; Oh SJ, 2003, NEUROLOGY, V61, P1507, DOI 10.1212/01.WNL.0000096166.28131.4C; VANSCHAIK IN, 2002, COCHRANE DB SYST REV, V2; VERMEULEN M, 1985, J NEUROL SCI, V70, P317, DOI 10.1016/0022-510X(85)90173-X; VERMEULEN M, 1998, IMMUNOLOGICAL INFECT, P111	10	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2008	7	2					115	116		10.1016/S1474-4422(07)70330-7	http://dx.doi.org/10.1016/S1474-4422(07)70330-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	261PY	18178526				2022-12-18	WOS:000253093700003
J	Liu, M				Liu, Ming			Stroke: encouragement and disappointment in clinical trials	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; ASPIRIN		Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Dept Neurol,Stroke Clin Res Unit, Chengdu 610041, Peoples R China; [Liu, Ming] Sichuan Univ, W China Hosp, Ctr Canc, Chengdu 610041, Peoples R China	Sichuan University; Sichuan University	Liu, M (corresponding author), Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Dept Neurol,Stroke Clin Res Unit, Chengdu 610041, Peoples R China.	wyplmh@hotmail.com						Gray CS, 2007, LANCET NEUROL, V6, P397, DOI 10.1016/S1474-4422(07)70080-7; Halkes PHA, 2007, LANCET NEUROL, V6, P115, DOI 10.1016/S1474-4422(06)70685-8; Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MAYER SA, 2007, CEREBROVASC DIS, V23, P10; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4	7	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2008	7	1					5	7		10.1016/S1474-4422(07)70300-9	http://dx.doi.org/10.1016/S1474-4422(07)70300-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	247FO	18093547				2022-12-18	WOS:000252063300004
J	Butcher, J				Butcher, James			Neuroproteomics comes of age	LANCET NEUROLOGY			English	Editorial Material												james@two-cultures.com		Butcher, James/0000-0001-8546-6093					0	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2007	6	10					850	851		10.1016/S1474-4422(07)70234-X	http://dx.doi.org/10.1016/S1474-4422(07)70234-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218SQ	17884675	Bronze			2022-12-18	WOS:000250035600012
J	Donnan, GA; Levi, C				Donnan, Geoffrey A.; Levi, Christopher			Glucose and the ischaemic brain: too much of a good thing?	LANCET NEUROLOGY			English	Editorial Material							DIABETIC-PATIENTS; STROKE; HYPERGLYCEMIA; SIZE		Univ Melbourne, Natl Stroke Res Inst, Melbourne, Vic, Australia; John Hunter Hosp, Dept Neurol, Newcastle, NSW, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; John Hunter Hospital	Donnan, GA (corresponding author), Univ Melbourne, Natl Stroke Res Inst, Melbourne, Vic, Australia.	gdonnan@unimelb.edu.au		Donnan, Geoffrey/0000-0001-6324-3403; Levi, Christopher/0000-0002-9474-796X				Baird TA, 2003, STROKE, V34, P2208, DOI 10.1161/01.STR.0000085087.41330.FF; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Donnan GA, 2006, STROKE, V37, P2521, DOI 10.1161/01.STR.0000239696.61545.4b; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Li PA, 2000, STROKE, V31, P183, DOI 10.1161/01.STR.31.1.183; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; MIDDLETON S, 2006, INTERN MED J, V36, pA1; Parsons MW, 2002, ANN NEUROL, V52, P20, DOI 10.1002/ana.10241; *UK GLUC INS STROK, 2007, LANCET NEUROL, V6, P397; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WAGNER KR, 1992, J CEREBR BLOOD F MET, V12, P213, DOI 10.1038/jcbfm.1992.31; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303	12	4	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2007	6	5					380	381		10.1016/S1474-4422(07)70086-8	http://dx.doi.org/10.1016/S1474-4422(07)70086-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161XO	17434082				2022-12-18	WOS:000246050600002
J	Butcher, J				Butcher, James			Cooperation is key, say neuromuscular-disease researchers	LANCET NEUROLOGY			English	News Item								Clinical trials of new compounds to treat rare neuromuscular diseases are being delayed because of Europe's fragmented research and health-care systems. But an EU-funded project called TREAT-NMD aims to provide researchers and clinicians with a road map for integration. James Butcher reports.				james@two-cultures.com							0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2007	6	4					298	299		10.1016/S1474-4422(07)70067-4	http://dx.doi.org/10.1016/S1474-4422(07)70067-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	149KE	17438644				2022-12-18	WOS:000245145000009
J	Fitzpatrick, M				Fitzpatrick, Michael			Autism and environmental toxicity	LANCET NEUROLOGY			English	Editorial Material									Barton House Hlth Ctr, London, England		Fitzpatrick, M (corresponding author), Barton House Hlth Ctr, London, England.	fitz@easynet.co.uk						Geier M.R., 2007, LANCET NEUROL, V6, P212; Grinker R.R., 2007, UNSTRANGE MINDS REMA; Medical Research Council, 2001, REV AUT RES EP CAUS; Veenstra-VanderWeele J, 2004, ANNU REV GENOM HUM G, V5, P379, DOI 10.1146/annurev.genom.5.061903.180050	4	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2007	6	4					297	297		10.1016/S1474-4422(07)70066-2	http://dx.doi.org/10.1016/S1474-4422(07)70066-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	149KE	17362832				2022-12-18	WOS:000245145000008
J	Tarsy, D				Tarsy, Daniel			Deep-brain stimulation for dystonia: new twists in assessment	LANCET NEUROLOGY			English	Editorial Material							PRIMARY GENERALIZED DYSTONIA; GLOBUS-PALLIDUS		Beth Israel Deaconess Med Ctr, Dept Neurol, Parkinsons Dis & Movement Disorders Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Tarsy, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, Parkinsons Dis & Movement Disorders Ctr, Boston, MA 02215 USA.	dtarsy@bidmc.harvard.edu						Aguiar PMD, 2002, LANCET NEUROL, V1, P316, DOI 10.1016/S1474-4422(02)00137-0; Bhidayasiri Roongroj, 2006, Expert Rev Neurother, V6, P863, DOI 10.1586/14737175.6.6.863; Castelnau P, 2005, ANN NEUROL, V57, P738, DOI 10.1002/ana.20457; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Eidelberg D, 1998, ANN NEUROL, V44, P303, DOI 10.1002/ana.410440304; Grabli D, 2006, MOVEMENT DISORD, V21, pS397; Greene P, 2005, NEW ENGL J MED, V352, P498, DOI 10.1056/NEJMe048333; Krauss JK, 2004, J CLIN NEUROPHYSIOL, V21, P18, DOI 10.1097/00004691-200401000-00004; KUPSCH A, 2006, NEW ENGL J MED, V355, P20; Tarsy D, 2006, NEW ENGL J MED, V355, P818, DOI 10.1056/NEJMra055549; Vidailhet M, 2005, NEW ENGL J MED, V352, P459, DOI 10.1056/NEJMoa042187; Vidailhet M, 2007, LANCET NEUROL, V6, P223, DOI 10.1016/S1474-4422(07)70035-2; Vitek JL, 1999, ANN NEUROL, V46, P22, DOI 10.1002/1531-8249(199907)46:1<22::AID-ANA6>3.0.CO;2-Z	13	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2007	6	3					201	202		10.1016/S1474-4422(07)70040-6	http://dx.doi.org/10.1016/S1474-4422(07)70040-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138BU	17303521				2022-12-18	WOS:000244338400003
J	Butcher, J				Butcher, James			Urine tests for Alzheimer's disease - are they fool's gold?	LANCET NEUROLOGY			English	Editorial Material								A urine test to aid the diagnosis of Alzheimer's disease could revolutionise the way patients with the disorder are diagnosed and treated. One company thinks that it has developed a urine test that works, but some in the academic community remain unconvinced.											0	4	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2007	6	2					106	107		10.1016/S1474-4422(07)70015-7	http://dx.doi.org/10.1016/S1474-4422(07)70015-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	130JG	17239795				2022-12-18	WOS:000243795300010
J	Dammann, O				Dammann, Olaf			Paediatric neurology: the many faces of development	LANCET NEUROLOGY			English	News Item									Hannover Med Sch, D-3000 Hannover, Germany	Hannover Medical School	Dammann, O (corresponding author), Hannover Med Sch, D-3000 Hannover, Germany.	dammann.olaf@mh-hannover.de						Campbell DB, 2006, P NATL ACAD SCI USA, V103, P16834, DOI 10.1073/pnas.0605296103; Cassidy James, 2006, PEDIATRICS, V117, P1843, DOI [10.1542/peds.2006-0421, DOI 10.1542/PEDS.2006-0338]; Schuchmann S, 2006, NAT MED, V12, P817, DOI 10.1038/nm1422; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Staudt M, 2006, NEUROLOGY, V67, P522, DOI 10.1212/01.wnl.0000227937.49151.fd	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					12	14		10.1016/S1474-4422(06)70664-0	http://dx.doi.org/10.1016/S1474-4422(06)70664-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119UI	17166793				2022-12-18	WOS:000243039000008
J	Torok, ME				Toeroek, M. E.			Neurological infections: clinical advances and emerging threats	LANCET NEUROLOGY			English	News Item							MENINGOCOCCAL DISEASE; CHILDREN		Hosp Trop Dis, Oxford Univ Clin Res Unit, Ho Chi Minh City, Vietnam		Torok, ME (corresponding author), Hosp Trop Dis, Oxford Univ Clin Res Unit, 190 Ben Ham Tu,Dist 5, Ho Chi Minh City, Vietnam.	etorok@oucru.org		Torok, Mili Estee/0000-0001-9098-8590				Arnon SS, 2006, NEW ENGL J MED, V354, P462, DOI 10.1056/NEJMoa051926; Carson PJ, 2006, CLIN INFECT DIS, V43, P723, DOI 10.1086/506939; Collinge J, 2006, LANCET, V367, P2068, DOI 10.1016/S0140-6736(06)68930-7; Dunfee RL, 2006, P NATL ACAD SCI USA, V103, P15160, DOI 10.1073/pnas.0605513103; Giuliani MM, 2006, P NATL ACAD SCI USA, V103, P10834, DOI 10.1073/pnas.0603940103; Harnden A, 2006, BRIT MED J, V332, P1295, DOI 10.1136/bmj.38789.723611.55; Thompson MJ, 2006, LANCET, V367, P397, DOI 10.1016/S0140-6736(06)67932-4; Yu HJ, 2006, EMERG INFECT DIS, V12, P914, DOI 10.3201/eid1206.051194	8	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					16	18		10.1016/S1474-4422(06)70666-4	http://dx.doi.org/10.1016/S1474-4422(06)70666-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119UI	17166795				2022-12-18	WOS:000243039000010
J	Weaver, FM; Stern, MB; Follett, K				Weaver, Frances M.; Stern, Matthew B.; Follett, Kenneth			Deep-brain stimulation in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material									Hines VA Med Ctr, Mid W Ctr Hlth Serv & Policy Res, Hines, IL USA; Northwestern Univ, Chicago, IL 60611 USA; Univ Penn Hlth Syst, Philadelphia, PA USA; Philadelphia VA Med Ctr, Philadelphia, PA USA; Univ Nebraska Med Ctr, Omaha, NE 68198 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Northwestern University; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Nebraska System; University of Nebraska Medical Center	Weaver, FM (corresponding author), Hines VA Med Ctr, Mid W Ctr Hlth Serv & Policy Res, Hines, IL USA.	frances.weaver@va.gov	Weaver, Frances/S-1540-2019					Anderson VC, 2005, ARCH NEUROL-CHICAGO, V62, P554, DOI 10.1001/archneur.62.4.554; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571; Vitek JL, 2002, STEREOT FUNCT NEUROS, V78, P119, DOI 10.1159/000068959; Weaver F, 2005, J NEUROSURG, V103, P956, DOI 10.3171/jns.2005.103.6.0956	5	4	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2006	5	11					900	901		10.1016/S1474-4422(06)70586-5	http://dx.doi.org/10.1016/S1474-4422(06)70586-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	099JY	17052655				2022-12-18	WOS:000241591600005
J	Morris, K				Morris, Kelly			Hallucinogen research inspires "neurotheology"	LANCET NEUROLOGY			English	News Item																			0	4	4	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2006	5	9					732	732		10.1016/S1474-4422(06)70541-5	http://dx.doi.org/10.1016/S1474-4422(06)70541-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	076QS					2022-12-18	WOS:000239973400010
J	Tan, NCK; Berkovic, SF				Tan, Nigel C. K.; Berkovic, Samuel F.			Prediction of drug resistance in epilepsy: not as easy as ABC	LANCET NEUROLOGY			English	Editorial Material									Natl Inst Neurosci, Dept Neurol, Singapore, Singapore; Univ Melbourne, Austin Hlth, Epilepsy Res Ctr, Heidelberg West, Vic, Australia; Univ Melbourne, Austin Hlth, Dept Med, Heidelberg West, Vic, Australia	National Neuroscience Institute (NNI); Florey Institute of Neuroscience & Mental Health; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Tan, NCK (corresponding author), Natl Inst Neurosci, Dept Neurol, Singapore, Singapore.	s.berkovic@unimelb.edu.au	jiang, yu/HGU-0029-2022	Tan, Nigel Choon Kiat/0000-0002-9213-5572; Berkovic, Samuel/0000-0003-4580-841X				Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; Grimes DA, 2002, LANCET, V359, P341, DOI 10.1016/S0140-6736(02)07500-1; Leschziner G, 2006, LANCET NEUROL, V5, P668, DOI 10.1016/S1474-4422(06)70500-2; MacDonald B, 2001, SEIZURE-EUR J EPILEP, V10, P347, DOI 10.1053/seiz.2000.0523; Remy S, 2006, BRAIN, V129, P18, DOI 10.1093/brain/awh682; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Stephen LJ, 2001, EPILEPSIA, V42, P357, DOI 10.1046/j.1528-1157.2001.29000.x; Szoeke CEI, 2006, LANCET NEUROL, V5, P189, DOI 10.1016/S1474-4422(06)70352-0; Tan NCK, 2006, CURR OPIN NEUROL, V19, P157, DOI 10.1097/01.wco.0000218232.66054.46	9	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2006	5	8					641	642		10.1016/S1474-4422(06)70505-1	http://dx.doi.org/10.1016/S1474-4422(06)70505-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	068ZV	16857567				2022-12-18	WOS:000239415100004
J	Goodin, D				Goodin, D			The return of natalizumab: weighing benefit against risk	LANCET NEUROLOGY			English	Editorial Material							TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; MULTIPLE-SCLEROSIS; THERAPEUTICS; MITOXANTRONE; MS		Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Goodin, D (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	Douglas.Goodin@ucsf.edu						Goodin DS, 2003, NEUROLOGY, V61, P1332, DOI 10.1212/01.WNL.0000095425.84407.39; Goodin DS, 2002, NEUROLOGY, V58, P169, DOI 10.1212/WNL.58.2.169; Krapf H, 2005, NEUROLOGY, V65, P690, DOI 10.1212/01.wnl.0000174439.70369.7a; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Yousry TA, 2006, NEW ENGL J MED, V354, P924, DOI 10.1056/NEJMoa054693	6	4	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2006	5	5					375	377		10.1016/S1474-4422(06)70419-7	http://dx.doi.org/10.1016/S1474-4422(06)70419-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	037LF	16632301				2022-12-18	WOS:000237147600003
J	Senior, K				Senior, K			UK Biobank launched to mixed reception	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2006	5	5					390	390		10.1016/S1474-4422(06)70436-7	http://dx.doi.org/10.1016/S1474-4422(06)70436-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	037LF	16639837				2022-12-18	WOS:000237147600019
J	Hayward, P				Hayward, P			Microglial role in neuropathic pain	LANCET NEUROLOGY			English	News Item																		Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223	1	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2006	5	2					118	119		10.1016/S1474-4422(06)70342-8	http://dx.doi.org/10.1016/S1474-4422(06)70342-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	006RO	16456938				2022-12-18	WOS:000234914800014
J	Olanow, CW				Olanow, CW			Movement disorders: a step in the right direction	LANCET NEUROLOGY			English	Editorial Material							PARKINSONS-DISEASE		Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Olanow, CW (corresponding author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.	Warren.olanow@mssm.edu						Fahn S, 2004, NEW ENGL J MED, V351, P2498; Gilks WP, 2005, LANCET, V365, P415, DOI 10.1016/S0140-6736(05)17830-1; LANG AE, IN PRESS ANN NEUROL; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; Vidailhet M, 2005, NEW ENGL J MED, V352, P459, DOI 10.1056/NEJMoa042187	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2006	5	1					3	5		10.1016/S1474-4422(05)70257-X	http://dx.doi.org/10.1016/S1474-4422(05)70257-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	998OI	16361007				2022-12-18	WOS:000234328100003
J	Polymenidou, M; Stoeck, K; Glatzel, M; Vey, M; Bellon, A; Aguzzi, A				Polymenidou, M; Stoeck, K; Glatzel, M; Vey, M; Bellon, A; Aguzzi, A			Coexistance of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease (vol 4, pg 805, 2005)	LANCET NEUROLOGY			English	Correction													Polymenidou, Magdalini/D-2254-2014; Aguzzi, Adriano/A-3351-2008; Glatzel, Markus/G-3356-2011	Glatzel, Markus/0000-0002-7720-8817; Aguzzi, Adriano/0000-0002-0344-6708				Polymenidou M, 2005, LANCET NEUROL, V4, P805, DOI 10.1016/S1474-4422(05)70225-8	1	4	4	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2005	4	12					795	795		10.1016/S1474-4422(05)70235-0	http://dx.doi.org/10.1016/S1474-4422(05)70235-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	989SG					2022-12-18	WOS:000233693500008
J	Pilcher, H				Pilcher, H			Protein culprit found for transverse myelitis?	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2005	4	11					702	702		10.1016/S1474-4422(05)70214-3	http://dx.doi.org/10.1016/S1474-4422(05)70214-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980GK	16265794				2022-12-18	WOS:000233002400012
J	Pilcher, H				Pilcher, H			Ability to tune out irrelevant information is impaired in AD	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2005	4	11					702	702		10.1016/S1474-4422(05)70214-3	http://dx.doi.org/10.1016/S1474-4422(05)70214-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980GK	16265794				2022-12-18	WOS:000233002400013
J	Enzinger, C; Fazekas, F				Enzinger, C; Fazekas, F			Functional MRI in multiple sclerosis: a simple motor task gives insights into a complex disease	LANCET NEUROLOGY			English	Editorial Material							FMRI; EVOLUTION; MS		Graz Univ, Dept Neurol, A-8036 Graz, Austria	University of Graz	Enzinger, C (corresponding author), Graz Univ, Dept Neurol, Auenbruggerpl 22, A-8036 Graz, Austria.	chris.enzinger@meduni-graz.at						Brex PA, 2002, NEW ENGL J MED, V346, P158, DOI 10.1056/NEJMoa011341; Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; FSL, FMRIB SOFTW LIB; Goldberg TE, 2004, TRENDS COGN SCI, V8, P325, DOI 10.1016/j.tics.2004.05.011; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; Matthews PM, 2004, CURR OPIN NEUROL, V17, P453, DOI 10.1097/01.wco.0000137537.06986.b0; Minneboo A, 2005, NEUROLOGY, V65, P56, DOI 10.1212/01.wnl.0000167538.24338.bb; Morgen K, 2004, BRAIN, V127, P2506, DOI 10.1093/brain/awh266; Pantano P, 2005, BRAIN, V128, P2146, DOI 10.1093/brain/awh549; Pittock SJ, 2004, ANN NEUROL, V56, P303, DOI 10.1002/ana.20197; Reddy H, 2000, NEUROLOGY, V54, P236, DOI 10.1212/WNL.54.1.236; Rocca MA, 2005, LANCET NEUROL, V4, P618, DOI 10.1016/S1474-4422(05)70171-X; Smith SM, 2005, HUM BRAIN MAPP, V24, P248, DOI 10.1002/hbm.20080; *SPM, MEMB COLL WELL DEP I; Stocker T, 2005, HUM BRAIN MAPP, V25, P237, DOI 10.1002/hbm.20096	15	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2005	4	10					589	590		10.1016/S1474-4422(05)70176-9	http://dx.doi.org/10.1016/S1474-4422(05)70176-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969PG	16168924				2022-12-18	WOS:000232245900004
J	Thomas, L				Thomas, L			A non-viral vector for in vivo gene delivery	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2005	4	10					602	602		10.1016/S1474-4422(05)70188-5	http://dx.doi.org/10.1016/S1474-4422(05)70188-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969PG	16208875				2022-12-18	WOS:000232245900015
J	Burton, A				Burton, A			Possible role for p53 in Huntington's disease	LANCET NEUROLOGY			English	News Item																			0	4	4	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2005	4	9					528	529		10.1016/S1474-4422(05)70157-5	http://dx.doi.org/10.1016/S1474-4422(05)70157-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	958VK	16136702				2022-12-18	WOS:000231476100010
J	Nelson, R				Nelson, R			Novel MMP inhibitor has potential for treatment of stroke	LANCET NEUROLOGY			English	News Item																			0	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2005	4	9					530	530		10.1016/S1474-4422(05)70159-9	http://dx.doi.org/10.1016/S1474-4422(05)70159-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	958VK	16136704				2022-12-18	WOS:000231476100012
J	Cox, A; Coles, A; Antoun, N; Malik, O; Lucchinnetti, C; Compston, A				Cox, A; Coles, A; Antoun, N; Malik, O; Lucchinnetti, C; Compston, A			Recurrent myelitis and optic neuritis in a 29-year-old woman	LANCET NEUROLOGY			English	Article							DEVICS-NEUROMYELITIS-OPTICA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MULTIPLE-SCLEROSIS; CLINICAL CHARACTERISTICS; TRANSVERSE MYELOPATHY; JAPANESE PATIENTS; PLASMA-EXCHANGE; VIRUS INFECTION; PREDICTORS; NEUROPATHY		Univ Cambridge, Dept Clin Neurosci, Cambridge, England; Charing Cross Hosp, Dept Neurol Sci, London, England; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA	University of Cambridge; Imperial College London; Mayo Clinic	Compston, A (corresponding author), Addenbrookes Hosp, Dept Clin Neurosci, Box 165, Cambridge CB2 2QQ, England.	alastair.compston@medschl.cam.ac.uk		Coles, Alasdair/0000-0003-4738-0760				ANDERSSON M, 1994, J NEUROL NEUROSUR PS, V57, P897, DOI 10.1136/jnnp.57.8.897; Bonnet F, 1999, LUPUS, V8, P244, DOI 10.1191/096120399678847696; Buchanan RJ, 2004, MULT SCLER J, V10, P660, DOI 10.1191/1352458504ms1086oa; Cabre P, 2001, NEUROLOGY, V56, P507, DOI 10.1212/WNL.56.4.507; CARRIGAN DR, 1980, P NATL ACAD SCI-BIOL, V77, P4297, DOI 10.1073/pnas.77.7.4297; CHONG HT, 2002, NEUROL J SE ASIA, V7, P35; CHONG WK, 1993, RADIOLOGY, V188, P119, DOI 10.1148/radiology.188.1.8099750; COLES AJ, IN PRESS J NEUROL; COLES AJ, 2004, PRACTICAL NEUROL, V4, P212; Compston A, 2004, CLIN MED, V4, P346, DOI 10.7861/clinmedicine.4-4-346; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Confavreux C, 2003, BRAIN, V126, P770, DOI 10.1093/brain/awg081; Cree BAC, 2004, NEUROLOGY, V63, P2039, DOI 10.1212/01.WNL.0000145762.60562.5D; Fardet L, 2003, ACTA NEUROL SCAND, V108, P193, DOI 10.1034/j.1600-0404.2003.02178.x; FLECHTNER KM, 1994, J NEUROL SCI, V126, P146, DOI 10.1016/0022-510X(94)90264-X; FREDRIKSON S, 1989, PERSPECT BIOL MED, V32, P237; Fukazawa T, 2000, J NEUROL, V247, P175, DOI 10.1007/s004150050558; FULFORD KWM, 1972, BRAIN, V95, P373, DOI 10.1093/brain/95.2.373; Ghezzi A, 2004, J NEUROL, V251, P47, DOI 10.1007/s00415-004-0271-0; Gibbs AN, 2002, RHEUMATOLOGY, V41, P470, DOI 10.1093/rheumatology/41.4.470; HARADA T, 1995, JPN J OPHTHALMOL, V39, P162; Keegan M, 2002, NEUROLOGY, V58, P143, DOI 10.1212/WNL.58.1.143; Kim JH, 2004, RHEUMATOL INT, V24, P244, DOI 10.1007/s00296-003-0399-8; Kira J, 1999, J NEUROL SCI, V166, P53, DOI 10.1016/S0022-510X(99)00115-X; Korteweg T, 2005, ANN NEUROL, V57, P606, DOI 10.1002/ana.20412; Kovacs B, 2000, ANN RHEUM DIS, V59, P120, DOI 10.1136/ard.59.2.120; Kumar N, 2004, ARCH NEUROL-CHICAGO, V61, P586, DOI 10.1001/archneur.61.4.586; KUROIWA Y, 1975, NEUROLOGY, V25, P845, DOI 10.1212/WNL.25.9.845; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; Le Souef PN, 2000, LANCET, V356, P242; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Lucchinetti CF, 2002, BRAIN, V125, P1450, DOI 10.1093/brain/awf151; Ma JJ, 1998, J NEUROIMMUNOL, V92, P109, DOI 10.1016/S0165-5728(98)00189-1; MANDLER RN, 1993, ANN NEUROL, V34, P162, DOI 10.1002/ana.410340211; MARTYN CN, 1993, J NEUROL NEUROSUR PS, V56, P167, DOI 10.1136/jnnp.56.2.167; Mirsattari SM, 2001, NEUROLOGY, V56, P317, DOI 10.1212/WNL.56.3.317; Modi G, 2001, J NEUROL NEUROSUR PS, V70, P500, DOI 10.1136/jnnp.70.4.500; NYBERGHANSEN R, 1972, ACTA NEUROL SCAND, V48, P397; OKINAKA S, 1958, NEUROLOGY, V8, P756, DOI 10.1212/WNL.8.10.756; OSUNTOKUN BO, 1973, TROPICAL NEUROLOGY, P161; Shaharao Vijaya, 2004, Indian Journal of Pediatrics, V71, P559, DOI 10.1007/BF02724305; SHIBASAKI H, 1981, J NEUROL SCI, V49, P253, DOI 10.1016/0022-510X(81)90083-6; SHYU WC, 1993, ANN NEUROL, V34, P625, DOI 10.1002/ana.410340420; Soderlin MK, 2002, ANN RHEUM DIS, V61, P911, DOI 10.1136/ard.61.10.911; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; Weinshenker BG, 2003, LANCET, V361, P889, DOI 10.1016/S0140-6736(03)12784-5; Weinshenker BG, 1999, ANN NEUROL, V46, P878, DOI 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q; Weinstock-Guttman B, 2003, MULT SCLER J, V9, P293, DOI 10.1191/1352458503ms909oa; Wingerchuk DM, 1999, NEUROLOGY, V53, P1107, DOI 10.1212/WNL.53.5.1107; Yamasaki K, 1999, BRAIN, V122, P1689, DOI 10.1093/brain/122.9.1689; Zajicek JP, 1999, QJM-INT J MED, V92, P103, DOI 10.1093/qjmed/92.2.103	51	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2005	4	8					510	516		10.1016/S1474-4422(05)70143-5	http://dx.doi.org/10.1016/S1474-4422(05)70143-5			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	951EX	16033693				2022-12-18	WOS:000230913000017
J	Silberstein, SD				Silberstein, SD			Cardiovascular risk factors associated with migraine	LANCET NEUROLOGY			English	Editorial Material									Thomas Jefferson Univ Hosp, Jefferson Headache Ctr, Philadelphia, PA 19107 USA	Jefferson University	Silberstein, SD (corresponding author), Thomas Jefferson Univ Hosp, Jefferson Headache Ctr, Philadelphia, PA 19107 USA.	Stephen.Silberstein@jefferson.edu						Bousser MG, 2001, WOLFFS HEADACHE OTHE, P349; Scher AI, 2005, NEUROLOGY, V64, P614, DOI 10.1212/01.WNL.0000151857.43225.49; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silberstein SD, 2004, LANCET, V363, P381, DOI 10.1016/S0140-6736(04)15440-8	4	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2005	4	7					391	392		10.1016/S1474-4422(05)70103-4	http://dx.doi.org/10.1016/S1474-4422(05)70103-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	938TA	15963440				2022-12-18	WOS:000230024700003
J	Holmoy, T; Vartdal, F				Holmoy, T; Vartdal, F			Infectious causes of multiple sclerosis	LANCET NEUROLOGY			English	Letter							MYELIN BASIC-PROTEIN; AUTOIMMUNITY		Univ Hosp Oslo, Rikshosp, Inst Immunol, Oslo, Norway; Univ Oslo, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo	Holmoy, T (corresponding author), Univ Hosp Oslo, Rikshosp, Inst Immunol, Oslo, Norway.	trygve.holmoy@medisin.uio.no	Franciotta, Diego/ABE-0957-2022	Franciotta, Diego/0000-0002-3014-3913; Lolli, Francesco/0000-0001-7181-6806				Gilden DH, 2005, LANCET NEUROL, V4, P195, DOI 10.1016/S1474-4422(05)01017-3; Holmoy T, 2004, J NEUROVIROL, V10, P278, DOI 10.1080/13550280490499524; HOLMOY T, IN PRESS J NEUROVIRO; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; Wucherpfennig KW, 2001, J CLIN INVEST, V108, P1097, DOI 10.1172/JCI200114235; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	6	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2005	4	5					268	268		10.1016/S1474-4422(05)70054-5	http://dx.doi.org/10.1016/S1474-4422(05)70054-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	919AE	15847838				2022-12-18	WOS:000228589900006
J	Calne, D; Schulzer, M; Mak, E; Stoessl, AJ				Calne, D; Schulzer, M; Mak, E; Stoessl, AJ			Treatment for the progression of Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							DOPAMINE TRANSPORTER; LEVODOPA; PRAMIPEXOLE		Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Calne, D (corresponding author), Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V5Z 1M9, Canada.	dbcalne@interchange.ubc.ca	Stoessl, A Jon/J-9661-2015	Stoessl, A Jon/0000-0002-9778-7246				CALNE DB, 1969, LANCET, V2, P973; Fahn S, 2004, NEW ENGL J MED, V351, P2498; Guttman M, 2001, NEUROLOGY, V56, P1559, DOI 10.1212/WNL.56.11.1559; Marek K, 2002, JAMA-J AM MED ASSOC, V287, P1653; Senn S, 1997, J CLIN EPIDEMIOL, V50, P749; Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561; Whone AL, 2003, ANN NEUROL, V54, P93, DOI 10.1002/ana.10609	7	4	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2005	4	4					206	206		10.1016/S1474-4422(05)70026-0	http://dx.doi.org/10.1016/S1474-4422(05)70026-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	910ID	15778097				2022-12-18	WOS:000227923600003
J	Passey, S				Passey, S			Gene mutation detected in Parkinson's disease	LANCET NEUROLOGY			English	News Item																			0	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2005	4	3					142	143		10.1016/S1474-4422(05)01003-3	http://dx.doi.org/10.1016/S1474-4422(05)01003-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	901QT	15744939				2022-12-18	WOS:000227297700008
J	Comi, G; Hartung, HP; Boneschi, FM				Comi, G; Hartung, HP; Boneschi, FM			Evidence for use of glatiramer acetate in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							RELAPSE RATE; DOUBLE-BLIND; MULTICENTER; DISABILITY; TRIAL		Inst Sci, Dept Neurol, I-20131 Milan, Italy; Univ Milan, Osped San Raffaele, I-20131 Milan, Italy; Univ Dusseldorf, D-40225 Dusseldorf, Germany	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Heinrich Heine University Dusseldorf	Comi, G (corresponding author), Inst Sci, Dept Neurol, Via Olgettina 48, I-20131 Milan, Italy.	hans-peter.hartung@uni-duesseldorf.de	Boneschi, Filippo Martinelli/H-8592-2012	martinelli boneschi, filippo/0000-0002-9955-1368				Boneschi FM, 2003, MULT SCLER, V9, P349, DOI 10.1191/1352458503ms932oa; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; Comi G, 2001, ANN NEUROL, V49, P290, DOI 10.1002/ana.64.abs; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; MUNARI L, 2004, COCHRANE LIB; Munari LM, 2004, LANCET NEUROL, V3, P641, DOI 10.1016/S1474-4422(04)00899-3; Sormani MP, 2002, NEUROLOGY, V58, P417	7	4	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					75	76		10.1016/S1474-4422(05)00975-0	http://dx.doi.org/10.1016/S1474-4422(05)00975-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15664539				2022-12-18	WOS:000226712300007
J	Elger, CE				Elger, CE			Epilepsy: a model for the study of brain function	LANCET NEUROLOGY			English	Editorial Material									Univ Kliniken Bonn, Klin Epileptol, Bonn, Germany	University of Bonn	Elger, CE (corresponding author), Univ Kliniken Bonn, Klin Epileptol, Bonn, Germany.	Christian.elger@ukb.uni-bonn.de						Adab N, 2004, J NEUROL NEUROSUR PS, V75, P1575, DOI 10.1136/jnnp.2003.029132; Bernard C, 2004, SCIENCE, V305, P532, DOI 10.1126/science.1097065; Eid T, 2004, LANCET, V363, P28, DOI 10.1016/S0140-6736(03)15166-5; Palmini A, 2004, NEUROLOGY, V62, pS2, DOI 10.1212/01.WNL.0000114507.30388.7E; Richardson MP, 2004, BRAIN, V127, P2419, DOI 10.1093/brain/awh293	5	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					3	3		10.1016/S1474-4422(04)00943-3	http://dx.doi.org/10.1016/S1474-4422(04)00943-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15620845				2022-12-18	WOS:000226250200003
J	Paterson, R				Paterson, R			How West Nile virus crosses the blood-brain barrier	LANCET NEUROLOGY			English	News Item																			0	4	4	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					18	18		10.1016/S1474-4422(04)00957-3	http://dx.doi.org/10.1016/S1474-4422(04)00957-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15645594				2022-12-18	WOS:000226250200016
J	Love, R				Love, R			Trial of haemophilia treatment for intracerebral haemorrhage	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2004	3	8					448	448		10.1016/S1474-4422(04)00834-8	http://dx.doi.org/10.1016/S1474-4422(04)00834-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	842OD	15303268				2022-12-18	WOS:000223012800002
J	McKeith, I				McKeith, I			Dementia in Parkinson's disease: common and treatable	LANCET NEUROLOGY			English	Editorial Material							LEWY BODY DEMENTIA; COGNITIVE IMPAIRMENT; RIVASTIGMINE; BODIES		Newcastle Gen Hosp, Wolfson Res Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital; Newcastle University - UK	McKeith, I (corresponding author), Newcastle Gen Hosp, Wolfson Res Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	i.g.mckeith@ncl.ac.uk	McKeith, Ian/AAH-3382-2021	McKeith, Ian/0000-0002-9250-0568				Aarsland D, 2003, ARCH NEUROL-CHICAGO, V60, P387, DOI 10.1001/archneur.60.3.387; Aarsland D, 2002, J NEUROL NEUROSUR PS, V73, P354; Aarsland D, 2002, J NEUROL NEUROSUR PS, V72, P708, DOI 10.1136/jnnp.72.6.708; Emre M, 2003, LANCET NEUROL, V2, P229, DOI 10.1016/S1474-4422(03)00351-X; Gomez-Tortosa E, 1999, NEUROLOGY, V53, P1284, DOI 10.1212/WNL.53.6.1284; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; McKeith IG, 2000, NEUROL CLIN, V18, P865, DOI 10.1016/S0733-8619(05)70230-9; Parkinson J., 1817, ESSAY SHAKING PALSY; Reading PJ, 2001, MOVEMENT DISORD, V16, P1171, DOI 10.1002/mds.1204; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	10	4	4	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2004	3	8					456	456		10.1016/S1474-4422(04)00821-X	http://dx.doi.org/10.1016/S1474-4422(04)00821-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	842OD	15261605				2022-12-18	WOS:000223012800016
J	Morris, K				Morris, K			Mind moves onscreen: brain-computer interface comes to trial	LANCET NEUROLOGY			English	News Item																			0	4	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					329	329		10.1016/S1474-4422(04)00787-2	http://dx.doi.org/10.1016/S1474-4422(04)00787-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15176409				2022-12-18	WOS:000221663000010
J	[Anonymous]				[Anonymous]			EU clinical trials directive: 0% inspiration, 100% perspiration?	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					321	321		10.1016/S1474-4422(04)00788-4	http://dx.doi.org/10.1016/S1474-4422(04)00788-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15157844				2022-12-18	WOS:000221663000001
J	Kirkham, F				Kirkham, F			Paediatric neurology: genes and the environment	LANCET NEUROLOGY			English	Editorial Material									Southampton Gen Hosp, London WC1N 2AP, England; UCL, Inst Child Hlth, Wolfson Ctr, Neurosci Unit, London WC1N 2AP, England	University of London; University College London	Kirkham, F (corresponding author), Southampton Gen Hosp, Mecklenburgh Sq, London WC1N 2AP, England.	F.Kirkham@ich.ucl.ac.uk	Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958				Canfield RL, 2003, NEW ENGL J MED, V348, P1517, DOI 10.1056/NEJMoa022848; Deng WB, 2003, P NATL ACAD SCI USA, V100, P6801, DOI 10.1073/pnas.1136624100; HOPPE C, BLOOD; Longman C, 2003, HUM MOL GENET, V12, P2853, DOI 10.1093/hmg/ddg307; Setty BNY, 2003, LANCET, V362, P1450, DOI 10.1016/S0140-6736(03)14689-2	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					18	18		10.1016/S1474-4422(03)00618-5	http://dx.doi.org/10.1016/S1474-4422(03)00618-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14693107				2022-12-18	WOS:000187447100021
J	Smitt, PS				Smitt, PS			Neuro-oncology: diagnosis in the spotlight	LANCET NEUROLOGY			English	Editorial Material							SURVIVAL		Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Smitt, PS (corresponding author), Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands.							Bernal F, 2003, NEUROLOGY, V60, P230, DOI 10.1212/01.WNL.0000041495.87539.98; Cole BF, 2003, CANCER, V97, P3053, DOI 10.1002/cncr.11449; Nutt CL, 2003, CANCER RES, V63, P1602; PATCHELL R, RANDOMIZED TRIAL DIR; van den Bent MJ, 2003, J CLIN ONCOL, V21, P2525, DOI 10.1200/JCO.2003.12.015; Vos MJ, 2003, J CLIN ONCOL, V21, P3559, DOI 10.1200/JCO.2003.01.001	6	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					14	14		10.1016/S1474-4422(03)00614-8	http://dx.doi.org/10.1016/S1474-4422(03)00614-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14693103				2022-12-18	WOS:000187447100017
J	Wokke, JHJ				Wokke, JHJ			Genes, trials, and care: the dynamics of neuromuscular disease	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; POLYMYOSITIS		Univ Utrecht, Dept Neurol, NL-3584 CX Utrecht, Netherlands	Utrecht University	Wokke, JHJ (corresponding author), Univ Utrecht, Dept Neurol, NL-3584 CX Utrecht, Netherlands.							Amato AA, 2003, NEUROLOGY, V61, P288, DOI 10.1212/WNL.61.3.288; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; Lu QL, 2003, NAT MED, V9, P1009, DOI 10.1038/nm897; Traynor BJ, 2003, J NEUROL NEUROSUR PS, V74, P1258, DOI 10.1136/jnnp.74.9.1258; van der Meulen MFG, 2003, NEUROLOGY, V61, P316, DOI 10.1212/WNL.61.3.316	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					16	16		10.1016/S1474-4422(03)00616-1	http://dx.doi.org/10.1016/S1474-4422(03)00616-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14693105				2022-12-18	WOS:000187447100019
J	McCrone, J				McCrone, J			Monkey business	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2003	2	12					772	772		10.1016/S1474-4422(03)00596-9	http://dx.doi.org/10.1016/S1474-4422(03)00596-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745AV	14636785				2022-12-18	WOS:000186665800021
J	Morris, K				Morris, K			Concern over research reawakens ecstasy neurotoxicity debate	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2003	2	11					650	650		10.1016/S1474-4422(03)00570-2	http://dx.doi.org/10.1016/S1474-4422(03)00570-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	734ZN	14594013				2022-12-18	WOS:000186088000002
J	Schneider, LS				Schneider, LS			Cholinesterase inhibitors for vascular dementia?	LANCET NEUROLOGY			English	Editorial Material							GALANTAMINE; MEMANTINE; EFFICACY; TRIAL		Univ So Calif, Dept Psychiat, Keck Sch Med, Los Angeles, CA 90033 USA; Univ So Calif, Dept Neurol, Keck Sch Med, Los Angeles, CA 90033 USA; Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Schneider, LS (corresponding author), Univ So Calif, Dept Psychiat, Keck Sch Med, Los Angeles, CA 90033 USA.							BLACK S, 2003, STROKE; Chui H, 1999, ALZ DIS ASSOC DIS, V13, pS124, DOI 10.1097/00002093-199912003-00018; Erkinjuntti T, 2002, LANCET, V359, P1283, DOI 10.1016/S0140-6736(02)08267-3; Kittner B, 1999, ALZ DIS ASSOC DIS, V13, pS166, DOI 10.1097/00002093-199912001-00023; Orgogozo JM, 2002, STROKE, V33, P1834, DOI 10.1161/01.STR.0000020094.08790.49; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Roman GC, 1999, ALZ DIS ASSOC DIS, V13, pS69, DOI 10.1097/00002093-199912001-00012; Schneider LS, 2002, LANCET, V359, P1265, DOI 10.1016/S0140-6736(02)08283-1; Wilcock G, 2002, INT CLIN PSYCHOPHARM, V17, P297, DOI 10.1097/00004850-200211000-00005; Wilkinson D, 2003, NEUROLOGY, V61, P479, DOI 10.1212/01.WNL.0000078943.50032.FC	10	4	4	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2003	2	11					658	659		10.1016/S1474-4422(03)00581-7	http://dx.doi.org/10.1016/S1474-4422(03)00581-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	734ZN	14572732				2022-12-18	WOS:000186088000013
J	Capobianco, M; Mancuso, M; Triggiani, L; Scaravilli, T; Bonifati, DM				Capobianco, M; Mancuso, M; Triggiani, L; Scaravilli, T; Bonifati, DM		Board Italian Trainees Assoc	The quality of neurology residency programmes in Italy	LANCET NEUROLOGY			English	Letter									Univ Pisa, Neurol Clin, Dept Neurosci, I-56126 Pisa, Italy	University of Pisa	Mancuso, M (corresponding author), Univ Pisa, Neurol Clin, Dept Neurosci, Via Roma 67, I-56126 Pisa, Italy.	mmancuso@inwind.it	Mancuso, Michelangelo/K-4170-2016	Mancuso, Michelangelo/0000-0003-2738-8562; TRIGGIANI, LEONARDO/0000-0002-1317-9316				Bonifati DM, 2003, EUR J NEUROL, V10, P301, DOI 10.1046/j.1468-1331.2003.00596.x; Hooker J, 2003, LANCET NEUROL, V2, P572, DOI 10.1016/S1474-4422(03)00507-6	2	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2003	2	10					594	594		10.1016/S1474-4422(03)00526-X	http://dx.doi.org/10.1016/S1474-4422(03)00526-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	723KR	14505580				2022-12-18	WOS:000185432000012
J	Melton, L				Melton, L			Osteoarthritis pain goes central	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2003	2	9					524	524		10.1016/S1474-4422(03)00521-0	http://dx.doi.org/10.1016/S1474-4422(03)00521-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	717VT	14509295				2022-12-18	WOS:000185112000010
J	McCrone, J				McCrone, J			Darwinian medicine	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	2	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2003	2	8					516	516		10.1016/S1474-4422(03)00494-0	http://dx.doi.org/10.1016/S1474-4422(03)00494-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	704AC	12878446				2022-12-18	WOS:000184314700022
J	Burton, A				Burton, A			Abciximab extends treatment window for stroke	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2003	2	7					390	390		10.1016/S1474-4422(03)00459-9	http://dx.doi.org/10.1016/S1474-4422(03)00459-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	694GF	12849109				2022-12-18	WOS:000183765300005
J	Lingor, P; von Boetticher, D; Bahr, M; Fassbender, K				Lingor, P; von Boetticher, D; Bahr, M; Fassbender, K			Paraneoplastic polymyositis in recurring adrenal gland carcinoma	LANCET NEUROLOGY			English	Editorial Material							DERMATOMYOSITIS; CANCER		Univ Gottingen, Univ Klinikum, Dept Neurol, D-37075 Gottingen, Germany	University of Gottingen	Lingor, P (corresponding author), Univ Gottingen, Univ Klinikum, Dept Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany.		Baehr, Mathias/K-2188-2014; Lingor, Paul/A-5394-2008	Lingor, Paul/0000-0001-9362-7096; Fassbender, Klaus/0000-0003-3596-868X				Brouwer R, 2001, ANN RHEUM DIS, V60, P116, DOI 10.1136/ard.60.2.116; Hill CL, 2001, LANCET, V357, P96, DOI 10.1016/S0140-6736(00)03540-6; SIGURGEIRSSON B, 1992, NEW ENGL J MED, V326, P363, DOI 10.1056/NEJM199202063260602	3	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2003	2	7					435	436		10.1016/S1474-4422(03)00440-X	http://dx.doi.org/10.1016/S1474-4422(03)00440-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	694GF	12849123				2022-12-18	WOS:000183765300019
J	Wolinsky, JS				Wolinsky, JS			Rational therapy for relapsing multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							MS; DISEASE; MRI		Univ Texas, Hlth Sci Ctr, Dept Neurol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Wolinsky, JS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Neurol, 6431 Fannin St, Houston, TX 77030 USA.							Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Edan G, 1997, J NEUROL NEUROSUR PS, V62, P112, DOI 10.1136/jnnp.62.2.112; Filippini G, 2003, LANCET, V361, P545, DOI 10.1016/S0140-6736(03)12512-3; Hartung HP, 2002, LANCET, V360, P2018, DOI 10.1016/S0140-6736(02)12023-X; Martino G, 2002, LANCET NEUROL, V1, P499, DOI 10.1016/S1474-4422(02)00223-5; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Neuhaus O, 2002, NEUROLOGY, V59, P990, DOI 10.1212/WNL.59.7.990; van der Laan LJW, 2002, J NEUROSCI RES, V67, P191, DOI 10.1002/jnr.10095; Wolinsky JS, 2002, CURR OPIN NEUROL, V15, P247, DOI 10.1097/00019052-200206000-00004; Wolinsky JS, 2002, NEUROLOGY, V59, P1284, DOI 10.1212/WNL.59.8.1284; Yong VW, 2002, NEUROLOGY, V59, P802, DOI 10.1212/WNL.59.6.802	11	4	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2003	2	5					271	272		10.1016/S1474-4422(03)00375-2	http://dx.doi.org/10.1016/S1474-4422(03)00375-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	669RC	12849176				2022-12-18	WOS:000182363400013
J	Caplan, L				Caplan, L			Saving the brain during coronary artery bypass grafting	LANCET NEUROLOGY			English	Editorial Material									Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Caplan, L (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, 330 Brookline Ave, Boston, MA 02215 USA.	lcaplan@caregroup.harvard.edu						BARBUT D, 1997, CURR PROB CARDIOLOGY, V22, P455; McKhann GM, 2002, ARCH NEUROL-CHICAGO, V59, P1422, DOI 10.1001/archneur.59.9.1422; Restrepo L, 2002, STROKE, V33, P2909, DOI 10.1161/01.STR.0000040408.75704.15; Selnes OA, 2001, ARCH NEUROL-CHICAGO, V58, P598, DOI 10.1001/archneur.58.4.598; Wityk RJ, 2001, ARCH NEUROL-CHICAGO, V58, P571, DOI 10.1001/archneur.58.4.571	5	4	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2003	2	4					211	211		10.1016/S1474-4422(03)00346-6	http://dx.doi.org/10.1016/S1474-4422(03)00346-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	658NH	12849206				2022-12-18	WOS:000181726700014
J	Kumagai, AK				Kumagai, AK			Diabetes and the blood-brain barrier	LANCET NEUROLOGY			English	Editorial Material									Univ Michigan, Sch Med, Dept Internal Med, JDRF Ctr Complicat Diabet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kumagai, AK (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, JDRF Ctr Complicat Diabet, 5570 MSRB-2,Box 0678, Ann Arbor, MI 48109 USA.	akumagai@umich.edu			NIDDK NIH HHS [RPO60DK-20572] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572, P60DK020572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Dai JP, 2002, BRAIN RES, V954, P311, DOI 10.1016/S0006-8993(02)03294-8; LORENZI M, 1986, DIABETOLOGIA, V29, P58, DOI 10.1007/BF02427282; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; PARDRIDGE WM, 1990, DIABETES, V39, P1040, DOI 10.2337/diabetes.39.9.1040; Starr JM, 2003, J NEUROL NEUROSUR PS, V74, P70, DOI 10.1136/jnnp.74.1.70	5	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2003	2	4					209	209		10.1016/S1474-4422(03)00344-2	http://dx.doi.org/10.1016/S1474-4422(03)00344-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	658NH	12849204				2022-12-18	WOS:000181726700012
J	de Moerloose, P; Boehlen, F				de Moerloose, P; Boehlen, F			Should neurologists measure D-dimer concentrations?	LANCET NEUROLOGY			English	Letter							VENOUS THROMBOEMBOLISM		Univ Hosp, Dept Med, Div Angiol & Haemostasis, Geneva, Switzerland	University of Geneva	de Moerloose, P (corresponding author), Univ Hosp, Dept Med, Div Angiol & Haemostasis, Geneva, Switzerland.	philippe.demoerloose@hcuge.ch						Ageno W, 2002, ARCH INTERN MED, V162, P2589, DOI 10.1001/archinte.162.22.2589; Berge E, 2001, THROMB RES, V101, P13, DOI 10.1016/S0049-3848(00)00380-7; Bounameaux H, 1997, QJM-INT J MED, V90, P437, DOI 10.1093/qjmed/90.7.437; de Moerloose P, 2000, THROMB HAEMOSTASIS, V83, P180; Di Napoli M, 2002, STROKE, V33, P1763, DOI 10.1161/01.STR.0000019124.54361.08; Kelly J, 2001, STROKE, V32, P262, DOI 10.1161/01.STR.32.1.262; Lowe GDO, 1999, THROMB HAEMOSTASIS, V82, P667; Tardy B, 2002, AM J MED, V113, P238, DOI 10.1016/S0002-9343(02)01151-8	8	4	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2003	2	2					77	77		10.1016/S1474-4422(03)00303-X	http://dx.doi.org/10.1016/S1474-4422(03)00303-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	638BY	12849262				2022-12-18	WOS:000180550600014
J	McCrone, J				McCrone, J			Feral children	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2003	2	2					132	132		10.1016/S1474-4422(03)00315-6	http://dx.doi.org/10.1016/S1474-4422(03)00315-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	638BY	12849276				2022-12-18	WOS:000180550600021
J	Brower, V				Brower, V			Fighting fire with fire in autoimmune disease	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2003	2	1					6	6		10.1016/S1474-4422(03)00283-7	http://dx.doi.org/10.1016/S1474-4422(03)00283-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	629DU	12849285				2022-12-18	WOS:000180035800009
J	Hennerici, M; Meairs, S				Hennerici, M; Meairs, S			Refined analysis of transcranial Doppler HITS	LANCET NEUROLOGY			English	Letter									Univ Heidelberg, Univ Klinikum Mannheim, Dept Neurol, D-68135 Mannheim, Germany	Ruprecht Karls University Heidelberg	Hennerici, M (corresponding author), Univ Heidelberg, Univ Klinikum Mannheim, Dept Neurol, D-68135 Mannheim, Germany.							Brucher R, 2002, STROKE, V33, P1969, DOI 10.1161/01.STR.0000022811.46115.70; Meairs S, 2000, LANCET, V355, P550, DOI 10.1016/S0140-6736(99)04361-5; NAYLOR AR, 2001, CEREBROVASCULAR ULTR, P317; PADAYACHEE TS, 1986, BRIT J SURG, V73, P98, DOI 10.1002/bjs.1800730204; Russell D, 2002, STROKE, V33, P1975, DOI 10.1161/01.STR.0000022809.46400.4B; Wei K, 1998, CIRCULATION, V97, P473	6	4	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2002	1	7					406	406		10.1016/S1474-4422(02)00216-8	http://dx.doi.org/10.1016/S1474-4422(02)00216-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	606KC	12849359				2022-12-18	WOS:000178732300014
J	Morris, K				Morris, K			Remapping the motor cortex - death of a homunculus?	LANCET NEUROLOGY			English	News Item																			0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2002	1	7					402	402		10.1016/S1474-4422(02)00213-2	http://dx.doi.org/10.1016/S1474-4422(02)00213-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	606KC					2022-12-18	WOS:000178732300011
J	Smitt, PS				Smitt, PS			Paraneoplastic neurological syndromes	LANCET NEUROLOGY			English	Letter									Erasmus Univ, Dept Neurol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam	Smitt, PS (corresponding author), Erasmus Univ, Dept Neurol, Dr Molewaterpl 40, NL-3015 GE Rotterdam, Netherlands.	sillevis@neuh.azr.nl						Smitt PS, 2000, NEW ENGL J MED, V342, P21, DOI 10.1056/NEJM200001063420104; Voltz R, 2002, LANCET NEUROL, V1, P294, DOI 10.1016/S1474-4422(02)00135-7	2	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2002	1	7					408	408		10.1016/S1474-4422(02)00218-1	http://dx.doi.org/10.1016/S1474-4422(02)00218-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	606KC	12849362				2022-12-18	WOS:000178732300016
J	Achim, C; Auer, R; Bergeron, C; Cardozo, A; Deprez, M; de Vos, R; Duyckaerts, C; Egensperger, R; Esiri, M; Frosch, MP; Giannini, C; Goebel, HH; Graeber, MB; Graham, DI; Gray, F; Haltia, M; Hashizuma, Y; Ikeda, K; Ironside, JW; Kreutzberg, GW; Lantos, P; Lowee, J; Ludwin, S; Matsumoto, Y; Olsson, Y; Sasaki, A; Scheithauer, BW; Takahashi, H; Tolnay, M; Trojanowski, JQ; Troost, D; Webster, HD				Achim, C; Auer, R; Bergeron, C; Cardozo, A; Deprez, M; de Vos, R; Duyckaerts, C; Egensperger, R; Esiri, M; Frosch, MP; Giannini, C; Goebel, HH; Graeber, MB; Graham, DI; Gray, F; Haltia, M; Hashizuma, Y; Ikeda, K; Ironside, JW; Kreutzberg, GW; Lantos, P; Lowee, J; Ludwin, S; Matsumoto, Y; Olsson, Y; Sasaki, A; Scheithauer, BW; Takahashi, H; Tolnay, M; Trojanowski, JQ; Troost, D; Webster, HD			Global democratic consensus on neuropathological disease criteria	LANCET NEUROLOGY			English	Editorial Material													Graeber, Manuel/H-3224-2011; Frosch, Matthew P/ABD-7456-2021; Auer, Roland/F-6661-2017	Frosch, Matthew P/0000-0002-3940-9861; Auer, Roland/0000-0001-9044-3419; Lowe, James/0000-0002-9856-1599; Ironside, James/0000-0001-5869-2108					0	4	4	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2002	1	6					340	340		10.1016/S1474-4422(02)00156-4	http://dx.doi.org/10.1016/S1474-4422(02)00156-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	599PB	12849392	Green Submitted			2022-12-18	WOS:000178343200015
J	Iwata, NK; Hayashi, T; Numaga, J; Yamamichi, N; Sakurai, M; Kanazawa, I				Iwata, NK; Hayashi, T; Numaga, J; Yamamichi, N; Sakurai, M; Kanazawa, I			Fits and deafness	LANCET NEUROLOGY			English	Editorial Material							KOYANAGI-HARADA DISEASE		Univ Tokyo, Grad Sch Med, Div Neurosci, Dept Neurol,Bunkyo Ku, Tokyo 1138655, Japan; Teikyo Univ, Sch Med, Dept Physiol, Tokyo 173, Japan; Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan	University of Tokyo; Teikyo University; University of Tokyo	Iwata, NK (corresponding author), Univ Tokyo, Grad Sch Med, Div Neurosci, Dept Neurol,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Hayashi, Toshihiro/A-6028-2008	Hayashi, Toshihiro/0000-0003-4362-7439				IKEDA M, 1992, EUR NEUROL, V32, P83, DOI 10.1159/000116797; ISLAM SMM, 1994, INVEST OPHTH VIS SCI, V35, P3890; MAEZAWA N, 1984, MICROBIOL IMMUNOL, V28, P219, DOI 10.1111/j.1348-0421.1984.tb00673.x; SNYDER DA, 1980, AM J OPHTHALMOL, V90, P69, DOI 10.1016/S0002-9394(14)75078-0	4	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2002	1	6					387	388		10.1016/S1474-4422(02)00165-5	http://dx.doi.org/10.1016/S1474-4422(02)00165-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	599PB	12849401				2022-12-18	WOS:000178343200024
J	Wade, DT				Wade, DT			Rehabilitation research - time for a change of focus	LANCET NEUROLOGY			English	Editorial Material							STROKE		Oxford Ctr Enablement, Oxford OX3 7LD, England	University of Oxford	Wade, DT (corresponding author), Oxford Ctr Enablement, Windmill Rd, Oxford OX3 7LD, England.			Wade, Derick/0000-0002-1188-8442				JANTRA P, 1992, ARCH PHYS MED REHAB, V73, P95; Kwakkel G, 2002, J NEUROL NEUROSUR PS, V72, P473; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; *STROK UN TRIAL CO, 2002, COCHRANE DATABASE SY, V2, DOI UNSP CD000107	4	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2002	1	4					209	209		10.1016/S1474-4422(02)00095-9	http://dx.doi.org/10.1016/S1474-4422(02)00095-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588KZ	12849449				2022-12-18	WOS:000177701800013
J	Frankish, H				Frankish, H			Peptide promotes axonal regrowth	LANCET NEUROLOGY			English	News Item																			0	4	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2002	1	3					142	142		10.1016/S1474-4422(02)00089-3	http://dx.doi.org/10.1016/S1474-4422(02)00089-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HB					2022-12-18	WOS:000177695100009
J	Zajicek, J				Zajicek, J			Cannabinoids on trial for multiple sclerosis	LANCET NEUROLOGY			English	Article									Derriford Hosp, Peninsula Med Sch, Plymouth PL 8DH, Devon, England	Derriford Hospital; University of Plymouth	Zajicek, J (corresponding author), Derriford Hosp, Peninsula Med Sch, Plymouth PL 8DH, Devon, England.			Murray, Dianna/0000-0003-3481-825X				FOX P, 2001, J NEUROL, V187, pS543; Killestein J, 2002, NEUROLOGY, V58, P1404, DOI 10.1212/WNL.58.9.1404; UNGERLEIDER J T, 1987, Advances in Alcohol and Substance Abuse, V7, P39	3	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2002	1	3					147	147		10.1016/S1474-4422(02)00068-6	http://dx.doi.org/10.1016/S1474-4422(02)00068-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HB	12849481				2022-12-18	WOS:000177695100015
J	McCrone, J				McCrone, J			Tetrachromats	LANCET NEUROLOGY			English	Editorial Material																			0	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2002	1	2								10.1016/S1474-4422(02)00051-0	http://dx.doi.org/10.1016/S1474-4422(02)00051-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HA	12849524				2022-12-18	WOS:000177695000023
J	Svenningsson, A; Frisell, T; Burman, J; Salzer, J; Fink, K; Hallberg, S; Hambraeus, J; Axelsson, M; Al Nimer, F; Sundstrom, P; Gunnarsson, M; Johansson, R; Mellergard, J; Rosenstein, I; Ayad, A; Sjoblom, I; Risedal, A; de Flon, P; Gilland, E; Lindeberg, J; Shawket, F; Piehl, F; Lycke, J				Svenningsson, Anders; Frisell, Thomas; Burman, Joachim; Salzer, Jonatan; Fink, Katharina; Hallberg, Susanna; Hambraeus, Joakim; Axelsson, Markus; Al Nimer, Faiez; Sundstrom, Peter; Gunnarsson, Martin; Johansson, Rune; Mellergard, Johan; Rosenstein, Igal; Ayad, Ahmad; Sjoblom, Irina; Risedal, Anette; de Flon, Pierre; Gilland, Eric; Lindeberg, Jonas; Shawket, Fadi; Piehl, Fredrik; Lycke, Jan			Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial	LANCET NEUROLOGY			English	Article							PLACEBO-CONTROLLED PHASE-3; INTERFERON BETA-1A; ORAL BG-12; MULTICENTER; FINGOLIMOD	Background B-cell depleting therapies are highly efficacious in relapsing-remitting multiple sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no phase 3 trial data are available. We therefore examined the safety and efficacy of rituximab compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis to obtain data that might allow inclusion of rituximab in treatment guidelines. Methods RIFUND-MS was a multicentre, rater-blinded, active-comparator, phase 3, randomised controlled trial done at 17 Swedish university and community hospitals. Key inclusion criteria for participants were: age 18-50 years; relapsing-remitting multiple sclerosis or clinically isolated syndrome according to prevailing McDonald criteria; 10 years or less since diagnosis; untreated or only exposed to interferons or glatiramer acetate; and with clinical or neuroradiological disease activity in the past year. Patients were automatically randomly assigned (1:1) by the treating physician using a randomisation module in the Swedish multiple sclerosis registry, without stratification, to oral dimethyl fumarate 240 mg twice daily or to intravenous rituximab 1000 mg followed by 500 mg every 6 months. Relapse evaluation, Expanded Disability Status Scale rating, and assessment of MRI scans were done by examining physicians and radiologists masked to treatment allocation. The primary outcome was the proportion of patients with at least one relapse (defined as subacute onset of new or worsening neurological symptoms compatible with multiple sclerosis with a duration of more than 24 h and preceded by at least 30 days of clinical stability), assessed in an intention-to-treat analysis using log-binomial regression with robust standard errors. This trial is registered at ClinicalTrials.gov, NCT02746744. Findings Between July 1, 2016, and Dec 18, 2018, 322 patients were screened for eligibility, 200 of whom were randomly assigned to a treatment group (100 assigned to rituximab and 100 assigned to dimethyl fumarate). The last patient completed 24-month follow-up on April 21, 2021. 98 patients in the rituximab group and 97 patients in the dimethyl fumarate group were eligible for the primary outcome analysis. Three (3%) patients in the rituximab group and 16 (16%) patients in the dimethyl fumarate group had a protocol-defined relapse during the trial, corresponding to a risk ratio of 0.19 (95% CI 0.06-0.62; p=0.0060). Infusion reactions (105 events [40.9 per 100 patient-years]) in the rituximab group and gastrointestinal reactions (65 events [47.4 per 100 patient-years]) and flush (65 events [47.4 per 100 patient-years]) in the dimethyl fumarate group were the most prevalent adverse events. There were no safety concerns. Interpretation RIFUND-MS provides evidence that rituximab given as 1000 mg followed by 500 mg every 6 months is superior to dimethyl fumarate in preventing relapses over 24 months in patients with early relapsing-remitting multiple sclerosis. Health economic and long-term safety studies of rituximab in patients with multiple sclerosis are needed.	[Svenningsson, Anders; Hallberg, Susanna; Shawket, Fadi] Danderyd Hosp, Dept Clin Sci, Karolinska Inst, Stockholm, Sweden; [Svenningsson, Anders; Hallberg, Susanna; Shawket, Fadi] Danderyd Hosp AB, Dept Neurol, Stockholm, Sweden; [Frisell, Thomas] Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden; [Burman, Joachim] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Salzer, Jonatan; Sundstrom, Peter] Umea Univ, Dept Clin Sci, Neurosci, Umea, Sweden; [Fink, Katharina; Al Nimer, Faiez; Piehl, Fredrik] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Fink, Katharina; Al Nimer, Faiez; Piehl, Fredrik] Stockholm Hlth Serv, Acad Specialist Ctr, Stockholm, Sweden; [Hambraeus, Joakim] Falun Cent Hosp, Dept Med, Sect Neurol, Falun, Sweden; [Axelsson, Markus; Rosenstein, Igal; Gilland, Eric; Lycke, Jan] Gothenburg Univ, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden; [Gunnarsson, Martin] Orebro Univ, Dept Neurol, Orebro, Sweden; [Johansson, Rune] Karlstad Hosp, Dept Neurol & Rehabil, Karlstad, Sweden; [Mellergard, Johan] Linkoping Univ Hosp, Dept Neurol, Linkoping, Sweden; [Mellergard, Johan] Linkoping Univ, Dept Biomed & Clin Sci, Linkoping, Sweden; [Rosenstein, Igal] Boras Hosp, Dept Neurol, Boras, Sweden; [Ayad, Ahmad] Capin St Goran Hosp, Dept Neurol, Stockholm, Sweden; [Sjoblom, Irina] Gavle Cent Hosp, Dept Med, Sect Neurol, Gavle, Sweden; [Risedal, Anette] Helsingborg Hosp, Dept Med, Sect Neurol, Helsingborg, Sweden; [de Flon, Pierre] Ostersund Hosp, Dept Med, Sect Neurol, Ostersund, Sweden; [Gilland, Eric] Kungsbacka Hosp, Dept Med, Sect Neurol, Kungsbacka, Sweden; [Lindeberg, Jonas] Nykoping Hosp, Dept Med, Sect Neurol, Nykoping, Sweden	Danderyds Hospital; Karolinska Institutet; Danderyds Hospital; Karolinska Institutet; Uppsala University; Umea University; Karolinska Institutet; Falun Hospital; University of Gothenburg; Orebro University; Linkoping University; Linkoping University; Helsingborgs Hospital	Svenningsson, A (corresponding author), Danderyd Hosp AB, Dept Neurol, Stockholm, Sweden.; Svenningsson, A (corresponding author), Danderyd Hosp, Dept Clin Sci, S-18288 Stockholm, Sweden.	anders.svenningsson@ki.se		Svenningsson, Anders/0000-0003-0663-2220; Al Nimer, Faiez/0000-0003-0937-5995	Swedish Research Council [2016-00398]	Swedish Research Council(Swedish Research CouncilEuropean Commission)	The study was funded in full by the Swedish Research Council, grant 2016-00398. We would like to direct a specific and warm gratitude towards all the multiple sclerosis nurses at the participating clinics who were key to making this trial possible. We also thank all the patients who spent the extra time undergoing assessments that was necessary for participation in a clinical trial.	Alping P, 2016, ANN NEUROL, V79, P950, DOI 10.1002/ana.24651; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1; Berntsson SG, 2018, ACTA NEUROL SCAND, V138, P327, DOI 10.1111/ane.12963; Boremalm M, 2019, EUR J NEUROL, V26, P1060, DOI 10.1111/ene.13936; Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; de Flon P, 2016, NEUROLOGY, V87, P141, DOI 10.1212/WNL.0000000000002832; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Granqvist M, 2018, JAMA NEUROL, V75, P320, DOI 10.1001/jamaneurol.2017.4011; Harding K, 2019, JAMA NEUROL, V76, P536, DOI 10.1001/jamaneurol.2018.4905; Hartung DM, 2015, NEUROLOGY, V84, P2185, DOI 10.1212/WNL.0000000000001608; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hauser SL, 2020, NEW ENGL J MED, V383, P546, DOI 10.1056/NEJMoa1917246; Hauser Stephen L, 2008, N Engl J Med, V358, P676, DOI 10.1056/NEJMoa0706383; Hawker K, 2009, ANN NEUROL, V66, P460, DOI 10.1002/ana.21867; Honce JM, 2019, NEUROLOGY, V92, pe723, DOI 10.1212/WNL.0000000000006916; Kappos L, 2007, LANCET, V370, P389, DOI 10.1016/S0140-6736(07)61194-5; Kappos L, 2021, JAMA NEUROL, V78, P558, DOI 10.1001/jamaneurol.2021.0405; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Kinkel RP, 2006, NEUROLOGY, V66, P678; Luna G, 2020, JAMA NEUROL, V77, P184, DOI 10.1001/jamaneurol.2019.3365; Polman Chris H, 2011, Ann Neurol, V69, P292, DOI 10.1002/ana.22366; Salzer J, 2016, NEUROLOGY, V87, P2074, DOI 10.1212/WNL.0000000000003331; Simpson-Yap S, 2021, NEUROLOGY, V97, pE1870, DOI 10.1212/WNL.0000000000012753; Spelman T, 2021, JAMA NEUROL, V78, P1197, DOI 10.1001/jamaneurol.2021.2738; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Vagberg M, 2017, ACTA NEUROL SCAND, V135, P17, DOI 10.1111/ane.12667	30	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2022	21	8					693	703		10.1016/S1474-4422(22)00209-5	http://dx.doi.org/10.1016/S1474-4422(22)00209-5			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	4P3VT	35841908				2022-12-18	WOS:000855325100016
J	Ashina, M; Lanteri-Minet, M; Pozo-Rosich, P; Ettrup, A; Christoffersen, CL; Josiassen, MK; Phul, R; Sperling, B				Ashina, Messoud; Lanteri-Minet, Michel; Pozo-Rosich, Patricia; Ettrup, Anders; Christoffersen, Cecilie Laurberg; Josiassen, Mette Krog; Phul, Ravinder; Sperling, Bjorn			Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial	LANCET NEUROLOGY			English	Article							PROPHYLACTIC MEDICATIONS; EPISODIC MIGRAINE; HEADACHE IMPACT; PATTERNS	Background The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and acceptable safety and tolerability in phase 3 trials, but benefits in the subpopulations of patients with previous preventive treatment failures were not examined. We aimed to investigate the safety and efficacy of eptinezumab for migraine prevention in adults with migraine and two-to-four previous preventive treatment failures. Methods DELIVER was a multicentre, multi-arm, phase 3b trial comprising a 24-week double-blind, placebo-controlled period and a 48-week dose-blinded extension. We recruited adults with episodic or chronic migraine with at least 4 monthly migraine days (as per International Headache Society guidelines) and documented evidence of two-to-four previous preventive treatment failures within the past 10 years, from 96 study locations across Europe (n=93) and the USA (n=3). Patients were randomly assigned (1:1:1) via a centralised randomisation system, stratified by baseline monthly headache days and country, to eptinezumab 100 mg, eptinezumab 300 mg, or placebo. The primary efficacy endpoint was the change from baseline in mean monthly migraine days (captured using a daily electronic diary) in weeks 1-12, assessed in the full analysis set. All participants and study personnel were masked to study drug assignments. The dose-blinded extension period is ongoing. Findings Between June 1, 2020, and Oct 7, 2021, 891 individuals were randomly assigned and received at least one dose of study drug (safety population; eptinezumab 100 mg n=299 [34%], eptinezumab 300 mg n=294 [33%], placebo n=298 [33%]). 865 patients completed the placebo-controlled period. The change from baseline to weeks 1-12 in mean monthly migraine days was -4.8 (SE 0.37) with eptinezumab 100 mg, -5.3 (0.37) with eptinezumab 300 mg, and -2.1 (0.38) with placebo. The difference from placebo in change in mean monthly migraine days from baseline was significant with eptinezumab 100 mg (-2.7 [95% CI -3.4 to -2.0]; p<0.0001) and eptinezumab 300 mg (-3.2 [-3.9 to -2.5]; p<0.0001). Treatment-emergent adverse events occurred in 127 (42%) of 299 patients in the eptinezumab 100 mg group, in 120 (41%) of 294 in the eptinezumab 300 mg group, and in 119 (40%) of 298 in the placebo group. The most common treatment-emergent adverse event was COVID-19 (20 [7%] of 299 patients in the eptinezumab 100 mg group, 17 [6%] of 294 in the eptinezumab 300 mg group, and 16 [5%] of 298 in the placebo group). Serious adverse events were uncommon (five [2%] of 299 in the eptinezumab 100 mg group, seven [2%] of 294 in the eptinezumab 300 mg group, four [1%] of 298 in the placebo group) and included anaphylactic reaction (eptinezumab 300 mg n=2) and COVID-19 (eptinezumab 100 mg n=1 and eptinezumab 300 mg n=1). Interpretation In adults with migraine and two-to-four previous preventive treatment failures, eptinezumab provided significant migraine preventive effects compared with placebo, with acceptable safety and tolerability, indicating that eptinezumab might be an effective treatment option for this patient population. The dose-blinded extension period will provide additional long-term safety data in patients with migraine and previous preventive treatment failures. Copyright (C) 2022. Published by Elsevier Ltd. All rights reserved.	[Ashina, Messoud] Univ Copenhagen, Rigshosp Glostrup, Danish Headache Ctr, Copenhagen, Denmark; [Lanteri-Minet, Michel] Ctr Hosp Univ Nice, Pain Dept, Nice, France; [Lanteri-Minet, Michel] Ctr Hosp Univ Nice, FHU InovPain, Nice, France; [Lanteri-Minet, Michel] Auvergne Univ, INSERM U1107 Migraine & Trigeminal Pain, Clermont Ferrand, France; [Pozo-Rosich, Patricia] Vall dHebron Univ Hosp, Headache Unit, Neurol Dept, Barcelona, Spain; [Pozo-Rosich, Patricia] Univ Autonoma Barcelona, Vall dHebron Res Inst, Dept Med, Headache & Neurol Pain Res Grp, Barcelona, Spain; [Ettrup, Anders; Christoffersen, Cecilie Laurberg; Josiassen, Mette Krog; Phul, Ravinder; Sperling, Bjorn] H Lundbeck, Copenhagen, Denmark	University of Copenhagen; CHU Nice; CHU Nice; Universite Clermont Auvergne (UCA); Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Lundbeck Corporation	Ashina, M (corresponding author), Univ Copenhagen, Rigshosp Glostrup, Dept Neurol, Danish Headache Ctr,Fac Hlth & Med Sci, DK-2600 Glostrup, Denmark.	ashina@dadlnet.dk			H Lundbeck	H Lundbeck(Lundbeck Corporation)	H Lundbeck.	Ailani J, 2021, HEADACHE, V61, P1021, DOI 10.1111/head.14153; Ashina M, 2021, J HEADACHE PAIN, V22, DOI 10.1186/s10194-021-01279-7; Ashina M, 2021, LANCET, V397, P1485, DOI 10.1016/S0140-6736(20)32160-7; Ashina M, 2020, NEW ENGL J MED, V383, P1866, DOI 10.1056/NEJMra1915327; Ashina M, 2020, CEPHALALGIA, V40, P241, DOI 10.1177/0333102420905132; Baker B, 2020, PHARMACOL RES PERSPE, V8, DOI 10.1002/prp2.567; Blumenfeld AM, 2013, HEADACHE, V53, P644, DOI 10.1111/head.12055; Dodick DW, 2020, HEADACHE, V60, P2220, DOI 10.1111/head.14007; Ferrari MD, 2019, LANCET, V394, P1030, DOI 10.1016/S0140-6736(19)31946-4; Ford JH, 2019, J MANAG CARE SPEC PH, V25, P46, DOI 10.18553/jmcp.2018.18058; Foster SA, 2022, CURR MED RES OPIN, V38, P653, DOI 10.1080/03007995.2021.2003127; Garcia-Martinez LF, 2020, J PHARMACOL EXP THER, V374, P93, DOI 10.1124/jpet.119.264671; Hepp Z, 2017, CEPHALALGIA, V37, P470, DOI 10.1177/0333102416678382; Holroyd KA, 2007, CEPHALALGIA, V27, P1156, DOI 10.1111/j.1468-2982.2007.01420.x; Houts CR, 2020, HEADACHE, V60, P2003, DOI 10.1111/head.13946; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Kudrow D, 2021, BMC NEUROL, V21, DOI 10.1186/s12883-021-02123-w; Latham J, 2016, HEADACHE, V56, P1398; Lipton RB, 2020, NEUROLOGY, V94, pE1365, DOI 10.1212/WNL.0000000000009169; McAllister P, 2022, CEPHALALGIA, V42, P1005, DOI 10.1177/03331024221089567; Mulleners WM, 2020, LANCET NEUROL, V19, P814, DOI 10.1016/S1474-4422(20)30279-9; National Institute for Health and Care Excellence, 2020, FREM PREV MIGR TECHN; National Institute for Health and Care Excellence, 2021, ER PREV MIGR TECHN A; National Institute for Health and Care Excellence (NICE), 2020, JOINT REPL PRIM HIP; Newman L, 2021, NEUROL-CLIN PRACT, V11, P206, DOI 10.1212/CPJ.0000000000001076; Olesen J, 2018, CEPHALALGIA, V38, P1, DOI 10.1177/0333102417738202; Pringsheim T, 2012, CAN J NEUROL SCI, V39, pS1; Reuter U, 2018, LANCET, V392, P2280, DOI 10.1016/S0140-6736(18)32534-0; Sacco S, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-018-0955-y; Silberstein S, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01186-3; Smith TR, 2021, J HEADACHE PAIN, V22, DOI 10.1186/s10194-021-01227-5; Smith TR, 2020, CLIN THER, V42, P2254, DOI 10.1016/j.clinthera.2020.11.007; Steiner TJ, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-018-0899-2; Tassorelli C, 2018, CEPHALALGIA, V38, P815, DOI 10.1177/0333102418758283; Wattiez AS, 2020, EXPERT OPIN THER TAR, V24, P91, DOI 10.1080/14728222.2020.1724285; Yang M, 2011, CEPHALALGIA, V31, P357, DOI 10.1177/0333102410379890	36	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2022	21	7					597	607		10.1016/S1474-4422(22)00185-5	http://dx.doi.org/10.1016/S1474-4422(22)00185-5			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3J4YF	35716692				2022-12-18	WOS:000833401200013
J	van Essen, TA; Lingsma, HF; Pisica, D; Singh, RD; Volovici, V; den Boogert, HF; Younsi, A; Peppel, LD; Heijenbrok-Kal, MH; Ribbers, GM; Walchenbach, R; Menon, DK; Hutchinson, P; Depreitere, B; Steyerberg, EW; Maas, AIR; de Ruiter, GCW; Peul, WC				van Essen, Thomas A.; Lingsma, Hester F.; Pisica, Dana; Singh, Ranjit D.; Volovici, Victor; den Boogert, Hugo F.; Younsi, Alexander; Peppel, Lianne D.; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.; Walchenbach, Robert; Menon, David K.; Hutchinson, Peter; Depreitere, Bart; Steyerberg, Ewout W.; Maas, Andrew I. R.; de Ruiter, Godard C. W.; Peul, Wilco C.		CENTER-TBI Collaboration Grp	Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study	LANCET NEUROLOGY			English	Article							BRAIN-INJURY; PROPENSITY SCORE; CENTER-TBI; MANAGEMENT; EVACUATION; OUTCOMES; QUALITY; TRIAL; SCALE; BIAS	Background Despite being well established, acute surgery in traumatic acute subdural haematoma is based on low-grade evidence. We aimed to compare the effectiveness of a strategy preferring acute surgical evacuation with one preferring initial conservative treatment in acute subdural haematoma. Methods We did a prospective, observational, comparative effectiveness study using data from participants enrolled in the Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) cohort. We included patients with no pre-existing severe neurological disorders who presented with acute subdural haematoma within 24 h of traumatic brain injury. Using an instrumental variable analysis, we compared outcomes between centres according to treatment preference for acute subdural haematoma (acute surgical evacuation or initial conservative treatment), measured by the case-mix-adjusted percentage of acute surgery per centre. The primary endpoint was functional outcome at 6 months as rated with the Glasgow Outcome Scale Extended, which was estimated with ordinal regression as a common odds ratio (OR) and adjusted for prespecified confounders. Variation in centre preference was quantified with the median OR (MOR). CENTER-TBI is registered with ClinicalTrials.gov , number NCT02210221, and the Resource Identification Portal (Research Resource Identifier SCR_015582). Findings Between Dec 19, 2014 and Dec 17, 2017, 4559 patients with traumatic brain injury were enrolled in CENTER-TBI, of whom 1407 (31%) presented with acute subdural haematoma and were included in our study. Acute surgical evacuation was done in 336 (24%) patients, by craniotomy in 245 (73%) of those patients and by decompressive craniectomy in 91 (27%). Delayed decompressive craniectomy or craniotomy after initial conservative treatment (n=982) occurred in 107 (11%) patients. The percentage of patients who underwent acute surgery ranged from 5.6% to 51.5% (IQR 12.3-35.9) between centres, with a two-times higher probability of receiving acute surgery for an identical patient in one centre versus another centre at random (adjusted MOR for acute surgery 1.8; p<0.0001]). Centre preference for acute surgery over initial conservative treatment was not associated with improvements in functional outcome (common OR per 23.6% [IQR increase] more acute surgery in a centre 0.92, 95% CI 0.77-1.09). Interpretation Our findings show that treatment for patients with acute subdural haematoma with similar characteristics differed depending on the treating centre, because of variation in the preferred approach. A treatment strategy preferring an aggressive approach of acute surgical evacuation over initial conservative treatment was not associated with better functional outcome. Therefore, in a patient with acute subdural haematoma for whom a neurosurgeon sees no clear superiority for acute surgery over conservative treatment, initial conservative treatment might be considered. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[van Essen, Thomas A.; Singh, Ranjit D.; Walchenbach, Robert; de Ruiter, Godard C. W.; Peul, Wilco C.] Leiden Univ Med Ctr, Univ Neurosurg Ctr Holland, Haaglanden Med Ctr, NL-2333 ZA Leiden, Netherlands; [van Essen, Thomas A.; Singh, Ranjit D.; Walchenbach, Robert; de Ruiter, Godard C. W.; Peul, Wilco C.] Haga Teaching Hosp, NL-2333 ZA Leiden, Netherlands; [Lingsma, Hester F.; Pisica, Dana; Volovici, Victor; Steyerberg, Ewout W.] Univ Med Ctr, Erasmus MC, Ctr Med Decis Sci, Dept Publ Hlth, Rotterdam, Netherlands; [Pisica, Dana; Volovici, Victor] Univ Med Ctr, Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [Peppel, Lianne D.; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Univ Med Ctr, Erasmus MC, Rijndam Rehabil, Rotterdam, Netherlands; [Peppel, Lianne D.; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Univ Med Ctr, Erasmus MC, Dept Rehabil Med, Rotterdam, Netherlands; [den Boogert, Hugo F.] Radboud Univ Nijmegen Med Ctr, Dept Neurosurg, Nijmegen, Netherlands; [Younsi, Alexander] Heidelberg Univ, Univ Hosp Heidelberg, Heidelberg, Germany; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Hutchinson, Peter] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge, England; Addenbrookes Hosp, Cambridge, England; [Hutchinson, Peter] Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England; [Depreitere, Bart] Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium; [Steyerberg, Ewout W.] Leiden Univ Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium	Haaglanden Medical Center; Leiden University; Leiden University Medical Center (LUMC); Haga Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; Ruprecht Karls University Heidelberg; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; KU Leuven; University Hospital Leuven; Leiden University; Leiden University Medical Center (LUMC); University of Antwerp; University of Antwerp	van Essen, TA (corresponding author), Leiden Univ Med Ctr, Univ Neurosurg Ctr Holland, Haaglanden Med Ctr, NL-2333 ZA Leiden, Netherlands.; van Essen, TA (corresponding author), Haga Teaching Hosp, NL-2333 ZA Leiden, Netherlands.	essen@lunic.nl	Rossi, Sandra/AHH-8015-2022; Posti, Jussi P./Y-2908-2019; Younsi, Alexander/AAW-7869-2020; Volovici, Victor/AAZ-8901-2020; Gomez, Pedro A./E-2411-2014; Sahuquillo, Juan/B-3577-2008; Raj, Rahul/K-7693-2012; Ribbers, Gerard/C-1454-2014	Rossi, Sandra/0000-0002-9963-8121; Posti, Jussi P./0000-0002-5925-5193; Younsi, Alexander/0000-0002-8218-9243; Volovici, Victor/0000-0002-5798-5360; Gomez, Pedro A./0000-0002-4185-5238; Dark, Paul/0000-0003-3309-0164; Kondziella, Daniel/0000-0001-5562-9808; Sahuquillo, Juan/0000-0003-0713-5875; Newcombe, Virginia/0000-0001-6044-9035; Williams, Guy/0000-0001-5223-6654; Golubovic, Jagos/0000-0001-5524-246X; Raj, Rahul/0000-0003-4243-9591; Ribbers, Gerard/0000-0002-6114-349X; Sanchez-Porras, Renan/0000-0002-9084-8114; Ragauskas, Arminas/0000-0001-9695-9512; Zeiler, Frederick/0000-0003-1737-0510	Hersenstichting Nederland [ps2014.06]; EU seventh Framework Programme [602150]; Hannelore Kohl Stiftung (Germany); OneMind (USA); Integra LifeSciences Corporation (USA); NeuroTrauma Sciences (USA)	Hersenstichting Nederland; EU seventh Framework Programme; Hannelore Kohl Stiftung (Germany); OneMind (USA); Integra LifeSciences Corporation (USA); NeuroTrauma Sciences (USA)	The authors' work on this study is funded by the Hersenstichting Nederland (the Dutch Brain Foundation, grant number ps2014.06) for the Dutch Neurotraumatology Quality Registry19 and the EU seventh Framework Programme (grant 602150) for CENTER-TBI. Additional support for CENTER-TBI was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences Corporation (USA), and from NeuroTrauma Sciences (USA). We thank all patients for their participation in the CENTER-TBI study; and all principal investigators and researchers for their collaboration and support.	Boef AGC, 2013, EPIDEMIOLOGY, V24, P937, DOI 10.1097/01.ede.0000434433.14388.a1; Brookhart MA, 2010, PHARMACOEPIDEM DR S, V19, P537, DOI 10.1002/pds.1908; Bullock MR, 2006, NEUROSURGERY S, V58, pSi, DOI DOI 10.1227/01.Neu.0000199773.49810.7f; Ceyisakar IE, 2022, NEUROCRIT CARE, V36, P846, DOI 10.1007/s12028-021-01386-y; Cnossen MC, 2018, CLIN EPIDEMIOL, V10, P841, DOI 10.2147/CLEP.S154500; Cnossen MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161367; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Davies NM, 2013, EPIDEMIOLOGY, V24, P363, DOI 10.1097/EDE.0b013e31828abafb; Essen TA, 2018, VARIATION NEUROSURGI, V161, P1; Feliciano CE, 2008, P R HEALTH SCI J, V27, P220; Gernsback JE, 2018, WORLD NEUROSURG, V120, pE414, DOI 10.1016/j.wneu.2018.08.095; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Kuramatsu JB, 2019, JAMA-J AM MED ASSOC, V322, P1392, DOI 10.1001/jama.2019.13014; Laborde-Casterot H, 2015, J CLIN EPIDEMIOL, V68, P1232, DOI 10.1016/j.jclinepi.2015.04.003; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Maciejewski ML, 2019, JAMA-J AM MED ASSOC, V321, P2124, DOI 10.1001/jama.2019.5646; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8; Munro D., 1934, NEW ENGL J MED, V210, P1; Nederlands Trial Register, 2004, IDENTIFIER TRIAL NL5; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Shibahashi K, 2020, J NEUROSURG, V133, P504, DOI 10.3171/2019.4.JNS182660; Shimoda K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.014; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; Swanson SA, 2018, INT J EPIDEMIOL, V47, P1289, DOI 10.1093/ije/dyx038; Swanson SA, 2015, AM J EPIDEMIOL, V181, P191, DOI 10.1093/aje/kwu284; Truong EI, 2021, J TRAUMA ACUTE CARE, V91, P114, DOI 10.1097/TA.0000000000003114; van Essen TA, 2020, JAMA-J AM MED ASSOC, V323, P665, DOI 10.1001/jama.2019.20851; Van Essen TA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033513; van Essen TA, 2019, J NEUROTRAUM, V36, P1184, DOI 10.1089/neu.2018.5869; van Essen TA, 2017, J NEUROTRAUM, V34, P881, DOI 10.1089/neu.2016.4495; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412; Younsi A, 2021, EUR J TRAUMA EMERG S, V47, P1499, DOI 10.1007/s00068-020-01419-9	44	3	3	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2022	21	7					620	631		10.1016/S1474-4422(22)00166-1	http://dx.doi.org/10.1016/S1474-4422(22)00166-1			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3J4YF	35526554	Green Submitted, Green Published			2022-12-18	WOS:000833401200015
J	Leonard, H; Downs, J; Benke, TA; Swanson, L; Olson, H; Demarest, S				Leonard, Helen; Downs, Jenny; Benke, Tim A.; Swanson, Lindsay; Olson, Heather; Demarest, Scott			CDKL5 deficiency disorder: clinical features, diagnosis, and management	LANCET NEUROLOGY			English	Review							QUALITY-OF-LIFE; FUNCTIONAL ABILITIES; REFRACTORY EPILEPSY; INFANTILE SPASMS; KETOGENIC DIET; MUTATIONS; CHILDREN; GENE; ONSET; PHENOTYPES	CDKL5 deficiency disorder (CDD) was first identified as a cause of human disease in 2004. Although initially considered a variant of Rett syndrome, CDD is now recognised as an independent disorder and classified as a developmental epileptic encephalopathy. It is characterised by early-onset (generally within the first 2 months of life) seizures that are usually refractory to polypharmacy. Development is severely impaired in patients with CDD, with only a quarter of girls and a smaller proportion of boys achieving independent walking; however, there is clinical variability, which is probably genetically determined. Gastrointestinal, sleep, and musculoskeletal problems are common in CDD, as in other developmental epileptic encephalopathies, but the prevalence of cerebral visual impairment appears higher in CDD. Clinicians diagnosing infants with CDD need to be familiar with the complexities of this disorder to provide appropriate counselling to the patients' families. Despite some benefit from ketogenic diets and vagal nerve stimulation, there has been little evidence that conventional antiseizure medications or their combinations are helpful in CDD, but further treatment trials are finally underway.	[Leonard, Helen; Downs, Jenny] Univ Western Australia, Telethon Kids Inst, Perth, WA 6009, Australia; [Downs, Jenny] Curtin Univ, Curtin Sch Allied Hlth, Perth, WA, Australia; [Benke, Tim A.; Demarest, Scott] Childrens Hosp Colorado, Dept Neurol, Aurora, CO USA; [Benke, Tim A.; Demarest, Scott] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Benke, Tim A.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO USA; [Benke, Tim A.; Demarest, Scott] Univ Colorado Denver, Dept Neurol, Aurora, CO USA; [Benke, Tim A.] Univ Colorado Denver, Dept Otolaryngol, Aurora, CO USA; [Swanson, Lindsay; Olson, Heather] Boston Childrens Hosp, Dept Neurol, Boston, MA USA	Telethon Kids Institute; University of Western Australia; Curtin University; Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Boston Children's Hospital	Leonard, H (corresponding author), Univ Western Australia, Telethon Kids Inst, Perth, WA 6009, Australia.	helen.leonard@telethonkids.org.au	Downs, Jenny/R-9947-2017	Downs, Jenny/0000-0001-7358-9037	NHMRC Senior Research Fellowship [1117105]; National Institute of Neurological Disorders and Stroke [K23 NS107646-04]; NIH [U01NS114312, U54HD061222]; Children's Hospital Foundation Ponzio Family Chair in Neurology Research; International Foundation for CDKL5 Research	NHMRC Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Hospital Foundation Ponzio Family Chair in Neurology Research; International Foundation for CDKL5 Research	The primary funding source for this Review was the NHMRC Senior Research Fellowship (number 1117105) awarded to HL. HO was funded through the National Institute of Neurological Disorders and Stroke (K23 NS107646-04). TAB was funded through the NIH (U54HD061222 and U01NS114312) and the Children's Hospital Foundation Ponzio Family Chair in Neurology Research. JD was funded through the NIH (U01NS114312) and the International Foundation for CDKL5 Research. LS was funded through the International Foundation for CDKL5 Research. Other funding sources did not have a role in this Review. We thank Conor Mackay for his painstaking efforts in the formatting of the tables and Mohammed Junaid for his assistance. We thank Elia Pestana-Knight and her team at the Cleveland Clinic CDKL5 Center of Excellence (Cleveland, OH, USA) for allowing the inclusion of their unpublished data.	Aledo-Serrano A, 2021, EPILEPSY BEHAV, V118, DOI 10.1016/j.yebeh.2021.107946; Alexander HB, 2018, EPILEPSY BEHAV, V78, P96, DOI 10.1016/j.yebeh.2017.11.006; Amin S, 2017, HIPPOKRATIA, V21, P130; Arican P, 2019, NEUROCASE, V25, P59, DOI 10.1080/13554794.2019.1612923; Axeen EJT, 2018, SEMIN FETAL NEONAT M, V23, P197, DOI 10.1016/j.siny.2018.01.003; Bahi-Buisson N, 2008, BRAIN, V131, P2647, DOI 10.1093/brain/awn197; Bahi-Buisson N, 2008, EPILEPSIA, V49, P1027, DOI 10.1111/j.1528-1167.2007.01520.x; Balestra D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174130; Baltussen LL, 2018, EMBO J, V37, DOI 10.15252/embj.201899763; Barbiero I, 2020, NEUROPHARMACOLOGY, V164, DOI 10.1016/j.neuropharm.2019.107897; Barbiero I, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174075; Benke TA, 2020, BRAIN, V143, P716, DOI 10.1093/brain/awaa055; Berg AT, 2021, EPILEPSIA, V62, P258, DOI 10.1111/epi.16750; Bernardo P, 2019, EPILEPTIC DISORD, V21, P271, DOI 10.1684/epd.2019.1071; Bertani I, 2006, J BIOL CHEM, V281, P32048, DOI 10.1074/jbc.M606325200; Brock D, 2021, J CHILD NEUROL, V36, P974, DOI 10.1177/08830738211019284; Cutri-French C, 2020, ANN NEUROL, V88, P396, DOI 10.1002/ana.25797; Dale T, 2021, EPILEPSY BEHAV, V122, DOI 10.1016/j.yebeh.2021.108152; Demarest S, 2021, NEUROLOGY, V96; Demarest S, 2019, PEDIATR NEUROL, V97, P38, DOI 10.1016/j.pediatrneurol.2019.03.017; Demarest ST, 2019, EPILEPSIA, V60, P1733, DOI 10.1111/epi.16285; Devinsky O, 2021, EPILEPSIA, V62, pE98, DOI 10.1111/epi.16923; Devinsky O, 2021, ANN CLIN TRANSL NEUR, V8, P639, DOI 10.1002/acn3.51306; Devinsky O, 2018, EPILEPSY BEHAV, V86, P131, DOI 10.1016/j.yebeh.2018.05.013; Downs J, 2019, QUAL LIFE RES, V28, P783, DOI 10.1007/s11136-018-2057-3; Eyers PA, 2018, EMBO J, V37, DOI 10.15252/embj.2018100848; Fallah MS, 2020, NEUROSCIENCE, V445, P50, DOI 10.1016/j.neuroscience.2020.01.041; Fazzari M, 2019, RNA BIOL, V16, P1414, DOI 10.1080/15476286.2019.1632633; Fehr S, 2016, NEUROLOGY, V87, P2206, DOI 10.1212/WNL.0000000000003352; Fehr S, 2016, AM J MED GENET A, V170, P2860, DOI 10.1002/ajmg.a.37851; Fehr S, 2015, J NEURODEV DISORD, V7, DOI 10.1186/1866-1955-7-2; Fehr S, 2013, EUR J HUM GENET, V21, P266, DOI 10.1038/ejhg.2012.156; Fuchs C, 2020, NEUROPHARMACOLOGY, V167, DOI 10.1016/j.neuropharm.2019.107746; Fuchs C, 2018, EUR J NEUROSCI, V47, P1054, DOI 10.1111/ejn.13923; Ga L, 2018, NAT NEUROSCI, V21, P1300, DOI 10.1038/s41593-018-0237-7; Gao YN, 2020, BRAIN, V143, P811, DOI 10.1093/brain/awaa028; Greene C, 2020, AM EPILEPSY SOC 74 A; Halmai JANM, 2020, NUCLEIC ACIDS RES, V48, P2372, DOI 10.1093/nar/gkz1214; HANEFELD F, 1985, BRAIN DEV-JPN, V7, P320, DOI 10.1016/S0387-7604(85)80037-1; Hector RD, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000200; Helbig I, 2018, HUM MUTAT, V39, P1476, DOI 10.1002/humu.23632; Heussler HS, 2018, J PAEDIATR CHILD H, V54, P1142, DOI 10.1111/jpc.14164; Jakimiec M, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10020107; Jian L, 2006, J PEDIATR-US, V149, P542, DOI 10.1016/j.jpeds.2006.06.015; Klein KM, 2011, NEUROLOGY, V76, P1436, DOI 10.1212/WNL.0b013e3182166e58; Knight EMP, 2022, LANCET NEUROL, V21, P417, DOI 10.1016/S1474-4422(22)00077-1; Kobayashi Y, 2021, BRAIN DEV-JPN, V43, P505, DOI 10.1016/j.braindev.2020.12.006; Kothur K, 2018, SEIZURE-EUR J EPILEP, V59, P132, DOI 10.1016/j.seizure.2018.05.005; Leonard H, 2022, EPILEPSIA, V63, P352, DOI 10.1111/epi.17125; Leonard H, 2021, EPILEPSY RES, V169, DOI 10.1016/j.eplepsyres.2020.106521; Liang JS, 2019, BRAIN DEV-JPN, V41, P783, DOI 10.1016/j.braindev.2019.05.003; Lim Z, 2018, EPILEPSY RES, V146, P36, DOI 10.1016/j.eplepsyres.2018.07.013; Lim Z, 2017, EPILEPSIA, V58, P1415, DOI 10.1111/epi.13813; Lindy AS, 2018, EPILEPSIA, V59, P1062, DOI 10.1111/epi.14074; Lo Martire V, 2017, J SLEEP RES, V26, P495, DOI 10.1111/jsr.12512; MacKay CI, 2021, CLIN GENET, V99, P157, DOI 10.1111/cge.13862; MacKay CI, 2020, AM J MED GENET A, V182, P1217, DOI 10.1002/ajmg.a.61504; Mangatt M, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0418-y; Mazurek MO, 2016, J AUTISM DEV DISORD, V46, P1906, DOI 10.1007/s10803-016-2723-7; Mefford HC, 2020, EPILEPSY CURR, V20, P88, DOI 10.1177/1535759720901734; Melani F, 2011, DEV MED CHILD NEUROL, V53, P354, DOI 10.1111/j.1469-8749.2010.03889.x; Melikishvili G, 2019, EPILEPSY BEHAV, V94, P308, DOI 10.1016/j.yebeh.2019.02.013; Mingorance A, 2020, VOICE PATIENT REPORT; Mori Y, 2018, J AUTISM DEV DISORD, V48, P1651, DOI 10.1007/s10803-017-3420-x; Mori Y, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-016-0563-3; Muller A, 2016, EUR J PAEDIATR NEURO, V20, P147, DOI 10.1016/j.ejpn.2015.09.001; Muir AM, 2019, EPILEPSY RES, V156, DOI 10.1016/j.eplepsyres.2019.106181; Mulcahey PJ, 2020, EXP NEUROL, V332, DOI 10.1016/j.expneurol.2020.113388; Munoz IM, 2018, EMBO J, V37, DOI 10.15252/embj.201899559; Neul JL, 2010, ANN NEUROL, V68, P944, DOI 10.1002/ana.22124; Olson H, 2020, 145 ANN M AM NEUROLO; Olson HE, 2021, J NEURODEV DISORD, V13, DOI 10.1186/s11689-021-09384-z; Olson HE, 2021, DEV MED CHILD NEUROL, V63, P1308, DOI 10.1111/dmcn.14908; Olson HE, 2019, PEDIATR NEUROL, V97, P18, DOI 10.1016/j.pediatrneurol.2019.02.015; Olson HE, 2017, ANN NEUROL, V81, P419, DOI 10.1002/ana.24883; Patnaik A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093079; Robertson J, 2018, J INTELLECT DEV DIS, V43, P392, DOI 10.3109/13668250.2017.1310829; Sakki HEA, 2018, BRIT J OPHTHALMOL, V102, P424, DOI 10.1136/bjophthalmol-2017-310694; Saldaris J, 2021, J CHILD NEUROL, V36, P998, DOI 10.1177/08830738211019576; Siri B, 2021, EUR J PAEDIATR NEURO, V33, P9, DOI 10.1016/j.ejpn.2021.04.007; Specchio N, 2017, EPILEPSIA, V58, pS163; Stosser MB, 2018, GENET MED, V20, P403, DOI 10.1038/gim.2017.114; Sullivan J, 2020, EPILEPSIA, V61, P2396, DOI 10.1111/epi.16722; Symonds JD, 2020, EUR J PAEDIATR NEURO, V24, P15, DOI 10.1016/j.ejpn.2019.12.008; Symonds JD, 2019, BRAIN, V142, P2303, DOI 10.1093/brain/awz195; Tang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10689-w; Tang YY, 2021, EUR J PAEDIATR NEURO, V31, P46, DOI 10.1016/j.ejpn.2021.02.004; Tangarorang J, 2019, AM J MED GENET A, V179, P249, DOI 10.1002/ajmg.a.61012; Tao J, 2004, AM J HUM GENET, V75, P1149, DOI 10.1086/426460; Terzic B, 2021, NEUROBIOL DIS, V148, DOI 10.1016/j.nbd.2020.105176; Trazzi S, 2018, HUM MOL GENET, V27, P1572, DOI 10.1093/hmg/ddy064; Trovo L, 2020, NEUROBIOL DIS, V138, DOI 10.1016/j.nbd.2020.104791; Wang HT, 2021, EPILEPSIA, V62, P517, DOI 10.1111/epi.16805; Weaving LS, 2004, AM J HUM GENET, V75, P1079, DOI 10.1086/426462; Williams K, 2021, DEV MED CHILD NEUROL, V63, P89, DOI 10.1111/dmcn.14657; Yawno T, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00246; Yennawar M, 2019, J NEUROSCI, V39, P4814, DOI 10.1523/JNEUROSCI.2041-18.2019; Zhu YC, 2019, DEV NEUROBIOL, V79, P8, DOI 10.1002/dneu.22639	99	3	3	4	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2022	21	6					563	576		10.1016/S1474-4422(22)00035-7	http://dx.doi.org/10.1016/S1474-4422(22)00035-7			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3Z0EK	35483386				2022-12-18	WOS:000844093900002
J	Zhao, JJ; Yuan, F; Song, CG; Yin, R; Chang, MZ; Zhang, W; Zhang, B; Yu, LP; Jia, Y; Ma, L; Song, YB; Wang, CK; Song, CH; Wang, XA; Shang, L; Yang, F; Jiang, W				Zhao, Jingjing; Yuan, Fang; Song, Changgeng; Yin, Rong; Chang, Mingze; Zhang, Wei; Zhang, Bei; Yu, Liping; Jia, Yi; Ma, Wiling; Song, Yongbin; Wang, Chengkai; Song, Chaohui; Wang, Xinfai; Shang, Lei; Yang, Fang; Jiang, Wen		OPENS Trial Investigators	Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial	LANCET NEUROLOGY			English	Article							CRITICALLY-ILL PATIENTS; CLINICAL NUTRITION; METOCLOPRAMIDE; GUIDELINE; FOOD	Background Early enteral nutrition is crucial for preventing malnutrition and improving outcomes in patients with severe stroke, but previous trials have provided conflicting results regarding the optimal nutritional strategy. We aimed to compare the efficacy and safety of three enteral feeding strategies in patients with severe stroke. Methods The Optimizing Early Enteral Nutrition in Severe Stroke (OPENS) study was a multicentre, investigator initiated, prospective, open-label, randomised controlled trial, with blinded outcome assessment, in 16 tertiary and district general hospitals in the west of China. Adult patients with acute severe ischaemic or haemorrhagic stroke (Glasgow Coma Scale score <= 12 or National Institutes of Health Stroke Scale score >= 11 on admission) who were expected to receive enteral nutrition for more than 7 days were randomly assigned (1:1:1) to full enteral nutrition (70-100% of estimated caloric requirements), modified full enteral nutrition (full enteral nutrition plus prokinetic agents), or hypocaloric enteral nutrition (40-60% of estimated caloric requirements) via a centralised web-based randomisation system. The assigned nutrition was initiated within 24 h after enrolment and continued for 7 days. The computer-generated randomisation sequence was prepared by a statistician not involved with the rest of the study. Randomisation was done with an automated permuted block size of six. The allocation was unblinded to participants and investigators. The primary efficacy outcome was the proportion of participants with poor outcome (modified Rankin Scale score >= 3) at day 90 and the prespecified primary safety outcome was mortality at day 90, assessed in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT02982668. Findings Between Jan 15, 2017, and Sept 23, 2020, 321 patients were randomly assigned (107 in each group) and 315 patients (175 [56%] men, median age 71 years, IQR 60-78) were included in the final analysis. The study was terminated ahead of schedule on Sept 23, 2020, because a significant difference between groups was detected in mortality. The proportion of participants with poor outcomes at 90 days did not differ (modified full enteral nutrition 86 [82%] of 105 patients vs full enteral nutrition 85 [80%] of 106 patients, adjusted odds ratio [OR] 0middot87, 95% CI 0middot41-1middot86, p=0middot721; hypocaloric enteral nutrition 76 [73%] of 104 patients vs full enteral nutrition 0middot61, 0middot30-1middot27, p=0middot186; hypocaloric enteral nutrition vs modified full enteral nutrition 0middot70, 0middot34-1middot46, p=0middot340). Hypocaloric enteral nutrition showed significantly higher 90-day mortality than did modified full enteral nutrition (35 [34%] of 104 patients vs 18 [17%] of 105 patients, adjusted OR 2middot89, 95% CI 1middot46-5middot72; p=0middot0023), whereas the difference was not significant between hypocaloric enteral nutrition and full enteral nutrition (24 [23%] of 106 patients; adjusted OR 1middot92, 95% CI 1middot00-3middot69; p=0middot049), and between modified full enteral nutrition and full enteral nutrition (adjusted OR 0middot61, 0middot29-1middot28; p=0middot187). The most common adverse event was pneumonia, the incidence of which showed no significant difference among groups (full enteral nutrition 82 [78%] of 105 patients, modified full enteral nutrition 83 [81%] of 103 patients, hypocaloric enteral nutrition 78 [75%] of 104 patients; p=0middot625). Interpretation In the early phase of severe stroke, modified full enteral nutrition or hypocaloric enteral nutrition did not significantly reduce the risk of a poor outcomes compared with full enteral nutrition over a 90-day period. Hypocaloric enteral nutrition might be associated with increased mortality compared with modified full enteral nutrition. Further studies are needed to investigate whether modified full enteral nutrition might be the optimal strategy. Copyright (c) 2022 Elsevier Ltd. All rights reserved.	[Zhao, Jingjing; Yuan, Fang; Song, Changgeng; Yang, Fang; Jiang, Wen] Fourth Mil Med Univ, Dept Neurol, Xijing Hosp, Xian 710032, Peoples R China; [Shang, Lei] Fourth Mil Med Univ, Dept Hlth Stat, Xian, Peoples R China; [Yin, Rong] PLA 940 Hosp, Dept Neurol, Lanzhou, Peoples R China; [Chang, Mingze] Xian 3 Hosp, Dept Neurol, Xian, Peoples R China; [Zhang, Wei] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian, Peoples R China; [Zhang, Bei] Xian Med Univ, Dept Neurol, Affiliated Hosp 1, Xian, Peoples R China; [Yu, Liping] First Peoples Hosp Xianyang, Dept Neurol, Xianyang, Peoples R China; [Jia, Yi] Xian Gaoxing Hosp, Dept Neurol, Xian, Peoples R China; [Ma, Wiling] Yulin 1 Hosp, Dept Neurol, Yulin, Peoples R China; [Song, Yongbin] Gen Hosp Xinjiang Mil Command, Dept Neurol, Urumqi, Peoples R China; [Wang, Chengkai] Tongthuan Peoples Hosp, Dept Neurol, Tongchuan, Peoples R China; [Song, Chaohui] Tongchuan Min Bur Hosp, Dept Neurol, Tongchuan, Peoples R China; [Wang, Xinfai] Xian Cent Hosp, Dept Neurol, Xian, Peoples R China; [Yuan, Fang] Guangzhou Univ Chinese Med, Dept Neurol, Affiliated Hosp 2, Guangzhou, Peoples R China; [Yin, Rong] Gansu Prov Cent Hosp, Dept Neurol, Lanzhou, Peoples R China; [Yang, Fang; Jiang, Wen] Shaanxi Cerebrovasc Dis Clin Res Ctr, Xian, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Xi'an Medical University; Guangzhou University of Chinese Medicine	Yang, F; Jiang, W (corresponding author), Fourth Mil Med Univ, Dept Neurol, Xijing Hosp, Xian 710032, Peoples R China.	fyangx_neuro@163.com; jiangwen@fmmu.edu.cn	Guo, Jun/AAC-3573-2021	Guo, Jun/0000-0001-8053-881X; Jiang, Wen/0000-0003-0612-2917; Yuan, Fang/0000-0002-4050-7362	Xijing Hospital Clinical Research Program [XJZT18ML15]; Shaanxi province Key Research and Development Project [2017DCXL-SF-02-02]; National Natural Science Foundation of China [81771406]	Xijing Hospital Clinical Research Program; Shaanxi province Key Research and Development Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Declaration of interests JZ reports grants from the Xijing Hospital Clinical Research Program (XJZT18ML15) outside the submitted work. MC reports grants from the Shaanxi province Key Research and Development Project (2018SF-035) outside the submitted work. WZ reports grants from the National Natural Science Foundation of China (81971003) outside the submitted work. LS reports grants from the National Natural Science Foundation of China (81773540 and 82173627) outside the submitted work. FYa reports grants from the Shaanxi province Key Research and Development Project (2020SF-306) outside the submitted work. WJ reports grants from the Shaanxi province Key Research and Development Project (2017DCXL-SF-02-02) for this study, and the National Natural Science Foundation of China (81771406 and 81974204) outside the submitted work. All other authors declare no competing interests.	Alberda C, 2009, INTENS CARE MED, V35, P1728, DOI 10.1007/s00134-009-1567-4; Arabi YM, 2015, NEW ENGL J MED, V372, P2398, DOI 10.1056/NEJMoa1502826; Booth CM, 2002, CRIT CARE MED, V30, P1429, DOI 10.1097/00003246-200207000-00005; Burgos R, 2018, CLIN NUTR, V37, P354, DOI 10.1016/j.clnu.2017.09.003; Clarke J, 2005, LANCET, V365, P764, DOI 10.1016/S0140-6736(05)17983-5; Coban E, 2019, MED B SISLI ETFAL HO, V53, P272, DOI 10.14744/SEMB.2018.81994; Curran MP, 2008, DRUGS, V68, P981, DOI 10.2165/00003495-200868070-00007; Dennis M, 2003, STROKE, V34, P1450, DOI 10.1161/01.STR.0000074037.49197.8C; Elke G, 2014, CRIT CARE, V18, DOI 10.1186/cc13720; Heyland DK, 2011, CRIT CARE, V15, DOI 10.1186/cc10546; Heyland DK, 2011, CRIT CARE MED, V39, P2619, DOI 10.1097/CCM.0b013e318226641d; Katagiri F, 2006, J PEPT SCI, V12, P311, DOI 10.1002/psc.726; Lee ZY, 2018, CLIN NUTR, V37, P1264, DOI 10.1016/j.clnu.2017.05.013; MacLaren R, 2008, JPEN-PARENTER ENTER, V32, P412, DOI 10.1177/0148607108319803; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; Mousavian SZ, 2020, JPEN-PARENTER ENTER, V44, P1475, DOI 10.1002/jpen.1782; Patejdl R, 2017, NEUROL RES, V39, P959, DOI 10.1080/01616412.2017.1367545; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Sabbouh T, 2018, NEUROCRIT CARE, V29, P374, DOI 10.1007/s12028-017-0436-1; Sato Y, 2021, NUTRIENTS, V13, DOI 10.3390/nu13030943; Sharma K, 2019, NUTR CLIN PRACT, V34, P12, DOI 10.1002/ncp.10232; Sung SF, 2013, CLIN NEUROL NEUROSUR, V115, P892, DOI 10.1016/j.clineuro.2012.08.034; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Weijs PJM, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0701-z; Wirth Rainer, 2013, Exp Transl Stroke Med, V5, P14, DOI 10.1186/2040-7378-5-14; Yamada T, 2017, INTENS CARE MED, V43, P1427, DOI 10.1007/s00134-017-4801-5; Yuan F, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1253-2	28	3	3	8	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2022	21	4					319	328		10.1016/S1474-4422(22)00010-2	http://dx.doi.org/10.1016/S1474-4422(22)00010-2			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	1Y0JM	35219379				2022-12-18	WOS:000807832700013
J	[Anonymous]				[Anonymous]			A decisive year for the neurological community	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2022	21	2					103	103		10.1016/S1474-4422(22)00001-1	http://dx.doi.org/10.1016/S1474-4422(22)00001-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZT4ER	35065025	Bronze			2022-12-18	WOS:000769111800002
J	Trotti, LM				Trotti, Lynn Marie			Idiopathic hypersomnia: does first to approval mean first-line treatment?	LANCET NEUROLOGY			English	Editorial Material							LONG-SLEEP TIME; DOUBLE-BLIND; MODAFINIL		[Trotti, Lynn Marie] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30329 USA; [Trotti, Lynn Marie] Emory Univ, Sch Med, Sleep Ctr, Atlanta, GA 30329 USA	Emory University; Emory University	Trotti, LM (corresponding author), Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30329 USA.; Trotti, LM (corresponding author), Emory Univ, Sch Med, Sleep Ctr, Atlanta, GA 30329 USA.	Lbecke2@emory.edu						Dauvilliers Y, 2022, LANCET NEUROL, V21, P53, DOI 10.1016/S1474-4422(21)00368-9; FDA, 2019, ENR STRAT CLIN TRIAL; Furlan AD, 2011, PAIN RES MANAG, V16, P337, DOI 10.1155/2011/465281; Inoue Y, 2021, SLEEP MED, V80, P315, DOI 10.1016/j.sleep.2021.01.018; Maski Kiran, 2021, J Clin Sleep Med, V17, P1881, DOI 10.5664/jcsm.9328; Mayer G, 2015, J SLEEP RES, V24, P74, DOI 10.1111/jsr.12201; Rabinowitz J, 2018, J AFFECT DISORDERS, V239, P79, DOI 10.1016/j.jad.2018.06.039; Trotti LM, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012714.pub2; US Food and Drug Administration, 2021, FDA GRANTS 1 ITS KIN	9	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					25	26		10.1016/S1474-4422(21)00419-1	http://dx.doi.org/10.1016/S1474-4422(21)00419-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XV0SP	34942131				2022-12-18	WOS:000734663200015
J	Sormani, MP; Waubant, E				Sormani, Maria Pia; Waubant, Emmanuelle			Paediatric multiple sclerosis: a lesson from TERIKIDS Comment	LANCET NEUROLOGY			English	Editorial Material							ORAL TERIFLUNOMIDE; DOUBLE-BLIND; SUBGROUP ANALYSES; EFFICACY; PHASE-3; SAFETY; TRIAL		[Sormani, Maria Pia] Univ Genoa, Biostat Unit, Dept Hlth Sci DISSAL, I-16132 Genoa, Italy; [Waubant, Emmanuelle] IRCCS, Osped Policlin San Martino, Genoa, Italy; [Waubant, Emmanuelle] Weill Inst Neurosci, UCSF MS Ctr, San Francisco, CA USA	University of Genoa; University of California System; University of California San Francisco	Sormani, MP (corresponding author), Univ Genoa, Biostat Unit, Dept Hlth Sci DISSAL, I-16132 Genoa, Italy.	mariapia.sormani@unige.it						[Anonymous], 2021, GLOBAL WIRE NEW 0618; Chitnis T, 2021, LANCET NEUROL, V20, P1001, DOI 10.1016/S1474-4422(21)00364-1; Confavreux C, 2014, LANCET NEUROL, V13, P247, DOI 10.1016/S1474-4422(13)70308-9; Devonshire V, 2012, LANCET NEUROL, V11, P420, DOI 10.1016/S1474-4422(12)70056-X; Miller AE, 2012, MULT SCLER J, V18, P1625, DOI 10.1177/1352458512450354; O'Connor P, 2011, NEW ENGL J MED, V365, P1293, DOI 10.1056/NEJMoa1014656; O'Connor PW, 2006, NEUROLOGY, V66, P894, DOI 10.1212/01.wnl.0000203121.04509.31; Signori A, 2015, EUR J NEUROL, V22, P960, DOI 10.1111/ene.12690; Waubant E, 2019, NEUROLOGY, V92, pE2538, DOI 10.1212/WNL.0000000000007572	9	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2021	20	12					971	+		10.1016/S1474-4422(21)00372-0	http://dx.doi.org/10.1016/S1474-4422(21)00372-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YZ6RX	34800403				2022-12-18	WOS:000755602800008
J	Livingstone, A; Servais, L; Wilkinson, DJC				Livingstone, Angus; Servais, Laurent; Wilkinson, Dominic J. C.			Crowdfunding for neuromuscular disease treatment: the ethical implications	LANCET NEUROLOGY			English	Letter							SPINAL MUSCULAR-ATROPHY		[Livingstone, Angus] Univ Oxford, Med Sch, Oxford, England; [Servais, Laurent] Univ Oxford, MDUK Oxford Neuromuscular Ctr, Dept Paediat, Oxford, England; [Wilkinson, Dominic J. C.] Univ Oxford, Fac Philosophy, Oxford Uehiro Ctr Pract Eth, Oxford, England; [Servais, Laurent] Univ Hosp Liege, Dept Paediat, Ctr Neuromuscular Dis, Div Child Neurol Reference, Liege, Belgium; [Wilkinson, Dominic J. C.] John Radcliffe Hosp, Newborn Care Unit, Oxford OX1 1PT, England; [Wilkinson, Dominic J. C.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia	University of Oxford; University of Oxford; University of Oxford; University of Liege; University of Oxford; Murdoch Children's Research Institute	Wilkinson, DJC (corresponding author), Univ Oxford, Fac Philosophy, Oxford Uehiro Ctr Pract Eth, Oxford, England.; Wilkinson, DJC (corresponding author), John Radcliffe Hosp, Newborn Care Unit, Oxford OX1 1PT, England.; Wilkinson, DJC (corresponding author), Murdoch Childrens Res Inst, Melbourne, Vic, Australia.	dominic.wilkinson@philosophy.ox.ac.uk		Livingstone, Angus/0000-0002-6018-8637	WellcomeTrust [203132/Z/16/Z]	WellcomeTrust(Wellcome Trust)	from these companies for a newborn screening programme in Belgium. All other authors declare no competing interests. This research was funded in part, by the WellcomeTrust (203132/Z/16/Z). The funders had no role in the preparation of this manuscript or the decision to submit for publication. LS has provided paid consultancy for Novartis Gene Therapy, Roche, and Biogen, and obtained funding	Berliner LS, 2017, SOC SCI MED, V187, P233, DOI 10.1016/j.socscimed.2017.02.008; Chand DH, 2021, J PEDIATR-US, V231, P265, DOI 10.1016/j.jpeds.2020.11.054; Dangouloff T, 2021, NEUROMUSCULAR DISORD, V31, P574, DOI 10.1016/j.nmd.2021.03.007; Dangouloff T, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-01695-7; Saleh SN, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.21684; Silver ER, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.26946; Snyder J, 2017, J MED ETHICS, V43, P364, DOI 10.1136/medethics-2016-103933	7	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2021	20	10					788	789		10.1016/S1474-4422(21)00266-0	http://dx.doi.org/10.1016/S1474-4422(21)00266-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UY8AW	34536401	Bronze			2022-12-18	WOS:000701741000011
J	Frisoni, GB; Hansson, O				Frisoni, Giovanni B.; Hansson, Oskar			Management of Alzheimer's disease takes a leap forward	LANCET NEUROLOGY			English	Editorial Material									[Frisoni, Giovanni B.] Univ Geneva, Ctr Memoire, CH-1205 Geneva, Switzerland; [Frisoni, Giovanni B.] Univ Hosp, CH-1205 Geneva, Switzerland; [Hansson, Oskar] Lund Univ, Clin Memory Res Unit, Dept Clin Sci Malmo, Lund, Sweden; [Hansson, Oskar] Skane Univ Hosp, Memory Clin, Skane, Sweden	University of Geneva; University of Geneva; Lund University; Lund University; Skane University Hospital	Frisoni, GB (corresponding author), Univ Geneva, Ctr Memoire, CH-1205 Geneva, Switzerland.; Frisoni, GB (corresponding author), Univ Hosp, CH-1205 Geneva, Switzerland.	giovanni.frisoni@hcuge.ch	Hansson, Oskar/A-7134-2013; Frisoni, Giovanni B./K-1360-2016; Frisoni, Giovanni/K-1360-2016	Hansson, Oskar/0000-0001-8467-7286; Frisoni, Giovanni B./0000-0002-6419-1753; Frisoni, Giovanni/0000-0001-7075-7082				Carmona-Iragui M, 2021, LANCET NEUROL, V20, P605, DOI 10.1016/S1474-4422(21)00129-0; Cullen NC, 2020, ANN CLIN TRANSL NEUR, V7, P1661, DOI 10.1002/acn3.51158; Fagan AM, 2021, LANCET NEUROL, V20, P615, DOI 10.1016/S1474-4422(21)00139-3; Mattsson N, 2019, JAMA NEUROL, V76, P791, DOI 10.1001/jamaneurol.2019.0765; Palmqvist S, 2020, JAMA-J AM MED ASSOC, V324, P772, DOI 10.1001/jama.2020.12134; Palmqvist S, 2016, BRAIN, V139, P1226, DOI 10.1093/brain/aww015; Schindler SE, 2019, NEUROLOGY, V93, pE1647, DOI 10.1212/WNL.0000000000008081; Verberk IMW, 2021, LANCET HEALTH LONGEV, V2, pE87, DOI 10.1016/S2666-7568(20)30061-1	8	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2021	20	8					586	587		10.1016/S1474-4422(21)00198-8	http://dx.doi.org/10.1016/S1474-4422(21)00198-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP6CG	34302774				2022-12-18	WOS:000677684700003
J	Greenberg, SM				Greenberg, Steven M.			Cerebral microbleeds and prediction of intracranial haemorrhage	LANCET NEUROLOGY			English	Editorial Material							METAANALYSIS; WARFARIN; STROKE		[Greenberg, Steven M.] Massachusetts Gen Hosp, Ctr Stroke Res, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Greenberg, SM (corresponding author), Massachusetts Gen Hosp, Ctr Stroke Res, Boston, MA 02114 USA.	sgreenberg@mgh.harvard.edu						Best JG, 2021, LANCET NEUROL, V20, P294, DOI 10.1016/S1474-4422(21)00024-7; Fang MC, 2007, AM J MED, V120, P700, DOI 10.1016/j.amjmed.2006.07.034; Jaakkola S, 2018, AM J CARDIOL, V121, P1182, DOI 10.1016/j.amjcard.2018.01.038; Katsanos AH, 2020, CIRCULATION, V142, P2371, DOI 10.1161/CIRCULATIONAHA.120.049768; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Salman RAS, 2019, LANCET, V393, P2613, DOI 10.1016/S0140-6736(19)30840-2; Schultz AP, 2019, ANN NEUROL, V86, P616, DOI 10.1002/ana.25560; van Opstal AM, 2017, LANCET NEUROL, V16, P115, DOI 10.1016/S1474-4422(16)30346-5; Zahuranec DB, 2014, NEUROLOGY, V82, P2180, DOI 10.1212/WNL.0000000000000519; Zhu WG, 2017, INT J CARDIOL, V227, P436, DOI 10.1016/j.ijcard.2016.11.015	10	3	3	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					252	+		10.1016/S1474-4422(21)00065-X	http://dx.doi.org/10.1016/S1474-4422(21)00065-X			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33743229				2022-12-18	WOS:000630325700007
J	Ziai, WC; Al-Kawaz, M				Ziai, Wendy C.; Al-Kawaz, Mais			Blood pressure management after endovascular therapy	LANCET NEUROLOGY			English	Editorial Material							THROMBECTOMY		[Ziai, Wendy C.; Al-Kawaz, Mais] Johns Hopkins Univ, Dept Neurol, Div Neurocrit Care, Baltimore, MD 21287 USA	Johns Hopkins University	Ziai, WC (corresponding author), Johns Hopkins Univ, Dept Neurol, Div Neurocrit Care, Baltimore, MD 21287 USA.	weziai@jhmi.edu						Anadani M, 2019, STROKE, V50, P2448, DOI 10.1161/STROKEAHA.118.024687; Chang JY, 2019, EUR NEUROL, V81, P216, DOI 10.1159/000502519; de Havenon A, 2018, STROKE, V49, P1981, DOI 10.1161/STROKEAHA.118.022133; Delgado-Mederos R, 2008, NEUROLOGY, V71, P552, DOI 10.1212/01.wnl.0000318294.36223.69; Maier B, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.573382; Matusevicius M, 2020, STROKE, V51, P519, DOI 10.1161/STROKEAHA.119.026914; Mazighi M, 2021, LANCET NEUROL, V20, P265, DOI 10.1016/S1474-4422(20)30483-X; Petersen NH, 2020, STROKE, V51, P914, DOI 10.1161/STROKEAHA.119.026596; Qureshi AI, 2016, NEW ENGL J MED, V375, P1033, DOI 10.1056/NEJMoa1603460; van Kranendonk KR, 2019, J NEUROINTERV SURG, V11, P464, DOI 10.1136/neurintsurg-2018-014141	10	3	3	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					248	249		10.1016/S1474-4422(21)00058-2	http://dx.doi.org/10.1016/S1474-4422(21)00058-2		MAR 2021	2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33647245				2022-12-18	WOS:000630325700004
J	Zerr, I				Zerr, Inga			RT-QuIC for detection of prodromal alpha-synucleinopathies	LANCET NEUROLOGY			English	Editorial Material									[Zerr, Inga] Georg August Univ, Dept Neurol, Univ Med Ctr, D-37075 Gottingen, Germany	University of Gottingen	Zerr, I (corresponding author), Georg August Univ, Dept Neurol, Univ Med Ctr, D-37075 Gottingen, Germany.	IngaZerr@med.uni-goettingen.de						Bongianni M, 2019, ANN CLIN TRANSL NEUR, V6, P2120, DOI 10.1002/acn3.50897; Candelise N, 2019, ANN NEUROL, V85, P691, DOI 10.1002/ana.25446; De Luca CMG, 2019, TRANSL NEURODEGENER, V8, DOI 10.1186/s40035-019-0164-x; Iranzo A, 2021, LANCET NEUROL, V20, P203, DOI 10.1016/S1474-4422(20)30449-X; Manne S, 2020, MOVEMENT DISORD, V35, P268, DOI 10.1002/mds.27907; Manne S, 2020, MOVEMENT DISORD, V35, P2230, DOI 10.1002/mds.28242; Rossi M, 2020, ACTA NEUROPATHOL, V140, P49, DOI 10.1007/s00401-020-02160-8; Sano K, 2018, MOL NEUROBIOL, V55, P3916, DOI 10.1007/s12035-017-0624-1; Shahnawaz M, 2020, NATURE, V578, P273, DOI 10.1038/s41586-020-1984-7; Wang ZR, 2021, JAMA NEUROL, V78, P30, DOI 10.1001/jamaneurol.2020.3311	10	3	3	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2021	20	3					165	+		10.1016/S1474-4422(21)00036-3	http://dx.doi.org/10.1016/S1474-4422(21)00036-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QK3CL	33609466				2022-12-18	WOS:000620258400004
J	[Anonymous]				[Anonymous]			Neurological burden and European investment: a disconnect	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					81	81		10.1016/S2215-0366(20)30462-4	http://dx.doi.org/10.1016/S2215-0366(20)30462-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	33484649	Green Published, hybrid			2022-12-18	WOS:000610201500003
J	Chen-Plotkin, AS				Chen-Plotkin, Alice S.			LRRK2 and survival in progressive supranuclear palsy	LANCET NEUROLOGY			English	Editorial Material									[Chen-Plotkin, Alice S.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Chen-Plotkin, AS (corresponding author), Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.	chenplot@pennmedicine.upenn.edu						Ali F, 2019, MOVEMENT DISORD, V34, P1144, DOI 10.1002/mds.27619; Diaz-Ortiz ME, 2020, TRENDS GENET, V36, P152, DOI 10.1016/j.tig.2019.12.002; Hoglinger GU, 2017, MOVEMENT DISORD, V32, P853, DOI 10.1002/mds.26987; Hoglinger GU, 2011, NAT GENET, V43, P699, DOI 10.1038/ng.859; Jabbari E, 2021, LANCET NEUROL, V20, P107, DOI 10.1016/S1474-4422(20)30394-X; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; STEELE JC, 1964, ARCH NEUROL-CHICAGO, V10, P333, DOI 10.1001/archneur.1964.00460160003001; Tolosa E, 2020, NAT REV NEUROL, V16, P97, DOI 10.1038/s41582-019-0301-2	8	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					83	84		10.1016/S1474-4422(20)30485-3	http://dx.doi.org/10.1016/S1474-4422(20)30485-3		JAN 2021	2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	33341148				2022-12-18	WOS:000610201500005
J	Cook, MJ				Cook, Mark J.			Advancing seizure forecasting from cyclical activity data	LANCET NEUROLOGY			English	Editorial Material							EPILEPSY; SYSTEM		[Cook, Mark J.] Univ Melbourne, Fac Med, Graeme Clark Inst, Melbourne, Vic 3010, Australia; [Cook, Mark J.] Univ Melbourne, Fac Engn, Graeme Clark Inst, Melbourne, Vic 3010, Australia	University of Melbourne; University of Melbourne	Cook, MJ (corresponding author), Univ Melbourne, Fac Med, Graeme Clark Inst, Melbourne, Vic 3010, Australia.; Cook, MJ (corresponding author), Univ Melbourne, Fac Engn, Graeme Clark Inst, Melbourne, Vic 3010, Australia.	markcook@unimelb.edu.au						Baud MO, 2019, EXP NEUROL, V315, P82, DOI 10.1016/j.expneurol.2019.02.006; BERCEL NA, 1964, ANN NY ACAD SCI, V117, P555, DOI 10.1111/j.1749-6632.1964.tb48206.x; Cook MJ, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00217; Cook MJ, 2013, LANCET NEUROL, V12, P563, DOI 10.1016/S1474-4422(13)70075-9; Durazzo TS, 2008, NEUROLOGY, V70, P1265, DOI 10.1212/01.wnl.0000308938.84918.3f; Goldenholz DM, 2017, EPILEPSY RES, V137, P145, DOI 10.1016/j.eplepsyres.2017.07.013; Karoly PJ, 2017, BRAIN, V140, P2169, DOI 10.1093/brain/awx173; Maturana MI, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15908-3; Proix T, 2021, LANCET NEUROL, V20, P127, DOI 10.1016/S1474-4422(20)30396-3; Quraishi IH, 2020, EPILEPSIA, V61, P138, DOI 10.1111/epi.16412	10	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					86	87		10.1016/S1474-4422(20)30414-2	http://dx.doi.org/10.1016/S1474-4422(20)30414-2		JAN 2021	2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	33341147				2022-12-18	WOS:000610201500007
J	Luigetti, M; Servidei, S				Luigetti, Marco; Servidei, Serenella			Patisiran in hereditary transthyretin-mediated amyloidosis	LANCET NEUROLOGY			English	Editorial Material									[Luigetti, Marco; Servidei, Serenella] Fdn Policlin Univ A Gemelli Ist Ricovero & Cura C, I-00168 Rome, Italy; [Luigetti, Marco; Servidei, Serenella] Univ Cattolica Sacro Cuore, Dipartimento Univ Neurosci, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Servidei, S (corresponding author), Fdn Policlin Univ A Gemelli Ist Ricovero & Cura C, I-00168 Rome, Italy.; Servidei, S (corresponding author), Univ Cattolica Sacro Cuore, Dipartimento Univ Neurosci, Rome, Italy.	serenella.servidei@unicatt.it	Servidei, Serenella/ABC-4262-2021	SERVIDEI, Serenella/0000-0001-8478-2799				Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153; Adams D, 2021, LANCET NEUROL, V20, P49, DOI 10.1016/S1474-4422(20)30368-9; Benson MD, 2018, NEW ENGL J MED, V379, P22, DOI 10.1056/NEJMoa1716793; Brannagan TH, 2020, EUR J NEUROL, V27, P1374, DOI 10.1111/ene.14285; Buxbaum JN, 2019, AMYLOID, V26, P10, DOI 10.1080/13506129.2018.1554563; Coelho T, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01399-4; Coelho T, 2013, J NEUROL, V260, P2802, DOI 10.1007/s00415-013-7051-7; Luigetti M, 2020, THER CLIN RISK MANAG, V16, P109, DOI 10.2147/TCRM.S219979; Richardson SJ, 2007, INT REV CYTOL, V258, P137, DOI 10.1016/S0074-7696(07)58003-4; van den Dorpel JJA, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01482-w	10	3	3	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					21	23		10.1016/S1474-4422(20)30397-5	http://dx.doi.org/10.1016/S1474-4422(20)30397-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33212064				2022-12-18	WOS:000600831400015
J	Motte, J; Gold, R				Motte, Jeremias; Gold, Ralf			High-dose biotin in multiple sclerosis:the end of the road	LANCET NEUROLOGY			English	Editorial Material									[Motte, Jeremias; Gold, Ralf] Ruhr Univ Bochum, Dept Neurol, St Josef Hosp, D-44791 Bochum, Germany	Ruhr University Bochum	Gold, R (corresponding author), Ruhr Univ Bochum, Dept Neurol, St Josef Hosp, D-44791 Bochum, Germany.	ralf.gold@rub.de						Birnbaum G, 2017, MULT SCLER RELAT DIS, V18, P141, DOI 10.1016/j.msard.2017.09.030; Cree BAC, 2020, LANCET NEUROL, V19, P988, DOI 10.1016/S1474-4422(20)30347-1; Demas A, 2020, NEUROL THER, V9, P181, DOI 10.1007/s40120-019-00175-2; Goldschmidt CH, 2020, NEUROTHERAPEUTICS, V17, P968, DOI 10.1007/s13311-020-00907-5; Kleine-Borgmann J, 2019, PAIN, V160, P2891, DOI 10.1097/j.pain.0000000000001683; Maillart E, 2019, NEUROLOGY, V92, P1060, DOI 10.1212/WNL.0000000000007576; Sedel F, 2016, NEUROPHARMACOLOGY, V110, P644, DOI 10.1016/j.neuropharm.2015.08.028; Sedel F, 2015, MULT SCLER RELAT DIS, V4, P159, DOI 10.1016/j.msard.2015.01.005; Tourbah A, 2016, MULT SCLER J, V22, P1719, DOI 10.1177/1352458516667568	9	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2020	19	12					965	966		10.1016/S1474-4422(20)30353-7	http://dx.doi.org/10.1016/S1474-4422(20)30353-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PG3EL	33222766				2022-12-18	WOS:000599622000003
J	[Anonymous]				[Anonymous]			Amid competing priorities, dementia must not be forgotten	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2020	20	9					685	685		10.1016/S1474-4422(21)00258-1	http://dx.doi.org/10.1016/S1474-4422(21)00258-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UK3MA	34418382	Bronze			2022-12-18	WOS:000691875800001
J	Launer, LJ				Launer, Lenore J.			Interrelationships among central insulin signalling, diabetes, and cognitive impairment	LANCET NEUROLOGY			English	Editorial Material							TYPE-2; DYSFUNCTION		[Launer, Lenore J.] NIA, Intramural Res Program, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Launer, LJ (corresponding author), NIA, Intramural Res Program, Baltimore, MD 21224 USA.	launerl@nia.nih.gov						Arnold SE, 2018, NAT REV NEUROL, V14, P168, DOI 10.1038/nrneurol.2017.185; Erus G, 2015, DIABETES CARE, V38, P97, DOI 10.2337/dc14-1196; Kullmann S, 2020, LANCET DIABETES ENDO, V8, P524, DOI 10.1016/S2213-8587(20)30113-3; Lewandowicz A, 2018, GERONTOL GERIATR MED, V4, DOI 10.1177/2333721418817396; Liu S, 2019, EXP NEUROL, V320, DOI 10.1016/j.expneurol.2019.113006; Punthakee Z, 2012, DIABETES CARE, V35, P787, DOI 10.2337/dc11-1855; Ruud J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15259; Srikanth V, 2020, LANCET DIABETES ENDO, V8, P535, DOI 10.1016/S2213-8587(20)30118-2; van Sloten TT, 2020, LANCET DIABETES ENDO, V8, P325, DOI 10.1016/S2213-8587(19)30405-X	9	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2020	19	8					640	642		10.1016/S1474-4422(20)30172-1	http://dx.doi.org/10.1016/S1474-4422(20)30172-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT8ZY	32445621				2022-12-18	WOS:000573228000006
J	Antonini, A				Antonini, Angelo			Health care for chronic neurological patients after COVID-19	LANCET NEUROLOGY			English	Editorial Material									[Antonini, Angelo] Univ Padua, Dept Neurosci, I-35138 Padua, Italy	University of Padua	Antonini, A (corresponding author), Univ Padua, Dept Neurosci, I-35138 Padua, Italy.	angelo3000@yahoo.com	Antonini, Angelo/H-9726-2019	Antonini, Angelo/0000-0003-1040-2807				Antonini A, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2767-4; Bloem BR, 2020, LANCET NEUROL, V19, P623, DOI 10.1016/S1474-4422(20)30064-8; Dorsey ER, 2016, MOVEMENT DISORD, V31, P1258, DOI 10.1002/mds.26744; Fasano A, MOV DISORD CLIN PRAC; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; McCartney M, 2020, LANCET, V395, P1248, DOI 10.1016/S0140-6736(20)30756-X; Nijkrake MJ, 2010, MOVEMENT DISORD, V25, P823, DOI 10.1002/mds.22813; Odin P, 2018, NPJ PARKINSON DIS, V4, DOI 10.1038/s41531-018-0051-7; Rompen L, 2020, J PARKINSON DIS, V10, P207, DOI 10.3233/JPD-191620; Webster P, 2020, LANCET	10	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2020	19	7					562	563		10.1016/S1474-4422(20)30157-5	http://dx.doi.org/10.1016/S1474-4422(20)30157-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MF5BW	32464102	Bronze, Green Published			2022-12-18	WOS:000545358600005
J	Jia, LP; Zhang, HL				Jia, Linpei; Zhang, Hongliang			Attention in subjective cognitive decline	LANCET NEUROLOGY			English	Letter									[Jia, Linpei] Capital Med Univ, Xuanwu Hosp, Dept Nephrol, Beijing, Peoples R China; [Zhang, Hongliang] Natl Nat Sci Fdn China, Dept Life Sci Natl Nat, Beijing 100085, Peoples R China	Capital Medical University; National Natural Science Foundation of China (NSFC)	Zhang, HL (corresponding author), Natl Nat Sci Fdn China, Dept Life Sci Natl Nat, Beijing 100085, Peoples R China.	drzhl@hotmail.com	Zhang, Hongliang/AAN-3077-2020; Jia, Linpei/J-3740-2019	Zhang, Hongliang/0000-0001-9205-5559; Jia, Linpei/0000-0003-0348-7814				Ballard C, 2001, ARCH NEUROL-CHICAGO, V58, P977, DOI 10.1001/archneur.58.6.977; Jessen F, 2020, LANCET NEUROL, V19, P271, DOI 10.1016/S1474-4422(19)30368-0; McDonough IM, 2019, YALE J BIOL MED, V92, P37; Posner MI, 2007, ANNU REV PSYCHOL, V58, P1, DOI 10.1146/annurev.psych.58.110405.085516; Rhodes S, 2018, ANN NY ACAD SCI, V1424, P52, DOI 10.1111/nyas.13652; Smart CM, 2014, BIOL PSYCHOL, V103, P144, DOI 10.1016/j.biopsycho.2014.08.016; Staub B, 2013, AGEING RES REV, V12, P459, DOI 10.1016/j.arr.2012.12.001	7	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2020	19	7					565	566		10.1016/S1474-4422(20)30186-1	http://dx.doi.org/10.1016/S1474-4422(20)30186-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MF5BW	32562676	Bronze			2022-12-18	WOS:000545358600007
J	Deuschl, G; Krack, P				Deuschl, Gunther; Krack, Paul			Intrepidly studying deep brain stimulation in patients with Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							SUBTHALAMIC NUCLEUS; MEDICAL THERAPY; MULTICENTER; DEVICE; TRIAL					g.deuschl@neurologie.uni-kiel.de	Deuschl, Gunther/A-7986-2010	Deuschl, Gunther/0000-0002-4176-9196; Krack, Paul/0000-0002-3508-7295				Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Kleiner-Fisman G, 2006, MOVEMENT DISORD, V21, pS290, DOI 10.1002/mds.20962; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; Krack P, 2019, MOVEMENT DISORD, V34, P1795, DOI 10.1002/mds.27860; Okun MS, 2012, LANCET NEUROL, V11, P140, DOI 10.1016/S1474-4422(11)70308-8; Schuepbach WMM, 2013, NEW ENGL J MED, V368, P610, DOI 10.1056/NEJMoa1205158; Timmermann L, 2015, LANCET NEUROL, V14, P693, DOI 10.1016/S1474-4422(15)00087-3; Vitek JL, 2020, LANCET NEUROL, V19, P491, DOI 10.1016/S1474-4422(20)30108-3; Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929; Williams A, 2010, LANCET NEUROL, V9, P581, DOI 10.1016/S1474-4422(10)70093-4	10	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2020	19	6					472	473		10.1016/S1474-4422(20)30138-1	http://dx.doi.org/10.1016/S1474-4422(20)30138-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6CK	32470409				2022-12-18	WOS:000544059200002
J	Burton, A				Burton, Adrian			Smartphones versus Parkinson's disease: i-PROGNOSIS	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					385	386		10.1016/S1474-4422(20)30115-0	http://dx.doi.org/10.1016/S1474-4422(20)30115-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32333892				2022-12-18	WOS:000573045100009
J	Fox, RJ				Fox, Robert J.			Feast or famine in multiple sclerosis therapeutics	LANCET NEUROLOGY			English	Editorial Material									[Fox, Robert J.] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Fox, RJ (corresponding author), Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH 44195 USA.	foxr@ccf.org						Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Chataway J, 2020, LANCET NEUROL, V19, P214, DOI 10.1016/S1474-4422(19)30485-5; Elliott C, 2019, BRAIN, V142, P2787, DOI 10.1093/brain/awz212; Fox RJ, 2018, NEW ENGL J MED, V379, P846, DOI 10.1056/NEJMoa1803583; Kappos L, 2018, LANCET, V391, P1263, DOI 10.1016/S0140-6736(18)30475-6; Khalil M, 2018, NAT REV NEUROL, V14, P577, DOI 10.1038/s41582-018-0058-z; Laursen JH, 2015, MULT SCLER J, V21, P1376, DOI 10.1177/1352458515603802; Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468; Vesterinen HM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117705	9	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					196	197		10.1016/S1474-4422(19)30487-9	http://dx.doi.org/10.1016/S1474-4422(19)30487-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	31981515	hybrid			2022-12-18	WOS:000514832700004
J	Pennell, PB				Pennell, Page B.			Unravelling the heterogeneity of epilepsy for optimal individualised treatment: advances in 2019	LANCET NEUROLOGY			English	Editorial Material									[Pennell, Page B.] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA; [Pennell, Page B.] Brigham & Womens Hosp, Div Epilepsy, 75 Francis St, Boston, MA 02115 USA; [Pennell, Page B.] Brigham & Womens Hosp, Div Womens Hlth, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Pennell, PB (corresponding author), Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA.; Pennell, PB (corresponding author), Brigham & Womens Hosp, Div Epilepsy, 75 Francis St, Boston, MA 02115 USA.; Pennell, PB (corresponding author), Brigham & Womens Hosp, Div Womens Hlth, 75 Francis St, Boston, MA 02115 USA.	ppennell@bwh.harvard.edu						Abou-Khalil B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07524-z; Bell GS, 2017, J NEUROL NEUROSUR PS, V88, P933, DOI 10.1136/jnnp-2017-316211; Cuello Oderiz C, 2019, JAMA NEUROL, DOI [10.1001/jamaneurol.2019.1463, DOI 10.1001/JAMANEUROL.2019.1463]; de Bruijn MAAM, 2019, NEUROLOGY, V92, pE2185, DOI 10.1212/WNL.0000000000007475; Tomson T, 2019, NEUROLOGY, V93, pE831, DOI 10.1212/WNL.0000000000008001; World Health Organization, 2019, SPECIAL INITIATIVE M; Youngerman BE, 2018, EPILEPSIA, V59, P595, DOI 10.1111/epi.14004	7	3	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					8	+		10.1016/S1474-4422(19)30430-2	http://dx.doi.org/10.1016/S1474-4422(19)30430-2			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM	31839250				2022-12-18	WOS:000502286000008
J	van der Ende, EL; Meeter, LH; Poos, JM				van der Ende, E. L.; Meeter, L. H.; Poos, J. M.			Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study (vol 18, pg 1103, 2019)	LANCET NEUROLOGY			English	Correction																		van der Ende EL, 2019, LANCET NEUROL, V18, P1103, DOI 10.1016/S1474-4422(19)30354-0	1	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					E1	E1		10.1016/S1474-4422(19)30354-0	http://dx.doi.org/10.1016/S1474-4422(19)30354-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM		Green Submitted			2022-12-18	WOS:000502286000001
J	Wu, SM; Cheng, YJ; Wu, B; Liu, M				Wu, Simiao; Cheng, Yajun; Wu, Bo; Liu, Ming			Stroke research in 2019: towards optimising treatment and prevention	LANCET NEUROLOGY			English	Editorial Material							LARGE VESSEL OCCLUSION; STENT RETRIEVER; THROMBECTOMY; ASPIRATION		[Wu, Simiao; Cheng, Yajun; Wu, Bo; Liu, Ming] Sichuan Univ, West China Hosp, Dept Neurol, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China; [Liu, Ming] Sichuan Univ, West China Hosp, Ctr Cerebrovasc Dis, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China; [Liu, Ming] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Liu, M (corresponding author), Sichuan Univ, West China Hosp, Dept Neurol, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.; Liu, M (corresponding author), Sichuan Univ, West China Hosp, Ctr Cerebrovasc Dis, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.; Liu, M (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China.	wyplmh@hotmail.com	Cheng, Yajun/P-3637-2018	Cheng, Yajun/0000-0002-5227-9811; WU, SIMIAO/0000-0002-4557-7386	National Key Research and Development Program of China; Ministry of Science and Technology of China [2016YFC1300500-505]; Key Research and Development Program; Science and Technology Department of Sichuan Province [2017SZ0007]; Major International (Regional) Joint Research Project; National Natural Science Foundation of China [81870937, 81671146, 81620108009, 81701156]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYGD18009]; National Key Development Plan for Precision Medicine Research [2017YFC0910004]	National Key Research and Development Program of China; Ministry of Science and Technology of China(Ministry of Science and Technology, China); Key Research and Development Program; Science and Technology Department of Sichuan Province; Major International (Regional) Joint Research Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University; National Key Development Plan for Precision Medicine Research	ML has received grants from the National Key Research and Development Program of China, the Ministry of Science and Technology of China (2016YFC1300500-505), the Key Research and Development Program, the Science and Technology Department of Sichuan Province (2017SZ0007), the Major International (Regional) Joint Research Project, the National Natural Science Foundation of China (81620108009), and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD18009). SW has received grant from the National Natural Science Foundation of China (81701156). BW has received grants from the National Natural Science Foundation of China (81870937, 81671146) and the National Key Development Plan for Precision Medicine Research (2017YFC0910004). YC declares no conflict of interests.	Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973; Anderson CS, 2019, LANCET, V393, P877, DOI 10.1016/S0140-6736(19)30038-8; Campbell BCV, 2019, LANCET, V394, P139, DOI 10.1016/S0140-6736(19)31053-0; Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644; Ma H, 2019, NEW ENGL J MED, V380, P1795, DOI 10.1056/NEJMoa1813046; Moullaali TJ, 2019, LANCET NEUROL, V18, P857, DOI 10.1016/S1474-4422(19)30196-6; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; Roshandel G, 2019, LANCET, V394, P672, DOI 10.1016/S0140-6736(19)31791-X; Salman RAS, 2019, LANCET, V393, P2613, DOI 10.1016/S0140-6736(19)30840-2; Turk AS, 2019, LANCET, V393, P998, DOI 10.1016/S0140-6736(19)30297-1	10	3	3	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					2	3		10.1016/S1474-4422(19)30448-X	http://dx.doi.org/10.1016/S1474-4422(19)30448-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM	31839243				2022-12-18	WOS:000502286000004
J	Shakespeare, T; Watson, N				Shakespeare, Tom; Watson, Nicholas			Is a four-limb exoskeleton a step in the wrong direction?	LANCET NEUROLOGY			English	Editorial Material									[Shakespeare, Tom] London Sch Hyg & Trop Med, London WC1E 7HT, England; [Watson, Nicholas] Univ Glasgow, Strathclyde Ctr Disabil Res, Glasgow, Lanark, Scotland	University of London; London School of Hygiene & Tropical Medicine; University of Glasgow	Shakespeare, T (corresponding author), London Sch Hyg & Trop Med, London WC1E 7HT, England.	tom.shakespeare@lshtm.ac.uk						Benabid AL, 2019, LANCET NEUROL, V18, P1112, DOI 10.1016/S1474-4422(19)30321-7; Bickenbach J, 2014, INT PERSP SPIN CORD; Clifton S, 2018, DISABIL SOC, V33, P20, DOI 10.1080/09687599.2017.1379951; Karimi MT, 2012, EXTERNAL POWERED ORT; Kennedy P, 2010, SPINAL CORD, V48, P144, DOI 10.1038/sc.2009.90; Lifshutz J, 2004, NEUROSURG FOCUS, V16, P1, DOI DOI 10.3171/FOC.2004.16.1.6; Munro D., 1949, REHABILITATION STIFL; Oliver M., 1996, UNDERSTANDING DISABI	8	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1071	1072		10.1016/S1474-4422(19)30352-7	http://dx.doi.org/10.1016/S1474-4422(19)30352-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	31587954				2022-12-18	WOS:000495892200006
J	Ellis, T				Ellis, Terry			Exercise in Parkinson's disease: are we narrowing in on the essential elements?	LANCET NEUROLOGY			English	Editorial Material							PEOPLE; MOTOR		[Ellis, Terry] Boston Univ, Dept Phys Therapy & Athlet Training, Boston, MA 02215 USA	Boston University	Ellis, T (corresponding author), Boston Univ, Dept Phys Therapy & Athlet Training, Boston, MA 02215 USA.	tellis@bu.edu						Ellis T, 2018, J PARKINSON DIS, V8, pS95, DOI 10.3233/JPD-181489; Ellis TD, 2019, PHYS THER, V99, P203, DOI 10.1093/ptj/pzy131; Fang XX, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.2421; Mak MK, 2017, NAT REV NEUROL, V13, P689, DOI 10.1038/nrneurol.2017.128; Petzinger GM, 2013, LANCET NEUROL, V12, P716, DOI 10.1016/S1474-4422(13)70123-6; Schenkman M, 2018, JAMA NEUROL, V75, P219, DOI 10.1001/jamaneurol.2017.3517; van der Kolk NM, 2019, LANCET NEUROL, V18, P998, DOI 10.1016/S1474-4422(19)30285-6; Vassilev I, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0238-9	8	3	3	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2019	18	11					982	983		10.1016/S1474-4422(19)30348-5	http://dx.doi.org/10.1016/S1474-4422(19)30348-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JC8HI	31521531				2022-12-18	WOS:000489517000003
J	Floel, A				Floeel, Agnes			Computerised speech and language therapy in post-stroke aphasia	LANCET NEUROLOGY			English	Editorial Material							STROKE; COMMUNICATION; MOTOR; CARE		[Floeel, Agnes] Univ Med Greifswald, Dept Neurol, D-17475 Greifswald, Germany	Greifswald Medical School	Floel, A (corresponding author), Univ Med Greifswald, Dept Neurol, D-17475 Greifswald, Germany.	agnes.floeel@uni-greifswald.de	Zhang, Nan/GZL-9061-2022					Brady MC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub4; Breitenstein C, 2017, LANCET, V389, P1528, DOI 10.1016/S0140-6736(17)30067-3; Doesborgh SJC, 2004, STROKE, V35, P141, DOI 10.1161/01.STR.0000105460.52928.A6; Ellis C, 2012, STROKE, V43, P1429, DOI 10.1161/STROKEAHA.111.647339; Engelter ST, 2006, STROKE, V37, P1379, DOI 10.1161/01.STR.0000221815.64093.8c; Floel A, 2014, NEUROIMAGE, V85, P934, DOI 10.1016/j.neuroimage.2013.05.098; Meinzer M, 2016, BRAIN, V139, P1152, DOI 10.1093/brain/aww002; Palmer R, 2019, LANCET NEUROL, V18, P821, DOI 10.1016/S1474-4422(19)30192-9; Stahl B, 2016, CORTEX, V85, P90, DOI 10.1016/j.cortex.2016.09.021; Wallace SJ, 2019, INT J STROKE, V14, P180, DOI 10.1177/1747493018806200	10	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2019	18	9					806	807		10.1016/S1474-4422(19)30199-1	http://dx.doi.org/10.1016/S1474-4422(19)30199-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IO1IZ	31397279	hybrid			2022-12-18	WOS:000479136100004
J	Han, XY; Zhou, HX				Han, Xueyan; Zhou, Huixuan			Monitoring traumatic brain injury in China	LANCET NEUROLOGY			English	Letter									[Han, Xueyan] Chinese Acad Med Sci, Sch Publ Hlth, Beijing, Peoples R China; [Han, Xueyan] Peking Union Med Coll, Beijing, Peoples R China; [Zhou, Huixuan] Beijing Sport Univ, Sch Sport Sci, Beijing 100084, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Beijing Sport University	Zhou, HX (corresponding author), Beijing Sport Univ, Sch Sport Sci, Beijing 100084, Peoples R China.	chouhuixuan@live.cn	Han, Xueyan/AAV-1142-2021; Zhou, Huixuan/GRY-5023-2022					Clark David E, 2018, Inj Epidemiol, V5, P11, DOI 10.1186/s40621-018-0149-8; Jiang JY, 2019, LANCET NEUROL, V18, P286, DOI 10.1016/S1474-4422(18)30469-1; National Health Commission, 2018, 2017 NAT REP SERV QU; Saran R, 2017, AM J KIDNEY DIS, V69, P713, DOI 10.1053/j.ajkd.2017.04.008	4	3	4	3	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2019	18	9					813	813		10.1016/S1474-4422(19)30237-6	http://dx.doi.org/10.1016/S1474-4422(19)30237-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IO1IZ	31397282	Bronze			2022-12-18	WOS:000479136100008
J	Popkirov, S; Baguley, DM; Carson, AJ; Brown, RJ; Stone, J				Popkirov, Stoyan; Baguley, David M.; Carson, Alan J.; Brown, Richard J.; Stone, Jon			The neurology of the Cuban "sonic attacks"	LANCET NEUROLOGY			English	Editorial Material													Stone, Jon/C-3119-2014	Stone, Jon/0000-0001-9829-8092					0	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2019	18	9					817	818		10.1016/S1474-4422(19)30246-7	http://dx.doi.org/10.1016/S1474-4422(19)30246-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IO1IZ	31279746				2022-12-18	WOS:000479136100012
J	Schmidt, J				Schmidt, Jens			Endpoint choice for inclusion body myositis: a step too far?	LANCET NEUROLOGY			English	Editorial Material									[Schmidt, Jens] Univ Med Ctr Gottingen, Neuromuscular Ctr, Muscle Immunobiol Grp, Dept Neurol, D-37075 Gottingen, Germany	University of Gottingen	Schmidt, J (corresponding author), Univ Med Ctr Gottingen, Neuromuscular Ctr, Muscle Immunobiol Grp, Dept Neurol, D-37075 Gottingen, Germany.	j.schmidt@gmx.org	Schmidt, Jens/B-5791-2013					Amato AA, 2014, NEUROLOGY, V83, P2239, DOI 10.1212/WNL.0000000000001070; Bohannon RW, 2017, J EVAL CLIN PRACT, V23, P377, DOI 10.1111/jep.12629; Espinosa-Ortega HF, 2017, CURR OPIN RHEUMATOL, V29, P591, DOI 10.1097/BOR.0000000000000433; Hanna MG, 2019, LANCET NEUROL, V18, P834, DOI 10.1016/S1474-4422(19)30200-5; Lach-Trifilieff E, 2014, MOL CELL BIOL, V34, P606, DOI 10.1128/MCB.01307-13; Miller FW, 2018, NAT REV RHEUMATOL, V14, P255, DOI 10.1038/nrrheum.2018.48; Morosetti R, 2006, P NATL ACAD SCI USA, V103, P16995, DOI 10.1073/pnas.0603386103; Rooks D, 2017, J AM GERIATR SOC, V65, P1988, DOI 10.1111/jgs.14927; Schmidt K, 2017, CURR OPIN RHEUMATOL, V29, P632, DOI 10.1097/BOR.0000000000000436	9	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2019	18	9					807	808		10.1016/S1474-4422(19)30279-0	http://dx.doi.org/10.1016/S1474-4422(19)30279-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IO1IZ	31397280				2022-12-18	WOS:000479136100005
J	Polizzi, A; Gentile, AE; Taruscio, D				Polizzi, Agata; Gentile, Amalia Egle; Taruscio, Domenica			Competing to raise awareness of rare diseases	LANCET NEUROLOGY			English	Editorial Material													Gentile, Amalia Egle/A-6652-2015; Gentile, Amalia Egle/AAI-8245-2021	Gentile, Amalia Egle/0000-0001-6979-4046; Gentile, Amalia Egle/0000-0001-6979-4046					0	3	3	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2019	18	8					721	722		10.1016/S1474-4422(18)30437-X	http://dx.doi.org/10.1016/S1474-4422(18)30437-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IH7ZF	30447970	Bronze			2022-12-18	WOS:000474722800013
J	Schindlbeck, KA; Eidelberg, D				Schindlbeck, Katharina A.; Eidelberg, David			Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							ALPHA-SYNUCLEIN; TRANSPORTER; MUTATION		[Schindlbeck, Katharina A.; Eidelberg, David] Feinstein Inst Med Res, Ctr Neurosci, Manhasset, NY 11030 USA	Northwell Health	Eidelberg, D (corresponding author), Feinstein Inst Med Res, Ctr Neurosci, Manhasset, NY 11030 USA.	deidelbe@northwell.edu		Schindlbeck, Katharina/0000-0002-5643-556X				Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Kim CY, 2017, SEMIN NEUROL, V37, P135, DOI 10.1055/s-0037-1601567; Knudsen K, 2018, LANCET NEUROL, V17, P618, DOI 10.1016/S1474-4422(18)30162-5; Liu SY, 2018, LANCET NEUROL, V17, P309, DOI 10.1016/S1474-4422(18)30032-2; Pagano G, 2017, ANN NEUROL, V81, P171, DOI 10.1002/ana.24859; Papadimitriou D, 2016, MOVEMENT DISORD, V31, P1226, DOI 10.1002/mds.26615; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Wile DJ, 2017, LANCET NEUROL, V16, P351, DOI 10.1016/S1474-4422(17)30056-X; Wilson H, 2019, LANCET NEUROL, V18, P748, DOI 10.1016/S1474-4422(19)30140-1	10	3	3	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2019	18	8					713	714		10.1016/S1474-4422(19)30242-X	http://dx.doi.org/10.1016/S1474-4422(19)30242-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IH7ZF	31229471				2022-12-18	WOS:000474722800006
J	Burton, A				Burton, Adrian			Meeting the neurological needs of refugees and other forcibly displaced people	LANCET NEUROLOGY			English	Editorial Material								Awareness of the particular neurological problems that can affect refugees and internally displaced people can expedite diagnosis, and cultural sensitivity and empathy can expedite treatment. But where are the guidelines to help? Adrian Burton investigates.											0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2019	18	6					524	525		10.1016/S1474-4422(19)30164-4	http://dx.doi.org/10.1016/S1474-4422(19)30164-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HY7RQ	31060946				2022-12-18	WOS:000468334100010
J	Corvol, JC; Buee, L				Corvol, Jean-Christophe; Buee, Luc			A new step towards targeting tau	LANCET NEUROLOGY			English	Editorial Material							PROGRESSIVE SUPRANUCLEAR PALSY; DIAGNOSTIC-CRITERIA		[Corvol, Jean-Christophe] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Inserm,CNRS,Inst Cerveau & Moelle,Dept Neurol, F-75013 Paris, France; [Buee, Luc] Univ Lille, CHU Lille, LabEx DISTALZ, Inserm,Lille Neurosci & Cognit,Team Alzheimer & T, Lille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille	Corvol, JC (corresponding author), Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Inserm,CNRS,Inst Cerveau & Moelle,Dept Neurol, F-75013 Paris, France.	jean-christophe.corvol@aphp.fr	Corvol, Jean-Christophe/F-2124-2017; BUEE, Luc/B-3126-2010	Corvol, Jean-Christophe/0000-0001-7325-0199; BUEE, Luc/0000-0002-6261-4230				Albert M, 2019, BRAIN, V142, P1736, DOI 10.1093/brain/awz100; Bensimon G, 2009, BRAIN, V132, P156, DOI 10.1093/brain/awn291; Boxer AL, 2019, LANCET NEUROL, V18, P549, DOI 10.1016/S1474-4422(19)30139-5; Boxer AL, 2017, LANCET NEUROL, V16, P552, DOI 10.1016/S1474-4422(17)30157-6; Boxer AL, 2014, LANCET NEUROL, V13, P676, DOI 10.1016/S1474-4422(14)70088-2; Cope TE, 2018, BRAIN, V141, P550, DOI 10.1093/brain/awx347; Derisbourg M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09659; Qureshi Irfan A, 2018, Alzheimers Dement (N Y), V4, P746, DOI 10.1016/j.trci.2018.10.007; Sato C, 2018, NEURON, V97, P1284, DOI 10.1016/j.neuron.2018.02.015; Tolosa E, 2014, MOVEMENT DISORD, V29, P470, DOI 10.1002/mds.25824	10	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2019	18	6					517	518		10.1016/S1474-4422(19)30161-9	http://dx.doi.org/10.1016/S1474-4422(19)30161-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HY7RQ	31122487				2022-12-18	WOS:000468334100005
J	Brainin, M				Brainin, Michael			Stroke epidemiology in China: which are the next steps?	LANCET NEUROLOGY			English	Editorial Material							PREVENTION		[Brainin, Michael] Danube Univ Krems, Dept Clin Neurosci & Prevent Med, A-3500 Krems, Austria	Danube University Krems	Brainin, M (corresponding author), Danube Univ Krems, Dept Clin Neurosci & Prevent Med, A-3500 Krems, Austria.	michael.brainin@donau-uni.ac.at						Feigin VL, 2018, NEW ENGL J MED, V379, P2429, DOI 10.1056/NEJMoa1804492; Feigin VL, 2016, NAT REV NEUROL, V12, P501, DOI 10.1038/nrneurol.2016.107; Feigin VL, 2016, LANCET NEUROL, V15, P913, DOI 10.1016/S1474-4422(16)30073-4; Johnson CO, 2019, LANCET NEUROL, V18, P439, DOI 10.1016/S1474-4422(19)30034-1; Lindsay P, 2014, INT J STROKE, V9, P4, DOI 10.1111/ijs.12371; Wang WZ, 2017, CIRCULATION, V135, P759, DOI 10.1161/CIRCULATIONAHA.116.025250; Wu SM, 2019, LANCET NEUROL, V18, P394, DOI 10.1016/S1474-4422(18)30500-3	7	3	9	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2019	18	4					325	+		10.1016/S1474-4422(19)30023-7	http://dx.doi.org/10.1016/S1474-4422(19)30023-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HO7ZR	30878096				2022-12-18	WOS:000461169400007
J	DeAngelis, LM				DeAngelis, Lisa M.			Global consequences of malignant CNS tumours: a call to action	LANCET NEUROLOGY			English	Editorial Material							NERVOUS-SYSTEM TUMORS; BRAIN; ASSOCIATION; RISK		[DeAngelis, Lisa M.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	DeAngelis, LM (corresponding author), Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.	deangell@mskcc.org						Amirian ES, 2016, CANCER EPIDEM BIOMAR, V25, P282, DOI 10.1158/1055-9965.EPI-15-0847; Braganza MZ, 2012, NEURO-ONCOLOGY, V14, P1316, DOI 10.1093/neuonc/nos208; Leece R, 2017, NEURO-ONCOLOGY, V19, P1553, DOI 10.1093/neuonc/nox091; Melin BS, 2017, NAT GENET, V49, P789, DOI 10.1038/ng.3823; Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131; Patel AP, 2019, LANCET NEUROL, V18, P376, DOI 10.1016/S1474-4422(18)30468-X; Schubart JR, 2008, NEURO-ONCOLOGY, V10, P61, DOI 10.1215/15228517-2007-040	7	3	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2019	18	4					324	325		10.1016/S1474-4422(19)30083-3	http://dx.doi.org/10.1016/S1474-4422(19)30083-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HO7ZR	30797716	hybrid			2022-12-18	WOS:000461169400006
J	Banos, JE; Cambra-Badii, I; Guardiola, E				Banos, Josep-E; Cambra-Badii, Irene; Guardiola, Elena			A physician with autism in a TV series	LANCET NEUROLOGY			English	Letter									[Banos, Josep-E; Cambra-Badii, Irene; Guardiola, Elena] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona 08003, Spain; [Cambra-Badii, Irene] Univ Buenos Aires, Sch Psychol, Buenos Aires, DF, Argentina	Pompeu Fabra University; University of Buenos Aires	Banos, JE (corresponding author), Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona 08003, Spain.	josepeladi.banos@upf.edu	Banos, Josep-E/D-8118-2014; Badii, Irene Cambra/ABC-7779-2020	Badii, Irene Cambra/0000-0003-1233-3243; banos, josep-e/0000-0001-8202-6893				Lai MC, 2015, LANCET PSYCHIAT, V2, P1013, DOI 10.1016/S2215-0366(15)00277-1; Morgan Jules, 2019, Lancet Neurol, V18, P143, DOI 10.1016/S1474-4422(18)30236-9; Nordahl-Hansen A, 2018, J AUTISM DEV DISORD, V48, P635, DOI 10.1007/s10803-017-3390-z	3	3	5	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2018	17	10					844	844		10.1016/S1474-4422(18)30317-X	http://dx.doi.org/10.1016/S1474-4422(18)30317-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GT9LD	30264725	Bronze			2022-12-18	WOS:000444862200012
J	LeWitt, PA				LeWitt, Peter A.			At last, a randomised controlled trial of apomorphine infusion	LANCET NEUROLOGY			English	Editorial Material							PARKINSONS-DISEASE; SUBCUTANEOUS INFUSION; PHARMACOKINETICS; THERAPY		[LeWitt, Peter A.] Henry Ford Hosp, Dept Neurol, West Bloomfield, MI 48322 USA; [LeWitt, Peter A.] Wayne State Univ, Sch Med, Detroit, MI 48201 USA	Henry Ford Health System; Wayne State University	LeWitt, PA (corresponding author), Henry Ford Hosp, Dept Neurol, West Bloomfield, MI 48322 USA.; LeWitt, PA (corresponding author), Wayne State Univ, Sch Med, Detroit, MI 48201 USA.	plewitt1@hfhs.org	LeWitt, Peter/AAW-4988-2020		Acorda; Adamas; Biotie; Cavion; Intec; Lundbeck; NeuroDerm; The Michael J Fox Foundation for Parkinson's Research; Parkinson Study Group; Roche; Sunovion; US WorldMeds	Acorda; Adamas; Biotie; Cavion; Intec; Lundbeck(Lundbeck Corporation); NeuroDerm; The Michael J Fox Foundation for Parkinson's Research; Parkinson Study Group; Roche(Roche Holding); Sunovion; US WorldMeds	PAL has served as a consultant or advisor for Abide, Acorda, Biogen, Britannia, Cavion, Sunovion, Intec, Jazz, Merz, NeuroDerm, Pfizer, Sage, SynAgile, Titan, and US WorldMeds, and has received speaker honoraria from Acadia, Lundbeck, and US WorldMeds. He is compensated for services as editor-in-chief of Clinical Neuropharmacology. The Parkinson's Disease and Movement Disorders Program that PAL directs has received clinical research grant support for conducting clinical trials from Acorda, Adamas, Biotie, Cavion, Intec, Lundbeck, NeuroDerm, The Michael J Fox Foundation for Parkinson's Research, The Parkinson Study Group, Roche, Sunovion, and US WorldMeds.	Anderson E, 2011, PARKINSONISM RELAT D, V17, P587, DOI 10.1016/j.parkreldis.2011.03.014; Bhidayasiri R, 2015, CLIN NEUROPHARMACOL, V38, P89, DOI 10.1097/WNF.0000000000000082; Katzenschlager R, 2018, LANCET NEUROL, V17, P749, DOI 10.1016/S1474-4422(18)30239-4; Lees AJ, 2016, MENTORED MADMAN W BU; LeWitt PA, 2004, NEUROLOGY, V62, pS8, DOI 10.1212/WNL.62.6_suppl_4.S8; LeWitt PA, 2015, MOVEMENT DISORD, V30, P64, DOI 10.1002/mds.26082; Olanow CW, 2014, LANCET NEUROL, V13, P141, DOI 10.1016/S1474-4422(13)70293-X; Poewe W, 2000, MOVEMENT DISORD, V15, P789, DOI 10.1002/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H; STIBE C, 1987, LANCET, V1, P871; Wenzel K, 2014, EXPERT REV NEUROTHER, V14, P833, DOI 10.1586/14737175.2014.928202	10	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2018	17	9					732	733		10.1016/S1474-4422(18)30284-9	http://dx.doi.org/10.1016/S1474-4422(18)30284-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GQ3AO	30055904				2022-12-18	WOS:000441532100002
J	Macaron, G; Cohen, JA				Macaron, Gabrielle; Cohen, Jeffrey A.			Integrating multiple sclerosis guidelines into practice	LANCET NEUROLOGY			English	Editorial Material							PHARMACOLOGICAL-TREATMENT; ECTRIMS/EAN GUIDELINE; PEOPLE		[Macaron, Gabrielle; Cohen, Jeffrey A.] Cleveland Clin, Neurol Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cohen, JA (corresponding author), Cleveland Clin, Neurol Inst, Cleveland, OH 44195 USA.	cohenj@ccf.org			Biogen Fellowship Grant [6873-P-FEL]	Biogen Fellowship Grant	GM is supported by Biogen Fellowship Grant 6873-P-FEL. JAC reports personal fees from Adamas, Celgene, Convelo, EMD Serono, Mylan, Novartis, PendoPharm, and Synthon, outside the submitted work; and has served as a co-editor of Multiple Sclerosis Journal-Experimental, Translational and Clinical.	Armstrong MJ, 2018, NEUROL-CLIN PRACT, V8, P58, DOI 10.1212/CPJ.0000000000000417; Comi G, 2017, LANCET, V389, P1347, DOI 10.1016/S0140-6736(16)32388-1; Graham R, 2011, CLINICAL PRACTICE GUIDELINES WE CAN TRUST, P1; Montalban X, 2018, EUR J NEUROL, V25, P215, DOI 10.1111/ene.13536; Montalban X, 2018, MULT SCLER J, V24, P96, DOI 10.1177/1352458517751049; Powers JH, 2011, ARCH INTERN MED, V171, P15, DOI 10.1001/archinternmed.2010.453; Rae-Grant A, 2018, NEUROLOGY, V90, P789, DOI 10.1212/WNL.0000000000005345; Rae-Grant A, 2018, NEUROLOGY, V90, P777, DOI 10.1212/WNL.0000000000005347; Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216; Sormani MP, 2017, LANCET NEUROL, V16, P252, DOI 10.1016/S1474-4422(17)30021-2	10	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2018	17	8					658	660		10.1016/S1474-4422(18)30248-5	http://dx.doi.org/10.1016/S1474-4422(18)30248-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN5BH	30033052				2022-12-18	WOS:000439057500006
J	Mefford, HC				Mefford, Heather C.			Expanding role of GABA(A) receptors in generalised epilepsies	LANCET NEUROLOGY			English	Editorial Material							MUTATION; TWINS		[Mefford, Heather C.] Univ Washington, Dept Pediat, Div Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Mefford, HC (corresponding author), Univ Washington, Dept Pediat, Div Med Genet, Seattle, WA 98195 USA.	hmefford@uw.edu						Allen AS, 2017, LANCET NEUROL, V16, P135, DOI 10.1016/S1474-4422(16)30359-3; Anney RJL, 2014, LANCET NEUROL, V13, P893, DOI 10.1016/S1474-4422(14)70171-1; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Berkovic SF, 1998, ANN NEUROL, V43, P435, DOI 10.1002/ana.410430405; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; de Kovel CGF, 2010, BRAIN, V133, P23, DOI 10.1093/brain/awp262; May P, 2018, LANCET NEUROL, V17, P699, DOI 10.1016/S1474-4422(18)30215-1; Vadlamudi L, 2004, NEUROLOGY, V62, P1127, DOI 10.1212/01.WNL.0000118201.89498.48	8	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2018	17	8					657	U3		10.1016/S1474-4422(18)30252-7	http://dx.doi.org/10.1016/S1474-4422(18)30252-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN5BH	30033051				2022-12-18	WOS:000439057500005
J	Schwamm, LH				Schwamm, Lee H.			The communicable nature of non-communicable diseases	LANCET NEUROLOGY			English	Letter							SOCIAL NETWORK		[Schwamm, Lee H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Schwamm, LH (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.	lschwamm@mgh.harvard.edu			US National Institute of Neurological Disorders and Stroke; Massachusetts Department of Public Health and LifeImage; Lundbeck; Medtronic; Penumbra; Genentech	US National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Massachusetts Department of Public Health and LifeImage; Lundbeck(Lundbeck Corporation); Medtronic(Medtronic); Penumbra; Genentech(Roche HoldingGenentech)	LHS declares grants from the US National Institute of Neurological Disorders and Stroke, personal fees from the Massachusetts Department of Public Health and LifeImage for consultancy, personal fees from Lundbeck for serving on a steering committee, personal fees from Medtronic for serving on a steering committee and organising a symposium, personal fees from Penumbra for serving on a data safety monitoring board, and alteplase and per patient fees from Genentech paid to his institution during a study (MR WITNESS, ClinicalTrials.gov number NCT01282242).	Aral S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14753; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P621; Christakis NA, 2007, NEW ENGL J MED, V357, P370, DOI 10.1056/NEJMsa066082; Ogunmoroti O, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003954; Schwamm LH, 2014, HEALTH AFFAIR, V33, P200, DOI 10.1377/hlthaff.2013.1021	5	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2018	17	8					665	665		10.1016/S1474-4422(18)30216-3	http://dx.doi.org/10.1016/S1474-4422(18)30216-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN5BH	30033057	Bronze			2022-12-18	WOS:000439057500010
J	Brooks, BR; Bravver, EK; Langford, VL; Bockenek, WL; Lindblom, SS				Brooks, Benjamin Rix; Bravver, Elena K.; Langford, Velma L.; Bockenek, William L.; Lindblom, Scott S.			Stage of prolonged survival in ALS	LANCET NEUROLOGY			English	Letter									[Brooks, Benjamin Rix; Bravver, Elena K.; Langford, Velma L.] Univ N Carolina, Sch Med, Atrium Hlth, Neurosci Inst, Charlotte, NC 28203 USA; [Bockenek, William L.] Univ N Carolina, Sch Med, Atrium Hlth, Dept Phys Med & Rehabil, Charlotte, NC 28203 USA; [Lindblom, Scott S.] Univ N Carolina, Sch Med, Atrium Hlth, Dept Internal Med, Charlotte, NC 28203 USA	University of North Carolina; University of North Carolina Charlotte; University of North Carolina; University of North Carolina Charlotte; University of North Carolina; University of North Carolina Charlotte	Brooks, BR (corresponding author), Univ N Carolina, Sch Med, Atrium Hlth, Neurosci Inst, Charlotte, NC 28203 USA.	benjamin.brooks@carolinashealthcare.org		Jones, Ashley/0000-0003-0470-0058; Al Khleifat, Ahmad/0000-0002-7406-9831				Fang T, 2018, LANCET NEUROL, V17, P416, DOI 10.1016/S1474-4422(18)30054-1; Langford VL, 2014, 25 INT S ALS MND BRU, pCW11; Satkunendrarajah K, 2016, EXP NEUROL, V276, P59, DOI 10.1016/j.expneurol.2015.09.011; Seibold H, 2018, STAT METHODS MED RES, V27, P3104, DOI 10.1177/0962280217693034; Vitacca M, 2018, EUR J NEUROL, V25, P556, DOI 10.1111/ene.13547	5	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2018	17	7					579	579		10.1016/S1474-4422(18)30207-2	http://dx.doi.org/10.1016/S1474-4422(18)30207-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GK8RP	29914701	Bronze			2022-12-18	WOS:000436495200009
J	Chaturvedi, S				Chaturvedi, Seemant			Is surveillance for restenosis justified after carotid revascularisation?	LANCET NEUROLOGY			English	Editorial Material									[Chaturvedi, Seemant] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA	University of Miami	Chaturvedi, S (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.	Schaturvedi@med.miami.edu						Bonati LH, 2018, LANCET NEUROL, V17, P587, DOI 10.1016/S1474-4422(18)30195-9; Chaturvedi S, 2016, NEUROLOGY, V87, P1; Inzitari D, 2000, NEW ENGL J MED, V342, P1693, DOI 10.1056/NEJM200006083422302; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Keyhani S, 2016, JAMA INTERN MED, V176, P626, DOI 10.1001/jamainternmed.2016.0678; Lal BK, 2008, J VASC SURG, V47, P63, DOI 10.1016/j.jvs.2007.09.038; Lal BK, 2012, LANCET NEUROL, V11, P755, DOI 10.1016/S1474-4422(12)70159-X; Zapata-Arriaza E, 2016, STROKE, V47, P2144, DOI 10.1161/STROKEAHA.116.012650	8	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2018	17	7					570	571		10.1016/S1474-4422(18)30199-6	http://dx.doi.org/10.1016/S1474-4422(18)30199-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GK8RP	29861140	hybrid			2022-12-18	WOS:000436495200002
J	Martin, R				Martin, Roland			Understanding risk of PML through multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; NATALIZUMAB		[Martin, Roland] Univ Zurich, Univ Hosp Zurich, Neurol Clin, Neuroimmunol & MS Res, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Martin, R (corresponding author), Univ Zurich, Univ Hosp Zurich, Neurol Clin, Neuroimmunol & MS Res, CH-8091 Zurich, Switzerland.	roland.martin@usz.ch						Biogen, MED INFORM; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Major E, 2018, LANCET NEUROL, V17, P467, DOI 10.1016/S1474-4422(18)30040-1; Major EO, 2010, ANNU REV MED, V61, P35, DOI 10.1146/annurev.med.080708.082655; Plavina T, 2014, ANN NEUROL, V76, P802, DOI 10.1002/ana.24286; Sospedra M, 2014, CLIN INFECT DIS, V59, P1588, DOI 10.1093/cid/ciu682; Tan CS, 2010, LANCET NEUROL, V9, P425, DOI 10.1016/S1474-4422(10)70040-5; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586	8	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2018	17	5					391	392		10.1016/S1474-4422(18)30122-4	http://dx.doi.org/10.1016/S1474-4422(18)30122-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GC7JA	29656736	Green Accepted			2022-12-18	WOS:000429968100007
J	Mitsumoto, H				Mitsumoto, Hiroshi			What if you knew the prognosis of your patients with ALS?	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; QUALITY STANDARDS SUBCOMMITTEE; PRACTICE PARAMETER UPDATE; MOTOR-NEURON DISEASE; AMERICAN ACADEMY; CARE; DIAGNOSIS; NEWS		[Mitsumoto, Hiroshi] Columbia Univ, Med Ctr, Eleanor & Lou Gehrig ALS Res Ctr, New York, NY 10032 USA	Columbia University	Mitsumoto, H (corresponding author), Columbia Univ, Med Ctr, Eleanor & Lou Gehrig ALS Res Ctr, New York, NY 10032 USA.	hm264@cumc.columbia.edu			US National Institutes of Health; Muscular Dystrophy Association; Spastic Paraplegia Foundation; US Centers for Disease Control and Prevention; Cytokinetics; Mitsubishi-Tanabe; Denali; Biohaven	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); Spastic Paraplegia Foundation; US Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Cytokinetics; Mitsubishi-Tanabe(Mitsubishi Tanabe Pharma Corporation); Denali; Biohaven	I report grants from the US National Institutes of Health, Muscular Dystrophy Association, Spastic Paraplegia Foundation, and the US Centers for Disease Control and Prevention; grants and personal fees from Cytokinetics; personal fees and other funding from Mitsubishi-Tanabe; and personal fees from Denali and Biohaven.	Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x; Aoun SM, 2016, J NEUROL SCI, V367, P368, DOI 10.1016/j.jns.2016.06.033; Aoun SM, 2016, AMYOTROPH LAT SCL FR, V17, P168, DOI 10.3109/21678421.2015.1111907; Jaspers K, 1953, DIE IDEE DES ARZTES; Miller RG, 2009, NEUROLOGY, V73, P1227, DOI 10.1212/WNL.0b013e3181bc01a4; Miller RG, 2009, NEUROLOGY, V73, P1218, DOI 10.1212/WNL.0b013e3181bc0141; Mitsumoto H, 2005, AMYOTROPH LATERAL SC, V6, P145, DOI 10.1080/14660820510028647; Mitsumoto H, 2007, JAMA-J AM MED ASSOC, V298, P207, DOI 10.1001/jama.298.2.207; Westeneng H-J, 2018, LANCET NEUROL	9	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2018	17	5					386	388		10.1016/S1474-4422(18)30111-X	http://dx.doi.org/10.1016/S1474-4422(18)30111-X			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GC7JA	29598921				2022-12-18	WOS:000429968100004
J	Bohnen, NI; Albin, RL				Bohnen, Nicolaas I.; Albin, Roger L.			Hypercholinergic activity in LRRK2 Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material									[Bohnen, Nicolaas I.; Albin, Roger L.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Bohnen, Nicolaas I.; Albin, Roger L.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; [Bohnen, Nicolaas I.; Albin, Roger L.] Univ Michigan, Udall Ctr, Ann Arbor, MI 48109 USA; [Bohnen, Nicolaas I.; Albin, Roger L.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Bohnen, NI (corresponding author), Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA.; Bohnen, NI (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.; Bohnen, NI (corresponding author), Univ Michigan, Udall Ctr, Ann Arbor, MI 48109 USA.; Bohnen, NI (corresponding author), VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA.	nbohnen@umich.edu			NINDS NIH HHS [P50 NS091856] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS091856] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams Jr, 2005, BRAIN, V128, P2777, DOI 10.1093/brain/awh607; Carnevale D., 2007, CNS & Neurological Disorders-Drug Targets, V6, P388; DeKosky ST, 2002, ANN NEUROL, V51, P145, DOI 10.1002/ana.10069; Kalia LV, 2015, JAMA NEUROL, V72, P100, DOI 10.1001/jamaneurol.2014.2704; Liu S- Y, 2018, LANCET NEUROL; Muller MLTM, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0377-9; Pont-Sunyer C, 2017, MOVEMENT DISORD, V32, P726, DOI 10.1002/mds.26964; Sarter M, 2014, EXP NEUROL, V257, P120, DOI 10.1016/j.expneurol.2014.04.032	8	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2018	17	4					290	291		10.1016/S1474-4422(18)30073-5	http://dx.doi.org/10.1016/S1474-4422(18)30073-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ3AO	29456160	Green Accepted			2022-12-18	WOS:000427458000002
J	Reiman, EM				Reiman, Eric M.			Long-term forgetting in preclinical Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							ASSOCIATION; DECLINE		[Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ 85006 USA	Banner Research; Banner Health; Banner Alzheimer's Institute	Reiman, EM (corresponding author), Banner Alzheimers Inst, Phoenix, AZ 85006 USA.	eric.reiman@bannerhealth.com						Caselli RJ, 2009, NEW ENGL J MED, V361, P255, DOI 10.1056/NEJMoa0809437; Donohue MC, 2017, JAMA-J AM MED ASSOC, V317, P2305, DOI 10.1001/jama.2017.6669; Fleisher AS, 2015, JAMA NEUROL, V72, P316, DOI 10.1001/jamaneurol.2014.3314; Harvey Philip D, 2017, Innov Clin Neurosci, V14, P30; Langbaum JB, 2014, ALZHEIMERS DEMENT, V10, P666, DOI 10.1016/j.jalz.2014.02.002; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Weston PSJ, 2018, LANCET NEUROL, V17, P123, DOI 10.1016/S1474-4422(17)30434-9	7	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2018	17	2					104	105		10.1016/S1474-4422(17)30458-1	http://dx.doi.org/10.1016/S1474-4422(17)30458-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT0PA	29413305	hybrid			2022-12-18	WOS:000422828500002
J	Dalakas, MC				Dalakas, Marinos C.			Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy	LANCET NEUROLOGY			English	Editorial Material							DISEASES; THERAPY; SAFETY		[Dalakas, Marinos C.] Thomas Jefferson Univ, Dept Neurol, Neuromuscular Div, Philadelphia, PA 19107 USA; [Dalakas, Marinos C.] Univ Athens, Med Sch, Dept Pathophysiol, Neuroimmunol Unit, Athens, Greece	Jefferson University; National & Kapodistrian University of Athens	Dalakas, MC (corresponding author), Thomas Jefferson Univ, Dept Neurol, Neuromuscular Div, Philadelphia, PA 19107 USA.; Dalakas, MC (corresponding author), Univ Athens, Med Sch, Dept Pathophysiol, Neuroimmunol Unit, Athens, Greece.	marinos.dalakas@jefferson.edu			Therapth Laboratory; Baxalta; Octapharma; Elsevier; Novartis; Hoffman La Roche; Dysimmune Diseases Foundation; Therapeutic Advances In Neurology; Genzyme; Merck Serono; Genesis; CSL Behring	Therapth Laboratory; Baxalta; Octapharma; Elsevier; Novartis(Novartis); Hoffman La Roche; Dysimmune Diseases Foundation; Therapeutic Advances In Neurology; Genzyme(Sanofi-AventisGenzyme Corporation); Merck Serono(Merck & Company); Genesis; CSL Behring	I report personal fees from Therapth Laboratory, Baxalta, Octapharma, Elsevier, Novartis, Hoffman La Roche, the Dysimmune Diseases Foundation, and Therapeutic Advances In Neurology and grants from Novartis, the Dysimmune Diseases Foundation, Genzyme, Merck Serono, Genesis, and CSL Behring.	Berger M, 2015, MUSCLE NERVE, V51, P315, DOI 10.1002/mus.24526; Berger M, 2011, CURR OPIN ALLERGY CL, V11, P532, DOI 10.1097/ACI.0b013e32834c22da; Dalakas MC, 2015, BBA-MOL BASIS DIS, V1852, P658, DOI 10.1016/j.bbadis.2014.06.013; Dalakas MC, 2011, NAT REV NEUROL, V7, P507, DOI 10.1038/nrneurol.2011.121; Dalakas MC, 2004, PHARMACOL THERAPEUT, V102, P177, DOI 10.1016/j.pharmthera.2004.04.002; Heimall J, 2016, J CLIN IMMUNOL, V36, P600, DOI 10.1007/s10875-016-0311-4; Hughes RAC, 2008, LANCET NEUROL, V7, P136, DOI 10.1016/S1474-4422(07)70329-0; van Schaik IN, 2017, LANCET NEUROL	8	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2018	17	1					20	21		10.1016/S1474-4422(17)30379-4	http://dx.doi.org/10.1016/S1474-4422(17)30379-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ7VE	29122522				2022-12-18	WOS:000418570500013
J	Scheffer, IE				Scheffer, Ingrid E.			A new classification and class 1 evidence transform clinical practice in epilepsy	LANCET NEUROLOGY			English	Editorial Material							ILAE COMMISSION; TERMINOLOGY; SEIZURES		[Scheffer, Ingrid E.] Univ Melbourne, Epilepsy Res Ctr, Florey Inst, Austin Hlth & Royal Childrens Hosp, Melbourne, Vic 3084, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne	Scheffer, IE (corresponding author), Univ Melbourne, Epilepsy Res Ctr, Florey Inst, Austin Hlth & Royal Childrens Hosp, Melbourne, Vic 3084, Australia.	scheffer@unimelb.edu.au	Scheffer, Ingrid E/G-1668-2013	Scheffer, Ingrid E/0000-0002-2311-2174	Australian National Health and Medical Research Council; US National Institutes of Health; UCB; GlaxoSmithKline; Sanofi; Eisai; Zogenix	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCB(UCB Pharma SA); GlaxoSmithKline(GlaxoSmithKline); Sanofi; Eisai(Eisai Co Ltd); Zogenix	I received grants from the Australian National Health and Medical Research Council and the US National Institutes of Health, speaker fees from UCB, GlaxoSmithKline, Sanofi, Eisai, and Zogenix, participated in an epilepsy consortium for GW Pharmaceuticals, I am the chair of a scientific advisory board for BioMarin and Nutricia; I receive royalties for a patent for diagnostic and therapeutic methods for epilepsy and mental retardation limited to females (WO/2009/086591), and hold a license for a patent for methods of treatment and diagnosis of epilepsy by detecting mutations in the SCN1A gene (WO/2006/133508).	Allen AS, 2017, LANCET NEUROL, V16, P135, DOI 10.1016/S1474-4422(16)30359-3; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Devinsky O, 2017, NEW ENGL J MED, V376, P2011, DOI 10.1056/NEJMoa1611618; Dwivedi R, 2017, NEW ENGL J MED, V377, P1639, DOI 10.1056/NEJMoa1615335; Fisher RS, 2017, EPILEPSIA, V58, P531, DOI 10.1111/epi.13671; Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709	7	3	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2018	17	1					7	8		10.1016/S1474-4422(17)30432-5	http://dx.doi.org/10.1016/S1474-4422(17)30432-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ7VE	29263009				2022-12-18	WOS:000418570500005
J	Cheong, WL; Reidpath, DD				Cheong, Wing Loong; Reidpath, Daniel D.			Palliative care in neurology	LANCET NEUROLOGY			English	Letter									[Cheong, Wing Loong] Monash Univ Malaysia, Sch Pharm, Subang Jaya 47500, Malaysia; [Reidpath, Daniel D.] Monash Univ Malaysia, Sch Med & Hlth Sci, Subang Jaya 47500, Malaysia	Monash University; Monash University Sunway; Monash University; Monash University Sunway	Cheong, WL (corresponding author), Monash Univ Malaysia, Sch Pharm, Subang Jaya 47500, Malaysia.	cheong.wingloong@monash.edu						[Anonymous], 2017, LANCET NEUROL, V16, P489, DOI 10.1016/S1474-4422(17)30176-X; [Anonymous], 2004, WORLD HLTH REP; Cecilia M, 2018, GLOBAL ATLAS PALLIAT; Eskandarieh S, 2016, NEUROEPIDEMIOLOGY, V46, P209, DOI 10.1159/000444019; Malaysia Hospis, 2016, PALL CAR NEEDS ASS M	5	3	3	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2017	16	11					868	868		10.1016/S1474-4422(17)30321-6	http://dx.doi.org/10.1016/S1474-4422(17)30321-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FJ3WM	29029842	Bronze			2022-12-18	WOS:000412663200009
J	Derfuss, T; Kappos, L				Derfuss, Tobias; Kappos, Ludwig			PML risk and natalizumab: the elephant in the room	LANCET NEUROLOGY			English	Editorial Material							OUTCOMES; SAFETY		[Kappos, Ludwig] Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Med, CH-4031 Basel, Switzerland; Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed, CH-4031 Basel, Switzerland; Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Clin Res, CH-4031 Basel, Switzerland; Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed Engn, CH-4031 Basel, Switzerland	University of Basel; University of Basel; University of Basel; University of Basel	Kappos, L (corresponding author), Univ Basel, Univ Hosp Basel, Neurol Clin & Policlin, Dept Med, CH-4031 Basel, Switzerland.	ludwig.kappos@usb.ch			Biogen; Genzyme; Novartis; Merck; Roche; Bayer Schering Pharma; European Union; Swiss National Foundation; Swiss MS Society; Actelion; Alkermes; Allergan; Almirall; Bayer; CSL Behring; df-mp legal agency; Excemed; GeNeuro SA; Mitsubishi Pharma; Pfizer; Receptos/Celgene; Sanofi-Aventis; Santhera; Swiss Multiple Sclerosis Society; Swiss National Research Foundation; Teva; UCB Pharma; Vianex; Neurostatus products	Biogen(Biogen); Genzyme(Sanofi-AventisGenzyme Corporation); Novartis(Novartis); Merck(Merck & Company); Roche(Roche Holding); Bayer Schering Pharma(Bayer AG); European Union(European Commission); Swiss National Foundation(Swiss National Science Foundation (SNSF)); Swiss MS Society; Actelion; Alkermes; Allergan(AbbVieAllergan); Almirall(Almirall); Bayer(Bayer AG); CSL Behring; df-mp legal agency; Excemed; GeNeuro SA; Mitsubishi Pharma; Pfizer(Pfizer); Receptos/Celgene(Bristol-Myers SquibbCelgene Corporation); Sanofi-Aventis(Sanofi-Aventis); Santhera; Swiss Multiple Sclerosis Society; Swiss National Research Foundation(Swiss National Science Foundation (SNSF)); Teva(Teva Pharmaceutical Industries); UCB Pharma(UCB Pharma SA); Vianex; Neurostatus products	TD serves on scientific advisory boards for Novartis, Merck, Biogen, Genzyme, GeNeuro, Mitsubishi Pharma, Roche, and Bayer Schering Pharma, has received funding for travel or speaker honoraria from Biogen, Genzyme, Novartis, Merck, Roche, and Bayer Schering Pharma, and receives research support from Biogen, Novartis, the European Union, the Swiss National Foundation, and the Swiss MS Society. LK's institution (University Hospital Basel) received in the last 3 years and used exclusively for research support and educational activities: Actelion, Alkermes, Allergan, Almirall, Bayer, Biogen, CSL Behring, df-mp legal agency, the European Union, Excemed, GeNeuro SA, Genzyme, Merck, Mitsubishi Pharma, Novartis, Pfizer, Receptos/Celgene, Roche, Sanofi-Aventis, Santhera, the Swiss Multiple Sclerosis Society, the Swiss National Research Foundation, Teva, UCB Pharma, and Vianex; and license fees for Neurostatus products.	[Anonymous], 2013, SEMIN NEUROL, V33, P26; Borchardt J, 2016, MULT SCLER RELAT DIS, V8, P145, DOI 10.1016/j.msard.2016.03.005; Campagnolo D, 2016, J NEUROVIROL, V22, P880, DOI 10.1007/s13365-016-0482-z; CAMPAGNOLO DI, 2016, NEUROLOGY, V87, pE25; Cutter GR, 2014, MULT SCLER J, V20, P1304, DOI 10.1177/1352458514531843; Ho PR, 2017, LANCET NEUROL; Kappos L, 2011, LANCET NEUROL, V10, P745, DOI 10.1016/S1474-4422(11)70149-1; Novak G, 2017, EXPERT OPIN DRUG SAF, V16, P501, DOI 10.1080/14740338.2017.1300251; O'Connor P, 2014, NEUROLOGY, V83, P78, DOI 10.1212/WNL.0000000000000541; Plavina T, 2014, ANN NEUROL, V76, P802, DOI 10.1002/ana.24286; Schwab N, 2012, NEUROLOGY, V78, P458, DOI 10.1212/WNL.0b013e3182478d4b; Schwab N, 2018, MULT SCLER J, V24, P563, DOI 10.1177/1352458517728814; Schwab N, 2017, NEUROLOGY, V88, P1197, DOI 10.1212/WNL.0000000000003739; Schwab N, 2013, NEUROLOGY, V81, P865, DOI 10.1212/WNL.0b013e3182a351fb; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; Vermersch P, 2011, NEUROLOGY, V76, P1697, DOI 10.1212/WNL.0b013e31821a446b; Villar LM, 2015, ANN NEUROL, V77, P447, DOI 10.1002/ana.24345	17	3	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2017	16	11					864	865		10.1016/S1474-4422(17)30335-6	http://dx.doi.org/10.1016/S1474-4422(17)30335-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FJ3WM	28969985				2022-12-18	WOS:000412663200006
J	Ouchi, Y				Ouchi, Yasuomi			Imaging neuroinflammation to monitor alpha-synucleinopathy	LANCET NEUROLOGY			English	Editorial Material							PARKINSONS-DISEASE; MICROGLIAL ACTIVATION		[Ouchi, Yasuomi] Hamamatsu Univ Sch Med, Preeminent Med Photon Educ & Res Ctr, Dept Biofunct Imaging, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Ouchi, Y (corresponding author), Hamamatsu Univ Sch Med, Preeminent Med Photon Educ & Res Ctr, Dept Biofunct Imaging, Hamamatsu, Shizuoka 4313192, Japan.	ouchi@hama-med.ac.jp			Japanese Ministry of Education Culture Sports Science and Technology; Japan Agency for Medical Research and Development; Takeda Science Foundation	Japanese Ministry of Education Culture Sports Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Takeda Science Foundation(Takeda Science Foundation (TSF))	I have received grants from the Japanese Ministry of Education Culture Sports Science and Technology, the Japan Agency for Medical Research and Development, and the Takeda Science Foundation.	Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; Goedert M, 2013, NAT REV NEUROL, V9, P13, DOI 10.1038/nrneurol.2012.242; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6; Iranzo A, 2016, LANCET NEUROL, V15, P405, DOI 10.1016/S1474-4422(16)00057-0; Ouchi Y, 2005, ANN NEUROL, V57, P168, DOI 10.1002/ana.20338; Ouchi Y, 2009, PARKINSONISM RELAT D, V15, P200; Stokholm MG, 2017, LANCET NEUROL; Terada T, 2016, ANN NUCL MED, V30, P579, DOI 10.1007/s12149-016-1099-2	9	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2017	16	10					763	764		10.1016/S1474-4422(17)30244-2	http://dx.doi.org/10.1016/S1474-4422(17)30244-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5PI	28684246				2022-12-18	WOS:000410379900003
J	Filippi, M; Rocca, MA				Filippi, Massimo; Rocca, Maria A.			Simvastatin and cognition in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							DISABILITY; THERAPY; TRIAL		[Filippi, Massimo] Univ Vita Salute San Raffaele, Inst Expt Neurol, Div Neurosci, Neuroimaging Res Unit, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Neurol, I-20132 Milan, Italy	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Filippi, M (corresponding author), Univ Vita Salute San Raffaele, Inst Expt Neurol, Div Neurosci, Neuroimaging Res Unit, I-20132 Milan, Italy.	filippi.massimo@hsr.it	Filippi, Massimo/K-1755-2018; Rocca, Maria Assunta/K-1619-2018	Filippi, Massimo/0000-0002-5485-0479; Rocca, Maria Assunta/0000-0003-2358-4320	Biogen Idec; Merk-Serono; Novartis; Teva Pharmaceutical Industries; Italian Ministry of Health; Fondazione Italiana Sclerosi Multipla; Cure PSP; Alzheimer's Drug Discovery Foundation; Jacques and Gloria Gossweiler Foundation (Switzerland); ARiSLA (Fondazione Italiana di Ricerca per la SLA)	Biogen Idec(Biogen); Merk-Serono; Novartis(Novartis); Teva Pharmaceutical Industries(Teva Pharmaceutical Industries); Italian Ministry of Health(Ministry of Health, Italy); Fondazione Italiana Sclerosi Multipla(Fondazione Italiana Sclerosi Multipla (FISM)); Cure PSP; Alzheimer's Drug Discovery Foundation; Jacques and Gloria Gossweiler Foundation (Switzerland); ARiSLA (Fondazione Italiana di Ricerca per la SLA)	MF is Editor-in-Chief of the Journal of Neurology; serves on a scientific advisory board for Teva Pharmaceutical Industries; has received compensation for consulting services or speaking activities, or both, from Biogen Idec, Merk-Serono, Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer's Drug Discovery Foundation, the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA). MAR has received speaker honoraria from Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, Teva, and Merk Serono; and receives research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla.	Chan D, 2017, LANCET NEUROL; Chataway J, 2014, LANCET, V383, P2213, DOI 10.1016/S0140-6736(13)62242-4; Marrie RA, 2010, NEUROLOGY, V74, P1041, DOI 10.1212/WNL.0b013e3181d6b125; Ontaneda D, 2017, LANCET, V389, P1357, DOI 10.1016/S0140-6736(16)31320-4; Pihl-Jensen G, 2015, CNS DRUGS, V29, P277, DOI 10.1007/s40263-015-0239-x; Rocca MA, 2015, LANCET NEUROL, V14, P302, DOI 10.1016/S1474-4422(14)70250-9; Sorensen PS, 2011, LANCET NEUROL, V10, P691, DOI 10.1016/S1474-4422(11)70144-2	7	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2017	16	8					572	+		10.1016/S1474-4422(17)30162-X	http://dx.doi.org/10.1016/S1474-4422(17)30162-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FA1LP	28600188	Green Submitted, hybrid			2022-12-18	WOS:000405201300002
J	French, JA				French, Jacqueline A.			Withdrawal of antiepileptic drugs: an individualised approach	LANCET NEUROLOGY			English	Editorial Material							EPILEPSY		[French, Jacqueline A.] NYU, Comprehens Epilepsy Ctr, New York, NY 10016 USA	New York University	French, JA (corresponding author), NYU, Comprehens Epilepsy Ctr, New York, NY 10016 USA.	jacqueline.french@nyumc.org	French, Jacqueline A/G-6795-2013	French, Jacqueline A/0000-0003-2242-8027	Eisai Medical Research; Lundbeck; Pfizer; UCB; Epilepsy Therapy Project; Epilepsy Research Foundation; Epilepsy Study Consortium; Accorda; Glaxo Smith-Kline; Impax; Johnson and Johnson; Marinus; Novartis; Sunovion; SK Life Sciences; Supernus Pharmaceuticals; Upsher-Smith; Vertex; LCGH	Eisai Medical Research(Eisai Co Ltd); Lundbeck(Lundbeck Corporation); Pfizer(Pfizer); UCB(UCB Pharma SA); Epilepsy Therapy Project; Epilepsy Research Foundation; Epilepsy Study Consortium; Accorda; Glaxo Smith-Kline(GlaxoSmithKline); Impax; Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Marinus; Novartis(Novartis); Sunovion; SK Life Sciences; Supernus Pharmaceuticals; Upsher-Smith; Vertex(Vertex Pharmaceuticals); LCGH	I have received grants from Eisai Medical Research, Lundbeck, Pfizer, UCB, the Epilepsy Therapy Project, the Epilepsy Research Foundation, and the Epilepsy Study Consortium, and other funds from Accorda, Eisai Medical Research, Glaxo Smith-Kline, Impax, Johnson and Johnson, Marinus, Novartis, Pfizer, Sunovion, SK Life Sciences, Supernus Pharmaceuticals, UCB, Upsher-Smith, Vertex, and LCGH. I am also president of the Epilepsy Study Consortium. All consulting is done on behalf of the Consortium, and fees are paid to the Consortium. NYU receives salary support from the Consortium.	Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; French JA, 2008, NEW ENGL J MED, V359, P166, DOI 10.1056/NEJMcp0801738; Lamberink HJ, 2017, LANCET NEUROL, DOI 10.1016/S1474-4422(17)30114-X; Schmidt D, 2017, SEIZURE-EUR J EPILEP, V44, P157, DOI 10.1016/j.seizure.2016.09.003; Strozzi I., 2015, COCHRANE DB SYST REV, V2	5	3	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2017	16	7					493	494		10.1016/S1474-4422(17)30136-9	http://dx.doi.org/10.1016/S1474-4422(17)30136-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX4MH	28499852				2022-12-18	WOS:000403208400004
J	Wokke, JH				Wokke, John H.			Another milestone in childhood spinal muscular atrophy	LANCET NEUROLOGY			English	Editorial Material									[Wokke, John H.] Univ Med Ctr Utrecht, Rudolf Magnus Brain Ctr, Dept Neurol & Neurosurg, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Wokke, JH (corresponding author), Univ Med Ctr Utrecht, Rudolf Magnus Brain Ctr, Dept Neurol & Neurosurg, NL-3508 GA Utrecht, Netherlands.	J.Wokke@umcutrecht.nl						Bertini E, 2017, LANCET NEUROL; Bordet T, 2010, PHARMACEUTICALS, V3, P345, DOI 10.3390/ph3020345; de Lattre C, 2013, ARCH PHYS MED REHAB, V94, P2218, DOI 10.1016/j.apmr.2013.04.001; Farrar MA, 2017, ANN NEUROL, V81, P355, DOI 10.1002/ana.24864; Finkel RS, 2016, LANCET, V388, P3017, DOI 10.1016/S0140-6736(16)31408-8; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Mercuri E, 2016, NEUROMUSCULAR DISORD, V26, P126, DOI 10.1016/j.nmd.2015.10.006; Mercuri E, 2012, LANCET NEUROL, V11, P443, DOI 10.1016/S1474-4422(12)70061-3; Wang CH, 2007, J CHILD NEUROL, V22, P1027, DOI 10.1177/0883073807305788; Wertz MH, 2016, HUM MOL GENET, V25, P2168, DOI 10.1093/hmg/ddw084	10	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2017	16	7					491	492		10.1016/S1474-4422(17)30121-7	http://dx.doi.org/10.1016/S1474-4422(17)30121-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX4MH	28460890				2022-12-18	WOS:000403208400003
J	Laforce, R; Verret, L; Poulin, S; Fortin, MP; Houde, M				Laforce, Robert, Jr.; Verret, Louis; Poulin, Stephane; Fortin, Marie-Pierre; Houde, Michele			Remi W Bouchard, a pioneer in behavioural neurology	LANCET NEUROLOGY			English	Letter									[Laforce, Robert, Jr.; Verret, Louis; Poulin, Stephane; Fortin, Marie-Pierre; Houde, Michele] Ctr Hosp Univ Quebec, Quebec City, PQ G1J 1Z4, Canada	Laval University	Laforce, R (corresponding author), Ctr Hosp Univ Quebec, Quebec City, PQ G1J 1Z4, Canada.	robert.laforce@fmed.ulaval.ca		Laforce, Robert Jr/0000-0002-2031-490X				BENSON DF, 1973, ARCH NEUROL-CHICAGO, V28, P339, DOI 10.1001/archneur.1973.00490230075011; BOUCHARD JP, 1978, CAN J NEUROL SCI, V5, P61, DOI 10.1017/S0317167100024793; Bouchard RW, 1979, L APHASIE, p266/76; Bouchard RW, 1996, CLIN DIAGNOSIS MANAG, p35/51; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2017	16	5					344	344		10.1016/S1474-4422(17)30094-7	http://dx.doi.org/10.1016/S1474-4422(17)30094-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ER4PH	28414648	Bronze			2022-12-18	WOS:000398782100011
J	Diener, HC				Diener, Hans-Christoph			The cause of stroke matters for secondary prevention	LANCET NEUROLOGY			English	Editorial Material							TRANSIENT ISCHEMIC ATTACK; ACUTE CORONARY SYNDROMES; CLOPIDOGREL; ASPIRIN; TICAGRELOR; RISK		[Diener, Hans-Christoph] Univ Duisburg Essen, Fac Med, D-45122 Essen, Germany; [Diener, Hans-Christoph] Univ Duisburg Essen, Dept Neurol, D-45122 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	Diener, HC (corresponding author), Univ Duisburg Essen, Fac Med, D-45122 Essen, Germany.; Diener, HC (corresponding author), Univ Duisburg Essen, Dept Neurol, D-45122 Essen, Germany.	hans.diener@uk-essen.de	Diener, Hans-Christoph/AAF-7275-2019		AstraZeneca; GlaxoSmithKline; Boehringer Ingelheim; Lundbeck; Novartis; Janssen-Cilag; Sanofi-Aventis; Syngis; Talecris; German Research Council; German Ministry of Education and Research; EU; National Institutes of Health; Bertelsmann Foundation; Heinz-Nixdorf Foundation	AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Boehringer Ingelheim(Boehringer Ingelheim); Lundbeck(Lundbeck Corporation); Novartis(Novartis); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Sanofi-Aventis(Sanofi-Aventis); Syngis; Talecris; German Research Council(German Research Foundation (DFG)); German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); EU(European Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bertelsmann Foundation; Heinz-Nixdorf Foundation	I have received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from Amgen, Allergan, AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, CoAxia, Covidien, Daiichi-Sankyo, D-Pharm, GlaxoSmithKline, Johnson & Johnson, Lilly, Merck Sharp & Dohme, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Pfizer, Sanofi, Servier, St Jude, and WebMD Global. Financial support for research projects was provided by AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Lundbeck, Novartis, Janssen-Cilag, Sanofi-Aventis, Syngis, and Talecris. The Department of Neurology at the University Duisburg-Essen received research grants from the German Research Council, German Ministry of Education and Research, EU, National Institutes of Health, Bertelsmann Foundation, and Heinz-Nixdorf Foundation.	Amarenco P, 2017, LANCET NEUROL; Benavente OR, 2012, NEW ENGL J MED, V367, P817, DOI 10.1056/NEJMoa1204133; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; DAVIES MJ, 1992, CIRCULATION, V85, P19; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Johnston SC, 2016, NEW ENGL J MED, V375, P35, DOI 10.1056/NEJMoa1603060; Rothwell PM, 2016, LANCET, V388, P365, DOI 10.1016/S0140-6736(16)30468-8; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Yusuf S, 2001, NEW ENGL J MED, V345, P494	11	3	3	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2017	16	4					256	257		10.1016/S1474-4422(17)30057-1	http://dx.doi.org/10.1016/S1474-4422(17)30057-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EN9RF	28327328				2022-12-18	WOS:000396336600005
J	Jensen, TS				Jensen, Troels Staehelin			Selective sodium channel blockers in trigeminal neuralgia	LANCET NEUROLOGY			English	Editorial Material									[Jensen, Troels Staehelin] Univ Aarhus, Dept Neurol, Norrebrogade 44, DK-8000 Aarhus C, Denmark; [Jensen, Troels Staehelin] Univ Aarhus, DPRC, Norrebrogade 44, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Jensen, TS (corresponding author), Univ Aarhus, Dept Neurol, Norrebrogade 44, DK-8000 Aarhus C, Denmark.; Jensen, TS (corresponding author), Univ Aarhus, DPRC, Norrebrogade 44, DK-8000 Aarhus C, Denmark.	tsjensen@ki.au.dk	Jensen, Troels Staehelin/A-3418-2009	Jensen, Troels Staehelin/0000-0002-3487-6380	Pfizer	Pfizer(Pfizer)	I report personal fees from Pfizer. Additionally, my department was invited to participate in Zakrzewska and colleagues' study, but we did not contribute any patients to the study and did not receive any economic compensation.	Brouwer BA, 2014, J PERIPHER NERV SYST, V19, P53, DOI 10.1111/jns5.12071; Cruccu G, 2016, NEUROLOGY, V87, P220, DOI 10.1212/WNL.0000000000002840; Dib-Hajj SD, 2013, NAT REV NEUROSCI, V14, P49, DOI 10.1038/nrn3404; Estacion M, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-92; Faber CG, 2012, P NATL ACAD SCI USA, V109, P19444, DOI 10.1073/pnas.1216080109; Han C, 2012, NEUROLOGY, V78, P1635, DOI 10.1212/WNL.0b013e3182574f12; Han CY, 2012, BRAIN, V135, P2613, DOI 10.1093/brain/aws187; Hoeijmakers JGJ, 2015, NEUROSCI LETT, V596, P51, DOI 10.1016/j.neulet.2014.12.056; Luiz AP, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0076-4; Maarbjerg S, 2017, CEPHALALGIA, DOI 10.1177/0333102416687280; Tanaka BS, 2016, MOL MED, DOI 10.2119/molmed.2016.00131; Xiao JB, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0089097, 10.1371/journal.pone.0093842, 10.1155/2014/584164]; Zakrzewska JM, 2017, LANCET NEUROL	13	3	4	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2017	16	4					255	256		10.1016/S1474-4422(17)30017-0	http://dx.doi.org/10.1016/S1474-4422(17)30017-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EN9RF	28222966				2022-12-18	WOS:000396336600004
J	Drouin, E; Drouin, G; Pereon, Y				Drouin, Emmanuel; Drouin, Guillaume; Pereon, Yann			The Babinski sign	LANCET NEUROLOGY			English	Letter									[Drouin, Emmanuel] Univ Tours, Ctr Etud Super Renaissance, Tours, France; [Drouin, Guillaume] Univ Nantes, Sch Med, Nantes, France; [Pereon, Yann] CHU Nantes, Ctr Reference Malad Neuromusculaires Nantes Anger, Hotel Dieu, F-44093 Nantes, France	Universite de Tours; Nantes Universite; Universite de Franche-Comte; Nantes Universite; CHU de Nantes	Pereon, Y (corresponding author), CHU Nantes, Ctr Reference Malad Neuromusculaires Nantes Anger, Hotel Dieu, F-44093 Nantes, France.	Yann.Pereon@univ-nantes.fr						Babinski J, 1896, CR SOC BIOL, V48, P207; vanGijn J, 1996, J NEUROL, V243, P675	2	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2017	16	3					180	180		10.1016/S1474-4422(16)30416-1	http://dx.doi.org/10.1016/S1474-4422(16)30416-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EK4ZC	28229883	Bronze			2022-12-18	WOS:000393935700008
J	Tatlisumak, T				Tatlisumak, Turgut			Can natalizumab be beneficial in acute ischaemic stroke?	LANCET NEUROLOGY			English	Editorial Material							FOCAL CEREBRAL-ISCHEMIA; ALPHA-4 INTEGRIN; INHIBITION; BRAIN; RATS		[Tatlisumak, Turgut] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Bla Straket Vaning 3, S-41135 Gothenburg, Sweden; [Tatlisumak, Turgut] Sahlgrens Univ Hosp, Dept Neurol, Bla Straket Vaning 3, S-41135 Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital	Tatlisumak, T (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Bla Straket Vaning 3, S-41135 Gothenburg, Sweden.; Tatlisumak, T (corresponding author), Sahlgrens Univ Hosp, Dept Neurol, Bla Straket Vaning 3, S-41135 Gothenburg, Sweden.	turgut.tatlisumak@neuro.gu.se			Boehringer Ingelheim; BrainsGate; Bayer; Pfizer; Lumosa Pharm	Boehringer Ingelheim(Boehringer Ingelheim); BrainsGate; Bayer(Bayer AG); Pfizer(Pfizer); Lumosa Pharm	I have received grants from Boehringer Ingelheim, BrainsGate, Bayer, Pfizer; and personal fees from Bayer, Pfizer, and Lumosa Pharm. I have a patent for a mast cell activation or degranulation blocking agent for the treatment of patients who have had thrombolyses.	Becker K, 2001, STROKE, V32, P206, DOI 10.1161/01.STR.32.1.206; Chamorro A, 2016, LANCET NEUROL, V15, P869, DOI 10.1016/S1474-4422(16)00114-9; Elkins J, 2017, LANCET NEUROL, V16, P217, DOI 10.1016/S1474-4422(16)30357-X; GARCIA JH, 1994, AM J PATHOL, V144, P188; Langhauser F, 2014, STROKE, V45, P1799, DOI 10.1161/STROKEAHA.114.005000; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Lindsberg PJ, 1996, CIRCULATION, V94, P939, DOI 10.1161/01.CIR.94.5.939; Llovera G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9853; Relton JK, 2001, STROKE, V32, P199, DOI 10.1161/01.STR.32.1.199; Sherman DG, 2001, NEUROLOGY, V57, P1428, DOI 10.1212/wnl.57.8.1428	10	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2017	16	3					176	177		10.1016/S1474-4422(16)30383-0	http://dx.doi.org/10.1016/S1474-4422(16)30383-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EK4ZC	28229882				2022-12-18	WOS:000393935700005
J	Badhiwala, JH; Nassiri, F; Kulkarni, AV; Spears, J; Almenawer, SA				Badhiwala, Jetan H.; Nassiri, Farshad; Kulkarni, Abhaya V.; Spears, Julian; Almenawer, Saleh A.			Mechanical thrombectomy after intravenous thrombolysis for acute ischaemic stroke	LANCET NEUROLOGY			English	Letter							TRIAL		[Badhiwala, Jetan H.; Nassiri, Farshad; Kulkarni, Abhaya V.; Spears, Julian] Univ Toronto, Toronto Western Hosp, Dept Neurosurg, 399 Bathurst St,West Wing 4-427, Toronto, ON M5T 2S8, Canada; [Almenawer, Saleh A.] McMaster Univ, Div Neurosurg, Hamilton, ON, Canada; [Almenawer, Saleh A.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; McMaster University; McMaster University	Badhiwala, JH (corresponding author), Univ Toronto, Toronto Western Hosp, Dept Neurosurg, 399 Bathurst St,West Wing 4-427, Toronto, ON M5T 2S8, Canada.	jetan.badhiwala@mail.utoronto.ca						Badhiwala JH, 2015, JAMA-J AM MED ASSOC, V314, P1832, DOI 10.1001/jama.2015.13767; Bracard S, 2016, LANCET NEUROL, V15, P1138, DOI 10.1016/S1474-4422(16)30177-6; Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9	3	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2017	16	2					103	103		10.1016/S1474-4422(16)30381-7	http://dx.doi.org/10.1016/S1474-4422(16)30381-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EH6VA	28102145	Bronze			2022-12-18	WOS:000391910800006
J	Berkovic, SF				Berkovic, Samuel F.			Epilepsy research in 2016: new treatment directions	LANCET NEUROLOGY			English	Editorial Material							SEIZURES; TRIAL		[Berkovic, Samuel F.] Univ Melbourne, Epilepsy Res Ctr, Heidelberg, Vic 3084, Australia	University of Melbourne	Berkovic, SF (corresponding author), Univ Melbourne, Epilepsy Res Ctr, Heidelberg, Vic 3084, Australia.	s.berkovic@unimelb.edu.au	jiang, yu/HGU-0029-2022	Berkovic, Samuel/0000-0003-4580-841X				Barba C, 2016, BRAIN, V139, P444, DOI 10.1093/brain/awv372; Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Chen ZB, 2016, NEUROLOGY, V86, P1086, DOI 10.1212/WNL.0000000000002484; French JA, 2016, LANCET, V388, P2153, DOI 10.1016/S0140-6736(16)31419-2; Kesselheim AS, 2016, NEUROLOGY, V87, P1796, DOI 10.1212/WNL.0000000000003259; Marguet SL, 2015, NAT MED, V21, P1436, DOI 10.1038/nm.3987; Pressler RM, 2015, LANCET NEUROL, V14, P469, DOI 10.1016/S1474-4422(14)70303-5; Privitera MD, 2016, LANCET NEUROL, V15, P365, DOI 10.1016/S1474-4422(16)00014-4	8	3	3	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					7	9		10.1016/S1474-4422(16)30334-9	http://dx.doi.org/10.1016/S1474-4422(16)30334-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27979357				2022-12-18	WOS:000389869200005
J	[Anonymous]				[Anonymous]			Towards greater transparency in clinical trial reporting	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2016	15	13					1295	1295		10.1016/S1474-4422(16)30296-4	http://dx.doi.org/10.1016/S1474-4422(16)30296-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EB6XV	27839634	Bronze			2022-12-18	WOS:000387529800001
J	Deo, S; Charlier, P				Deo, Saudamini; Charlier, Philippe			For Franz Kafka, insomnia was a literary method	LANCET NEUROLOGY			English	Letter									[Deo, Saudamini; Charlier, Philippe] UFR Hlth Sci UVSQ, Sect Med & Forens Anthropol, F-78180 Montigny Le Bretonneux, France; [Charlier, Philippe] Hosp Nanterre, Ctr Accueil & Soins, Nanterre, France	UDICE-French Research Universities; Universite Paris Saclay	Charlier, P (corresponding author), UFR Hlth Sci UVSQ, Sect Med & Forens Anthropol, F-78180 Montigny Le Bretonneux, France.	philippe.charlier@uvsq.fr						Coralli A, 2016, LANCET NEUROL, V15, P787, DOI [10.1016/S1474-4422(16)30051-5, 10.1016/S1474-4422(16)30168-5]; Kafka F., 2000, METAMORPHOSIS PENAL; Kafka F, 1976, COMMUNICATION; Kafka Franz, 1976, DIARIES 1910 1923; Mishara Aaron L, 2010, Philos Ethics Humanit Med, V5, P13, DOI 10.1186/1747-5341-5-13	5	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2016	15	12					1207	1207		10.1016/S1474-4422(16)30241-1	http://dx.doi.org/10.1016/S1474-4422(16)30241-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EA0YO	27751548	Bronze			2022-12-18	WOS:000386315700016
J	Schneider, LS				Schneider, Lon S.			WHO's dementia research priorities: a prescription for failure?	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS		[Schneider, Lon S.] USC, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California Keck Hospital	Schneider, LS (corresponding author), USC, Keck Sch Med, Los Angeles, CA 90033 USA.	lschneid@usc.edu						Boyle PA, 2013, ANN NEUROL, V74, P478, DOI 10.1002/ana.23964; Brayne C, 2012, LANCET, V380, P1441, DOI 10.1016/S0140-6736(12)61803-0; Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1; Prince M., 2015, WORLD ALZHEIMERS REP; Shah H, 2016, LANCET NEUROL, V15, P1283, DOI 10.1016/S1474-4422(16)30235-6; Winblad B, 2016, LANCET NEUROL, V15, P455, DOI 10.1016/S1474-4422(16)00062-4	6	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2016	15	12					1202	1203		10.1016/S1474-4422(16)30258-7	http://dx.doi.org/10.1016/S1474-4422(16)30258-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EA0YO	27751538				2022-12-18	WOS:000386315700006
J	Logroscino, G				Logroscino, Giancarlo			Classifying change and heterogeneity in amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Editorial Material							DIAGNOSIS; CRITERIA; ALS		[Logroscino, Giancarlo] Univ Bari Aldo Moro, Dept Basic Med Neurosci & Sense Organs, Neurodegenerat Dis Unit, Bari, Italy; [Logroscino, Giancarlo] Univ Bari Aldo Moro, Dept Clin Res Neurol, Pia Fdn Card G Panico Hosp, Lecce, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Logroscino, G (corresponding author), Univ Bari Aldo Moro, Dept Basic Med Neurosci & Sense Organs, Neurodegenerat Dis Unit, Bari, Italy.; Logroscino, G (corresponding author), Univ Bari Aldo Moro, Dept Clin Res Neurol, Pia Fdn Card G Panico Hosp, Lecce, Italy.	giancarlo.logroscino@uniba.it						Al-Chalabi A, 2016, LANCET NEUROL, V15, P1182, DOI 10.1016/S1474-4422(16)30199-5; Bedlack RS, 2016, NEUROLOGY, V86, P808, DOI 10.1212/WNL.0000000000002251; Brain W., 1962, MOTOR NEURONE DIS; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Elamin M, 2013, NEUROLOGY, V80, P1590, DOI 10.1212/WNL.0b013e31828f18ac; Fatima M, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0226-y; Logroscino G, 2010, J NEUROL NEUROSUR PS, V81, P385, DOI 10.1136/jnnp.2009.183525; Marin B., 2016, INT J EPIDEMIOL; Menon P, 2015, LANCET NEUROL, V14, P478, DOI 10.1016/S1474-4422(15)00014-9	10	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2016	15	11					1111	1112		10.1016/S1474-4422(16)30206-X	http://dx.doi.org/10.1016/S1474-4422(16)30206-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DX3MJ	27647633				2022-12-18	WOS:000384276900006
J	Baizabal-Carvallo, JF; Jankovic, J				Baizabal-Carvallo, Jose Fidel; Jankovic, Joseph			Functional (psychogenic) saccadic oscillations and oculogyric crises	LANCET NEUROLOGY			English	Letter							MOVEMENT-DISORDERS		[Baizabal-Carvallo, Jose Fidel; Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Parkinsons Dis Ctr & Movement Disorders Clin, Houston, TX 77030 USA	Baylor College of Medicine	Jankovic, J (corresponding author), Baylor Coll Med, Dept Neurol, Parkinsons Dis Ctr & Movement Disorders Clin, Houston, TX 77030 USA.	josephj@bcm.edu						Jankovic J, 2016, J NEUROPSYCHIATRY CL, DOI [10.1176/appi, DOI 10.1176/APPI]; Kaski D, 2015, LANCET NEUROL, V14, P1196, DOI 10.1016/S1474-4422(15)00226-4; Lemos J, 2013, CURR OPIN NEUROL, V26, P59, DOI 10.1097/WCO.0b013e32835c5e1d; Thenganatt MA, 2015, NEUROL CLIN, V33, P205, DOI 10.1016/j.ncl.2014.09.013; ZAHN JR, 1978, J NEUROL NEUROSUR PS, V41, P617, DOI 10.1136/jnnp.41.7.617	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2016	15	8					791	791		10.1016/S1474-4422(16)00126-5	http://dx.doi.org/10.1016/S1474-4422(16)00126-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO1NR	27302355	Bronze			2022-12-18	WOS:000377545800015
J	Saute, JAM; Jardim, LB				Morales Saute, Jonas Alex; Jardim, Laura Bannach			Riluzole in patients with hereditary cerebellar ataxia	LANCET NEUROLOGY			English	Letter							CLINICAL-TRIALS; DOUBLE-BLIND		[Morales Saute, Jonas Alex; Jardim, Laura Bannach] Hosp Clin Porto Alegre, Med Genet Serv, BR-90035903 Porto Alegre, RS, Brazil; [Jardim, Laura Bannach] Univ Fed Rio Grande do Sul, Dept Internal Med, Porto Alegre, RS, Brazil; [Jardim, Laura Bannach] Univ Fed Rio Grande do Sul, Postgrad Program Med Med Sci, Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul	Jardim, LB (corresponding author), Hosp Clin Porto Alegre, Med Genet Serv, BR-90035903 Porto Alegre, RS, Brazil.	ljardim@hcpa.edu.br	Saute, Jonas Alex Morales/F-6635-2015	Saute, Jonas Alex Morales/0000-0003-1141-6573				Durr A, 2015, LANCET NEUROL, V14, P968, DOI 10.1016/S1474-4422(15)00217-3; Saute JAM, 2015, J NEUROL SCI, V358, P72, DOI 10.1016/j.jns.2015.08.019; Saute JAM, 2012, CEREBELLUM, V11, P488, DOI 10.1007/s12311-011-0316-8; Ristori G, 2010, NEUROLOGY, V74, P839, DOI 10.1212/WNL.0b013e3181d31e23; Romano S, 2015, LANCET NEUROL, V14, P985, DOI 10.1016/S1474-4422(15)00201-X	5	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2016	15	8					788	789		10.1016/S1474-4422(16)00128-9	http://dx.doi.org/10.1016/S1474-4422(16)00128-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO1NR	27302350	Bronze			2022-12-18	WOS:000377545800011
J	Schneider, JA				Schneider, Julie A.			The cerebral cortex in cerebral amyloid angiopathy	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS-DISEASE; BRAIN ATROPHY		[Schneider, Julie A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Armour Acad Ctr,Dept Pathol Neuropathol, Chicago, IL 60612 USA; [Schneider, Julie A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Armour Acad Ctr,Dept Neurol Sci, Chicago, IL 60612 USA	Rush University; Rush University	Schneider, JA (corresponding author), Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Armour Acad Ctr,Dept Pathol Neuropathol, Chicago, IL 60612 USA.; Schneider, JA (corresponding author), Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Armour Acad Ctr,Dept Neurol Sci, Chicago, IL 60612 USA.	julie_a_schneider@rush.edu			NIA NIH HHS [K08 AG000849] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boyle PA, 2015, NEUROLOGY, V85, P1930, DOI 10.1212/WNL.0000000000002175; Crystal HA, 2014, CURR ALZHEIMER RES, V11, P309, DOI 10.2174/1567205011666140302194358; Dumas A, 2012, ANN NEUROL, V72, P76, DOI 10.1002/ana.23566; Erten-Lyons D, 2013, JAMA NEUROL, V70, P616, DOI 10.1001/jamaneurol.2013.1957; Fotiadis P, 2016, LANCET NEUROL, V15, P811, DOI 10.1016/S1474-4422(16)30030-8; Jagust WJ, 2008, ANN NEUROL, V63, P72, DOI 10.1002/ana.21296; McDonald CR, 2009, NEUROLOGY, V73, P457, DOI 10.1212/WNL.0b013e3181b16431; Peca S, 2013, NEUROLOGY, V81, P1659, DOI 10.1212/01.wnl.0000435291.49598.54; Samuraki M, 2015, J ALZHEIMERS DIS, V48, P517, DOI 10.3233/JAD-150274; Zheng L, 2016, J CEREBR BLOOD F MET, V36, P204, DOI 10.1038/jcbfm.2015.152	10	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2016	15	8					778	779		10.1016/S1474-4422(16)30100-4	http://dx.doi.org/10.1016/S1474-4422(16)30100-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO1NR	27302344				2022-12-18	WOS:000377545800003
J	Voskuhl, R; Wang, H; Elashoff, RM				Voskuhl, Rhonda; Wang, HeJing; Elashoff, Robert M.			Why use sex hormones in relapsing-remitting multiple sclerosis? Reply	LANCET NEUROLOGY			English	Letter							PLACEBO-CONTROLLED PHASE-3; ORAL BG-12; GLATIRAMER		[Voskuhl, Rhonda; Wang, HeJing; Elashoff, Robert M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Voskuhl, R (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.	rvoskuhl@ucla.edu						Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Langer-Gould A, 2016, LANCET NEUROL, V15, P22, DOI 10.1016/S1474-4422(15)00348-8; Voskuhl RR, 2016, LANCET NEUROL, V15, P35, DOI 10.1016/S1474-4422(15)00322-1	5	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2016	15	8					790	791		10.1016/S1474-4422(16)00129-0	http://dx.doi.org/10.1016/S1474-4422(16)00129-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO1NR	27302354	Bronze			2022-12-18	WOS:000377545800014
J	Tan, EK				Tan, Eng-King			Chromosomal deletion at 22q11.2 and Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material									[Tan, Eng-King] Singapore Gen Hosp, Duke NUS Med Sch, Natl Neurosci Inst, Singapore 169608, Singapore	National Neuroscience Institute (NNI); National University of Singapore; Singapore General Hospital	Tan, EK (corresponding author), Singapore Gen Hosp, Duke NUS Med Sch, Natl Neurosci Inst, Singapore 169608, Singapore.	gnrtek@sgh.com.sg						Butcher NJ, 2013, JAMA NEUROL, V70, P1359, DOI 10.1001/jamaneurol.2013.3646; Foo JN, 2012, NAT REV NEUROL, V8, P508, DOI 10.1038/nrneurol.2012.148; Hacihamdioglu B, 2015, APPL CLIN GENET, V8, P123, DOI 10.2147/TACG.S82105; Mok KY, 2016, LANCET NEUROL; Ogaki K, 2014, PARKINSONISM RELAT D, V20, P945, DOI 10.1016/j.parkreldis.2014.06.020; Tan EK, 2011, LANCET NEUROL, V10, P869, DOI 10.1016/S1474-4422(11)70185-5; Zaleski C, 2009, AM J MED GENET A, V149A, P525, DOI 10.1002/ajmg.a.32650	7	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2016	15	6					538	540		10.1016/S1474-4422(16)00115-0	http://dx.doi.org/10.1016/S1474-4422(16)00115-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI9PW	27017470	hybrid			2022-12-18	WOS:000373835900005
J	Shakir, R				Shakir, Raad			Neurological expertise is essential for Zika virus infection	LANCET NEUROLOGY			English	Letter							GUILLAIN-BARRE-SYNDROME		[Shakir, Raad] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, London W6 8RF, England	Imperial College London	Shakir, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, London W6 8RF, England.	r.shakir@imperial.ac.uk						[Anonymous], 2016, LANCET, V387, P96; Hughes RAC, 2005, ARCH NEUROL-CHICAGO, V62, P1194, DOI 10.1001/archneur.62.8.1194; Hughes RAC, 2003, NEUROLOGY, V61, P736, DOI 10.1212/WNL.61.6.736; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Pritchard J, 2008, POSTGRAD MED J, V84, P532, DOI 10.1136/jnnp.2006.097709; UK Department of Health, 2011, CLIN GUID IMM US; van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121	7	3	3	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					353	354		10.1016/S1474-4422(16)00072-7	http://dx.doi.org/10.1016/S1474-4422(16)00072-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP	26922438				2022-12-18	WOS:000371974000011
J	Moreau, C; Devos, D; Defebvre, L				Moreau, Caroline; Devos, David; Defebvre, Luc			Acetylcholinesterase inhibitors and gait: a steadying hand?	LANCET NEUROLOGY			English	Editorial Material							PARKINSONS-DISEASE; DISORDERS; HISTORY		[Moreau, Caroline; Devos, David; Defebvre, Luc] Univ Lille 2, CHRU Lille, Serv Neurol & Pathol Mouvement Pole Neurosci & Ap, Hop Roger Salengro,INSERM,UMR 1171, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille	Moreau, C (corresponding author), Univ Lille 2, CHRU Lille, Serv Neurol & Pathol Mouvement Pole Neurosci & Ap, Hop Roger Salengro,INSERM,UMR 1171, Lille, France.	caroline.moreau@chru-lille.fr	Devos, David/E-4059-2013	Devos, David/0000-0002-2417-799X				Bohnen NI, 2009, NEUROLOGY, V73, P1670, DOI 10.1212/WNL.0b013e3181c1ded6; Bohnen NI, 2011, BEHAV BRAIN RES, V221, P564, DOI 10.1016/j.bbr.2009.12.048; Devos D, 2014, J NEUROL NEUROSUR PS, V85, P668, DOI 10.1136/jnnp-2013-306439; Ferraye MU, 2010, BRAIN, V133, P205, DOI 10.1093/brain/awp229; Gurevich T, 2014, DRUGS R&D, V14, P57, DOI 10.1007/s40268-014-0038-8; Hausdorff JM, 1998, MOVEMENT DISORD, V13, P428, DOI 10.1002/mds.870130310; Henderson EJ., 2016, LANCET NEUROL; Karachi C, CHOLINGERIC MESENCEP, V120, P2745; Liu AKL, 2015, ACTA NEUROPATHOL, V129, P527, DOI 10.1007/s00401-015-1392-5; Takakusaki K, 2008, J NEUROL, V255, P19, DOI 10.1007/s00415-008-4004-7	10	3	4	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2016	15	3					232	233		10.1016/S1474-4422(16)00003-X	http://dx.doi.org/10.1016/S1474-4422(16)00003-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DE1ON	26795875	hybrid			2022-12-18	WOS:000370396400002
J	Devos, D; Moreau, C				Devos, David; Moreau, Caroline			Opicapone for motor fluctuations in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							O-METHYLTRANSFERASE INHIBITORS		[Devos, David] Univ Lille, Dept Med Pharmacol, Lille, France; [Devos, David; Moreau, Caroline] Univ Lille, INSERM, U1171, Lille, France; [Devos, David; Moreau, Caroline] Univ Lille, Dept Neurol & Movement Disorders, Lille, France; Lille Univ Hosp, Lille, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille	Devos, D (corresponding author), Univ Lille, Dept Med Pharmacol, Lille, France.	david.devos@chru-lille.fr	Devos, David/E-4059-2013	Devos, David/0000-0002-2417-799X				Corvol JC, 2011, ANN NEUROL, V69, P111, DOI 10.1002/ana.22155; Deane KH., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004554.PUB2; Ferreira JJ, 2015, EUR J NEUROL, V22, P815, DOI 10.1111/ene.12666; Ferreira J. J., 2015, LANCET NEUROL; Lang AE, 2014, LANCET, V384, P1164, DOI 10.1016/S0140-6736(14)60962-4; Marin C, 2010, INT REV NEUROBIOL, V95, P191, DOI [10.1016/B978-0-12-381326-8.00008-9, 10.1016/B978-0-12-381326-8-00008-9]; Moreau C, 2015, BRAIN, V138, P1271, DOI 10.1093/brain/awv063; Muller T, 2015, DRUGS, V75, P157, DOI 10.1007/s40265-014-0343-0; Stocchi F, 2010, ANN NEUROL, V68, P18, DOI 10.1002/ana.22060	9	3	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2016	15	2					127	128		10.1016/S1474-4422(15)00346-4	http://dx.doi.org/10.1016/S1474-4422(15)00346-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DA9GC	26725545				2022-12-18	WOS:000368116000003
J	Meador, KJ				Meador, Kimford J.			Valproic acid: reducing the risks of prenatal exposure	LANCET NEUROLOGY			English	Editorial Material							EPILEPSY; LAMOTRIGINE; TRIAL		[Meador, Kimford J.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Stanford University	Meador, KJ (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	kmeador@stanford.edu	Meador, Kimford/W-6167-2019	Meador, Kimford/0000-0002-7471-882X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS038455] Funding Source: NIH RePORTER; NINDS NIH HHS [U01 NS038455] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baker GA, 2015, NEUROLOGY, V84, P382, DOI 10.1212/WNL.0000000000001182; Christensen J, 2013, JAMA-J AM MED ASSOC, V309, P1696, DOI 10.1001/jama.2013.2270; Glauser TA, 2010, NEW ENGL J MED, V362, P790, DOI 10.1056/NEJMoa0902014; Marson AG, 2007, LANCET, V369, P1016, DOI 10.1016/S0140-6736(07)60461-9; Meador KJ, 2016, NEUROLOGY, V86, P297, DOI 10.1212/WNL.0000000000002119; Meador KJ, 2013, LANCET NEUROL, V12, P244, DOI 10.1016/S1474-4422(12)70323-X; Prescribing and Medicines Team Health and Social Care Information Centre, 2015, PRESCR DISP COMM ENG; Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x; Tomson T, 2015, LANCET NEUROL, VS1474-4422; Trinka E, 2013, J NEUROL NEUROSUR PS, V84, P1138, DOI 10.1136/jnnp-2011-300376	10	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2016	15	2					132	133		10.1016/S1474-4422(15)00357-9	http://dx.doi.org/10.1016/S1474-4422(15)00357-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DA9GC	26655850	Green Accepted			2022-12-18	WOS:000368116000006
J	Jensen, TS; Finnerup, NB				Jensen, Troels S.; Finnerup, Nanna B.			Plasticity of pain revisited in 2015	LANCET NEUROLOGY			English	Editorial Material							CORTICAL REORGANIZATION; CORTEX		[Jensen, Troels S.; Finnerup, Nanna B.] Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark; [Jensen, Troels S.] Aarhus Univ, Danish Pain Res Ctr, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University	Jensen, TS (corresponding author), Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark.	tsjensen@clin.au.dk	Finnerup, Nanna Brix/ABA-8219-2020; Jensen, Troels Staehelin/A-3418-2009	Finnerup, Nanna Brix/0000-0001-5541-0240; Jensen, Troels Staehelin/0000-0002-3487-6380	Novo Nordisk Fonden [NNF14OC0011633] Funding Source: researchfish	Novo Nordisk Fonden(Novo Nordisk Foundation)		Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Koga K, 2015, NEURON, V85, P377, DOI 10.1016/j.neuron.2014.12.021; Makin TR, 2015, BRAIN, V138, P2140, DOI 10.1093/brain/awv161; Mancini F, 2015, PAIN, V156, P1936, DOI 10.1097/j.pain.0000000000000253; Navratilova E, 2015, J NEUROSCI, V35, P7264, DOI 10.1523/JNEUROSCI.3862-14.2015	6	3	3	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					19	21		10.1016/S1474-4422(15)00343-9	http://dx.doi.org/10.1016/S1474-4422(15)00343-9			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700902				2022-12-18	WOS:000366313900011
J	Vos, SJB; Fagan, AM				Vos, Stephanie J. B.; Fagan, Anne M.			Alzheimer's disease biomarker states	LANCET NEUROLOGY			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; RECOMMENDATIONS; PREVALENCE; AGE		[Vos, Stephanie J. B.] Maastricht Univ, Inst Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Alzheimer Ctr Limburg, NL-6200 MD Maastricht, Netherlands; [Fagan, Anne M.] Washington Univ, Sch Med, Dept Neurol, Alzheimers Dis Res Ctr,Hope Ctr Neurol Disorders, St Louis, MO 63110 USA	Maastricht University; Washington University (WUSTL)	Vos, SJB (corresponding author), Maastricht Univ, Inst Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Alzheimer Ctr Limburg, NL-6200 MD Maastricht, Netherlands.	s.vos@maastrichtuniversity.nl						Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Jack CR, 2015, JAMA NEUROL, V72, P511, DOI 10.1001/jamaneurol.2014.4821; Jack CR, 2014, LANCET NEUROL, V13, P997, DOI 10.1016/S1474-4422(14)70194-2; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Jack CR, 2012, ANN NEUROL, V71, P765, DOI 10.1002/ana.22628; Jack Jr CR, 2015, LANCET NEUROL; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Knopman DS, 2012, NEUROLOGY, V78, P1576, DOI 10.1212/WNL.0b013e3182563bbe; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Vos SJB, 2015, BRAIN, V138, P1327, DOI 10.1093/brain/awv029; Vos SJB, 2013, LANCET NEUROL, V12, P957, DOI 10.1016/S1474-4422(13)70194-7	11	3	3	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					25	26		10.1016/S1474-4422(15)00335-X	http://dx.doi.org/10.1016/S1474-4422(15)00335-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26597326				2022-12-18	WOS:000366313900014
J	Lindhout, D				Lindhout, Dick			Epilepsy treatment: precision medicine at a crossroads	LANCET NEUROLOGY			English	Editorial Material							ANTIEPILEPTIC DRUGS; GILBERTS-SYNDROME; RISK		[Lindhout, Dick] Univ Med Ctr Utrecht, Dept Med Genet, NL-3508 Utrecht, Netherlands; [Lindhout, Dick] SEIN, NL-2130 AM Hoofddorp, Netherlands	Utrecht University; Utrecht University Medical Center	Lindhout, D (corresponding author), Univ Med Ctr Utrecht, Dept Med Genet, POB 85090, NL-3508 Utrecht, Netherlands.	d.lindhout@umcutrecht.nl	Lindhout, Dick/AAH-5765-2019	Lindhout, Dick/0000-0001-9580-624X				Baker GA, 2015, NEUROLOGY, V84, P382, DOI 10.1212/WNL.0000000000001182; Boerma RS, 2015, NEUROTHERAPEUTICS; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; Charlton RA, 2011, DRUG SAFETY, V34, P157, DOI 10.2165/11584970-000000000-00000; EpiPM Consortium, 2015, LANCET NEUROL; Kim YS, 2014, SEIZURE-EUR J EPILEP, V23, P208, DOI 10.1016/j.seizure.2013.11.015; Kinirons P, 2006, EPILEPSY RES, V70, P144, DOI 10.1016/j.eplepsyres.2006.03.012; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LINDHOUT D, 1992, NEUROLOGY, V42, P111; POSNER J, 1989, BRIT J CLIN PHARMACO, V28, P117, DOI 10.1111/j.1365-2125.1989.tb03514.x	10	3	4	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2015	14	12					1148	1149		10.1016/S1474-4422(15)00295-1	http://dx.doi.org/10.1016/S1474-4422(15)00295-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW2WZ	26581961				2022-12-18	WOS:000364855100005
J	Fugate, JE; Rabinstein, AA				Fugate, Jennifer E.; Rabinstein, Alejandro A.			The diagnosis of posterior reversible encephalopathy syndrome reply	LANCET NEUROLOGY			English	Letter									[Fugate, Jennifer E.; Rabinstein, Alejandro A.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic	Fugate, JE (corresponding author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.	fugate.jennifer@mayo.edu						Datar S, 2015, EPILEPSIA, V56, P564, DOI 10.1111/epi.12933; Frumin E, 2014, WEST J EMERG MED, V15, P217, DOI 10.5811/westjem.2013.9.16191; Fugate JE, 2015, LANCET NEUROL, V14, P914, DOI 10.1016/S1474-4422(15)00111-8; Rajajee V, 2011, NEUROCRIT CARE, V37, P1059; Sha ZY, 2015, EPILEPSY BEHAV, V48, P70, DOI 10.1016/j.yebeh.2015.05.027	5	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2015	14	11					1075	1075		10.1016/S1474-4422(15)00257-4	http://dx.doi.org/10.1016/S1474-4422(15)00257-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT7DY	26466778				2022-12-18	WOS:000362975200010
J	Lochner, P; Nardone, R; Brigo, F; Tamber, MS; Zuccoli, G				Lochner, Piergiorgio; Nardone, Raffaele; Brigo, Francesco; Tamber, Mandeep S.; Zuccoli, Giulio			The diagnosis of posterior reversible encephalopathy syndrome	LANCET NEUROLOGY			English	Letter									[Lochner, Piergiorgio; Nardone, Raffaele; Brigo, Francesco] Franz Tappeiner Hosp, Dept Neurol, I-39012 Merano, Italy; [Nardone, Raffaele] Paracelsus Med Univ, Christian Doppler Clin, Dept Neurol, Salzburg, Austria; [Lochner, Piergiorgio] Univ A Avogadro, Dept Neurol, Novara, Italy; [Brigo, Francesco] Univ Verona, Sect Clin Neurol, Dept Neurol Neuropsychol Morphol & Movement Sci, I-37100 Verona, Italy; [Tamber, Mandeep S.] Univ Pittsburgh, Sch Med, Children Hosp Pittsburgh UPMC, Dept Pediat Neurosurg, Pittsburgh, PA USA; [Zuccoli, Giulio] Univ Pittsburgh, Sch Med, Neuroradiol Sect, Pittsburgh, PA USA	Ospedale Franz Tappeiner; Paracelsus Private Medical University; University of Eastern Piedmont Amedeo Avogadro; University of Verona; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lochner, P (corresponding author), Franz Tappeiner Hosp, Dept Neurol, I-39012 Merano, Italy.	piergiorgio.lochner@googlemail.com	Tamber, Mandeep/ABF-5085-2020; Lochner, Piergiorgio/AAB-6784-2020; Brigo, Francesco/H-6513-2013	Tamber, Mandeep/0000-0003-3329-1011; Lochner, Piergiorgio/0000-0002-2101-6066; Nardone, Raffaele/0000-0001-5243-6760; Brigo, Francesco/0000-0003-0928-1577; /0000-0001-9734-8035				Bauerle J, 2012, J NEUROIMAGING, V22, P42, DOI 10.1111/j.1552-6569.2010.00546.x; Facchini A, 2013, NEUROCRIT CARE, V19, P376, DOI 10.1007/s12028-013-9852-z; Fugate JE, 2015, LANCET NEUROL, V14, P914, DOI 10.1016/S1474-4422(15)00111-8; Furtado A, 2015, NEURORADIOLOGY, V57, P721, DOI 10.1007/s00234-015-1511-y; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2015	14	11					1074	1075		10.1016/S1474-4422(15)00256-2	http://dx.doi.org/10.1016/S1474-4422(15)00256-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT7DY	26466776				2022-12-18	WOS:000362975200009
J	Christine, CW				Christine, Chadwick W.		FS Zone Writing Comm	NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. (vol 14, pg 795, 2015)	LANCET NEUROLOGY			English	Correction									[Christine, Chadwick W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Christine, CW (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.							Christine CW, 2015, LANCET NEUROL, V14, P979, DOI 10.1016/S1474-4422(15)00144-1	1	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2015	14	10					979	979		10.1016/S1474-4422(15)00144-1	http://dx.doi.org/10.1016/S1474-4422(15)00144-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR2VI		Green Accepted, Green Submitted			2022-12-18	WOS:000361188400008
J	[Anonymous]				[Anonymous]			Societies can both grow old and lower dementia burden	LANCET NEUROLOGY			English	Editorial Material																			0	3	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2015	14	10					967	967		10.1016/S1474-4422(15)00223-9	http://dx.doi.org/10.1016/S1474-4422(15)00223-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR2VI	26376964				2022-12-18	WOS:000361188400001
J	Launer, LJ				Launer, Lenore J.			Preventing Alzheimer's disease is difficult	LANCET NEUROLOGY			English	Editorial Material									NIA, Intramural Res Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Launer, LJ (corresponding author), NIA, Intramural Res Program, Bethesda, MD 20892 USA.	launerl@nia.nih.gov						Andrieu S, 2015, LANCET NEUROL; Launer LJ, 2005, NEUROBIOL AGING, V26, P335, DOI 10.1016/j.neurobiolaging.2004.03.016; National Institutes of Health, ACC MED PARTN ALZH D	3	3	3	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2015	14	9					872	874		10.1016/S1474-4422(15)00193-3	http://dx.doi.org/10.1016/S1474-4422(15)00193-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CP4YZ	26293557				2022-12-18	WOS:000359889800005
J	Elling, C; Galic, M; Steigerwald, I				Elling, Christian; Galic, Maja; Steigerwald, Ilona			Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy	LANCET NEUROLOGY			English	Letter							PERIPHERAL NEUROPATHY; RANDOMIZED-WITHDRAWAL; EXTENDED-RELEASE; EFFICACY; TOLERABILITY		[Elling, Christian; Galic, Maja; Steigerwald, Ilona] Grunenthal, Med Affairs Europe & Australia, D-52078 Aachen, Germany	Grunenthal Group	Elling, C (corresponding author), Grunenthal, Med Affairs Europe & Australia, Zieglerstr 6, D-52078 Aachen, Germany.	ilona.steigerwald@grunenthal.com						Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Schwartz S, 2015, CLIN DRUG INVEST, V35, P95, DOI 10.1007/s40261-014-0249-3; Schwartz S, 2011, CURR MED RES OPIN, V27, P151, DOI 10.1185/03007995.2010.537589; Vadivelu N, 2015, THER CLIN RISK MANAG, V11, P95, DOI 10.2147/TCRM.S32193; Vinik AI, 2014, DIABETES CARE, V37, P2302, DOI 10.2337/dc13-2291	5	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					684	685		10.1016/S1474-4422(15)00059-9	http://dx.doi.org/10.1016/S1474-4422(15)00059-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26067117	Bronze			2022-12-18	WOS:000356195900016
J	Finnerup, NB; Attal, N				Finnerup, Nanna B.; Attal, Nadine			Tapentadol prolonged release in the treatment of neuropathic pain related to diabetic polyneuropathy Reply	LANCET NEUROLOGY			English	Letter							PERIPHERAL NEUROPATHY; RANDOMIZED-WITHDRAWAL; EFFICACY		[Finnerup, Nanna B.] Aarhus Univ, Dept Clin Med, Danish Pain Res Ctr, Aarhus, Denmark; [Attal, Nadine] INSERM, U987, Boulogne, France; [Attal, Nadine] Hop Ambroise Pare, Ctr Evaluat & Traitement La Douleur, Boulogne, France	Aarhus University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Finnerup, NB (corresponding author), Aarhus Univ, Dept Clin Med, Danish Pain Res Ctr, Aarhus, Denmark.	nadine.attal@apr.aphp.fr	Finnerup, Nanna Brix/ABA-8219-2020	Finnerup, Nanna Brix/0000-0001-5541-0240				Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Schwartz S, 2011, CURR MED RES OPIN, V27, P151, DOI 10.1185/03007995.2010.537589; Vinik AI, 2014, DIABETES CARE, V37, P2302, DOI 10.2337/dc13-2291	3	3	3	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					685	686		10.1016/S1474-4422(15)00060-5	http://dx.doi.org/10.1016/S1474-4422(15)00060-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26067119				2022-12-18	WOS:000356195900017
J	Shakir, R				Shakir, Raad			Neurologists are key to the WHO global dementia strategy	LANCET NEUROLOGY			English	Letter									World Federat Neurol, London W6 0NB, England		Shakir, R (corresponding author), World Federat Neurol, 1 Lyr Sq, London W6 0NB, England.	raad.shakir@wfneurology.org						The Lancet Neurology, 2015, LANCET NEUROL, V14, P455; United Nations General Assembly, 2011 HIGH LEV M PREV	2	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					686	686		10.1016/S1474-4422(15)00052-6	http://dx.doi.org/10.1016/S1474-4422(15)00052-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26026332	Bronze			2022-12-18	WOS:000356195900018
J	Hill, MD; Menon, BK				Hill, Michael D.; Menon, Bijoy K.			Desmoteplase for late treatment of stroke: still in the dark	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; THROMBOLYSIS; TRIAL		[Hill, Michael D.; Menon, Bijoy K.] Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary Stroke Program, Calgary, AB T2N 2T9, Canada	University of Calgary	Hill, MD (corresponding author), Univ Calgary, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary Stroke Program, Calgary, AB T2N 2T9, Canada.	michael.hill@ucalgary.ca	Hill, Michael D/C-9073-2012; MENON, BIJOY K/B-7718-2014	Hill, Michael D/0000-0002-6269-1543; 	Alberta Innovates [201300690] Funding Source: researchfish	Alberta Innovates		Albers GW, 2015, LANCET NEUROL; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792; Furlan AJ, 2006, STROKE, V37, P1227, DOI 10.1161/01.STR.0000217403.66996.6d; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hacke W, 2009, LANCET NEUROL, V8, P141, DOI 10.1016/S1474-4422(08)70267-9; Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780; Kleindorfer DO, 2007, NEUROCRIT CARE, V7, P31, DOI 10.1007/s12028-007-0029-5; Puetz V, 2008, INT J STROKE, V3, P230, DOI 10.1111/j.1747-4949.2008.00221.x; Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061	12	3	3	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2015	14	6					560	561		10.1016/S1474-4422(15)00061-7	http://dx.doi.org/10.1016/S1474-4422(15)00061-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CI5WG	25937441				2022-12-18	WOS:000354829900002
J	Bono, F; Morelli, M; Quattrone, A				Bono, Francesco; Morelli, Maurizio; Quattrone, Aldo			Facial dystonia as depicted in art in the time of Leonardo da Vinci	LANCET NEUROLOGY			English	Letter									[Bono, Francesco; Morelli, Maurizio; Quattrone, Aldo] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Inst Neurol, Catanzaro, Italy; [Bono, Francesco; Quattrone, Aldo] CNR, Neuroimaging Res Unit, IBFM CNR, Catanzaro, Italy	Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioimmagini e Fisiologia Molecolare (IBFM-CNR)	Bono, F (corresponding author), Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Inst Neurol, Catanzaro, Italy.	f.bono@unicz.it	QUATTRONE, Aldo/A-6734-2016	QUATTRONE, Aldo/0000-0003-2001-957X				Bora G, 1987, PARAGONE, P142; Fahn S, 1987, CLASSIFICATION INVES, P332; Kemp M, 2010, DISEGNI LEONARDO VIN, P128; LeDoux MS, 2009, PARKINSONISM RELAT D, V15, P483, DOI 10.1016/j.parkreldis.2009.04.006; MARSDEN CD, 1976, J NEUROL NEUROSUR PS, V39, P1204, DOI 10.1136/jnnp.39.12.1204; Moro F., 1983, PARAGONE, V16, P26; PARKES D, 1981, NEUROLOGY, V31, P498; Wood HC, 1937, NERVOUS DIS THEIR DI, P1887	8	3	3	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2015	14	4					351	351		10.1016/S1474-4422(15)70012-8	http://dx.doi.org/10.1016/S1474-4422(15)70012-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Neurosciences & Neurology	CE5RD	25681174				2022-12-18	WOS:000351892400008
J	Kunte, H; Farhadi, HF; Sheth, KN; Simard, JM; Kronenberg, G				Kunte, Hagen; Farhadi, H. Francis; Sheth, Kevin N.; Simard, J. Marc; Kronenberg, Golo			Sulfonylureas-a novel treatment to reduce tissue damage after acute spinal cord injury?	LANCET NEUROLOGY			English	Letter							RILUZOLE		[Kunte, Hagen] Charite, NeuroCure Clin Res Ctr, Dept Neurol, D-13353 Berlin, Germany; [Farhadi, H. Francis] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Sheth, Kevin N.] Yale Univ, Sch Med, Dept Neurol, Div Neurocrit Care & Emergency Neurol, New Haven, CT 06510 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Dept Neurosurg,Dept Pathol, Baltimore, MD 21201 USA; [Kronenberg, Golo] Charite, Dept Psychiat & Psychotherapy, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University System of Ohio; Ohio State University; Yale University; University System of Maryland; University of Maryland Baltimore; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kunte, H (corresponding author), Charite, NeuroCure Clin Res Ctr, Dept Neurol, D-13353 Berlin, Germany.	hagen.kunte@charite.de	Kronenberg, Golo/F-8772-2010; Farhadi, H. Francis/E-3051-2011	Farhadi, H Francis/0000-0002-4668-8512; Kronenberg, Golo/0000-0002-5310-9849	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS060801] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS060801] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Grossman RG, 2014, J NEUROTRAUM, V31, P239, DOI 10.1089/neu.2013.2969; Kurland DB, 2013, PHARMACEUTICALS, V6, P1287, DOI 10.3390/ph6101287; Mehta RI, 2013, J NEUROPATH EXP NEUR, V72, P871, DOI 10.1097/NEN.0b013e3182a32e40; Ramer LM, 2014, LANCET NEUROL, V13, P1241, DOI 10.1016/S1474-4422(14)70144-9; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044	5	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2015	14	4					352	352		10.1016/S1474-4422(15)70013-X	http://dx.doi.org/10.1016/S1474-4422(15)70013-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CE5RD	25792091	Green Accepted			2022-12-18	WOS:000351892400009
J	Galpern, WR				Galpern, Wendy R.			Clinical trials for multiple system atrophy	LANCET NEUROLOGY			English	Editorial Material							STATEMENT; DIAGNOSIS		NINDS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Galpern, WR (corresponding author), NINDS, NIH, 6001 Execut Blvd 2225, Bethesda, MD 20892 USA.	galpernw@ninds.nih.gov						Achey M, 2014, MOVEMENT DISORD, V29, P871, DOI 10.1002/mds.25903; Brooks DJ, 2009, MOVEMENT DISORD, V24, P949, DOI 10.1002/mds.22413; Gilman S, 2008, NEUROLOGY, V71, P670, DOI 10.1212/01.wnl.0000324625.00404.15; Low PA, 2014, LANCET NEUROL, V13, P268, DOI 10.1016/S1474-4422(13)70301-6; Poewe W, 2014, LANCET NEUROL; Stankovic I, 2014, MOVEMENT DISORD, V29, P857, DOI 10.1002/mds.25880; Stefanova N, 2008, EXP NEUROL, V210, P421, DOI 10.1016/j.expneurol.2007.11.022; Stefanova N, 2009, LANCET NEUROL, V8, P1172, DOI 10.1016/S1474-4422(09)70288-1; Wenning GK, 2004, MOVEMENT DISORD, V19, P1391, DOI 10.1002/mds.20255; Wenning GK, 2013, LANCET NEUROL, V12, P264, DOI 10.1016/S1474-4422(12)70327-7	10	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2015	14	2					126	127		10.1016/S1474-4422(14)70311-4	http://dx.doi.org/10.1016/S1474-4422(14)70311-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AY9KS	25498733				2022-12-18	WOS:000347869400002
J	Dodick, DW; Goadsby, PJ; Spierings, ELH; Scherer, JC; Sweeney, SP; Grayzel, DS				Dodick, David W.; Goadsby, Peter J.; Spierings, Egilius L. H.; Scherer, Joel C.; Sweeney, Steven P.; Grayzel, David S.			Site of effect of LY2951742 for migraine prophylaxis Reply	LANCET NEUROLOGY			English	Letter							BLOOD-BRAIN-BARRIER		[Dodick, David W.] Mayo Clin, Dept Neurol, Phoenix, AZ 85054 USA; [Goadsby, Peter J.] Kings Coll London, NIHR Wellcome Trust Clin Res Facil, London WC2R 2LS, England; [Spierings, Egilius L. H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Scherer, Joel C.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Sweeney, Steven P.; Grayzel, David S.] Arteaus Therapeut, Cambridge, MA USA	Mayo Clinic; Mayo Clinic Phoenix; University of London; King's College London; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Eli Lilly	Dodick, DW (corresponding author), Mayo Clin, Dept Neurol, Phoenix, AZ 85054 USA.	dodick.david@mayo.edu	Goadsby, Peter J/Z-1970-2019	Goadsby, Peter J/0000-0003-3260-5904				Ardridge WM, 1985, J NEUROCHEM, V44, P1771; Dodick DW, 2014, LANCET NEUROL, V13, P885, DOI 10.1016/S1474-4422(14)70128-0; FELGENHAUER K, 1974, KLIN WOCHENSCHR, V52, P1158, DOI 10.1007/BF01466734; PARDRIDGE WM, 1987, METABOLISM, V36, P892, DOI 10.1016/0026-0495(87)90099-0; Wang YF, 1996, PHARMACEUT RES, V13, P398, DOI 10.1023/A:1016092525901; Yu YJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009835	6	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					32	33		10.1016/S1474-4422(14)70309-6	http://dx.doi.org/10.1016/S1474-4422(14)70309-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25496895				2022-12-18	WOS:000346885300022
J	Lang, AE				Lang, Anthony E.			In pursuit of prodromal Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							MODIFYING THERAPIES; FUTURE; RISK		[Lang, Anthony E.] Univ Toronto, Toronto, ON, Canada; [Lang, Anthony E.] Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada; [Lang, Anthony E.] Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Lang, AE (corresponding author), Univ Toronto, Toronto, ON, Canada.	lang@uhnres.utoronto.ca	Lang, Anthony/ABF-8114-2021	Lang, Anthony/0000-0003-1229-3667				Abbott RD, 2001, NEUROLOGY, V57, P456, DOI 10.1212/WNL.57.3.456; Adler CH, 2014, NEUROLOGY, V83, P406, DOI 10.1212/WNL.0000000000000641; AlDakheel A, 2014, NEUROTHERAPEUTICS, V11, P6, DOI 10.1007/s13311-013-0218-1; Berg D, 2014, MOVEMENT DISORD, V29, P454, DOI 10.1002/mds.25844; Berg D, 2013, LANCET NEUROL, V12, P514, DOI 10.1016/S1474-4422(13)70047-4; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Bonifati V., 2014, PARKINSONISM RELA S1, V20, P523, DOI DOI 10.1016/51353-8020(13)70009-9; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Lang AE, 2010, NAT MED, V16, P1223, DOI 10.1038/nm.2220; Postuma RB, 2009, NEUROLOGY, V72, P1296, DOI 10.1212/01.wnl.0000340980.19702.6e; Ross GW, 2008, ANN NEUROL, V63, P167, DOI 10.1002/ana.21291; Schrag A, 2014, LANCET; Shiba M, 2000, MOVEMENT DISORD, V15, P669, DOI 10.1002/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5	13	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					27	28		10.1016/S1474-4422(14)70230-3	http://dx.doi.org/10.1016/S1474-4422(14)70230-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25435388	hybrid			2022-12-18	WOS:000346885300016
J	Muntoni, F; Cross, JH				Muntoni, Francesco; Cross, J. Helen			Paediatric neurology: from molecular mechanisms to targeted treatments	LANCET NEUROLOGY			English	Editorial Material							MIGRATING PARTIAL SEIZURES; INFANCY; MUTATIONS; EPILEPSY		[Muntoni, Francesco] UCL Inst Child Hlth, Dev Neurosci Programme, London WC1N 1EH, England; Great Ormond St Hosp Sick Children, London WC1N 1EH, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Muntoni, F (corresponding author), UCL Inst Child Hlth, Dev Neurosci Programme, London WC1N 1EH, England.	f.muntoni@ucl.ac.uk	Cross, J. Helen/ACK-3032-2022	Cross, J. Helen/0000-0001-7345-4829				Bearden D, 2014, ANN NEUROL, V76, P457, DOI 10.1002/ana.24229; Bushby K, 2014, MUSCLE NERVE, V50, P477, DOI 10.1002/mus.24332; Fiorillo C, 2014, HUM MUTAT, V35, P298, DOI 10.1002/humu.22491; Jamuar SS, 2014, NEW ENGL J MED, V371, P733, DOI 10.1056/NEJMoa1314432; McTague A, 2013, BRAIN, V136, P1578, DOI 10.1093/brain/awt073; Milligan CJ, 2014, ANN NEUROL, V75, P581, DOI 10.1002/ana.24128; Ng J, 2014, BRAIN, V137, P1107, DOI 10.1093/brain/awu022; SCHEFFER IE, 1995, BRAIN, V118, P61, DOI 10.1093/brain/118.1.61; Scoto M, NEUROLOGY IN PRESS; Voit T, 2014, LANCET NEUROL, V13, P987, DOI 10.1016/S1474-4422(14)70195-4; Wang YX, 2014, NAT GENET, V46, P601, DOI 10.1038/ng.2974	11	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					16	18		10.1016/S1474-4422(14)70304-7	http://dx.doi.org/10.1016/S1474-4422(14)70304-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25496887				2022-12-18	WOS:000346885300010
J	Uceyler, N; Sommer, C				Ueceyler, Nurcan; Sommer, Claudia			Pain: from new perspectives to novel treatments	LANCET NEUROLOGY			English	Editorial Material									[Ueceyler, Nurcan; Sommer, Claudia] Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany	University of Wurzburg	Uceyler, N (corresponding author), Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany.	sommer@uni-wuerzburg.de	Sommer, Claudia/A-9820-2010	Sommer, Claudia/0000-0002-7064-5002; Uceyler, Nurcan/0000-0001-6973-6428				Iyer SM, 2014, NAT BIOTECHNOL, V32, P274, DOI 10.1038/nbt.2834; Rice ASC, 2014, LANCET, V383, P1637, DOI 10.1016/S0140-6736(13)62337-5; Serra J, 2014, ANN NEUROL, V75, P196, DOI 10.1002/ana.24065; Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/NMETH.2935, 10.1038/nmeth.2935]; Uceyler N, 2013, BRAIN, V136, P1857, DOI 10.1093/brain/awt053; Wright BD, 2014, NEURON, V82, P836, DOI 10.1016/j.neuron.2014.04.006	6	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					22	23		10.1016/S1474-4422(14)70296-0	http://dx.doi.org/10.1016/S1474-4422(14)70296-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25496890				2022-12-18	WOS:000346885300013
J	Logroscino, G; Ludolph, A				Logroscino, Giancarlo; Ludolph, Albert			Amyotrophic lateral sclerosis: new ideas from cancer Comment	LANCET NEUROLOGY			English	Editorial Material							EPIDEMIOLOGY		[Logroscino, Giancarlo] Univ Aldo Moro, Pia Fdn Card G Panico,Hosp Tricase, Dept Basic Med Neurosci & Sense Organs,Univ Bari, Neurodegenerat Dis Unit,Dept Clin Res Neurol, I-73039 Bari, Italy; [Ludolph, Albert] Univ Ulm, Dept Neurol, D-89069 Ulm, Germany	Universita degli Studi di Bari Aldo Moro; Ulm University	Logroscino, G (corresponding author), Univ Aldo Moro, Pia Fdn Card G Panico,Hosp Tricase, Dept Basic Med Neurosci & Sense Organs,Univ Bari, Neurodegenerat Dis Unit,Dept Clin Res Neurol, I-73039 Bari, Italy.	giancarlo.logroscino@uniba.it	LOGROSCINO, GIANCARLO/K-5148-2016	LOGROSCINO, GIANCARLO/0000-0003-0423-3242				Al-Chalabi A, 2014, LANCET NEUROL; Al-Chalabi A, 2013, NAT REV NEUROL, V9, P617, DOI 10.1038/nrneurol.2013.203; Braak H, 2013, NAT REV NEUROL, V9, P708, DOI 10.1038/nrneurol.2013.221; Brettschneider J, 2013, ANN NEUROL, V74, P20, DOI 10.1002/ana.23937; Freischmidt A, 2014, BRAIN, V137, P2938, DOI 10.1093/brain/awu249; Logroscino G, 2008, J NEUROL NEUROSUR PS, V79, P6, DOI 10.1136/jnnp.2006.104828; Logroscino G, 2010, J NEUROL NEUROSUR PS, V81, P385, DOI 10.1136/jnnp.2009.183525; Phukan J, 2012, J NEUROL NEUROSUR PS, V83, P102, DOI 10.1136/jnnp-2011-300188; Robins JM, 2009, ADV LONGITUDINAL DAT; Uenal H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093932	10	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2014	13	11					1067	1068		10.1016/S1474-4422(14)70177-2	http://dx.doi.org/10.1016/S1474-4422(14)70177-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR7TZ	25300935				2022-12-18	WOS:000343783900005
J	Gratz, PP; Gralla, J; Mottle, HP; Schroth, G				Gratz, Pascal P.; Gralla, Jan; Mottle, Heinrich P.; Schroth, Gerhard			Embolic strokes of undetermined source: support for a new clinical construct	LANCET NEUROLOGY			English	Letter									[Gratz, Pascal P.; Gralla, Jan; Schroth, Gerhard] Univ Hosp Bern, Inselspital, Dept Diagnost & Intervent Neuroradiol, CH-3010 Bern, Switzerland; [Mottle, Heinrich P.] Univ Hosp Bern, Inselspital, Dept Neurol, CH-3010 Bern, Switzerland; Univ Bern, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern	Gratz, PP (corresponding author), Univ Hosp Bern, Inselspital, Dept Diagnost & Intervent Neuroradiol, CH-3010 Bern, Switzerland.	pascal.gratz@insel.ch						Hart RG, 2014, LANCET NEUROL, V13, P429, DOI 10.1016/S1474-4422(13)70310-7; Marder VJ, 2006, STROKE, V37, P2086, DOI 10.1161/01.STR.0000230307.03438.94; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Niesten JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088882; Weisstanner C, 2014, EUR RADIOL, V24, P1735, DOI 10.1007/s00330-014-3200-3	5	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2014	13	10					967	967		10.1016/S1474-4422(14)70196-6	http://dx.doi.org/10.1016/S1474-4422(14)70196-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AP3EZ	25231517				2022-12-18	WOS:000341959700005
J	Basner, M; Dinges, DF				Basner, Mathias; Dinges, David F.			Lost in space: sleep	LANCET NEUROLOGY			English	Editorial Material							DURATION; MISSION		[Basner, Mathias; Dinges, David F.] Univ Penn, Dept Psychiat, Div Sleep & Chronobiol, Unit Expt Psychiat,Perelman Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Perelman Sch Med, Dept Psychiat, Div Sleep & Chronobiol,Unit Expt Psychiat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Basner, M (corresponding author), Univ Penn, Dept Psychiat, Div Sleep & Chronobiol, Unit Expt Psychiat,Perelman Sch Med, Philadelphia, PA 19104 USA.	basner@upenn.edu	Dinges, David/P-7183-2019					Arendt J, 2012, CHRONOBIOL INT, V29, P379, DOI 10.3109/07420528.2012.668997; Banner M, 2011, ACTA ASTRONAUT, V69, P949; Barger LK, 2012, SLEEP, V35, P1423, DOI 10.5665/sleep.2128; Barger LK, 2014, LANCET NEUROL; Basner M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093298; Basner M, 2013, P NATL ACAD SCI USA, V110, P2635, DOI 10.1073/pnas.1212646110; Mader TH, 2011, OPHTHALMOLOGY, V118, P2058, DOI 10.1016/j.ophtha.2011.06.021; NASA, 2014, PSYCH VIG TEST PVT I; National Aeronautics and Space Administration (NASA), 2014, OP GROUND TEST PROT; Schmid SM, 2014, LANCET DIABETES ENDO; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117	11	3	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2014	13	9					860	862		10.1016/S1474-4422(14)70176-0	http://dx.doi.org/10.1016/S1474-4422(14)70176-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO5SK	25127233				2022-12-18	WOS:000341405400005
J	Elger, CE				Elger, Christian E.			Epilepsy: lost in translation	LANCET NEUROLOGY			English	Editorial Material							CONTROLLED-RELEASE CARBAMAZEPINE		Univ Bonn, Med Ctr, Dept Epileptol, D-53105 Bonn, Germany	University of Bonn	Elger, CE (corresponding author), Univ Bonn, Med Ctr, Dept Epileptol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	christian.elger@ukb.uni-bonn.de						Baulac M, 2012, LANCET NEUROL, V11, P579, DOI 10.1016/S1474-4422(12)70105-9; Brodie MJ, 2007, NEUROLOGY, V68, P402, DOI 10.1212/01.wnl.0000252941.50833.4a; Cook MJ, 2013, LANCET NEUROL, V12, P563, DOI 10.1016/S1474-4422(13)70075-9; Costa J, 2011, EPILEPSIA, V52, P1280, DOI 10.1111/j.1528-1167.2011.03047.x; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Glauser T, 2013, EPILEPSIA, V54, P551, DOI 10.1111/epi.12074; Glauser TA, 2010, NEW ENGL J MED, V362, P790, DOI 10.1056/NEJMoa0902014; Hoppe C, 2007, ARCH NEUROL-CHICAGO, V64, P1595, DOI 10.1001/archneur.64.11.1595; Lewis DV, 2014, ANN NEUROL, V75, P178, DOI 10.1002/ana.24081; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Simonato M, 2014, LANCET NEUROLOGY	11	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2014	13	9					862	863		10.1016/S1474-4422(14)70125-5	http://dx.doi.org/10.1016/S1474-4422(14)70125-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO5SK	25127172				2022-12-18	WOS:000341405400006
J	Khatri, P; Yeatts, SD				Khatri, Pooja; Yeatts, Sharon D.		IMS III Trialists	Complexity of the endovascular intervention and clinical outcomes in acute ischaemic stroke reply	LANCET NEUROLOGY			English	Letter									[Khatri, Pooja; Yeatts, Sharon D.; IMS III Trialists] Dept Neurol & Rehabil Med, Cincinnati, OH 45208 USA		Khatri, P (corresponding author), Dept Neurol & Rehabil Med, 260 Stetson St,ML 0525, Cincinnati, OH 45208 USA.	pooja.khatri@uc.edu						Khatri P, 2014, LANCET NEUROL, V13, P567, DOI 10.1016/S1474-4422(14)70066-3; Wechsler LR, 2003, STROKE, V34, P1224, DOI 10.1161/01.STR.0000068782.15297.28	2	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2014	13	9					865	866		10.1016/S1474-4422(14)70175-9	http://dx.doi.org/10.1016/S1474-4422(14)70175-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO5SK	25142454				2022-12-18	WOS:000341405400011
J	Dubois, B; Feldman, HH; Jacova, C				Dubois, B.; Feldman, H. H.; Jacova, C.			Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (vol 13, pg 614, 2014)	LANCET NEUROLOGY			English	Correction																		Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0	1	3	3	2	41	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2014	13	8					757	757		10.1016/S1474-4422(14)70155-3	http://dx.doi.org/10.1016/S1474-4422(14)70155-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AL9JB					2022-12-18	WOS:000339456300008
J	Feldman, V				Feldman, Virginia			Neurodevelopmental toxicity: still more questions than answers	LANCET NEUROLOGY			English	Letter									Kaiser Permanente Northwest, Portland, OR 97219 USA	Kaiser Permanente	Feldman, V (corresponding author), Kaiser Permanente Northwest, Portland, OR 97219 USA.	feldmanvi@gmail.com						Bazian Ltd, 2009, IND CRIT APPR STUD R; Bellinger DC, 2012, ENVIRON HEALTH PERSP, V120, P501, DOI 10.1289/ehp.1104170; Boyle CA, 2011, PEDIATRICS, V127, P1034, DOI 10.1542/peds.2010-2989; CDC, CDC DATA NHIS NATL H; Grandjean P, 2014, LANCET NEUROL, V13, P330, DOI 10.1016/S1474-4422(13)70278-3; Horton MK, 2011, PEDIATRICS, V127, pE699, DOI 10.1542/peds.2010-0133; Jankovic J, ETIOLOGY PATHOGENESI; Kieburtz K, 2013, MOVEMENT DISORD, V28, P8, DOI 10.1002/mds.25150; Neisser U, 1997, AM SCI, V85, P440; Scientific Committee on Health & Environmental Risk of the European Union, 2011, OP CRIT REV AN NEW E	10	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2014	13	7					645	646		10.1016/S1474-4422(14)70115-2	http://dx.doi.org/10.1016/S1474-4422(14)70115-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK5RI	24943336				2022-12-18	WOS:000338483600007
J	Girard, SL; Rouleau, GA				Girard, Simon L.; Rouleau, Guy A.			Genome-wide association study in FTD: divide to conquer	LANCET NEUROLOGY			English	Editorial Material							FRONTOTEMPORAL DEMENTIA; MUTATIONS; TAU		[Girard, Simon L.] McGill Univ, Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Rouleau, Guy A.] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada; [Girard, Simon L.] Univ Montreal, CRCHUM, Montreal, PQ, Canada	McGill University; McGill University; Universite de Montreal	Girard, SL (corresponding author), McGill Univ, Genome Quebec Innovat Ctr, Montreal, PQ, Canada.	guy.rouleau@mcgill.ca		Girard, Simon/0000-0002-4089-2280				Amor S, 2014, IMMUNOLOGY, V141, P287, DOI 10.1111/imm.12134; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Brady OA, 2013, HUM MOL GENET, V22, P685, DOI 10.1093/hmg/dds475; Cordell HJ, 2013, NAT GENET, V45, P822, DOI 10.1038/ng.2637; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Ferrari R, 2014, LANCET NEUROL; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Rohrer JD, 2011, CURR OPIN NEUROL, V24, P542, DOI 10.1097/WCO.0b013e32834cd442	8	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2014	13	7					643	644		10.1016/S1474-4422(14)70070-5	http://dx.doi.org/10.1016/S1474-4422(14)70070-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK5RI	24943334				2022-12-18	WOS:000338483600005
J	Kieseier, BC; Wiendl, H				Kieseier, Bernd C.; Wiendl, Heinz			New evidence for teriflunomide in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							ORAL FINGOLIMOD		[Kieseier, Bernd C.] Univ Dusseldorf, Dept Neurol, Fac Med, D-40225 Dusseldorf, Germany; [Wiendl, Heinz] Univ Munster, Dept Neurol, D-48149 Munster, Germany	Heinrich Heine University Dusseldorf; University of Munster	Kieseier, BC (corresponding author), Univ Dusseldorf, Dept Neurol, Fac Med, D-40225 Dusseldorf, Germany.	bernd.kieseier@uni-duesseldorf.de	Wiendl, Heinz/AAX-6041-2021	Wiendl, Heinz/0000-0003-4310-3432				Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Confavreux C, 2014, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70308-9; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Hauser SL, 2013, ANN NEUROL, V74, P317, DOI 10.1002/ana.24009; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kieseier BC, 2011, NAT REV NEUROL, V7, P255, DOI 10.1038/nrneurol.2011.41; O'Connor P, 2011, NEW ENGL J MED, V365, P1293, DOI 10.1056/NEJMoa1014656; Oh Jiwon, 2013, Neurol Clin Pract, V3, P254	8	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2014	13	3					234	235		10.1016/S1474-4422(14)70012-2	http://dx.doi.org/10.1016/S1474-4422(14)70012-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AC1NW	24461573				2022-12-18	WOS:000332264300002
J	Geschwind, MD				Geschwind, Michael D.			Doxycycline for Creutzfeldt-Jakob disease: a failure, but a step in the right direction	LANCET NEUROLOGY			English	Editorial Material							INTRAVENTRICULAR PENTOSAN POLYSULFATE; HUMAN PRION DISEASE; EFFICACY; TETRACYCLINES; THERAPEUTICS; QUINACRINE; INFUSION; TRIAL		Univ Calif San Francisco, Memory & Aging Ctr, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Geschwind, MD (corresponding author), Univ Calif San Francisco, Memory & Aging Ctr, Dept Neurol, Box 1207, San Francisco, CA 94143 USA.	mgeschwind@memory.ucsf.edu			NATIONAL INSTITUTE ON AGING [P01AG021601, R01AG031189] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG021601, R01 AG031189] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berry DB, 2013, P NATL ACAD SCI USA, V110, pE4160, DOI 10.1073/pnas.1317164110; Bone I, 2008, EUR J NEUROL, V15, P458, DOI 10.1111/j.1468-1331.2008.02108.x; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; Collinge J, 2009, LANCET NEUROL, V8, P334, DOI 10.1016/S1474-4422(09)70049-3; De Luigi A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001888; Doh-Ura K, 2004, J VIROL, V78, P4999, DOI 10.1128/JVI.78.10.4999-5006.2004; Forloni G, 2002, P NATL ACAD SCI USA, V99, P10849, DOI 10.1073/pnas.162195499; Geschwind MD, 2013, NEUROLOGY, V81, P2015, DOI 10.1212/WNL.0b013e3182a9f3b4; Haik S, 2014, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70307-7; Honda H, 2012, NEUROPATHOLOGY, V32, P124, DOI 10.1111/j.1440-1789.2011.01245.x; Johnson DY, 2013, JAMA NEUROL, V70, P254, DOI 10.1001/2013.jamaneurol.139; Kawasaki Y, 2007, J VIROL, V81, P12889, DOI 10.1128/JVI.01563-07; Lu D, 2013, J PHARMACOL EXP THER, V347, P325, DOI 10.1124/jpet.113.205799; Mead S, 2011, NEUROLOGY, V77, P1674, DOI 10.1212/WNL.0b013e3182364890; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Otto M, 2004, NEUROLOGY, V62, P714, DOI 10.1212/01.WNL.0000113764.35026.EF; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Ponto C., 2013, INFO NEUROLOGIE PSYC, P2; Prusiner SB, 2012, SCIENCE, V336, P1511, DOI 10.1126/science.1222951; Rabinovici GD, 2006, NEUROLOGY, V66, P286, DOI 10.1212/01.wnl.0000196440.00297.67; Tagliavini F., 2008, ALZHEIMERS DEMENT, V4(5s), pT149; Trevitt CR, 2006, BRAIN, V129, P2241, DOI 10.1093/brain/awl150; Tsuboi Y, 2009, NEUROPATHOLOGY, V29, P632, DOI 10.1111/j.1440-1789.2009.01058.x	23	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2014	13	2					130	132		10.1016/S1474-4422(14)70001-8	http://dx.doi.org/10.1016/S1474-4422(14)70001-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	301QE	24411710	Green Submitted			2022-12-18	WOS:000330546200003
J	Rabinstein, AA				Rabinstein, Alejandro A.			Intracranial aneurysms: individualising the risk of rupture	LANCET NEUROLOGY			English	Editorial Material							ANGIOGRAPHY		Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic	Rabinstein, AA (corresponding author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.	rabinstein.alejandro@mayo.edu						Brinjikji W, 2012, AM J NEURORADIOL, V33, P49, DOI 10.3174/ajnr.A2739; Burns JD, 2009, STROKE, V40, P406, DOI 10.1161/STROKEAHA.108.519165; Cebral JR, 2011, AM J NEURORADIOL, V32, P264, DOI 10.3174/ajnr.A2274; Greying JP, 2013, LANCET NEUROL; Lindekleiv H, 2012, STROKE, V43, P1885, DOI 10.1161/STROKEAHA.112.651315; Rabinstein AA, 2010, LANCET NEUROL, V9, P504, DOI 10.1016/S1474-4422(10)70087-9; Vlak MHM, 2013, STROKE, V44, P1256, DOI 10.1161/STROKEAHA.111.000679; Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0; Wermer MJH, 2006, STROKE, V37, P414, DOI 10.1161/01.STR.0000199077.06390.35; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3	10	3	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2014	13	1					25	27		10.1016/S1474-4422(13)70272-2	http://dx.doi.org/10.1016/S1474-4422(13)70272-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	280AL	24290160				2022-12-18	WOS:000329000900015
J	Trenkwalder, C; Benes, H; Grote, L				Trenkwalder, C.; Benes, H.; Grote, L.			Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension (vol 12, pg 1141, 2013)	LANCET NEUROLOGY			English	Correction													Trenkwalder, Claudia/ABD-6559-2021; Trenkwalder, Claudia/AHD-1232-2022; Grote, Ludger/C-9958-2013	Trenkwalder, Claudia/0000-0001-6407-1199; 				Trenkwalder C, 2013, LANCET NEUROL, V12, P1141, DOI 10.1016/S1474-4422(13)70239-4	1	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2013	12	12					1133	1133		10.1016/S1474-4422(13)70239-4	http://dx.doi.org/10.1016/S1474-4422(13)70239-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	265BG					2022-12-18	WOS:000327924100006
J	Sander, JW				Sander, Josemir W.			Reducing the risk of sudden death during epilepsy monitoring	LANCET NEUROLOGY			English	Editorial Material							UNEXPECTED DEATH		[Sander, Josemir W.] NIHR Univ Coll London Hosp Biomed Res Ctr, Dept Clin & Expt Epilepsy, UCL Inst Neurol, London WC1N 3BG, England; [Sander, Josemir W.] SEIN Stichting Epilepsie Instellingen Nederland, Heemstede, Netherlands	University College London Hospitals NHS Foundation Trust; University of London; University College London	Sander, JW (corresponding author), NIHR Univ Coll London Hosp Biomed Res Ctr, Dept Clin & Expt Epilepsy, UCL Inst Neurol, London WC1N 3BG, England.	l.sander@ucl.ac.uk	Sander, Josemir/C-1576-2008	Sander, Josemir/0000-0001-6041-9661				Bird JM, 1997, EPILEPSIA, V38, pS52, DOI 10.1111/j.1528-1167.1997.tb06295.x; Lamberts RJ, 2013, NEUROLOGY, V81, P1252, DOI 10.1212/WNL.0b013e3182a6cbeb; Lamberts RJ, 2012, EPILEPSIA, V53, P253, DOI 10.1111/j.1528-1167.2011.03360.x; Langan Y, 2005, NEUROLOGY, V64, P1131, DOI 10.1212/01.WNL.0000156352.61328.CB; Lhatoo SD, 2010, ANN NEUROL, V68, P787, DOI 10.1002/ana.22101; NASHEF L, 1995, J NEUROL NEUROSUR PS, V58, P462, DOI 10.1136/jnnp.58.4.462; Ryvlin P, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70214-X; Sander JW, 2013, LANCET, DOI DOI 10.1016/S0140-6736(13)60899-5; Surges R, 2012, CURR OPIN NEUROL, V25, P201, DOI 10.1097/WCO.0b013e3283506714; Surges R, 2009, NAT REV NEUROL, V5, P492, DOI 10.1038/nrneurol.2009.118	10	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2013	12	10					935	936		10.1016/S1474-4422(13)70216-3	http://dx.doi.org/10.1016/S1474-4422(13)70216-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	237XV	24012375				2022-12-18	WOS:000325905800004
J	Shevel, E				Shevel, Elliot			Intracranial and extracranial arteries in migraine	LANCET NEUROLOGY			English	Letter							HEADACHE		Headache Clin, Johannesburg, South Africa		Shevel, E (corresponding author), Headache Clin, Johannesburg, South Africa.	drshevel@headclin.co.za						Amin FM, 2013, LANCET NEUROL, V12, P454, DOI 10.1016/S1474-4422(13)70067-X; Guo S, 2013, CEPHALALGIA, V33, P301, DOI 10.1177/0333102412475239; IVERSEN HK, 1990, LANCET, V336, P837, DOI 10.1016/0140-6736(90)92339-J; Shevel E, 2011, HEADACHE, V51, P409, DOI 10.1111/j.1526-4610.2011.01844.x	4	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2013	12	9					847	847		10.1016/S1474-4422(13)70169-8	http://dx.doi.org/10.1016/S1474-4422(13)70169-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	210WU	23948171				2022-12-18	WOS:000323866600009
J	Stuve, O; Paul, F				Stuve, Olaf; Paul, Friedemann			Progressive multiple sclerosis: desperately seeking remedy	LANCET NEUROLOGY			English	Editorial Material							NATURAL-HISTORY; CANNABINOIDS; TRIAL		[Stuve, Olaf] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75216 USA; [Stuve, Olaf] VA North Texas Hlth Care Syst, Neurol Sect, Med Serv, Dallas, TX USA; [Stuve, Olaf] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-80290 Munich, Germany; [Paul, Friedemann] Charite, NeuroCure Clin Res Ctr, D-13353 Berlin, Germany	University of Texas System; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System; Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stuve, O (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75216 USA.	olaf.stuve@utsouthwestern.edu	Paul, Friedemann/ABF-9415-2020	paul, friedemann/0000-0002-6378-0070				Goodman AD, 2010, ANN NEUROL, V68, P494, DOI 10.1002/ana.22240; Gowran A, 2011, CNS NEUROSCI THER, V17, P637, DOI 10.1111/j.1755-5949.2010.00195.x; Hasseldam H, 2011, INT J NEUROSCI, V121, P510, DOI 10.3109/00207454.2011.582237; Kieseier BC, 2011, NAT REV NEUROL, V7, P255, DOI 10.1038/nrneurol.2011.41; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Tremlett H, 2010, NEUROLOGY, V74, P2004, DOI 10.1212/WNL.0b013e3181e3973f; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1; Zajicek J, 2013, LANCET NEUROL, V12, P857, DOI 10.1016/S1474-4422(13)70159-5	10	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2013	12	9					840	841		10.1016/S1474-4422(13)70181-9	http://dx.doi.org/10.1016/S1474-4422(13)70181-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	210WU	23867356				2022-12-18	WOS:000323866600002
J	Anderson, C				Anderson, Craig			Thrombolysis with alteplase after stroke: extending outcomes	LANCET NEUROLOGY			English	Editorial Material							TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE		[Anderson, Craig] Royal Prince Alfred Hosp, George Inst Global Hlth, Camperdown, NSW 2050, Australia; [Anderson, Craig] Univ Sydney, Camperdown, NSW 2050, Australia	George Institute for Global Health; University of Sydney; University of Sydney	Anderson, C (corresponding author), Royal Prince Alfred Hosp, George Inst Global Hlth, POB M201,Missenden Rd, Camperdown, NSW 2050, Australia.	canderson@georgeinstitute.org.au		Anderson, Craig/0000-0002-7248-4863				Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609; Ayerbe L, 2013, STROKE, V44, P1105, DOI 10.1161/STROKEAHA.111.679340; Crosby RD, 2003, J CLIN EPIDEMIOL, V56, P395, DOI 10.1016/S0895-4356(03)00044-1; Haley WE, 2011, QUAL LIFE RES, V20, P799, DOI 10.1007/s11136-010-9810-6; Sandercock P, 2013, LANCET NEUROL, V12, P768, DOI 10.1016/S1474-4422(13)70130-3; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Walters SJ, 2005, QUAL LIFE RES, V14, P1523, DOI 10.1007/s11136-004-7713-0; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7	8	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2013	12	8					731	732		10.1016/S1474-4422(13)70149-2	http://dx.doi.org/10.1016/S1474-4422(13)70149-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	195GP	23791821	hybrid			2022-12-18	WOS:000322690600004
J	Fratta, P				Fratta, Pietro			Antisense makes sense for amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Editorial Material							OLIGONUCLEOTIDE THERAPY; SOD1; ALS		[Fratta, Pietro] UCL, Dept Neurodegenerat Dis, London WC1N 3BG, England; [Fratta, Pietro] UCL, Inst Neurol, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Fratta, P (corresponding author), UCL, Dept Neurodegenerat Dis, Queen Sq, London WC1N 3BG, England.	p.fratta@prion.ucl.ac.uk	Fratta, Pietro/G-1296-2019	Fratta, Pietro/0000-0002-8762-8188; fratta, pietro/0000-0002-7554-1632	Medical Research Council [G1000287] Funding Source: Medline; MRC [G1000287] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andersen PM, 2011, NAT REV NEUROL, V7, P603, DOI 10.1038/nrneurol.2011.150; Bosco DA, 2010, NAT NEUROSCI, V13, P1396, DOI 10.1038/nn.2660; Clark MB, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000625; Haidet-Phillips AM, 2011, NAT BIOTECHNOL, V29, P824, DOI 10.1038/nbt.1957; Majounie E, 2012, LANCET NEUROL, V11, P323, DOI 10.1016/S1474-4422(12)70043-1; Miller TM, 2013, LANCET NEUROL, DOI DOI 10.1016/S1474-4; Saccon R, BRAIN IN PRESS; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI25424; Southwell AL, 2012, TRENDS MOL MED, V18, P634, DOI 10.1016/j.molmed.2012.09.001; Winer L, 2013, JAMA NEUROL, V70, P201, DOI 10.1001/jamaneurol.2013.593	10	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2013	12	5					416	417		10.1016/S1474-4422(13)70059-0	http://dx.doi.org/10.1016/S1474-4422(13)70059-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142ZS	23541757				2022-12-18	WOS:000318836700002
J	Miller, TM; Pestronk, A; David, W				Miller, T. M.; Pestronk, A.; David, W.			An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (vol 12, pg 435, 2013)	LANCET NEUROLOGY			English	Correction																		Miller TM, 2013, LANCET NEUROL, V12, P435, DOI 10.1016/S1474-4422(13)70061-9	1	3	3	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2013	12	5					423	423		10.1016/S1474-4422(13)70061-9	http://dx.doi.org/10.1016/S1474-4422(13)70061-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142ZS		hybrid, Green Accepted			2022-12-18	WOS:000318836700007
J	Birbeck, GL				Birbeck, Gretchen L.			Epilepsy in Africa: caution and optimism	LANCET NEUROLOGY			English	Editorial Material									Michigan State Univ, INPEP, E Lansing, MI 48824 USA	Michigan State University	Birbeck, GL (corresponding author), Michigan State Univ, INPEP, E Lansing, MI 48824 USA.	birbeck@msu.edu						COCKERELL OC, 1995, J NEUROL NEUROSUR PS, V58, P570, DOI 10.1136/jnnp.58.5.570; Crepin S, 2009, CLIN NUTR, V28, P219, DOI 10.1016/j.clnu.2009.03.010; Kaiser C, 2011, AM J TROP MED HYG, V85, P225, DOI 10.4269/ajtmh.2011.10-0544; Kvalsund MP, 2012, CURR OPIN NEUROL, V25, P179, DOI 10.1097/WCO.0b013e328350baf8; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Meyer AC, 2010, B WORLD HEALTH ORGAN, V88, P260, DOI 10.2471/BLT.09.064147; Mu J, 2011, NEUROLOGY, V77, P132, DOI 10.1212/WNL.0b013e318223c784; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Ngugi AK, 2013, LANCET NEUROL, V12, P253, DOI 10.1016/S1474-4422(13)70003-6; Preux PM, 2005, LANCET NEUROL, V4, P21, DOI 10.1016/S1474-4422(04)00963-9	10	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2013	12	3					220	222		10.1016/S1474-4422(12)70324-1	http://dx.doi.org/10.1016/S1474-4422(12)70324-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138SW	23375963				2022-12-18	WOS:000318531300004
J	Lindhout, D				Lindhout, Dick			Antiepileptic drugs during pregnancy and cognitive outcomes	LANCET NEUROLOGY			English	Editorial Material							SUPPLEMENTATION; PREVENTION; RISK; ACID		[Lindhout, Dick] Univ Med Ctr Utrecht, Dept Med Genet, NL-3508 AB Utrecht, Netherlands; [Lindhout, Dick] SEIN Epilepsy Inst Netherlands, Heemstede, Netherlands	Utrecht University; Utrecht University Medical Center	Lindhout, D (corresponding author), Univ Med Ctr Utrecht, Dept Med Genet, POB 85090, NL-3508 AB Utrecht, Netherlands.	d.lindhout@umcutrecht.nl	Lindhout, Dick/AAH-5765-2019	Lindhout, Dick/0000-0001-9580-624X				CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; Jentink J, 2010, PHARMACOEPIDEM DR S, V19, P803, DOI 10.1002/pds.1975; Marean A, 2011, HUM MOL GENET, V20, P3678, DOI 10.1093/hmg/ddr289; Meador KJ, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(12)70323-X; Tomson T, 2011, LANCET NEUROL, V10, P609, DOI 10.1016/S1474-4422(11)70107-7; WALD N, 1991, LANCET, V338, P131	6	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2013	12	3					219	220		10.1016/S1474-4422(13)70012-7	http://dx.doi.org/10.1016/S1474-4422(13)70012-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138SW	23352200				2022-12-18	WOS:000318531300003
J	Cross, JH				Cross, J. Helen			Nodding syndrome-a challenge for African public health	LANCET NEUROLOGY			English	Editorial Material									Great Ormond St Hosp Children NHS Fdn Trust, UCL Inst Child Hlth, Neurosci Unit, London WC1N 3LU, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Cross, JH (corresponding author), Great Ormond St Hosp Children NHS Fdn Trust, UCL Inst Child Hlth, Neurosci Unit, 4-5 Long Yard, London WC1N 3LU, England.	h.cross@ucl.ac.uk	Cross, J. Helen/ACK-3032-2022	Cross, J. Helen/0000-0001-7345-4829				Lacey M, 2003, LANCET NEUROL, V2, P714, DOI 10.1016/S1474-4422(03)00599-4; Reik Lul, 2012, Morbidity and Mortality Weekly Report, V61, P52; Sejvar JJ, 2013, LANCET NEUROL; WHO, NODD SYNDR DEV ILLN; Winkler AS, 2008, EPILEPSIA, V49, P2008, DOI 10.1111/j.1528-1167.2008.01671.x	5	3	3	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2013	12	2					125	126		10.1016/S1474-4422(12)70326-5	http://dx.doi.org/10.1016/S1474-4422(12)70326-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	081NZ	23305743				2022-12-18	WOS:000314330200005
J	Vidale, S				Vidale, Simone			Restenosis after carotid endarterectomy and stenting	LANCET NEUROLOGY			English	Letter									St Anna Hosp, Dept Neurol, I-22020 San Fermo Battaglia, Como, Italy	University of Ferrara; Arcispedale Sant'Anna	Vidale, S (corresponding author), St Anna Hosp, Dept Neurol, I-22020 San Fermo Battaglia, Como, Italy.	simone.vidale@hsacomo.org	vidale, simone/AAJ-4466-2020					Lal BK, 2007, SEMIN VASC SURG, V20, P259, DOI 10.1053/j.semvascsurg.2007.10.009; Lal BK, 2012, LANCET NEUROL, V11, P755, DOI 10.1016/S1474-4422(12)70159-X; Perler BA, 2007, SEMIN VASC SURG, V20, P252, DOI 10.1053/j.semvascsurg.2007.10.008; Simon DI, 2012, CIRC J, V76, P1811, DOI 10.1253/circj.CJ-12-0801	4	3	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2013	12	2					130	130		10.1016/S1474-4422(12)70261-2	http://dx.doi.org/10.1016/S1474-4422(12)70261-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	081NZ	23151440				2022-12-18	WOS:000314330200010
J	Jagust, W				Jagust, William			Tracking brain amyloid-beta in presymptomatic Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material									[Jagust, William] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Jagust, William] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Jagust, W (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, 132 Barker Hall, Berkeley, CA 94720 USA.	jagust@berkeley.edu	Jagust, William/ABE-6426-2020					Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Fleisher AS, 2012, LANCET NEUROL; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Reiman EM, 2012, LANCET NEUROL; Villemagne VL, 2011, ANN NEUROL, V69, P181, DOI 10.1002/ana.22248	7	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2012	11	12					1018	1020		10.1016/S1474-4422(12)70255-7	http://dx.doi.org/10.1016/S1474-4422(12)70255-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044CX	23137951				2022-12-18	WOS:000311598100005
J	Schmidt, D				Schmidt, Dieter			Time to withdraw AEDs after successful epilepsy surgery	LANCET NEUROLOGY			English	Editorial Material							ANTIEPILEPTIC DRUG-WITHDRAWAL; SEIZURE-FREE PATIENTS; RECURRENCE		Epilepsy Res Grp, D-14163 Berlin, Germany	Epilepsy Research Group	Schmidt, D (corresponding author), Epilepsy Res Grp, Goethestr 5, D-14163 Berlin, Germany.	dbschmidt@t-online.de						Boshuisen K, 2012, OPTN SRTR ANN REP; Boshuisen K, 2009, PEDIATR NEUROL, V41, P332, DOI 10.1016/j.pediatrneurol.2009.04.025; CHADWICK D, 1991, LANCET, V337, P1175; Lossius MI, 2008, EPILEPSIA, V49, P455, DOI 10.1111/j.1528-1167.2007.01323.x; Schmidt D, 2004, EPILEPSIA, V45, P179, DOI 10.1111/j.0013-9580.2004.37803.x; Sillanpaa M, 2006, EPILEPSY BEHAV, V8, P713, DOI 10.1016/j.yebeh.2006.02.014	6	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2012	11	9					745	746		10.1016/S1474-4422(12)70176-X	http://dx.doi.org/10.1016/S1474-4422(12)70176-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	994DS	22841351				2022-12-18	WOS:000307911700005
J	Charles, A				Charles, Andrew			Defining and refining 5-HT receptor targets for migraine	LANCET NEUROLOGY			English	Editorial Material							5-HT1B/1D AGONISTS; TRIPTANS; LASMIDITAN; PROFILE		Univ Calif Los Angeles, David Geffen Sch Med, Headache Res & Treatment Program, Dept Neurol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Charles, A (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Headache Res & Treatment Program, Dept Neurol, Los Angeles, CA 90095 USA.	acharles@ucla.edu						Classey JD, 2010, BRAIN RES, V1361, P76, DOI 10.1016/j.brainres.2010.09.004; Dodick D, 2004, HEADACHE, V44, P414, DOI 10.1111/j.1526-4610.2004.04078.x; Edvinsson L, 2008, CEPHALALGIA, V28, P1245, DOI 10.1111/j.1468-2982.2008.01675.x; Farkkila M, 2012, LANCET NEUROL, V11, P405, DOI 10.1016/S1474-4422(12)70047-9; Ferrari MD, 2002, CEPHALALGIA, V22, P633, DOI 10.1046/j.1468-2982.2002.00404.x; Ferrari MD, 2010, CEPHALALGIA, V30, P1170, DOI 10.1177/0333102410375512; Goadsby P.J., 2007, HDB EXP PHARM, V177, P129, DOI DOI 10.1007/978-3-540-33823-9_5; Nelson DL, 2010, CEPHALALGIA, V30, P1159, DOI 10.1177/0333102410370873	8	3	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2012	11	5					383	384		10.1016/S1474-4422(12)70062-5	http://dx.doi.org/10.1016/S1474-4422(12)70062-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	930KM	22459548				2022-12-18	WOS:000303138300003
J	Rudick, RA				Rudick, Richard A.			MS clinical trials: what can subgroup analyses teach us?	LANCET NEUROLOGY			English	Editorial Material							PLACEBO-CONTROLLED TRIAL		Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Neurol Inst, Cleveland, OH 44106 USA	Cleveland Clinic Foundation	Rudick, RA (corresponding author), Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Neurol Inst, Cleveland, OH 44106 USA.	rudickr@ccf.org						Devonshire V, 2012, LANCET NEUROL, V11, P420, DOI 10.1016/S1474-4422(12)70056-X; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; Giovannoni G, 2011, LANCET NEUROL, V10, P329, DOI 10.1016/S1474-4422(11)70023-0; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Hernandez AV, 2006, AM HEART J, V151, P257, DOI 10.1016/j.ahj.2005.04.020; Hutchinson M, 2009, J NEUROL, V256, P405, DOI 10.1007/s00415-009-0093-1; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; Polman Chris H, 2006, N Engl J Med, V354, P899; ROSE AS, 1970, NEUROLOGY, V20, P1	10	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2012	11	5					386	388		10.1016/S1474-4422(12)70066-2	http://dx.doi.org/10.1016/S1474-4422(12)70066-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	930KM	22494954				2022-12-18	WOS:000303138300005
J	Okun, MS; Gallo, BV; Mandybur, G				Okun, M. S.; Gallo, B., V; Mandybur, G.			Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial (vol 11, pg 140, 2012)	LANCET NEUROLOGY			English	Correction																		Okun MS, 2012, LANCET NEUROL, V11, P140, DOI 10.1016/S1474-4422(11)70308-8	1	3	3	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2012	11	3					208	208		10.1016/S1474-4422(11)70308-8	http://dx.doi.org/10.1016/S1474-4422(11)70308-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	902BZ					2022-12-18	WOS:000301014900006
J	[Anonymous]				[Anonymous]			A grand plan for Alzheimer's disease and related dementias	LANCET NEUROLOGY			English	Editorial Material																			0	3	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2012	11	3					201	201		10.1016/S1474-4422(12)70026-1	http://dx.doi.org/10.1016/S1474-4422(12)70026-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	902BZ	22341026				2022-12-18	WOS:000301014900001
J	Ryvlin, P; Rheims, S				Ryvlin, Philippe; Rheims, Sylvain			Epilepsy: new epidemiological and therapeutic perspectives	LANCET NEUROLOGY			English	Editorial Material							SUDDEN UNEXPECTED DEATH; SEIZURES; RISK		[Ryvlin, Philippe] Hosp Civils Lyon, Dept Funct Neurol & Epileptol, Inst Child & Adolescent Epilepsy IDEE, Lyon, France; Univ Lyon 1, F-69365 Lyon, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ryvlin, P (corresponding author), Hosp Civils Lyon, Dept Funct Neurol & Epileptol, Inst Child & Adolescent Epilepsy IDEE, Lyon, France.	ryvlin@cermep.fr	Ryvlin, Philippe/O-5214-2016; Ryvlin, Philippe/K-7402-2019	Ryvlin, Philippe/0000-0001-7775-6576; Ryvlin, Philippe/0000-0001-7775-6576; Rheims, Sylvain/0000-0002-4663-8515				Kwan P, 2011, LANCET NEUROL, V10, P881, DOI 10.1016/S1474-4422(11)70154-5; Morrell MJ, 2011, NEUROLOGY, V77, P1295, DOI 10.1212/WNL.0b013e3182302056; Ryvlin P, 2011, LANCET NEUROL, V10, P961, DOI 10.1016/S1474-4422(11)70193-4; Sillanpaa M, 2010, NEW ENGL J MED, V363, P2522, DOI 10.1056/NEJMoa0911610; Tomson T, 2008, LANCET NEUROL, V7, P1021, DOI 10.1016/S1474-4422(08)70202-3; Tomson T, 2011, LANCET NEUROL, V10, P609, DOI 10.1016/S1474-4422(11)70107-7	6	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2012	11	1					5	7		10.1016/S1474-4422(11)70273-3	http://dx.doi.org/10.1016/S1474-4422(11)70273-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	868HG	22172610				2022-12-18	WOS:000298513700004
J	Dodick, DW				Dodick, David W.			Suboccipital steroid injections for cluster headache	LANCET NEUROLOGY			English	Editorial Material									Mayo Clin Arizona, Dept Neurol, Phoenix, AZ 85054 USA	Mayo Clinic; Mayo Clinic Phoenix	Dodick, DW (corresponding author), Mayo Clin Arizona, Dept Neurol, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA.	dodick.david@mayo.edu						Afridi SK, 2006, PAIN, V122, P126, DOI 10.1016/j.pain.2006.01.016; Ambrosini A, 2005, PAIN, V118, P92, DOI 10.1016/j.pain.2005.07.015; Ashkenazi A, 2008, J NEUROL NEUROSUR PS, V79, P415, DOI 10.1136/jnnp.2007.124420; Francis GJ, 2010, NEUROLOGY, V75, P463, DOI 10.1212/WNL.0b013e3181eb58c8; Leroux E, 2011, LANCET NEUROL, V10, P891, DOI 10.1016/S1474-4422(11)70186-7	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2011	10	10					867	869		10.1016/S1474-4422(11)70197-1	http://dx.doi.org/10.1016/S1474-4422(11)70197-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832OP	21903478				2022-12-18	WOS:000295814600003
J	Albanese, A				Albanese, Alberto			Cell therapy for Parkinson's disease: have the glory days gone?	LANCET NEUROLOGY			English	Editorial Material							DOPAMINE NEURONS; TRANSPLANTATION; GRAFTS; TISSUE		Univ Cattolica Sacro Cuore, Ist Neurol Carlo Besta, I-20123 Milan, Italy	Catholic University of the Sacred Heart; IRCCS Istituto Neurologico Besta	Albanese, A (corresponding author), Univ Cattolica Sacro Cuore, Ist Neurol Carlo Besta, I-20123 Milan, Italy.	alberto.albanese@unicatt.it	Albanese, Alberto/K-7396-2016	Albanese, Alberto/0000-0002-5864-0006				COHEN J, 1994, SCIENCE, V263, P600, DOI 10.1126/science.8303261; Farag ES, 2009, NEUROLOGY, V73, P1095, DOI 10.1212/WNL.0b013e3181bbff1c; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Gross RE, 2011, LANCET NEUROL, V10, P509, DOI 10.1016/S1474-4422(11)70097-7; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Holden C, 2009, SCIENCE, V326, P358, DOI 10.1126/science.326_358; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; Olanow CW, 2008, MOVEMENT DISORD, V23, pS613, DOI 10.1002/mds.22061; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Schumacher JM, 2000, NEUROLOGY, V54, P1042, DOI 10.1212/WNL.54.5.1042; Stover NP, 2005, ARCH NEUROL-CHICAGO, V62, P1833, DOI 10.1001/archneur.62.12.1833; WATTS RL, 2001, PARKINSONISM RELAT D, V7, P587	13	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2011	10	6					492	493		10.1016/S1474-4422(11)70101-6	http://dx.doi.org/10.1016/S1474-4422(11)70101-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774HK	21565558				2022-12-18	WOS:000291376100002
J	Kieseier, BC; Wiendl, H				Kieseier, Bernd C.; Wiendl, Heinz			Transforming multiple sclerosis trials into practical reality	LANCET NEUROLOGY			English	Editorial Material							ORAL FINGOLIMOD; FTY720		[Kieseier, Bernd C.] Univ Dusseldorf, Dept Neurol, D-4000 Dusseldorf, Germany; [Wiendl, Heinz] Univ Munster, Dept Neurol, D-4400 Munster, Germany	Heinrich Heine University Dusseldorf; University of Munster	Kieseier, BC (corresponding author), Univ Dusseldorf, Dept Neurol, D-4000 Dusseldorf, Germany.	bernd.kieseier@uni-duesseldorf.de	Wiendl, Heinz/AAX-6041-2021	Wiendl, Heinz/0000-0003-4310-3432				Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Hohlfeld R, 2011, NEUROLOGY, V76, pS28, DOI 10.1212/WNL.0b013e31820db40f; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Khatri B, 2011, LANCET NEUROL, V10, P520, DOI 10.1016/S1474-4422(11)70099-0; Kieseier BC, 2007, CNS DRUGS, V21, P483, DOI 10.2165/00023210-200721060-00005; Kieseier BC, 2011, NAT REV NEUROL, V7, P255, DOI 10.1038/nrneurol.2011.41; Wiendl H, 2009, NEUROLOGY, V72, P1008, DOI 10.1212/01.wnl.0000344417.42972.54	9	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2011	10	6					493	494		10.1016/S1474-4422(11)70100-4	http://dx.doi.org/10.1016/S1474-4422(11)70100-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774HK	21571592				2022-12-18	WOS:000291376100003
J	Clifton, GL				Clifton, Guy L.		NABIS H II Investigators	Hypothermia in patients with brain injury: the way forward? Reply	LANCET NEUROLOGY			English	Letter									[Clifton, Guy L.; NABIS H II Investigators] Univ Texas Houston, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Sch Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Clifton, GL (corresponding author), Univ Texas Houston, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Sch Med, Houston, TX 77030 USA.	guy.l.clifton@uth.tmc.edu						Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803	1	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2011	10	5					406	407		10.1016/S1474-4422(11)70087-4	http://dx.doi.org/10.1016/S1474-4422(11)70087-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	761TV		Bronze			2022-12-18	WOS:000290424800010
J	Honeybul, S; Ho, KM; Lind, CRP; Gillett, GR				Honeybul, S.; Ho, K. M.; Lind, C. R. P.; Gillett, G. R.			Hypothermia in patients with brain injury: the way forward?	LANCET NEUROLOGY			English	Letter							DECOMPRESSIVE CRANIECTOMY		[Honeybul, S.] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6009, Australia; [Honeybul, S.] Royal Perth Hosp, Perth, WA 6009, Australia; [Ho, K. M.] Univ Western Australia, Dept Intens Care Med, Perth, WA USA; [Ho, K. M.] Univ Western Australia, Sch Populat Hlth, Perth, WA USA; [Lind, C. R. P.] Univ Western Australia, Sch Surg, Perth, WA USA; [Gillett, G. R.] Univ Otago, Dunedin Hosp, Dunedin, New Zealand; [Gillett, G. R.] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand	University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; Dunedin Public Hospital; University of Otago; University of Otago	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au	Lind, Christopher/K-3629-2012; Ho, Kwok M./E-3546-2010	Lind, Christopher/0000-0001-9991-1725; Ho, Kwok M./0000-0002-6705-6004				Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Curley G, 2010, CRIT CARE MED, V38, P1348, DOI 10.1097/CCM.0b013e3181d8cf2b; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; Sakoh M, 2003, AM J PHYSIOL-HEART C, V285, pH17, DOI 10.1152/ajpheart.01112.2002	8	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2011	10	5					405	406		10.1016/S1474-4422(11)70086-2	http://dx.doi.org/10.1016/S1474-4422(11)70086-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	761TV	21511192				2022-12-18	WOS:000290424800009
J	Parnetti, L				Parnetti, Lucilla			Biochemical diagnosis of neurodegenerative diseases gets closer	LANCET NEUROLOGY			English	Editorial Material							ALPHA-SYNUCLEIN; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; ELEVATED LEVELS; OLIGOMERS; PLASMA		Univ Perugia, Neurol Sect, Ctr Memory Disturbances, Lab Clin Neurochem, I-6126 Perugia, Italy	University of Perugia	Parnetti, L (corresponding author), Univ Perugia, Neurol Sect, Ctr Memory Disturbances, Lab Clin Neurochem, I-6126 Perugia, Italy.	parnetti@unipg.it	Parnetti, Lucilla/K-8258-2016	Parnetti, Lucilla/0000-0001-5722-3967				Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; HUGHES AJ, 1992, NEUROLOGY, V42, P1142, DOI 10.1212/WNL.42.6.1142; MOLLENHAUER B, 2011, LANCET NEUROL, DOI DOI 10.1016/S1474-4422(11:70014-X.; Mollenhauer B, 2010, BIOMARK MED, V4, P683, DOI 10.2217/BMM.10.90; Paleologou KE, 2009, BRAIN, V132, P1093, DOI 10.1093/brain/awn349; PARNETTI L, MOV DISORD IN PRESS; Tokuda T, 2010, NEUROLOGY, V75, P1766, DOI 10.1212/WNL.0b013e3181fd613b; Tokuda T, 2006, BIOCHEM BIOPH RES CO, V349, P162, DOI 10.1016/j.bbrc.2006.08.024	9	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2011	10	3					203	205		10.1016/S1474-4422(11)70019-9	http://dx.doi.org/10.1016/S1474-4422(11)70019-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	736HR	21317043				2022-12-18	WOS:000288482200004
J	Bermel, RA; Cohen, JA				Bermel, Robert A.; Cohen, Jeffrey A.			Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options	LANCET NEUROLOGY			English	Editorial Material							INTERFERON; FINGOLIMOD; TRIAL		[Bermel, Robert A.; Cohen, Jeffrey A.] Cleveland Clin, Neurol Inst, Mellen Ctr MS Treatment & Res, Cleveland, OH 44106 USA	Cleveland Clinic Foundation	Bermel, RA (corresponding author), Cleveland Clin, Neurol Inst, Mellen Ctr MS Treatment & Res, Cleveland, OH 44106 USA.	cohenj@ccf.org		Bermel, Robert/0000-0003-2334-6883				Axtell RC, 2010, NAT MED, V16, P406, DOI 10.1038/nm.2110; Baranzini SE, 2010, NATURE, V464, P1351, DOI 10.1038/nature08990; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Goodman AD, 2010, ANN NEUROL, V68, P494, DOI 10.1002/ana.22240; Green AJ, 2010, BRAIN, V133, P1591, DOI 10.1093/brain/awq080; Kapoor R, 2010, LANCET NEUROL, V9, P681, DOI 10.1016/S1474-4422(10)70131-9; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494	8	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2011	10	1					4	5		10.1016/S1474-4422(10)70282-9	http://dx.doi.org/10.1016/S1474-4422(10)70282-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	701HX	21163434				2022-12-18	WOS:000285810100003
J	Sejvar, JJ				Sejvar, James J.			Neurological infections: influenza in the spotlight	LANCET NEUROLOGY			English	Editorial Material							GUILLAIN-BARRE-SYNDROME; UNITED-STATES; COMPLICATIONS		[Sejvar, James J.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30033 USA; [Sejvar, James J.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30033 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Sejvar, JJ (corresponding author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30033 USA.	jsejvar@cdc.gov						Brouwer MC, 2010, NEUROLOGY, V75, P1533, DOI 10.1212/WNL.0b013e3181f96297; Chohan G, 2010, J NEUROL NEUROSUR PS, V81, P1243, DOI 10.1136/jnnp.2009.197962; Davis LE, 2010, CURR NEUROL NEUROSCI, V10, P476, DOI 10.1007/s11910-010-0135-1; Ekstrand JJ, 2010, ANN NEUROL, V68, P762, DOI 10.1002/ana.22184; Prothro C., 2010, Morbidity and Mortality Weekly Report, V59, P657; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795	6	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2011	10	1					16	18		10.1016/S1474-4422(10)70308-2	http://dx.doi.org/10.1016/S1474-4422(10)70308-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	701HX	21163441				2022-12-18	WOS:000285810100010
J	[Anonymous]				[Anonymous]			How much is dementia care worth?	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2010	9	11					1037	1037		10.1016/S1474-4422(10)70257-X	http://dx.doi.org/10.1016/S1474-4422(10)70257-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	680PL	20965430				2022-12-18	WOS:000284246800001
J	[Anonymous]				[Anonymous]			Dispelling the stigma of Huntington's disease	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2010	9	8					751	751		10.1016/S1474-4422(10)70170-8	http://dx.doi.org/10.1016/S1474-4422(10)70170-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	635LS	20650398				2022-12-18	WOS:000280657800001
J	Versino, M; Biagi, F; Bianchi, PI; Zardini, E; Colnaghi, S; Moglia, A; Corazza, GR; Franciotta, D				Versino, Maurizio; Biagi, Federico; Bianchi, Paola Ilaria; Zardini, Elisabetta; Colnaghi, Silvia; Moglia, Arrigo; Corazza, Gino Roberto; Franciotta, Diego			Gluten sensitivity and the CNS: diagnosis and treatment	LANCET NEUROLOGY			English	Letter							CELIAC-DISEASE		[Versino, Maurizio; Zardini, Elisabetta; Colnaghi, Silvia; Moglia, Arrigo] Univ Pavia, Dept Neurol Sci, I-27100 Pavia, Italy; [Versino, Maurizio; Zardini, Elisabetta; Colnaghi, Silvia; Moglia, Arrigo; Franciotta, Diego] Univ Pavia, Ist Ricovero & Cura Carattere Sci, Neurol Inst C Mondino, I-27100 Pavia, Italy; [Biagi, Federico; Bianchi, Paola Ilaria; Corazza, Gino Roberto] Univ Pavia, Celiac Ctr, Dept Internal Med 1, Ist Ricovero & Cura Carattere Sci,Policlin San Ma, I-27100 Pavia, Italy	University of Pavia; IRCCS Fondazione Casimiro Mondino; University of Pavia; University of Pavia	Versino, M (corresponding author), Univ Pavia, Dept Neurol Sci, Via Palestro 3, I-27100 Pavia, Italy.	diego.franciotta@mondino.it	Biagi, Federico/G-2812-2011; Franciotta, Diego/K-8262-2016; Colnaghi, Silvia/S-8336-2017; Corazza, Gino Roberto/K-8500-2016; Franciotta, Diego/ABE-0957-2022; Rodrigo, Luis/A-6278-2010	Biagi, Federico/0000-0002-2227-4622; Franciotta, Diego/0000-0002-3014-3913; Colnaghi, Silvia/0000-0002-0577-7623; Corazza, Gino Roberto/0000-0001-9532-0573; Franciotta, Diego/0000-0002-3014-3913; Rodrigo, Luis/0000-0003-1717-9345; Versino, Maurizio/0000-0003-1813-9492				Freeman HJ, 2008, CAN J GASTROENTEROL, V22, P909, DOI 10.1155/2008/824631; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; Hadjivassiliou M, 2008, ANN NEUROL, V64, P332, DOI 10.1002/ana.21450; Hadjivassiliou M, 2010, LANCET NEUROL, V9, P318, DOI 10.1016/S1474-4422(09)70290-X; Versino M, 2009, NEUROLOGY, V72, P2046, DOI 10.1212/WNL.0b013e3181a92c12	5	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2010	9	7					653	653		10.1016/S1474-4422(10)70148-4	http://dx.doi.org/10.1016/S1474-4422(10)70148-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	617NF	20610340				2022-12-18	WOS:000279286900008
J	Rodriguez-Oroz, MC				Rodriguez-Oroz, Maria C.			Deep brain stimulation for advanced Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							TRIAL		Univ Navarra Clin, Ctr Invest Med Aplicada, Pamplona 31008, Spain	University of Navarra	Rodriguez-Oroz, MC (corresponding author), Univ Navarra Clin, Ctr Invest Med Aplicada, Pamplona 31008, Spain.	mcroroz@unav.es	Rodriguez-Oroz, Maria Cruz/D-1490-2018	Rodriguez-Oroz, Maria Cruz/0000-0001-5962-772X				Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Ruiz PJG, 2008, MOVEMENT DISORD, V23, P1130, DOI 10.1002/mds.22063; Manson AJ, 2002, MOVEMENT DISORD, V17, P1235, DOI 10.1002/mds.10281; Parsons TD, 2006, LANCET NEUROL, V5, P578, DOI 10.1016/S1474-4422(06)70475-6; Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929; Williams A, 2010, LANCET NEUROL, V9, P581, DOI 10.1016/S1474-4422(10)70093-4	6	3	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2010	9	6					558	559		10.1016/S1474-4422(10)70108-3	http://dx.doi.org/10.1016/S1474-4422(10)70108-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	607NY	20434404				2022-12-18	WOS:000278512000003
J	Steiner, I				Steiner, Israel			PML: underdiagnosed in MS patients on natalizumab	LANCET NEUROLOGY			English	Letter									Rabin Med Ctr, Dept Neurol, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center	Steiner, I (corresponding author), Rabin Med Ctr, Dept Neurol, IL-49100 Petah Tiqwa, Israel.	isteiner@cc.huji.ac.il						*BIOG ID, TYSABRI TOUCH PRESCR; Clifford DB, 2010, LANCET NEUROL, V9, P438, DOI 10.1016/S1474-4422(10)70028-4; Sadiq SA, 2010, J NEUROL, V257, P954, DOI 10.1007/s00415-009-5444-4	3	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2010	9	6					564	564		10.1016/S1474-4422(10)70122-8	http://dx.doi.org/10.1016/S1474-4422(10)70122-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	607NY	20494319				2022-12-18	WOS:000278512000006
J	Batocchi, AP; Della Marca, G; Frisullo, G				Batocchi, Anna Paola; Della Marca, Giacomo; Frisullo, Giovanni			Complement-mediated cytotoxicity of antibodies to the GABA(B) receptor	LANCET NEUROLOGY			English	Letter							AUTOIMMUNE AGRYPNIA		[Batocchi, Anna Paola; Della Marca, Giacomo; Frisullo, Giovanni] Univ Cattolica Sacro Cuore, Dept Neurosci, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Batocchi, AP (corresponding author), Univ Cattolica Sacro Cuore, Dept Neurosci, Rome, Italy.	annapaola.batocchi@rm.unicatt.it	Frisullo, Giovanni/ABC-7406-2021; Della Marca, Giacomo/A-8159-2010	Della Marca, Giacomo/0000-0001-6914-799X; Frisullo, Giovanni/0000-0002-1604-6594				Batocchi AP, 2001, ANN NEUROL, V50, P668, DOI 10.1002/ana.1261; Frisullo G, 2007, EXP NEUROL, V204, P808, DOI 10.1016/j.expneurol.2007.01.012; Lancaster E, 2010, LANCET NEUROL, V9, P67, DOI 10.1016/S1474-4422(09)70324-2	3	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2010	9	4					343	343		10.1016/S1474-4422(10)70070-3	http://dx.doi.org/10.1016/S1474-4422(10)70070-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	576KA	20298957				2022-12-18	WOS:000276142000008
J	Rejdak, K; Petzold, A; Ng, K; Afra, J; Dujmovic, I; Stelmasiak, Z; Ryglewicz, D; Kwiecinski, H; Grisold, W; Vecsei, L				Rejdak, Konrad; Petzold, Axel; Ng, Karl; Afra, Judit; Dujmovic, Irena; Stelmasiak, Zbigniew; Ryglewicz, Danuta; Kwiecinski, Hubert; Grisold, Wolfgang; Vecsei, Laszlo			Neurology training around the world: asking the trainees	LANCET NEUROLOGY			English	Letter									[Rejdak, Konrad; Stelmasiak, Zbigniew] Med Univ Lublin, Dept Neurol, Lublin, Poland; [Petzold, Axel] UCL, Dept Neuroimmunol, Inst Neurol, London, England; [Ng, Karl] Royal N Shore Hosp, Dept Neurol & Clin Neurophysiol, Sydney, NSW, Australia; [Ng, Karl] Univ Sydney, Sydney, NSW 2006, Australia; [Afra, Judit] Natl Inst Neurosurg, Budapest, Hungary; [Dujmovic, Irena] Belgrade Sch Med, Inst Neurol, Belgrade, Serbia; [Ryglewicz, Danuta] Inst Neurol & Psychiat, Dept Neurol, Warsaw, Poland; [Kwiecinski, Hubert] Med Univ Warsaw, Dept Neurol, Warsaw, Poland; [Grisold, Wolfgang] KFJ Hosp, Dept Neurol, Vienna, Austria; [Vecsei, Laszlo] Univ Szeged, Dept Neurol, Szeged, Hungary	Medical University of Lublin; University of London; University College London; Royal North Shore Hospital; University of Sydney; University of Sydney; University of Belgrade; Medical University of Warsaw; Szeged University	Rejdak, K (corresponding author), Med Univ Lublin, Dept Neurol, Lublin, Poland.	krejdak@europe.com	Petzold, Axel/C-1090-2009; Vecsei, Laszlo/ABA-6137-2021; Vécsei, László/B-2066-2010	Petzold, Axel/0000-0002-0344-9749; Vécsei, László/0000-0001-8037-3672; Rejdak, Konrad/0000-0002-7019-6681				Bergen DC, 2006, J NEUROL SCI, V246, P59, DOI 10.1016/j.jns.2006.02.003; Fuller Geraint, 2007, Pract Neurol, V7, P356, DOI 10.1136/jnnp.2007.134155; Grisold W, 2007, EUR J NEUROL, V14, P241, DOI 10.1111/j.1468-1331.2006.01663.x; Hooker J, 2003, LANCET NEUROL, V2, P572, DOI 10.1016/S1474-4422(03)00507-6; REJDAK K, 2006, WCN NEWSLETTER, V21, P9	5	3	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					32	33		10.1016/S1474-4422(09)70352-7	http://dx.doi.org/10.1016/S1474-4422(09)70352-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	20083035				2022-12-18	WOS:000273199700021
J	Tardieu, M				Tardieu, Marc			Paediatric neurology: brain development at an interface between genetics, the environment, and the immune system	LANCET NEUROLOGY			English	Editorial Material							AICARDI-GOUTIERES-SYNDROME; ENCEPHALITIS; MUTATIONS		Univ Paris 11, AP HP, Hop Bicetre, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Tardieu, M (corresponding author), Univ Paris 11, AP HP, Hop Bicetre, Paris, France.	marc.tardieu@bct.aphp.fr						Alcais A, 2009, J CLIN INVEST, V119, P2506, DOI 10.1172/JCI38111; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; Dale RC, 2009, ANN NEUROL, V66, P704, DOI 10.1002/ana.21807; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Florance NR, 2009, ANN NEUROL, V66, P11, DOI 10.1002/ana.21756; Henneke M, 2009, NAT GENET, V41, P773, DOI 10.1038/ng.398; LEBAS, 2009, J CHILD NEUROL, DOI DOI 10.1177/0883073809343319; Mizuguchi M, 1997, BRAIN DEV-JPN, V19, P81, DOI 10.1016/S0387-7604(96)00063-0; Neilson DE, 2009, AM J HUM GENET, V84, P44, DOI 10.1016/j.ajhg.2008.12.009; Rice GI, 2009, NAT GENET, V41, P829, DOI 10.1038/ng.373; Sancho-Shimizu V, 2007, CURR OPIN ALLERGY CL, V7, P495, DOI 10.1097/ACI.0b013e3282f151d2; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	12	3	3	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					13	14		10.1016/S1474-4422(09)70307-2	http://dx.doi.org/10.1016/S1474-4422(09)70307-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	20083027				2022-12-18	WOS:000273199700008
J	Ramagopalan, SV; Giovannoni, G				Ramagopalan, Sreeram V.; Giovannoni, Gavin			Can we predict multiple sclerosis?	LANCET NEUROLOGY			English	Editorial Material							INFECTIOUS-MONONUCLEOSIS; RISK; SUSCEPTIBILITY; METAANALYSIS		[Ramagopalan, Sreeram V.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Ramagopalan, Sreeram V.] Univ Oxford, John Radcliffe Hosp, Dept Clin Neurol, Oxford OX3 9DU, England; [Ramagopalan, Sreeram V.; Giovannoni, Gavin] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol Sci, London, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of London; Queen Mary University London	Ramagopalan, SV (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.	g.giovannoni@qmul.ac.uk						De Jager PL, 2008, NEUROLOGY, V70, P1113, DOI 10.1212/01.wnl.0000294325.63006.f8; De Jager PL, 2008, BRAIN, V131, P1701, DOI 10.1093/brain/awn118; De Jager PL, 2009, NAT GENET, V41, P776, DOI 10.1038/ng.401; DEJAGER PL, 2009, LANCET NEUROL; Dyment DA, 2005, HUM MOL GENET, V14, P2019, DOI 10.1093/hmg/ddi206; Dyment DA, 2004, LANCET NEUROL, V3, P104, DOI 10.1016/S1474-4422(03)00663-X; Ebers GC, 2008, LANCET NEUROL, V7, P268, DOI 10.1016/S1474-4422(08)70042-5; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Hernan MA, 2005, BRAIN, V128, P1461, DOI 10.1093/brain/awh471; Hintzen RQ, 2008, NEUROLOGY, V70, P1059, DOI 10.1212/01.wnl.0000306413.29367.82; JERSILD C, 1973, LANCET, V2, P1221; Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832; Nielsen TR, 2009, MULT SCLER J, V15, P431, DOI 10.1177/1352458508100037; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; Thacker EL, 2006, ANN NEUROL, V59, P499, DOI 10.1002/ana.20820; Willer CJ, 2005, BMJ-BRIT MED J, V330, P120, DOI 10.1136/bmj.38301.686030.63	16	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2009	8	12					1077	1079		10.1016/S1474-4422(09)70273-X	http://dx.doi.org/10.1016/S1474-4422(09)70273-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	523WS	19879193				2022-12-18	WOS:000272106100004
J	Schulte-Altedorneburg, G; Liebig, T; Bruckmann, H; Jansen, O				Schulte-Altedorneburg, Gernot; Liebig, Thomas; Brueckmann, Hartmut; Jansen, Olav			Treatment of basilar artery occlusion: a prospective randomised therapeutic study is needed	LANCET NEUROLOGY			English	Letter							INTRAARTERIAL; FIBRINOLYSIS		[Schulte-Altedorneburg, Gernot] Stadt Klinikum Munchen GmbH, Klinikum Munchen Harlaching, Inst Radiol Neuroradiol & Nucl Med, D-81545 Munich, Germany; [Liebig, Thomas] Tech Univ Munich, Klinikum Rechts Isar, Dept Neuroradiol, D-8000 Munich, Germany; [Brueckmann, Hartmut] Univ Munich, Klinikum Grosshadern, Dept Neuroradiol, D-8000 Munich, Germany; [Jansen, Olav] Univ Hosp Schleswig Holstein, Dept Neuroradiol, Kiel, Germany	Munchen Klinik; Technical University of Munich; University of Munich; University of Kiel; Schleswig Holstein University Hospital	Schulte-Altedorneburg, G (corresponding author), Stadt Klinikum Munchen GmbH, Klinikum Munchen Harlaching, Inst Radiol Neuroradiol & Nucl Med, D-81545 Munich, Germany.	gernot.schulte-altedorneburg@klinikum-muenchen.de	Jansen, Olav/D-2547-2010					Eckert B, 2005, STROKE, V36, P1160, DOI 10.1161/01.STR.0000165918.80812.1e; Lindsberg PJ, 2006, STROKE, V37, P922, DOI 10.1161/01.STR.0000202582.29510.6b; LOCKAU H, 2009, WORLD FED INT THER N; Pfefferkorn T, 2008, STROKE, V39, P1496, DOI 10.1161/STROKEAHA.107.505123; Schonewille WJ, 2009, LANCET NEUROL, V8, P724, DOI 10.1016/S1474-4422(09)70173-5; Schulte-Altedorneburg G, 2006, AM J NEURORADIOL, V27, P2042	6	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2009	8	12					1084	1085		10.1016/S1474-4422(09)70310-2	http://dx.doi.org/10.1016/S1474-4422(09)70310-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	523WS	19909904				2022-12-18	WOS:000272106100009
J	Pericak-Vance, MA; Haines, JL				Pericak-Vance, Margaret A.; Haines, Jonathan L.			Beyond proof of principle: new genes for Alzheimer's disease through collaboration	LANCET NEUROLOGY			English	Editorial Material							GENOME-WIDE ASSOCIATION; IDENTIFIES VARIANTS; SUSCEPTIBILITY; ONSET; APOE; REVEALS; RISK; CLU		[Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33138 USA; [Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37232 USA	University of Miami; Vanderbilt University	Pericak-Vance, MA (corresponding author), Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33138 USA.	mpericak@med.miami.edu			NATIONAL INSTITUTE ON AGING [R01AG019085] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG019085-01A1, R01 AG019085] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abraham R, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-44; Beecham GW, 2009, AM J HUM GENET, V84, P35, DOI 10.1016/j.ajhg.2008.12.008; Bertram L, 2008, AM J HUM GENET, V83, P623, DOI 10.1016/j.ajhg.2008.10.008; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Carrasquillo MM, 2009, NAT GENET, V41, P192, DOI 10.1038/ng.305; Coon KD, 2007, J CLIN PSYCHIAT, V68, P613, DOI 10.4088/JCP.v68n0419; Grupe A, 2007, HUM MOL GENET, V16, P865, DOI 10.1093/hmg/ddm031; Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440; Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439; Li H, 2008, ARCH NEUROL-CHICAGO, V65, P45, DOI 10.1001/archneurol.2007.3; PERICAKVANCE MA, 1995, TRENDS GENET, V11, P504, DOI 10.1016/S0168-9525(00)89161-1; Reiman EM, 2007, NEURON, V54, P713, DOI 10.1016/j.neuron.2007.05.022	12	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2009	8	11					977	979		10.1016/S1474-4422(09)70277-7	http://dx.doi.org/10.1016/S1474-4422(09)70277-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	513GC	19833292	Green Accepted			2022-12-18	WOS:000271309600006
J	Wrigley, BJ; Lip, GYH				Wrigley, Benjamin J.; Lip, Gregory Y. H.			Can the WATCHMAN device truly PROTECT from stroke in atrial fibrillation?	LANCET NEUROLOGY			English	Editorial Material							PREVENTION; APPENDAGE; THERAPY; CLOSURE; RISK		[Wrigley, Benjamin J.; Lip, Gregory Y. H.] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Wrigley, BJ (corresponding author), Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England.	g.y.h.lip@bham.ac.uk						Block PC, 2009, JACC-CARDIOVASC INTE, V2, P594, DOI 10.1016/j.jcin.2009.05.005; Holmes DR, 2009, LANCET, V374, P534, DOI 10.1016/S0140-6736(09)61343-X; Hughes M, 2008, THROMB HAEMOSTASIS, V99, P295, DOI 10.1160/TH07-08-0508; HWANG JJ, 1994, CARDIOLOGY, V85, P69, DOI 10.1159/000176648; Lip GYH, 2007, LANCET NEUROL, V6, P981, DOI 10.1016/S1474-4422(07)70264-8; LIP GYH, CHEST IN PRESS; Maisel WH, 2009, NEW ENGL J MED, V360, P2601, DOI 10.1056/NEJMp0903763; Onalan Orhan, 2005, Expert Rev Cardiovasc Ther, V3, P619, DOI 10.1586/14779072.3.4.619; Palareti G, 2009, THROMB HAEMOSTASIS, V102, P268, DOI 10.1160/TH08-11-0730; Sick PB, 2007, J AM COLL CARDIOL, V49, P1490, DOI 10.1016/j.jacc.2007.02.035	10	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2009	8	10					877	878		10.1016/S1474-4422(09)70244-3	http://dx.doi.org/10.1016/S1474-4422(09)70244-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	498BS	19747647				2022-12-18	WOS:000270111200006
J	Menon, BK; Demchuk, AM				Menon, Bijoy K.; Demchuk, Andrew M.			Is acute stroke treatment heading towards a more endovascular approach?	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; MANAGEMENT		[Menon, Bijoy K.; Demchuk, Andrew M.] Univ Calgary, Foothills Med Ctr, Dept Clin Neurosci, Calgary Stroke Program, Calgary, AB T2N 2T9, Canada	University of Calgary	Menon, BK (corresponding author), Univ Calgary, Foothills Med Ctr, Dept Clin Neurosci, Calgary Stroke Program, Calgary, AB T2N 2T9, Canada.	ademchuk@ucalgary.ca	MENON, BIJOY K/B-7718-2014; Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789				Broderick J, 2004, STROKE, V35, P904, DOI 10.1161/01.STR.0000121641.77121.98; Broderick JP, 2007, STROKE, V38, P2127, DOI 10.1161/STROKEAHA.107.483131; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; Hill MD, 2006, AM J NEURORADIOL, V27, P1612; Khatri P, 2008, INT J STROKE, V3, P130, DOI 10.1111/j.1747-4949.2008.00151.x; King S, 2007, AM J NEURORADIOL, V28, P1890, DOI 10.3174/ajnr.A0702; Langer D, 2009, STROKE, V40, P2761, DOI 10.1161/STROKEAHA.108.544957; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; MAZIGHI M, 2009, LANCET NEUROL, DOI DOI 10.1016/S1474-4422(09)70182-6; Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24; Saqqur M, 2007, STROKE, V38, P948, DOI 10.1161/01.STR.0000257304.21967.ba; Smith WS, 2006, AM J NEURORADIOL, V27, P1177	12	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2009	8	9					778	779		10.1016/S1474-4422(09)70206-6	http://dx.doi.org/10.1016/S1474-4422(09)70206-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	487AD	19647487				2022-12-18	WOS:000269241700003
J	[Anonymous]				[Anonymous]			A network of brain banks fit for the future	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2009	8	8					691	691		10.1016/S1474-4422(09)70185-1	http://dx.doi.org/10.1016/S1474-4422(09)70185-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	477YV	19608090	Bronze			2022-12-18	WOS:000268555800001
J	Gauthier, S				Gauthier, Serge			Will CSF analysis become routine in people with memory complaints?	LANCET NEUROLOGY			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; CRITERIA		McGill Ctr Studies Aging, Douglas Mental Hlth Res Inst, Montreal, PQ H4H 1R3, Canada	McGill University	Gauthier, S (corresponding author), McGill Ctr Studies Aging, Douglas Mental Hlth Res Inst, 6825 LaSalle Blvd, Montreal, PQ H4H 1R3, Canada.	serge.gauthier@mcgill.ca						Amieva H, 2008, ANN NEUROL, V64, P492, DOI 10.1002/ana.21509; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Gauthier S, 2008, LANCET NEUROL, V7, P668, DOI 10.1016/S1474-4422(08)70146-7; Jack CR, 2009, BRAIN, V132, P1355, DOI 10.1093/brain/awp062; Kivipelto M, 2006, LANCET NEUROL, V5, P735, DOI 10.1016/S1474-4422(06)70537-3; Poirier Judes, 2008, Current Pharmacogenomics & Personalized Medicine, V6, P63, DOI 10.2174/187569208784017494; Reisberg B, 2008, INT PSYCHOGERIATR, V20, P1, DOI 10.1017/S1041610207006412; Visser PJ, 2009, LANCET NEUROL, V8, P619, DOI 10.1016/S1474-4422(09)70139-5; Xia WM, 2009, ARCH NEUROL-CHICAGO, V66, P190, DOI 10.1001/archneurol.2008.565	9	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2009	8	7					595	596		10.1016/S1474-4422(09)70145-0	http://dx.doi.org/10.1016/S1474-4422(09)70145-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466EN	19523878				2022-12-18	WOS:000267643700003
J	Williams, R				Williams, Ruth			Robert Miller: a frontline fighter of amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Biographical-Item												ruth.williams@absw.org.uk							0	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2009	8	7					608	608		10.1016/S1474-4422(09)70163-2	http://dx.doi.org/10.1016/S1474-4422(09)70163-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466EN	19539235				2022-12-18	WOS:000267643700015
J	Boysen, G				Boysen, Gudrun			ACTIVE A: balancing the benefits and risks of clopidogrel and aspirin	LANCET NEUROLOGY			English	Editorial Material							STROKE		Univ Copenhagen, Bispebjerg Hosp, Dept Neurol, DK-2400 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital	Boysen, G (corresponding author), Univ Copenhagen, Bispebjerg Hosp, Dept Neurol, DK-2400 Copenhagen, Denmark.	gb0l@bbh.regionh.dk						Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Flaker GC, 2006, AM HEART J, V152, P967, DOI 10.1016/j.ahj.2006.06.024; Keller TT, 2007, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD005158.PUB2; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Sandercock P, 1997, LANCET, V349, P1569	6	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2009	8	6					507	508		10.1016/S1474-4422(09)70109-7	http://dx.doi.org/10.1016/S1474-4422(09)70109-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	448UQ	19446266				2022-12-18	WOS:000266287900005
J	Struhal, W; Hess, B; Sztriha, L; Falup-Pecurariu, C; Findling, O; Sellner, J				Struhal, Walter; Hess, Barbara; Sztriha, Laszlo; Falup-Pecurariu, Cristian; Findling, Oliver; Sellner, Johann			EAYNT: promoting training in neuro-rehabilitation	LANCET NEUROLOGY			English	Letter									[Struhal, Walter; Hess, Barbara; Sztriha, Laszlo; Falup-Pecurariu, Cristian; Findling, Oliver; Sellner, Johann] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, EAYNT, D-81675 Munich, Germany	Technical University of Munich	Struhal, W (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, EAYNT, D-81675 Munich, Germany.	sellner@lrz.tum.de	Selllner, Johann/AAB-1263-2019; Findling, Oliver/AAE-3815-2019; Falup-Pecurariu, Cristian/AAP-9286-2020	Sztriha, Laszlo/0000-0003-4639-3180				Dimyan MA, 2008, NEUROLOGY, V70, pE52, DOI 10.1212/01.wnl.0000309216.81257.3f; Gilhus NE, 2002, EUR J NEUROL, V9, P349, DOI 10.1046/j.1468-1331.2002.00424.x	2	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2009	8	6					511	511		10.1016/S1474-4422(09)70117-6	http://dx.doi.org/10.1016/S1474-4422(09)70117-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	448UQ	19446270				2022-12-18	WOS:000266287900009
J	[Anonymous]				[Anonymous]			Chagas disease: the forgotten American neuroinfection	LANCET NEUROLOGY			English	Editorial Material																			0	3	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2009	8	6					501	501		10.1016/S1474-4422(09)70113-9	http://dx.doi.org/10.1016/S1474-4422(09)70113-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	448UQ	19446265	Bronze			2022-12-18	WOS:000266287900001
J	Kasner, SE				Kasner, Scott E.			Paracetamol for stroke: easy in practice, but not in trials	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC STROKE; BODY-TEMPERATURE; CLINICAL-TRIAL; ACETAMINOPHEN; MORTALITY		Univ Penn, Med Ctr, Comprehens Stroke Ctr, Dept Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kasner, SE (corresponding author), Univ Penn, Med Ctr, Comprehens Stroke Ctr, Dept Neurol, Philadelphia, PA 19104 USA.	kasner@mail.med.upenn.edu	Kasner, Scott/C-6109-2011					AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; den Hertog HM, 2009, LANCET NEUROL, V8, P434, DOI 10.1016/S1474-4422(09)70051-1; Dippel DWJ, 2003, BMC CARDIOVASC DISOR, V3, DOI 10.1186/1471-2261-3-2; Dippel DWJ, 2001, STROKE, V32, P1607, DOI 10.1161/01.STR.32.7.1607; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Kalafut MA, 2001, STROKE, V32, P381; Kasner SE, 2006, LANCET NEUROL, V5, P603, DOI 10.1016/S1474-4422(06)70495-1; Kasner SE, 2002, STROKE, V33, P130, DOI 10.1161/hs0102.101477; Koennecke HC, 2001, NEUROLOGY, V57, P2301, DOI 10.1212/WNL.57.12.2301; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404	11	3	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2009	8	5					415	416		10.1016/S1474-4422(09)70069-9	http://dx.doi.org/10.1016/S1474-4422(09)70069-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	435UE	19297249				2022-12-18	WOS:000265368000003
J	Schneck, MJ				Schneck, Michael J.			Hemicraniectomy for hemispheric infarction and the HAMLET study: a sequel is needed	LANCET NEUROLOGY			English	Editorial Material							MIDDLE CEREBRAL-ARTERY; DECOMPRESSIVE SURGERY; MALIGNANT INFARCTION		Loyola Univ Chicago, Stritch Sch Med, Maywood, IL 60153 USA	Loyola University Chicago	Schneck, MJ (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Maywood, IL 60153 USA.	mschneck@lumc.edu						HOFFMEIJER J, 2009, LANCET NEUROL; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4	4	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2009	8	4					303	304		10.1016/S1474-4422(09)70048-1	http://dx.doi.org/10.1016/S1474-4422(09)70048-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	425CH	19269253				2022-12-18	WOS:000264614100003
J	Perucca, E; Tornson, T				Perucca, Emilio; Tornson, Torbjorn			Epilepsy: seizures, syndromes, and survival	LANCET NEUROLOGY			English	Editorial Material							CHILDREN		[Perucca, Emilio] Univ Pavia, Dept Internal Med & Therapeut, Pavia & Clin Pharmacol Unit,Clin Trial Ctr, IRCCS C Mondino Fdn,Inst Neurol, I-27100 Pavia, Italy; [Tornson, Torbjorn] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden	IRCCS Fondazione Casimiro Mondino; University of Pavia; Karolinska Institutet	Perucca, E (corresponding author), Univ Pavia, Dept Internal Med & Therapeut, Pavia & Clin Pharmacol Unit,Clin Trial Ctr, IRCCS C Mondino Fdn,Inst Neurol, Via Palestro 3, I-27100 Pavia, Italy.	perucca@unipv.it	Perucca, Emilio/Q-7308-2019	Perucca, Emilio/0000-0001-8703-223X				Appleton R, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001905.pub2; FAUGHT E, 2008, NEUROLOGY, DOI DOI 10.1212/01.WNL.0000319693-10338.BG; FREEMAN JM, 2008, EPILEPSIA, DOI DOI 10.1111/J.1528-1167.2008.01740; Mpimbaza A, 2008, PEDIATRICS, V121, pE58, DOI 10.1542/peds.2007-0930; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Noachtar S, 2008, NEUROLOGY, V70, P607, DOI 10.1212/01.wnl.0000297512.18364.40; Vestergaard M, 2008, LANCET, V372, P457, DOI 10.1016/S0140-6736(08)61198-8	7	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2009	8	1					10	12		10.1016/S1474-4422(08)70274-6	http://dx.doi.org/10.1016/S1474-4422(08)70274-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	386CU	19081503				2022-12-18	WOS:000261860700006
J	Tyler, KL				Tyler, Kenneth L.			Neurological infections: advances in therapy, outcome, and prediction	LANCET NEUROLOGY			English	Editorial Material							ADULTS		[Tyler, Kenneth L.] Univ Colorado, Denver Hlth Sci Ctr, Denver, CO 80220 USA; [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Tyler, KL (corresponding author), Univ Colorado, Denver Hlth Sci Ctr, Denver, CO 80220 USA.	ken.tyler@uchsc.edu	Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888				de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334; Krishnan MN, 2008, NATURE, V455, P242, DOI 10.1038/nature07207; Loeb M, 2008, ANN INTERN MED, V149, P232, DOI 10.7326/0003-4819-149-4-200808190-00004; Mai NTH, 2007, NEW ENGL J MED, V357, P2431, DOI 10.1056/NEJMoa070852; Nigrovic LE, 2008, PEDIATRICS, V122, P726, DOI 10.1542/peds.2007-3275; Palacios G, 2008, NEW ENGL J MED, V358, P991, DOI 10.1056/NEJMoa073785; Scarborough M, 2007, NEW ENGL J MED, V357, P2441, DOI 10.1056/NEJMoa065711	7	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2009	8	1					19	21		10.1016/S1474-4422(08)70279-5	http://dx.doi.org/10.1016/S1474-4422(08)70279-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	386CU	19081508				2022-12-18	WOS:000261860700011
J	Williams, R				Williams, Ruth			Profile Richard Lipton: migraines, magnets, and much, much more	LANCET NEUROLOGY			English	Biographical-Item												ruth.williams@absw.org.uk							0	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2008	7	12					1088	1088		10.1016/S1474-4422(08)70253-9	http://dx.doi.org/10.1016/S1474-4422(08)70253-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	379KV	19007735				2022-12-18	WOS:000261396000012
J	Bartsch, T				Bartsch, Thorsten			Suboccipital neurostimulation in medically intractable chronic daily headache	LANCET NEUROLOGY			English	Editorial Material							OCCIPITAL NERVE-STIMULATION; CHRONIC CLUSTER HEADACHE; EXPERIENCE		Univ Hosp Schleswig Holstein, Dept Neurol, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Bartsch, T (corresponding author), Univ Hosp Schleswig Holstein, Dept Neurol, Kiel Schittenhelmstr 10, D-24105 Kiel, Germany.	t.bartsch@neurologie.uni-kiel.de	Bartsch, Thorsten/F-9950-2010; Bartsch, Thorsten/AAR-5564-2021	Bartsch, Thorsten/0000-0001-8387-5731; Bartsch, Thorsten/0000-0001-8387-5731				Bartsch T, 2008, CEPHALALGIA, V28, P285, DOI 10.1111/j.1468-2982.2007.01531.x; Burns B, 2008, LANCET NEUROL, V7, P1001, DOI 10.1016/S1474-4422(08)70217-5; Burns B, 2007, LANCET, V369, P1099, DOI 10.1016/S0140-6736(07)60328-6; Leone M, 2008, CEPHALALGIA, V28, P787, DOI 10.1111/j.1468-2982.2008.01627.x; Leone M, 2007, LANCET NEUROL, V6, P289, DOI 10.1016/S1474-4422(07)70061-3; Magis D, 2007, LANCET NEUROL, V6, P314, DOI 10.1016/S1474-4422(07)70058-3; Matharu MS, 2004, BRAIN, V127, P220, DOI 10.1093/brain/awh022; Scbwedt TJ, 2008, CURR PAIN HEADACHE R, V12, P62, DOI 10.1007/s11916-008-0012-7; Schwedt TJ, 2007, CEPHALALGIA, V27, P153, DOI 10.1111/j.1468-2982.2007.01272.x	9	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2008	7	11					977	979		10.1016/S1474-4422(08)70218-7	http://dx.doi.org/10.1016/S1474-4422(08)70218-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	370EP	18845481				2022-12-18	WOS:000260745800003
J	Frankish, H				Frankish, Helen			Lancet Asia medical forum - call for papers	LANCET NEUROLOGY			English	Editorial Material									The Lancet Neurol, London NW1 7BY, England		Frankish, H (corresponding author), The Lancet Neurol, London NW1 7BY, England.	helen.frankish@lancet.com						Liu M, 2007, LANCET NEUROL, V6, P456, DOI 10.1016/S1474-4422(07)70004-2; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5	2	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2008	7	9					771	771		10.1016/S1474-4422(08)70180-7	http://dx.doi.org/10.1016/S1474-4422(08)70180-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345HZ					2022-12-18	WOS:000258988400009
J	[Anonymous]				[Anonymous]			Time to confront the global dementia crisis	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2008	7	9					761	761		10.1016/S1474-4422(08)70180-7	http://dx.doi.org/10.1016/S1474-4422(08)70180-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345HZ					2022-12-18	WOS:000258988400001
J	Bogousslavsky, J; Piechowski-Jozwiak, B				Bogousslavsky, Julien; Piechowski-Jozwiak, Bartlomiej			Prothrombotic recombinant activated factor VII in intracerebral haemorrhage: FAST but not focused?	LANCET NEUROLOGY			English	Editorial Material							STROKE		[Bogousslavsky, Julien] Genolier Swiss Med Network, Dept Neurol, CH-1823 Glion Sur Montreux, Switzerland; [Piechowski-Jozwiak, Bartlomiej] LUX MED Med Clin, PL-02342 Warsaw, Poland		Bogousslavsky, J (corresponding author), Genolier Swiss Med Network, Dept Neurol, CH-1823 Glion Sur Montreux, Switzerland.	jbogousslavsky@valmontgenolier.ch	Piechowski-Jozwiak, Bartlomiej/HCI-4426-2022	Piechowski-Jozwiak, Bartlomiej/0000-0001-7814-0028; PIECHOWSKI-JOZWIAK, BARTLOMIEJ/0000-0002-1886-9949				BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P824, DOI 10.1136/jnnp.53.10.824; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Suri MFK, 2008, NEUROCRIT CARE, V9, P177, DOI 10.1007/s12028-008-9106-7	5	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2008	7	8					670	672		10.1016/S1474-4422(08)70147-9	http://dx.doi.org/10.1016/S1474-4422(08)70147-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	330VA	18635013				2022-12-18	WOS:000257969700006
J	Morris, K				Morris, Kelly			Shedding light on the role of poverty in brain development	LANCET NEUROLOGY			English	Editorial Material												vital@dircon.co.uk							0	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2008	7	8					676	677		10.1016/S1474-4422(08)70154-6	http://dx.doi.org/10.1016/S1474-4422(08)70154-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	330VA	18635017				2022-12-18	WOS:000257969700013
J	Klein, C				Klein, Christine			DYT16: a new twist to familial dystonia	LANCET NEUROLOGY			English	Editorial Material									Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany	University of Lubeck	Klein, C (corresponding author), Med Univ Lubeck, Dept Neurol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	christine.klein@neuro.uni-luebeck.de	Klein, Christine/AGK-8003-2022	Klein, Christine/0000-0003-2102-3431				Camargos S, 2008, LANCET NEUROL, V7, P207, DOI 10.1016/S1474-4422(08)70022-X; Gonzalez-Alegre P, 2007, SEMIN NEUROL, V27, P151, DOI 10.1055/s-2007-971170; Hewett J, 2003, J NEUROSCI RES, V72, P158, DOI 10.1002/jnr.10567; Klein C, 2007, LANCET NEUROL, V6, P652, DOI 10.1016/S1474-4422(07)70174-6; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2008	7	3					192	193		10.1016/S1474-4422(08)70023-1	http://dx.doi.org/10.1016/S1474-4422(08)70023-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	268KZ	18243800				2022-12-18	WOS:000253580000002
J	Hobart, JC; Cano, SJ; Zajicek, JP; Thompson, AJ				Hobart, J. C.; Cano, S. J.; Zajicek, J. P.; Thompson, A. J.			Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations (vol 6, pg 1094, 2007)	LANCET NEUROLOGY			English	Correction													Thompson, Alan J/C-2654-2008	Thompson, Alan J/0000-0002-4333-8496				Hobart JC, 2007, LANCET NEUROL, V6, P1094, DOI 10.1016/S1474-4422(07)70290-9	1	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2008	7	1					25	25		10.1016/S1474-4422(07)70314-9	http://dx.doi.org/10.1016/S1474-4422(07)70314-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	247FO		Bronze			2022-12-18	WOS:000252063300020
J	Rees, MI				Rees, Mark I.			The conundrum of complexity in epilepsy	LANCET NEUROLOGY			English	Editorial Material							ASSOCIATION		Univ Coll Swansea, Inst Life Sci, Sch Med, Wales Epilepsy Res Network, Swansea SA2 8PP, W Glam, Wales	Swansea University	Rees, MI (corresponding author), Univ Coll Swansea, Inst Life Sci, Sch Med, Wales Epilepsy Res Network, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	m.i.rees@swansea.ac.uk	Rees, Mark I/J-3129-2012	Rees, Mark I/0000-0003-3570-5986	Medical Research Council [G0601585] Funding Source: Medline; MRC [G0601585] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Berkovic SF, 2006, TRENDS NEUROSCI, V29, P391, DOI 10.1016/j.tins.2006.05.009; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cavalleri GL, 2007, LANCET NEUROL, V6, P970, DOI 10.1016/S1474-4422(07)70247-8; Gourfinkel-An I, 2004, LANCET NEUROL, V3, P209, DOI 10.1016/S1474-4422(04)00706-9; Greenberg DA, 2007, CURR NEUROL NEUROSCI, V7, P320, DOI 10.1007/s11910-007-0049-8; Tan NCK, 2004, EPILEPSIA, V45, P1429, DOI 10.1111/j.0013-9580.2004.22904.x; Turnbull J, 2005, HUM MOL GENET, V14, P2491, DOI 10.1093/hmg/ddi250	7	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2007	6	11					943	944		10.1016/S1474-4422(07)70253-3	http://dx.doi.org/10.1016/S1474-4422(07)70253-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	226VX	17945146				2022-12-18	WOS:000250617700004
J	Albers, GW				Albers, Gregory W.			Warfarin prevails for stroke prevention in atrial fibrillation-even in octogenarians	LANCET NEUROLOGY			English	Editorial Material							ASPIRIN		Stanford Univ, Med Ctr, Stanford Stroke Ctr, Palo Alto, CA 94304 USA	Stanford University	Albers, GW (corresponding author), Stanford Univ, Med Ctr, Stanford Stroke Ctr, Palo Alto, CA 94304 USA.	albers@stanford.edu		Albers, Gregory/0000-0003-0263-4632				Aguilar MI, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006186.pub2; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1	6	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2007	6	10					844	846		10.1016/S1474-4422(07)70227-2	http://dx.doi.org/10.1016/S1474-4422(07)70227-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218SQ	17884669				2022-12-18	WOS:000250035600005
J	Traynor, BJ; Singleton, A				Traynor, Bryan J.; Singleton, Andrew			Genome-wide association studies and ALS: are we there yet?	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS		Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA; NIA, Neurogenet Lab, NIH, Bethesda, MD USA; Univ Virginia, Ctr Publ Hlth Gen, Charlottesville, VA 22903 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Virginia	Singleton, A (corresponding author), Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA.	singleta@mail.nih.gov	Traynor, Bryan J/G-5690-2010; Singleton, Andrew B/C-3010-2009		NATIONAL INSTITUTE ON AGING [Z01AG000933] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Dunckley T, 2007, NEW ENGL J MED, V357, P775, DOI 10.1056/NEJMoa070174; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Frayling TM, 2007, NAT REV GENET, V8, P657, DOI 10.1038/nrg2178; Gros-Louis F, 2006, BBA-MOL BASIS DIS, V1762, P956, DOI 10.1016/j.bbadis.2006.01.004; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Schymick JC, 2007, LANCET NEUROL, V6, P322, DOI 10.1016/S1474-4422(07)70037-6; van de Leemput J, 2007, PLOS GENET, V3, P1076, DOI 10.1371/journal.pgen.0030108; van Es MA, 2007, LANCET NEUROL, V6, P869, DOI 10.1016/S1474-4422(07)70222-3	9	3	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2007	6	10					841	843		10.1016/S1474-4422(07)70225-9	http://dx.doi.org/10.1016/S1474-4422(07)70225-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218SQ	17884667				2022-12-18	WOS:000250035600003
J	Butcher, J				Butcher, James			On reflection - Women in neurology	LANCET NEUROLOGY			English	Editorial Material												james@two-cultures.com		Butcher, James/0000-0001-8546-6093					0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2007	6	9					762	762		10.1016/S1474-4422(07)70210-7	http://dx.doi.org/10.1016/S1474-4422(07)70210-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	204SV	17706561				2022-12-18	WOS:000249065200013
J	Hiraga, A				Hiraga, Akiyuki			Early prediction of prognosis in Guillain-Barre syndrome	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED TRIAL; PLASMA-EXCHANGE		Chiba Univ, Grad Sch Med, Dept Neurol, Chiba, Japan	Chiba University	Hiraga, A (corresponding author), Chiba Univ, Grad Sch Med, Dept Neurol, 1-8-1 Inohana, Chiba, Japan.	hiragaa@yahoo.co.jp		Hiraga, Akiyuki/0000-0003-3341-6654; Kuwabara, Satoshi/0000-0002-4716-8578				Chio A, 2003, NEUROLOGY, V60, P1146, DOI 10.1212/01.WNL.0000055091.96905.D0; Hadden RDM, 2001, NEUROLOGY, V56, P758, DOI 10.1212/WNL.56.6.758; Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9; Hughes RAC, 1997, LANCET, V349, P225; MCKHANN, 1985, NEUROLOGY, V35, P1096; Mori M, 2000, BRAIN, V123, P2171, DOI 10.1093/brain/123.10.2171; Rees JH, 1998, J NEUROL NEUROSUR PS, V64, P74, DOI 10.1136/jnnp.64.1.74; van Koningsveld R, 2007, LANCET NEUROL, V6, P589, DOI 10.1016/S1474-4422(07)70130-8; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Yuki N, 2005, CURR OPIN IMMUNOL, V17, P577, DOI 10.1016/j.coi.2005.09.004	10	3	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2007	6	7					572	573		10.1016/S1474-4422(07)70155-2	http://dx.doi.org/10.1016/S1474-4422(07)70155-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	184WJ	17582351				2022-12-18	WOS:000247673000002
J	[Anonymous]				[Anonymous]			An acute need for better stroke care	LANCET NEUROLOGY			English	Editorial Material																			0	3	3	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2007	6	7					571	571		10.1016/S1474-4422(07)70154-0	http://dx.doi.org/10.1016/S1474-4422(07)70154-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	184WJ	17582350	Bronze			2022-12-18	WOS:000247673000001
J	Winn, HR; Temkin, NR; Anderson, GD; Dikmen, SS				Winn, H. Richard; Temkin, Nancy R.; Anderson, Gail D.; Dikmen, Sureyya S.			Magnesium for neuroprotection after traumatic brain injury	LANCET NEUROLOGY			English	Editorial Material									Mt Sinai Sch Med, Dept Neurosurg & Nuerosci, New York, NY 10029 USA; Univ Washington, Seattle, WA 98195 USA	Icahn School of Medicine at Mount Sinai; University of Washington; University of Washington Seattle	Winn, HR (corresponding author), Mt Sinai Sch Med, Dept Neurosurg & Nuerosci, New York, NY 10029 USA.	richard.winn@mountsinai.org						Maas AI, 2007, LANCET NEUROL, V6, P20, DOI 10.1016/S1474-4422(06)70668-8; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5	2	3	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2007	6	6					478	479		10.1016/S1474-4422(07)70116-3	http://dx.doi.org/10.1016/S1474-4422(07)70116-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	175WO	17509478				2022-12-18	WOS:000247044900007
J	Berge, E				Berge, Eivind			Heparin for acute ischaemic stroke: a never-ending story?	LANCET NEUROLOGY			English	Editorial Material							TRIALS		Ullevaal Univ Hosp, Oslo, Norway	University of Oslo	Berge, E (corresponding author), Ullevaal Univ Hosp, Oslo, Norway.	eivind.berge@medisin.uio.no						Adams HP, 1998, JAMA-J AM MED ASSOC, V279, P1265, DOI 10.1001/jama.279.16.1265; Al-Sadat A, 2002, STROKE, V33, P1574, DOI 10.1161/01.STR.0000018081.33541.E3; Berge E, 2002, CEREBROVASC DIS, V13, P73, DOI 10.1159/000047752; Coull BM, 2002, STROKE, V33, P1934, DOI 10.1161/01.STR.0000028456.18614.93; GUBITZ G, 2004, COCHRANE DB SYST REV, V3; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Schulz KF, 2005, LANCET, V365, P1657, DOI 10.1016/S0140-6736(05)66516-6; Wong KS, 2007, LANCET NEUROL, V6, P407, DOI 10.1016/S1474-4422(07)70079-0	8	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2007	6	5					381	382		10.1016/S1474-4422(07)70087-X	http://dx.doi.org/10.1016/S1474-4422(07)70087-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161XO	17434083				2022-12-18	WOS:000246050600003
J	Burton, A				Burton, Adrian			Let's talk about brains: International Brain Awareness Week	LANCET NEUROLOGY			English	Editorial Material												adrianburton1@yahoo.es							0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2007	6	5					390	391		10.1016/S1474-4422(07)70095-9	http://dx.doi.org/10.1016/S1474-4422(07)70095-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161XO	17434090				2022-12-18	WOS:000246050600011
J	Soto, C				Soto, Claudio			Reversibility of prion-induced neurodegeneration	LANCET NEUROLOGY			English	Editorial Material							DISEASES; BIOLOGY; ALTERS		Univ Texas, Med Branch, George & Cynthia Mitchell Ctr Neurodegenerat Dis, Dept Neurol, Galveston, TX 77550 USA; Univ Texas, Med Branch, George & Cynthia Mitchell Ctr Neurodegenerat Dis, Dept Neurosci & Cell Biol, Galveston, TX 77550 USA; Univ Texas, Med Branch, George & Cynthia Mitchell Ctr Neurodegenerat Dis, Dept Biochem & Mol Biol, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Soto, C (corresponding author), Univ Texas, Med Branch, George & Cynthia Mitchell Ctr Neurodegenerat Dis, Dept Neurol, Galveston, TX 77550 USA.	clsoto@utmb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050349] Funding Source: NIH RePORTER; NINDS NIH HHS [NS050349, R01 NS050349-03, R01 NS050349] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Cunningham C, 2003, EUR J NEUROSCI, V17, P2147, DOI 10.1046/j.1460-9568.2003.02662.x; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Lansbury PT, 2006, NATURE, V443, P774, DOI 10.1038/nature05290; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mallucci GR, 2007, NEURON, V53, P325, DOI 10.1016/j.neuron.2007.01.005; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Russelakis-Carneiro M, 2004, AM J PATHOL, V165, P1839, DOI 10.1016/S0002-9440(10)63439-6; Soto C, 2004, NAT REV MICROBIOL, V2, P809, DOI 10.1038/nrmicro1003; Soto C, 2004, NAT MED, V10, pS63, DOI 10.1038/nm1069; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; SOTO C, IN PRESS ARCH NEUROL	13	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2007	6	4					294	295		10.1016/S1474-4422(07)70064-9	http://dx.doi.org/10.1016/S1474-4422(07)70064-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	149KE	17362830	Green Accepted			2022-12-18	WOS:000245145000006
J	Reimenschneider, M; Perry, A; Reifenberger, G				Reimenschneider, M. J.; Perry, A.; Reifenberger, G.			Histological classification and molecular genetics of meningiomas. (vol 5, pg 1045, 2006)	LANCET NEUROLOGY			English	Correction													Reifenberger, Guido/AAE-3599-2019					Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1	1	3	3	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2007	6	2					105	105		10.1016/S1474-4422(07)70014-5	http://dx.doi.org/10.1016/S1474-4422(07)70014-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	130JG					2022-12-18	WOS:000243795300009
J	Rijntjes, M; Hamzei, F; Weiller, C				Rijntjes, Michel; Hamzei, Farsin; Weiller, Cornelius			Neurorehabilitation: no more constraint for large randomised trials	LANCET NEUROLOGY			English	Editorial Material							INDUCED MOVEMENT THERAPY; STROKE		Univ Freiburg, Dept Neurol, D-79106 Freiburg, Germany	University of Freiburg	Weiller, C (corresponding author), Univ Freiburg, Dept Neurol, Breisacherstr 64, D-79106 Freiburg, Germany.	cornelius.weiller@uniklinik-freiburg.de	Hamzei, Farsin/AAL-5913-2021					Dobkin BH, 2004, LANCET NEUROL, V3, P528, DOI 10.1016/S1474-4422(04)00851-8; Hamzei F, 2006, NEUROIMAGE, V31, P710, DOI 10.1016/j.neuroimage.2005.12.035; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Rijntjes M, 2005, NEUROREHAB NEURAL RE, V19, P238, DOI 10.1177/1545968305279205; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	6	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2007	6	2					99	101		10.1016/S1474-4422(07)70009-1	http://dx.doi.org/10.1016/S1474-4422(07)70009-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	130JG	17239791				2022-12-18	WOS:000243795300004
J	Perez-Tur, J				Perez-Tur, Jordi			Parkinson's disease genetics: a complex disease comes to the clinic	LANCET NEUROLOGY			English	Editorial Material							WHOLE-GENOME ASSOCIATION		CSIC, Inst Biomed Valencia, Mol Genet Unit, E-46010 Valencia, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Perez-Tur, J (corresponding author), CSIC, Inst Biomed Valencia, Mol Genet Unit, E-46010 Valencia, Spain.	jpereztur@ibv.csic.es	Perez-Tur, Jordi/A-2143-2010	Perez-Tur, Jordi/0000-0002-9111-1712				Clarimon J, 2006, AM J HUM GENET, V78, P1082, DOI 10.1086/504727; Elbaz A, 2006, LANCET NEUROL, V5, P917, DOI 10.1016/S1474-4422(06)70579-8; Farrer MJ, 2006, AM J HUM GENET, V78, P1084, DOI 10.1086/504728; Fung HC, 2006, LANCET NEUROL, V5, P911, DOI 10.1016/S1474-4422(06)70578-6; Goris A, 2006, AM J HUM GENET, V78, P1088, DOI 10.1086/504726; Li YH, 2006, AM J HUM GENET, V78, P1090, DOI 10.1086/504725; Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rocca WA, 2004, ANN NEUROL, V56, P495, DOI 10.1002/ana.20228	10	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2006	5	11					896	897		10.1016/S1474-4422(06)70580-4	http://dx.doi.org/10.1016/S1474-4422(06)70580-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	099JY	17052652	Green Submitted			2022-12-18	WOS:000241591600002
J	Goodin, D				Goodin, Douglas			The use of MRI in the diagnosis of multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material									Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Goodin, D (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.	douglas.goodin@ucsf.edu	Calabrese, Massimiliano/I-6195-2012					Charil A, 2006, LANCET NEUROL, V5, P841, DOI 10.1016/S1474-4422(06)70572-5; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; ENGELL T, 1989, ACTA NEUROL SCAND, V79, P428, DOI 10.1111/j.1600-0404.1989.tb03811.x; GILBERT JJ, 1983, ARCH NEUROL-CHICAGO, V40, P533, DOI 10.1001/archneur.1983.04050080033003; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Kappos L, 2005, MULT SCLER, V11, pS10	6	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2006	5	10					808	809		10.1016/S1474-4422(06)70558-0	http://dx.doi.org/10.1016/S1474-4422(06)70558-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	087YD	16987725				2022-12-18	WOS:000240777800005
J	Frankish, H				Frankish, H			Drug shows potential for treatment of Huntington's disease	LANCET NEUROLOGY			English	News Item																			0	3	3	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					476	477		10.1016/S1474-4422(06)70463-X	http://dx.doi.org/10.1016/S1474-4422(06)70463-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16739299				2022-12-18	WOS:000237906000013
J	Gauthier, S				Gauthier, S			Cholinesterase inhibitors in late-stage Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							DONEPEZIL		McGill Ctr Studies Aging, Montreal, PQ, Canada	McGill University	Gauthier, S (corresponding author), McGill Ctr Studies Aging, Montreal, PQ, Canada.	serge.gauthier@mcgill.ca						Cummings Jeffrey L, 2005, Am J Geriatr Pharmacother, V3, P137, DOI 10.1016/S1543-5946(05)80020-0; Feldman H, 2005, INT J GERIATR PSYCH, V20, P559, DOI 10.1002/gps.1325; Gauthier S, 2005, INT J GERIATR PSYCH, V20, P459, DOI 10.1002/gps.1341; Hogan DB, 2006, LANCET, V367, P1031, DOI 10.1016/S0140-6736(06)68395-5; ROCKWOOD K, 2006, CMAJ, V174, P1117; Winblad B, 2006, LANCET, V367, P1057, DOI 10.1016/S0140-6736(06)68350-5	6	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					468	469		10.1016/S1474-4422(06)70454-9	http://dx.doi.org/10.1016/S1474-4422(06)70454-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16713915				2022-12-18	WOS:000237906000005
J	Thomas, L				Thomas, L			Stem-cell factor induces angiogenesis in vivo	LANCET NEUROLOGY			English	News Item																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					474	474		10.1016/S1474-4422(06)70459-8	http://dx.doi.org/10.1016/S1474-4422(06)70459-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16739295				2022-12-18	WOS:000237906000009
J	Lasmezas, CI				Lasmezas, CI			Of mice and men ... and vCJD	LANCET NEUROLOGY			English	Editorial Material							CREUTZFELDT-JAKOB-DISEASE; SPONGIFORM ENCEPHALOPATHY AGENT; VARIANT; PRIMATES; GENOTYPE		Scripps Florida, Dept Infectol, Jupiter, FL USA	State University System of Florida; University of Florida	Lasmezas, CI (corresponding author), Scripps Florida, Dept Infectol, Jupiter, FL USA.	lasmezas@scripps.edu						Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Bishop MT, 2006, LANCET NEUROL, V5, P393, DOI 10.1016/S1474-4422(06)70413-6; Brandel JP, 2003, LANCET, V362, P128, DOI 10.1016/S0140-6736(03)13867-6; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; Cervenakova L, 1998, P NATL ACAD SCI USA, V95, P13239, DOI 10.1073/pnas.95.22.13239; Herzog C, 2004, LANCET, V363, P422, DOI 10.1016/S0140-6736(04)15487-1; Lasmezas CI, 2001, P NATL ACAD SCI USA, V98, P4142, DOI 10.1073/pnas.041490898; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Wadsworth JDF, 2004, SCIENCE, V306, P1793, DOI 10.1126/science.1103932; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	11	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2006	5	5					374	375		10.1016/S1474-4422(06)70414-8	http://dx.doi.org/10.1016/S1474-4422(06)70414-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	037LF	16632300				2022-12-18	WOS:000237147600002
J	Bourke, SC; Tomlinson, M; Williams, TL; Bullock, RE; Shaw, PJ; Gibson, GJ				Bourke, SC; Tomlinson, M; Williams, TL; Bullock, RE; Shaw, PJ; Gibson, GJ			Non-invasive ventilation in amyotrophic lateral sclerosis - Reply	LANCET NEUROLOGY			English	Editorial Material							DISEASE; ALS		Univ Newcastle Upon Tyne, Dept Resp Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Neurol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Anaesthesia, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Bourke, SC (corresponding author), Univ Newcastle Upon Tyne, Dept Resp Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	Stephen.bourke@northumbria-healthcare.nhs.uk	Shaw, Pamela J/A-5215-2009; Shaw, Pamela J/A-7620-2010	Shaw, Pamela/0000-0002-8925-2567				Bourke SC, 2003, NEUROLOGY, V61, P171, DOI 10.1212/01.WNL.0000076182.13137.38; Bourke SC, 2002, AMYOTROPH LATERAL SC, V3, P145, DOI 10.1080/146608202760834157; Cedarbaum JM, 2001, AMYOTROPH LATERAL SC, V2, P19, DOI 10.1080/146608201300079373; Weijer C, 2000, BMJ-BRIT MED J, V321, P756, DOI 10.1136/bmj.321.7263.756	4	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2006	5	4					292	293		10.1016/S1474-4422(06)70391-X	http://dx.doi.org/10.1016/S1474-4422(06)70391-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	029CI					2022-12-18	WOS:000236535200008
J	Dennis, M				Dennis, M			Dysphagia in acute stroke: a long-awaited trial	LANCET NEUROLOGY			English	Editorial Material									Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Dennis, M (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland.	martin.dennis@ed.ac.uk		dennis, martin/0000-0003-1148-8972				Carnaby G, 2006, LANCET NEUROL, V5, P31, DOI 10.1016/S1474-4422(05)70252-0; Clarke J, 2005, LANCET, V365, P764, DOI 10.1016/S0140-6736(05)17983-5; DRUMMOND A, 1994, CLIN REHABIL, V9, P283; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Norton B, 1996, BRIT MED J, V312, P13, DOI 10.1136/bmj.312.7022.13; Parker CJ, 2001, CLIN REHABIL, V15, P42, DOI 10.1191/026921501666968247; Smithard DG, 1996, STROKE, V27, P1200, DOI 10.1161/01.STR.27.7.1200	7	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2006	5	1					16	17		10.1016/S1474-4422(05)70265-9	http://dx.doi.org/10.1016/S1474-4422(05)70265-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	998OI	16361015				2022-12-18	WOS:000234328100011
J	Mielke, J				Mielke, J			Phenobarbital for convulsive epilepsy at primary care level	LANCET NEUROLOGY			English	Editorial Material									Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe	University of Zimbabwe	Mielke, J (corresponding author), Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe.	mielke@ecoweb.co.zw						Adamolekun B, 1999, EPILEPSIA, V40, P507, DOI 10.1111/j.1528-1157.1999.tb00749.x; DEKKER PA, 2002, WHOMSDMBD0202; NODOYE NF, 2005, SEIZURE, V14, P106; Scott RA, 2001, B WORLD HEALTH ORGAN, V79, P344; Wang WZ, 2006, LANCET NEUROL, V5, P46, DOI 10.1016/S1474-4422(05)70254-4; Wang WZ, 2003, NEUROLOGY, V60, P1544, DOI 10.1212/01.WNL.0000059867.35547.DE; WHO, 2000, GLOB CAMP EP OUT SHA	7	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2006	5	1					17	18		10.1016/S1474-4422(05)70266-0	http://dx.doi.org/10.1016/S1474-4422(05)70266-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	998OI	16361016				2022-12-18	WOS:000234328100012
J	Dawson, J; Walters, M				Dawson, J; Walters, M			Development and validation of a stroke recognition tool	LANCET NEUROLOGY			English	Editorial Material							EMERGENCY; TRIALS; SCREEN		Western Infirm & Associated Hosp, Acute Stroke Unit, Glasgow, Lanark, Scotland		Dawson, J (corresponding author), Western Infirm & Associated Hosp, Acute Stroke Unit, Glasgow, Lanark, Scotland.	gcl203@clinmed.gla.ac.uk						Azzimondi G, 1997, STROKE, V28, P537, DOI 10.1161/01.STR.28.3.537; Bray JE, 2005, CEREBROVASC DIS, V20, P28, DOI 10.1159/000086201; Hacke W, 2004, LANCET, V363, P768; Harbison J, 1999, LANCET, V353, P1935, DOI 10.1016/S0140-6736(99)00966-6; Kidwell CS, 2000, STROKE, V31, P71, DOI 10.1161/01.STR.31.1.71; Kothari RU, 1999, ANN EMERG MED, V33, P373, DOI 10.1016/S0196-0644(99)70299-4; LIBMAN RB, 1995, ARCH NEUROL-CHICAGO, V52, P1119, DOI 10.1001/archneur.1995.00540350113023; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Nor AM, 2005, LANCET NEUROL, V4, P727, DOI 10.1016/S1474-4422(05)70201-5; Ulaki, 2000, Acad Emerg Med, V7, P1165; Wojner-Alexandrov AW, 2005, STROKE, V36, P1512, DOI 10.1161/01.STR.0000170700.45340.39	11	3	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2005	4	11					691	693		10.1016/S1474-4422(05)70204-0	http://dx.doi.org/10.1016/S1474-4422(05)70204-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980GK	16239173				2022-12-18	WOS:000233002400003
J	Halliday, G				Halliday, G			Clarifying Lewy-body parkinsonism with visual hallucinations	LANCET NEUROLOGY			English	Editorial Material							DISEASE; DISORDERS; PATHOLOGY; DEMENTIA		Prince Wales Med Res Inst, Sydney, NSW, Australia; Univ New S Wales, Sydney, NSW, Australia	Prince Wales Medical Research Institute; University of New South Wales Sydney	Halliday, G (corresponding author), Prince Wales Med Res Inst, Sydney, NSW, Australia.	g.halliday@unsw.edu.au	Halliday, Glenda M/E-8555-2011	Halliday, Glenda M/0000-0003-0422-8398				Benarroch EE, 2005, BRAIN, V128, P338, DOI 10.1093/brain/awh376; Braak H, 2005, NEUROLOGY, V64, P1404, DOI 10.1212/01.WNL.0000158422.41380.82; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Calne DB, 2004, PARKINSONISM RELAT D, V10, P319, DOI 10.1016/j.parkreldis.2004.03.006; Grossi D, 2005, INT J GERIATR PSYCH, V20, P668, DOI 10.1002/gps.1339; Harding AJ, 2002, BRAIN, V125, P391, DOI 10.1093/brain/awf033; Hughes AJ, 2002, BRAIN, V125, P861, DOI 10.1093/brain/awf080; Katzenschlager R, 2003, MOVEMENT DISORD, V18, P1123, DOI 10.1002/mds.10523; KOSAKA K, 1988, CLIN NEUROPATHOL, V7, P299; Litvan I, 2003, MOVEMENT DISORD, V18, P467, DOI 10.1002/mds.10459; Merims D, 2004, J NEURAL TRANSM, V111, P1447, DOI 10.1007/s00702-004-0209-9; Parkkinen L, 2005, ANN NEUROL, V57, P82, DOI 10.1002/ana.20321; Williams DR, 2005, LANCET NEUROL, V4, P605, DOI 10.1016/S1474-4422(05)70146-0	13	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2005	4	10					588	589		10.1016/S1474-4422(05)70175-7	http://dx.doi.org/10.1016/S1474-4422(05)70175-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969PG	16168923				2022-12-18	WOS:000232245900003
J	Kern, R; Kreisel, S; Zoubaa, S; Szabo, K; Gass, A; Hennerici, M				Kern, R; Kreisel, S; Zoubaa, S; Szabo, K; Gass, A; Hennerici, M			Cognitive impairment, aphasia, and seizures in a 51-year-old man	LANCET NEUROLOGY			English	Article							CEREBRAL AMYLOID ANGIOPATHY; REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY; LOBAR INTRACEREBRAL HEMORRHAGE; APOLIPOPROTEIN-E GENOTYPE; GIANT-CELL ARTERITIS; GRADIENT-ECHO MRI; ALZHEIMERS-DISEASE; ENCEPHALOPATHY; DIAGNOSIS; DEMENTIA		Univ Heidelberg, Klinikum Mannheim, Dept Neurol, D-68167 Mannheim, Germany; Univ Heidelberg, Dept Neuropathol, D-6900 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kern, R (corresponding author), Univ Heidelberg, Klinikum Mannheim, Dept Neurol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	kern@neuro.ma.uni-heidelberg.de	Szabo, Kristina/AAE-7978-2021					Anders KH, 1997, HUM PATHOL, V28, P1237, DOI 10.1016/S0046-8177(97)90196-9; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; Baezner H, 2003, Ther Umsch, V60, P541, DOI 10.1024/0040-5930.60.9.541; Caulo M, 2001, AM J NEURORADIOL, V22, P1072; Eckman MH, 2003, STROKE, V34, P1710, DOI 10.1161/01.STR.0000078311.18928.16; Eng JA, 2004, ANN NEUROL, V55, P250, DOI 10.1002/ana.10810; ESIRI MM, 1986, J NEUROL NEUROSUR PS, V49, P1221, DOI 10.1136/jnnp.49.11.1221; Freund M, 2001, EUR RADIOL, V11, P309, DOI 10.1007/s003300000653; Garg RK, 2001, POSTGRAD MED J, V77, P24, DOI 10.1136/pmj.77.903.24; GRAY F, 1985, ANN NEUROL, V18, P54, DOI 10.1002/ana.410180110; Greenberg SM, 1997, STROKE, V28, P1418, DOI 10.1161/01.STR.28.7.1418; Greenberg SM, 2004, STROKE, V35, P1415, DOI 10.1161/01.STR.0000126807.69758.0e; GREENBERG SM, 1993, NEUROLOGY, V43, P2073, DOI 10.1212/WNL.43.10.2073; Greenberg SM, 1999, NEUROLOGY, V53, P1135, DOI 10.1212/WNL.53.5.1135; Greenberg SM, 1998, NEUROLOGY, V50, P961, DOI 10.1212/WNL.50.4.961; Greenberg SM, 1996, NEUROLOGY, V46, P1751, DOI 10.1212/WNL.46.6.1751; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Greenberg SM, 1996, STROKE, V27, P1333, DOI 10.1161/01.STR.27.8.1333; Harkness KAC, 2004, EUR J NEUROL, V11, P59, DOI 10.1046/j.1351-5101.2003.00707.x; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Imaoka K, 1999, J NEUROL, V246, P661, DOI 10.1007/s004150050428; KENNEDY PG, 2004, J NEUROL NEUROSUR S1, V75, P10; Knudsen KA, 2001, NEUROLOGY, V56, P537, DOI 10.1212/WNL.56.4.537; LACOMBE P, 1977, BRAIN RES, V129, P129, DOI 10.1016/0006-8993(77)90975-1; Lamy C, 2004, J NEUROIMAGING, V14, P89, DOI 10.1177/1051228403258161; LOES DJ, 1990, AM J NEURORADIOL, V11, P485; MANDYBUR TI, 1986, J NEUROPATH EXP NEUR, V45, P79, DOI 10.1097/00005072-198601000-00007; MANDYBUR TI, 1992, CLIN NEUROPHARMACOL, V15, P241, DOI 10.1097/00002826-199206000-00005; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; McCarron MO, 2004, LANCET NEUROL, V3, P484, DOI 10.1016/S1474-4422(04)00825-7; McCarron MO, 1999, STROKE, V30, P1643, DOI 10.1161/01.STR.30.8.1643; MELO TP, 1993, EUR NEUROL, V33, P9, DOI 10.1159/000116890; Miller JH, 1999, CLIN RADIOL, V54, P422, DOI 10.1016/S0009-9260(99)90825-5; MURPHY MN, 1985, STROKE, V16, P514, DOI 10.1161/01.STR.16.3.514; O'Donnell HC, 2000, NEW ENGL J MED, V342, P240, DOI 10.1056/NEJM200001273420403; Oh U, 2004, NEUROLOGY, V62, P494, DOI 10.1212/01.WNL.0000106951.94624.DF; OKAZAKI H, 1979, MAYO CLIN PROC, V54, P22; Pavlakis SG, 1999, J CHILD NEUROL, V14, P277, DOI 10.1177/088307389901400502; POWERS JM, 1990, ACTA NEUROPATHOL, V81, P95, DOI 10.1007/BF00662644; Premkumar DRD, 1996, AM J PATHOL, V148, P2083; Roob G, 1999, NEUROLOGY, V52, P991, DOI 10.1212/WNL.52.5.991; Rosand J, 2000, NEUROLOGY, V55, P947, DOI 10.1212/WNL.55.7.947; Sarazin M, 2002, EUR J NEUROL, V9, P353, DOI 10.1046/j.1468-1331.2002.00393.x; Singhal AB, 2004, ARCH NEUROL-CHICAGO, V61, P411, DOI 10.1001/archneur.61.3.411; Smith EE, 2004, NEUROLOGY, V63, P1606, DOI 10.1212/01.WNL.0000142966.22886.20; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Tsushima Y, 2003, AM J NEURORADIOL, V24, P88; VANLEY CT, 1981, HUM PATHOL, V12, P609, DOI 10.1016/S0046-8177(81)80044-5; VINTERS HV, 1990, ANN NEUROL, V28, P34, DOI 10.1002/ana.410280108; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; VONSATTEL JPG, 1991, ANN NEUROL, V30, P637, DOI 10.1002/ana.410300503; Walker DA, 2004, AM J ROENTGENOL, V182, P1547, DOI 10.2214/ajr.182.6.1821547; WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x; YONG WH, 1992, ARCH NEUROL-CHICAGO, V49, P51, DOI 10.1001/archneur.1992.00530250055016	55	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2005	4	7					445	450		10.1016/S1474-4422(05)70122-8	http://dx.doi.org/10.1016/S1474-4422(05)70122-8			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	938TA	15963448				2022-12-18	WOS:000230024700019
J	Mocellin, R; Velakoulis, D; Gonzales, M; Lloyd, J; Tomlinson, EB				Mocellin, R; Velakoulis, D; Gonzales, M; Lloyd, J; Tomlinson, EB			Weight loss, falls, and neuropsychiatric symptoms in a 56-year-old man	LANCET NEUROLOGY			English	Article							CREUTZFELDT-JAKOB-DISEASE; PARANEOPLASTIC LIMBIC ENCEPHALITIS; CENTRAL-NERVOUS-SYSTEM; POTASSIUM CHANNEL ANTIBODY; SLEEP BEHAVIOR DISORDER; CEREBROSPINAL-FLUID; CEREBRAL VASCULITIS; HODGKINS-DISEASE; 14-3-3 PROTEINS; CROHNS-DISEASE		Royal Melbourne Hosp, Melbourne Neuropsychiat Ctr, Neuropsychiat Unit, Parkville, Vic 3052, Australia; Royal Melbourne Hosp, Dept Anat Pathol, Parkville, Vic 3052, Australia	Royal Melbourne Hospital; Royal Melbourne Hospital	Mocellin, R (corresponding author), Royal Melbourne Hosp, Melbourne Neuropsychiat Ctr, Neuropsychiat Unit, 2nd Floor,John Cade Bldg,Grattan St, Parkville, Vic 3052, Australia.	ramon.mocellin@nh.org.au	Velakoulis, Dennis/A-4778-2008	Velakoulis, Dennis/0000-0002-8842-8479				Bak TH, 2001, J NEUROL NEUROSUR PS, V71, P40, DOI 10.1136/jnnp.71.1.40; Bataller L, 2003, NEUROL CLIN, V21, P221, DOI 10.1016/S0733-8619(02)00037-3; Berg D, 2003, NAT REV NEUROSCI, V4, P752, DOI 10.1038/nrn1197; Boeve BF, 1998, NEUROLOGY, V51, P363, DOI 10.1212/WNL.51.2.363; Bohnen NILJ, 1997, NEUROLOGY, V49, P246, DOI 10.1212/WNL.49.1.246; Brohee P, 1997, J NEUROIMAGING, V7, P195, DOI 10.1111/jon199773195; Buckley C, 2001, ANN NEUROL, V50, P73, DOI 10.1002/ana.1097; CARR I, 1982, LANCET, V1, P844; Caviness JN, 2003, PARKINSONISM RELAT D, V9, P185, DOI 10.1016/S1353-8020(02)00054-8; Chapman T, 2000, NEUROLOGY, V55, P1396, DOI 10.1212/WNL.55.9.1396; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; Gerard A, 2002, MEDICINE, V81, P443, DOI 10.1097/00005792-200211000-00005; Green AJE, 2001, J NEUROL NEUROSUR PS, V70, P744, DOI 10.1136/jnnp.70.6.744; Greicius MD, 2002, J NEUROL NEUROSUR PS, V72, P691, DOI 10.1136/jnnp.72.6.691; Grimes DA, 1999, NEUROLOGY, V53, P1969, DOI 10.1212/WNL.53.9.1969; Gultekin SH, 2000, BRAIN, V123, P1481, DOI 10.1093/brain/123.7.1481; Haik S, 2000, NEUROLOGY, V55, P1401, DOI 10.1212/WNL.55.9.1401; Hart PE, 1998, J NEUROL NEUROSUR PS, V64, P160, DOI 10.1136/jnnp.64.2.160; Hasan S, 1998, AM J PSYCHIAT, V155, P1113, DOI 10.1176/ajp.155.8.1113; HOLLAND BA, 1987, MAGNETIC RESONANCE I, P259; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; Imbesi SG, 1999, AM J ROENTGENOL, V173, P1494, DOI 10.2214/ajr.173.6.10584789; Javedan SP, 1997, NEUROSURGERY, V41, P823, DOI 10.1097/00006123-199710000-00011; Kelley RE, 2004, FRONT BIOSCI-LANDMRK, V9, P946, DOI 10.2741/1259; Kung S, 2002, PSYCHOSOMATICS, V43, P498, DOI 10.1176/appi.psy.43.6.498; LACOMIS D, 1990, J COMPUT ASSIST TOMO, V14, P115, DOI 10.1097/00004728-199001000-00021; Liguori R, 2001, BRAIN, V124, P2417, DOI 10.1093/brain/124.12.2417; Mendez OE, 2003, J NEUROIMAGING, V13, P147, DOI 10.1177/1051228403251085; NEWMAN NJ, 1990, BIOL PSYCHIAT, V27, P529, DOI 10.1016/0006-3223(90)90444-7; Newsom-Davis J, 2003, ANN NY ACAD SCI, V998, P202, DOI 10.1196/annals.1254.022; Rees JH, 2001, BRAIN, V124, P2223, DOI 10.1093/brain/124.11.2223; Rust P, 2001, J CLIN NEUROSCI, V8, P361, DOI 10.1054/jocn.2000.0864; Saiz A, 1999, ANN NEUROL, V46, P774, DOI 10.1002/1531-8249(199911)46:5<774::AID-ANA14>3.0.CO;2-N; Sanchez-Valle R, 2002, NEUROSCI LETT, V320, P69, DOI 10.1016/S0304-3940(02)00045-9; Schenck CH, 1996, NEUROLOGY, V46, P388, DOI 10.1212/WNL.46.2.388; Schluter A, 2004, CLIN NEUROL NEUROSUR, V106, P110, DOI 10.1016/j.clineuro.2003.09.004; Thieben MJ, 2004, NEUROLOGY, V62, P1177, DOI 10.1212/01.WNL.0000122648.19196.02; Tschampa HJ, 2001, J NEUROL NEUROSUR PS, V71, P33, DOI 10.1136/jnnp.71.1.33; Vincent A, 2004, BRAIN, V127, P701, DOI 10.1093/brain/awh077; Wasserman BA, 2001, AM J ROENTGENOL, V177, P455, DOI 10.2214/ajr.177.2.1770455; West Sterling G, 2003, Curr Rheumatol Rep, V5, P116, DOI 10.1007/s11926-003-0039-z; Wiltfang J, 1999, J NEUROCHEM, V73, P2485, DOI 10.1046/j.1471-4159.1999.0732485.x	42	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2005	4	6					381	388		10.1016/S1474-4422(05)70100-9	http://dx.doi.org/10.1016/S1474-4422(05)70100-9			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	931EQ	15907743				2022-12-18	WOS:000229469000018
J	Smith, RA; Brooks, BR				Smith, RA; Brooks, BR			Treatment of pseudobulbar affect in ALS	LANCET NEUROLOGY			English	Editorial Material									Ctr Neurol Study, La Jolla, CA USA; Univ Wisconsin, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison	Smith, RA (corresponding author), Ctr Neurol Study, La Jolla, CA USA.							Brooks BR, 2004, NEUROLOGY, V63, P1364; KLEIN M, 1989, J PHARMACOL EXP THER, V251, P207; LANDAU WM, 1974, ARCH NEUROL-CHICAGO, V31, P217; Meininger V, 2005, LANCET NEUROL, V4, P70, DOI 10.1016/S1474-4422(05)00970-1; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; SMITH RA, 1991, HDB CLIN NEUROLOGY, V15; Turner BJ, 2003, AMYOTROPH LATERAL SC, V4, P171, DOI 10.1080/14660820310009389	7	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2005	4	5					270	270		10.1016/S1474-4422(05)70058-2	http://dx.doi.org/10.1016/S1474-4422(05)70058-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	919AE	15847840				2022-12-18	WOS:000228589900010
J	Boeve, BF				Boeve, BF			Evidence for cholinesterase-inhibitor therapy for dementia associated with Parkinson's disease	LANCET NEUROLOGY			English	Letter							RIVASTIGMINE		Mayo Clin, Coll Med, Dept Neurol, Div Behav Neurol, Rochester, MN 55905 USA	Mayo Clinic	Boeve, BF (corresponding author), Mayo Clin, Coll Med, Dept Neurol, Div Behav Neurol, 200 1st St SW, Rochester, MN 55905 USA.	bboeve@mayo.edu						Aarsland D, 2003, ARCH NEUROL-CHICAGO, V60, P387, DOI 10.1001/archneur.60.3.387; Aarsland D, 1999, INT J GERIATR PSYCH, V14, P866, DOI 10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.3.CO;2-Q; Apaydin H, 2002, ARCH NEUROL-CHICAGO, V59, P102, DOI 10.1001/archneur.59.1.102; Emre M, 2004, NEW ENGL J MED, V351, P2509, DOI 10.1056/NEJMoa041470; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2005	4	3					137	138		10.1016/S1474-4422(05)00997-X	http://dx.doi.org/10.1016/S1474-4422(05)00997-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	901QT	15721821				2022-12-18	WOS:000227297700003
J	Butcher, J				Butcher, J			Parkin gene therapy could treat Parkinson's disease	LANCET NEUROLOGY			English	News Item														Butcher, James/0000-0001-8546-6093					0	3	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					82	82		10.1016/S1474-4422(05)00982-8	http://dx.doi.org/10.1016/S1474-4422(05)00982-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15709224				2022-12-18	WOS:000226712300013
J	Jagust, W				Jagust, W			Dementia: finding the signals in the noise	LANCET NEUROLOGY			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE		Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Jagust, W (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.	jagust@berkeley.edu	Jagust, William/ABE-6426-2020					Bentham P, 2004, LANCET, V363, P2105; Dickerson BC, 2004, ANN NEUROL, V56, P27, DOI 10.1002/ana.20163; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Yaffe K, 2004, JAMA-J AM MED ASSOC, V292, P2237, DOI 10.1001/jama.292.18.2237	5	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					10	11		10.1016/S1474-4422(04)00949-4	http://dx.doi.org/10.1016/S1474-4422(04)00949-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15620851				2022-12-18	WOS:000226250200009
J	Mastaglia, FL				Mastaglia, FL			Neuromuscular disorders: molecular and therapeutic insights	LANCET NEUROLOGY			English	Editorial Material							INCLUSION-BODY MYOSITIS; GUILLAIN-BARRE-SYNDROME		Univ Western Australia, Queen Elizabeth II Med Ctr, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia	University of Western Australia	Mastaglia, FL (corresponding author), Univ Western Australia, Queen Elizabeth II Med Ctr, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia.	flmast@cyllene.uwa.edu.au						Fratta P, 2004, NEUROLOGY, V63, P1114, DOI 10.1212/01.WNL.0000138574.56908.5D; Meredith C, 2004, AM J HUM GENET, V75, P703, DOI 10.1086/424760; Price P, 2004, TISSUE ANTIGENS, V64, P575, DOI 10.1111/j.1399-0039.2004.00310.x; van Koningsveld R, 2004, LANCET, V363, P192, DOI 10.1016/S0140-6736(03)15324-X; Yuki N, 2004, P NATL ACAD SCI USA, V101, P11404, DOI 10.1073/pnas.0402391101	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					6	7		10.1016/S1474-4422(04)00946-9	http://dx.doi.org/10.1016/S1474-4422(04)00946-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15620848				2022-12-18	WOS:000226250200006
J	Nelson, R				Nelson, R			Brain-cancer stem cells may drive tumour formation	LANCET NEUROLOGY			English	News Item																			0	3	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					17	17		10.1016/S1474-4422(04)00955-X	http://dx.doi.org/10.1016/S1474-4422(04)00955-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15645592				2022-12-18	WOS:000226250200014
J	Broderick, J				Broderick, J			Gross underfunding of stroke research	LANCET NEUROLOGY			English	Letter									Univ Cincinnati, Dept Neurol, Cincinnati, OH 45221 USA	University of Cincinnati	Broderick, J (corresponding author), Univ Cincinnati, Dept Neurol, Cincinnati, OH 45221 USA.	joseph.broderick@uc.edu						American Heart Association, 2003, HEART DIS STROK STAT; Broderick JP, 2004, STROKE, V35, P205, DOI 10.1161/01.STR.0000106160.34316.19; Kleindorfer D, 2004, STROKE, V35, pE27, DOI 10.1161/01.STR.0000109767.11426.17; *NIH, EST FUND VAR DIS CON; Pendlebury ST, 2004, STROKE, V35, P2368, DOI 10.1161/01.STR.0000140632.83868.a2; *STROK ASS, 1998, STROK CAR RED BURD D	6	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2004	3	12					705	706		10.1016/S1474-4422(04)00930-5	http://dx.doi.org/10.1016/S1474-4422(04)00930-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	873MD	15556800				2022-12-18	WOS:000225283500014
J	Allain, H; Bentue-Ferrer, D; Akwa, Y				Allain, H; Bentue-Ferrer, D; Akwa, Y			Mild cognitive impairment: a treatment at last?	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS-DISEASE; TRIAL; DONEPEZIL		Univ Rennes 1, Lab Clin & Experimental Pharmacol, Ctr Memoire Ressource Rech Bretagne, Fac Med, F-35014 Rennes, France; INSERM, U488, F-94275 Le Kremlin Bicetre, France	CHU Rennes; Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm)	Allain, H (corresponding author), Univ Rennes 1, Lab Clin & Experimental Pharmacol, Ctr Memoire Ressource Rech Bretagne, Fac Med, F-35014 Rennes, France.	Herve.Allain@univ-rennes1.fr	Akwa, Yvette/I-5223-2018	Akwa, Yvette/0000-0003-2181-4612				Allain H, 2002, Rev Neurol (Paris), V158, pS35; Bentham P, 2004, LANCET, V363, P2105; DEDEYN PP, 2003, MEMORY BASIC CONCEPT, P488; Dubois B, 2004, LANCET NEUROL, V3, P246, DOI 10.1016/S1474-4422(04)00710-0; Mecocci P, 2004, NEUROL RES, V26, P598, DOI 10.1179/016164104225017659; Salloway S, 2004, NEUROLOGY, V63, P651, DOI 10.1212/01.WNL.0000134664.80320.92; Sramek JJ, 1996, LIFE SCI, V58, P1201, DOI 10.1016/0024-3205(96)00081-1	7	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2004	3	11					643	643		10.1016/S1474-4422(04)00901-9	http://dx.doi.org/10.1016/S1474-4422(04)00901-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	865CL	15488455				2022-12-18	WOS:000224680000014
J	Nelson, R				Nelson, R			Utrophin therapy for Duchenne muscular dystrophy?	LANCET NEUROLOGY			English	News Item																			0	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2004	3	11					637	637		10.1016/S1474-4422(04)00891-9	http://dx.doi.org/10.1016/S1474-4422(04)00891-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	865CL	15515235				2022-12-18	WOS:000224680000004
J	Linazasoro, G				Linazasoro, G			Closed doors and false expectations: cell-based therapies for PD	LANCET NEUROLOGY			English	Editorial Material												glinazasoro@terra.es						BORKLUND A, 2003, LANCET NEUROL, V2, P437; Lang AE, 2004, LANCET NEUROL, V3, P309, DOI 10.1016/S1474-4422(04)00740-9; Oh MY, 2002, NEUROSURGERY, V50, P1268; 2003, NATURE, V422, P787	4	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2004	3	8					454	455		10.1016/S1474-4422(04)00820-8	http://dx.doi.org/10.1016/S1474-4422(04)00820-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	842OD	15261604				2022-12-18	WOS:000223012800015
J	Bax, M				Bax, M			Diagnostic assessment of children with cerebral palsy	LANCET NEUROLOGY			English	Editorial Material							ORIGIN		Univ London Imperial Coll Sci Technol & Med, Sch Med, Chelsea & Westminster Hosp, London, England	Imperial College London	Bax, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Chelsea & Westminster Hosp, London, England.	m.bax@imperial.ac.uk						Ashwal S, 2004, NEUROLOGY, V62, P851, DOI 10.1212/01.WNL.0000117981.35364.1B; Hagberg B, 2001, ACTA PAEDIATR, V90, P271, DOI 10.1080/080352501300067532; KRAGELOHMANN I, 1995, DEV MED CHILD NEUROL, V37, P379; RUTTER R, 1970, NEUROPSYCHIATRIC STU; STANLEY F, 2001, CEREBRAL PALSIES EPI; Wallace SJ, 2001, DEV MED CHILD NEUROL, V43, P713, DOI 10.1017/S0012162201001281	6	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2004	3	7					395	395		10.1016/S1474-4422(04)00802-6	http://dx.doi.org/10.1016/S1474-4422(04)00802-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832ZQ	15207793				2022-12-18	WOS:000222306600012
J	Bradbury, J				Bradbury, J			Mitochondrial fusion protein mutated in CMT2A	LANCET NEUROLOGY			English	News Item																			0	3	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					326	326		10.1016/S1474-4422(04)00781-1	http://dx.doi.org/10.1016/S1474-4422(04)00781-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15176403				2022-12-18	WOS:000221663000004
J	Carmichael, G				Carmichael, G			Left temporoparietal junction performs social reasoning	LANCET NEUROLOGY			English	News Item																			0	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					328	328		10.1016/S1474-4422(04)00785-9	http://dx.doi.org/10.1016/S1474-4422(04)00785-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15176407				2022-12-18	WOS:000221663000008
J	Love, R				Love, R			Mitochondria back in the spotlight in Parkinson's disease	LANCET NEUROLOGY			English	News Item																			0	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					326	326		10.1016/S1474-4422(04)00782-3	http://dx.doi.org/10.1016/S1474-4422(04)00782-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15176404				2022-12-18	WOS:000221663000005
J	Theodore, WH; Fisher, RS				Theodore, WH; Fisher, RS			Brain stimulation for epilepsy (vol 3, pg 111, 2004)	LANCET NEUROLOGY			English	Correction																		Theodore WH, 2004, LANCET NEUROL, V3, P111, DOI 10.1016/S1474-4422(03)00664-1	1	3	4	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					332	332		10.1016/S1474-4422(04)00765-3	http://dx.doi.org/10.1016/S1474-4422(04)00765-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ					2022-12-18	WOS:000221663000014
J	de la Torre, JC				de la Torre, JC			Is Alzheimer's disease a neurodegenrative or vascular disorder? (vol 3, pg 184, 2004)	LANCET NEUROLOGY			English	Correction																		de la Torre JC, 2004, LANCET NEUROL, V3, P184, DOI 10.1016/S1474-4422(04)00683-0	1	3	3	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2004	3	5					270	270		10.1016/S1474-4422(04)00733-1	http://dx.doi.org/10.1016/S1474-4422(04)00733-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817EL		Bronze			2022-12-18	WOS:000221160700019
J	Morris, K				Morris, K			New-wave neurotechnology: small-scale makes big promises	LANCET NEUROLOGY			English	News Item																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2004	3	4					202	202		10.1016/S1474-4422(04)00727-6	http://dx.doi.org/10.1016/S1474-4422(04)00727-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	814QU	15077610				2022-12-18	WOS:000220990000010
J	Archibald, S				Archibald, S			A spoonful of trehalose makes the protein aggregations go down	LANCET NEUROLOGY			English	News Item																			0	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2004	3	3					137	137		10.1016/S1474-4422(04)00694-5	http://dx.doi.org/10.1016/S1474-4422(04)00694-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	802MK					2022-12-18	WOS:000220167400005
J	Volicer, L				Volicer, L			End-of-life care and bereavement: effect on family carers	LANCET NEUROLOGY			English	Editorial Material									Boston Univ, Sch Med, EN Rogers Mem Vet Hosp, Bedford, England		Volicer, L (corresponding author), Boston Univ, Sch Med, EN Rogers Mem Vet Hosp, Bedford, England.	volicer.ladislav@bedford.va.gov	Volicer, Ladislav/K-7576-2019	Volicer, Ladislav/0000-0002-6939-7531				BODNAR JC, 1994, PSYCHOL AGING, V9, P372; Grant I, 2002, PSYCHOSOM MED, V64, P477, DOI 10.1097/00006842-200205000-00012; Schulz R, 2003, NEW ENGL J MED, V349, P1936, DOI 10.1056/NEJMsa035373; Volicer L, 2001, ALZ DIS ASSOC DIS, V15, P194, DOI 10.1097/00002093-200110000-00005; Volicer Ladislav, 2003, Am J Hosp Palliat Care, V20, P191; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1097/00130535-200301000-00002	6	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2004	3	3					144	144		10.1016/S1474-4422(04)00677-5	http://dx.doi.org/10.1016/S1474-4422(04)00677-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	802MK	14980528				2022-12-18	WOS:000220167400015
J	Wenning, GK; Colosimo, C; Geser, F; Poewe, W				Wenning, GK; Colosimo, C; Geser, F; Poewe, W			For postprandial hypotension (vol 3, pg 93, 2004)	LANCET NEUROLOGY			English	Correction													Colosimo, Carlo/AAY-8552-2020	Colosimo, Carlo/0000-0002-2216-3973				Wenning GK, 2004, LANCET NEUROL, V3, P93, DOI 10.1016/S1474-4422(03)00662-8	1	3	3	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2004	3	3					137	137		10.1016/S1474-4422(04)00695-7	http://dx.doi.org/10.1016/S1474-4422(04)00695-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	802MK					2022-12-18	WOS:000220167400006
J	Oransky, I				Oransky, I			Gates Foundation gives $27 million to fight Japanese encephalitis	LANCET NEUROLOGY			English	News Item																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2004	3	2					74	74		10.1016/S1474-4422(03)00645-8	http://dx.doi.org/10.1016/S1474-4422(03)00645-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	772AQ	14969239				2022-12-18	WOS:000188818500002
J	van Doorn, PA; van Koningswald, R				van Doorn, PA; van Koningswald, R			Immunotherapy for Guillain-Barre syndrome	LANCET NEUROLOGY			English	Editorial Material									Erasmus MC, Dept Neurol, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	van Doorn, PA (corresponding author), Erasmus MC, Dept Neurol, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.	p.a.vandoorn@erasmusmc.nl						Hahn AF, 1998, LANCET, V352, P635, DOI 10.1016/S0140-6736(97)12308-X; Hughes RAC, 2003, NEUROLOGY, V61, P736, DOI 10.1212/WNL.61.6.736; HUGHES RAC, 2002, COCHRANE LIB; HUGHES RAC, COCHRANE LIB; RAPHAEL JC, 2002, COCHRANE LIB; van Koningsveld R, 2004, LANCET, V363, P192, DOI 10.1016/S0140-6736(03)15324-X	6	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2004	3	2					84	84		10.1016/S1474-4422(03)00660-4	http://dx.doi.org/10.1016/S1474-4422(03)00660-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	772AQ	14746999				2022-12-18	WOS:000188818500017
J	Kennedy, PGE				Kennedy, PGE			Neurological infection	LANCET NEUROLOGY			English	Editorial Material									Univ Glasgow, Dept Neurol, Inst Neurol Sci, So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow	Kennedy, PGE (corresponding author), Univ Glasgow, Dept Neurol, Inst Neurol Sci, So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland.	P.G.Kennedy@clinmed.gla.ac.uk						Anthony IC, 2003, BRAIN, V126, P1058, DOI 10.1093/brain/awg118; Davis LE, 2003, BRAIN, V126, P1013, DOI 10.1093/brain/awg141; Hevner R, 2003, LANCET NEUROL, V2, P567, DOI 10.1016/S1474-4422(03)00506-4; Kastenbauer S, 2003, BRAIN, V126, P1015, DOI 10.1093/brain/awg113; SEJVAR IJ, 2003, JAMA-J AM MED ASSOC, V290, P511; Solomon T, 2003, LANCET, V361, P821, DOI 10.1016/S0140-6736(03)12709-2	6	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					13	13		10.1016/S1474-4422(03)00613-6	http://dx.doi.org/10.1016/S1474-4422(03)00613-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14693102				2022-12-18	WOS:000187447100016
J	Love, R				Love, R			First disease model created by RNA interference	LANCET NEUROLOGY			English	News Item																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					7	7		10.1016/S1474-4422(03)00639-2	http://dx.doi.org/10.1016/S1474-4422(03)00639-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14700057				2022-12-18	WOS:000187447100009
J	Senior, K				Senior, K			Copper may have a positive effect on Alzheimer's disease	LANCET NEUROLOGY			English	News Item																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					8	8		10.1016/S1474-4422(03)00640-9	http://dx.doi.org/10.1016/S1474-4422(03)00640-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14700058				2022-12-18	WOS:000187447100010
J	Oransky, I				Oransky, I			Neurologists say Florida woman is very unlikely to recover	LANCET NEUROLOGY			English	News Item																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2003	2	12					715	715		10.1016/S1474-4422(03)00600-8	http://dx.doi.org/10.1016/S1474-4422(03)00600-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745AV	14649237				2022-12-18	WOS:000186665800003
J	Larkin, M				Larkin, M			Individual differences in pain perception confirmed	LANCET NEUROLOGY			English	News Item																		Coghill RC, 2003, ANESTHESIOLOGY, V98, P1312, DOI 10.1097/00000542-200306000-00003	1	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2003	2	8					454	454		10.1016/S1474-4422(03)00469-1	http://dx.doi.org/10.1016/S1474-4422(03)00469-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	704AC	15320345				2022-12-18	WOS:000184314700002
J	McCrone, J				McCrone, J			Quantum mind	LANCET NEUROLOGY			English	Editorial Material																			0	3	4	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2003	2	7					450	450		10.1016/S1474-4422(03)00466-6	http://dx.doi.org/10.1016/S1474-4422(03)00466-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	694GF	12849132				2022-12-18	WOS:000183765300022
J	Keswani, SC; Wityk, R				Keswani, SC; Wityk, R			A case of splanchnic steal syndrome?	LANCET NEUROLOGY			English	Editorial Material							POSTPRANDIAL HYPOTENSION; SYNCOPE; OLDER		Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Keswani, SC (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, 600 N Wolfe St, Baltimore, MD 21287 USA.							ARONOW WS, 1994, J AM GERIATR SOC, V42, P930, DOI 10.1111/j.1532-5415.1994.tb06582.x; Aronow WS, 1997, J AM GERIATR SOC, V45, P1051, DOI 10.1111/j.1532-5415.1997.tb05965.x; JANSEN RWMM, 1995, ANN INTERN MED, V122, P286, DOI 10.7326/0003-4819-122-4-199502150-00009; LIPSITZ LA, 1986, AM J CARDIOL, V58, P810, DOI 10.1016/0002-9149(86)90359-0	4	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2003	2	6					379	379		10.1016/S1474-4422(03)00413-7	http://dx.doi.org/10.1016/S1474-4422(03)00413-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	682WH	12849155				2022-12-18	WOS:000183115000021
J	Burton, A				Burton, A			Take your pyridostigmine: that's an (ethical?) order!	LANCET NEUROLOGY			English	News Item																			0	3	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2003	2	5					268	268		10.1016/S1474-4422(03)00399-5	http://dx.doi.org/10.1016/S1474-4422(03)00399-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	669RC	12849173				2022-12-18	WOS:000182363400010
J	Taal, W; van der Dussen, DH; van Erven, L; van Dijk, JG				Taal, W; van der Dussen, DH; van Erven, L; van Dijk, JG			Neurally-mediated complete heart block	LANCET NEUROLOGY			English	Editorial Material							SYNCOPE		Leiden Univ, Med Ctr, Dept Neurol & Clin Neurophysiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Dijk, JG (corresponding author), Leiden Univ, Med Ctr, Dept Neurol & Clin Neurophysiol, POB 9600, NL-2300 RC Leiden, Netherlands.	j.g.van_dijk.neur@lumc.nl		Taal, Walter/0000-0002-5530-7259				HART G, 1982, PACE, V5, P564, DOI 10.1111/j.1540-8159.1982.tb02279.x; JAMES TN, 1980, AM J CARDIOL, V45, P1182, DOI 10.1016/0002-9149(80)90476-2; JAMES TN, 1970, J LAB CLIN MED, V76, P240; LEVIN B, 1972, NEUROLOGY, V22, P1086, DOI 10.1212/WNL.22.10.1086; SEDA PE, 1980, BRIT HEART J, V44, P221	5	3	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2003	2	4					255	256		10.1016/S1474-4422(03)00355-7	http://dx.doi.org/10.1016/S1474-4422(03)00355-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	658NH	12849215				2022-12-18	WOS:000181726700022
J	Bradbury, J				Bradbury, J			Second gene identified for familial hemiplegic migraine	LANCET NEUROLOGY			English	News Item																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2003	2	3					137	137		10.1016/S1474-4422(03)00336-3	http://dx.doi.org/10.1016/S1474-4422(03)00336-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	648NV	12849225				2022-12-18	WOS:000181158200003
J	Heckmann, JG; Lang, CJG; Stefan, H; Neundorfer, B				Heckmann, JG; Lang, CJG; Stefan, H; Neundorfer, B			The vegetarian who ate a sausage with curry sauce	LANCET NEUROLOGY			English	Editorial Material							NONCONVULSIVE STATUS EPILEPTICUS		Univ Erlangen Nurnberg, Dept Neurol, D-91052 Erlangen, Germany	University of Erlangen Nuremberg	Heckmann, JG (corresponding author), Univ Erlangen Nurnberg, Dept Neurol, D-91052 Erlangen, Germany.							Kaplan PW, 2000, EPILEPTIC DISORD, V2, P185; McCarron MO, 2002, EUR J NEUROL, V9, P178, DOI 10.1046/j.1468-1331.2002.0354b.x; NIEDERMEYER E, 1979, ARCH NEUROL-CHICAGO, V36, P417, DOI 10.1001/archneur.1979.00500430047006; Scholtes FB, 1996, J NEUROL NEUROSUR PS, V61, P93, DOI 10.1136/jnnp.61.1.93; WATEMBERG N, 1996, NEW ENGL J MED, V335, P209	5	3	3	1	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2003	2	1					62	62		10.1016/S1474-4422(03)00268-0	http://dx.doi.org/10.1016/S1474-4422(03)00268-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	629DU	12849302				2022-12-18	WOS:000180035800024
J	Rinkel, GJE				Rinkel, GJE			Treatment of patients with aneurysmal subarachnoid haemorrhage	LANCET NEUROLOGY			English	Editorial Material									Univ Utrecht, Med Ctr, Dept Neurol, Rudolf Magnus Inst Neurosci, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Rinkel, GJE (corresponding author), Univ Utrecht, Med Ctr, Dept Neurol, Rudolf Magnus Inst Neurosci, POB 85500, NL-3508 GA Utrecht, Netherlands.							Cloft HJ, 2002, AM J NEURORADIOL, V23, P1706; Derdeyn CP, 2002, J NEUROSURG, V96, P837, DOI 10.3171/jns.2002.96.5.0837; Lusseveld E, 2002, J NEUROL NEUROSUR PS, V73, P591, DOI 10.1136/jnnp.73.5.591; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6	4	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2003	2	1					12	12		10.1016/S1474-4422(03)00259-X	http://dx.doi.org/10.1016/S1474-4422(03)00259-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	629DU	12849293				2022-12-18	WOS:000180035800016
J	McKeith, I				McKeith, I			Galantamine for vascular dementia	LANCET NEUROLOGY			English	Editorial Material									Newcastle Gen Hosp, Wolfson Res Ctr, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital; Newcastle University - UK	McKeith, I (corresponding author), Newcastle Gen Hosp, Wolfson Res Ctr, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.		McKeith, Ian/AAH-3382-2021	McKeith, Ian/0000-0002-9250-0568				Erkinjuntti T, 2002, LANCET, V359, P1283, DOI 10.1016/S0140-6736(02)08267-3; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; Schneider LS, 2002, LANCET, V359, P1265, DOI 10.1016/S0140-6736(02)08283-1	3	3	4	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2002	1	4					210	210		10.1016/S1474-4422(02)00096-0	http://dx.doi.org/10.1016/S1474-4422(02)00096-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588KZ	12849450				2022-12-18	WOS:000177701800014
J	Bradbury, J				Bradbury, J			Gene found for another idiopathic epilepsy	LANCET NEUROLOGY			English	News Item																			0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2002	1	1					7	7		10.1016/S1474-4422(02)00032-7	http://dx.doi.org/10.1016/S1474-4422(02)00032-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588GQ					2022-12-18	WOS:000177694100011
J	Coutts, SB; Yu, AYX				Coutts, Shelagh B.; Yu, Amy Y. X.			Tenecteplase for acute stroke: the thrombolysis puzzle	LANCET NEUROLOGY			English	Editorial Material							ALTEPLASE		[Coutts, Shelagh B.] Univ Calgary, Cumming Sch Med, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB T2N 2T9, Canada; [Coutts, Shelagh B.] Univ Calgary, Cumming Sch Med, Hotchkiss Brain Inst, Dept Radiol, Calgary, AB T2N 2T9, Canada; [Coutts, Shelagh B.] Univ Calgary, Cumming Sch Med, Hotchkiss Brain Inst, Dept Community Hlth Sci, Calgary, AB T2N 2T9, Canada; [Yu, Amy Y. X.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada	University of Calgary; University of Calgary; University of Calgary; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Coutts, SB (corresponding author), Univ Calgary, Cumming Sch Med, Hotchkiss Brain Inst, Dept Clin Neurosci, Calgary, AB T2N 2T9, Canada.; Coutts, SB (corresponding author), Univ Calgary, Cumming Sch Med, Hotchkiss Brain Inst, Dept Radiol, Calgary, AB T2N 2T9, Canada.; Coutts, SB (corresponding author), Univ Calgary, Cumming Sch Med, Hotchkiss Brain Inst, Dept Community Hlth Sci, Calgary, AB T2N 2T9, Canada.	scoutts@ucalgary.ca			Heart & Stroke Foundation of Canada; Canadian Institutes of Health Research	Heart & Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	SBC is the Principal investigator of the TEMPO-2 trial, for which Boehringer Ingelheim provides study drug (tenecteplase). AYXY declares funding support from the Heart & Stroke Foundation of Canada and the Canadian Institutes of Health Research.	Bivard A, 2022, LANCET NEUROL, V21, P520, DOI 10.1016/S1474-4422(22)00171-5; Campbell BCV, 2018, NEW ENGL J MED, V378, P1573, DOI 10.1056/NEJMoa1716405; Campbell BCV, 2020, JAMA-J AM MED ASSOC, V323, P1257, DOI 10.1001/jama.2020.1511; Haley EC, 2005, STROKE, V36, P607, DOI 10.1161/01.STR.0000154872.73240.e9; Kvistad CE, 2022, LANCET NEUROL, V21, P511, DOI 10.1016/S1474-4422(22)00124-7; Law ZK, 2022, STROKE, V53, P1141, DOI 10.1161/STROKEAHA.121.035191; Logallo N, 2017, LANCET NEUROL, V16, P781, DOI 10.1016/S1474-4422(17)30253-3	7	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2022	21	6					496	+		10.1016/S1474-4422(22)00172-7	http://dx.doi.org/10.1016/S1474-4422(22)00172-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3Z0EK	35525249				2022-12-18	WOS:000844093900016
J	Hentzen, C; Musco, S; Amarenco, G; Del Popolo, G; Panicker, JN				Hentzen, Claire; Musco, Stefania; Amarenco, Gerard; Del Popolo, Giulio; Panicker, Jalesh N.			Approach and management to patients with neurological disorders reporting sexual dysfunction	LANCET NEUROLOGY			English	Review							SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; ERECTILE DYSFUNCTION; MULTIPLE-SCLEROSIS; DIABETES-MELLITUS; YOUNG MEN; WOMEN; EJACULATION; NERVE	Sexual difficulties are common in patients with neurological disorders, and different domains of sexual function-desire, arousal, orgasm, and ejaculation-can be affected. Advances in the past 7 years in structural and functional neuroimaging have contributed to a greater understanding of the neural pathways involved in the regulation of sexual functions in health and disease, and this increased knowledge might help with development of future therapeutic strategies. A comprehensive assessment of patients includes history taking-covering the different domains of dysfunction, and primary, secondary, and tertiary contributory factors-as well as clinical examination in select patients (ie, patients for whom an associated non-neurological cause for sexual dysfunction is suspected). Investigations, such as assessment of associated cardiovascular risk factors, might also be indicated in specific situations. PDE5A inhibitors and intracavernosal injections of the prostaglandin alprostadil are effective for treating erectile dysfunction; however, options for managing other domains of sexual dysfunction in men and women remain poor. Research into different domains of sexual dysfunction is likely to lead to additional therapeutic strategies in the future.	[Hentzen, Claire; Amarenco, Gerard] Sorbonne Univ, Hop Tenon, AP HP, Grp Rech Clin Neurourol GREEN, Paris, France; [Hentzen, Claire; Panicker, Jalesh N.] Natl Hosp Neurol & Neurosurg, Dept Uroneurol, London, England; [Hentzen, Claire; Panicker, Jalesh N.] UCL, Fac Brain Sci, UCL Queen Sq Inst Neurol, London, England; [Musco, Stefania; Del Popolo, Giulio] Azienda Osped Univ Careggi, Neurourol Dept, Florence, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of Florence; Azienda Ospedaliero Universitaria Careggi	Hentzen, C (corresponding author), Hop Tenon, AP HP, Serv Neurourol, F-75020 Paris, France.	claire.hentzen.mpr@gmail.com	Hentzen, Claire/ABF-9564-2021	Hentzen, Claire/0000-0002-9223-4925				Abdel-Meguid T. A., 2017, Journal of King Abdulaziz University - Medical Sciences, V24, P1; Afferi L, 2020, ANDROLOGY-US, V8, P1660, DOI 10.1111/andr.12878; Ahmed RM, 2015, J ALZHEIMERS DIS, V46, P677, DOI 10.3233/JAD-150034; Akre C, 2015, CHILD CARE HLTH DEV, V41, P963, DOI 10.1111/cch.12282; Alexander M, 2018, ARCH PHYS MED REHAB, V99, P299, DOI 10.1016/j.apmr.2017.09.001; Alexander MS, 2016, J SEX MARITAL THER, V42, P36, DOI 10.1080/0092623X.2015.1010674; Allen K, 2020, J SEX MED, V17, P603, DOI 10.1016/j.jsxm.2019.12.007; Bala A, 2018, SEX MED REV, V6, P29, DOI 10.1016/j.sxmr.2017.07.002; Birke H, 2019, PAIN MED, V20, P1132, DOI 10.1093/pm/pny122; Boller Francois, 2015, Handb Clin Neurol, V130, P289, DOI 10.1016/B978-0-444-63247-0.00016-X; Bove R, 2016, NEUROLOGY, V87, P1457; Bozkurt M, 2014, J SEX MED, V11, P1816, DOI 10.1111/jsm.12458; Bronner Gila, 2015, Handb Clin Neurol, V130, P297, DOI 10.1016/B978-0-444-63247-0.00017-1; Cacioppo S, 2017, SEX MED REV, V5, P434, DOI 10.1016/j.sxmr.2017.07.006; Calabro RS, 2014, J SEX MED, V11, P1807, DOI 10.1111/jsm.12569; Calisir A, 2021, ANDROLOGIA, V53, DOI 10.1111/and.13947; Chehensse C, 2017, ANN NEUROL, V81, P35, DOI 10.1002/ana.24819; Chehensse C, 2013, HUM REPROD UPDATE, V19, P507, DOI 10.1093/humupd/dmt029; Chochina Lucie, 2016, Sex Med Rev, V4, P257, DOI 10.1016/j.sxmr.2016.02.005; Choi EK, 2018, NEUROUROL URODYNAM, V37, P1785, DOI 10.1002/nau.23525; Choi EK, 2017, UROLOGY, V108, P225, DOI 10.1016/j.urology.2016.11.052; Chung E, 2020, ASIAN J ANDROL, V22, P39, DOI 10.4103/aja.aja_127_19; Courtois Frederique, 2015, Handb Clin Neurol, V130, P225, DOI 10.1016/B978-0-444-63247-0.00013-4; Dafsari HS, 2020, BRAIN STIMUL, V13, P1697, DOI 10.1016/j.brs.2020.09.019; Dai HH, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018583; Dehghan-Nayeri N, 2017, MULT SCLER RELAT DIS, V12, P49, DOI 10.1016/j.msard.2017.01.005; Del Popolo G, 2020, EUR UROL FOCUS, V6, P868, DOI 10.1016/j.euf.2019.12.002; Dulski J, 2019, PARKINSONISM RELAT D, V64, P138, DOI 10.1016/j.parkreldis.2019.04.001; Dunya CP, 2021, NEUROUROL URODYNAM, V40, P1661, DOI 10.1002/nau.24733; Dunya CP, 2020, NEUROUROL URODYNAM, V39, P83, DOI 10.1002/nau.24232; Durcan R, 2019, EUR J NEUROL, V26, P979, DOI 10.1111/ene.13919; El-Shaer W, 2021, ANDROLOGY-US, V9, P1166, DOI 10.1111/andr.13010; European Association of Urology, NEUR; Facchinetti P, 2014, NEUROSCIENCE, V272, P207, DOI 10.1016/j.neuroscience.2014.04.064; Ferrucci R, 2016, J NEUROL SCI, V369, P5, DOI 10.1016/j.jns.2016.07.058; Francomano D, 2017, J ENDOCRINOL INVEST, V40, P275, DOI 10.1007/s40618-016-0557-y; Fraser EE, 2020, ARCH PHYS MED REHAB, V101, P2080, DOI 10.1016/j.apmr.2020.06.028; Furukawa S, 2017, INT J IMPOT RES, V29, P30, DOI 10.1038/ijir.2016.40; Gainotti G, 2017, CORTEX, V96, P134, DOI 10.1016/j.cortex.2017.06.025; Giannantoni A, 2015, WORLD J UROL, V33, P2095, DOI 10.1007/s00345-015-1578-4; Giuliano F, 2019, TOXINS, V11, DOI 10.3390/toxins11050283; Gruenwald I, 2007, MULT SCLER J, V13, P95, DOI 10.1177/1352458506071134; Hadiji N, 2017, SPINAL CORD, V55, P612, DOI 10.1038/sc.2017.5; Henning O, 2019, EPILEPSIA, V60, P1984, DOI 10.1111/epi.16311; Jacobsen P, 2019, J SEX MED, V16, P1638, DOI 10.1016/j.jsxm.2019.06.018; Jeon N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227128; Jia DD, 2016, SPINAL CORD, V54, P494, DOI 10.1038/sc.2016.3; Kazemi Z, 2021, ARCH WOMEN MENT HLTH, V24, P437, DOI 10.1007/s00737-020-01080-6; Kell CA, 2005, J NEUROSCI, V25, P5984, DOI 10.1523/JNEUROSCI.0712-05.2005; Kitzmuller G, 2015, SEX DISABIL, V33, P499, DOI 10.1007/s11195-015-9404-x; Komisaruk BR, 2011, J SEX MED, V8, P2822, DOI 10.1111/j.1743-6109.2011.02388.x; Komisaruk BR, 2004, BRAIN RES, V1024, P77, DOI 10.1016/j.brainres.2004.07.029; Kozyrev N, 2012, J SEX MARITAL THER, V38, P418, DOI 10.1080/0092623X.2011.606887; Krychman M, 2020, J COSMET DERMATOL-US, V19, P404, DOI 10.1111/jocd.13262; Labat JJ, 2010, PROG UROL, V20, P973, DOI 10.1016/j.purol.2010.08.062; Labat JJ, 2008, NEUROUROL URODYNAM, V27, P306, DOI 10.1002/nau.20505; Ladegaard PBJ, 2021, SEX MED-UK, V9, DOI 10.1016/j.esxm.2021.100338; Latella D, 2021, J INTEGR NEUROSCI, V20, P477, DOI 10.31083/j.jin2002051; Leduc BE, 2015, J SPINAL CORD MED, V38, P57, DOI 10.1179/2045772314Y.0000000225; Li V, 2020, NEUROLOGY, V95, pE2924, DOI 10.1212/WNL.0000000000011030; Li Zhong-Tai, 2018, Zhonghua Nan Ke Xue, V24, P713; Lombardi G, 2015, BJU INT, V115, P47, DOI 10.1111/bju.13055; Lombardi G, 2009, J SEX MED, V6, P535, DOI 10.1111/j.1743-6109.2008.01106.x; Lucio AC, 2014, MULT SCLER J, V20, P1761, DOI 10.1177/1352458514531520; Luijten SPR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58966-9; Majzoub A, 2016, TRANSL ANDROL UROL, V5, P248, DOI 10.21037/tau.2016.03.11; Marck CH, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0735-8; Maseroli E, 2018, SEX MED REV, V6, P508, DOI 10.1016/j.sxmr.2018.02.009; Mata-Marin D, 2021, BRAIN CONNECT, V11, P639, DOI 10.1089/brain.2020.0868; Monti M, 2020, SPINAL CORD, V58, P1128, DOI 10.1038/s41393-020-0469-8; Overgoor MLE, 2013, J UROLOGY, V189, P626, DOI 10.1016/j.juro.2012.10.020; Overgoor MLE, 2015, NEUROUROL URODYNAM, V34, P343, DOI 10.1002/nau.22566; Panicker JN, 2015, LANCET NEUROL, V14, P720, DOI 10.1016/S1474-4422(15)00070-8; Parada M, 2018, J SEX MED, V15, P217, DOI 10.1016/j.jsxm.2017.12.006; Park HJ, 2019, INT J STEM CELLS, V12, P206, DOI 10.15283/ijsc18122; Pavone C, 2020, UROLOGY, V139, P129, DOI 10.1016/j.urology.2020.01.027; Ploteau S, 2018, NEUROUROL URODYNAM, V37, P971, DOI 10.1002/nau.23435; Pratt-Chapman ML, 2021, SYST REV-LONDON, V10, DOI 10.1186/s13643-021-01707-4; Previnaire J G, 2017, Spinal Cord Ser Cases, V3, P17096, DOI 10.1038/s41394-017-0023-x; Raciti L, 2020, J SEX MED, V17, P1914, DOI 10.1016/j.jsxm.2020.06.010; Rathore C, 2019, EPILEPSY BEHAV, V100, DOI 10.1016/j.yebeh.2019.106495; Rees PM, 2007, LANCET, V369, P512, DOI 10.1016/S0140-6736(07)60238-4; Robert H, 2019, PROG UROL, V29, P529, DOI 10.1016/j.purol.2019.08.002; Salonia A, EAU GUIDELINES SEXUA; Shechter A, 2020, INT J IMPOT RES, V32, P440, DOI 10.1038/s41443-019-0207-y; Simpson GK, 2013, J HEAD TRAUMA REHAB, V28, P202, DOI 10.1097/HTR.0b013e31828dc5ae; Skoufias S, 2018, J SEX MED, V15, P1558, DOI 10.1016/j.jsxm.2018.09.003; Sramkova T, 2017, SEX MED-UK, V5, pE255, DOI 10.1016/j.esxm.2017.07.003; Streur CS, 2020, J SEX MED, V17, P1694, DOI 10.1016/j.jsxm.2020.05.026; Tao LH, 2018, EPILEPSY BEHAV, V85, P150, DOI 10.1016/j.yebeh.2018.06.003; Taylor Bridget, 2006, Nurs Stand, V21, P35; Tudor KI, 2018, J NEUROL, V265, P2789, DOI 10.1007/s00415-018-9064-8; Uribe OL, 2020, INT J IMPOT RES, V32, P434, DOI 10.1038/s41443-019-0196-x; Veening JG, 2015, EUR J PHARMACOL, V753, P209, DOI 10.1016/j.ejphar.2014.07.045; Winder K, 2018, J NEUROL, V265, P783, DOI 10.1007/s00415-018-8763-5; Winder K, 2017, BRAIN, V140, P1706, DOI 10.1093/brain/awx080; Winder K, 2016, ANN NEUROL, V80, P490, DOI 10.1002/ana.24746; Winder K, 2015, J NEUROL, V262, P2731, DOI 10.1007/s00415-015-7907-0; Wise NJ, 2017, J SEX MED, V14, P1380, DOI 10.1016/j.jsxm.2017.08.014; Wise NJ, 2016, SOIOAFFECTIVE NEUROS, V6, DOI 10.3402/snp.v6.31481; Xardel V, 2021, PROG UROL, V31, P223, DOI 10.1016/j.purol.2021.01.001; Zermann DH, 2006, J UROLOGY, V175, P1041, DOI 10.1016/S0022-5347(05)00344-7; Zhang D, 2019, BMC UROL, V19, DOI 10.1186/s12894-018-0431-7; Zhang Y, 2020, J NEUROIMMUNOL, V338, DOI 10.1016/j.jneuroim.2019.577093; Zhou XQ, 2021, J NEUROTRAUM, V38, P1225, DOI 10.1089/neu.2020.7454; Zimmerman LL, 2018, NEUROMODULATION, V21, P707, DOI 10.1111/ner.12846	106	2	2	5	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2022	21	6					551	562		10.1016/S1474-4422(22)00036-9	http://dx.doi.org/10.1016/S1474-4422(22)00036-9			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3Z0EK	35405093				2022-12-18	WOS:000844093900003
J	Clark, D; Joannides, A; Adeleye, AO; Bajamal, AH; Bashford, T; Biluts, H; Budohoski, K; Ercole, A; Fernandez-Mendez, R; Figaji, A; Gupta, DK; Hartl, R; Iaccarino, C; Khan, T; Laeke, T; Rubiano, A; Shabani, HK; Sichizya, K; Tewari, M; Tirsit, A; Thu, M; Tripathi, M; Trivedi, R; Devi, BI; Servadei, F; Menon, D; Kolias, A; Hutchinson, P				Clark, David; Joannides, Alexis; Adeleye, Amos Olufemi; Bajamal, Abdul Hafid; Bashford, Tom; Biluts, Hagos; Budohoski, Karol; Ercole, Ari; Fernandez-Mendez, Rocio; Figaji, Anthony; Gupta, Deepak Kumar; Hartl, Roger; Iaccarino, Corrado; Khan, Tariq; Laeke, Tsegazeab; Rubiano, Andres; Shabani, Hamisi K.; Sichizya, Kachinga; Tewari, Manoj; Tirsit, Abenezer; Thu, Myat; Tripathi, Manjul; Trivedi, Rikin; Devi, Bhagavatula Indira; Servadei, Franco; Menon, David; Kolias, Angelos; Hutchinson, Peter		Global Neurotrauma Outcomes Study	Casemix, management, and mortality of patients receiving emergency neurosurgery for traumatic brain injury in the Global Neurotrauma Outcomes Study: a prospective observational cohort study	LANCET NEUROLOGY			English	Article							INTENSIVE-CARE; CRITICAL ILLNESS; HEAD-INJURY; MULTICENTER; SURGERY; IMPACT; RECOMMENDATIONS; CLASSIFICATION; EPIDEMIOLOGY; HEMATOMA	Background Traumatic brain injury (TBI) is increasingly recognised as being responsible for a substantial proportion of the global burden of disease. Neurosurgical interventions are an important aspect of care for patients with TBI, but there is little epidemiological data available on this patient population. We aimed to characterise differences in casemix, management, and mortality of patients receiving emergency neurosurgery for TBI across different levels of human development. Methods We did a prospective observational cohort study of consecutive patients with TBI undergoing emergency neurosurgery, in a convenience sample of hospitals identified by open invitation, through international and regional scientific societies and meetings, individual contacts, and social media. Patients receiving emergency neurosurgery for TBI in each hospital's 30-day study period were all eligible for inclusion, with the exception of patients undergoing insertion of an intracranial pressure monitor only, ventriculostomy placement only, or a procedure for drainage of a chronic subdural haeinatoma. The primary outcome was mortality at 14 days postoperatively (or last point of observation if the patient was discharged before this time point). Countries were stratified according to their Human Development Index (HDI)-a composite of life expectancy, education, and income measures-into very high HDI, high HDI, medium HDI, and low HDI tiers. Mixed effects logistic regression was used to examine the effect of HDI on mortality while accounting for and quantifying between-hospital and between-country variation. Findings Our study included 1635 records from 159 hospitals in 57 countries, collected between Nov 1, 2018, and Jan 31, 2020. 328 (20%) records were from countries in the very high HDI tier, 539 (33%) from countries in the high HDI tier, 614 (38%) from countries in the medium HDI tier, and 154 (9%) from countries in the low HDI tier. The median age was 35 years (IQR 24-51), with the oldest patients in the very high HDI tier (median 54 years, IQR 34-69) and the youngest in the low HDI tier (median 28 years, IQR 20-38). The most common procedures were elevation of a depressed skull fracture in the low HDI tier (69 [45%]), evacuation of a supratentorial extradural haematoma in the medium HDI tier (189 [31%]) and high HDI tier (173 [32%]), and evacuation of a supratentorial acute subdural haematoma in the very high HDI tier (155 [47%]). Median time from injury to surgery was 13 h (IQR 6-32). Overall mortality was 18% (299 of 1635). After adjustment for casernix, the odds of mortality were greater in the medium HDI tier (odds ratio [OR] 2.84, 95% CI 1.55-5.2) and high HDI tier (2.26, 1.23-4.15), but not the low HDI tier (1.66, 0.61-4.46), relative to the very high HDI tier. There was significant between-hospital variation in mortality (median OR 2.04, 95% CI 1.17-2.49). Interpretation Patients receiving emergency neurosurgery for TBI differed considerably in their admission characteristics and management across human development settings. Level of human development was associated with mortality. Substantial opportunities to improve care globally were identified, including reducing delays to surgery. Between-hospital variation in mortality suggests changes at an institutional level could influence outcome and comparative effectiveness research could identify best practices. Copyright The Author(s). Published by Elsevier Ltd.	[Clark, David; Joannides, Alexis; Bashford, Tom; Budohoski, Karol; Ercole, Ari; Fernandez-Mendez, Rocio; Trivedi, Rikin; Menon, David; Kolias, Angelos; Hutchinson, Peter] Univ Cambridge, Natl Inst Hlth Res, Global Hlth Res Grp Neurotrauma, Cambridge, England; [Clark, David; Sichizya, Kachinga] Univ Teaching Hosp, Neurosurg Div, Lusaka, Zambia; [Adeleye, Amos Olufemi] Univ Ibadan, Coll Med, Dept Surg, Ibadan, Nigeria; [Bajamal, Abdul Hafid] Dr Soetoino Hosp, Dept Neurosurg, Surabaya, Jawa Timur, Indonesia; [Biluts, Hagos; Laeke, Tsegazeab; Tirsit, Abenezer] Addis Ababa Univ, Coll Hlth Sci, Dept Surg, Addis Ababa, Oromia, Ethiopia; [Figaji, Anthony] Univ Cape Town, Div Neurosurg, Rondebosch, Western Cape, South Africa; [Figaji, Anthony] Univ Cape Town, Neurosci Inst, Rondebosch, Western Cape, South Africa; [Gupta, Deepak Kumar] All India Inst Med Sci, Dept Neurosurg, Delhi, India; [Hartl, Roger] Weill Cornell Med, Dept Neurol Surg, New York, NY USA; [Iaccarino, Corrado] Univ Hosp Parma, Neurosurg Div, Parma, Emilia Romagna, Italy; [Khan, Tariq] North West Gen Hosp & Res Ctr, Dept Neurosurg, Peshawar, Khyber Pakhtunk, Pakistan; [Rubiano, Andres] Univ El Bosque, Dept Neurosurg, Bogota, Colombia; [Shabani, Hamisi K.] Muhimbili Orthopaed Inst, Dept Neurol Surg, Dar Es Salaam, Tanzania; [Shabani, Hamisi K.] Muhimbili Univ, Coll Allied Hlth Sci, Dar Es Salaam, Tanzania; [Tewari, Manoj; Tripathi, Manjul] Post Grad Inst Med Educ & Res Chandigarh, Dept Neurosurg, Chandigarh, India; [Thu, Myat] Yangon Gen Hosp, Dept Neurosurg, Yangon, Yangon Region, Myanmar; [Devi, Bhagavatula Indira] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India; [Servadei, Franco] Humanitas Univ, Humanitas Clin & Res Ctr IRCCS, Milan, Italy; [Servadei, Franco] Humanitas Univ, Dept Biomed Sci, Milan, Italy	University of Cambridge; University of Zambia; University of Ibadan; Addis Ababa University; University of Cape Town; University of Cape Town; All India Institute of Medical Sciences (AIIMS) New Delhi; Cornell University; University of Parma; University Hospital of Parma; Universidad El Bosque; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; National Institute of Mental Health & Neurosciences - India; Humanitas University; Humanitas University	Clark, D (corresponding author), Addenbrookes Hosp, Div Neurosurg, Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	djc83@cam.ac.uk	Ozair, Ahmad/B-9701-2018; Ghimire, Prajwal/AAL-7905-2020; Bauer, Marlies/ABC-2537-2021; Hamouda, Waeel Ossama/C-3936-2017; Emhamed, Marwa Saed/AAI-4521-2021; Bouhuwaish, Ahmad/AAX-8333-2020; Bruzzaniti, Placido/ABE-3207-2020; Dolachee, Ali Adnan/W-1488-2018; Lasica, Nebojsa/ABA-4157-2021; Amorim, Robson/AAK-1368-2021; Lapolla, Pierfrancesco/AAT-8407-2021; okere, oghenekevwe/ACR-9423-2022; Cherian, Iype/GYE-1120-2022; Hassani, Fahd Derkaoui/O-3469-2019; Fawaz, Charbel/GVU-2732-2022; Jabal, Mohamed Sobhi/ABA-6661-2021; Bashford, Tom/H-9586-2019; Javed, Saad/AAB-9239-2019; Posti, Jussi P./Y-2908-2019; Bavishi, Devi/AAQ-9718-2021; Hoz, Samer S./T-3160-2017; Bauer, Marlies/GQI-1439-2022; Elhadi, Muhammed/AAU-5641-2020; Ercole, Ari/B-6288-2009	Ozair, Ahmad/0000-0001-6570-4541; Ghimire, Prajwal/0000-0003-2884-956X; Hamouda, Waeel Ossama/0000-0002-4627-0992; Emhamed, Marwa Saed/0000-0003-2522-3254; Bouhuwaish, Ahmad/0000-0001-7182-1277; Bruzzaniti, Placido/0000-0003-1873-7687; Dolachee, Ali Adnan/0000-0001-9048-6099; Lasica, Nebojsa/0000-0002-4600-7756; Amorim, Robson/0000-0003-2391-7519; Lapolla, Pierfrancesco/0000-0002-3088-5263; okere, oghenekevwe/0000-0003-1325-5080; Hassani, Fahd Derkaoui/0000-0001-9996-0412; Jabal, Mohamed Sobhi/0000-0003-2891-8633; Bashford, Tom/0000-0003-0228-9779; Javed, Saad/0000-0003-0792-9130; Posti, Jussi P./0000-0002-5925-5193; Bavishi, Devi/0000-0003-1498-2458; Hoz, Samer S./0000-0003-4584-5931; Bauer, Marlies/0000-0002-2338-8349; Elhadi, Muhammed/0000-0001-6406-4212; Hanko, Martin/0000-0002-6524-6517; Sakar, Mustafa/0000-0002-8344-4074; Ercole, Ari/0000-0001-8350-8093; Hanalioglu, Sahin/0000-0003-4988-4938; Skola, Josef/0000-0002-6795-3020; Cossu, Giulia/0000-0003-0913-8965; Bandyopadhyay, Soham/0000-0001-6553-3842; Khizar, Ahtesham/0000-0003-2333-038X; Garcia-Martin, Andoni/0000-0001-5948-5370; Tropeano, Maria Pia/0000-0002-4653-1232; Rzeplinski, Radoslaw/0000-0002-1112-6261; GANDIA GONZALEZ, MARIA LUISA/0000-0002-5683-1300; Beane, Abigail/0000-0001-7046-1580; Fadalla, Tarig/0000-0002-6050-0475; Mediratta, Saniya/0000-0002-5187-140X; Alamri, Alexander/0000-0002-9345-9237; Golubovic, Jagos/0000-0001-5524-246X; Kuntawi Aji, Yunus/0000-0002-1877-6312; Figaji, Anthony A./0000-0002-3357-6490; Osei-Poku, Dorcas/0000-0001-8707-582X; Hernandez-Hernandez, Miguel Angel/0000-0002-7907-0639; Moustakis, Nikolaos/0000-0002-9604-3210; Marhold, Franz/0000-0001-8338-8060; Balogun, James A./0000-0002-0737-5265; Barthelemy, Ernest/0000-0002-4001-9342; Berra, Luigi Valentino/0000-0003-2605-9089; venturini, sara/0000-0002-9541-0090	National Institute for Health Research Global Health Research Group on Neurotrauma [16/137/105]	National Institute for Health Research Global Health Research Group on Neurotrauma	This research was commissioned by the National Institute for Health Research Global Health Research Group on Neurotrauma (16/137/105) using UK aid from the UK Government. The funder has not been involved in the drafting of this protocol or review of this manuscript. We are grateful to Stuart Fergusson for his invaluable advice on designing and running a study of this nature. Finally, we are grateful to our patients with traumatic brain injury for their assistance in our endeavour to improve care for patients with this injury.	Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; AMACHER AL, 1987, NEUROSURGERY, V20, P954; Ameratunga S, 2006, LANCET, V367, P1533, DOI 10.1016/S0140-6736(06)68654-6; [Anonymous], 2016, BRIT J SURG, DOI DOI 10.1002/BJS.10151; Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Bashford T, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000768; Biccard BM, 2018, LANCET, V391, P1589, DOI [10.1016/S0140-6736(18)30001-1, 10.1016/s0140-6736(18)30001-1]; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Buang S S, 2012, Med J Malaysia, V67, P393; Clark D, 2020, INT J SURG PROTOC, V20, P1, DOI 10.1016/j.isjp.2020.02.001; Corley J, 2019, WORLD NEUROSURG, V132, P434, DOI 10.1016/j.wneu.2019.08.240; Corley J, 2019, WORLD NEUROSURG, V123, P295, DOI 10.1016/j.wneu.2018.12.042; Dagenais GR, 2020, LANCET, V395, P785, DOI 10.1016/S0140-6736(19)32007-0; Dunser MW, 2006, CRIT CARE MED, V34, P1234, DOI 10.1097/01.CCM.0000208360.70835.87; Eaton J, 2017, WORLD NEUROSURG, V105, P257, DOI 10.1016/j.wneu.2017.05.153; Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI [10.1016/S1474-4422(18)30499-X, 10.1136/bmj.l94, 10.1016/S1474-4422(19)30034-1]; Gao GY, 2020, LANCET NEUROL, V19, P670, DOI 10.1016/S1474-4422(20)30182-4; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Husum H, 2003, J TRAUMA, V54, P1188, DOI 10.1097/01.TA.0000073609.12530.19; Kehoe A, 2015, EMERG MED J, V32, P911, DOI 10.1136/emermed-2015-205265; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Luck T, 2015, ANZ J SURG, V85, P610, DOI 10.1111/ans.13138; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; MENDELOW AD, 1979, BRIT MED J, V2, P134, DOI 10.1136/bmj.2.6182.134-a; Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Mock CN, 2015, LANCET, V385, P2209, DOI 10.1016/S0140-6736(15)60091-5; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Nielsen K, 2012, PREHOSP EMERG CARE, V16, P381, DOI 10.3109/10903127.2012.664245; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Robba C, 2021, LANCET NEUROL, V20, P548, DOI 10.1016/S1474-4422(21)00138-1; Robertson Faith C, 2020, World Neurosurg X, V6, P100058, DOI 10.1016/j.wnsx.2019.100058; Rubiano AM, 2020, J NEUROSCI RURAL PRA, V11, P7, DOI 10.1055/s-0040-1701370; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; UNDP, HUMAN DEV REPORT 201; Vincent JL, 2014, LANCET RESP MED, V2, P380, DOI 10.1016/S2213-2600(14)70061-X; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; World Health Organization, 2018, GLOBAL STATUS REPORT, DOI DOI 10.3109/08830185.2014.902452	47	2	2	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2022	21	5					438	449		10.1016/S1474-4422(22)00037-0	http://dx.doi.org/10.1016/S1474-4422(22)00037-0			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	2R9KM	35305318	Green Published, Bronze			2022-12-18	WOS:000821423000017
J	De Cock, VC; Dodet, P; Leu-Semenescu, S; Aerts, C; Castelnovo, G; Abril, B; Drapier, S; Olivet, H; Corbille, AG; Leclair-Visonneau, L; Sallansonnet-Froment, M; Lebouteux, M; Anheim, M; Ruppert, E; Vitello, N; Eusebio, A; Lambert, I; Marques, A; Fantini, ML; Devos, D; Monaca, C; Benard-Serre, N; Lacombe, S; Vidailhet, M; Arnulf, I; Doulazmi, M; Roze, E				De Cock, Valerie Cochen; Dodet, Pauline; Leu-Semenescu, Smaranda; Aerts, Cecile; Castelnovo, Giovanni; Abril, Beatriz; Drapier, Sophie; Olivet, Helene; Corbille, Anne-Gaelle; Leclair-Visonneau, Laurene; Sallansonnet-Froment, Magali; Lebouteux, Marie; Anheim, Mathieu; Ruppert, Elisabeth; Vitello, Nicolas; Eusebio, Alexandre; Lambert, Isabelle; Marques, Ana; Fantini, Maria Livia; Devos, David; Monaca, Christelle; Benard-Serre, Nicolas; Lacombe, Sandy; Vidailhet, Marie; Arnulf, Isabelle; Doulazmi, Mohamed; Roze, Emmanuel			Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study	LANCET NEUROLOGY			English	Article							PROLONGED RELEASE; INTESTINAL GEL; SLEEP; THERAPY; VALIDATION; SCALE	Background Insomnia is a frequent complaint of patients with Parkinson's disease, and it negatively affects quality of life. Drugs that improve both sleep and parkinsonism would be of major benefit to patients with Parkinson's disease-related insomnia. We aimed to test the safety and efficacy of subcutaneous night-time only apomorphine infusion in patients with Parkinson's disease and insomnia. Methods We did a randomised, multicentre, double-blind, placebo-controlled, crossover trial in 11 expert centres in Parkinson's disease and sleep centres in France. Participants aged 35-90 years with fluctuating Parkinson's disease and moderate to severe insomnia (Insomnia Severity Index score 15) were randomly assigned to either first receive night-time subcutaneous apomorphine (up to 5 mg/h) or matching placebo. Randomisation was done using a computer-generated plan in blocks of four, stratified by centre. This first intervention was followed by a 14-night washout period, then crossover to the other intervention. The treatment periods consisted of a 10-night titration phase followed by a 7-night fixed-dose phase. The dose was adjusted during the titration phase on the basis of a daily telephone call assessing sleep quality and treatment tolerability. The primary efficacy endpoint was the difference in Parkinson's disease sleep scale (PDSS) scores from the beginning to the end of each treatment period. Analysis was done on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT02940912. Findings Between Jan 31, 2017, and Jan 29, 2021, 46 participants were enrolled. 25 (54%) patients were randomly assigned to receive apomorphine first and 21 (46%) patients to receive placebo first. Mean change in PDSS score was significantly greater with night-time apomorphine infusion (15.18 [SD 24.34]) compared with placebo (5.23 [21.52]; treatment effect 9.95 [95% CI 0.88-19.03]; p=0.041). Adverse events were reported in 25 (54%) participants during the apomorphine period and in 17 (37%) participants during the placebo period (p=0.16). Apomorphine was associated with more frequent dizziness than was placebo (seven [15%] vs 0; p=0.041). Interpretation Subcutaneous night-time only apomorphine infusion improved sleep disturbances according to difference on PDSS score, with an overall safety profile consistent with previous studies in Parkinson's disease. This treatment might be useful to manage sleep disturbances in patients with advanced Parkinson's disease and moderate to severe insomnia. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[De Cock, Valerie Cochen; Aerts, Cecile] Univ Montpellier, Sleep & Neurol Dept, Beau Soleil Clin, Montpellier, France; [De Cock, Valerie Cochen; Aerts, Cecile] Univ Montpellier, EuroMov, Digital Hlth Mot, Montpellier, France; [Dodet, Pauline; Leu-Semenescu, Smaranda; Arnulf, Isabelle] Pitie Salpetriere Univ Hosp, Sleep Disorders Unit, Paris, France; [Castelnovo, Giovanni] Univ Hosp Nimes, Dept Neurol, Nimes, France; [Abril, Beatriz] Univ Hosp Nimes, Sleep Dept, Nimes, France; [Drapier, Sophie] Univ Rennes 1, Pontchaillou Univ Hosp, Dept Neurol, Rennes, France; [Olivet, Helene] Polyclin Rennes St Laurent, Sleep Dept, Rennes, France; [Leclair-Visonneau, Laurene] INSERM, C1C1413, Clin Neurophysiol Dept, Nantes, France; [Corbille, Anne-Gaelle] INSERM, Univ Hosp Nantes, CIC1413, Nantes, France; [Sallansonnet-Froment, Magali; Lebouteux, Marie] Hop Instruct Armees Percy, Clamart, France; [Anheim, Mathieu] Univ Hosp Strasbourg, Dept Neurol, Strasbourg, France; [Anheim, Mathieu] Strasbourg Univ, INSERM U964 CNRS UMR7104, Genet Inst & Mol & Cellular Biol IGBMC, Illkirch Graffenstaden, France; [Ruppert, Elisabeth] Strasbourg Univ, Federat Translat Med Strasbourg FMTS, Strasbourg, France; [Vitello, Nicolas] Pergola Clin, Sleep Dept, Vichy, France; [Eusebio, Alexandre] CHU Timone, AP HM, Dept Neurol & Movement Disorders, Marseille, France; [Eusebio, Alexandre] Aix Marseille Univ, Inst Neurosci, INT, CNRS, Marseille, France; [Lambert, Isabelle] Timone Hosp, Epileptol Dept, Sleep Unit, Marseille, France; [Marques, Ana; Fantini, Maria Livia] Univ Clermont Auvergne, UFR Med, EA 7280, Clermont Ferrand, France; [Devos, David; Monaca, Christelle] Univ Lille, CHU Lille, INSERM, LiINCog,Lille Neurosci & Cognit,UMR S1172, Lille, France; [Benard-Serre, Nicolas; Lacombe, Sandy] Beau Soleil Clin, Dept Epidemiol & Biostat, Montpellier, France; [Vidailhet, Marie; Roze, Emmanuel] Salpetriere Hosp, AP HP, DMU Neurosci 6, Paris, France; [Vidailhet, Marie; Roze, Emmanuel] Sorbonne Univ, Paris Brain Inst, CNRS, INSERM, Paris, France; [Doulazmi, Mohamed] Sorbonne Univ, Inst Biol Paris Seine, CNRS, Adaptat Biol & Vieillissement UMR8256, Paris, France	Beau Soleil Clinic; Universite de Montpellier; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Nimes; CHU Rennes; Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Clermont Auvergne (UCA); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Beau Soleil Clinic; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	De Cock, VC (corresponding author), Univ Montpellier, EuroMov, Digital Hlth Mot, Montpellier, France.; De Cock, VC (corresponding author), Univ Montpellier, Beau Soleil Clin, Sleep & Neurol Dept, Pole Sommeil & Neurol, Montpellier, France.	valerie.cochen@gmail.com	Leclair-Visonneau, Laurène/GZL-7934-2022	Leclair-Visonneau, Laurène/0000-0001-6379-0765; Doulazmi, Mohamed/0000-0002-0313-1490	Orkyn; Aguettant Pharma	Orkyn; Aguettant Pharma(Dexcel Pharma)	Orkyn and Aguettant Pharma.	American Academy of Sleep Medicine, 2014, INT CLASS SLEEP DIS, DOI DOI 10.1176/APPI.BOOKS.9780890425596.893619; ASKENASY JJM, 1985, NEUROLOGY, V35, P527, DOI 10.1212/WNL.35.4.527; Auffret M, 2018, CLIN DRUG INVEST, V38, P287, DOI 10.1007/s40261-018-0619-3; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; BERGONZI P, 1974, CONFIN NEUROL, V36, P5; Bhidayasiri R, 2016, PARKINSONISM RELAT D, V33, pS36, DOI 10.1016/j.parkreldis.2016.11.016; Chaudhuri KR, 2012, EUR J NEUROL, V19, P105, DOI 10.1111/j.1468-1331.2011.03442.x; Chaudhuri KR, 2002, J NEUROL NEUROSUR PS, V73, P629, DOI 10.1136/jnnp.73.6.629; Comella CL, 2005, NEUROLOGY, V64, P1450, DOI 10.1212/01.WNL.0000158652.74601.48; Dalrymple-Alford JC, 2010, NEUROLOGY, V75, P1717, DOI 10.1212/WNL.0b013e3181fc29c9; Fernandez-Pajarin G, 2016, J PARKINSON DIS, V6, P787, DOI 10.3233/JPD-160886; Ruiz PJG, 2008, MOVEMENT DISORD, V23, P1130, DOI 10.1002/mds.22063; Ruiz PJG, 2006, MOVEMENT DISORD, V21, P727, DOI 10.1002/mds.20852; Gjerstad MD, 2007, J NEUROL NEUROSUR PS, V78, P476, DOI 10.1136/jnnp.2006.100370; Hogl B, 2003, NEUROPSYCHOPHARMACOL, V28, P1866, DOI 10.1038/sj.npp.1300250; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Katzenschlager R, 2018, LANCET NEUROL, V17, P749, DOI 10.1016/S1474-4422(18)30239-4; LEEMAN AL, 1987, BRIT J CLIN PHARMACO, V24, P637, DOI 10.1111/j.1365-2125.1987.tb03223.x; Marinus J, 2018, LANCET NEUROL, V17, P559, DOI 10.1016/S1474-4422(18)30127-3; Martinez-Martin P, 2015, MOVEMENT DISORD, V30, P510, DOI 10.1002/mds.26067; Martinez-Martin P, 2013, J NEUROL, V260, P228, DOI 10.1007/s00415-012-6624-1; Martinez-Martin P, 2011, J PARKINSON DIS, V1, P197, DOI 10.3233/JPD-2011-11037; Martinez-Martin P, 2011, MOVEMENT DISORD, V26, P399, DOI 10.1002/mds.23462; Meira B, 2021, NPJ PARKINSONS DIS, V7, DOI 10.1038/s41531-021-00194-7; NAUSIEDA PA, 1982, CLIN NEUROPHARMACOL, V5, P183, DOI 10.1097/00002826-198205020-00003; Olanow CW, 2014, LANCET NEUROL, V13, P141, DOI 10.1016/S1474-4422(13)70293-X; Pahwa R, 2007, NEUROLOGY, V68, P1108, DOI 10.1212/01.wnl.0000258660.74391.c1; Poewe WH, 2007, LANCET NEUROL, V6, P513, DOI 10.1016/S1474-4422(07)70108-4; Reuter I, 1999, ACTA NEUROL SCAND, V100, P163; Ricciardi L, 2016, MOVEMENT DISORD, V31, P597, DOI 10.1002/mds.26564; Roth T, 2009, SLEEP DISORDERS MED, V9, P218; Sesar A, 2017, J NEUROL, V264, P946, DOI 10.1007/s00415-017-8477-0; Tomlinson CL, 2010, MOVEMENT DISORD, V25, P2649, DOI 10.1002/mds.23429; Trenkwalder C, 2011, MOVEMENT DISORD, V26, P644, DOI 10.1002/mds.23476; Trenkwalder C, 2011, MOVEMENT DISORD, V26, P90, DOI 10.1002/mds.23441	35	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2022	21	5					428	437		10.1016/S1474-4422(22)00085-0	http://dx.doi.org/10.1016/S1474-4422(22)00085-0			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	2R9KM	35429481				2022-12-18	WOS:000821423000016
J	Aloisi, F; Salvetti, M				Aloisi, Francesca; Salvetti, Marco			Epstein-Barr virus and multiple sclerosis: supporting causality	LANCET NEUROLOGY			English	Editorial Material									[Aloisi, Francesca] Ist Super Sanit, Dept Neurosci, I-00161 Rome, Italy; [Salvetti, Marco] Sapienza Univ Rome, Dept Neurosci Mental Hlth & Sensory Organs, Rome, Italy; [Salvetti, Marco] IRCCS Neuromed, Pozzilli, Italy	Istituto Superiore di Sanita (ISS); Sapienza University Rome; IRCCS Neuromed	Aloisi, F (corresponding author), Ist Super Sanit, Dept Neurosci, I-00161 Rome, Italy.	francesca.aloisi@iss.it						Bar-Or A, 2020, TRENDS MOL MED, V26, P296, DOI 10.1016/j.molmed.2019.11.003; Bjornevik K, 2022, SCIENCE, V375, P296, DOI 10.1126/science.abj8222; Cohen JI, 2018, ADV EXP MED BIOL, V1045, P477, DOI 10.1007/978-981-10-7230-7_22; derach F, 2021, MICROORGANISMS, V9, P2191; Jacobs BM, 2020, MULT SCLER J, V26, P1281, DOI 10.1177/1352458520907901; Levin LI, 2005, JAMA-J AM MED ASSOC, V293, P2496, DOI 10.1001/jama.293.20.2496; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Pham HPT, 2021, MULT SCLER RELAT DIS, V56, DOI 10.1016/j.msard.2021.103282; Salvetti M, 2009, CURR OPIN NEUROL, V22, P201, DOI 10.1097/WCO.0b013e32832b4c8d; Sundstrom P, 2004, NEUROLOGY, V62, P2277, DOI 10.1212/01.WNL.0000130496.51156.D7	10	2	2	4	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2022	21	4					300	301		10.1016/S1474-4422(22)00086-2	http://dx.doi.org/10.1016/S1474-4422(22)00086-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	1Y0JM	35305331				2022-12-18	WOS:000807832700005
J	Hill, G; Regan, S; Francis, R				Hill, Georgina; Regan, Sandra; Francis, Richard		Stroke Priority Setting Partnersh	Research priorities to improve stroke outcomes	LANCET NEUROLOGY			English	Letter							EXERCISE		[Hill, Georgina; Regan, Sandra; Francis, Richard] Stroke Assoc, London EC1V 2PR, England		Francis, R (corresponding author), Stroke Assoc, London EC1V 2PR, England.	richard.francis@stroke.org.uk	; Hammerbeck, Ulrike/K-1780-2015	Kontou, Eirini/0000-0001-5837-9891; Kennedy, Niamh/0000-0001-7492-0828; Hammerbeck, Ulrike/0000-0003-2657-4347; Todhunter-Brown, Alex/0000-0003-4941-7985				[Anonymous], 2019, BMJ, V18, P88, DOI [DOI 10.1136/BMJ.L94, DOI 10.1136/bmj.l94]; Diechmann MD, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11111499; Hvid LG, 2021, SPORTS MED, V51, P1651, DOI 10.1007/s40279-021-01453-6; James Lind Alliance, 2021, JLA GUID; King D, 2020, AGE AGEING, V49, P277, DOI 10.1093/ageing/afz163; Langeskov-Christensen M, 2021, NEUROLOGY, V96, pE203, DOI 10.1212/WNL.0000000000011241; Motl RW, 2017, LANCET NEUROL, V16, P848, DOI 10.1016/S1474-4422(17)30281-8; Pollock A, 2012, LANCET NEUROL, V11, P209, DOI 10.1016/S1474-4422(12)70029-7; UK Clinical Research Collaboration, UK HLTH RES AN 2018; Zivadinov R, 2016, EXPERT REV NEUROTHER, V16, P777, DOI 10.1080/14737175.2016.1181543	10	2	2	3	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2022	21	4					312	313		10.14256/j.Lancet.15891	http://dx.doi.org/10.14256/j.Lancet.15891			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	1Y0JM	35305334				2022-12-18	WOS:000807832700008
J	Cree, BAC; Oksenberg, JR; Hauser, SL				Cree, Bruce A. C.; Oksenberg, Jorge R.; Hauser, Stephen L.			Multiple sclerosis: two decades of progress	LANCET NEUROLOGY			English	Editorial Material							B-CELL FOLLICLES		[Hauser, Stephen L.] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hauser, SL (corresponding author), Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA.	stephen.hauser@ucsf.edu			National Institute of Neurological Disorders and Stroke [R35NS111644]; National Multiple Sclerosis Society [RR 2005-A-13]; Valhalla Foundation; Genentech	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Multiple Sclerosis Society(National Multiple Sclerosis Society); Valhalla Foundation; Genentech(Roche HoldingGenentech)	BACC has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Horizon, Neuron23, Novartis, Sanofi, TGTherapeutics, and Therini; and has received research support from Genentech. SLH serves on the board of directors for Neurona and on scientific advisory boards for Accure, Alector, Annexon, and Molecular Stethoscope; and has received travel reimbursement and writing assistance from F Hoffmann-La Roche and Novartis AG for CD20-related meetings and presentations. JRO declares no competing interests. This work was supported by grants from the National Institute of Neurological Disorders and Stroke (R35NS111644), the National Multiple Sclerosis Society (RR 2005-A-13), and the Valhalla Foundation.	Absinta M, 2021, NATURE, V597, P709, DOI 10.1038/s41586-021-03892-7; Bjornevik K, 2022, SCIENCE, V375, P296, DOI 10.1126/science.abj8222; Brandle SM, 2016, P NATL ACAD SCI USA, V113, P7864, DOI 10.1073/pnas.1522730113; Cree BAC, 2019, ANN NEUROL, V85, P653, DOI 10.1002/ana.25463; Cree BAC, 2016, ANN NEUROL, V80, P499, DOI 10.1002/ana.24747; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Hauser SL, 2020, AM J MED, V133, P1380, DOI 10.1016/j.amjmed.2020.05.049; Ineichen BV, 2021, INVEST RADIOL, V56, P773, DOI 10.1097/RLI.0000000000000804; Kuerten S, 2020, P NATL ACAD SCI USA, V117, P21512, DOI 10.1073/pnas.2011249117; Ma Qin, 2021, Proc Natl Acad Sci U S A, V118, DOI 10.1073/pnas.2111920118; Madireddy L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09773-y; Magliozzi R, 2007, BRAIN, V130, P1089, DOI 10.1093/brain/awm038; Obermeier B, 2008, NAT MED, V14, P688, DOI 10.1038/nm1714; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Ramaglia V, 2019, ELIFE, V8, DOI 10.7554/eLife.48051; Ramesh A, 2020, P NATL ACAD SCI USA, V117, P22932, DOI 10.1073/pnas.2008523117; Schirmer L, 2019, NATURE, V573, P75, DOI 10.1038/s41586-019-1404-z; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Wang J, 2020, CELL, V183, P1264, DOI 10.1016/j.cell.2020.09.054	20	2	2	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					211	214		10.1016/S1474-4422(22)00040-0	http://dx.doi.org/10.1016/S1474-4422(22)00040-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35182500	Green Accepted			2022-12-18	WOS:000759721800008
J	Diener, HC				Diener, Hans Christoph			CGRP-targeted drugs for migraine: still many uncertainties	LANCET NEUROLOGY			English	Editorial Material									[Diener, Hans Christoph] Univ Duisburg Essen, Dept Neuroepidemiol, Inst Med Informat Biometry & Epidemiol, Fac Med, D-45147 Essen, Germany	University of Duisburg Essen	Diener, HC (corresponding author), Univ Duisburg Essen, Dept Neuroepidemiol, Inst Med Informat Biometry & Epidemiol, Fac Med, D-45147 Essen, Germany.	hans.diener@uk-essen.de						Al-Hassany L, 2022, LANCET NEUROL, V21, P284, DOI 10.1016/S1474-4422(21)00409-9; Ashina M, 2021, LANCET, V397, P1496, DOI 10.1016/S0140-6736(20)32162-0; Diener HC, 2020, HEADACHE, V60, P649, DOI 10.1111/head.13749; GOADSBY PJ, 1988, ANN NEUROL, V23, P193, DOI 10.1002/ana.410230214; Mulder IA, 2020, ANN NEUROL, V88, P771, DOI 10.1002/ana.25831; Ray JC, 2021, J NEUROL NEUROSUR PS, V92, P1325, DOI 10.1136/jnnp-2020-324674; Reuter U, 2022, CEPHALALGIA, V42, P108, DOI 10.1177/03331024211053571; Roberto G, 2015, CEPHALALGIA, V35, P118, DOI 10.1177/0333102414550416; VanderPluym JH, 2021, JAMA-J AM MED ASSOC, V325, P2357, DOI 10.1001/jama.2021.7939; Yang CP, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.28544	10	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					209	210		10.1016/S1474-4422(21)00468-3	http://dx.doi.org/10.1016/S1474-4422(21)00468-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35093197				2022-12-18	WOS:000759721800007
J	Sellebjerg, F; Magyari, M				Sellebjerg, Finn; Magyari, Melinda			The prognostic value of neurofilament light chain in serum Comment	LANCET NEUROLOGY			English	Editorial Material							BIOMARKER		[Sellebjerg, Finn] Copenhagen Univ Hosp Rigshosp, Danish Multiple Sclerosis Ctr, Dept Neurol, DK-2600 Glostrup, Denmark; Copenhagen Univ Hosp Rigshosp, Danish Multiple Sclerosis Registry, Dept Neurol, DK-2600 Glostrup, Denmark; Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark	Rigshospitalet; Rigshospitalet; University of Copenhagen	Sellebjerg, F (corresponding author), Copenhagen Univ Hosp Rigshosp, Danish Multiple Sclerosis Ctr, Dept Neurol, DK-2600 Glostrup, Denmark.	finn.thorup.sellebjerg@regionh.dk		Sellebjerg, Finn/0000-0002-1333-9623; Magyari, Melinda/0000-0002-0972-5222				Benkert P, LANCET NEUROL, V21, P244; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Gafson AR, 2020, BRAIN, V143, P1975, DOI 10.1093/brain/awaa098; Hviid CVB, 2020, SCAND J CLIN LAB INV, V80, P291, DOI 10.1080/00365513.2020.1730434; Kapoor R, 2020, NEUROLOGY, V95, P436, DOI 10.1212/WNL.0000000000010346; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Manouchehrinia A, 2020, NEUROLOGY, V94, pE2457, DOI 10.1212/WNL.0000000000009571; Manouchehrinia A, 2020, ANN CLIN TRANSL NEUR, V7, P139, DOI 10.1002/acn3.50972; Polymeris AA, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa166; Wieske L, 2021, NEUROTHERAPEUTICS, V18, P2351, DOI 10.1007/s13311-021-01136-0	10	2	2	3	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					207	208		10.1016/S1474-4422(22)00034-5	http://dx.doi.org/10.1016/S1474-4422(22)00034-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35182499				2022-12-18	WOS:000759721800006
J	[Anonymous]				[Anonymous]			Rare diseases: maintaining momentum	LANCET NEUROLOGY			English	Editorial Material																			0	2	2	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					203	203		10.1016/S1474-4422(22)00046-1	http://dx.doi.org/10.1016/S1474-4422(22)00046-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35182497				2022-12-18	WOS:000759721800003
J	Spiegelhalder, K; Feige, B; Riemann, D; Kyle, SD				Spiegelhalder, Kai; Feige, Bernd; Riemann, Dieter; Kyle, Simon D.			Daridorexant for insomnia disorder	LANCET NEUROLOGY			English	Editorial Material									[Spiegelhalder, Kai; Feige, Bernd; Riemann, Dieter] Univ Freiburg, Fac Med, Dept Psychiat & Psychotherapy, Med Ctr, D-79104 Freiburg, Germany; [Kyle, Simon D.] Univ Oxford, Sir Jules Thorn Sleep & Circadian Neurosci Inst, Nuffield Dept Clin Neurosci, Oxford, England	University of Freiburg; University of Oxford	Spiegelhalder, K (corresponding author), Univ Freiburg, Fac Med, Dept Psychiat & Psychotherapy, Med Ctr, D-79104 Freiburg, Germany.	kai.spiegelhalder@uniklinik-freiburg.de		Kyle, Simon/0000-0002-9581-5311				Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Buysse DJ, 2006, SLEEP, V29, P1155, DOI 10.1093/sleep/29.9.1155; Mignot E, 2022, LANCET NEUROL, V21, DOI 10.1016/S1474-4422(21)00436-1; Mitchell LJ, 2019, SLEEP MED REV, V47, P90, DOI 10.1016/j.smrv.2019.06.002; Morin CM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.26; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Qaseem A, 2016, ANN INTERN MED, V165, P125, DOI 10.7326/M15-2175; Riemann D, 2017, J SLEEP RES, V26, P675, DOI 10.1111/jsr.12594; Xue T, 2022, SLEEP MED REV, V61, DOI 10.1016/j.smrv.2021.101573	9	2	2	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2022	21	2					104	105		10.1016/S1474-4422(22)00007-2	http://dx.doi.org/10.1016/S1474-4422(22)00007-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZT4ER	35065026				2022-12-18	WOS:000769111800003
J	Costa, ACS; Brandao, AC; Boada, R; Barrionuevo, VL; Taylor, HG; Roth, E; Stasko, MR; Johnson, MW; Assir, FF; Roberto, MP; Salmona, P; Abreu-Silveira, G; Bederman, I; Prendergast, E; Huls, A; Abrishamcar, S; Mustacchi, Z; Scheidemantel, T; Roizen, NJ; Ruedrich, S				Costa, Alberto C. S.; Brandao, Ana C.; Boada, Richard; Barrionuevo, Veridiana L.; Taylor, Hudson G.; Roth, Elizabeth; Stasko, Melissa R.; Johnson, Mark W.; Assir, Fernanda F.; Roberto, Maria P.; Salmona, Patricia; Abreu-Silveira, Guilherme; Bederman, Ilya; Prendergast, Erin; Huls, Anke; Abrishamcar, Sarina; Mustacchi, Zan; Scheidemantel, Thomas; Roizen, Nancy J.; Ruedrich, Stephen			Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial	LANCET NEUROLOGY			English	Article							NMDA RECEPTOR ANTAGONIST; TS65DN MOUSE MODEL; ALZHEIMERS-DISEASE	Background Down syndrome is a chromosomal disorder with considerable neurodevelopmental impact and neurodegenerative morbidity. In a pilot trial in young adults with Down syndrome, memantine (a drug approved for Alzheimer's disease) showed a significant effect on a secondary measure of episodic memory. We aimed to test whether memantine would improve episodic memory in adolescents and young adults with Down syndrome. Methods We did a randomised, double-blind, placebo-controlled phase 2 trial with a parallel design, stratified by age and sex. Participants (aged 15-32 years) with either trisomy 21 or complete unbalanced translocation of chromosome 21 and in general good health were recruited from the community at one site in Brazil and another in the USA. Participants were randomly assigned (1:1) to receive either memantine (20 mg/day orally) or placebo for 16 weeks. Computer-generated randomisation tables for both sites (allocating a placebo or drug label to each member of a unique pair of participants) were centrally produced by an independent statistician and were shared only with investigational pharmacists at participating sites until unblinding of the study. Participants and investigators were masked to treatment assignments. Neuropsychological assessments were done at baseline (T1) and week 16 (T2). The primary outcome measure was change from baseline to week 16 in the California Verbal Learning Test-second edition short-form (CVLT-II-sf) total free recall score, assessed in the per-protocol population (ie, participants who completed 16 weeks of treatment and had neuropsychological assessments at T1 and T2). Linear mixed effect models were fit to data from the per-protocol population. Safety and tolerability were monitored and analysed in all participants who started treatment. Steady-state concentrations in plasma of memantine were measured at the end of the trial. This study is registered at ClinicalTrials.gov, number NCT02304302. Findings From May 13, 2015, to July 22, 2020, 185 participants with Down syndrome were assessed for eligibility and 160 (86%) were randomly assigned either memantine (n=81) or placebo (n=79). All participants received their allocated treatment. Linear mixed effect models were fit to data from 149 (81%) participants, 73 in the memantine group and 76 in the placebo group, after 11 people (eight in the memantine group and three in the placebo group) discontinued due to COVID-19 restrictions, illness of their caregiver, adverse events, or low compliance. The primary outcome measure did not differ between groups (CVLT-II-sf total free recall score, change from baseline 0.34 points [95% CI -0.98 to 1.67], p=0.61). Memantine was well tolerated, with infrequent mild-to-moderate adverse events, the most common being viral upper respiratory infection (nine [11%] participants in the memantine group and 12 [15%] in the placebo group) and transient dizziness (eight [10%] in the memantine group and six [8%] in the placebo group). No serious adverse events were observed. Amounts of memantine in plasma were substantially lower than those considered therapeutic for Alzheimer's disease. Interpretation Memantine was well tolerated, but cognition-enhancing effects were not recorded with a 20 mg/day dose in adolescents and young adults with Down syndrome. Exploratory analyses point to a need for future work. Funding Alana Foundation. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Costa, Alberto C. S.; Roth, Elizabeth; Stasko, Melissa R.; Johnson, Mark W.; Roizen, Nancy J.] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; [Costa, Alberto C. S.; Scheidemantel, Thomas; Ruedrich, Stephen] Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA; [Bederman, Ilya; Prendergast, Erin] Case Western Reserve Univ, Sch Med, Dept Genet & Genome Sci, Cleveland, OH USA; [Brandao, Ana C.; Assir, Fernanda F.; Roberto, Maria P.; Abreu-Silveira, Guilherme] Hosp Israelita Albert Einstein, Sao Paulo, Brazil; [Boada, Richard] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Barrionuevo, Veridiana L.; Salmona, Patricia; Mustacchi, Zan] Sao Paulo Ctr Clin Studies & Res CEPEC SP, Sao Paulo, Brazil; [Taylor, Hudson G.] Ohio State Univ, Nationwide Childrens Hosp Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Huls, Anke; Abrishamcar, Sarina] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA; [Huls, Anke] Emory Univ, Rollins Sch Publ Hlth, Gangarosa Dept Environm Hlth, Atlanta, GA USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Hospital Israelita Albert Einstein; University of Colorado System; University of Colorado Anschutz Medical Campus; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Emory University; Rollins School Public Health; Emory University; Rollins School Public Health	Costa, ACS (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pediat, Div Neurol & Epilepsy, Cleveland, OH 44106 USA.	alberto.costa@case.edu	Huels, Anke/J-8743-2019	Huels, Anke/0000-0002-6005-417X; Abrishamcar, Sarina/0000-0001-9478-7374; Costa, Alberto/0000-0002-7855-1190	Alana Foundation	Alana Foundation	Alana Foundation.	Ahmad-Sabry Mohammad-Hazem, 2015, Middle East J Anaesthesiol, V23, P51; Basten IA, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8120205; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Boada R, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.66; Carr J, 2018, J APPL RES INTELLECT, V31, P743, DOI 10.1111/jar.12438; Costa AC, 2012, NAT REV NEUROL, V8, P182, DOI 10.1038/nrneurol.2012.40; Costa ACS, 2008, NEUROPSYCHOPHARMACOL, V33, P1624, DOI 10.1038/sj.npp.1301535; Costa ACS, 2014, CNS NEUROL DISORD-DR, V13, P16, DOI 10.2174/18715273113126660183; Costa ACS, 2013, CNS DRUGS, V27, P679, DOI 10.1007/s40263-013-0089-3; Dang V, 2014, BIOL PSYCHIAT, V75, P179, DOI 10.1016/j.biopsych.2013.05.024; Hamlett ED, 2020, GLIA, V68, P1347, DOI 10.1002/glia.23779; Hanney M, 2012, LANCET, V379, P528, DOI 10.1016/S0140-6736(11)61676-0; Kishi T, 2017, J ALZHEIMERS DIS, V60, P401, DOI 10.3233/JAD-170424; Koenig KA, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab088; Lee NR, 2011, AJIDD-AM J INTELLECT, V116, P290, DOI 10.1352/1944-7558-116.4.290; Lee SE, 2020, TRENDS MOL MED, V26, P150, DOI 10.1016/j.molmed.2019.10.001; Li GW, 2017, INT J EPIDEMIOL, V46, P746, DOI 10.1093/ije/dyw320; Mai CT, 2019, BIRTH DEFECTS RES, V111, P1420, DOI 10.1002/bdr2.1589; Orkin AM, 2021, JAMA-J AM MED ASSOC, V326, P257, DOI 10.1001/jama.2021.9941; Park JW, 2021, CLIN PHARM DRUG DEV, V10, P1209, DOI 10.1002/cpdd.931; Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013; Patterson D, 2005, NAT REV GENET, V6, P137, DOI 10.1038/nrg1525; Pennington BF, 2003, CHILD DEV, V74, P75, DOI 10.1111/1467-8624.00522; Scott-McKean JJ, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/9235796; Sinai A, 2018, J ALZHEIMERS DIS, V61, P717, DOI 10.3233/JAD-170624; Sinis N, 2007, CLIN J PAIN, V23, P237, DOI 10.1097/AJP.0b013e31802f67a7; Stegen S, 2010, CLIN NEUROPSYCHOL, V24, P189, DOI 10.1080/13854040903266910; Strupp M, 2013, SEMIN NEUROL, V33, P286, DOI 10.1055/s-0033-1354594; Valis M, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00943; Victorino DB, 2017, BASIC CLIN PHARMACOL, V121, P382, DOI 10.1111/bcpt.12816	30	2	2	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					31	41		10.1016/S1474-4422(21)00369-0	http://dx.doi.org/10.1016/S1474-4422(21)00369-0			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	XV0SP	34942135				2022-12-18	WOS:000734663200020
J	Kantarci, K				Kantarci, Kejal			2021 marks a new era for Alzheimer's therapeutics	LANCET NEUROLOGY			English	Editorial Material									[Kantarci, Kejal] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA	Mayo Clinic	Kantarci, K (corresponding author), Mayo Clin, Dept Radiol, Rochester, MN 55905 USA.	kantarci.kejal@mayo.edu						Cummings J, 2021, JPAD-J PREV ALZHEIM, V8, P398, DOI [10.14283/jpad.2021.41, 10.1002/alz.12444]; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Leuzy A, 2021, NEUROLOGY, V97, pE1681, DOI 10.1212/WNL.0000000000012727; Liu CC, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc9375; Mintun MA, 2021, NEW ENGL J MED, V384, P1691, DOI 10.1056/NEJMoa2100708; Novak P.K.B., 2021, NATURE AGING, V1, P521, DOI DOI 10.1038/S43587-021-00070-2; Pascoal TA, 2021, NAT MED, V27, P1592, DOI 10.1038/s41591-021-01456-w; Thijssen EH, 2021, LANCET NEUROL, V20, P739, DOI 10.1016/S1474-4422(21)00214-3; US Food Drug Administration, 2021, FDA GRANTS ACC APPR; Zalocusky KA, 2021, NAT NEUROSCI, V24, P786, DOI 10.1038/s41593-021-00851-3	10	2	2	5	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					3	4		10.1016/S1474-4422(21)00412-9	http://dx.doi.org/10.1016/S1474-4422(21)00412-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XV0SP	34942134	Green Published			2022-12-18	WOS:000734663200004
J	Ponsford, J; Spitz, G; Hicks, AJ				Ponsford, Jennie; Spitz, Gershon; Hicks, Amelia J.			Highlights in traumatic brain injury research in 2021	LANCET NEUROLOGY			English	Editorial Material									[Ponsford, Jennie; Spitz, Gershon; Hicks, Amelia J.] Monash Epworth Rehabil Res Ctr, Richmond, Vic 3121, Australia; [Ponsford, Jennie; Spitz, Gershon; Hicks, Amelia J.] Monash Univ, Sch Psychol Sci, Turner Inst Brain & Mental Hlth, Clayton, Vic, Australia	Monash University; Monash University	Ponsford, J (corresponding author), Monash Epworth Rehabil Res Ctr, Richmond, Vic 3121, Australia.; Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Turner Inst Brain & Mental Hlth, Clayton, Vic, Australia.	jennie.ponsford@monash.edu						Arciniegas DB, 2020, J NEUROPSYCH CLIN N, V32, pE1; Brawman-Mintzer O, 2021, J NEUROTRAUM, V38, P1943, DOI 10.1089/neu.2020.7146; Connolly LJ, 2021, BMC NEUROL, V21, DOI 10.1186/s12883-021-02292-8; Dijkland SA, 2021, J NEUROTRAUM, V38, P1377, DOI 10.1089/neu.2020.7300; Graham NSN, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abg9922; Helmrich IRAR, 2022, QUAL LIFE RES, V31, P451, DOI 10.1007/s11136-021-02932-z; Sandera AM, 2021, NEUROPSYCHOL REHABIL, V31, P1105, DOI 10.1080/09602011.2020.1762670; van der Vlegel M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112473	8	2	2	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					5	6		10.1016/S1474-4422(21)00424-5	http://dx.doi.org/10.1016/S1474-4422(21)00424-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XV0SP	34942137				2022-12-18	WOS:000734663200005
J	Rafii, MS				Rafii, Michael S.			Development of treatments for Down syndrome	LANCET NEUROLOGY			English	Editorial Material							MOUSE MODEL					mrafii@usc.edu						Antonarakis SE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0143-7; Boada R, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.66; Costa ACS, 2022, LANCET NEUROL, V21, P31, DOI 10.1016/S1474-4422(21)00369-0; Fernandez F, 2007, NAT NEUROSCI, V10, P411, DOI 10.1038/nn1860; Fortea J, 2021, LANCET NEUROL, V20, P930, DOI 10.1016/S1474-4422(21)00245-3; Hanney M, 2012, LANCET, V379, P528, DOI 10.1016/S0140-6736(11)61676-0; Kleschevnikov AM, 2004, J NEUROSCI, V24, P8153, DOI 10.1523/JNEUROSCI.1766-04.2004; Lockrow J, 2011, BEHAV BRAIN RES, V221, P610, DOI 10.1016/j.bbr.2010.03.036; REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095-177; Scott-McKean JJ, 2011, LEARN MEMORY, V18, P774, DOI 10.1101/lm.024182.111	10	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					22	23		10.1016/S1474-4422(21)00411-7	http://dx.doi.org/10.1016/S1474-4422(21)00411-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XV0SP	34942129				2022-12-18	WOS:000734663200013
J	Kluger, BM; Quill, TE				Kluger, Benzi M.; Quill, Timothy E.			Advancing neuropalliative care	LANCET NEUROLOGY			English	Letter							PALLIATIVE CARE; NEEDS		[Kluger, Benzi M.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14618 USA; [Kluger, Benzi M.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14618 USA; [Quill, Timothy E.] Univ Rochester, Med Ctr, Dept Palliat Care & Med, Rochester, NY 14618 USA	University of Rochester; University of Rochester; University of Rochester	Kluger, BM (corresponding author), Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14618 USA.; Kluger, BM (corresponding author), Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14618 USA.	benzi_kluger@urmc.rochester.edu		Miyasaki, Janis/0000-0002-6372-6007				Buzgova R, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00651-9; Chahine LM, 2008, EUR J NEUROL, V15, P1265, DOI 10.1111/j.1468-1331.2008.02319.x; Creutzfeldt CJ, 2018, NEUROLOGY, V91, P217, DOI 10.1212/WNL.0000000000005916; Creutzfeldt CJ, 2016, NEUROL-CLIN PRACT, V6, P40, DOI 10.1212/CPJ.0000000000000213; Di Luca DG, 2020, PARKINSONISM RELAT D, V77, P13, DOI 10.1016/j.parkreldis.2020.06.011; Hall K, 2017, NPJ PARKINSONS DIS, V3, DOI 10.1038/s41531-017-0016-2; Kross EK, 2014, CHEST, V145, P313, DOI 10.1378/chest.13-1351; Miranda SP, 2019, J SURG EDUC, V76, P1691, DOI 10.1016/j.jsurg.2019.06.010; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Selvaraj S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018020; Singh G, 2021, LANCET GLOB HEALTH, V9, pE1129, DOI 10.1016/S2214-109X(21)00164-9; Tarolli CG, 2020, ANN PALLIAT MED, V9, pS44, DOI 10.21037/apm.2019.11.11; The Lancet Neurology, 2021, Lancet Neurol, V20, P409, DOI 10.1016/S1474-4422(21)00142-3	13	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2021	20	11					885	886		10.1016/S1474-4422(21)00333-1	http://dx.doi.org/10.1016/S1474-4422(21)00333-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WL5PY	34687624	Bronze			2022-12-18	WOS:000710458300006
J	Fanciulli, A; Wenning, GK				Fanciulli, Alessandra; Wenning, Gregor K.			Autonomic failure: a neglected presentation of Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material									[Fanciulli, Alessandra; Wenning, Gregor K.] Med Univ Innsbruck, Dysauton Ctr, A-6020 Innsbruck, Austria; [Wenning, Gregor K.] Med Univ Innsbruck, Lab Translat Neurodegenerat Res, Dept Neurol, Div Clin Neurobiol, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Fanciulli, A (corresponding author), Med Univ Innsbruck, Dysauton Ctr, A-6020 Innsbruck, Austria.	alessandra.fanciulli@i-med.ac.at						Berg D, 2018, MOVEMENT DISORD, V33, P1643, DOI 10.1002/mds.27431; Coon EA, 2020, NEUROLOGY, V95, pE889, DOI 10.1212/WNL.0000000000010002; Fanciulli A, 2020, ANN NEUROL, V88, P643, DOI 10.1002/ana.25834; Giannini G, 2018, NEUROLOGY, V91, pE1245, DOI 10.1212/WNL.0000000000006243; Horsager J, 2020, BRAIN, V143, P3077, DOI 10.1093/brain/awaa238; Kaufmann H, 2017, ANN NEUROL, V81, P287, DOI 10.1002/ana.24877; Miglis MG, 2021, LANCET NEUROL, V20, P671, DOI 10.1016/S1474-4422(21)00176-9; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; Sharabi Y, 2021, LANCET NEUROL, V20, P868, DOI 10.1016/S1474-4422(21)00219-2; Singer W, 2021, ANN NEUROL, V89, P1212, DOI 10.1002/ana.26089	10	2	2	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2021	20	10					781	782		10.1016/S1474-4422(21)00292-1	http://dx.doi.org/10.1016/S1474-4422(21)00292-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UY8AW	34536397				2022-12-18	WOS:000701741000007
J	Koga, S; Dickson, DW; Wszolek, Z				Koga, Shunsuke; Dickson, Dennis W.; Wszolek, Zbigniew			Neuropathology of progressive supranuclear palsy after treatment with tilavonemab	LANCET NEUROLOGY			English	Letter									[Koga, Shunsuke; Dickson, Dennis W.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Wszolek, Zbigniew] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Wszolek, Z (corresponding author), Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.	wszolek.zbigniew@mayo.edu	Koga, Shunsuke/AFL-8279-2022	Koga, Shunsuke/0000-0001-8868-9700	Jaye F and Betty F Dyer Foundation; NIH [U54 NS100693, UG3-NS104095, R01 AG062348]; NIH/NIA; NIH/NINDS [1U19AG063911, U19AG063911]; Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program; Haworth Family Professorship in Neurodegenerative Diseases fund; Albertson Parkinson's Research Foundation; Biohaven Pharmaceuticals [BHV4157-206, BHV3241-301]; Neuraly [NLY01-PD-1]; Vigil Neuroscience [VGL101-01.001]; AbbVie [M15-562, M15-563];  [228PD201]	Jaye F and Betty F Dyer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program; Haworth Family Professorship in Neurodegenerative Diseases fund; Albertson Parkinson's Research Foundation; Biohaven Pharmaceuticals; Neuraly; Vigil Neuroscience; AbbVie(AbbVie); 	SK receives research support by a Jaye F and Betty F Dyer Foundation Fellowship in progressive supranuclear palsy research and CurePSP. DWD receives support from the NIH (U54 NS100693, UG3-NS104095, R01 AG062348) , and Tau Consortium. ZKW is partially supported by the NIH/NIA and NIH/NINDS (1U19AG063911, Federal Award Identification Number U19AG063911) , Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program, the gifts from The Sol Goldman Charitable Trust, and the Donald G and Jodi P Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as principal investigator or coprincipal investigator on Biogen (228PD201) , Biohaven Pharmaceuticals (BHV4157-206 and BHV3241-301) , Neuraly, (NLY01-PD-1) , and Vigil Neuroscience, (VGL101-01.001) grants. He serves as coprincipal investigator of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience. He served as Mayo Clinic Floridasite principal investigator for the protocols: AbbVie, M15-562 "A study to assess efficacy, safety, tolerability, and pharmacokinetics ofABBV-8E12 in subjects with progressive supranuclear palsy (PSP) ", AbbVie, M15-563 "An extension study ofABBV-8E12 in progressive supranuclear palsy (PSP) ", and C2N Diagnostics C2N-8E12-WW-104 "Safety, tolerability, and pharmacokinetics of C2N-8E12 in subjects with progressive supranuclear palsy".	Hoglinger GU, 2021, LANCET NEUROL, V20, P182, DOI 10.1016/S1474-4422(20)30489-0; Hoglinger GU, 2017, MOVEMENT DISORD, V32, P853, DOI 10.1002/mds.26987; Kim B, 2021, ACTA NEUROPATHOL, V142, P243, DOI 10.1007/s00401-021-02318-y; Plotkin SS, 2020, NEUROBIOL DIS, V144, DOI 10.1016/j.nbd.2020.105010; West T, 2017, JPAD-J PREV ALZHEIM, V4, P236, DOI 10.14283/jpad.2017.36; Yanamandra K, 2013, NEURON, V80, P402, DOI 10.1016/j.neuron.2013.07.046	6	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2021	20	10					786	787		10.1016/S1474-4422(21)00283-0	http://dx.doi.org/10.1016/S1474-4422(21)00283-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UY8AW	34536399	Green Accepted, Bronze			2022-12-18	WOS:000701741000010
J	Salman, RAS; Keerie, C; Stephen, J; Lewis, S; Dennis, MS; Newby, DE; Wardlaw, JM; Lip, GYH; White, PM; Baigent, C; Lasserson, D; Oliver, C; Party-Jones, A; O'Mahony, F; Amoils, S; Bamford, J; Armitage, J; Emberson, J; Lowe, G; Rinkel, G; Innes, K; Adamczuk, K; Dinsmore, L; Dreyer, J; Milne, G; Walker, A; Hutchison, A; Williams, C; Fraser, R; Anderson, R; Covil, K; Stewart, K; Rees, J; Norrie, J; Hall, P; Bullen, A; Stoddart, A; Moullaali, TJ; Palmer, J; Dinsrnore, L; Sakka, E; Perthen, J				Salman, R. Al-Shahi; Keerie, C.; Stephen, J.; Lewis, S.; Dennis, M. S.; Newby, D. E.; Wardlaw, J. M.; Lip, G. Y. H.; White, P. M.; Baigent, C.; Lasserson, D.; Oliver, C.; Party-Jones, A.; O'Mahony, F.; Amoils, S.; Bamford, J.; Armitage, J.; Emberson, J.; Lowe, G.; Rinkel, G.; Innes, K.; Adamczuk, K.; Dinsmore, L.; Dreyer, J.; Milne, G.; Walker, A.; Hutchison, A.; Williams, C.; Fraser, R.; Anderson, R.; Covil, K.; Stewart, K.; Rees, J.; Norrie, J.; Hall, P.; Bullen, A.; Stoddart, A.; Moullaali, T. J.; Palmer, J.; Dinsrnore, L.; Sakka, E.; Perthen, J.		SoSTART Collaboration	Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non trial	LANCET NEUROLOGY			English	Article							SPONTANEOUS INTRACEREBRAL HEMORRHAGE; ANTITHROMBOTIC TREATMENT; STROKE PREVENTION; SUBDURAL-HEMATOMA; RECURRENT STROKE; MANAGEMENT; RISK; METAANALYSIS; PREVALENCE; VALIDATION	Background Oral anticoagulation reduces the rate of systemic embolism for patients with atrial fibrillation by two-thirds, but its benefits for patients with previous intracranial haemorrhage are uncertain. In the Start or STop Anticoagulants Randomised Trial (SoSTART), we aimed to establish whether starting is non-inferior to avoiding oral anticoagulation for survivors of intracranial haemorrhage who have atrial fibrillation. Methods SoSTART was a prospective, randomised, open-label, assessor-masked, parallel-group, pilot phase trial done at 67 hospitals in the UK. We recruited adults (aged >= 18 years) who had survived at least 24 h after symptomatic spontaneous intracranial haemorrhage, had atrial fibrillation, and had a CHA2DS2-VASc score of at least 2. Web-based computerised randomisation incorporating a minimisation algorithm allocated participants (1:1) to start or avoid long-term (>= 1 year) full treatment dose open-label oral anticoagulation. The participants assigned to start oral anticoagulation received either a direct oral anticoagulant or vitamin K antagonist, and the group assigned to avoid oral anticoagulation received standard clinical practice (antiplatelet agent or no antithrombotic agent). The primary outcome was recurrent symptomatic spontaneous intracranial haemorrhage, and was adjudicated by an individual masked to treatment allocation. All outcomes were ascertained for at least 1 year after randomisation and assessed in the intention-to-treat population of all randomly assigned participants, using Cox proportional hazards regression adjusted for minimisation covariates. We planned a sample size of 190 participants (one-sided p=0.025, power 90%, allowing for non-adherence) based on a non-inferiority margin of 12% (or adjusted hazard ratio [HR] of 3.2). This trial is registered with ClinicalTrials.gov (NCT03153150) and is complete. Findings Between March 29, 2018, and Feb 27, 2020, consent was obtained at 61 sites for 218 participants, of whom 203 were randomly assigned at a median of 115 days (IQR 49-265) after intracranial haemorrhage onset. 101 were assigned to start and 102 to avoid oral anticoagulation. Participants were followed up for median of 1.2 years (IQR 0.97-1.95; completeness 97.2%). Starting oral anticoagulation was not non-inferior to avoiding oral anticoagulation: eight (8%) of 101 in the start group versus four (4%) of 102 in the avoid group had intracranial haemorrhage recurrences (adjusted HR 2.42 [95% CI 0.72-8.09]; p=0.152). Serious adverse events occurred in 17 (17%) participants in the start group and 15 (15%) in the avoid group. 22 (22%) patients in the start group and 11 (11%) patients in the avoid group died during the study. Interpretation Whether starting oral anticoagulation was non-inferior to avoiding it for people with atrial fibrillation after intracranial haemorrhage was inconclusive, although rates of recurrent intracranial haemorrhage were lower than expected. In view of weak evidence from analyses of three composite secondary outcomes, the possibility that oral anticoagulation might be superior for preventing symptomatic major vascular events should be investigated in adequately powered randomised trials.	[Salman, R. Al-Shahi; Keerie, C.; Stephen, J.; Lewis, S.; Dennis, M. S.; Newby, D. E.; Wardlaw, J. M.; Innes, K.; Adamczuk, K.; Dinsmore, L.; Dreyer, J.; Milne, G.; Walker, A.; Hutchison, A.; Williams, C.; Fraser, R.; Anderson, R.; Covil, K.; Stewart, K.; Rees, J.; Hall, P.; Bullen, A.; Stoddart, A.; Moullaali, T. J.; Palmer, J.; Dinsrnore, L.; Sakka, E.] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Lip, G. Y. H.] Univ Liverpool, Liverpool, Merseyside, England; [Party-Jones, A.] Univ Manchester, Manchester, Lancs, England; [White, P. M.] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England; [White, P. M.] Newcastle Upon Tyne Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Baigent, C.; Armitage, J.; Emberson, J.] Univ Oxford, Oxford, England; [Lasserson, D.; Lowe, G.] Univ Warwick, Warwick, England; [Oliver, C.] Patient Publ Representat, Edinburgh, Midlothian, Scotland; [Bamford, J.] Univ Leeds, Leeds, W Yorkshire, England; [Rinkel, G.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Norrie, J.] Univ Edinburgh, Edinburgh Clin Trials Unit, Edinburgh, Midlothian, Scotland; [White, P. M.; Perthen, J.] Newcastle Upon Tyne Hosp NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England	University of Edinburgh; University of Liverpool; University of Manchester; Newcastle University - UK; Newcastle University - UK; University of Oxford; University of Warwick; University of Leeds; Utrecht University; Utrecht University Medical Center; University of Edinburgh; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Salman, RAS (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland.	rustam.al-shahi@ed.ac.uk	Bamford, John/ABE-6218-2021		Medical Research Council [G10026051]; Chest Heart & Stroke Scotland; British Heart Foundation [CS/18/2/33719]; National Institute for Health Research clinical research network; National Health Service Research Scotland (NRS) Scottish Stroke Research Network; National Health Service Lothian Research and Development - Scottish Funding Council; Chief Scientist Office; NRS [E131252]	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chest Heart & Stroke Scotland; British Heart Foundation(British Heart Foundation); National Institute for Health Research clinical research network; National Health Service Research Scotland (NRS) Scottish Stroke Research Network; National Health Service Lothian Research and Development - Scottish Funding Council; Chief Scientist Office; NRS	We thank all participants, their relatives or carers, and their primary care practitioners; the outcome event adjudicator, imaging adjudicators, the trial steering committee, and the data monitoring committee. We thank Edinburgh Clinical Trials Unit staff for their involvement. We thank the Medical Research Council (G10026051), Chest Heart & Stroke Scotland (Res 16 A166), and the British Heart Foundation (CS/18/2/33719) for funding the trial via the University of Edinburgh. We acknowledge the support of the National Institute for Health Research clinical research network, the National Health Service Research Scotland (NRS) Scottish Stroke Research Network, and the support of the NRS through the Edinburgh clinical research facility (E131252) and National Health Service Lothian Research and Development. Imaging acquisition, processing, and data collection were performed at the Edinburgh Imaging Facility, University of Edinburgh, which is part of the SINAPSE collaboration (funded by the Scottish Funding Council and the Chief Scientist Office).	Andersen KK, 2009, STROKE, V40, P2068, DOI 10.1161/STROKEAHA.108.540112; Arboix Adria, 2012, ISRN Neurol, V2012, P498303, DOI 10.5402/2012/498303; Berge E, 2016, INT J STROKE, V11, P663, DOI 10.1177/1747493016641963; Bruno A, 2011, STROKE, V42, P2276, DOI 10.1161/STROKEAHA.111.613273; Bruno A, 2010, STROKE, V41, P1048, DOI 10.1161/STROKEAHA.109.571562; Cao Y, 2020, STROKE VASC NEUROL, V5, P396, DOI 10.1136/svn-2020-000433; Chao TF, 2016, CIRCULATION, V133, P1540, DOI 10.1161/CIRCULATIONAHA.115.019794; Clark TG, 2002, LANCET, V359, P1309, DOI 10.1016/S0140-6736(02)08272-7; Counsell C, 2002, STROKE, V33, P1041, DOI 10.1161/hs0402.105909; Dennis M, 2012, STROKE, V43, P851, DOI 10.1161/STROKEAHA.111.639708; Dowlatshahi D, 2020, INT STROK C; Freedman B, 2016, LANCET, V388, P806, DOI 10.1016/S0140-6736(16)31257-0; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hindricks G, 2021, EUR HEART J, V42, P373, DOI [10.1093/eurheartj/ehaa612, 10.15829/1560-4071-2021-4701]; Horstmann S, 2014, EUR J NEUROL, V21, P570, DOI 10.1111/ene.12215; Hrobjartsson A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1119; Khurram A, 2014, STROKE, V45, P1151, DOI 10.1161/STROKEAHA.113.004298; Kirchhof P, 2016, EUROPACE, V18, DOI [10.1016/j.rec.2016.11.033, 10.1093/europace/euw295, 10.5603/KP.2016.0172]; Klijn CJM, 2019, EUR STROKE J, V4, P198, DOI 10.1177/2396987319841187; Korompoki E, 2017, NEUROLOGY, V89, P687, DOI 10.1212/WNL.0000000000004235; Kuramatsu JB, 2015, JAMA-J AM MED ASSOC, V313, P824, DOI 10.1001/jama.2015.0846; Li LX, 2021, LANCET NEUROL, V20, P437, DOI 10.1016/S1474-4422(21)00075-2; Linn J, 2010, NEUROLOGY, V74, P1346, DOI 10.1212/WNL.0b013e3181dad605; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Maxwell AE, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1909-4; Morris NA, 2016, NEUROCRIT CARE, V24, P226, DOI 10.1007/s12028-015-0178-x; Murthy SB, 2021, JAMA NEUROL, V78, P809, DOI 10.1001/jamaneurol.2021.0925; Murthy SB, 2017, STROKE, V48, P1594, DOI 10.1161/STROKEAHA.116.016327; Nielsen PB, 2015, CIRCULATION, V132, P517, DOI 10.1161/CIRCULATIONAHA.115.015735; Perry LA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012144.pub2; Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134; Rodrigues MA, 2018, LANCET NEUROL, V17, P232, DOI 10.1016/S1474-4422(18)30006-1; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Salman RAS, 2019, LANCET, V393, P2613, DOI 10.1016/S0140-6736(19)30840-2; Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6; Seiffge DJ, 2019, J NEUROL, V266, P3126, DOI 10.1007/s00415-019-09536-1; Shoamanesh A, 2021, INT J STROKE, V16, P321, DOI 10.1177/1747493020968424; Strong B, 2021, JAMA NEUROL, V78, P666, DOI 10.1001/jamaneurol.2021.0873; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; van Nieuwenhuizen KM, 2020, EUR STROKE J, V5, P336, DOI 10.1177/2396987320953394; van Nieuwenhuizen KM, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0898-4; Wilson C, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2413-6; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; Xu Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191137	45	2	2	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2021	20	10					842	853		10.1016/S1474-4422(21)00264	http://dx.doi.org/10.1016/S1474-4422(21)00264			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UY8AW					2022-12-18	WOS:000701741000019
J	Abbott, A				Abbott, Anne			Asymptomatic carotid stenosis and stroke risk	LANCET NEUROLOGY			English	Letter							ENDARTERECTOMY		[Abbott, Anne] Monash Univ, Cent Clin Sch, Neurosci Dept, Melbourne, Vic 3004, Australia	Monash University	Abbott, A (corresponding author), Monash Univ, Cent Clin Sch, Neurosci Dept, Melbourne, Vic 3004, Australia.	anne.l.abbott@gmail.com						Abbott AL, 2020, J VASC SURG, V71, P257, DOI 10.1016/j.jvs.2019.04.490; Halliday A, 2010, LANCET, V376, P1074, DOI 10.1016/S0140-6736(10)61197-X; Howard DPJ, 2021, LANCET NEUROL, V20, P193, DOI 10.1016/S1474-4422(20)30484-1; Munster AB, 2015, NEUROLOGY, V85, P365, DOI 10.1212/WNL.0000000000001781; Nicolaides AN, 2010, J VASC SURG, V52, P1486, DOI 10.1016/j.jvs.2010.07.021; Rothwell PM, 2000, STROKE, V31, P615, DOI 10.1161/01.STR.31.3.615; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	7	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2021	20	9					698	699		10.1016/S1474-4422(21)00199-X	http://dx.doi.org/10.1016/S1474-4422(21)00199-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UK3MC	34418388	Bronze			2022-12-18	WOS:000691876000007
J	Dale, RC; Ramanathan, S				Dale, C. Russell; Ramanathan, Sudarshini			Clinical decision making in MOG antibody-associated disease	LANCET NEUROLOGY			English	Editorial Material							MYELIN-OLIGODENDROCYTE GLYCOPROTEIN		[Dale, C. Russell; Ramanathan, Sudarshini] Univ Sydney, Fac Med & Hlth, Childrens Hosp Westmead, Neuroimmunol Grp,Kids Neurosci Ctr,Sydney Med Sch, Sydney, NSW, Australia; [Dale, C. Russell] Childrens Hosp Westmead, TY Nelson Dept Paediat Neurol, Sydney, NSW, Australia; [Ramanathan, Sudarshini] Concord Hosp, Dept Neurol, Sydney, NSW, Australia	University of Sydney; University of Sydney; Concord Repatriation General Hospital	Dale, RC (corresponding author), Univ Sydney, Fac Med & Hlth, Childrens Hosp Westmead, Neuroimmunol Grp,Kids Neurosci Ctr,Sydney Med Sch, Sydney, NSW, Australia.; Dale, RC (corresponding author), Childrens Hosp Westmead, TY Nelson Dept Paediat Neurol, Sydney, NSW, Australia.	russell.dale@health.nsw.gov.au						Armangue T, 2020, LANCET NEUROL, V19, P234, DOI 10.1016/S1474-4422(19)30488-0; Holmoy T, 2021, J NEUROL, V268, P4522, DOI 10.1007/s00415-020-10235-5; Jarius S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0718-0; Jurynczyk M, 2017, BRAIN, V140, P617, DOI 10.1093/brain/aww350; Lang K, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000386; Marignier R, 2021, LANCET NEUROL, V20, P762, DOI 10.1016/S1474-4422(21)00218-0; Ramanathan S, 2018, J NEUROL NEUROSUR PS, V89, P127, DOI 10.1136/jnnp-2017-316880; Ramanathan S, 2016, MULT SCLER J, V22, P470, DOI 10.1177/1352458515593406; Ramanathan S, 2016, AUTOIMMUN REV, V15, P307, DOI 10.1016/j.autrev.2015.12.004; Zhou D, 2006, P NATL ACAD SCI USA, V103, P19057, DOI 10.1073/pnas.0607242103	10	2	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2021	20	9					695	697		10.1016/S1474-4422(21)00247-7	http://dx.doi.org/10.1016/S1474-4422(21)00247-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UK3MC	34418387				2022-12-18	WOS:000691876000006
J	Wijeratne, T; Grisold, W; Baneke, P; Helme, A; King, R; Carrol, W				Wijeratne, Tissa; Grisold, Wolfgang; Baneke, Peer; Helme, Anne; King, Rachel; Carrol, William			World Brain Day 2021: a call to stop multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material									[Wijeratne, Tissa] Western Hlth, AIMSS Melbourne Med Sch, Dept Neurol & Med, St Albans, Vic, Australia; [Grisold, Wolfgang] Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria; [Baneke, Peer; Helme, Anne; King, Rachel] Multiple Sclerosis Int Fed, London, England; [Carrol, William] Sir Charles Gairdner Hosp, Dept Neurol, Perth, WA, Australia	Ludwig Boltzmann Institute; University of Western Australia	Wijeratne, T (corresponding author), Western Hlth, AIMSS Melbourne Med Sch, Dept Neurol & Med, St Albans, Vic, Australia.	tissa.wijeratne@wh.org.au		Wijeratne, Tissa/0000-0002-1701-7111; Helme, Anne/0000-0001-8880-2347	Merck; Roche; Sanofi Genzyme; Biogen; Bristol Myers Squibb; Viatris; Novartis; Janssen (Johnson Johnson)	Merck(Merck & Company); Roche(Roche Holding); Sanofi Genzyme(Sanofi-AventisGenzyme Corporation); Biogen(Biogen); Bristol Myers Squibb(Bristol-Myers Squibb); Viatris; Novartis(Novartis); Janssen (Johnson Johnson)(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc)	PB, AH, and RK are employees of MSIF, which receives money from a range of corporate sponsors, recently including Biogen, Bristol Myers Squibb (formerly Celgene), Janssen (Johnson & Johnson), Merck, Viatris (formerly Mylan), Novartis, Roche, and Sanofi Genzyme. All other authors declare no competing interests.	The Lancet Neurology, LANCET NEUROL, V20, P497; Walton C, 2020, MULT SCLER J, V26, P1816, DOI 10.1177/1352458520970841; Wijeratne T, 2019, LANCET NEUROL, V18, P914, DOI 10.1016/S1474-4422(19)30281-9	3	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2021	20	8					597	598		10.1016/S1474-4422(21)00200-3	http://dx.doi.org/10.1016/S1474-4422(21)00200-3		JUL 2021	2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP6CG	34166643	Bronze			2022-12-18	WOS:000677684700009
J	Gilat, M; D'Cruz, N; Ginis, P; Vandenberghe, W; Nieuwboer, A				Gilat, Moran; D'Cruz, Nicholas; Ginis, Pieter; Vandenberghe, Wim; Nieuwboer, Alice			Freezing of gait and levodopa	LANCET NEUROLOGY			English	Letter									[Gilat, Moran; D'Cruz, Nicholas; Ginis, Pieter; Nieuwboer, Alice] Katholieke Univ Leuven, Dept Rehabil Sci, Neurorehabil Res Grp eNRGy, B-3000 Leuven, Belgium; [Vandenberghe, Wim] Katholieke Univ Leuven, Dept Neurosci, Lab Parkinson Res, Leuven, Belgium; [Vandenberghe, Wim] Univ Hosp Leuven, Dept Neurol, Leuven, Belgium	KU Leuven; KU Leuven; KU Leuven; University Hospital Leuven	Gilat, M (corresponding author), Katholieke Univ Leuven, Dept Rehabil Sci, Neurorehabil Res Grp eNRGy, B-3000 Leuven, Belgium.	moran.gilat@kuleuven.be		Ginis, Pieter/0000-0002-6762-3347; D'Cruz, Nicholas/0000-0002-5306-5903	EU [838576]; Jacques and Gloria Gossweiler Foundation; Horizon 2020 Innovative Medicines initiative Mobilise-D project [820820]; Industrial Research Funds KU Leuven project [3M200670]; Flemish Research Foundation [FWO-G0A5619N]; Michael J Fox Foundation DeFOG project [16347]; Flemish Research Foundation	EU(European Commission); Jacques and Gloria Gossweiler Foundation; Horizon 2020 Innovative Medicines initiative Mobilise-D project; Industrial Research Funds KU Leuven project; Flemish Research Foundation(FWO); Michael J Fox Foundation DeFOG project; Flemish Research Foundation(FWO)	MG is funded by the EU's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement (838576). ND and AN are supported by funding from the Jacques and Gloria Gossweiler Foundation. PG and AN are funded by the Horizon 2020 Innovative Medicines initiative Mobilise-D project (820820), Industrial Research Funds KU Leuven project (3M200670), Flemish Research Foundation (FWO-G0A5619N), and the Michael J Fox Foundation DeFOG project (16347). WV is supported by research funding of the Flemish Research Foundation.	Cilia R, 2020, BRAIN, V143, P2490, DOI 10.1093/brain/awaa181; Kim R, 2018, PARKINSONISM RELAT D, V51, P49, DOI 10.1016/j.parkreldis.2018.02.047; Koehler PJ, 2021, LANCET NEUROL, V20, P97, DOI 10.1016/S1474-4422(19)30091-2; SCHWAB RS, 1965, PSYCHIAT NEUROL, V150, P345	4	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2021	20	7					505	505		10.1016/S1474-4422(21)00175-7	http://dx.doi.org/10.1016/S1474-4422(21)00175-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZC9UB	34146503	Green Accepted, Bronze			2022-12-18	WOS:000757854400006
J	Hardy, J; Salih, D				Hardy, John; Salih, Dervis			TREM2-mediated activation of microglia breaks link between amyloid and tau	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS-DISEASE; TRANSGENIC MICE; HYPOTHESIS		[Hardy, John] UCL Inst Neurol, Dementia Res Inst, Reta Lilla Weston Res Labs, London WC1N 3BG, England; UCL Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Hardy, J (corresponding author), UCL Inst Neurol, Dementia Res Inst, Reta Lilla Weston Res Labs, London WC1N 3BG, England.	j.hardy@ucl.ac.uk	Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423; Salih, Dervis/0000-0001-7651-8998				De Strooper B, 2016, CELL, V164, P603, DOI 10.1016/j.cell.2015.12.056; Edwards FA, 2019, TRENDS NEUROSCI, V42, P310, DOI 10.1016/j.tins.2019.03.003; Ising C, 2019, NATURE, V575, P669, DOI 10.1038/s41586-019-1769-z; Jones L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013950; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Lee SH, 2021, NEURON, V109, P1283, DOI 10.1016/j.neuron.2021.02.010; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Matarin M, 2015, CELL REP, V10, P633, DOI 10.1016/j.celrep.2014.12.041; Salih DA, 2019, BRAIN COMMUN, V1, DOI 10.1093/braincomms/fcz022; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049	11	2	2	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2021	20	6					416	417		10.1016/S1474-4422(21)00133-2	http://dx.doi.org/10.1016/S1474-4422(21)00133-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	SG4TT	34022161	Green Submitted			2022-12-18	WOS:000653434700004
J	Husein, N; Thijs, RD; Bunschoten, JW; Keezer, MR; Sander, JW				Husein, Nafisa; Thijs, Roland D.; Bunschoten, Johanna W.; Keezer, Mark R.; Sander, Josemir W.			Concerns about lamotrigine	LANCET NEUROLOGY			English	Letter							CARDIAC DEATH; EPILEPSY		[Husein, Nafisa; Keezer, Mark R.] Univ Montreal, Sch Publ Hlth, Montreal, PQ, Canada; [Keezer, Mark R.] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada; [Thijs, Roland D.; Bunschoten, Johanna W.; Keezer, Mark R.; Sander, Josemir W.] Stichting Epilepsie Instellingen Nederland, Heemstede, Netherlands; [Thijs, Roland D.; Bunschoten, Johanna W.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands; [Thijs, Roland D.; Sander, Josemir W.] UCL Queen Sq Inst Neurol, London WC1N 3BG, England; [Thijs, Roland D.; Sander, Josemir W.] Chalfont Ctr Epilepsy, Gerrards Cross, England	Universite de Montreal; Universite de Montreal; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of London; University College London	Sander, JW (corresponding author), Stichting Epilepsie Instellingen Nederland, Heemstede, Netherlands.; Sander, JW (corresponding author), UCL Queen Sq Inst Neurol, London WC1N 3BG, England.; Sander, JW (corresponding author), Chalfont Ctr Epilepsy, Gerrards Cross, England.	l.sander@ucl.ac.uk	Thijs, Roland D/AGE-5180-2022; Sander, Josemir/C-1576-2008	Thijs, Roland D/0000-0003-1435-8970; Sander, Josemir/0000-0001-6041-9661	Medtronic; UCB; Dutch Epilepsy Foundation; De Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie; Netherlands Organization for Health Research and Development; UK Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme; Dr Marvin Weil Epilepsy Research Fund; Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie; UK Epilepsy Society; Eisai	Medtronic(Medtronic); UCB(UCB Pharma SA); Dutch Epilepsy Foundation; De Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie; Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); UK Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme; Dr Marvin Weil Epilepsy Research Fund; Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie; UK Epilepsy Society; Eisai(Eisai Co Ltd)	NH and JWB declare no competing interests. RDT receives research support from Medtronic; fees as speaker or consultant from Theravance Biopharma and Arvelle Therapeutics; and lecture fees from Medtronic, UCB, and Novartis. MRK reports unrestricted educational grants and research grants for investigator-initiated studies from UCB and Eisai. JWS reports fees as speaker or consultant from Eisai, UCB, GW Pharmaceuticals, Arvelle, and Zogenix. RDT received research support from the Dutch Epilepsy Foundation, De Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, and the Netherlands Organization for Health Research and Development. JWS is based at University College London Hospital and University College London Comprehensive Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. JWS receives support from the Dr Marvin Weil Epilepsy Research Fund, the Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, and the UK Epilepsy Society.	Ad Hoc International League Against Epilepsy and the American Epilepsy Society Task Force, 2021, FDA SAF WARN CARD EF; Bardai A, 2015, HEART, V101, P17, DOI 10.1136/heartjnl-2014-305664; de Lange IM, 2018, EPILEPSIA, V59, P1154, DOI 10.1111/epi.14191; Surges R, 2021, EPILEPTIC DISORD, V23, P17, DOI 10.1684/epd.2021.1254; Tomson T, 2013, EPILEPSIA, V54, P135, DOI 10.1111/j.1528-1167.2012.03689.x	5	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2021	20	6					418	419		10.1016/S1474-4422(21)00132-0	http://dx.doi.org/10.1016/S1474-4422(21)00132-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	SG4TT	34022162	Green Submitted, Bronze			2022-12-18	WOS:000653434700005
J	Wang, A; Karunungan, KL; Shlobin, NA; DiCesare, JAT; Holly, LT				Wang, Andrew; Karunungan, Krystal L.; Shlobin, Nathan A.; DiCesare, Jasmine A. T.; Holly, Langston T.			Diversity and inclusion in neurosurgery	LANCET NEUROLOGY			English	Letter									[Wang, Andrew] Charles R Drew Univ Med & Sci, Coll Med, Los Angeles, CA 90024 USA; [Wang, Andrew; Karunungan, Krystal L.; DiCesare, Jasmine A. T.; Holly, Langston T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Shlobin, Nathan A.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Northwestern University; Feinberg School of Medicine	Wang, A (corresponding author), Charles R Drew Univ Med & Sci, Coll Med, Los Angeles, CA 90024 USA.; Wang, A (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.	andrewwang@mednet.ucla.edu						[Anonymous], 2021, LANCET NEUROL, V20, P161, DOI 10.1016/S1474-4422(21)00034-X; Demetriades AK, 2020, LANCET NEUROL, V19, P645, DOI 10.1016/S1474-4422(20)30226-X; Gundemir S, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00282; Norton EJ, 2020, LANCET NEUROL, V19, P382, DOI 10.1016/S1474-4422(20)30080-6; Wilson TA, 2020, J NEUROSURG, V132, P802, DOI 10.3171/2018.10.JNS18859	5	2	2	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2021	20	6					419	420		10.1016/S1474-4422(21)00111-3	http://dx.doi.org/10.1016/S1474-4422(21)00111-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	SG4TT	34022163	Bronze			2022-12-18	WOS:000653434700007
J	Cendes, F				Cendes, Fernando			Epilepsy care in China and its relevance for other countries	LANCET NEUROLOGY			English	Editorial Material							DEMONSTRATION PROJECT; TREATMENT GAP		[Cendes, Fernando] Univ Estadual Campinas, Dept Neurol, BR-13083887 Campinas, SP, Brazil	Universidade Estadual de Campinas	Cendes, F (corresponding author), Univ Estadual Campinas, Dept Neurol, BR-13083887 Campinas, SP, Brazil.	fcendes@unicamp.br	Cendes, Fernando/C-1301-2012	Cendes, Fernando/0000-0001-9336-9568				Alva-Diaz C, 2021, EPILEPSIA, V62, P984, DOI 10.1111/epi.16850; Beghi E, 2019, LANCET NEUROL, V18, P357, DOI 10.1016/S1474-4422(18)30454-X; Davagnanam I, 2020, NEUROLOGY, V95, pE1236, DOI 10.1212/WNL.0000000000010171; Ding D, 2021, LANCET NEUROL, V20, P316, DOI 10.1016/S1474-4422(21)00023-5; Garcia HH, 2016, NEW ENGL J MED, V374, P2335, DOI [10.1056/NEJMoa1515520, 10.1056/NEJMc1609161]; Li LM, 2007, ARQ NEURO-PSIQUIAT, V65, P58, DOI 10.1590/S0004-282X2007001000010; Noronha ALA, 2004, ARQ NEURO-PSIQUIAT, V62, P761, DOI 10.1590/S0004-282X2004000500003; Wang WZ, 2008, B WORLD HEALTH ORGAN, V86, P964, DOI 10.2471/BLT.07.047050; Wang WZ, 2003, NEUROLOGY, V60, P1544, DOI 10.1212/01.WNL.0000059867.35547.DE; World Health Organization, 2019, EP PUBL HLTH IMP SUM	10	2	2	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2021	20	5					333	334		10.1016/S1474-4422(21)00096-X	http://dx.doi.org/10.1016/S1474-4422(21)00096-X		APR 2021	2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WV8FC	33770528				2022-12-18	WOS:000717465200008
J	Kasner, SE				Kasner, Scott E.			Antithrombotic therapy for cervical arterial dissection	LANCET NEUROLOGY			English	Editorial Material							STROKE; ASPIRIN; ANTICOAGULATION		[Kasner, Scott E.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kasner, SE (corresponding author), Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.	kasner@mail.med.upenn.edu						Engelter ST, 2021, LANCET NEUROL, V20, P341, DOI 10.1016/S1474-4422(21)00044-2; Georgiadis D, 2009, NEUROLOGY, V72, P1810, DOI 10.1212/WNL.0b013e3181a2a50a; Johnston SC, 2020, NEW ENGL J MED, V383, P207, DOI 10.1056/NEJMoa1916870; Johnston SC, 2018, NEW ENGL J MED, V379, P215, DOI 10.1056/NEJMoa1800410; Lyrer P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000255.pub2; Markus HS, 2015, LANCET NEUROL, V14, P361, DOI 10.1016/S1474-4422(15)70018-9; Meinel TR, 2020, STROKE, V51, P2597, DOI 10.1161/STROKEAHA.120.030686; Touze E, 2003, NEUROLOGY, V61, P1347, DOI 10.1212/01.WNL.0000094325.95097.86; Wang YJ, 2013, NEW ENGL J MED, V369, P11, DOI 10.1056/NEJMoa1215340; Weimar C, 2010, J NEUROL NEUROSUR PS, V81, P869, DOI 10.1136/jnnp.2009.192153	10	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2021	20	5					328	329		10.1016/S1474-4422(21)00073-9	http://dx.doi.org/10.1016/S1474-4422(21)00073-9		APR 2021	2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WV8FC	33765421				2022-12-18	WOS:000717465200004
J	Savelieff, MG; Feldman, EL				Savelieff, Masha G.; Feldman, Eva L.			Lessons for clinical trial design in Friedreich's ataxia	LANCET NEUROLOGY			English	Editorial Material									[Savelieff, Masha G.; Feldman, Eva L.] Univ Michigan, NeuroNetwork Emerging Therapies, Ann Arbor, MI 48109 USA; [Feldman, Eva L.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, NeuroNetwork Emerging Therapies, Ann Arbor, MI 48109 USA.; Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.	efeldman@umich.edu						Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cook A, 2017, BRIT MED BULL, V124, P19, DOI 10.1093/bmb/ldx034; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Grobe-Einsler M, 2021, MOVEMENT DISORD, V36, P1242, DOI 10.1002/mds.28478; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; Reetz K, 2021, LANCET NEUROL, V20, P362, DOI 10.1016/S1474-4422(21)00027-2; Reetz K, 2017, LANCET NEUROL, V16, P954, DOI 10.1016/S1474-4422(16)30287-3; Reetz K, 2015, LANCET NEUROL, V14, P174, DOI 10.1016/S1474-4422(14)70321-7; Schmitz-Hubsch T, 2006, NEUROLOGY, V66, P1717, DOI 10.1212/01.wnl.0000219042.60538.92; Strawser C, 2017, EXPERT REV NEUROTHER, V17, P895, DOI 10.1080/14737175.2017.1356721	10	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2021	20	5					330	332		10.1016/S1474-4422(21)00064-8	http://dx.doi.org/10.1016/S1474-4422(21)00064-8		APR 2021	3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WV8FC	33770529				2022-12-18	WOS:000717465200006
J	Blott, J				Blott, Jonathan			Smart homes for the future of dementia care	LANCET NEUROLOGY			English	Editorial Material																			0	2	2	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					264	264		10.1016/S1474-4422(19)30249-2	http://dx.doi.org/10.1016/S1474-4422(19)30249-2		MAR 2021	1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	31278065				2022-12-18	WOS:000630325700016
J	Grossman, M				Grossman, Murray			Lessons learned from a progressive supranuclear palsy trial	LANCET NEUROLOGY			English	Editorial Material							RICHARDSON-OLSZEWSKI-SYNDROME; PATHOLOGY; DISEASE		[Grossman, Murray] Univ Penn, Penn Frontotemporal Degenerat Ctr, Philadelphia, PA 19104 USA; [Grossman, Murray] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Grossman, Murray] Hosp Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Grossman, M (corresponding author), Univ Penn, Penn Frontotemporal Degenerat Ctr, Philadelphia, PA 19104 USA.; Grossman, M (corresponding author), Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Grossman, M (corresponding author), Hosp Univ Penn, Philadelphia, PA 19104 USA.	mgrossma@pennmedicine.upenn.edu			National Institutes of Health [AG066597, AG054519, AG052943]; Wyncote Foundation; Peisach Family Foundation; Samuel Newhouse Foundation; Avid and Life Medical Sciences; Biogen; Alector; PassageBio; Prevail	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wyncote Foundation; Peisach Family Foundation; Samuel Newhouse Foundation; Avid and Life Medical Sciences; Biogen(Biogen); Alector; PassageBio; Prevail	MG is supported by grants from the National Institutes of Health (AG066597, AG054519, and AG052943), the Wyncote Foundation, The Peisach Family Foundation, and the Samuel Newhouse Foundation; receives support as a consultant to PassageBio and Biogen; receives in-kind research support from Avid and Life Medical Sciences; and participates in treatment trials sponsored by PassageBio, Biogen, Prevail, and Alector.	Grimm MJ, 2020, MOVEMENT DISORD, V35, P2301, DOI 10.1002/mds.28263; Hoglinger GU, 2021, LANCET NEUROL, V20, P182, DOI 10.1016/S1474-4422(20)30489-0; Litvan I, 1996, NEUROLOGY, V47, P1, DOI 10.1212/WNL.47.1.1; Moore KM, 2020, LANCET NEUROL, V19, P145, DOI 10.1016/S1474-4422(19)30394-1; Nath U, 2001, BRAIN, V124, P1438, DOI 10.1093/brain/124.7.1438; Parjane N, 2020, DIGITAL SPEECH ANAL, DOI [10.1101/2020.09.18.20197657, DOI 10.1101/2020.09.18.20197657]; Robinson JL, 2020, J NEUROPATH EXP NEUR, V79, P296, DOI 10.1093/jnen/nlz141; Robinson JL, 2018, BRAIN, V141, P2181, DOI 10.1093/brain/awy146; West T, 2017, JPAD-J PREV ALZHEIM, V4, P236, DOI 10.14283/jpad.2017.36; Yanamandra K, 2013, NEURON, V80, P402, DOI 10.1016/j.neuron.2013.07.046	10	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2021	20	3					162	163		10.1016/S1474-4422(21)00035-1	http://dx.doi.org/10.1016/S1474-4422(21)00035-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QK3CL	33609464				2022-12-18	WOS:000620258400002
J	Winkler, AS; Leonardi, M; Michael, BD; Abd-Allah, F; Carroll, W; Guekht, A				Winkler, Andrea Sylvia; Leonardi, Matilde; Michael, Benedict Daniel; Abd-Allah, Foad; Carroll, William; Guekht, Alla		Global COVID-19 Neuro Res	A WHO resolution on epilepsy and other neurological disorders	LANCET NEUROLOGY			English	Letter									[Winkler, Andrea Sylvia] Tech Univ Munich, Dept Neurol, Ctr Global Hlth, Sch Med, Munich, Germany; [Winkler, Andrea Sylvia] Univ Oslo, Inst Hlth & Soc, Ctr Global Hlth, Oslo, Norway; [Leonardi, Matilde] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurol, Publ Hlth Disabil Unit, Milan, Italy; [Michael, Benedict Daniel] NIHR Hlth Protect Res Unit Emerging & Zoonot Infe, Liverpool, Merseyside, England; [Michael, Benedict Daniel] Univ Liverpool, Inst Infect Vet & Ecol Sci, Liverpool, Merseyside, England; [Michael, Benedict Daniel] Walton Ctr NHS Fdn Trust, Dept Neurol, Liverpool, Merseyside, England; [Abd-Allah, Foad] Cairo Univ, Kasr Alainy Sch Med, Dept Neurol, Cairo, Egypt; [Carroll, William] Univ Western Australia, Dept Neurol, Sir Charles Gairdner Hosp, Perron Inst Neurol & Translat Sci, Nedlands, WA, Australia; [Guekht, Alla] Moscow Res & Clin Ctr Neuropsychiat, Moscow, Russia; [Guekht, Alla] Russian Natl Res Med Univ, Moscow, Russia	Technical University of Munich; University of Oslo; IRCCS Istituto Neurologico Besta; University of Liverpool; Walton Centre; Egyptian Knowledge Bank (EKB); Cairo University; University of Western Australia; Pirogov Russian National Research Medical University	Winkler, AS (corresponding author), Tech Univ Munich, Dept Neurol, Ctr Global Hlth, Sch Med, Munich, Germany.; Winkler, AS (corresponding author), Univ Oslo, Inst Hlth & Soc, Ctr Global Hlth, Oslo, Norway.	andrea.winkler@tum.de	Guekht, Alla/N-3422-2019	Guekht, Alla/0000-0002-1170-6127; Westenberg, Erica/0000-0001-8297-3962; Michael, Benedict/0000-0002-8693-8926	School of Medicine, Technical University of Munich [H.40001.1.7-08]	School of Medicine, Technical University of Munich	Special thanks go to Prof Bernhard Hemmer, Department of Neurology, Technical University of Munich, for his ongoing support of the Global COVID-19 Neuro Research Coalition and to Erica Westenberg for coordinating the Coalition. The secretariat of the Coalition has been supported by the School of Medicine, Technical University of Munich, Grant Number H.40001.1.7-08.	Feigin VL, 2020, LANCET NEUROL, V19, P255, DOI 10.1016/S1474-4422(19)30411-9; Knauss S, 2019, LANCET NEUROL, V18, P1078, DOI 10.1016/S1474-4422(19)30392-8; WHO, 2020, GLOBAL ACTIONS EPILE; WHO, 2019, EPILEPSY PUBLIC HLTH; Winkler AS, 2020, LANCET NEUROL, V19, P482, DOI 10.1016/S1474-4422(20)30150-2	5	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2021	20	3					171	+		10.1016/S1474-4422(21)00026-0	http://dx.doi.org/10.1016/S1474-4422(21)00026-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QK3CL	33609470	Bronze			2022-12-18	WOS:000620258400009
J	[Anonymous]				[Anonymous]			Diversity and inclusion in clinical neurosciences	LANCET NEUROLOGY			English	Editorial Material																			0	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2021	20	3					161	161		10.1016/S1474-4422(21)00034-X	http://dx.doi.org/10.1016/S1474-4422(21)00034-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QK3CL	33609463	Bronze			2022-12-18	WOS:000620258400001
J	Goyal, M; Marko, M				Goyal, Mayank; Marko, Martha			Optimising prehospital stroke triage in a changing landscape	LANCET NEUROLOGY			English	Editorial Material							ENDOVASCULAR THROMBECTOMY; ISCHEMIC-STROKE		[Goyal, Mayank] Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada; [Goyal, Mayank] Univ Calgary, Dept Radiol, Calgary, AB T2N 1N4, Canada; [Marko, Martha] Med Univ Vienna, Dept Neurol, Vienna, Austria	University of Calgary; University of Calgary; Medical University of Vienna	Goyal, M (corresponding author), Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada.; Goyal, M (corresponding author), Univ Calgary, Dept Radiol, Calgary, AB T2N 1N4, Canada.	mgoyal@ucalgary.ca						Duvekot MHC, 2021, LANCET NEUROL, V20, P213, DOI 10.1016/S1474-4422(20)30439-7; Goyal M, 2020, J NEUROINTERV SURG, V12, P545, DOI 10.1136/neurintsurg-2020-015807; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Holodinsky JK, 2018, JAMA NEUROL, V75, P1477, DOI 10.1001/jamaneurol.2018.2424; Menon BK, 2019, CIRCULATION, V139, P169, DOI 10.1161/CIRCULATIONAHA.118.036701; Ospel JM, 2020, NEURORADIOLOGY, V62, P715, DOI 10.1007/s00234-020-02371-6; Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647; Walsh KB, 2019, INT J STROKE, V14, P592, DOI 10.1177/1747493019866621; Yang PF, 2020, NEW ENGL J MED, V382, P1981, DOI 10.1056/NEJMoa2001123	9	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2021	20	3					166	168		10.1016/S1474-4422(20)30488-9	http://dx.doi.org/10.1016/S1474-4422(20)30488-9		FEB 2021	4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QK3CL	33422192				2022-12-18	WOS:000620258400005
J	Wu, SM; Anderson, CS				Wu, Simiao; Anderson, Craig S.			Healthy eating for secondary stroke prevention	LANCET NEUROLOGY			English	Editorial Material							RISK		[Wu, Simiao] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu 610041, Peoples R China; [Anderson, Craig S.] Univ New South Wales, Fac Med, George Inst Global Hlth, Sydney, NSW, Australia; [Anderson, Craig S.] Peking Univ, Hlth Sci Ctr, George Inst Global Hlth China, Beijing, Peoples R China	Sichuan University; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; Peking University	Wu, SM (corresponding author), Sichuan Univ, West China Hosp, Dept Neurol, Chengdu 610041, Peoples R China.	simiao.wu@hotmail.com		WU, SIMIAO/0000-0002-4557-7386	National Natural Science Foundation of China [81701156]; West China Hospital, Sichuan University [ZYGD18009]; National Health and Medical Research Council of Australia [APP1175861, APP1149987, IISR-2017-101947, IISR-2018-102649]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); West China Hospital, Sichuan University(Sichuan University); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	SW has received grants from the National Natural Science Foundation of China (81701156) and West China Hospital, Sichuan University (ZYGD18009) for stroke research. CSA has received grants from the National Health and Medical Research Council of Australia (APP1175861 and APP1149987), grants for stroke research (IISR-2017-101947 and IISR-2018-102649), lecture fees, and travel reimbursement from Takeda China, and Advisory Board fees from Boehringer Ingelheim.	English C, 2021, LANCET NEUROL, V20, P150, DOI 10.1016/S1474-4422(20)30433-6; Krishnamurthi RV, 2020, NEUROEPIDEMIOLOGY, V54, P171, DOI 10.1159/000506396; Li YP, 2011, J NUTR, V141, P1834, DOI 10.3945/jn.111.143883; Micha R, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008705; Mohan KM, 2011, STROKE, V42, P1489, DOI 10.1161/STROKEAHA.110.602615; Olaiya MT, 2017, STROKE, V48, P2504, DOI 10.1161/STROKEAHA.117.017499; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Willett W, 2019, LANCET, V393, P447, DOI 10.1016/S0140-6736(18)31788-4; Wood AM, 2018, LANCET, V391, P1513, DOI 10.1016/S0140-6736(18)30134-X; Yusuf S, 2020, LANCET, V395, P795, DOI 10.1016/S0140-6736(19)32008-2	10	2	2	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					87	89		10.1016/S1474-4422(20)30450-6	http://dx.doi.org/10.1016/S1474-4422(20)30450-6		JAN 2021	3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	33347807				2022-12-18	WOS:000610201500008
J	Ducros, A				Ducros, Anne			Oral steroids for episodic cluster headache	LANCET NEUROLOGY			English	Editorial Material							DOUBLE-BLIND; DIAGNOSIS		[Ducros, Anne] Univ Montpellier, CHU Montpellier, Gui de Chauliac Hosp, Dept Neurol, F-34000 Montpellier, France	Universite de Montpellier; CHU de Montpellier	Ducros, A (corresponding author), Univ Montpellier, CHU Montpellier, Gui de Chauliac Hosp, Dept Neurol, F-34000 Montpellier, France.	a-ducros@chu-montpellier.fr	Ducros, Anne/D-1899-2010	Ducros, Anne/0000-0001-5560-5013				Ambrosini A, 2005, PAIN, V118, P92, DOI 10.1016/j.pain.2005.07.015; Becker WJ, 2013, HEADACHE, V53, P1191, DOI 10.1111/head.12145; de Coo IF, 2019, CEPHALALGIA, V39, P626, DOI 10.1177/0333102418804160; Goadsby PJ, 2019, NEW ENGL J MED, V381, P132, DOI 10.1056/NEJMoa1813440; Hoffmann J, 2018, LANCET NEUROL, V17, P75, DOI 10.1016/S1474-4422(17)30405-2; JAMMES JL, 1975, DIS NERV SYST, V36, P375; Leroux E, 2011, LANCET NEUROL, V10, P891, DOI 10.1016/S1474-4422(11)70186-7; Liu LH, 2017, CHINESE MED J-PEKING, V130, P2601, DOI 10.4103/0366-6999.217094; Obermann M, 2021, LANCET NEUROL, V20, P29, DOI 10.1016/S1474-4422(20)30363-X	9	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					19	20		10.1016/S1474-4422(20)30402-6	http://dx.doi.org/10.1016/S1474-4422(20)30402-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33245859				2022-12-18	WOS:000600831400013
J	Tsivgoulis, G; Katsanos, AH				Tsivgoulis, Georgios; Katsanos, Aristeidis H.			Important advances in stroke research in 2020	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE		[Tsivgoulis, Georgios] Natl & Kapodistrian Univ Athens, Dept Neurol 2, Attikon Hosp, Sch Med, Athens 15344, Greece; [Tsivgoulis, Georgios] Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Memphis, TN 38163 USA; [Katsanos, Aristeidis H.] McMaster Univ, Div Neurol, Hamilton, ON, Canada; [Katsanos, Aristeidis H.] Populat Hlth Res Inst, Hamilton, ON, Canada	Athens Medical School; National & Kapodistrian University of Athens; University Hospital Attikon; University of Tennessee System; University of Tennessee Health Science Center; McMaster University; Population Health Research Institute	Tsivgoulis, G (corresponding author), Natl & Kapodistrian Univ Athens, Dept Neurol 2, Attikon Hosp, Sch Med, Athens 15344, Greece.; Tsivgoulis, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Memphis, TN 38163 USA.	tsivgoulisgiorg@yahoo.gr						Amarenco P, 2020, NEW ENGL J MED, V382, P9, DOI 10.1056/NEJMoa1910355; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Hill MD, 2020, LANCET, V395, P878, DOI 10.1016/S0140-6736(20)30258-0; Johnston SC, 2020, NEW ENGL J MED, V383, P207, DOI 10.1056/NEJMoa1916870; Katsanos AH, 2019, ANN NEUROL, V86, P395, DOI 10.1002/ana.25544; Katsanos AH, 2020, JAMA NEUROL, V77, P1308, DOI 10.1001/jamaneurol.2020.2494; Nogueira RG, 2020, STROKE, V51, P3182, DOI 10.1161/STROKEAHA.120.030796; Yang PF, 2020, NEW ENGL J MED, V382, P1981, DOI 10.1056/NEJMoa2001123	8	2	2	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					2	3		10.1016/S1474-4422(20)30431-2	http://dx.doi.org/10.1016/S1474-4422(20)30431-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33340477	Bronze, Green Published			2022-12-18	WOS:000600831400003
J	[Anonymous]				[Anonymous]			Rapid drug access and scientific rigour: a delicate balance	LANCET NEUROLOGY			English	Editorial Material																			0	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					1	1		10.1016/S1474-4422(20)30452-X	http://dx.doi.org/10.1016/S1474-4422(20)30452-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33340471	Bronze			2022-12-18	WOS:000600831400002
J	Solomon, T; Benjamin, L; Singh, B; Lant, S; Ellul, MA				Solomon, Tom; Benjamin, Laura; Singh, Bhagteshwar; Lant, Suzannah; Ellul, Mark A.			Provisional case definitions for COVID-19-associated neurological disease Reply	LANCET NEUROLOGY			English	Letter									[Solomon, Tom; Singh, Bhagteshwar; Lant, Suzannah; Ellul, Mark A.] Univ Liverpool, Inst Infect Vet & Ecol Sci, Natl Inst Hlth Res Hlth Protect Res Unit Emerging, Liverpool L69 7BE, Merseyside, England; [Solomon, Tom; Ellul, Mark A.] Walton Ctr Natl Hlth Serv Fdn Trust, Liverpool, Merseyside, England; [Benjamin, Laura] UCL, Queen Sq Inst Neurol, London, England; [Singh, Bhagteshwar] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India	University of Liverpool; Walton Centre; University of London; University College London; Christian Medical College & Hospital (CMCH) Vellore	Solomon, T (corresponding author), Univ Liverpool, Inst Infect Vet & Ecol Sci, Natl Inst Hlth Res Hlth Protect Res Unit Emerging, Liverpool L69 7BE, Merseyside, England.; Solomon, T (corresponding author), Walton Ctr Natl Hlth Serv Fdn Trust, Liverpool, Merseyside, England.	tsolomon@liverpool.ac.uk	Ellul, Mark/HGU-9086-2022	Ellul, Mark/0000-0002-6115-8245; Lant, Suzannah/0000-0003-0852-7803; Singh, Bhagteshwar/0000-0002-9039-3674; Benjamin, Laura/0000-0002-9685-1664	MRC [MR/V033441/1] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ferreira MLB, 2020, LANCET NEUROL, V19, P826, DOI 10.1016/S1474-4422(20)30232-5; Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; Fitzner J, 2018, B WORLD HEALTH ORGAN, V96, P122, DOI 10.2471/BLT.17.194514; Kong WH, 2020, NAT MICROBIOL, V5, P675, DOI 10.1038/s41564-020-0713-1; Mallewa M, 2013, LANCET GLOB HEALTH, V1, pE153, DOI 10.1016/S2214-109X(13)70060-3; World Health Organization, 2020, SURV CAS DEF HUM INF	6	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2020	19	11					891	+						3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3OI	33098794	Green Submitted, Green Published, Bronze			2022-12-18	WOS:000581121200014
J	Vitek, JL; Starr, PA				Vitek, Jerrold L.; Starr, Philip A.			Studies of deep brain stimulation in Parkinson's disease	LANCET NEUROLOGY			English	Letter							DEVICE		[Vitek, Jerrold L.] Univ Minnesota, Sch Med, Dept Neurol, Minneapolis, MN 55455 USA; [Starr, Philip A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Francisco	Vitek, JL (corresponding author), Univ Minnesota, Sch Med, Dept Neurol, Minneapolis, MN 55455 USA.	vitek004@umn.edu						Deuschl G, 2020, LANCET NEUROL, V19, P472, DOI 10.1016/S1474-4422(20)30138-1; Follett KA, 2010, NEW ENGL J MED, V362, P2077, DOI 10.1056/NEJMoa0907083; Okun MS, 2012, LANCET NEUROL, V11, P140, DOI 10.1016/S1474-4422(11)70308-8; Vitek JL, 2020, LANCET NEUROL, V19, P491, DOI 10.1016/S1474-4422(20)30108-3; Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929	5	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					807	+		10.1016/S1474-4422(20)30323-9	http://dx.doi.org/10.1016/S1474-4422(20)30323-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3NN	32949537	Bronze			2022-12-18	WOS:000581119100011
J	Bianucci, R; Kirkpatrick, CL; Perciaccante, A; Galassi, FM; Lippi, D; Appenzeller, O; Nerlich, AG				Bianucci, Raffaella; Kirkpatrick, Casey L.; Perciaccante, Antonio; Galassi, Francesco Maria; Lippi, Donatella; Appenzeller, Otto; Nerlich, Andreas G.			A case of congenital Horner syndrome from the 16th century	LANCET NEUROLOGY			English	Letter									[Bianucci, Raffaella] Univ Warwick, Warwick Med Sch, Biomed Sci, Coventry CV4 7AL, W Midlands, England; [Bianucci, Raffaella] Univ Turin, Dept Publ Hlth & Paediat Sci, Legal Med Sect, Turin, Italy; [Bianucci, Raffaella] Fac Med, Lab Anthropol Bioculturelle Droit Etique & Sante, UMR 7268, Marseille, France; [Kirkpatrick, Casey L.] Paleooncol Res Org, Minneapolis, MN USA; [Kirkpatrick, Casey L.] Univ Western Ontario, Dept Anthropol, London, ON, Canada; [Perciaccante, Antonio] Azienda Sanit Univ Giuliano Isontina, San Giovanni di Dio Hosp, Dept Med, Gorizia, Italy; [Galassi, Francesco Maria] Flinders Univ S Australia, Coll Humanities Arts & Social Sci, Archaeol, Adelaide, SA, Australia; [Galassi, Francesco Maria] FAPAB Res Ctr, Avola, Italy; [Lippi, Donatella] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Appenzeller, Otto] New Mexico Hlth Enhancement & Marathon Clin Res F, Albuquerque, NM USA; [Appenzeller, Otto] New Mexico Museum Nat Hist & Sci, Albuquerque, NM USA; [Nerlich, Andreas G.] Acad Clin Munich Bogenhausen, Inst Pathol, Munich, Germany	University of Warwick; University of Turin; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Aix-Marseille Universite; Western University (University of Western Ontario); Flinders University South Australia; University of Florence; Munchen Klinik	Bianucci, R (corresponding author), Univ Warwick, Warwick Med Sch, Biomed Sci, Coventry CV4 7AL, W Midlands, England.; Bianucci, R (corresponding author), Univ Turin, Dept Publ Hlth & Paediat Sci, Legal Med Sect, Turin, Italy.; Bianucci, R (corresponding author), Fac Med, Lab Anthropol Bioculturelle Droit Etique & Sante, UMR 7268, Marseille, France.	r.bianucci@warwick.ac.uk		Kirkpatrick, Casey/0000-0001-9755-6459; Galassi, Francesco Maria/0000-0001-8902-3142				Horner F, 1869, KLIN MONATSBL AUGENH, V7, P193; Jeffery A R, 1998, J AAPOS, V2, P159, DOI 10.1016/S1091-8531(98)90008-8; Kanagalingam S, 2015, EYE BRAIN, V7, P35, DOI 10.2147/EB.S63633	3	2	2	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2020	19	8					646	647		10.1016/S1474-4422(20)30214-3	http://dx.doi.org/10.1016/S1474-4422(20)30214-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT8ZY	32702330	Bronze			2022-12-18	WOS:000573228000022
J	Sturke, R; Malekzadeh, A; Michels, K; Glass, R				Sturke, Rachel; Malekzadeh, Arianne; Michels, Kathleen; Glass, Roger			Implementation science for brain disorders	LANCET NEUROLOGY			English	Letter									[Sturke, Rachel; Malekzadeh, Arianne; Michels, Kathleen; Glass, Roger] Fogarty Int Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Sturke, R (corresponding author), Fogarty Int Ctr, Bethesda, MD 20892 USA.	sturkerachel@mail.nih.gov						[Anonymous], ETV CPC PROC; Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI [10.1016/S1474-4422(18)30499-X, 10.1136/bmj.l94, 10.1016/S1474-4422(19)30034-1]; Fogarty International Center, 2019, GLOB BRAIN DIS RES; Kulkarni AV, 2017, NEW ENGL J MED, V377, P2456, DOI 10.1056/NEJMoa1707568; Zeitvogel K., 2018, FOGARTY SUPPORTED RE	5	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2020	19	8					645	645		10.1016/S1474-4422(20)30213-1	http://dx.doi.org/10.1016/S1474-4422(20)30213-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT8ZY	32702329	Bronze			2022-12-18	WOS:000573228000020
J	[Anonymous]				[Anonymous]			Disparities in neurological care: time to act on inequalities	LANCET NEUROLOGY			English	Editorial Material																			0	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2020	19	8					635	635		10.1016/S1474-4422(20)30211-8	http://dx.doi.org/10.1016/S1474-4422(20)30211-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT8ZY	32702321	Bronze			2022-12-18	WOS:000573228000003
J	Levy, M				Levy, Michael			Interleukin-6 receptor blockade for the treatment of NMOSD	LANCET NEUROLOGY			English	Editorial Material							OPTICA SPECTRUM DISORDER; SATRALIZUMAB; MULTICENTER; EFFICACY; SAFETY		[Levy, Michael] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Levy, Michael] Harvard Med Sch, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Levy, M (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.; Levy, M (corresponding author), Harvard Med Sch, Boston, MA 02114 USA.	mlevy11@mgh.harvard.edu						Chihara N, 2011, P NATL ACAD SCI USA, V108, P3701, DOI 10.1073/pnas.1017385108; Cree BAC, 2019, LANCET, V394, P1352, DOI 10.1016/S0140-6736(19)31817-3; Kimbrough DJ, 2012, MULT SCLER RELAT DIS, V1, P180, DOI 10.1016/j.msard.2012.06.002; Mihara M, 2005, EXPERT OPIN BIOL TH, V5, P683, DOI 10.1517/14712598.5.5.683; Paul F, 2018, EXPERT OPIN INV DRUG, V27, P265, DOI 10.1080/13543784.2018.1443077; Pittock SJ, 2019, NEW ENGL J MED, V381, P614, DOI 10.1056/NEJMoa1900866; Traboulsee A, 2020, LANCET NEUROL, V19, P402, DOI 10.1016/S1474-4422(20)30078-8; Uzawa A, 2017, CLIN CHIM ACTA, V469, P144, DOI 10.1016/j.cca.2017.03.006; Yamamura T, 2019, NEW ENGL J MED, V381, P2114, DOI 10.1056/NEJMoa1901747; Zhang C, 2020, LANCET NEUROL, V19, P391, DOI 10.1016/S1474-4422(20)30070-3	10	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					370	371		10.1016/S1474-4422(20)30081-8	http://dx.doi.org/10.1016/S1474-4422(20)30081-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32333886				2022-12-18	WOS:000573045100003
J	Maher, C; Littlewood, C				Maher, Chris; Littlewood, Chris			Unanswered questions from the Evoke trial	LANCET NEUROLOGY			English	Letter									[Maher, Chris] Univ Sydney, Sch Publ Hlth, Inst Musculoskeletal Hlth, Sydney, NSW 2050, Australia; [Littlewood, Chris] Manchester Metropolitan Univ, Fac Hlth Psychol & Social Care, Manchester, Lancs, England	University of Sydney; Manchester Metropolitan University	Maher, C (corresponding author), Univ Sydney, Sch Publ Hlth, Inst Musculoskeletal Hlth, Sydney, NSW 2050, Australia.	christopher.maher@sydney.edu.au	Maher, Christopher/AAC-6267-2019	Maher, Christopher/0000-0002-1628-7857				Australian Department of Health-Therapeutic Goods Administration, 2019, DOC REL REG ADV EV S; Duarte RV, 2020, PAIN, V161, P24, DOI 10.1097/j.pain.0000000000001689; Mekhail N, 2020, LANCET NEUROL, V19, P123, DOI 10.1016/S1474-4422(19)30414-4	3	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					380	380		10.1016/S1474-4422(20)30110-1	http://dx.doi.org/10.1016/S1474-4422(20)30110-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32333889	Green Accepted, Bronze			2022-12-18	WOS:000573045100021
J	Uchiyama, S				Uchiyama, Shinichiro			Intensive medical management of intracranial arterial stenosis	LANCET NEUROLOGY			English	Editorial Material							PREVALENCE		[Uchiyama, Shinichiro] Int Univ Hlth & Welf, Clin Res Ctr Med, Tokyo, Japan; [Uchiyama, Shinichiro] Sanno Med Ctr, Ctr Brain & Cerebral Vessels, Tokyo 1078332, Japan; [Uchiyama, Shinichiro] Sanno Hosp, Tokyo 1078332, Japan	International University of Health & Welfare	Uchiyama, S (corresponding author), Int Univ Hlth & Welf, Clin Res Ctr Med, Tokyo, Japan.; Uchiyama, S (corresponding author), Sanno Med Ctr, Ctr Brain & Cerebral Vessels, Tokyo 1078332, Japan.; Uchiyama, S (corresponding author), Sanno Hosp, Tokyo 1078332, Japan.	suchiyama@iuhw.ac.jp						Alexander MJ, 2019, STROKE, V50, P889, DOI 10.1161/STROKEAHA.118.023996; Amarenco P, 2018, NEW ENGL J MED, V378, P2182, DOI 10.1056/NEJMoa1802712; Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180; Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335; Hobeanu C, 2017, STROKE, V48, P1005, DOI 10.1161/STROKEAHA.116.015171; Hoshino T, 2017, STROKE, V48, P1779, DOI 10.1161/STROKEAHA.117.016874; Hurford R, 2020, LANCET NEUROL, V19, P413, DOI 10.1016/S1474-4422(20)30079-X; Uchiyama S, 2019, J STROKE CEREBROVASC, V28, P2232, DOI 10.1016/j.jstrokecerebrovasdis.2019.05.005; Zaidat OO, 2015, JAMA-J AM MED ASSOC, V313, P1240, DOI 10.1001/jama.2015.1693	9	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					371	373		10.1016/S1474-4422(20)30100-9	http://dx.doi.org/10.1016/S1474-4422(20)30100-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32333887	hybrid			2022-12-18	WOS:000573045100004
J	Mudigoudar, B; Wheless, J				Mudigoudar, Basanagoud; Wheless, James			Safety of adjunctive treatment with cenobamate in patients with uncontrolled focal seizures	LANCET NEUROLOGY			English	Letter									[Mudigoudar, Basanagoud] Le Bonheur Childrens Hosp, Le Bonheur Comprehens Epilepsy Program, Memphis, TN 38103 USA; Le Bonheur Childrens Hosp, Neurosci Inst, Memphis, TN 38103 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Div Pediat Neurol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Mudigoudar, B (corresponding author), Le Bonheur Childrens Hosp, Le Bonheur Comprehens Epilepsy Program, Memphis, TN 38103 USA.	bmudigou@uthsc.edu	Mudigoudar, Basanagoud/AFP-2500-2022					Abou-Khalil B, 2018, EPILEPSY RES, V147, P80, DOI 10.1016/j.eplepsyres.2018.08.011; Krauss GL, 2020, LANCET NEUROL, V19, P38, DOI 10.1016/S1474-4422(19)30399-0; McGinnis E, 2016, EPILEPSIA, V57, P1416, DOI 10.1111/epi.13466; Nakamura M, 2019, EUR J PHARMACOL, V855, P175, DOI 10.1016/j.ejphar.2019.05.007	4	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2020	19	4					288	288		10.1016/S1474-4422(20)30069-7	http://dx.doi.org/10.1016/S1474-4422(20)30069-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KW1GS	32199091	Bronze			2022-12-18	WOS:000520920500009
J	Heselmans, A				Heselmans, Annemie			Research participation for patients with spinal cord injury	LANCET NEUROLOGY			English	Letter									[Heselmans, Annemie] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, B-3000 Leuven, Belgium	KU Leuven	Heselmans, A (corresponding author), Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, B-3000 Leuven, Belgium.	annemie.heselmans@gmail.com						Angeli CA, 2018, NEW ENGL J MED, V379, P1244, DOI 10.1056/NEJMoa1803588; Benabid AL, 2019, LANCET NEUROL, V18, P1112, DOI 10.1016/S1474-4422(19)30321-7; Davis GM, 2008, ARTIF ORGANS, V32, P625, DOI 10.1111/j.1525-1594.2008.00622.x; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Harkema SJ, 2018, JAMA NEUROL, V75, P1569, DOI 10.1001/jamaneurol.2018.2617; Shakespeare T, 2019, LANCET NEUROL, V18, P1071, DOI 10.1016/S1474-4422(19)30352-7	6	2	2	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2020	19	2					109	109		10.1016/S1474-4422(19)30489-2	http://dx.doi.org/10.1016/S1474-4422(19)30489-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KE1XC	31978356	Bronze			2022-12-18	WOS:000508351900011
